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Preface
In both epidemiological and clinical studies as well as the meta-analyses thereof,
low plasma levels of high-density lipoprotein (HDL) cholesterol (HDL-C)
identified individuals at increased risk of major coronary events. Observational
studies also found inverse associations between HDL-C and risks of ischemic
stroke, diabetes mellitus type 2, and various cancers. In addition, HDLs exert
many effects in vitro and in vivo which protect the organism from chemical or
biological harm and thereby may interfere with the pathogenesis of atherosclerosis,
diabetes, and cancer but also other inflammatory diseases. Moreover, in several
animal models transgenic overexpression or exogenous application of apolipopro-
tein Α-I (apoA-I), the most abundant protein of HDL, decreased or prevented the
development of atherosclerosis, glucose intolerance, or tissue damage induced by
ischemia or mechanical injury.
However, as yet drugs increasing HDL-C such as fibrates, niacin, or inhibitors of
cholesteryl ester transfer protein have failed to consistently and significantly reduce
the risk of major cardiovascular events, especially when combined with statins.
Moreover, mutations in several human genes as well as targeting of several murine
genes were found to modulate HDL-C levels without changing cardiovascular risk
and atherosclerotic plaque load, respectively, into the opposite direction as
expected from the inverse correlation of HDL-C levels and cardiovascular risk in
epidemiological studies. Because of these controversial data, the pathogenic role,
and, hence, the suitability of HDL as a therapeutic target, has been increasingly
questioned. Because of the frequent confounding of low HDL-C with hypertrigly-
ceridemia, it has been argued that low HDL-C is an innocent bystander of (post-
prandial) hypertriglyceridemia or another culprit related to insulin resistance or
inflammation.
These complex relationships are depicted in Fig. 1. It is important to note that
previous intervention and genetic studies targeted HDL-C, i.e., the cholesterol
measured by clinical laboratories in HDL. By contrast to the pro-atherogenic and,
hence, disease causing cholesterol in LDL (measured or estimated by clinical
laboratories as LDL cholesterol, LDL-C) which after internalization turns
macrophages of the arterial intima into pro-inflammatory foam cells, the cholesterol
in HDL (i.e., HDL-C) neither exerts nor reflects any of the potentially anti-
atherogenic activities of HDL. By contrast to LDL-C, HDL-C is only a nonfunc-
tional surrogate marker for estimating HDL particle number and size without
v
deciphering the heterogeneous composition and, hence, functionality of HDL. HDL
particles are heterogeneous and complex macromolecules carrying hundreds of
lipid species and dozens of proteins as well as microRNAs. This physiological
heterogeneity is further increased in pathological conditions due to additional
quantitative and qualitative molecular changes of HDL components which have
been associated with both loss of physiological function and gain of pathological
dysfunction. This structural and functional complexity of HDL has prevented clear
assignments of molecules to the many functions of HDL. Detailed knowledge of
structure–function relationships of HDL-associated molecules is a prerequisite to
test them for their relative importance in the pathogenesis of HDL-associated
diseases. The identification of the most relevant biological activities of HDL and
their mediating molecules within HDL, as well as their cellular interaction partners,
is pivotal for the successful development of anti-atherogenic and anti-diabetogenic
drugs as well as of diagnostic biomarkers for the identification, treatment stratifica-
tion, and monitoring of patients at increased risk for cardiovascular diseases or
diabetes mellitus but also other diseases which show associations with HDL.
This Handbook of Experimental Pharmacology on HDL emerged from the
European Cooperation in Science and Technology (COST) Action BM0904 entitled
“HDL—from biological understanding to clinical exploitation” (HDLnet: http://
cost-bm0904.gr/). This COST Action was run from 2010 to 2014 and involved
more than 200 senior and junior scientists from 16 European countries. HDLnet has
been a scientific network dedicated to the study of HDL in health and disease, to the
identification of targets for novel HDL-based therapies, and to the discovery of
biomarkers which can be used for diagnostics, prevention, and therapy of cardio-
vascular disease. HDLnet fostered the cooperation and interaction of European


























































Fig. 1 Possible pathophysiological relationships of low HDL cholesterol with its associated
diseases
vi Preface
promotion of early career scientists, the gain of technological know-how, and the
dissemination of old and new knowledge on HDL to the scientific and medical
community as well as the lay public. In this setting, the chapters of this handbook
have been written by cooperative and interactive efforts of many senior scientists of
the HDLnet consortium and colleagues from the United States. It is published as
open access through COST funding so that the knowledge on HDL can be spread
without limitation.
As the chairman and vice-chairman of HDLnet, the editors of this Handbook of
Experimental Pharmacology issue like to thank not only the authors of the
22 chapters of this handbook but all members of the COST Action for their engaged
participation and cooperation. We thank Ms. Zinovia Papatheodorou (senior
Administrative Officer of the grant holder FORTH, Heraklion) for excellent grant
administrative work in HDLnet, the Science Officers Dr. Magdalena Radwanska
and Dr Inga Dadeshidze, the Administrative Officers Ms Anja van der Snickt and
Ms Jeannette Nchung (all from COST Office, Brussels, Belgium), as well as the DC
Rapporteur, Prof. Marieta Costache (Bucharest, Romania), for their excellent
support and sustained interest in our Action. We gratefully acknowledge Andrea
Bardelli and Giulia Miotto from COST Publications Office for their help in
publishing this book as an open access Final Action Publication (FAP). Finally
we wish to thank Prof. Martin Michel for his interest and guidance as well as
Susanne Dathe and Wilma McHugh from Springer who supported us with patience
and enthusiasm in the production of this book.
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Pitié – Salpétrière University Hospital, Paris, France
ICAN, Paris, France
e-mail: anatol.kontush@upmc.fr; m.lhomme@ican-institute.org; john.chapman@upmc.fr
M. Lindahl
Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
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Abstract
A molecular understanding of high-density lipoprotein (HDL) will allow a more
complete grasp of its interactions with key plasma remodelling factors and with
cell-surface proteins that mediate HDL assembly and clearance. However, these
particles are notoriously heterogeneous in terms of almost every physical,
chemical and biological property. Furthermore, HDL particles have not lent
themselves to high-resolution structural study through mainstream techniques
like nuclear magnetic resonance and X-ray crystallography; investigators have
therefore had to use a series of lower resolution methods to derive a general
structural understanding of these enigmatic particles. This chapter reviews
current knowledge of the composition, structure and heterogeneity of human
plasma HDL. The multifaceted composition of the HDL proteome, the multiple
major protein isoforms involving translational and posttranslational
modifications, the rapidly expanding knowledge of the HDL lipidome, the
highly complex world of HDL subclasses and putative models of HDL particle
structure are extensively discussed. A brief history of structural studies of both
plasma-derived and recombinant forms of HDL is presented with a focus on
detailed structural models that have been derived from a range of techniques
spanning mass spectrometry to molecular dynamics.
Keywords
HDL • Composition • Structure • Heterogeneity • Proteomics • Lipidomics •
Proteome • Lipidome • Post-translational • Modifications
High-density lipoprotein (HDL) is a small, dense, protein-rich lipoprotein as
compared to other lipoprotein classes, with a mean size of 8–10 nm and density of
1.063–1.21 g/ml (Kontush and Chapman 2012). HDL particles are plurimolecular,
quasi-spherical or discoid, pseudomicellar complexes composed predominantly of
polar lipids solubilised by apolipoproteins. HDL also contains numerous other
proteins, including enzymes and acute-phase proteins, and may contain small
amounts of nonpolar lipids. Furthermore, HDL proteins often exist in multiple
isoforms and readily undergo posttranslational modification. As a consequence of
such diverse compositional features, HDL particles are highly heterogeneous in their
structural, chemical and biological properties. This chapter reviews current knowl-
edge of the composition, structure and heterogeneity of human plasma HDL.
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1 HDL Subclasses
Human plasma HDLs are a highly heterogeneous lipoprotein family consisting of
several subclasses differing in density, size, shape and lipid and protein composi-
tion (Table 1).
Differences in HDL subclass distribution were first described by Gofman and
colleagues in the early 1950s by using analytic ultracentrifugation (De Lalla and
Gofman 1954), the gold standard technique for HDL separation. Two HDL
subclasses were identified: the less dense (1.063–1.125 g/mL), relatively lipid-
rich form was classified asHDL2 and the more dense (1.125–1.21 g/mL), relatively
protein-rich form as HDL3. The two major HDL subclasses can be separated by
other ultracentrifugation methods, such as rate-zonal ultracentrifugation
(Franceschini et al. 1985) or single vertical spin ultracentrifugation (Kulkarni
et al. 1997). Ultracentrifugation methods are accurate and precise but require
expensive instruments, time and technical skills. A precipitation method has been
proposed for HDL2 and HDL3 separation and quantitation (Gidez et al. 1982),
which is inexpensive and easier, but with a high degree of interlaboratory
variability. HDL2 and HDL3 can be further fractionated in distinct subclasses
with different electrophoretic mobilities by non-denaturing polyacrylamide gradi-
ent gel electrophoresis (GGE) (Nichols et al. 1986), which separates HDL
subclasses on the basis of particle size. Two HDL2 and three HDL3 subclasses
have been identified and their particle size characterised by this method: HDL3c,
7.2–7.8 nm diameter; HDL3b, 7.8–8.2 nm; HDL3a, 8.2–8.8 nm; HDL2a, 8.8.–
9.7 nm; and HDL2b, 9.7–12.0 nm. The equivalent subclasses of HDL with similar
size distribution may be preparatively isolated by isopycnic density gradient ultra-
centrifugation (Chapman et al. 1981; Kontush et al. 2003).
Agarose gel electrophoresis allows analytical separation of HDL according to
surface charge and shape into α-migrating particles, which represent the majority
of circulating HDL, and preβ-migrating particles, consisting of nascent discoidal
and poorly lipidated HDL. Agarose gels can be stained with Coomassie blue or with
anti-apolipoprotein A-I (apoA-I) antibodies, and the relative protein content of the
two HDL subclasses can be determined (Favari et al. 2004). The plasma preβ-HDL
concentration can be also quantified using a sandwich enzyme immunoassay (Miida
et al. 2003). The assay utilises a monoclonal antibody which specifically recognises
apoA-I bound to preβ-HDL. The agarose gel and the GGE can be combined into a
2-dimensional (2D) electrophoretic method, which separates HDL according to
charge in the first run and according to size in the second run. Gels can be stained
with apolipoprotein-specific antibodies, typically with anti-apoA-I antibodies,
allowing the detection of distinct HDL subclasses (Asztalos et al. 2007). This is
by far the method with the highest resolving power: up to 12 distinct apoA-I-
containing HDL subclasses can be identified, referred to as preβ (preβ1 and preβ2), α
(α1, α2, α3 and α4) and preα (preα1, preα2, preα3) according to their mobility and
size (Asztalos and Schaefer 2003a, b).
According to the protein component, HDL can be separated into particles
containing apoA-I with (LpA-I:A-II) or without apoA-II (LpA-I) by an
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electroimmunodiffusion technique in agarose gels; plasma concentration of LpA-I
and LpA-I:A-II can be determined from a calibration curve (Franceschini
et al. 2007).
More recently, a nuclear magnetic resonance (NMR) method for HDL subclass
analysis has been proposed, based on the concept that each lipoprotein particle of a
given size has its own characteristic lipid methyl group NMR signal (Otvos
et al. 1992). According to the NMR signals, three HDL subclasses can be identified:
large HDL (8.8–13.0 nm diameter), medium HDL (8.2–8.8 nm) and small HDL
(7.3–8.2 nm); results are expressed as plasma particle concentration. The relative
plasma content of small, medium and large HDL (according to the same cut-off)
can also be determined by GGE, dividing the absorbance profile into the three size
intervals (Franceschini et al. 2007).
HDL subfractionation on an analytical scale has been generally accomplished by
the different techniques in academic laboratories; however, clinical interest in HDL
heterogeneity has been growing in the last 10 years and a number of laboratory tests
for determining HDL subclass distribution are now available, including GGE, NMR
and 2D gel electrophoresis (Mora 2009). Whether evaluation of HDL subfractions
is performed by academic or commercial laboratories, there are a number of factors
that confound the interpretation of the results of such analyses. The number and
nomenclature of HDL subclasses are not uniform among the different techniques;
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moreover, each subclass contains distinct subpopulations, as identified by, e.g. 2D
electrophoresis. In addition, whereas some methodologies measure HDL subclass
concentrations, others describe the percent distribution of the HDL subclasses
relative to the total or characterise the HDL distribution by average particle
diameter. As a consequence, there is little relation among HDL subfractionation
data produced by different analytical techniques. A panel of experts has recently
proposed a classification of HDL by physical properties, which integrates terminol-
ogy from several methods and defines five HDL subclasses, termed very large,
large, medium, small and very small HDL (Rosenson et al. 2011). The proposed
nomenclature, possibly together with widely accepted standards and quality
controls, should help in defining the relationship between HDL subclasses and
cardiovascular risk as well as in assessing the clinical effects of HDL modifying
drugs.
2 Molecular Components of HDL
2.1 Proteome
2.1.1 Major Protein Components
Proteins form the major structural and functional component of HDL particles.
HDL carries a large number of different proteins as compared to other lipoprotein
classes (Table 2). HDL proteins can be divided into several major subgroups which
include apolipoproteins, enzymes, lipid transfer proteins, acute-phase response
proteins, complement components, proteinase inhibitors and other protein
components. Whereas apolipoproteins and enzymes are widely recognised as key
functional HDL components, the role of minor proteins, primarily those involved in
complement regulation, protection from infections and the acute-phase response,
has received increasing attention only in recent years, mainly as a result of advances
in proteomic technologies (Heinecke 2009; Hoofnagle and Heinecke 2009;
Davidsson et al. 2010; Shah et al. 2013). These studies have allowed reproducible
identification of more than 80 proteins in human HDL (Heinecke 2009; Hoofnagle
and Heinecke 2009; Davidsson et al. 2010; Shah et al. 2013) (for more details see
the HDL Proteome Watch at http://homepages.uc.edu/~davidswm/HDLproteome.
html). Numerous proteins involved in the acute-phase response, complement regu-
lation, proteinase inhibition, immune response and haemostasis were unexpectedly
found as components of normal human plasma HDL, raising the possibility that
HDL may play previously unsuspected roles in host defence mechanisms and
inflammation (Hoofnagle and Heinecke 2009).
Importantly, the composition of the HDL proteome may depend on the method
of HDL isolation. Indeed, ultracentrifugation in highly concentrated salt solutions
of high ionic strength can remove some proteins from HDL, whereas other methods
of HDL isolation (gel filtration, immunoaffinity chromatography, precipitation)
provide HDL extensively contaminated with plasma proteins or subject HDL to
unphysiological conditions capable of modifying its structure and/or composition
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Table 2 Major components of the HDL proteome
Protein Mr, kDa Major function
Number of proteomic
studies in which the
protein was detecteda
Apolipoproteins
ApoA-I 28 Major structural and functional
apolipoprotein, LCAT activator
14
ApoA-II 17 Structural and functional
apolipoprotein
13
ApoA-IV 46 Structural and functional
apolipoprotein
14
ApoC-I 6.6 Modulator of CETP activity,
LCAT activator
12
ApoC-II 8.8 Activator of LPL 12
ApoC-III 8.8 Inhibitor of LPL 14
ApoC-IV 11 Regulates TG metabolism 6
ApoD 19 Binding of small hydrophobic
molecules
11
ApoE 34 Structural and functional
apolipoprotein, ligand for LDL-R
and LRP
13
ApoF 29 Inhibitor of CETP 8
ApoH 38 Binding of negatively charged
molecules
8
ApoJ 70 Binding of hydrophobic molecules,
interaction with cell receptors
11
ApoL-I 44/46 Trypanolytic factor of human serum 14




LCAT 63 Esterification of cholesterol to
cholesteryl esters
4
PON1 43 Calcium-dependent lactonase 12
PAF-AH
(LpPLA2)
53 Hydrolysis of short-chain oxidised
phospholipids
GSPx-3 22 Reduction of hydroperoxides by
glutathione
Lipid transfer proteins
PLTP 78 Conversion of HDL into larger and
smaller particles, transport of LPS
5
CETP 74 Heteroexchange of CE and TG and




SAA1 12 Major acute-phase reactant 10
SAA4 15 Minor acute-phase reactant 10
Alpha-2-HS-
glycoprotein
39 Negative acute-phase reactant 9
(continued)
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(e.g. extreme pH and ionic strength involved in immunoaffinity separation). Thus,
proteomics of apoA-I-containing fractions isolated from human plasma by a
non-denaturing approach of fast protein liquid chromatography (FPLC) reveal the
presence of up to 115 individual proteins per fraction, only up to 32 of which were
identified as HDL-associated proteins in ultracentrifugally isolated HDL (Collins
et al. 2010). Indeed, co-elution with HDL of plasma proteins of matching size is
inevitable in FPLC-based separation; the presence of a particular protein across a
range of HDL-containing fractions of different size isolated by FPLC on the basis of
their association with phospholipid would however suggest that such a protein is
indeed associated with HDL (Gordon et al. 2010). Remarkably, several of the most
abundant plasma proteins, including albumin, haptoglobin and alpha-2-macroglob-
ulin, are indeed present in all apoA-I-containing fractions isolated by FPLC (Col-
lins et al. 2010), suggesting their partial association with HDL by a non-specific,
low-affinity binding.
Table 2 (continued)
Protein Mr, kDa Major function
Number of proteomic












52 Inhibitor of serine proteinases 11

















Hemopexin 52 Heme binding and transport 8
aOut of total of 14 proteomic studies according to Shah et al. (2013). Only proteins detected in
more than 50 % of the studies are listed, together with seven others previously known to be
associated with HDL (apoC-IV, apoH, LCAT, PAF-AH, GSPx-3, PLTP, CETP)
CE cholesteryl ester, CETP cholesteryl ester transfer protein, GSPx-3 glutathione selenoperoxidase
3,Hrp haptoglobin-related protein, LDL-R LDL receptor, LCAT lecithin/cholesterol acyltransferase,
LPL lipoprotein lipase, LpPLA2 lipoprotein-associated phospholipase A2, LRP LDL receptor-related
protein, PAF-AH platelet-activating factor acetyl hydrolase, PL phospholipid, PLTP phospholipid
transfer protein, PON1 paraoxonase 1, SAA serum amuloid A, TG triglyceride
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Apolipoproteins
Apolipoprotein A-I is the major structural and functional HDL protein which
accounts for approximately 70 % of total HDL protein. Almost all HDL particles
are believed to contain apoA-I (Asztalos and Schaefer 2003a, b; Schaefer
et al. 2010). Major functions of apoA-I involve interaction with cellular receptors,
activation of lecithin/cholesterol acyltransferase (LCAT) and endowing HDL with
multiple anti-atherogenic activities. Circulating apoA-I represents a typical amphi-
pathic protein that lacks glycosylation or disulfide linkages and contains eight
alpha-helical amphipathic domains of 22 amino acids and two repeats of
11 amino acids. As a consequence, apoA-I binds avidly to lipids and possesses
potent detergent-like properties. ApoA-I readily moves between lipoprotein
particles and is also found in chylomicrons and very low-density lipoprotein
(VLDL). As for many plasma apolipoproteins, the main sites for apoA-I synthesis
and secretion are the liver and small intestine.
ApoA-II is the second major HDL apolipoprotein which represents approxi-
mately 15–20 % of total HDL protein. About a half of HDL particles may contain
apoA-II (Duriez and Fruchart 1999). ApoA-II is more hydrophobic than apoA-I and
circulates as a homodimer composed of two identical polypeptide chains (Shimano
2009; Puppione et al. 2010) connected by a disulfide bridge at position 6 (Brewer
et al. 1972). ApoA-II equally forms heterodimers with other cysteine-containing
apolipoproteins (Hennessy et al. 1997) and is predominantly synthesised in the liver
but also in the intestine (Gordon et al. 1983).
ApoA-IV, an O-linked glycoprotein, is the most hydrophilic apolipoprotein
which readily exchanges between lipoproteins and also circulates in a free form.
ApoA-IV contains thirteen 22-amino acid tandem repeats, nine of which are highly
alpha-helical; many of these helices are amphipathic and may serve as lipid-binding
domains. In man, apoA-IV is synthesised in the intestine and is secreted into the
circulation with chylomicrons.
ApoCs form a family of small exchangeable apolipoproteins primarily
synthesised in the liver. ApoC-I is the smallest apolipoprotein which associates
with both HDL and VLDL and can readily exchange between them. ApoC-I carries
a strong positive charge and can thereby bind free fatty acids and modulate activities
of several proteins involved in HDL metabolism. Thus, apoC-I is involved in the
activation of LCAT and inhibition of hepatic lipase and cholesteryl ester transfer
protein (CETP). ApoC-II functions as an activator of several triacylglycerol lipases
and is associated with HDL and VLDL.ApoC-III is predominantly present in VLDL
with small amounts found in HDL. The protein inhibits lipoprotein lipase (LPL) and
hepatic lipase and decreases the uptake of chylomicrons by hepatic cells. ApoC-IV
induces hypertriglyceridemia when overexpressed in mice (Allan and Taylor 1996;
Kim et al. 2008). In normolipidemic plasma, greater than 80 % of the protein resides
in VLDL, with most of the remainder in HDL. The HDL content of apoC-IV is much
lower as compared to the other apoC proteins.
ApoD is a glycoprotein mainly associated with HDL (McConathy and
Alaupovic 1973). The protein is expressed in many tissues, including liver and
intestine. ApoD does not possess a typical apolipoprotein structure and belongs to
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the lipocalin family which also includes retinol-binding protein, lactoglobulin and
uteroglobulin. Lipocalins are small lipid transfer proteins with a limited amino acid
sequence identity but with a common tertiary structure. Lipocalins share a structur-
ally conserved beta-barrel fold, which in many lipocalins bind hydrophobic ligands.
As a result, apoD transports small hydrophobic ligands, with a high affinity for
arachidonic acid (Rassart et al. 2000). In plasma, apoD forms disulfide-linked
homodimers and heterodimers with apoA-II.
ApoE is a key structural and functional glycoprotein component of HDL despite
its much lower content in HDL particles as compared to apoA-I (Utermann 1975).
The major fraction of circulating apoE is carried by triglyceride-containing
lipoproteins where it serves as a ligand for apoB/apoE receptors and ensures
lipoprotein binding to cell-surface glycosaminoglycans. Similar to apoA-I and
apoA-II, apoE contains eight amphipathic alpha-helical repeats and displays
detergent-like properties towards phospholipids (Lund-Katz and Phillips 2010).
ApoE is synthesised in multiple tissues and cell types, including liver, endocrine
tissues, central nervous system and macrophages.
ApoF is a sialoglycoprotein present in human HDL and low-density lipoprotein
(LDL) (Olofsson et al. 1978), also known as lipid transfer inhibitor protein (LTIP)
as a consequence of its ability to inhibit CETP. ApoF is synthesised in the liver and
heavily glycosylated with both O- and N-linked sugar groups. Such glycosylation
renders the protein highly acidic and results in a molecular mass some 40 % greater
than predicted (Lagor et al. 2009).
ApoH, also known as beta-2-glycoprotein 1, is a multifunctional N- and
O-glycosylated protein. ApoH binds to various kinds of negatively charged
molecules, primarily to cardiolipin, and may prevent activation of the intrinsic
blood coagulation cascade by binding to phospholipids on the surface of damaged
cells. Such binding properties are ensured by a positively charged domain. ApoH
regulates platelet aggregation and is expressed by the liver.
ApoJ (also called clusterin and complement-associated protein SP-40,40) is an
antiparallel disulfide-linked heterodimeric glycoprotein. Human apoJ consists of
two subunits designated alpha (34–36 kDa) and beta (36–39 kDa) which share
limited homology (de Silva et al. 1990a, b) and are linked by five disulfide bonds.
The distinct structure of apoJ allows binding of both a wide spectrum of hydropho-
bic molecules on the one hand and of specific cell-surface receptors on the other.
ApoL-I is a key component of the trypanolytic factor of human serum associated
with HDL (Duchateau et al. 1997). ApoL-I possesses a glycosylation site and shares
structural and functional similarities with intracellular apoptosis-regulating
proteins of the Bcl-2 family. ApoL-I displays high affinity for phosphatidic acid
and cardiolipin (Zhaorigetu et al. 2008) and is expressed in pancreas, lung, prostate,
liver, placenta and spleen.
ApoM is an apolipoprotein found mainly in HDL (Axler et al. 2007) which
possesses an eight stranded antiparallel beta-barrel lipocalin fold and a hydrophobic
pocket that ensures binding of small hydrophobic molecules, primarily sphingo-
sine-1-phosphate (S1P) (Ahnstrom et al. 2007; Christoffersen et al. 2011). ApoM
reveals 19 % homology with apoD, another apolipoprotein member of the lipocalin
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family (Sevvana et al. 2009), and is synthesised in the liver and kidney. The binding
of apoM to lipoproteins is assured by its hydrophobic N-terminal signal peptide
which is retained on secreted apoM, a phenomenon atypical for plasma
apolipoproteins (Axler et al. 2008; Christoffersen et al. 2008; Dahlback and Nielsen
2009).
ApoO, a minor HDL component expressed in several human tissues (Lamant
et al. 2006), is present in HDL, LDL and VLDL, belongs to the proteoglycan family
and contains chondroitin sulphate chains, a unique feature distinguishing it from
other apolipoproteins. The physiological function of apoO remains unknown
(Nijstad et al. 2011).
Minor apolipoprotein components isolated within the density range of HDL are
also exemplified by apoB and apo(a), which reflect the presence of lipoprotein
(a) and result from overlap in the hydrated densities of large, light HDL2 and
lipoprotein (a) (Davidson et al. 2009).
Enzymes
LCAT catalyses the esterification of cholesterol to cholesteryl esters in plasma
lipoproteins, primarily in HDL but also in apoB-containing particles. Approxi-
mately 75 % of plasma LCAT activity is associated with HDL. In plasma, LCAT
is closely associated with apoD, which frequently co-purify (Holmquist 2002). The
LCAT gene is primarily expressed in the liver and, to a lesser extent, in the brain
and testes. The LCAT protein is heavily N-glycosylated. The tertiary structure of
LCAT is maintained by two disulfide bridges and involves an active site covered by
a lid (Rousset et al. 2009). LCAT contains two free cysteine residues at positions
31 and 184.
Human paraoxonases (PON) are calcium-dependent lactonases PON1, PON2
and PON3 (Goswami et al. 2009). In the circulation, PON1 is almost exclusively
associated with HDL; such association is mediated by HDL surface phospholipids
and requires the hydrophobic leader sequence retained in the secreted PON1.
Human PON1 is largely synthesised in the liver but also in the kidney and colon
(Mackness et al. 2010). Hydrolysis of homocysteine thiolactone has been proposed
to represent a major physiologic function of PON1 (Jakubowski 2000). The name
“PON” however reflects the ability of PON1 to hydrolyse the organophosphate
substrate paraoxone together with other organophosphate substrates and aromatic
carboxylic acid esters. Catalytic activities of the enzyme involve reversible binding
to the substrate as the first step of hydrolytic cleavage. PON1 is structurally
organised as a six-bladed beta-propeller, with each blade consisting of four beta-
sheets (Harel et al. 2004). Two calcium atoms needed for the stabilisation of the
structure and the catalytic activity of the enzyme are located in the central tunnel of
the enzyme. Three helices, located at the top of the propeller, are involved in the
anchoring of PON1 to HDL. The enzyme is N-glycosylated and may contain a
disulfide bond. PON2, another member of the PON family, is an intracellular
enzyme not detectable in serum despite its expression in many tissues, including
the brain, liver, kidney and testis. The enzyme hydrolyses organophosphate
substrates and aromatic carboxylic acid esters. PON3 possesses properties which
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are similar to those of PON1, such as requirement for calcium, N-glycosylation,
secretion in the circulation with retained signal peptide and association with HDL.
PON3 displays potent lactonase, limited arylesterase and no PON activities and is
predominantly expressed in the liver.
Platelet-activating factor acetyl hydrolase (PAF-AH) equally termed
lipoprotein-associated phospholipase A2 (LpPLA2) is a calcium-independent,
N-glycosylated enzyme, which degrades PAF by hydrolysing the sn-2 ester bond
to yield biologically inactive lyso-PAF (Mallat et al. 2010). The enzyme cleaves
phospholipid substrates with a short residue at the sn-2 position and can therefore
hydrolyse proinflammatory oxidised short-chain phospholipids; however, it is inac-
tive against long-chain non-oxidised phospholipids. PAF-AH is synthesised
throughout the brain, white adipose tissue and placenta. Macrophages represent
the most important source of the circulating enzyme (McIntyre et al. 2009). Plasma
PAF-AH circulates in association with LDL and HDL particles, with the majority of
the enzyme bound to small, dense LDL and to lipoprotein (a) (Tselepis et al. 1995).
The crystal structure of PAF-AH reveals a typical lipase alpha/beta-hydrolase fold
and a catalytic triad (Samanta and Bahnson 2008). The active site is close to the
lipoprotein surface and at the same time accessible to the aqueous phase. Two
clusters of hydrophobic residues build a lipid-binding domain ensuring association
with lipoproteins.
Plasma glutathione selenoperoxidase 3 (GSPx-3), also called glutathione per-
oxidase 3, is distinct from two other members of the GSPx family termed GSPx-1
and GSPx-2 which represent erythrocyte and liver cytosolic enzymes. All GSPx
enzymes protect biomolecules from oxidative damage by catalysing the reduction
of hydrogen peroxide, lipid peroxides and organic hydroperoxide, in a reaction
involving glutathione. Human GSPx-3 is a homotetrameric protein containing
selenium as a selenocysteine residue at position 73. Human GSPx-3 is synthesised
in the liver, kidney, heart, lung, breast and placenta. In plasma, GSPx-3 is exclu-
sively associated with HDL (Chen et al. 2000).
Lipid Transfer Proteins
Phospholipid transfer protein (PLTP) belongs to the bactericidal permeability-
increasing protein (BPI)/lipopolysaccharide (LPS)-binding protein (LBP)/Plunc
superfamily of proteins. PLTP is synthesised in the placenta, pancreas, lung,
kidney, heart, liver, skeletal muscle and brain. In the circulation, PLTP is primarily
associated with HDL and converts it into larger and smaller particles. PLTP also
plays a role in extracellular phospholipid transport and can bind LPS. The protein
contains multiple glycosylation sites and is stabilised by a disulfide bond. PLTP is a
positive acute-phase reactant with a potential role in the innate immune system.
CETP equally belongs to the BPI/LBP/Plunc superfamily and contains multiple
N-glycosylation sites. It is primarily expressed by the liver and adipose tissue. In
the circulation, CETP shuttles between HDL and apoB-containing lipoproteins and
facilitates the bidirectional transfer of cholesteryl esters and triglycerides between
them. The structure of CETP includes a hydrophobic tunnel filled with two
cholesteryl ester molecules and plugged by an amphiphilic phosphatidylcholine
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(PC) molecule at each end (Qiu et al. 2007). Such interactions additionally endow
CETP with PC transfer activity. CETP may also undergo conformational changes to
accommodate lipoprotein particles of different sizes (Qiu et al. 2007).
Acute-Phase Response Proteins
Positive acute-phase response proteins, whose plasma concentrations are markedly
elevated by acute inflammation, form a large family of HDL-associated proteins
(Vaisar et al. 2007; Heinecke 2009). Under normal conditions, the content of such
proteins in HDL is however much lower as compared to apolipoproteins. On the
other hand, plasma levels of several HDL apolipoproteins, such as apoA-I and
apoA-IV, are reduced during the acute-phase response (Navab et al. 2004); such
proteins can therefore be considered as negative acute-phase response proteins.
Serum amyloid A (SAA) proteins, major acute-phase reactants, are secreted
during the acute phase of the inflammatory response. In humans, three SAA
isoforms, SAA1, SAA2 and SAA4, are produced predominantly by the liver.
Hepatic expression of SAA1 and SAA2 in the liver is induced during the acute-
phase reaction, resulting in increase in their circulating levels by as much as 1,000-
fold from basal concentrations of about 1–5 mg/l (Khovidhunkit et al. 2004). By
contrast, SAA4 is expressed constitutively in the liver and is therefore termed
constitutive SAA. SAA1, the major member of this family, is predominantly carried
by HDL in human, rabbit and murine plasma (Hoffman and Benditt 1982; Marhaug
et al. 1982; Cabana et al. 1996). In the circulation, SAA1 does not exist in a free
form and associates with non-HDL lipoproteins in the absence of HDL (Cabana
et al. 2004).
LBP is an acute-phase glycoprotein capable of binding the lipid A moiety of
LPS of Gram-negative bacteria and facilitating LPS diffusion (Wurfel et al. 1994).
LBP/LPS complexes appear to interact with the CD14 receptor to enhance cellular
responses to LPS. LBP also binds phospholipids, thereby acting as a lipid exchange
protein (Yu et al. 1997), and belongs to the same BPI/LBP/Plunc protein superfam-
ily as PLTP and CETP.
Fibrinogen is a common acute-phase protein and a cofactor in platelet aggrega-
tion synthesised by the liver, which is converted by thrombin into fibrin during
blood coagulation. Fibrinogen is a disulfide-linked heterohexamer which contains
two sets of three non-identical chains (alpha, beta and gamma).
Alpha-1-acid glycoprotein 2, equally termed orosomucoid-2, belongs to the
calycin protein superfamily which also includes lipocalins and fatty acid-binding
proteins. The protein appears to modulate activity of the immune system during the
acute-phase reaction. In plasma, the protein is N-glycosylated and stabilised by
disulfide bonds.
Alpha-2-HS-glycoprotein (fetuin-A) promotes endocytosis, possesses opsonic
properties and influences the mineral phase of bone. The protein shows affinity for
calcium and barium ions and contains two chains, A and B, which are held together
by a single disulfide bond. Alpha-2-HS-glycoprotein is synthesised in the liver and
secreted into plasma.
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Complement Components
Several complement components associate with HDL. Complement component
3 (C3) plays a central role in the activation of the complement system through both
classical and alternative activation pathways. C3 exists in a form of two chains, beta
and alpha, linked by a disulfide bond. C4 is a key component involved in the
activation of the classical pathway of the complement system, which circulates as a
disulfide-linked trimer of alpha, beta and gamma chains. C4b-binding protein
controls the classical pathway of complement activation and binds as a cofactor to
C3b/C4b inactivator, which then hydrolyses complement fragment C4b. C9 is a
pore-forming subunit of the membrane attack complex that provides an essential
contribution to the innate and adaptive immune response by forming pores in the
plasma membrane of target cells.
Vitronectin is another HDL-associated protein involved in complement regula-
tion. The protein belongs to cell-to-substrate adhesion molecules present in serum
and tissues, which interact with glycosaminoglycans and proteoglycans and can be
recognised by members of the integrin family. In complement regulation,
vitronectin serves as an inhibitor of the membrane-damaging effect of the terminal
cytolytic pathway. Vitronectin is largely expressed in the liver but also in visceral
tissue and adrenals. The presence of vitronectin in HDL raises the possibility that
certain HDL components can be derived from non-cellular sources or cells distinct
from those that synthesise apoA-I in the liver and intestine (Heinecke 2009).
Proteinase Inhibitors
A family of proteins in HDL contains serine proteinase inhibitor domains (Vaisar
et al. 2007). Serine protease inhibitors (serpins) are important regulators of
biological pathways involved in inflammation, coagulation, angiogenesis and
matrix degradation. HDL-associated serpins are exemplified by alpha-1-
antitrypsin which in the circulation is exclusively present in HDL (Karlsson
et al. 2005; Ortiz-Munoz et al. 2009). Alpha-2-antiplasmin, a serpin that inhibits
plasmin and trypsin and inactivates chymotrypsin, is another key proteinase inhibi-
tor which circulates in part associated with HDL. HDL also carries inter-alpha-
trypsin inhibitor heavy chain H4 and bikunin, two components of inter-alpha-
trypsin inhibitors consisting of three of four heavy chains selected from the groups
1 to 4 and one light chain selected from the alpha-1-microglobulin/bikunin precur-
sor or Kunitz-type protease inhibitor 2 groups. The full complex inhibits trypsin,
plasmin and lysosomal granulocytic elastase. Inter-alpha-trypsin inhibitor heavy
chain H4 is produced in the liver and is cleaved by kallikrein to yield 100 and
35 kDa fragments in plasma, and the resulting 100 kDa fragment is further
converted to a 70 kDa fragment. Bikunin is a light chain of the inter-alpha-trypsin
inhibitor, which is produced via proteolytic cleavage of the alpha-1-microglobulin/
bikunin precursor protein together with alpha-1-microglobulin and trypstatin.
Other proteolysis-related proteins which are detected on HDL include
haptoglobin-related protein (Hrp), kininogen-1, prothrombin, angiotensinogen
and procollagen C-proteinase enhancer-2 (PCPE2). Hrp contains a crippled cata-
lytic triad residue that may allow it to act as a decoy substrate to prevent proteolysis.
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Kininogen-1 (alpha-2-thiol proteinase inhibitor) plays an important role in blood
coagulation and inhibits the thrombin- and plasmin-induced aggregation of
thrombocytes. Prothrombin is a precursor of thrombin, a key serine protease of
the coagulation pathway. Angiotensinogen is a an alpha-2-globulin that is pro-
duced constitutively mainly by the liver and represents a substrate for renin whose
action forms angiotensin I. PCPE2 binds to the C-terminal propeptide of type I or II
procollagens and enhances the cleavage of the propeptide by bone morphogenetic
protein 1 (BMP-1, also termed procollagen C-proteinase).
Other Protein Components
HDL equally transports distinct proteins displaying highly specialised functions.
The metabolic purpose of such association is unclear; it might prolong the residence
time of a protein or represent a mechanism for protein conservation in the circula-
tion. For example, plasma retinol-binding protein, which delivers retinol from the
liver stores to peripheral tissues, co-isolates with HDL3 (Vaisar et al. 2007). In
plasma, the complex of retinol-binding protein and retinol interacts with
transthyretin, thereby preventing loss of retinol-binding protein by filtration
through the kidney glomeruli. As a corollary, transthyretin, a homotetrameric
thyroid hormone-binding protein, is equally present on HDL (Hortin et al. 2006;
Vaisar et al. 2007; Davidson et al. 2009). Serotransferrin, an iron-transport
glycoprotein largely produced in the liver, is also in part associated with HDL.
Hemopexin, an iron-binding protein that binds heme and transports it to the liver
for breakdown and iron recovery, equally co-isolates with HDL3 (Vaisar
et al. 2007).
HDL also carries proteins involved in the regulation of various biological
functions, such as Wnt signalling molecules, which participate in cell-to-cell
signalling (Neumann et al. 2009), and progranulin, a precursor of granulins
which play a role in inflammation, wound repair and tissue remodelling.
In addition, HDL transports lysosomal proteins, such as prenylcysteine oxidase,
which is involved in the degradation of prenylated proteins (Vaisar et al. 2007).
Other minor abundance proteins reported to be associated with HDL are albumin,
alpha-1B-glycoprotein, alpha-amylase, vitamin D-binding protein and platelet
basic protein (Vaisar et al. 2007; Davidson et al. 2009).
In addition to proteins, HDL carries a large number of small peptides in the mass
range from 1 to 5 kDa (Hortin et al. 2006). These peptides are present in HDL at low
concentrations of about 1 % of total HDL protein, with some representing
fragments of larger proteins, such as apoB, fibrinogen and transthyretin (Hortin
et al. 2006). The association of small peptides with HDL as a vehicle may represent
a pathway for peptide delivery or scavenging, in order to slow renal clearance and
proteolysis (Hortin et al. 2006).
Heterogeneity in HDL Proteins
HDL proteins are non-uniformly distributed across HDL subpopulations. Indeed,
proteomic analysis of five HDL subpopulations isolated from normolipidemic
subjects by isopycnic density gradient ultracentrifugation identifies five distinct
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patterns of distribution of individual protein components across the HDL density
subfractions (Davidson et al. 2009) (Fig. 1). The most interesting of these
distributions identifies small, dense HDL3b and 3c as particle subpopulations in
which seven proteins occur predominantly, notably apoJ, apoL-1, apoF, PON1/3,
PLTP and PAF-AH. Activities of HDL-associated enzymes (LCAT, PON1,
PAF-AH) are equally elevated in small, dense HDL3c (Kontush et al. 2003;
Kontush and Chapman 2010). The HDL3c proteome also contains apoA-I; apoA-
II; apoD; apoM; SAA 1, 2, and 4; apoC-I; apoC-II; and apoE (Davidson et al. 2009).
Consistent with these data, apoL-I (Hajduk et al. 1989), apoF (He et al. 2008; Lagor
et al. 2009), apoJ (de Silva et al. 1990a, b; Bergmeier et al. 2004), PON1 (Kontush
et al. 2003; Bergmeier et al. 2004), apoA-IV (Bisgaier et al. 1985; Ohta et al. 1985),
apoM (Wolfrum et al. 2005), apoD (Campos and McConathy 1986) and SAA1/
2 (Benditt and Eriksen 1977; Coetzee et al. 1986) are known to preferentially
co-isolate with dense HDL3. Furthermore, small, dense HDL may also represent
a preferential carrier for human CETP (Marcel et al. 1990). On the other hand,
apoE, apoC-I, apoC-II and apoC-III preferentially localise to large, light HDL2
(Schaefer et al. 1979; Cheung and Albers 1982; Schaefer and Asztalos 2007;
Davidson et al. 2009) (Fig. 1). Importantly, these associations can in part be
confirmed using an alternative approach of gel filtration subfractionation of HDL
particles (Gordon et al. 2010).
The low HDL content of the majority of these proteins of less than one copy per
HDL particle suggests internal heterogeneity of the HDL3c subfraction. This
conclusion is further consistent with the isolation of a unique particle containing
the trypanosome lytic factor apoL-I, plus apoA-I and Hrp, in the HDL3 density
range (Shiflett et al. 2005).
In a similar fashion, apoF co-isolates with dense HDL (mean density, 1.134 g/ml)
which also contains apoA-I, apoC-II, apoE, apoJ, apoD and PON1 (He et al. 2008).
Complexes formed by PON1 with human phosphate-binding protein and apoJ
represent another example of protein–protein interactions occurring within the
HDL particle spectrum (Vaisar 2009).
Specific protein–protein interactions should thus drive the formation of such
complexes in the circulation. In support of such a mechanism, PLTP in human
plasma resides on lipid-poor complexes dominated by apoJ and proteins implicated
in host defence and inflammation (Cheung et al. 2010).
In addition and as mentioned above (Sect. 1), immunoaffinity technique allows
separating HDL particles containing only apoA-I (LpA-I) from those containing
both apoA-I and apoA-II (LpA-I:A-II) (Duriez and Fruchart 1999). ApoA-I is
typically distributed approximately equally between LpA-I and LpA-I:A-II,
whereas virtually all apoA-II is in LpA-I:A-II (Duriez and Fruchart 1999). LpA-I
and LpA-I:A-II contain approximately 35 and 65 % of plasma apoA-I, respectively
(James et al. 1988). On the other hand, approximately half of HDL particles contain
apoA-II (Wroblewska et al. 2009). In addition to apoA-II, the two subclasses may
differ in their content of other proteins, as exemplified by PON1 which preferably
associates with LpA-I (Moren et al. 2008).














































































Fig. 1 Abundance pattern of proteins across healthy normolipidemic HDL subpopulations. Class
A: exclusively present in small, dense HDL3b and 3c. Class B: enriched in small, dense HDL3b
and 3c. Class C: equally abundant across HDL subpopulations. Class D: enriched in large, light
HDL2b and 2a. Class E: exclusively present in large, light HDL2b and 2a [modified from
(Davidson et al. 2009)]
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LpA-I particles can be further subfractionated according to size. The number of
apoA-I molecules in such subpopulations is increased from two to three to four with
an increase in the particle size (Gauthamadasa et al. 2010). On the other hand, the
entire population of LpA-I:A-II demonstrates the presence of only two apoA-I
molecules per particle, while the number of apoA-II molecules varies from one
dimeric apoA-II to two and then to three. Upon compositional analyses of individ-
ual subpopulations, LpA-I:A-II exhibits comparable proportions for major lipid
classes across subfractions, while LpA-I components show significant variability
(Gauthamadasa et al. 2010).
Another important subpopulation of HDL particles is formed by apoE-
containing HDL. The presence of apoE facilitates expansion of the lipid core as a
result of the accumulation of cholesteryl ester, with formation of large, lipid-rich
HDL; these particles represent an excellent ligand for the LDL receptor (Hatters
et al. 2006).
The diversity of molecules which bind to HDL suggests that the lipoprotein can
serve as a versatile adsorptive surface for proteins and peptides to form complexes
playing roles not only in lipid metabolism but equally in acute-phase response,
innate immune response, complement activation, plaque stability and proteolysis
inhibition (Heinecke 2009). As the abundance of the most of HDL-associated
proteins is below 1 mol/mol HDL (i.e. less than 1 copy per HDL particle), it
remains however unclear as to how they are distributed among minor HDL
subpopulations of potentially distinct origin and function. Specific proteins may
therefore be confined to distinct HDL subpopulations of distinct origin and func-
tion, which are differentially distributed across the HDL particle spectrum
(Davidson et al. 2009). The HDL fraction as a whole therefore appears to represent
“a collection of individualised species with distinct functionalities that happen to
have similar physicochemical properties” (Shah et al. 2013) and are primarily
defined by specific protein–protein interactions facilitated by the presence of
phospholipid, rather than “a transient ensemble of randomly exchanging proteins”
(Gordon et al. 2013; Shah et al. 2013).
2.1.2 Protein Isoforms, Translational and Posttranslational
Modifications
In line with the evolvement of proteomics, a large number of proteins have been
identified in HDL as described in the previous section (Vaisar et al. 2007). In
addition, most proteins are expressed as different isoforms due to co- and posttrans-
lational modifications (Karlsson et al. 2005; Candiano et al. 2008). This makes the
proteome of HDL both complex and dynamic, which most likely result in various
HDL particles with different protein composition in respect to the environment.
Common posttranslational modifications (PTMs) such as glycosylations, truncations
and phosphorylations change the charge and/or the size of the protein, which can be
utilised for separation of the isoforms, andmodern mass spectrometric techniques can
be used to detect, characterise and nowadays also measure even small mass
differences in proteins. However, although isoforms of major HDL proteins have
been known for decades (Zannis et al. 1980; Hussain and Zannis 1990), surprisingly
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little is still known on how these variations of the HDL proteome affect the function-
ality. The following is a comprehensive review of isoforms patterns described in
common human HDL apolipoproteins, apoA-I, apoA-II, apoC-III and SAA, and their
possible functional relevance.
ApoA-I (pI 5.3/28 kDa, accession no. P02647) is normally found as different
charge isoforms; besides the major isoform (70–75 % of total apoA-I) and the
slightly more basic pre-apoA-I (5–10 % of total apoA-I), also two more acidic
isoforms are generally detected by isoelectric focusing (IEF) and 2D gel electro-
phoresis (2-DE) (Contiero et al. 1997; Karlsson et al. 2005). The nature of these
acidic isoforms is still unclear. An early report suggested deamidation of Gln or Asn
residues, resulting in a +1 charge shift, which could be formed during the analytical
procedure (Ghiselli et al. 1985). At the same time, a few reports indicated the
importance of acidic apoA-I in vivo; increased levels of acidic apoA-I, while
decreased levels of the major form, were found in LDL from obese subjects,
especially in women (Karlsson et al. 2009). Also, higher degree of deamidated
apoA-I has been shown in relation to diabetes (Jaleel et al. 2010) and acidic apoA-I
may be more vulnerable to methionine oxidation (Fernandez-Irigoyen et al. 2005).
In 2-DE HDL protein patterns also 30–35 kDa variants of apoA-I are usually
detected (Karlsson et al. 2005). Although mass spectrometry (MS) analysis was
in agreement with O-glycosylation at two potential sites (Thr78 or Thr92), this has
not been confirmed by others, and it is generally regarded that apoA-I is not
N-linked or O-linked glycosylated. In contrast, non-enzymatically glycation of
apoA-I has been found in association to diabetes and believed to affect apoA-I
functions, such as LCAT activation (Fievet et al. 1995; Nobecourt et al. 2007; Park
et al. 2010).
Another potentially important PTM of apoA-I is truncation. During atheroscle-
rotic inflammation, apoA-I might be N-terminally and C-terminally truncated by
released proteases. Specific cleavage sites at Tyr42, Phe57, Tyr216 and Phe253 for
chymase have been identified that in reconstituted HDL reduces its ability to
promote cholesterol efflux (Lee et al. 2003; Usami et al. 2013). Low amounts of
C-terminally truncated apoA-I can be measured in normal serum (Usami
et al. 2011) and fragmented apoA-I is a feature in plasma from children with
nephrotic syndrome, a condition linked to higher risk of atherosclerosis (Santucci
et al. 2011). Truncation has also been implicated in apoA-I dimerisation as studied
in apoA-I Milano (R197C) and apoA-I Paris (R175C) (Calabresi et al. 2001; Favari
et al. 2007; Gursky et al. 2013). Notably, apoA-I with an apparent molecular mass
of 50 kDa, consistent with dimeric apoA-I, has been found in patients with
myocardial infarction (Majek et al. 2011) but also appears to be present in HDL
from healthy individuals (Karlsson et al. 2005). Finally, oxidatively modified
apoA-I have been extensively studied during the recent years by the help of MS
techniques, as described in detail in several reviews elsewhere (e.g. Nicholls and
Hazen 2009; Shao 2012). It has been proposed that myeloperoxidase-mediated
inflammation results in oxidation of apoA-I. Specific sites have been identified
for methionine oxidation, for nitrated/chlorinated tyrosines and for lysines modified
by reactive carbonyls. Importantly, the modifications have been coupled to
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functional impairment in apoA-I activity such as ABCA1-mediated cholesterol
efflux and are linked to cardiovascular disease.
ApoA-II (pI 5.0/8.7 kDa, accession no. P02652) is mostly found as two isoforms
in HDL that differ slightly according to pI and molecular mass, probably due to
O-linked glycosylation/sialylation (Karlsson et al. 2005; Halim et al. 2013). Similar
to apoA-I, the protein is produced as a more basic pro-form (Hussain and Zannis
1990). In contrast, apoA-II appears to be quickly processed to the mature form, as
the pro-form is not found in the circulation. In addition to glycosylation, phosphor-
ylation at Ser68, C-terminal truncated variants (des-Gln and des-Thr-Gln) and a
cysteinylated variant has been detected in the circulation (Jin and Manabe 2005;
Nelsestuen et al. 2008; Zhou et al. 2009). ApoA-II also forms a homodimer at
Cys29 that is abundant in plasma (Gillard et al. 2005; Jin and Manabe 2005).
Overall, more than ten different variants of apoA-II are present in humans, but
the physiological relevance of this heterogeneity is unclear. However, sialylated
apoA-II appear to be selectively associated to HDL3 (Remaley et al. 1993; Karlsson
et al. 2005), and elevated levels of modified apoA-II isoforms have been linked to
premature delivery in pregnant women (Flood-Nichols et al. 2013).
ApoC-III (pI 4.7/8.8 kDa, accession no. P02656) is generally found as three
charge isoforms depending on O-linked glycosylation (GalGalNAc) at Thr94 with
or without sialylation; disialylated apoC-III2, monosialylated apoCIII1 and
non-sialylated apoC-III0 (Karlsson et al. 2005; Bruneel et al. 2008). An early report
showed that glycosylation is not necessary for apoC-III secretion and does not
affect its relative affinity to different lipoprotein particles (Roghani and Zannis
1988), and, as judged by gel electrophoresis and MS analysis of HDL and plasma,
the non-sialylated variant is least abundant, usually less than 5 % of total apoC-III
in normal individuals (Wopereis et al. 2003; Bruneel et al. 2008; Mazur et al. 2010;
Holleboom et al. 2011). In addition to glycosylation, apoC-III can also be
C-terminal truncated (des-Ala and des-Ala-Ala), which further increases the num-
ber of isoforms (Bondarenko et al. 1999; Jin and Manabe 2005; Nicolardi
et al. 2013a). Interestingly, novel results strongly suggest that glycosylation of
apoC-III is an important event in the regulation of lipid metabolism (Holleboom
et al. 2011; Baenziger 2012). Thus, apoC-III is exclusively glycosylated by GalNAc
transferase 2 (GALNT2) (Holleboom et al. 2011; Schjoldager et al. 2012), and
heterozygotes with a loss-of-function mutation in GALNT2 present with an altered
apoC-III isoform pattern with more of the non-sialylated variant and less of the
monosialylated variant, while the total apoC-III plasma concentration was about the
same as compared to wild-type controls (Holleboom et al. 2011). This is then linked
to reduced inhibition of lipoprotein lipase and improved triglyceride clearance. In
line, the production rate of apoC-III1 and -III2 is more strongly correlated with
plasma triglyceride levels than apoC-III0 (Mauger et al. 2006), increased apoC-III1/
apoC-III0 ratio has been found in diabetic subjects (Jian et al. 2013), and HDL3
from subjects with low HDL-C is characterised by higher levels of monosialylated
apoC-III than subjects with high HDL-C (Mazur et al. 2010). The evaluation of
apoC-III isoforms is complicated by the fact that apoC-III0 can be separated into a
non-glycosylated form and glycosylated but non-sialylated forms (Bruneel
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et al. 2008; Holleboom et al. 2011; Nicolardi et al. 2013a). Moreover, a recent MS
study of 96 serum samples showed that 30 % of the individuals displayed an apoC-
III pattern with additional glycosylated variants, characterised by fucosylation
(Nicolardi et al. 2013b). The relevance of these glycosylated non-sialylated variants
of apoC-III, as of the C-terminal truncated forms, is yet unclear, but may explain
somewhat contradictory results showing higher relative levels of non- and less-
sialylated apoC-III in obese subjects than in lean subjects (Harvey et al. 2009;
Karlsson et al. 2009), although obesity is generally associated with high triglyceride
levels.
SAA exists in a form of SAA1 (pI 5.9/11.7 kDa, accession no. P0DJI8) and
SAA2 (pI 8.3/11.6 kDa, accession no. P0DJI9). The two proteins display about
93 % sequence homology, and depending on natural variation in alleles, SAA1 is
separated into five isoforms, SAA1.1 to SAA1.5, and SAA2 is separated into two
isoforms SAA2.1 and SAA2.2 (often also denoted as alpha, beta, etc.), with one to
three amino acid difference between the isoforms. In addition, both N-terminal and
C-terminal truncated variants of SAA1/SAA2 are detected in serum (Ducret
et al. 1996; Kiernan et al. 2003; de Seny et al. 2008). By using a combined 2-DE/
MS and SELDI-TOF approach, eight isoforms were identified in HDL after LPS
infusion in healthy individuals; besides native SAA1.1 and SAA2.1, N-terminal
truncations (des-R, -RS and -RSFF) of each variant were also found (Levels
et al. 2011). Interestingly, a subgroup, based on HDL protein profile, characterised
by elevated antioxidative PON1 activity showed a delayed response of SAA to LPS
in particular for the most truncated (des-RSFF) variants. Otherwise, very little is
known about differential physiological relevance of the SAA isoforms. However,
SAA2.1 but not SAA1.1 has been shown to promote cholesterol efflux from
macrophages (Kisilevsky and Tam 2003). Today, contradictory results make it
unclear whether the increased level of SAA in inflammation, believed to replace
apoA-I in HDL, actually is a mechanism in atherosclerosis or merely is a marker for
inflammation (de Beer et al. 2010; Chiba et al. 2011; Kisilevsky and Manley 2012).
Future differential quantitative MS analysis of the highly homologous SAA
isoforms such as described by Sung et al. (2012) may resolve this controversy.
Sensitive MS techniques have revealed a large number of proteins associated to
HDL. Most of them are also expressed as different isoforms depending on transla-
tional and posttranslational modifications. This leads to a need to develop
MS-based methods for specific and reliable quantification of protein isoforms.
With appropriate standards, measurements can be performed with low coefficient
of variation and with a specificity superior to, e.g. immunoassays. Consequently,
such applications in the field of HDL are being presented by using, e.g. multiple
reaction monitoring and top-down proteomics with high-resolution MS (Mazur
et al. 2010; Sung et al. 2012). Another interesting and fairly simple approach is to
use ratio determinations, e.g. modified/native protein expression (Nelsestuen
et al. 2008). As these measures are concentration-independent, they bear a potential
to reduce individual variations. Furthermore, such MS approaches are not only
useful for PTMs but also of value to understand the impact of protein variations
caused by genetic polymorphism. For example, a recent study of heterozygotes
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with an apoA-I mutation (K131Del) showed that, in contrast to what could be
expected, the mutant protein was more abundantly expressed in HDL than the
native protein (Ljunggren et al. 2013). Herein four HDL proteins that are all
expressed as different isoforms have been discussed: two (apoA-I and apoC-III)
in which PTMs have been shown to be important for lipid metabolism and two
(apoA-II and SAA) in which the role of PTMs is still unclear. In light of the vital
importance of carboxylations and truncations in the processes of haemostasis,
which also involves other PTMs such as phosphorylation, hydroxylation, glycosyl-
ation and sulphation, it appears highly unlikely that the diversity in the “HDLome”
would not be relevant for lipid metabolism and cardiovascular disease. Therefore,
characterisation of PTMs is probably one of the most challenging but also one of the
most important tasks in order to understand the complex function of HDL.
2.2 Lipidome
The real power of lipidomic technologies involving mass spectrometry results from
their ability to provide quantitative data on individual molecular species of lipids
and on low-abundance lipid molecules. The pioneering study of Wiesner and
colleagues published in 2009 (Wiesner et al. 2009) provided reference values for
the lipidome of HDL isolated from healthy normolipidemic controls by FPLC. In an
attempt to further characterise HDL composition and address its inherent heteroge-
neity, we recently reported the phospho- and sphingolipidome of five major HDL
subpopulations isolated from healthy normolipidemic subjects (Camont
et al. 2013).
2.2.1 Phospholipids
Phosphatidylcholine is the principal plasma phospholipid that accounts for 32–
35 mol % of total lipids in HDL (Wiesner et al. 2009) (Table 3). PC is a structural
lipid, consistent with its even distribution across HDL subpopulations (Fig. 2).
Major molecular species of PC are represented by the 16:0/18:2, 18:0/18;2 and
16:0/20:4 species (Lhomme et al. 2012). As compared to other lipoproteins, HDL is
enriched in PC containing polyunsaturated fatty acid moieties (Wiesner et al. 2009).
LysoPC is an important phospholipid subclass in HDL (1.4–8.1 mol % of total
lipids; Table 3). It is derived from the regulated degradation of PC by
phospholipases, including LCAT, consistent with the preferential association of
the latter with HDL particles (Kontush et al. 2007). More specifically, LCAT was
reported earlier to associate mainly with small, dense HDL particles, which are also
enriched in lysoPC by approximately twofold as compared to large, light HDL
(Camont et al. 2013) (Fig. 2). LysoPC is also produced by the hydrolytic action of
Lp-PLA2 on oxidised PC or by secreted PLA2 under pro-atherogenic conditions,
such as oxidative stress and inflammation, and constitutes therefore a potential
biomarker of inflammation. Major molecular species of HDL lysoPC contain
saturated fatty acid moieties of predominantly 16 and 18 carbon atoms, reflecting
LCAT preference for 16 and 18 carbon atom long PCs (Lhomme et al. 2012). As
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considerable amounts of serum lysoPC are also associated with albumin (Wiesner
et al. 2009), HDL contamination by the both compounds is typical for FPLC
isolation. However, in HDL isolated by isopycnic density gradient ultracentrifuga-
tion, lysoPC content in HDL is two- to tenfold lower (Camont et al. 2013; Stahlman
et al. 2013).
Phosphatidylethanolamine (PE) is moderately abundant in HDL (0.7–
0.9 mol % of total lipids; Table 3), and its content tends to increase with increasing
HDL hydrated density (Wiesner et al. 2009; Camont et al. 2013) (Fig. 2). PE
principal molecular species are represented by the 36:2 and 38:4 fatty acid residues
in HDL (Kontush et al. 2007).
Table 3 Major components of the HDL lipidome


























Free fatty acids 16:0, 18:0, 18:1a
Isoprostane-containing PC ND (IPGE2/D2-PC (36:4))a
Data are shown for HDL obtained from normolipidemic healthy subjects according to Deguchi
et al. (2000), Kontush et al. (2007), Wiesner et al. (2009), Camont et al. (2013), Stahlman
et al. (2013), Pruzanski et al. (2000), Sattler et al. (2010), Argraves et al. (2011)
SPC sphingosylphosphorylcholine, S1P sphingosine-1-phosphate, IPGE2 isoprostaglandin E2
a no quantitative data available, major molecular species identified
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Plasmalogens contain a vinyl ether-linked fatty acid essential for their specific
antioxidative properties (Maeba and Ueta 2003). PC-plasmalogens are the most
abundant species in HDL (2.2–3.5 mol %) but represent less than 10 % of total PC
(Stahlman et al. 2013). On the contrary, PE-plasmalogens and PE are equally
































































Highly enriched in dense HDL3
Enriched in dense HDL3
Equally abundant
Enriched in light HDL2
Highly enriched in light HDL2
Fig. 2 Abundance pattern of lipids across healthy normolipidemic HDL subpopulations. Class A:
highly enriched in small, dense HDL3b and 3c (>1.5-fold relative to HDL2b). Class B: enriched in
small, dense HDL3b and 3c (1.2–1.5-fold relative to HDL2b). Class C: equally abundant across
HDL subpopulations (<1.2-fold variations between HDL2b and HDL3b+ 3c). Class D: enriched
in large, light HDL2b (1.2–1.5-fold relative to HDL3b + 3c). Class E: highly enriched in large,
light HDL2b (>1.5-fold relative to HDL3b + 3c). S1P, sphingosine-1-phosphate
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mainly polyunsaturated species: 38:5 and 36:2 in PC-plasmalogens (Stahlman
et al. 2013) and 18:0/20:4 and 16:0/20:4 in PE-plasmalogens (Wiesner et al. 2009).
Phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerol
(PG), phosphatidic acid (PA) and cardiolipin are negatively charged
phospholipids present in HDL (Table 3) which may significantly impact on its net
surface charge (Rosenson et al. 2011; Lhomme et al. 2012). The content of these
lipids can thereby modulate lipoprotein interactions with lipases, membrane proteins,
extracellular matrix and other protein components; indeed, such interactions are
largely charge-dependent.
PI, similarly to PE, is moderately abundant in HDL (0.5–0.8 mol %; Table 3) and
tends to be enriched in small, dense HDL (Fig. 2). Major molecular species of PI in
HDL include the 18:0/20:3 and 18:0/20:4 species (Lee et al. 2010).
PS is a minor negatively charged phospholipid component of HDL (0.016–
0.030 mol %; Table 3). This phospholipid was very recently reported to be highly
enriched (34-fold) in the small, dense HDL3c subpopulation relative to large, light
HDL2 (Fig. 2) (Camont et al. 2013) as well as in small discoid preβ HDL and small
nascent HDL formed by ABCA1 (up to 2.5 mol % of total lipids) (see Kontush and
Chapman 2012 for review). Interestingly, small, dense HDL also displayed potent
biological activities which correlated positively with PS content in HDL (Camont
et al. 2013). This lipid could therefore, in part, account for enhanced functionality
of HDL3c.
PA, a second messenger, is both a common metabolic precursor and an enzy-
matic product of phospholipid metabolism. This negatively charged lipid is present
in very low abundance in HDL (0.006–0.009 mol %; Table 3) but, similarly to PS, is
enriched in small, dense HDL (by more than threefold) (Camont et al. 2013)
(Table 3). This observation might reflect preferential association of PA with
apoL-I which is equally enriched in small, dense HDL (Kontush and Chapman
2012).
PG is a metabolic precursor of cardiolipin present in HDL in very low amounts
(0.004–0.006 mol %; Table 3). PG tends to be enriched in small, dense particles
(Camont et al. 2013) (Fig. 2).
Cardiolipin is a minor anionic phospholipid present in trace amounts in HDL
(0.08–0.2 mol %; Table 3). This lipid with potent anticoagulant properties may
contribute to the effects of lipoproteins on coagulation and platelet aggregation
(Deguchi et al. 2000).
Together, these data indicate that although negatively charged lipids represent
minor HDL constituents (0.8 mol % of total lipids), they are highly enriched in
small, dense HDL, consistent with the elevated surface electronegativity of this
subpopulation (Rosenson et al. 2011).
Isoprostanes are well established as biomarkers of oxidative stress and are
predominantly associated with HDL (see Kontush and Chapman 2012 for review).
Major molecular species of isoprostane-containing PCs include 5,6-epoxy-
isoprostaglandine A2-PC (EIPGA2-PC) 36:3, 5,6 EIPGE2-PC 36:4, IPGE2/D2-
PC 36:4, IPGF-PC 36:4, IPGE2/D2-PC 38:4 and IPGF-PC 38:4 (Pruzanski et al. 2000)
(Table 3).
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2.2.2 Sphingolipids
Sphingomyelin, a structural lipid which enhances surface lipid rigidity (Rye
et al. 1996; Saito et al. 2000), is the major sphingolipid in circulating HDL (5.6–
6.6 mol % of total lipids) (Wiesner et al. 2009; Camont et al. 2013; Stahlman
et al. 2013) (Table 3), which largely originates from triacylglyceride-rich
lipoproteins and only to a minor extent from nascent HDL (Nilsson and Duan
2006). Major molecular species of sphingomyelin are the 16:0 and 24:1 species
(Lhomme et al. 2012). Unlike negatively charged PL, sphingomyelin is depleted by
up to 30 % in small, dense relative to large, light HDL (Kontush et al. 2007; Camont
et al. 2013) (Fig. 2). This result may, in part, reflect the low abundance of
sphingomyelin in nascent HDL, a metabolic precursor of HDL3c, and suggest
distinct metabolic pathways for HDL subpopulations.
Among lysosphingolipids, S1P is particularly interesting as this bioactive lipid
plays key roles in vascular biology (Lucke and Levkau 2010). More than 90 % of
circulating sphingoid base phosphates are found in HDL and albumin-containing
fractions (Table 3) (Kontush and Chapman 2012). Interestingly, S1P associates
preferentially with small, dense HDL particles (up to tenfold enrichment compared
to large, light HDL) (Kontush et al. 2007) (Fig. 2) consistent with the high content
in apoM, a specific carrier of S1P, in small, dense particles (Davidson et al. 2009).
Other biologically active lysosphingolipids carried by HDL are represented by
lysosphingomyelin and lysosulfatide (Lhomme et al. 2012).
Ceramide is a sphingolipid intermediate implicated in cell signalling, apoptosis,
inflammatory responses, mitochondrial function and insulin sensitivity (Lipina and
Hundal 2011). This lipid is poorly transported by HDL, which carries only
25 mol % of total plasma ceramide (Wiesner et al. 2009), and constitutes only
between 0.022 and 0.097 mol % of total HDL lipids (Wiesner et al. 2009; Argraves
et al. 2011; Camont et al. 2013; Stahlman et al. 2013) (Table 3). Similarly to
sphingomyelin, this product of sphingomyelin hydrolysis is enriched in large, light
HDL (Fig. 2), suggesting common metabolic pathways for these lipids. This
hypothesis is however not supported by the pattern of major molecular species of
ceramide observed in HDL, which are the 24:0 and 24:1 species (Wiesner
et al. 2009; Stahlman et al. 2013).
Lipidomic data on glycosphingolipids, gangliosides and sulfatides are scarce
(Lhomme et al. 2012). Hexosyl and lactosyl species constitute the major
glycosphingolipids in plasma lipoproteins (Scherer et al. 2010) (Table 3).
2.2.3 Neutral Lipids
Unesterified (free) sterols are located in the surface lipid monolayer of HDL
particles and regulate its fluidity. HDL sterols are dominated by cholesterol,
reflecting the key role of lipoproteins in cholesterol transport through the body.
Other sterols are present in lipoproteins at much lower levels as exemplified by
minor amounts of lathosterol, ergosterol, phytosterols (β-sitosterol, campesterol),
oxysterols and estrogens (largely circulating as esters) (Kontush and Chapman
2012). Free cholesterol, whose affinity for sphingomyelin is now well established,
tends to preferentially associate with large, light HDL (Fig. 2).
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Cholesteryl esters (CE) are largely (up to 80 %) formed in plasma HDL (Fig. 2),
as a result of transesterification of PL and cholesterol catalysed by LCAT. These
highly hydrophobic lipids form the lipid core of HDL and contribute up to 36 mol %
of total HDL lipid (Wiesner et al. 2009; Camont et al. 2013; Stahlman et al. 2013)
(Table 3). Most of HDL CE is accounted for by cholesteryl linoleate (Lhomme
et al. 2012). A pioneering work on CE molecular species distribution across HDL
subpopulations using gas chromatography showed very similar profiles between
HDL2 and HDL3 particles (Vieu et al. 1996).
HDL-associated triacylglycerides (TAG) are dominated by species containing
oleic, palmitic and linoleic acid moieties (Lhomme et al. 2012) and represent
around 3 mol % of total HDL lipids (Vieu et al. 1996; Kontush et al. 2007; Wiesner
et al. 2009; Camont et al. 2013; Stahlman et al. 2013) (Table 3). Similarly to CE,
TAG species profile is conserved between HDL2 and HDL3 (Vieu et al. 1996).
Minor bioactive lipids present in HDL include diacylglycerides (DAG),
monoacylglycerides (MAG) and free fatty acids (Lhomme et al. 2012). In the
study of Vieu et al., sn-1,2 and sn-1,3 isomers of DAG species were identified in
HDL (Vieu et al. 1996). More recently, detailed characterisation of DAG molecular
species in HDL revealed 16:0/18:1 and 18:1/18:1 as major species, estimating their
content at 0.2 mol % of total lipids (Stahlman et al. 2013) (Table 3).
HDL composition in free fatty acids shows a predominance of palmitic, stearic
and oleic acid-containing species (Lhomme et al. 2012).
Together, available lipidomic studies have already provided detailed
characterisation of HDL isolated using two complementary techniques, FPLC
(Wiesner et al. 2009) and ultracentrifugation (Kontush et al. 2007; Camont
et al. 2013). The latter studies demonstrated preferential association of negatively
charged lipids (PS, PA) and S1P with small, dense HDL together with preferential
association of sphingomyelin and ceramide with large, light particles, consistent
with distinct metabolic origins and potent biological activities of small, dense HDL
(Camont et al. 2013). These data illustrate the power of lipidomics to provide
crucial information on the metabolism and function of lipoproteins relevant for
the development of cardiovascular disease, which can in turn deliver novel
biomarkers of cardiovascular risk.
3 The Structure of HDL
3.1 Introduction/Brief History
When it was becoming clear that plasma levels of HDL were inversely correlated
with cardiovascular disease, numerous laboratories were already doing pioneering
work on the structure of human plasma HDL (Edelstein et al. 1972; Jonas 1972;
Laggner et al. 1973; Atkinson et al. 1974; Schonfeld et al. 1976; Tardieu
et al. 1976). Knowing little about the nature of the stabilising proteins, Scanu and
colleagues used detailed compositional studies to build models of human HDL3
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particles (Shen et al. 1977; Scanu 1978). Concepts derived from these studies with
respect to fundamental packing of the protein and various lipid components still
apply today. After the sequences of the major HDL proteins, apolipoprotein A-I and
apoA-II, were reported in the 1970s (Brewer et al. 1972, 1978), Segrest (Segrest
et al. 1974) and others (McLachlan 1977) quickly noted periodically repeating units
that, when mapped on a helical wheel plot, indicated the presence of amphipathic
alpha helices. With hydrophobic faces mediating lipid interactions and polar faces
interacting with water, these structures turned out to be responsible for the
detergent-like ability of these proteins to solubilise lipids into stabile lipoprotein
particles. At around the same time, Jonas and colleagues were learning how to
combine purified apolipoproteins with lipids under control of detergents to produce
recombinant forms of HDL (Matz and Jonas 1982). Furthermore, the work of
Nichols et al was exploring new ways to characterise these particles by native
electrophoresis (Nichols et al. 1983). Because the electron microscopy work of
Forte indicated that they likely have a discoid shape (Forte and Nordhausen 1986),
these particles were referred to as reconstituted (r)HDL discs. Their compositional
simplicity and homogeneity quickly made them a mainstay for HDL structural
studies.
Segrest et al. and others (Wlodawer et al. 1979) proposed in the late 1970s that
the α-helices of apoA-I were arranged around the circumference of discoidal HDL
with the long axis of the helices perpendicular to the acyl chains (Fig. 3). This
became known as the “belt” or “bicycle wheel” model. Alternatively, other
investigators theorised that the 22-amino acid helical repeats were an ideal length
to traverse the bilayer edge with the helices parallel to the acyl chains (Jonas
et al. 1989; Nolte and Atkinson 1992). The intervening proline residues were
thought to induce hairpin turns that punctuated the repeats. This “picket fence”
model was favoured during the early 1990s because of supporting infrared
(IR) spectroscopy studies (Brasseur et al. 1990) and the fact that the model
accounted nicely for the experimentally observed size classes of apoA-I containing
HDL (Wald et al. 1990). Furthermore, the plausibility of the picket fence model was
supported by Phillips et al. using molecular modelling techniques (Phillips
et al. 1997).
However, the publication of the first successful X-ray crystal structure of a
lipid-free fragment of apoA-I by Borhani et al. (1997) brought fresh energy to the
debate. The crystal structure showed a tetramer of highly α-helical apoA-I
molecules arranged in a ring-shaped complex with no evidence of hairpin turns
that would be prevalent in the picket fence. The belt model picked up more
support with methodologically updated IR experiments performed by Koppaka
et al. (1999) that contradicted the earlier IR studies supporting the picket fence in
rHDL discs. Over the next few years, several laboratories reported results that
supported the belt orientation using methodologies like fluorescence energy transfer
(Li et al. 2000) and lipid-based fluorescence quenching (Panagotopulos et al. 2001).
With the question of helical orientation largely addressed, much of the focus for the
first decade of the 2000s centred on determining the spatial relationships between
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apoA-I molecules on these discs. This effort was aided by the detailed “double belt”
computer model put forth in the classic paper by Segrest (Segrest et al. 1999).
The preceding paragraphs quickly summarise a tremendous amount of work
between 1970 and 2000 aimed at understanding the structure of HDL and its
recombinant forms, and by no means does it do justice to all contributions. For
more complete discussions of this period of HDL structural research, the reader is
referred to the classic review series by Brouillette (Brouillette and Anantharamaiah
1995; Brouillette et al. 2001). In addition, due to space limitations, this section will
not focus on the structure of lipid-free apolipoproteins nor their proposed
mechanisms for lipid binding and particle generation. The reader is directed to
the recent review by Phillips (Phillips 2013) for an excellent discussion of these
issues. For the purposes of this section, we will focus on work done over the last
14 years that has built upon the concept of the double belt model in both
reconstituted and “real” circulating plasma HDL.
Fig. 3 The double belt model for a rHDL discoidal particle and its various refinements. The
classic LL 5/5 double belt model for apoA-I as proposed by Segrest (Segrest et al. 2000) is shown
in panel (a). Each amphipathic helical domain is shown in a different colour with helix 5 in green
at the front. This model did not include the N-terminal 43 a.a. The “belt and buckle” model (b)
does not form a continuous circle around the particle but has its N-terminal 43 a.a. folding back
across the belts (40). The “looped belt” (c) features a localised separation between residues
133 and 146 (helix 5) (41). The “solar flares” model (d) encapsulates the lipid with an antiparallel
double belt but has disorganised domains that resemble solar flares erupting between residues
165 and 180. The double superhelix model (e) maintains similar intermolecular contact among the
molecules of apoA-I as the double belt, but the lipid is stabilised as an elongated micelle and no
intramolecular contact is made between the N- and C-termini of apoA-I
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3.2 HDL in the Test Tube
3.2.1 Discoid HDL
Discoid HDLs probably exist in human plasma but are extremely short-lived due to
the fact that they are excellent substrates for LCAT (Jonas 2002). HDL discs have
been detected in sequestered compartments like peripheral lymph and interstitial
fluid which likely have lower LCAT activity (Sloop et al. 1983). As stated above,
discs can be reconstituted in vitro, and these particles exhibit many of the traits of
native HDL such as LCAT activation (Jonas and McHugh 1984), lipid transfer
(Davidson et al. 1995) and receptor binding (Liadaki et al. 2000).
The most well-studied rHDL discs consist of two apoA-I molecules, are ~96 Å in
diameter and ~47 Å in thickness and contain 150–200 phospholipid molecules
(Jonas 1986; Jonas et al. 1989). This “benchmark” particle was used as a basis for
the original double belt molecular model (Segrest et al. 1999). In this model, two
ring-shaped apoA-I molecules encapsulate a lipid membrane leaflet in an antiparal-
lel orientation (Segrest 1977; Segrest et al. 1999; Brouillette et al. 2001; Klon
et al. 2002a) in which helix 5 of both apoA-I molecules directly oppose each other
(Fig. 3a). In this configuration, there are two possible interfaces between the
molecules depending on how they are stacked: left to left (LL) and right to right
(RR). Computer analysis indicated that an LL interface in which helix 5 (more
specifically, glycine 129) of both molecules are directly opposed produced the
highest weighted score of potential salt bridges between the apoA-I molecules
(Segrest et al. 1999). This is called the LL5/5 (G129j) registry and, interestingly,
is the same orientation found in the Borhani crystal structure (Borhani et al. 1997).
This orientation was experimentally validated in three studies that utilised chemical
cross-linking to derive the molecular orientation of the two apoA-I molecules in
these particles. Two from our laboratory were highly consistent with the 5/5
orientation across most of the molecule, although certain cross-links were also
consistent with a second 5/2 registry (Davidson and Hilliard 2003; Silva
et al. 2005). Cross-linking studies by Bhat et al. (2005) were also consistent with
the general 5/5 belt model for most of the molecule, but these investigators
proposed that the N- and C-terminal 40–50 residues doubled back on the molecule
(Fig. 3b). This refinement was called the “belt and buckle”. Electron paramagnetic
resonance studies performed by Martin and colleagues (Martin et al. 2006) on 96 Å
rHDL particles were also consistent with a 5/5 antiparallel double belt orientation
over most of the particle circumference. However, they observed that the spin
coupling signatures of residues 134–145 (within helix 5) were consistent with a
looping region that causes a localised opening between the parallel belts. This
“looped belt” was proposed to be a potential site by which LCAT could gain access
to the cholesterol and phospholipid acyl chains that are otherwise buried in the lipid
bilayer (Fig. 3c). Using hydrogen/deuterium exchange (HDX) experiments, Wu and
colleagues proposed an alternative refinement of the double belt model which
included the full-length apoA-I (Wu et al. 2007). This “solar flares” model again
featured a 5/5 double belt for most of the particle, but the N-termini were modelled
as globular nodules (Fig. 3d). The HDX profile of the region between 165 and
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180 suggested that this region loops off the particle edge and could be a site for
LCAT interaction. This argument was bolstered by results showing that added
LCAT could alter the exchange patterns of these residues and that mutations in
this region affected LCAT activity. The conclusions of this study were called into
some question by a more recent HDX study performed by Chetty et al. on similar
particles that failed to support the existence of the looped solar flares (Chetty
et al. 2013). They showed that almost all of apoA-I was helical in the discs with
the exception of the first 6 and last 7 residues. Interestingly, the region between
residues 125 and 158 exhibited bimodal exchange kinetics, suggesting that this
region flits between a helical and less ordered structure. This is consistent with the
looped belt idea (Martin et al. 2006), but the putative solar flares region
(Wu et al. 2007) was not found to be particularly dynamic in this study. The authors
suggested that this region is responsible for absorbing changes in particle size by
unfolding under conditions when lipid surface area is limiting. This is consistent
with previous studies from our laboratory which used lipid-based fluorescence
quenching agents to show that this same region changes its exposure to lipid
when the particle diameter is reduced (Maiorano et al. 2004).
The recent publication of a high-resolution (2.2 Å) crystal structure of a lipid-
free truncation mutant of apoA-I (Δ185–243) also strongly supports the double belt
model (Mei and Atkinson 2011). Although lipid-free, the dimeric apoA-I formed a
curved structure derived from long, kinked alpha helices. Interestingly, much of the
structure resembled the 5/5 double belt, even down to a similar degree of curvature.
The model also suggested increased temperature factors in helix 5 hinting that there
could be a separation of the helices at this site, consistent with the looped belt idea.
This advance should prove to be a valuable guide for future modelling of both the
lipid-free and lipid-bound forms of apoA-I.
The models discussed above conform to the generally accepted idea that these
rHDLs are discoid in shape. However, Hazen and colleagues proposed a model that
departed from this idea (Wu et al. 2009). Based on small-angle neutron scattering
(SANS), they proposed that antiparallel apoA-I molecules form a double superhe-
lix (DSH) that encapsulates a cigar-shaped micelle of phospholipids (Fig. 3e). Thus,
the particles resemble an ellipsoid rather than a disc. Despite the different shape, the
overall molecular interactions along the interface of the two apoA-I molecules are
the same as the 5/5 double belt model. However, unlike in the planar disc, the N-
and C-termini are not predicted interact in the DSH. The viability of this model
remains under debate as molecular dynamics studies suggest that this model rapidly
collapses to a disc-shaped structure (Jones et al. 2010). Even simulations done by
the group that proposed the model seem to indicate that the elongated structure
collapses to an oblate spheroid, though they argue it remains micellar (Gogonea
et al. 2010). Going forward, this model must be squared with observations of disc-
like shapes by electron microscopy (Zhang et al. 2011), EPR data (Jones
et al. 2010), and the quantised changes in particle size that can be readily
demonstrated by reconstituting different lipid to protein ratios (Wald et al. 1990).
In addition to experimental work, significant progress has been made using
molecular dynamics to simulate the structure of rHDL discs. The earliest
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simulations by Klon et al. utilised apoA-I lacking the N-terminal 43 amino acids
(Klon et al. 2002b). The short 1 ns simulations were performed using the 5/5 double
belt model, encapsulating simulated phospholipids in a standard ~96 Å particle as a
starting point. The simulations provided four major conclusions. First, the overall
structure remained intact over the course of the simulation, arguing the physical
plausibility of the structure. Second, specific salt bridges were found to be impor-
tant with regard to the molecular registry of the two apoA-I molecules. Third, the
punctuating proline residues were found to induce peri-helical “kinks” that also
played a role in molecular registry. Finally, the motions of the molecule suggested
that apoA-I may have the potential to change its molecular registry. This concept
was first proposed in the fluorescence resonance energy transfer experiments of Li
et al. (2002), and the concept was later supported by certain chemical cross-links
(Silva et al. 2005). This idea of molecular registry shifts on the HDL particle surface
raises fascinating implications with respect to alternative interactions with the wide
array of HDL docking proteins.
Further simulations in which lipids were added to or subtracted from the system
showed that apoA-I can twist into a saddle-shaped structure in response to lipid
removal (Gu et al. 2010). These results were supported by independent studies
(Miyazaki et al. 2010) and in subsequent temperature jump studies using full-length
apoA-I (Jones et al. 2011). Segrest and colleagues concluded that apoA-I maintains
minimal surface bilayers and responds to changes in surface lipid content by
winding or unwinding of this twisted saddle shape. It is important to emphasise,
however, that these twisted models of dimeric apoA-I maintain similar intermolec-
ular contacts as the planar double belt model and thus are consistent with the
fluorescence, EPR and cross-linking data described above.
3.2.2 Spherical rHDL
Although the majority of HDL particles in human plasma are spherical, these
particles are extremely understudied from a structural point of view. Spherical
HDL particles contain a neutral lipid core composed of cholesteryl ester and
triglyceride and thus lack a particle “edge” to constrain the apolipoproteins as in
the discs. The helical domains have the potential to spread across the phospholipid
surface penetrating past the phosphate group to interact with the acyl chains.
Segrest et al. (1994) argued early on that if apoA-I exists in a belt-like model in
discoidal particles, the fundamental interactions of apoA-I helices with the phos-
pholipid acyl chains should not change significantly in spheres. Brasseur (Brasseur
et al. 1990) and Borhani (Borhani et al. 1997) have also argued the similarity in
apoA-I structure between the two shapes. These arguments were supported by
circular dichroism and fluorescence studies showing that apoA-I secondary struc-
ture content and the exposure of Trp residues do not undergo gross changes when a
reconstituted discoidal particle converts to a sphere in the presence of LCAT (Jonas
et al. 1990). In addition, careful NMR studies suggested that the changes in
conformation of apoA-I between reconstituted discs and spheres are primarily
limited to the apoA-I N-terminus (Sparks et al. 1992).
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Using the cross-linking approach, we studied the structure of reconstituted
apoA-I-containing spherical particles generated by incubating rHDL discs with
LCAT under controlled conditions (Silva et al. 2008). These spheres contained a
largely cholesteryl ester core and were of roughly similar diameter to the “bench-
mark” discs described above. Cross-linking experiments showed that these spheres
contained 3 molecules of apoA-I, vs. only two in the discs. Quite surprisingly, the
cross-linking pattern derived in the spheres was almost identical to that of the discs.
Our solution to the problem of how the exact same molecular interactions occur
between two apoA-Is in a disc vs. three in a sphere was the “trefoil model” (Fig. 4).
In this scheme, kinks were added in helix 5 and 10 of apoA-I. Two antiparallel belts
as per the double belt model are then bent 120 on these kinks and a third molecule,
bent the same way, was inserted. This formed a three-dimensional cage-like
structure in which the helical domains in each of the three apoA-I molecules
made exactly the same salt bridge interactions postulated for the original double
belt. This cage can be envisioned to encapsulate a neutral lipid ester core and
support the surface polar lipids in the intervening open spaces, or lines, between the
molecules.
Studying the exact same particles using SANS, Wu and colleagues came to a
different conclusion (Wu et al. 2011). The low-resolution molecular envelope of the
protein component was consistent with three different architectures: (1) two apoA-I
molecules in a double belt with the third as a separate hairpin, called the helical
dimer with hairpin (HdHp), (2) three separate hairpins (3Hp), or (3) an integrated
trimer (iT) which is similar to the trefoil arrangement. Based on chemical cross-
linking, the authors argued that the data was most consistent with the HdHp model.
Despite the differences in the HdHp and the trefoil arrangements from a conceptual
point of view, the models are quite similar from a molecular perspective in that the
interactions in both models are predicted to be similar. All contacts in the trefoil are
intermolecular where the interactions within the hairpined apoA-I are intramolecu-
lar, but the same sequences interact in all molecules. Thus, the epitopes on the HDL
particles should be similar in both models and therefore might be expected to
Fig. 4 The development of the trefoil model for a spherical particle from the double belt. The
classic LL 5/5 double belt for apoA-I is shown in panel (a) coloured as in Fig. 3. (b) Kinks are
introduced within helix 5 and helix 10 and the molecules are bent 60 out of the plane of the disc. A
third molecule of apoA-I, bent the same way, can now be introduced. (c) The trefoil model
demonstrates similar intermolecular contacts between all three apoA-I molecules
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interact similarly with HDL docking proteins. It should also be noted that an
alternative spherical model that is related to the trefoil organisation was proposed
by Gursky (Gursky 2013) that invokes different hinge domains as extrapolated
from the crystal structure of the lipid-free apoA-I fragment (Mei and Atkinson
2011). Distinction between these models awaits the development of strategies that
allow for the higher resolution determination of cross-link span on particles
containing more than two molecules of apoA-I.
Catte et al. made initial explorations into the structure of reconstituted spherical
particles using a combination of atomistic and course-grained molecular dynamics
simulations (Catte et al. 2008). The simulated particle consisted of a saddle-shaped
rHDL particle with two molecules of apoA-I in which surface phospholipids were
replaced in silico with cholesteryl ester (CE) molecules. During the simulations, the
CE is sequestered into a core that was well covered by the surface protein and
phospholipid, forming a prolate ellipsoid shape. The overall helicity and salt bridge
orientation between the resident apoA-I molecules remained similar to the disc
models, though there was an increase in overall salt bridge number. Despite an
uncertain relationship with experimentally derived spherical particles, these
simulations are consistent with the idea that apoA-I structures in discs and spheres
are generally similar. The same group later simulated particles that more closely
resembled those appearing in plasma (Segrest et al. 2013). Their data suggested that
spheres created under artificial conditions in the test tube may represent kinetically
trapped species with artificially high ratios of surface lipids with respect to the
scaffold proteins. However, again, the resident apoA-I particles exhibited overall
similar structures.
3.3 “Real” HDL Particles
Reconstituted HDL discs and spheres have been a critical tool for understanding the
fundamental arrangements of apoA-I on the HDL particle surface. The homogene-
ity of these preparations allowed the use of traditional spectrophotometric
approaches such as circular dichroism, NMR, EPR, etc. However, the ultimate
goal has always been to understand HDL in its natural plasma form. As outlined in
other sections of this chapter, human plasma HDL as isolated by density gradient
ultracentrifugation is heterogeneous in almost every property: protein composition,
lipid composition, particle size, particle shape and particle charge. This heteroge-
neity precludes the use of most traditional structural techniques. For example,
circular dichroism studies of a mixed system in which apoA-I is present either in
several different conformations or with other apolipoproteins will produce averaged
data that will likely not be applicable to any of the particles present in the sample.
Even attempts to simplify these particles, such as by immunoisolating only those
particles that contain apoA-I but not apoA-II (LpA-I), still result in preparations
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with unacceptable compositional and size heterogeneity for informative structural
studies. For these reasons, our understanding of HDL structure in authentic plasma
HDL particles has lagged far behind the reconstituted forms.
The use of mass spectrometry as a structural tool has finally allowed this barrier
to be breached. With the mass accuracy and resolution of modern mass
spectrometers, it is possible to identify cross-links that are specific for a given
protein, even in the presence of many others. Taking advantage of this, we studied
5 density subfractions of normal human plasma HDL as delineated by ultracentri-
fugation. In order to simplify the particles to the extent possible, we isolated those
particles containing predominantly apoA-I (Huang et al. 2011). Surprisingly, we
noted cross-linking patterns that were remarkably similar to those found in the
reconstituted spheres and discs, irrespective of the particle size or density. This
strongly suggested that the general features of apoA-I structure are related among
lipid-associated forms of all sizes, shapes and origin. Careful measurements of the
protein/lipid components indicated a range 3–5 apoA-I molecules per particle,
depending on size. In fact, an important outcome of this study was the realisation
that the surface of HDL particle is dominated by protein. For example, we deter-
mined that apoA-I accounts for 87 % of the surface of an LpA-I3c particle. This only
reduces to 71 % in the larger LpA-I2b particles. This is in agreement with the
assertions of Segrest et al. (2013) whose compositional calculations indicate that
apoA-I is much more tightly packed on native spheres than it is on typical
reconstituted particles. Figure 5 shows one proposal for how 4 and 5 apoA-Is can
be accommodated by changing the hinge bend angles of the trefoil while
maintaining the same intermolecular interactions, and hence cross-linking pattern.
Furthermore, we proposed that HDL particle size is modulated via a twisting
motion of the resident apoA-Is, consistent with the MD studies of the Segrest lab
(Catte et al. 2008). Combining these data, we developed the first detailed molecular
models for native LpA-I HDL particles, exemplified by that for LpA-I2b in Fig. 6. In
this model, apoA-I forms an 11 nm cage stabilising ~170 molecules of phospholipid
at a physiological packing density. The cutaway shows a cavity of correct volume
for the ~143 CEs and ~23 TGs measured in the core. These are the first detailed,
molecular-scale models of native plasma HDL to be proposed.
Taking another MS approach, Chetty et al. used HDX to study spherical LpA-I
particles isolated from human plasma by ultracentrifugation and further isolated by
high-resolution gel filtration chromatography (Chetty et al. 2013). These particles
were approximately 10 nm in diameter and contained on average 5 molecules of
apoA-I per particle as measured by cross-linking. Comparing these directly to a
benchmark rHDL disc, they found that the total helical content was similar between
the native spheres and the reconstituted discs. Strikingly, the HDX profiles were
also quite similar between the two with both showing near-complete helicity with
the exception of the first and last 6 or so residues. Like the discs, the plasma spheres
showed bimodal HDX kinetics indicating a possible loop region in helix 5 of
apoA-I. Interestingly, the length of this partially disordered segment was similar
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to that of rHDL discs of 8 nm in diameter, suggesting that apoA-I on these spheres is
more tightly packed than in the 96 Å discs. This is consistent with higher number of
apoA-I molecules on the surface. Overall, these studies reinforce the idea that the
global apoA-I organisation does not change significantly between particles of
different shape or origin; however, more subtle conformational adaptations may
occur in localised regions of the protein in response to changes in either particle
diameter or surface packing density.
Fig. 5 Models of apoA-I in human plasma HDL particles of various size and number of apoA-I
molecules. (a) The trefoil model is shown as a schematic with each molecule of apoA-I in a
different colour. (b) LpA-I2b contains 5 apoA-I molecules, but shows a similar cross-linking
patterns to reconstituted particles that have only 2 and 3 molecules of apoA-I. This figure shows
that more apoA-I molecules can be added to the trefoil framework by increasing the hinge bend
angle and adding more apoA-I molecules. (c) A possible model for LpA-I2a that has four apoA-I
molecules on average. (d) Further reductions in HDL particle size may be accomplished by a
twisting action of the resident apoA-I molecules
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Fig. 6 Molecular model of a human plasma LpA-I2b particle. (a) Five molecules of apoA-I are
shown in an organisation shown schematically in Fig. 5b. Phospholipid headgroups (tan) are
present in the intervening spaces (lunes) between the apoA-I belts (purple). (b) A cross section of the
same particle showing the helical belts floating atop the acyl chains of the phospholipids (brown).
Note the large internal cavity that is of sufficient volume to contain the number of triglycerides and
cholesteryl ester molecules that have been measured in these particles (Huang et al. 2011). (Colour
figure online)
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Conclusions and Perspectives
HDL, a lipoprotein class historically and classically defined and isolated on the
basis of its hydrated density alone, is a highly heterogeneous particle family
consisting of multiple subclasses differing in hydrated density, size, shape and
lipid and protein composition. HDL-associated proteins have been considered
until now to predominate in determining the particle structure and biological
function of all HDL particles. Indeed, HDL is distinguished from other lipopro-
tein classes by its cargo of a large number (>80) of different proteins whose
abundance may vary by more than 1,000-fold and which fall into several major
subgroups, including apolipoproteins, diverse enzymes, lipid transfer proteins,
acute-phase response proteins, complement components and proteinase
inhibitors; additional functions, such as host defence and inflammation, cannot
be excluded. Many of the individual proteins are present as distinct isoforms due
to co- and posttranslational modification, thereby adding a further dimension to
the complex and dynamic HDL structure.
It would be erroneous however to consider that the proteome(s) of HDL
particles solely determines their respective functions, particularly as cutting
edge lipidomic technologies have recently revealed significant—and indeed
determinant—roles of specific HDL lipid components in particle function. In
this regard, negatively charged phospholipids, and notably molecular species of
phosphatidylserines, are intimately associated with the cellular cholesterol
efflux, antioxidative, antiapoptotic and anti-inflammatory actions of small
dense HDL3 particles and equally modulate platelet activity (Camont
et al. 2013). In addition, earlier studies have suggested that both core neutral
lipids in HDL (cholesteryl esters and triacylglycerols) and surface lipids can
impact surface fluidity and, in turn, antioxidative and other functions (Zerrad-
Saadi et al. 2009; Camont et al. 2013).
Increasingly then, a new concept is emerging, one in which specific protein
and lipid components interact closely to form individual HDL particle species,
such as overall compositional and structural features translating into expression
of highly defined biological functions (Camont et al. 2011; Shah et al. 2013).
Clearly we are at the beginning of a new era in our understanding of HDL
structure and function, with the promise of exciting mechanistic insights into
function, which, in turn, will translate into new therapeutic strategies to harness
the anti-atherosclerotic potential of HDL.
The central thesis that specific protein–protein interactions may drive the
formation of lipoprotein complexes in the HDL particle spectrum is equally
emergent. Indeed, the diversity of molecules which bind to HDL suggests that
the lipoprotein can serve as a versatile adsorptive surface for proteins to form
complexes playing roles not only in lipid metabolism but equally in the acute-
phase response, innate immune response, complement activation, proteolysis
inhibition and plaque stability.
More comprehensive understanding of HDL structure is critical to future
progress in HDL biology. A molecular understanding of HDL-bound apoA-I
will allow further insight into its interactions with key plasma remodelling
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factors, such as LCAT, PLTP or CETP, and in addition with cell-surface proteins
that mediate HDL assembly and clearance, such as ABCA1 and scavenger
receptor B-I. A firm handle on these interactions would contribute to therapeutic
manipulation that could enhance the protective features of HDL with respect to
cardiovascular disease, or perhaps other pathologies (Gordon et al. 2011).
Because HDL and its recombinant analogues have been resistant to traditional
high-resolution structural approaches such as NMR or X-ray crystallography,
investigators have been forced to apply a series of lower resolution techniques to
the problem. As described above, these approaches have led to a general
understanding of apoA-I structure in HDL that can be summarised by the
following statements: (1) apoA-I pairs with itself in a double belt-like arrange-
ment in almost all of its lipidated states; (2) apoA-I interacts via intermolecular
salt bridges that commonly stabilise the registry in the 5/5 orientation, though
there may be a possibility of dynamic shifts to other orientations; and (3) despite
a similar general organisation among different types of HDL particles, specific
regions within the scaffold can undergo conformational changes depending on
particle size or perhaps composition—possible sites include the N- and
C-termini and central region in helix 5 or between residues 165 and 180.
These conformationally dynamic sites are attractive possibilities for the interac-
tion of lipid-modifying docking proteins such as LCAT and CETP.
Now that these conformationally dynamic sites within apoA-I have been
proposed, it will be important to specifically define their importance for key
HDL remodelling reactions. This will require well-designed site-directed muta-
genesis experiments in reconstituted particles and antibody blocking
experiments in native plasma particles. Furthermore, cross-linking studies hold
much promise for directly mapping the sites of interaction for plasma
remodelling factors on HDL-bound apoA-I.
Finally, yet another key unanswered question relates to the unknown effects
of other HDL structural proteins on apoA-I structure. ApoA-II is commonly
found with apoA-I on many HDL particles and would be expected to have a
significant impact not only on properties such as protein packing on the particle
surface but also on the conformation of apoA-I in a functionally significant way.
For example, does apoA-II perform distinct structural and protein docking roles
vs. apoA-I? How does each of these proteins determine the components of the
bound lipidome in individual particle species? Resolution of these and other
questions will continue to require the use of both reconstituted and native,
authentic HDL particles combined with the appropriate application of multiple
structural techniques (including continued attempts at X-ray crystallography).
It is poignant to consider that in 2014 we still lack critically important insights
into HDL structure as it relates to the intravascular metabolism and
atheroprotective function of these pseudomicellar, quasi-spherical particles.
Had sufficient effort been invested in solving these unknowns heretofore, then
perhaps our costly forays—and failures—into HDL-targeted therapeutics over
the past 15 years could at least partially have been avoided.
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Abstract
In this chapter, we review how HDL is generated, remodeled, and catabolized in
plasma. We describe key features of the proteins that participate in these
processes, emphasizing how mutations in apolipoprotein A-I (apoA-I) and the
other proteins affect HDL metabolism.
The biogenesis of HDL initially requires functional interaction of apoA-I
with the ATP-binding cassette transporter A1 (ABCA1) and subsequently
interactions of the lipidated apoA-I forms with lecithin/cholesterol
acyltransferase (LCAT). Mutations in these proteins either prevent or impair
the formation and possibly the functionality of HDL.
Remodeling and catabolism of HDL is the result of interactions of HDL with
cell receptors and other membrane and plasma proteins including hepatic lipase
(HL), endothelial lipase (EL), phospholipid transfer protein (PLTP), cholesteryl
ester transfer protein (CETP), apolipoprotein M (apoM), scavenger receptor
class B type I (SR-BI), ATP-binding cassette transporter G1 (ABCG1), the F1
subunit of ATPase (Ecto F1-ATPase), and the cubulin/megalin receptor.
Similarly to apoA-I, apolipoprotein E and apolipoprotein A-IV were shown to
form discrete HDL particles containing these apolipoproteins which may have
important but still unexplored functions. Furthermore, several plasma proteins
were found associated with HDL and may modulate its biological functions. The
effect of these proteins on the functionality of HDL is the topic of ongoing
research.
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1 Biogenesis of HDL
The biogenesis of HDL is a complex process and involves several membrane bound
and plasma proteins (Zannis et al. 2004a). The first step in HDL biogenesis involves
secretion of apoA-I mainly by the liver and the intestine (Zannis et al. 1985).
Secreted apoA-I interacts functionally with ABCA1, and this interaction leads to
the transfer of cellular phospholipids and cholesterol to lipid-poor apoA-I. The
lipidated apoA-I is gradually converted to discoidal particles enriched in
unesterified cholesterol. The esterification of free cholesterol by the enzyme leci-
thin/cholesterol acyltransferase (LCAT) (Zannis et al. 2006a) converts the discoidal
to spherical HDL particles (Fig. 1).
The absence or inactivating mutations in apoA-I, ABCA1, and LCAT prevent
the formation of apoA-I-containing HDL (Daniil et al. 2011). For this reason, we
classify the apoA-I, ABCA1, and LCAT interactions that will be discussed in this
chapter as early steps in the biogenesis of HDL. Following a similar pathway, apoE
and apoA-IV can also synthesize HDL particles that contain these proteins (Duka
et al. 2013; Kypreos and Zannis 2007). The first part of this review provides
important information on the unique properties of apoA-I that permits it to acquire
lipids via interactions with ABCA1 and LCAT. It also provides examples of how
specific mutations in apoA-I disrupt specific steps in the pathway of HDL biogene-
sis and generate distinct aberrant HDL phenotypes. The HDL phenotypes described
here can serve as molecular markers that could be used for the diagnosis, prognosis,
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and potential treatment of HDL abnormalities or dyslipidemias associated
with HDL.
1.1 ATP-Binding Cassette Transporter A1 (ABCA1)
1.1.1 Structure of apoA-I and Its Interactions with ABCA1 In Vitro
apoA-I contains 22 or 11 amino acid repeats which, according to the models of
Nolte and Atkinson (1992), are organized in amphipathic a-helices (Segrest
et al. 1974). Based on the crystal structure of apoA-I in solution (Borhani
et al. 1997, 1999), a belt model was proposed to explain the structure of apoA-I
on discoidal HDL particles (Segrest et al. 1999). Various models have been
proposed to explain the arrangement of apoA-I on spherical HDL particles based
on structural work and cross-linking(Wu et al. 2011; Silva et al. 2008; Huang
et al. 2011). Details on the structure of apoA-I and HDL are provided in chapter
“Structure of HDL: Particle Subclasses and Molecular Components.”
ABCA1 is a ubiquitous protein that belongs to the ABC family of transporters
and is expressed abundantly in the liver, macrophages, brain, and various other
tissues (Langmann et al. 1999; Kielar et al. 2001). ABCA1 is localized only on the
basolateral surface of the hepatocytes (Neufeld et al. 2002); it is also found on
endocytic vesicles and was shown to travel between late endocytic vesicles and the
cell surface (Neufeld et al. 2001). ABCA1 promotes efflux of cellular phospholipids
Fig. 1 Schematic representation of the pathway of the biogenesis of HDL containing apoA-I or
apoE or apoA-IV
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and cholesterol to lipid-free or minimally lipidated apoA-I and other
apolipoproteins, but not to spherical HDL particles (Wang et al. 2000; Remaley
et al. 2001).
Studies in HeLa cells that expressed an ABCA1 green fluorescence fusion
protein showed the intracellular trafficking of ABCA1 complexed to apoA-I
(Neufeld et al. 2001, 2002). Other studies showed that in macrophages ABCA1
associates with apoA-I in the coated pits, is internalized, interacts with intracellular
lipid pools, and is re-secreted as a lipidated particle (Takahashi and Smith 1999;
Smith et al. 2002; Lorenzi et al. 2008). A similar pathway that leads to transcytosis
has been described in endothelial cells (Cavelier et al. 2006; Ohnsorg et al. 2011).
A series of cell culture and in vitro experiments investigated the ability of apoA-
I mutants to promote ABCA1-mediated efflux of cholesterol and phospholipids and
to cross-link to ABCA1. These mutants had amino-terminal deletions, carboxy-
terminal deletions that removed the 220-231 region, carboxy-terminal deletions that
maintained the 220-231 region, and double deletions of the amino- and carboxy-
terminal regions (Chroni et al. 2003).
These studies presented in Chroni et al. (2003) showed that wild-type (WT) -
ABCA1-mediated cholesterol and phospholipid efflux was not affected by amino-
terminal apoA-I deletions, but it was diminished by carboxy-terminal deletions in
which residues 220-231 were removed. Efflux was not affected by deletion of the
carboxy-terminal 232-243 region, and it was restored to 80 % of WT control by
double deletions of both the amino- and carboxy-termini (Zannis et al. 2004a,
2006a; Chroni et al. 2003; Reardon et al. 2001). Lipid efflux was either unaffected
or moderately reduced by a variety of point mutations or deletions of internal
helices 2–7. The findings indicated that different combinations of central helices
can promote lipid efflux (Chroni et al. 2004a, b). Chemical cross-linking/
immunoprecipitation studies showed that the ability of apoA-I mutants to promote
ABCA1-depended lipid efflux is correlated with the ability of these mutants to be
cross-linked efficiently to ABCA1 (Chroni et al. 2004b). Cross-linking between
apoA-I and ABCA1 and cholesterol efflux was also affected by mutations in
ABCA1 that are found in patients with Tangier disease. The majority of the
ABCA1 mutants cross-link poorly to WT apoA-I and have diminished capacity to
promote cholesterol efflux (Bodzioch et al. 1999; Fitzgerald et al. 2002). A notable
exemption is the ABCA1[W590S] mutant which cross-linked stronger to apoA-I
than to WT ABCA1 but had diminished capacity to promote cholesterol efflux and
to promote formation of HDL (Bodzioch et al. 1999; Fitzgerald et al. 2001, 2002).
We suggested that this ABCA1 mutation may have altered the environment of the
binding site of ABCA1 in such a way that the binding of apoA-I is strong but not
productive and thus prevented efficient lipid efflux (Chroni et al. 2004b).
1.1.2 Interaction of apoA-I with ABCA1 In Vivo Initiates
the Biogenesis of HDL
Inactivating mutations in ABCA1 found in patients with Tangier disease are
associated with very low levels of total plasma and HDL cholesterol, diminished
capacity to promote cholesterol efflux, formation of preβ-migrating particles, and
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abnormal lipid deposition in various tissues (Daniil et al. 2011; Brunham
et al. 2006b; Orso et al. 2000; Assmann et al. 2001; Timmins et al. 2005).
Analysis of the serum of carriers with ABCA1 mutations by two-dimensional
gel electrophoresis and western blotting using a rabbit polyclonal anti-human
apoA-I antibody showed that subjects homozygous or compound mutant hetero-
zygous for ABCA1 fail to form α-HDL particles, but instead they form preβ- and
other small-size particles (Fig. 2).
As explained later, such particles are found in the plasma of mice expressing
C-terminal mutants and may be created by mechanisms that involve nonproductive
interactions between ABCA1 and apoA-I (Chroni et al. 2007; Fotakis et al. 2013a).
Several ABCA1 mutations in humans that alter the functions of ABCA1 are
associated with increased susceptibility to atherosclerosis (Singaraja et al. 2003).
Specific amino-acid substitutions found in the Danish general population were
associated with increased risk for ischemic heart disease and reduced life expec-
tancy through unknown mechanisms (Frikke-Schmidt et al. 2008). Inactivation of
the ABCA1 gene in mice leads to low total serum cholesterol levels, lipid deposi-
tion in various tissues, impaired growth, and neuronal development and mimics the
phenotype described for patients with Tangier disease (Orso et al. 2000). In addition
ABCA1-deficient mice exhibit moderate increase in cholesterol absorption in
response to high cholesterol diet (McNeish et al. 2000; Aiello et al. 2002). The
role of ABCA1 on the lipid content of bile salts and cholesterol secretion is not clear
(Vaisman et al. 2001; Groen et al. 2001).
Bone marrow transplantation experiments indicated that ABCA1 plays an
important role in the control of macrophage recruitment to the tissues (Van Eck
et al. 2002, 2006).
The contribution of ABCA1 in the pathogenesis of atherosclerosis in mice is
presented in chapter “Mouse Models of Disturbed HDL Metabolism” (Hoesha and
Van Eck). In men and mice, the majority of HDL is produced by the liver (Brunham
et al. 2006a). When the liver and intestinal ABCA1 genes were inactivated in mice,
Fig. 2 Two-dimensional gel electrophoresis of plasma obtained from homozygotes or compound
heterozygotes ABCA1-deficient human subjects with Tangier disease as indicated [Adapted from
Daniil et al. (2011)]
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HDL was not found in plasma, indicating that the liver and the intestine are the only
sites that contribute to the production of HDL (Timmins et al. 2005). Following
intestinal-specific inactivation of the ABCA1 gene in mice, the HDL that was
generated by the liver accounted for 70 % of the HDL found in WT mice (Brunham
et al. 2006a). In mice that do not express hepatic ABCA1, the HDL concentration in
the lymph was greatly diminished despite the fact that the intestine contributes 30 %
to the synthesis of HDL. This implies that the HDL that is produced in the intestine
is secreted directly into the plasma (Brunham et al. 2006a). This is further supported
by the finding that in mice that do not express intestinal ABCA1, the apoA-I and
cholesterol concentration of lymph was not affected (Brunham et al. 2006a).
In liver-specific or whole-body ABCA1 knockout mice, the plasma HDL cata-
bolism and the fractional catabolic rate of HDL by the liver and to a lesser extent by
the kidney and the adrenal is increased (Timmins et al. 2005; Singaraja et al. 2006).
In ABCA1-deficient mice, lipidated apoA-I particles or preβ-HDL failed to mature
and are rapidly catabolized by the kidney (Timmins et al. 2005).
1.1.3 Unique Mutations in apoA-I May Affect apoA-I/ABCA1
Interactions and Inhibit the First Step in the Pathway of HDL
Biogenesis
The in vivo interactions of apoA-I with ABCA1 were studied systematically by
adenovirus-mediated gene transfer of WT and mutant apoA-I forms. Similar studies
were performed to probe the interactions of lipid-bound apoA-I with LCAT. Four to
five days postinfection plasma was collected and analyzed for lipids and lipoproteins
and by two-dimensional gel electrophoresis to identify the HDL subpopulations. The
plasma was fractionated by density gradient ultracentrifugation and fast protein liquid
chromatography (FPLC), and the HDL fraction was analyzed by electron microscopy
(EM) to assess the size and shape of HDL (Chroni et al. 2003; Reardon et al. 2001).
Also the hepatic mRNA levels of apoA-I were determined to ensure that there was
comparable expression of the WT and the mutant apoA-I forms (Zannis et al. 2004a;
Chroni et al. 2003, 2007; Reardon et al. 2001).
We have studied most recently the effect of two sets of point mutations in the
218-222 and 225-230 region of apoA-I that affects apoA-I/ABCA1 interactions on
the biogenesis of HDL. Adenovirus-mediated gene transfer of these mutants in
apoA-I/ x apoE/ mice (Fotakis et al. 2013a, b) showed that compared to the
WT apoA-I, the expression of an apoA-I[L218A/L219A/V221A/L222A] mutant
decreased plasma cholesterol, apoA-I, and HDL cholesterol levels and generated
preβ- and α4 HDL subpopulations (Fotakis et al. 2013a) (Table 1 and Fig. 3a–g).
To eliminate the involvement of apoE in the generation of apoE-containing HDL
particles (Kypreos and Zannis 2007), the apoA-I[L218A/L219A/V221A/L222A]
mutant was expressed in apoA-I/ x apoE/ mice via adenovirus-mediated gene
transfer (Fotakis et al. 2013a). In this mouse background, the FPLC fractionation of
the plasma showed the near absence of an HDL cholesterol peak. Density gradient
ultracentrifugation of the plasma showed small amount of the apoA-I in HDL3 and
in d< 1.21 g/ml fractions (Fig. 3a). EM analysis showed the presence of discoidal
particles along with larger particles corresponding in size to IDL/LDL (Fig. 3b).
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Table 1 Plasma lipids and hepatic mRNA levels of apoA-I/ or apoA-I/ x apoE/ mice















WT apoA-I in apoA-I/ mice 278 74 78 24 100 26 260 40
apoA-I[L218A/L219A/V221A/
L222A] in apoA-I/ mice
45 14 50 20 95 24 41 5
WT apoA-I in apoA-I/ x
apoE/ mice
1,343 104 294 129 100 13 –
apoA-I[L218A/L219A/V221A/
L222A] in apoA-I/ x apoE/
mice
778 52 18 2 92 23 –
apoA-I[L218A/L219A/V221A/
L222A] plus LCAT in apoA-I/
x apoE/ mice
754 122 37 10 90 3 –
Fig. 3 (a–g) ApoA-I mutations and their effect on the HDL phenotypes. Analysis of plasma of
apoA-I/ x apoE/ mice infected with adenoviruses expressing the WT apoA-I or the apoA-I
[L218A/L219A/V221A/L222A] mutant, as indicated, by density gradient ultracentrifugation and
SDS-PAGE (a, e). EM analysis of HDL fractions 6–7 obtained from apoA-I/ x apoE/ mice
expressing the WT apoA-I or the apoA-I[L218A/L219A/V221A/L222A] mutant, as indicated,
following density gradient ultracentrifugation of plasma (b, f). SDS gel electrophoresis showing
apoprotein composition of fractions 6 and 7 (c) used for the EM analysis in panel b.
Two-dimensional gel electrophoresis of plasma of apoA-I/ x apoE/ mice infected with
adenoviruses expressing WT apoA-I or the apoA-I[L218A/L219A/V221A/L222A] mutant, as
indicated (d, g)
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These particles may originate from apoB-48 containing lipoproteins that are found
in the HDL fractions (Fig. 3c). Two-dimensional gel electrophoresis showed the
presence of only preβ-HDL particles (Fig. 3d). Control experiments showed that
WT apoA-I when expressed in apoA-I/ x apoE/ mice floated predominantly in
the HDL2/HDL3 region and generated spherical particles and normal preβ- and
α-HDL subpopulation (Fig. 3e–g).
Co-expression of the apoA-I[L218A/L219A/V221A/L222A] mutant and human
LCAT in apoA-I/ x apoE/ mice did not correct the plasma apoA-I levels and
did not correct the aberrant HDL phenotype.
The findings shed light to previous studies which showed that carboxy-terminal
deletion mutants that lacked the 220-231 region of apoA-I prevented the biogenesis
of normal α-HDL particles but allowed the formation of preβ-HDL particles
(Chroni et al. 2003, 2007).
Studies discussed in a later section showed that naturally occurring point
mutations in apoA-I when expressed in mouse models activate LCAT insufficiently
and in some instances lead to the accumulation of discoidal HDL particles in
plasma (Koukos et al. 2007a, b; Chroni et al. 2005a). A characteristic feature of
these mutations is that they could be corrected in vivo by the co-expression of the
mutant apoA-I and LCAT.
The phenotype produced by the apoA-I[L218A/L219A/V221A/L222A]
mutations is distinct from all previously described phenotypes and cannot be
corrected by overexpression of LCAT. In addition, the mutant protein had reduced
capability to promote the ABCA1-mediated cholesterol efflux. Although other
interpretations are possible, the in vivo and in vitro data suggest that the interaction
of the apoA-I [L218A/L219A/V221A/L222A] mutant with ABCA1 results in
defective lipidation of apoA-I that leads to the generation of preβ-HDL particles
that are not a good substrate for LCAT. If this interpretation is correct, the normal
lipidation of apoA-I may require a precise initial orientation of the apoA-I ligand
within the binding site of ABCA1 that is similar to that described for enzyme-
substrate interactions. Such a configuration would allow correct lipidation of apoA-
I that could subsequently undergo cholesterol esterification and formation of mature
HDL, whereas incorrectly lipidated apoA-I becomes a poor substrate for LCAT.
In addition to the unique role of the L218/L219/V221/L222 residues in the
biogenesis of HDL, the same residues are also required to confer trans-endothelial
transport capacity (Ohnsorg et al. 2011) and bactericidal activity (Biedzka-Sarek
et al. 2011) to apoA-I. These overall properties suggest that the L218/L219/V221/
L222 residues represent an effector domain for several activities of apoA-I.
The phenotype generated by the expression of the apoA-I[F225A/V227A/
F229A/L230A] mutant was similar to that obtained with the apoA-I[L218A/
L219A/V221A/L222A] mutant. However co-expression of the apoA-I[F225A/
V227A/F229A/L230A] mutant and human LCAT corrected the abnormal HDL
levels, created normal preβ- and α-HDL subpopulations, and generated spherical
HDL particles (Fotakis et al. 2013b).
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1.2 Lecithin/Cholesterol Acyltransferase (LCAT)
1.2.1 Interactions of Lipid-Bound ApoA-I with LCAT
Plasma LCAT is a 416 amino acid long plasma protein that is synthesized and
secreted primarily by the liver and to a much lesser extent by the brain and the testis
(Warden et al. 1989; Simon and Boyer 1970). LCAT interacts with discoidal and
spherical HDL and catalyzes the transfer of the 2-acyl group of lecithin or
phosphatidylethanolamine to the free hydroxyl residue of cholesterol to form
cholesteryl ester, using apoA-I as an activator (Fielding et al. 1972; Zannis
et al. 2004b). It also catalyzes the reverse reaction of esterification of lysolecithin
to lecithin (Subbaiah et al. 1980). The esterification of free cholesterol of HDL
in vivo converts the discoidal to mature spherical HDL particles (Jonas 2000;
Chroni et al. 2005a). Regarding the mechanism of activation of LCAT by apoA-I,
it has been proposed that residues R130 and K133 play an important role in the
formation of an amphipathic presentation tunnel located between helices 5-5 in the
double belt model. Such a tunnel could allow migration of the hydrophobic acyl
chains of phospholipids and the amphipathic unesterified cholesterol from the
bilayer to the active site of LCAT that contains sites for phospholipase activity
and esterification activity (Jones et al. 2009). The esterification of the cholesterol
converts the 3.67 residues per turn helices to an idealized 3.6 residues per turn helix
(Borhani et al. 1997).
Mutations in LCAT are associated with two phenotypes. The familial LCAT
deficiency (FLD) is characterized by the inability of the mutant LCAT to esterify
cholesterol on HDL and LDL and the accumulation of discoidal HDL in the plasma.
The fish eye disease (FED) is characterized by the inability of mutant LCAT to
esterify cholesterol on HDL only. Both diseases are characterized by low HDL
levels (Santamarina-Fojo et al. 2001) and formation of preβ- and α4
subpopulations.
Analysis of plasma of patients with complete LCAT deficiency (homozygous or
compound heterozygous carriers of functional LCAT mutations) by
two-dimensional electrophoresis shows mostly the presence of small α-HDL sub-
population (Daniil et al. 2011) (Fig. 4a, b). Analysis of plasma of LCAT-deficient
mice by two-dimensional electrophoresis shows the presence of preβ- and small-
size α4 HDL particles (Fig. 4c). Expression of human LCAT by adenovirus-
mediated gene transfer generated large-size α-HDL subpopulations (Fig. 4d). In
contrast, expression of a LCAT mutant generated preβ-HDL along with small-size
α4, α3, and α2 HDL subpopulations (Fig. 4e).
Sera obtained from LCAT heterozygotes had increased capacity to promote
ABCA1-mediated cholesterol efflux and decreased capacity to promote ABCG1-
and SR-BI-mediated cholesterol efflux from macrophages as compared with sera
obtained from normal subjects. These properties were attributed to the increased
preβ- and decreased α-HDL subpopulations in the sera of the LCAT heterozygotes
(Calabresi et al. 2009b). Heterozygosity for LCAT mutations in the Italian popu-
lation was not associated with increased preclinical atherosclerosis (Calabresi
et al. 2009a).
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The LCAT activation ability of apoA-I is inhibited following treatment with
MPO (Shao et al. 2008). In addition myeloperoxidase modification alters several
functions of HDL and generates pro-inflammatory HDL particles (Undurti
et al. 2009).
1.2.2 ApoA-I Mutations that Affect apoA-I/LCAT Interactions
Several naturally occurring apoA-I mutations that produce pathological phenotypes
have been described (Zannis et al. 2006b; Sorci-Thomas and Thomas 2002;
Miettinen et al. 1997b). It has been estimated that structural mutations of apoA-I
occur in 0.3 % of the Japanese population and may affect the plasma HDL levels
(Yamakawa-Kobayashi et al. 1999). From a total of 46 natural mutations of apoA-I,
25 are associated with low HDL levels, and 17 of these mutants reduce the capacity
of apoA-I to activate LCAT (Sorci-Thomas and Thomas 2002; Zannis et al. 2006b).
These mutations are clustered predominantly in or at the vicinity of helix 6 of apoA-I
and some of them predispose to atherosclerosis (Huang et al. 1998; Miller et al. 1998;
Miettinen et al. 1997b; Miccoli et al. 1996). Here we describe how some represen-
tative mutations of this category affect the biogenesis and maturation of HDL.
Fig. 4 (a–e) Two-dimensional gel electrophoresis from plasma obtained from one homozygote
and one compound heterozygote for LCAT deficiency as indicated (a, b) (Daniil et al. 2011).
Two-dimensional gel electrophoresis of plasma obtained from plasma of control LCAT/ mice
(a) and LCAT/ mice infected with an adenovirus expressing either the WT human LCAT (d) or
human LCAT[T147I] found in a patient with fish eye disease (e). LCAT cDNA probes of WT and
LCAT mutants were provided by Dr. J.A. Kuivenhoven (Medical Center of Groningen)
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Previous studies showed that hemizygotes (compound heterozygotes for an
apoA-I null allele and an apoA-I(L141R)Pisa allele) had greatly decreased plasma
apoA-I levels and near absence of HDL cholesterol. Plasma from hemizygotes
contained preβ1-HDL and low concentration of small particles with alpha electro-
phoretic mobility (Miccoli et al. 1997). Heterozygotes for apoA-I(L141R)Pisa had
approximately half-normal values for HDL cholesterol and plasma apoA-I (Miccoli
et al. 1996; Pisciotta et al. 2003). Three male hemizygote patients and one hetero-
zygote patient developed coronary stenosis (Miccoli et al. 1996).
Other studies also showed that heterozygotes for apoA-I(L159R)FIN mutation
had greatly reduced plasma levels of HDL cholesterol and apoA-I (Miettinen
et al. 1997a) that was mainly distributed in the HDL3 region and had abnormal
electrophoretic mobility (Miettinen et al. 1997b; McManus et al. 2001). They also
had small-size (8–9 nm) HDL particles and decreased plasma and HDL cholesteryl
ester levels (Miettinen et al. 1997b; McManus et al. 2001). Human HDL containing
apoA-I(L159R)FIN had increased fractional catabolic rate compared to normal
HDL, indicating increased catabolism of the mutant apoA-I protein (Miettinen
et al. 1997a, b). Only one affected patient with this mutation had clinically
manifested atherosclerosis (Miettinen et al. 1997b).
To explain the etiology and potential therapy of genetically determined low
levels of HDL resulting from natural apoA-I mutations, we have studied the in vitro
and in vivo properties of the naturally occurring mutants, apoA-I[L141A]Pisa and
apoA-I[L159R]FIN (Koukos et al. 2007a). In vitro studies showed that both
mutants were secreted efficiently from cells, had normal ability to promote
ABCA1-mediated cholesterol efflux, but greatly diminished capacity to activate
LCAT (0.4–2 % of WT apoA-I). Adenovirus-mediated gene transfer showed that
compared to WT apoA-I, expression of either of the two mutants in apoA-I-
deficient (apoA-I/) mice greatly decreased total plasma cholesterol and apoA-I
levels as well as the CE/TC ratio compared to WT apoA-I (Table 2). Another
change that was associated with differences between the WT apoA-I and either of
Table 2 Plasma lipids and hepatic mRNA levels of apoA-I/ mice expressing WT and the













apo A-I WT 148 11 0.78 0.01 63 1 100 32 186 34
apoA-I (L141R)Pisa 23 0.4 0.44 0.03 11 2.8 88 9 17 4
apoA-I
(L141R)Pisa + LCAT
184 53 0.68 0.01 41 0.3 91 2 224 7
apoA-I (L159R)FIN 16 5 0.13 0.04 25 4 216 32 25 9
apoA-I
(L159R)FIN + LCAT
224 22 0.73 0.01 53 15 63 9 190 20
apo A-I (R159L)Oslo 43 13 0.23 0.01 36 4 117 30 66 31
apo A-I (R160L)Oslo 250 47 0.082 0.01 62 11 60 1 127 26
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the two mutants was the greatly decreased HDL cholesterol peak as determined by
FPLC fractionation of the plasma. Density gradient ultracentrifugation of plasma
showed great reduction of the amount of apoA-I that floated in the HDL region of
the apoA-I[L141R]Pisa mutant as compared to WT apoA-I (Fig. 5a, d). EM analysis
Fig. 5 (a–m) ApoA-I mutation that influence activity of LCAT. Analysis of plasma of apoA-I/
mice infected with adenoviruses expressing the WT apoA-I or the apoA-I[L141]Pisa mutant alone
or in combination with human LCAT by density gradient ultracentrifugation and SDS-PAGE (a, d,
g) as indicated. EM analysis of HDL fractions 6–7 obtained from apoA-I/ mice expressing the
WT apoA-I or the apoA-I[L141R]Pisa or mutant alone or in combination with human LCAT,
following density gradient ultracentrifugation of plasma, as indicated (b, e, h). Two-dimensional
gel electrophoresis of plasma of apoA-I/ mice infected with adenoviruses expressing WT apoA-
I or the apoA-I[L141q]Pisa or mutant alone or in combination with human LCAT, as indicated (c, f,
i). Western blot analysis of plasma from apoA-I/ mice infected with adenoviruses expressing
either the control protein, GFP, or the WT apoA-I or the apoA-I(L141R)Pisa alone or in combina-
tion with human LCAT, as indicated at the top of the figure (j). Schematic representation showing
the pathway of biogenesis of HDL (k) and how the apoA-I(L141R)Pisa and apoA-I(L159R)FIN
mutants affect the esterification of cholesterol of the pre-HDL particles and prevent their conver-
sion to discoidal and spherical HDL, thus promoting their catabolism (l). Schematic representation
showing the inability of the apoA-I(R160L)Oslo mutant to convert the discoidal to spherical HDL
particles (m)
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of the HDL fractions obtained by density gradient ultracentrifugation showed the
presence of a large number of spherical HDL for WT apoA-I but only a few
spherical HDL particles for the apoA-I[L141R]Pisa mutant (Fig. 5b, e).
Two-dimensional gel electrophoresis of the plasma showed the formation of
small amount of preβ-HDL and large amount of α1, α2, α3, α4 HDL subpopulations
for the WT apoA-I and only preβ- and small-size α4 HDL subpopulations for the
apoA-I[L141R]Pisa mutant (Fig. 5c, f). Similar results were observed for apoA-I
[L159R]FIN (Koukos et al. 2007a).
Coinfection of apoA-I/ mice with adenoviruses expressing either of the two
mutants and human LCAT normalized the plasma apoA-I, the total plasma choles-
terol levels, and the CE/TC ratio (Table 2) and increased the HDL cholesterol peak
and the amount of apoA-I that floated in the HDL region (Fig. 5g). It also generated
large amount of spherical HDL (Fig. 5h) and restored the normal preβ- and α-HDL
subpopulations (Fig. 5i). Similar results were observed for apoA-I[L159R]FIN
(Koukos et al. 2007a).
Another interesting naturally occurring apoA-I mutation is the apoA-I
[R160L]Oslo. Previous studies showed that heterozygotes of apoA-I[R160L]Oslo
have approximately 60 and 70 % of normal HDL and apoA-I levels, respectively,
from preβ1-and small-size α-HDL particles and have a 30 % reduction in their
plasma LCAT activity (Leren et al. 1997). Gene transfer of the apoA-I[R160L]Oslo
mutant in apoA-I/ mice resulted in low plasma cholesterol and apoA-I levels
(Table 2) and generated discoidal particles with α4 electrophoretic mobility. The
aberrant phenotype could be corrected by co-expression of this mutant with
human LCAT (Koukos et al. 2007b).
Similar but not identical phenotypes were produced by expressing the
bioengineered apoA-I[R160V/H162A] and apoA-I[R149A] mutants and the natu-
rally occurring mutants apoA-I[R151C]Paris and apoA-I[L144R]Zaragosa (Haase
et al. 2011; Chroni et al. 2005a; Koukos et al. 2007b). This phenotype could be
corrected by co-expression of the mutant with human LCAT.
The last two mutations have not been associated with incidence of atherosclero-
sis in humans.
The apoA-I mutations discussed here offer a valuable tool to dissect the molec-
ular events which lead to the biogenesis of HDL and possibly to understand the
types of molecular interactions between apoA-I and LCAT which lead to the
activation of the enzyme.
In our case, residues R149, R153, and R160 were reported to create a positive
electrostatic potential around apoA-I. Mutations in these residues reduced drasti-
cally the ability of rHDL particles containing these apoA-I mutants to activate
LCAT in vitro (Roosbeek et al. 2001). Based on the “belt” model for discoidal
rHDL, these residues are located on the hydrophilic face of the apoA-I helices and
do not form intramolecular salt bridges in the antiparallel apoA-I dimer that covers
the fatty acyl chain of the discoidal particle. This arrangement allows in principle
these apoA-I residues to form salt bridges or hydrogen bonds with appropriate
residues of LCAT and thus contribute to LCAT activation.
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To explain the low HDL levels and the abnormal HDL phenotype of the apoA-
I/ mice expressing the apoA-I(L141R)Pisa, we analyzed the relative abundance of
the endogenous mouse LCAT following gene transfer of the apoA-I(L141R)Pisa
mutant alone or in the presence of LCAT. This analysis showed a dramatic increase
of the mouse LCAT in mice expressing the apoA-I(L141R)Pisa mutant as compared
to mice expressing the WT apoA-I. Coinfection of apoA-I/ mice with the apoA-I
(L141R)Pisa mutant and human LCAT restored the mouse LCAT to normal levels
(those observed in the presence of WT apoA-I) (Fig. 5j). The depletion of the
endogenous LCAT in mice expressing the mutant forms of apoA-I could be the
result of rapid degradation of endogenous mouse LCAT bound to minimally
lipidated apoA-I mutants possibly by the kidney.
The ability of the apoA-I[L141R]Pisa and apoA-I(L159R)FIN mutants to be
secreted efficiently from cells and to promote ABCA1-mediated cholesterol efflux
suggests that the functional interactions between apoA-I and ABCA1 that lead to
the lipidation of apoA-I are normal and the low apoA-I and HDL levels caused by
these two mutants are the result of fast removal of the lipidated nascent HDL
particles from the plasma compartment. This interpretation is supported by the
increased catabolic rate of HDL containing apoA-I(L159R)FIN (Miettinen
et al. 1997b) and the accumulation of proapoA-I in the plasma of hemizygotes for
apoA-I(L141R)Pisa (Miccoli et al. 1996). Accumulation of proapoA-I has been
previously observed in patients with Tangier disease (Zannis et al. 1982) that are
characterized by increased catabolic rate of HDL (Assmann et al. 2001). It has been
also shown previously that cubilin, a 600 KDa membrane protein, binds both apoA-
I and HDL and promotes their catabolism by the kidney (Kozyraki et al. 1999;
Hammad et al. 1999).
Previous studies showed that preβ-HDL is an efficient substrate of LCAT
(Nakamura et al. 2004b). In the presence of excess LCAT, the esterification of
the cholesterol of the newly formed preβ-particles appears to prevent their fast
catabolism and allows them to proceed in the formation of discoidal and spherical
HDL. In the case of the apoA-I[R160L]Oslo, the HDL pathway appears to be
inhibited in the step of the conversion of the discoidal to spherical HDL particles.
Figure 5k–m depicts the normal pathway of the biogenesis of HDL (Fig. 5k) and the
disruption of this pathway by the apoA-I(L141R)Pisa and apoA-I(L159R)FIN
(Fig. 5l) and apoA-I[R160L]Oslo mutants (Fig. 5m).
1.3 ApoA-I Mutations May Induce Hypertriglyceridemia
and/or Hypercholesterolemia
A series of apoA-I mutations had resulted in severe hypertriglyceridemia (Chroni
et al. 2004a; 2005b) (Table 3). The most recently studied case was apoA-I[D89A/
E91A/E92A] mutant where the charged residues were substituted by alanines. The
capacity of the apoA-I[D89A/E91A/E92A] mutant to promote ABCA1-mediated
cholesterol efflux and activate LCAT in vitro was approximately 2/3 of that of WT
apoA-I (Kateifides et al. 2011).
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In vivo studies using adenovirus-mediated gene transfer in apoA-I-deficient
mice showed that compared to WT apoA-I, the apoA-I[D89A/E91A/E92A] mutant
increased plasma and HDL cholesterol, reduced the CE/TC ratio, and caused severe
hypertriglyceridemia (Table 3) (Kateifides et al. 2011). Following density gradient
ultracentrifugation of plasma, approximately 40 % of the apoA-I mutant was
distributed in the VLDL/IDL region. In contrast, the WT apoA-I was distributed
in the HDL2/HDL3 region (Fig. 6a). Whereas the WT apoA-I formed spherical
HDL (Fig. 5b), the apoA-I[D89A/E91A/E92A] mutant formed mostly spherical
and few discoidal HDL particles as determined by EM (Fig. 6b). Two-dimensional
gel electrophoresis showed that WT apoA-I formed normal preβ- and α-HDL
subpopulations, whereas the apoA-I[D89A/E91A/E92A] mutants formed preβ-
and α4 HDL subpopulations (Fig. 6c) (Kateifides et al. 2011).
Co-expression of apoA-I[D89A/E91A/E92A] mutants and human lipoprotein
lipase in apoA-I-deficient mice abolished hypertriglyceridemia (Table 3),
redistributed apoA-I in the HDL2/HDL3 regions (Fig. 6d), restored in part the
α1,2,3,4 HDL subpopulations (Fig. 6f), but did not change significantly the choles-
terol ester to total cholesterol ratio (Table 3) or the formation of discoidal HDL
particles (Fig. 6e) (Kateifides et al. 2011).
The findings indicate that residues D89, E91, and E92 of apoA-I are important for
plasma cholesterol and triglyceride homeostasis as well as for the maturation of HDL.
The lipid, lipoprotein, and HDL profiles generated by another mutant, apoA-I
[K94A/K96A], where the charged residues were changed to Alanines, were similar
to those of WT apoA-I, indicating that the observed changes on the HDL phenotype
were unique for the charged residues D89, E91, and E92 (Kateifides et al. 2011).
Expression of a deletion mutant, apoA-I[Δ89-99], in apoA-I/ mice, increased
plasma cholesterol levels, increased the plasma preβ-HDL subpopulation,
generated discoidal HDL particles, but did not induce hypertriglyceridemia (Chroni
et al. 2005b).
Table 3 Plasma lipids and hepatic mRNA levels of apoA-I/ mice expressing WT and the













apo A-I/ 33 6 – 42 7 – –
WT apoA-I 268 55 0.72 0.06 70 11 100 32 283 84
apo A-I [D89A/
E91A/E92A]




122 56 0.44 0.14 49 16 41 6 99 18
apo A-I [Δ(62–
78)]
220 16 – 986 289 130 5 265 36
apo A-I [E110A/
E111A]
520 45 – 1,510 590 69 23 204 27
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Fig. 6 (a–h) Effects of apoA-I mutations on the induction of dyslipidemia. Location of the apoA-I
mutations that cause hypertriglyceridemia as indicated. Analysis of plasma of apoA-I/ mice
infected with adenoviruses expressing the apoA-I[D89A/E91A/E92A] mutant alone or in combi-
nation with human LPL, as indicated, by density gradient ultracentrifugation and SDS-PAGE (a,
d). EM analysis of HDL fractions 6–7 obtained from apoA-I/ mice expressing the apoA-I
[D89A/E91A/E92A] mutant alone or in combination with LPL, as indicated, following density
gradient ultracentrifugation of plasma (b, e). Two-dimensional gel electrophoresis of plasma of
apoA-I/ mice infected with adenoviruses expressing the apoA-I[D89A/E91A/E92A] mutant
alone or in combination with LPL, as indicated (c, f). Schematic representation of the solvent
inaccessible interhelical charged interactions of apoA-I dimers arranged in an antiparallel
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1.3.1 Potential Mechanism of Dyslipidemia Resulting from apoA-I
Mutations
The apoA-I[D89A/E91A/E92A] mutant has two similar characteristics with two other
mutants in different regions of apoA-I, the apoA-I[Δ(61-78)] and the apoA-I [E110A/
E111A] (Chroni et al. 2004a; 2005b), that cause hypertriglyceridemia (Table 3). The
first characteristic is that all three mutants caused accumulation of apoA-I in the VLDL/
IDL region. As shown previously, the accumulation of apoA-I in the lower densities
affects the in vitro lipolysis of the VLDL/IDL fraction by exogenous lipoprotein lipase
(Chroni et al. 2004a; 2005b). The second characteristic is that the three apoA-I mutants
have lost negative-charged residues that are present in the WT sequence. The E78,
D89, and E111 residues have the ability to form solvent inaccessible salt bridges with
positively charged residues present in the antiparallel apoA-I molecule of a discoidal
HDL particle (Segrest et al. 1999) (Fig. 6g).
In these arrangements of the apoA-I molecules on the HDL particle, residues
E78 in helix 2, D89 in helix 3, and E111 in helix 4 can form solvent inaccessible salt
bridges with residues R188 in helix 8, R177 in helix 7, and H155 in helix 6, respec-
tively, of the antiparallel strand. The affinity of all three mutants for triglyceride-
rich lipoprotein particles is further supported by binding studies to triglyceride-rich
emulsion particles (Gorshkova and Atkinson 2011).
It is interesting that in the 11/3 α-helical wheel residues E78, D89, and E111 are
all located in wheel position 2. With the exception of R188, all other five residues
involved in salt bridges are conserved in mammals.
The lipid and lipoprotein abnormalities observed in this mutant suggest that the
increased abundance of apoA-I in the VLDL/IDL region may create lipoprotein
lipase insufficiency that is responsible for the induction of hypertriglyceridemia.
The persistence of discoidal particle following the lipoprotein lipase treatment
indicates a direct effect of the [D89A/E91A/E92A] mutation in the activation of
LCAT in vivo. Previous studies showed that discoidal and small-size HDL particles
and LCAT associated with them may be catabolized fast by the kidney and thus
lead to LCAT insufficiency and reduced plasma HDL levels (Koukos et al. 2007a;
Timmins et al. 2005; Miettinen et al. 1997a).
It is conceivable that loosening of the structure of apoA-I around the D89 or E92
area due to the substitution of the original residues by alanines may provide new
surfaces for interaction of HDL with other proteins or lipoprotein particles such as
VLDL in ways that inhibit triglyceride hydrolysis. Furthermore, the accumulation
of discoidal HDL as well as the formation of preβ- and small α4 HDL particles as
shown by the in vivo experiments indicate that replacement of D89, E91, and E92
by A has a direct impact on the activation of LCAT.
The preceding analyses described in Figs. 3, 4, 5, and 6 demonstrate that expres-
sion of mutant apoA-I forms in different mouse models disrupted specific steps along
the pathway of the biogenesis of HDL and generated discrete lipid and HDL

Fig. 6 (continued) orientation in the belt model of rHDL (g). The pathway of HDL biogenesis.
Superimposed on the pathway are defects that inhibit different steps of this pathway (h)
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phenotypes (Zannis et al. 2006b). The phenotypes generated included inhibition of
the formation of HDL (Chroni et al. 2003, 2007; Fotakis et al. 2013a, b), generation of
unstable intermediates (Koukos et al. 2007a), inhibition of the activation of LCAT
(Chroni et al. 2005a; Koukos et al. 2007b), and increase in plasma cholesterol or
increase in both plasma cholesterol and triglycerides (Chroni et al. 2004a, 2005b;
Kateifides et al. 2011) (Fig. 6h).
1.4 ApoE and apoA-IV Participate in the Biogenesis of HDL
Particles Containing the Corresponding Proteins
Using adenovirus‐mediated gene transfer in apoA‐I‐ or ABCA1‐deficient mice, we
obtained unequivocal evidence that apoE of any phenotype participates in the
biogenesis of apoE‐containing HDL particles (HDL-E) using a similar pathway
that is used for the biogenesis of apoA-I-containing HDL particles (Kypreos and
Zannis 2007). In the initial experiments, gene transfer of an apoE4‐expressing
adenovirus increased both HDL and the triglyceride‐rich VLDL/IDL/LDL fraction
and generated discoidal HDL particles (Fig. 7a). Control experiments showed the
absence of discoidal or spherical HDL-size particles in the plasma of apoA-I-
deficient mice. The involvement of ABCA1 which was established by gene transfer
of apoE in ABCA1/ mice prior to and after treatment with apoE4, and indicated
that apoE4 could not promote formation of HDL particles in ABCA1/ mice
Fig. 7 EM analysis of apoA-I/ and ABCA1/ mice following infection with adenovirus
expressing human apoE4 as indicated (a, b). EM analysis of apoA-I/ mice following infection
with adenovirus expressing human apoE4 and LCAT (c). FPLC profile of apoA-I/ mice
expressing apoE4 and LCAT (d). Analyses of the plasma of apoA-I/ mice following infection
with adenovirus expressing human apoA-IV by density gradient ultracentrifugation and
SDS-PAGE (e), EM (f), and two-dimensional gel electrophoresis (g)
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(Fig. 7b). Other experiments in apoA-I/ x apoE/ mice established that residues
1-202 of apoE are sufficient to promote biogenesis of apoE-containing HDL
(Vezeridis et al. 2011). Coinfection of apoA‐I/ mice with a mixture of
adenoviruses expressing both apoE4 and human LCAT converted the discoidal to
spherical HDL (Fig. 7c), suggesting that LCAT is essential for the maturation of the
discoidal apoE‐containing HDL to spherical particles (Kypreos and Zannis 2007).
The LCAT treatment also cleared the triglyceride‐rich lipoproteins and increased
the HDL cholesterol peak as determined by FPLC (Fig. 7d).
These findings suggest that in contrast to apoA-I where the C-terminal domain is
required for the biogenesis of HDL (Chroni et al. 2007), the carboxy-terminal
domain of apoE is not required for HDL formation. Overall, the findings indicate
that apoE has a dual functionality. In addition to its documented role in the
clearance of triglyceride‐rich lipoproteins, it participates in the biogenesis of
HDL-E in a process that is similar to that of apoA‐I.
HDL-E thus formed may have antioxidant and anti‐inflammatory functions
similar to those described for apoA‐I‐containing HDL, which may contribute to
the atheroprotective properties of apoE (Mineo et al. 2003; Plump et al. 1992;
Schaefer et al. 1986; Navab et al. 2000). ApoE‐containing HDL may also have
important biological functions in the brain (Li et al. 2003).
A similar set of gene transfer experiments in apoA-I/ and apoA-I/ x apoE/
mice also established that similar to apoE, apoA-IV also participates in the biogene-
sis of apoA-IV containing HDL (HDL-A-IV) and requires for this purpose the
activity of ABCA1 and LCAT (Duka et al. 2013).
Gene transfer of apoA-IV in apoA-I/ mice did not change plasma lipid levels.
Density gradient ultracentrifugation showed that apoA-IV floated in the HDL2/
HDL3 region (Fig. 7e), promoted the formation of spherical HDL particles as
determined by electron microscopy (Fig. 7f), and generated mostly α- and a few
preβ-HDL subpopulations as determined by two-dimensional gel electrophoresis
(Fig. 7g). When expressed in apoA-I/ apoE/ mice, apoA-IV increased
plasma cholesterol and triglyceride levels and shifted the distribution of the
apoA-IV protein in the lower density fractions. This treatment likewise generated
spherical particles and α- and preβ-like HDL subpopulations. Co-expression of
apoA-IV and LCAT in apoA-I/ mice restored the formation of HDL-A-IV.
Spherical and α-migrating HDL particles were not detectable following gene
transfer of apoA-IV in ABCA1/ or LCAT/ mice (Duka et al. 2013). The
ability of apoA-IV to promote biogenesis of HDL may explain previously reported
anti-inflammatory and atheroprotective properties of apoA-IV.
In vitro studies showed that lipid-free apoA-IV and reconstituted HDL-A-IV
promoted ABCA1- and scavenger receptor BI (SR-BI)-mediated cholesterol efflux,
with the same efficiency as apoA-I and apoE (Chroni et al. 2005c; Duka et al. 2013).
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1.5 Clinical Relevance of the Aberrant HDL Phenotypes
Genome-wide association studies indicated that specific gene loci were associated
with low or high HDL cholesterol and triglyceride levels and could in principle
affect the risk for coronary artery disease (CAD) (Teslovich et al. 2010). Prospec-
tive population studies have also shown that HDL has a protective role against CAD
(Gordon et al. 1989). The beneficial functions of HDL are also supported by the
atheroprotective effect of apoA-I overexpression in transgenic mice (Rubin
et al. 1991; Paszty et al. 1994) or rabbits (Emmanuel et al. 1996) or following
adenovirus-mediated gene transfer in mice (Belalcazar et al. 2003; Benoit
et al. 1999; Tangirala et al. 1999). The studies described above provide molecular
markers that could be used for the diagnosis, prognosis, and potential treatment of
HDL abnormalities or dyslipidemias associated with the biogenesis and remodeling
of HDL. Diagnostic phenotypes such as those depicted in Figs. 2a–c, 3a–d, 4a, b,
5d–f, and 6a–c can be used to assess defects in apoA-I, ABCA1, and LCAT
respectively.
The HDL phenotypes observed in human patients carrying the apoA-I
[L141R]Pisa and apoA-I[L159R]Fin mutations resemble closely the phenotypes
observed in apoA-I-deficient mice expressing these mutants and indicate the valid-
ity of the gene transfer studies in mice to establish defects in HDL biogenesis. It is
possible that phenotypes generated by mutagenesis of apoA-I may exist in the
human population and can be detected by one or more of the analyses described
previously. The correction of the aberrant HDL phenotypes by treatment with
LCAT suggests a potential therapeutic intervention for HDL abnormalities that
result from specific mutations in apoA-I or conditions that result in low HDL levels.
Additional supporting evidence has been obtained by adenovirus-mediated gene
transfer of human LCAT in squirrel monkeys. This treatment increased two-fold the
HDL levels without affecting apoA-I levels, increased the size of HDL, and
decreased apoB levels (Amar et al. 2009).
The potential contribution of apoA-I mutations to hypertriglyceridemia in
humans is interesting. Hypertriglyceridemia resulting from apoA-I mutations may
be further aggravated by other genetic and environment factors such as diabetes and
thyroid status. The contribution of apoA-I mutations to hypertriglyceridemia could
be addressed in future studies in selected populations of patients with hypertrigly-
ceridemia of unknown etiology.
2 Remodeling and Catabolism of HDL
Following synthesis by the liver and the intestine, HDL is remodeled by various
plasma proteins and is subsequently catabolized in the plasma by cell receptors and
other plasma proteins (Fig. 8a–d).
Turnover studies showed that the mean plasma residence time of radiolabeled
125I-HDL2 and HDL3 was 6 days for normal subjects (Schaefer et al. 1979) and
0.22 days for patients with Tangier disease (Schaefer et al. 1981). Using stable
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isotope turnover kinetic measurements, the resident time was estimated to be 4–5
days. The fractional catabolic rates (FCR) were expressed as pools per day, and the
secretion rates that were determined by this method for men and women were
similar. The FCR were not affected significantly by diet, diabetes, or LDL receptor
defects, but it was increased in subjects with increased glucose tolerance (Marsh
et al. 2000). HDL remodeling affects the structure and metabolic turnover of HDL
and generates a dynamic mixture of discrete HDL subfractions that vary in size,
shape, apolipoprotein, and lipid composition and functions (Siggins et al. 2007;
Fielding and Fielding 2007; Xu and Nilsson-Ehle 2007; Harder and McPherson
2007).
Remodeling of HDL by the action of hepatic lipase (HL) and endothelial lipase
(EL) involves hydrolysis of residual triglycerides and some phospholipids of HDL
(Maugeais et al. 2003a; Santamarina-Fojo et al. 2004), leads to the conversion of
HDL2 to HDL3 and preβ-HDL (Ishida et al. 2003; Krauss et al. 1974; Breckenridge
et al. 1982; Brunzell and Deeb 2001), and accelerates the catabolism of HDL.
Preβ-HDL formation also requires the functions of apolipoprotein M (apoM)
(Wolfrum et al. 2005).
Portion of the cholesteryl esters formed by the actions of LCAT can be trans-
ferred to VLDL/IDL/LDL by the cholesteryl ester transfer protein (CETP)
Fig. 8 (a–d) Schematic representation of the pathway of HDL remodeling by the action of hepatic
and endothelial lipase (a), CETP (b), PLTP (c), and SR-BI, ABCG1, and HDL holoparticle uptake
by F1-ATPase (d)
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(Hopkins and Barter 1980; Barter et al. 2003) The phospholipid transfer protein
(PLTP) can transfer the phospholipids from VLDL/IDL to the HDL particle during
lipolysis to generate HDL2 and can also convert HDL3 particles to HDL2 and
preβ-HDL (Tall et al. 1983; Lusa et al. 1996). HDL-binding proteins/receptors or
transporters have been documented at all steps of HDL metabolism and involve the
SR-BI, which is mostly expressed in hepatocytes, macrophages, and steroidogenic
tissues and mediates selective CE uptake by the cells and tissues and cholesterol
efflux (Gu et al. 1998; Krieger 1999; Rohrl and Stangl 2013; Pagler et al. 2006a);
the ABCG1, which mediates cholesterol efflux (Nakamura et al. 2004a); the ecto-
F1-ATPase subunit, which mediates HDL holoparticle uptake by the liver (Martinez
et al. 2003, 2007); and the cubilin/megalin receptors for removal of apoA-I and
preβ-HDL by the kidney (Martinez et al. 2007).
2.1 ATP-Binding Cassette Transporter G1
HDL can be remodeled following interactions with ABCG1, a 67 kDa protein,
which is a member of the ABC family of half transporters. ABCG1 is expressed in
the spleen, thymus, lung, and brain (Savary et al. 1996; Croop et al. 1997;
Nakamura et al. 2004a) and was reported to be localized on plasma membrane,
the Golgi, and recycling endosomes (Wang et al. 2006; Vaughan and Oram 2005;
Sturek et al. 2010a; Xie et al. 2006a). The expression of ABCG1 is induced by LXR
agonists in macrophages and the liver or by cholesterol loading in macrophages
(Klucken et al. 2000; Venkateswaran et al. 2000; Wang et al. 2006).
Overexpression of ABCG1 promotes cholesterol efflux from different cells to
HDL but not to lipid-free apoA-I (Wang et al. 2004, 2006; Nakamura
et al. 2004a; Vaughan and Oram 2005) (Fig. 8d). HDL obtained from CETP-
deficient subjects or patients treated with the CETP inhibitors torcetrapib or
anacetrapib was shown to have enhanced ability to promote ABCG1-dependent
cholesterol efflux from macrophages (Matsuura et al. 2006; Yvan-Charvet
et al. 2007, 2010). ABCG1-mediated cholesterol efflux to HDL is abolished by
mutations in the ATP-binding Walker A motif indicating that the ATP-binding
domain in ABCG1 is essential for both lipid transport activity and protein traffick-
ing (Vaughan and Oram 2005). In addition, ABCG1 was shown to promote efflux
of 7-ketocholesterol and related oxysterols from macrophages and endothelial cells
to HDL, thus protecting cells from apoptosis (Terasaka et al. 2007; Li et al. 2010).
In macrophages, ABCG1, and not SR-BI or ABCA1, has been shown recently to be
primarily responsible for free cholesterol mobilization to rHDL (Cuchel
et al. 2010a).
Studies in ABCG1-deficient mice also suggested that ABCG1 plays a critical
role in the efflux of cellular cholesterol to HDL (Kennedy et al. 2005). Studies using
intraperitoneal injection of mice with [3H]cholesterol-labeled J774 macrophages
with either increased or reduced ABCG1 expression, as well as primary
macrophages lacking ABCG1 expression, and measurement of the macrophage-
derived [3H]cholesterol levels in plasma and feces, showed that ABCG1 plays a
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critical role in promoting macrophage reverse cholesterol transport in vivo (Wang
et al. 2007). Nevertheless, the studies in ABCG1-deficient and ABCG1 transgenic
mice showed that plasma lipids, HDL, and other lipoprotein levels were not
affected (Kennedy et al. 2005; Out et al. 2007; Burgess et al. 2008). Other studies
showed that loss of ABCG1 gene in mice results in massive lipid accumulation in
hepatocytes and in macrophages within multiple tissues, with the more marked
accumulation in pulmonary macrophages (Kennedy et al. 2005; Out et al. 2006,
2007; Burgess et al. 2008; Baldan et al. 2006; Ranalletta et al. 2006; Wojcik
et al. 2008). In addition, ABCG1 has been suggested to mediate cholesterol efflux
to HDL particles from other cell types than macrophages, including adipocytes
(Zhang et al. 2010) and human placental endothelial cells, where it may facilitate
the transfer of maternal cholesterol to the fetus (Stefulj et al. 2009).
Previous studies indicated that there is little or no specificity of ABCG1 for the
acceptor of cholesterol since LDL, HDL2, HDL3, phospholipid/apoA-I particles of
various sizes and small unilamellar particles can function as acceptors for choles-
terol from cells in an ABCG1-mediated manner (Sankaranarayanan et al. 2009;
Favari et al. 2009). However, a recent study by us showed that the ABCG1-
mediated efflux of cholesterol to rHDL containing different apoA-I mutants is
diminished by deletion of the carboxyl-terminal domain 185-243 from full-length
apoA-I (Daniil et al. 2013). Analysis of rHDL used in these studies suggested that
the impairment of ABCG1-mediated cholesterol efflux is not due to major
differences in particle composition or size between rHDL particles containing
WT apoA-I or apoA-I[Δ(185-243)].
The mechanism by which ABCG1 promotes sterol efflux to extracellular
acceptors has not been resolved. The earlier studies failed to detect specific HDL
association in BHK or HEK293 cells overexpressing the human ABCG1 (Wang
et al. 2004; Sankaranarayanan et al. 2009). Also the initial studies had suggested
that ABCG1 is localized to both the plasma membrane and internal membrane
structures (Vaughan and Oram 2005; Wang et al. 2006; Xie et al. 2006b), while
more recent studies suggested that ABCG1 is localized to endosomes and recycling
endosomes (Sturek et al. 2010b; Tarling and Edwards 2011). It has been proposed
that ABCG1 could transport sterols across the bilayer of endosomes before their
fusion with the plasma membrane and thus redistribute these sterols to the outer
leaflet of the plasma membrane and facilitate their subsequent efflux of sterols to
HDL or other acceptors (Tarling and Edwards 2011; Vaughan and Oram 2005).
However, the similar pattern of lipid-free and rHDL-bound apoA-I mutants to
promote ABCA1- and ABCG1-mediated cholesterol efflux is compatible with a
transient localization of ABCG1 in the plasma membrane that will allow its
interaction with lipoprotein acceptors (Chroni et al. 2003, 2004b; Daniil et al.
2013). The similar cholesterol efflux capacity of lipid-free and lipidated apoA-I
mutants could favor a model where lipid-free apoA-I is lipidated in an ABCA1-
mediated process, changes its conformation, and subsequently accepts more choles-
terol from membrane pools generated by ABCA1 or ABCG1.
The different capacity of rHDL-associated apoA-I[Δ(185-243)] mutant to pro-
mote ABCG1-mediated cholesterol and 7-ketocholesterol efflux (Daniil et al. 2013)
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may be related to the looser association of 7-ketocholesterol with the plasma
membrane compared to cholesterol (Kan et al. 1992).
The finding that lipid-free and lipid-bound apoA-I[Δ(185-243)] has reduced
capacity to promote ABCA1- and ABCG1-mediated cholesterol efflux, respec-
tively, may have physiological significance since proteolysis of HDL-associated
apoA-I in vivo may affect its ability to promote cholesterol efflux from
macrophages. In this regard, proteolysis of apoA-I by metalloproteinases present
in the arterial wall or alveolar macrophages (Russell et al. 2002; Galis et al. 1995)
produces various fragments that correspond to apoA-I cleaved after residues 191 or
188 and are compatible in size with apoA-I[Δ(185-243)] (Lindstedt et al. 1999;
Eberini et al. 2002). This may explain the accumulation of foam cells containing
high cholesterol levels in alveolar macrophages of ABCG1-deficient mice
(Kennedy et al. 2005; Out et al. 2006).
A recent study using high-density genotyping arrays containing single-
nucleotide polymorphisms suggested an association between HDL cholesterol
levels in humans and ABCG1 (Edmondson et al. 2011). Recent genetic association
studies in humans identified functional variants in ABCG1 associated with
increased risk of coronary artery disease (Xu et al. 2011; Schou et al. 2012),
suggesting an important role of ABCG1 in the protection from atherosclerosis
and cardiovascular disease.
2.2 Phospholipid Transfer Protein
Phospholipid transfer protein (PLTP) transfers phospholipids, diacylglycerol (Rao
et al. 1997), free cholesterol (Nishida and Nishida 1997), R-tocopherol (vitamin E)
(Kostner et al. 1995), and lipopolysaccharide among lipoproteins and between
lipoproteins and cells (Hailman et al. 1996; Levels et al. 2005) (Fig. 8c). In vitro
studies have identified a number of functions for PLTP in HDL metabolism (Albers
and Cheung 2004; Siggins et al. 2007). PLTP displays two major functions in
circulation: (1) it transforms HDL particles in a conversion or fusion process
whereby small HDL3 particles are fused leading to the generation of large fused
HDL particles and preβ-HDL that can participate in cholesterol removal from cells
(Vikstedt et al. 2007a), and (2) it transfers post-lipolytic VLDL surface
phospholipids to HDL (Albers and Cheung 2004; Siggins et al. 2007). Functions
of PLTP which may influence the formation of atherosclerotic lesions include the
generation of acceptors for lipid efflux from cells, regulation of plasma HDL levels,
protection of lipoproteins from oxidation, and regulation of production of athero-
genic lipoproteins (Jiang et al. 2001).
In human plasma, two distinct forms of PLTP are present, one with high activity
(HA-PLTP) and the other with low activity (LA-PLTP) (Oka et al. 2000;
Karkkainen et al. 2002). It was reported that phospholipid transfer activity is a
prerequisite for efficient PLTP-mediated HDL enlargement (Huuskonen
et al. 2000) and that enrichment of triglyceride in the HDL core could promote
such fusion (Rye et al. 1998). Of these two forms, only the high specific activity
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PLTP promotes macrophage cholesterol efflux via fusion of HDL particles that
leads to the release of lipid-poor preβ-mobile apoA-I particles which act as efficient
cholesterol acceptors (Vikstedt et al. 2007a). The mechanisms by which LA-PLTP
is generated and its physiological functions are currently unknown. However, since
apoE is able to interact with PLTP, and apoE-containing proteoliposomes can
activate inactive or low active PLTP, the presence of apoE in PLTP complexes is
expected to enhance PLTP activity. This is consistent with the suggestion that apoE
may play a role in regulating the PLTP activity level in plasma (Janis et al. 2005).
HA- and LA-PLTP forms are surface-active proteins, and the low active form was
demonstrated to dock more strongly onto a phospholipid monolayer surface as
compared to HA-PLTP form (Setala et al. 2007). It is therefore possible that
LA-PLTP form could play other important lipid transfer-independent functions
such as signaling on cell surface as suggested (Albers et al. 2012).
Although the role of PLTP in lipoprotein metabolism and atherogenesis has been
intensively studied in gene-targeted mouse models and using in vitro experiments,
the physiological role of PLTP in human metabolism is far from being resolved.
Genetic approach has provided some evidence that genetic variation at the PLTP
locus affects its phospholipid transfer activity and HDL particle size and might
highlight its relevance in cholesterol efflux process (Vergeer et al. 2010a). PLTP-
deficient mice have a marked decrease in HDL and apoA-I (Jiang et al. 1999) but
reduced atherosclerosis in the background of apoE/ or apoB-transgenic mice
(Jiang et al. 2001). It has also been reported that macrophage-derived PLTP
contributes significantly to total plasma PLTP activity and deficiency of PLTP in
macrophages leads to reduced atherosclerosis in LDLr/ mice (Vikstedt
et al. 2007b). There is also an interesting interaction between PLTP and CETP
since it was demonstrated that purified PLTP enhances cholesteryl ester transfer
from HDL3 to VLDL (Tollefson et al. 1988), although PLTP has no cholesterol
ester transfer activity of its own. Moreover, CETP transgenic/PLTP KO mice have
significantly lower plasma CETP activity as compared to that of CETP transgenic
mice (Kawano et al. 2000). Currently, the physiological relevance of this PLTP-
CETP interaction in HDL metabolism is poorly understood.
2.3 apoM
Apolipoprotein M (apoM), which is also involved in HDL remodeling (Fig. 8a), is a
26 kDa glycoprotein that belongs to the lipocalin protein superfamily and has been
shown to bind lipophilic ligands in its hydrophobic binding pocket (Xu and
Dahlback 1999; Nielsen et al. 2009; Dahlback and Nielsen 2009; Hu et al. 2010).
It is secreted by the liver and to a lesser extent by the kidney and associates with
HDL through its retained N-terminal signal peptide (Christoffersen et al. 2008a;
Axler et al. 2008) and to a lesser extent with other lipoproteins. ApoM is involved in
the recycling of small lipophilic ligands via the multi-ligand receptor megalin
(Nielsen et al. 2009) and has been shown to participate in the remodeling and
maturation of HDL in plasma.
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Studies in humans and in mice overexpressing or lacking apoM have shown a
positive association between plasma apoM levels and total as well as HDL and LDL
cholesterol concentrations (Axler et al. 2007; Plomgaard et al. 2009; Christoffersen
et al. 2008b). Lack of hepatocyte nuclear factor-1α (HNF-1α) (Shih et al. 2001) or
inhibition of apoM expression in C57BL/6 mice injected with small interfering
RNA for apoM (Wolfrum et al. 2005) is characterized by diminished concentration
of preβ-HDL particles and presence of large-size HDL particles. In vitro
experiments using plasma obtained from WT mice, apoM knockout, and apoM
transgenic mice showed that apoM increases the formation of preβ-HDL particles
following incubation of the plasma at 37 C (Christoffersen et al. 2008b).
These studies also indicate that apoM-containing HDL particles isolated from
human plasma and the plasma of apoM transgenic mice have increased capacity to
stimulate cholesterol efflux from macrophage foam cells and are more efficient in
protecting against LDL oxidation (Wolfrum et al. 2005; Christoffersen
et al. 2008b). Cell culture studies indicated that expression of apoM in cells
transfected with ABCA1 increases the size of preβ-HDL (Mulya et al. 2010).
Reduced plasma apoM levels have been reported in animal models of diabetes
and some patients with diabetes and metabolic syndrome (Plomgaard et al. 2009;
Dullaart et al. 2009; Xu et al. 2006), indicating potential involvement of apoM in
the development of diabetes. Genetic linkage studies in Chinese populations have
also associated two single-nucleotide polymorphisms (SNPs) located in the apoM
proximal promoter region (SNP T-778C and SNP T-855C) with the development of
coronary artery disease (Xu et al. 2008; Jiao et al. 2007) and one of them (the
T-778C) associated with susceptibility to coronary artery disease.
Adenovirus-mediated gene transfer of apoM in LDL-receptor-deficient mice or
hepatic overexpression of apoM in apoM transgenic mice partially protected the
mice from atherosclerosis development (Christoffersen et al. 2008b; Wolfrum
et al. 2005). Data accumulating until now strongly suggest a protective role for
apoM, and the protection might be mediated via HDL.
2.4 Hepatic Lipase and Endothelial Lipase
HDL is first remodeled in the circulation and subsequently catabolized by cells and
tissues. Hepatic lipase (HL) and endothelial lipase (EL) are two plasma lipases
playing an important role in HDL remodeling (Fig. 8a). HL and EL have specificity
primarily for phospholipids and to a lesser extend for triglycerides of apoB-
containing lipoprotein remnants and large HDL (Maugeais et al. 2003a;
Santamarina-Fojo et al. 2004). HL-deficient mice exhibit elevated levels of large
HDL particles enriched in phospholipids and apoE (Homanics et al. 1995) and
reduced atherosclerosis in the background of apoE/ mice (Karackattu et al. 2006;
Mezdour et al. 1997). In contrast, overexpression of HL in mice reduced plasma
HDL levels (Braschi et al. 1998). A rat liver perfusion of human native HDL2 or
triglyceride-enriched HDL promoted the formation of the preβ1-HDL subspecies
and a reduction of the α-HDL2 (Barrans et al. 1994). These changes were attributed
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to the triglyceride lipase activity of HL (Barrans et al. 1994). Characterization of
preβ1-HDL showed that these particles contain one to two molecules of apoA-I,
associated with phospholipids, and some free and esterified cholesterol (Guendouzi
et al. 1999). When compared to triglyceride-rich HDL2, remnant-HDL2 had lost on
the average one molecule of apoA-I, 60 % of triglycerides, and 15 % of
phospholipids. The estimated composition supported the hypothesis that HL had
splitted the initial particle into one preβ1-HDL and one remnant-HDL2. Remnant-
HDL2 had different composition and properties from HDL3, suggesting that HL
did not promote the direct conversion of HDL2 to HDL3 (Guendouzi et al. 1999).
Analysis of HL transgenic rabbits suggested that HL reduces the size of α-migrating
HDL and increases the rate of catabolism of apoA-I (Kee et al. 2002). Cell studies
showed that HL promotes selective HDL3 cholesterol ester uptake independent
from SR-BI and that proteoglycans are needed for the HL action on selective CE
uptake (Brundert et al. 2003). Earlier studies in mice deficient in both HL and EL
suggested an additive effect of HL and EL on plasma HDL levels but not on
macrophage-mediated reverse cholesterol transport in mice (Brown et al. 2010).
However, a recent study demonstrated that targeted inactivation of both HL and EL
in mice promoted macrophage-to-feces RCT and enhanced HDL antioxidant
properties (Escola-Gil et al. 2013).
HL-deficient patients have elevated plasma concentrations of cholesterol in the
HDL and β-VLDL and increased concentration of triglycerides and phospholipids
in the LDL and HDL (Breckenridge et al. 1982). Analyses carried out in complete
and partial HL-deficient subjects as well as in normotriglyceridemic and hyper-
triglyceridemic controls suggested that HL activity is important for physiologically
balanced HDL metabolism (Ruel et al. 2004). However, the presence of HL may
not be necessary for normal HDL-mediated reverse cholesterol transport process
and is not associated with pro-atherogenic changes in HDL composition and
metabolism (Ruel et al. 2004). In addition, another Mendelian randomization
study showed that subjects with loss-of-function genetic variants of HL have
elevated levels of HDL cholesterol, but are not associated with risk of ischemic
cardiovascular disease and therefore may not be protected against ischemic cardio-
vascular disease (Johannsen et al. 2009).
Endothelial lipase (EL) has phospholipase activity (mostly PLA1 activity) and
low levels of triglyceride lipase activity (Jaye et al. 1999). Overexpression of EL in
mice markedly decreased plasma HDL cholesterol and apoA-I levels, had a modest
effect on apoB-containing lipoproteins, and increased 2.5–3-fold the uptake of the
HDL by the kidney and the liver (Ishida et al. 2003; Maugeais et al. 2003a). In
contrast, the EL deficiency in mice increased HDL cholesterol levels (Ishida
et al. 2003; Ma et al. 2003) and reduced atherosclerosis in the background of
apoE/ mice (Ishida et al. 2004). Analysis of atherosclerosis prone LDLR/ x
ApoB(100/100) mice suggested that EL and the HDL cholesterol levels were
regulated by SREBPs and VEGF-A (Kivela et al. 2012). Overexpression of EL in
mice markedly decreased plasma HDL cholesterol and apoA-I levels and had a
modest effect on apoB-containing lipoproteins (Maugeais et al. 2003b; Ishida
et al. 2003). Furthermore, the HDL phospholipid and cholesteryl ester content
HDL Biogenesis, Remodeling, and Catabolism 81
decreased, while HDL triglyceride content increased (Nijstad et al. 2009) and the
free cholesterol content remained unaltered. Fast protein liquid chromatography
analysis and agarose gel electrophoresis showed that the expression of EL resulted
in the generation of small preβ-HDL particles (Nijstad et al. 2009). In addition,
overexpression of EL increased the selective uptake of hepatic HDL cholesteryl
ester by SR-BI as well as hepatic holoparticle uptake. This resulted in a dramatic
increase in the uptake of the HDL protein, but not the cholesteryl ester moieties,
into the kidneys (Nijstad et al. 2009). These data support a model in which
EL-mediated phospholipid hydrolysis of HDL destabilizes the particle, resulting
in the shedding of poorly lipidated apoA-I from the particle surface, which are
preferentially cleared by the kidneys and via increased selective uptake by SR-BI.
Several genetic EL variants have been reported to be associated with plasma
HDL-C levels (deLemos et al. 2002; Edmondson et al. 2009), and genome-wide
association studies have shown that single-nucleotide polymorphisms (SNPs) near
LIPG (EL) are associated with plasma HDL-C levels (Kathiresan et al. 2008a,
2009; Teslovich et al. 2010). However, the relationship of genetic variation in the
EL locus with the risk for coronary artery disease remains uncertain (Vergeer
et al. 2010b). A newer study showed that carriers of an EL mutant characterized
by complete loss of function had significantly higher plasma HDL cholesterol
levels compared to carriers having partial loss-of-function mutations (Singaraja
et al. 2013). Apolipoprotein B-depleted serum from carriers of HL with complete
loss of function had significantly enhanced capacity to promote cholesterol efflux as
compared to apoB-depleted serum obtained from HL carriers with partial loss of
function (Singaraja et al. 2013). In the same study, it was reported that carriers of
certain EL mutations exhibited trends toward reduced coronary artery disease in
four independent cohorts (Singaraja et al. 2013).
2.5 Cholesteryl Ester Transfer Protein
Cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters
from HDL to VLDL, IDL, and LDL in exchange for triglycerides (Fig. 8b). It was
estimated that 66 % of the cholesteryl esters of HDL return to the liver by the action
of CETP, indicating an important role of CETP in reverse cholesterol transport
(Barter et al. 2003), and 33 % by the action of SR-BI (Fielding and Fielding 2007).
Deficiency in CETP in humans is associated with increased plasma levels of HDL
(hyperalphalipoproteinemia) (Inazu et al. 1990; Maruyama et al. 2003) and
decreased levels of small preβ1-HDL particles (Arai et al. 2000; Asztalos 2004).
An early study showed that the hyperalphalipoproteinemia and high plasma HDL
cholesterol levels in a Japanese family without incidence of atherosclerosis was the
result of deficiency in CETP (Koizumi et al. 1985). Inhibition of CETP activity by
CETP inhibitors increased HDL cholesterol levels and the size of HDL particle and
decreased LDL cholesterol levels in human subjects, but did not increase
atheroprotection (Landmesser et al. 2012; Brousseau et al. 2004; de Grooth
et al. 2002). However, subsequent studies indicated that heterozygous mutations
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in CETP increase the risk for CAD (Hirano et al. 1995, 1997; Zhong et al. 1996).
The effect of CETP on the HDL pathway was also studied in mice expressing the
human CETP gene. CETP transgenic mice have a significant decrease in apoA-I
and HDL levels (Melchior et al. 1994) and increased preβ-HDL levels (Francone
et al. 1996) and are susceptible to atherosclerosis in the background of apoE/ or
LDLr/ mice (Plump et al. 1999).
2.6 Scavenger Receptor BI
2.6.1 Role of SR-BI in HDL Remodeling Based on Its In Vitro
Interactions with Its Ligands
SR-BI is an 82 kDa membrane glycoprotein consisting of a large extracellular
domain, two transmembrane domains, and two cytoplasmic amino and carboxy-
terminal domains (Krieger 1999). SR-BI is primarily expressed in the liver, steroido-
genic tissues, and endothelial cells but is also found in other tissues (Acton
et al. 1996), and it binds a variety of ligands including HDL, LDL, VLDL, and
modified lipoproteins. SR-BI has also been shown to affect chylomicron metabolism
in vivo and bind non-HDL lipoproteins in vitro (Out et al. 2004b, 2005; Krieger
1999, 2001; Acton et al. 1994, 1996; Murao et al. 1997). The most important
property of SR-BI is considered its ability to act as the HDL receptor (Fig. 8d).
It has been shown that SR-BI binds to native HDL and discoidal reconstituted
HDL containing apoA-I or apoE, through their apolipoprotein moieties (Krieger
2001; Chroni et al. 2005c; Liadaki et al. 2000; Xu et al. 1997). When it is bound to
HDL, SR-BI mediates selective uptake of cholesteryl ester, triglycerides,
phospholipids, and vitamin E from HDL to cells (Acton et al. 1996; Greene
et al. 2001; Thuahnai et al. 2001; Stangl et al. 1999; Gu et al. 1998, 2000b;
Urban et al. 2000). It also promotes bidirectional movement of unesterified choles-
terol (Ji et al. 1997; Gu et al. 2000a). Interactions of HDL with SR-BI are
responsible for mobilization of free cholesterol from the whole body
(Ji et al. 1997; Gu et al. 2000a; Cuchel et al. 2010b). SR-BI-mediated HDL
holoparticle endocytosis may also be involved in SR-BI-mediated selective CE
uptake under certain conditions in some types of cells (Pagler et al. 2006b; Ahras
et al. 2008). To understand the molecular interaction of SR-BI with HDL, SR-BI
mutants which display altered biological functions were generated by in vitro
mutagenesis. A SR-BI[M158R] mutant does not bind HDL (Gu et al. 2000a). A
SR-BI[Q402R/Q418R] mutant also does not bind HDL, but in contrast with the first
mutant, it binds LDL (Gu et al. 2000a; b). A SR-BI[G420H] mutant has normal
selective cholesteryl ester uptake but reduced cholesterol efflux to HDL and
reduced hydrolysis of internalized cholesteryl esters (Parathath et al. 2004). Cell
culture cholesterol efflux studies using rHDL containing mutated apoA-I and these
SR-BI mutants showed that the greater reduction of cholesterol efflux in cells
expressing WT SR-BI was with the mutants apoA-I[D102A/D103A] and apoA-I
[R160V/H162A] (21 % and 49 %, respectively) (Liu et al. 2002).
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Follow-up in vivo studies showed apoA-I-deficient mice infected with an ade-
novirus expressing the apoA-I[D102A/D103A] had an HDL phenotype that resem-
bled that of WT apoA-I (Chroni et al. 2005a). In contrast, mice expressing the
apoA-I[R160V/H162A] had a phenotype similar to that described for apoA-I
[R160L]Oslo that could be corrected by co-expression of the apoA-I[R160L]Oslo
mutant and human LCAT (Chroni et al. 2005a). Following density gradient ultra-
centrifugation, the apoA-I[R160V/H162A] mutant that floated in the HDL region
was decreased relatively to WT apoA-I, and it was shifted toward the HDL3 region
(Chroni et al. 2005a).
When the mutant SR-BI[M158R] was examined, several apoA-I mutants tested
had reduced efflux and bound less tightly compared to WT apoA-I with the
exception of rHDL that contained the mutant apoA-I[A160V/H162A]. The binding
of this mutant was almost as tight to the cells that expressed SR-BI[M158R] mutant
as it was for the cells that expressed WT SR-BI (Liu et al. 2002). Based on these
findings, it was suggested that efficient SR-BI-mediated cholesterol efflux requires
not only direct binding (Gu et al. 2000a) but also the formation of a productive
complex between SR-BI and the rHDL particle (Liu et al. 2002).
2.6.2 In Vivo Functions of SR-BI
Expression of SR-BI in the liver was shown to be critical for the control of plasma
levels of HDL cholesterol (HDL-C) (Leiva et al. 2011; Zhang et al. 2007), and its
expression in the steroidogenic tissues is important for synthesis of steroid
hormones (Landschulz et al. 1996; Krieger 1999). Transgenic mice expressing
SR-BI in the liver had decreased apoA-I and HDL cholesterol levels and increased
clearance of VLDL and LDL (Wang et al. 1998; Ueda et al. 1999). SR-BI-deficient
mice had decreased HDL cholesterol clearance (Out et al. 2004a), twofold
increased plasma cholesterol, and presence of large-size abnormal apoE-enriched
particles that were distributed in the HDL/IDL/LDL region (Rigotti et al. 1997).
The in vivo phenotypes generated by overexpression or deficiency of SR-BI are
consistent with its in vitro functions to promote selectively lipid transport from
HDL to cells and efflux of free cholesterol from cells. SR-BI has also been shown to
affect chylomicron metabolism in vivo (Out et al. 2004b; 2005).
Deficiency of SR-BI in mice reduced greatly the cholesteryl ester stores of
steroidogenic tissues and decreased the secretion of biliary cholesterol by approxi-
mately 50 %. However, the SR-BI deficiency did not affect the secretion of the pool
size of bile acids or the fecal secretion of bile acids and the intestinal cholesterol
absorption (Rigotti et al. 1997; Mardones et al. 2001). These findings established
that two important functions of SR-BI are the transfer of the CE of HDL to the liver
and subsequent incorporation into the bile for excretion (Rigotti et al. 1997;
Mardones et al. 2001) and the delivery of cholesteryl esters to the steroidogenic
tissues where it is utilized for synthesis of steroid hormones (Ji et al. 1999). Further-
more SR-BI controls the concentrations and composition of plasma HDL (Krieger
2001; Wang et al. 1998; Ueda et al. 1999; Rigotti et al. 1997; Webb et al. 2002) and
protects different mouse models from atherosclerosis (Hildebrand et al. 2010;
Arai et al. 1999; Ueda et al. 2000; Kozarsky et al. 2000; Huszar et al. 2000;
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Trigatti et al. 1999; Braun et al. 2002, 2003; Karackattu et al. 2005; Zhang
et al. 2005).
SR-BI deficiency also caused defective maturation of oocytes and red blood cells
due to accumulation of cholesterol in the plasma membrane of progenitor cells
(Trigatti et al. 1999; Holm et al. 2002) and caused infertility in the female but not
the male mice (Trigatti et al. 1999; Yesilaltay et al. 2006a). The infertility could be
corrected by restoration of SR-BI gene by adenovirus-mediated gene transfer
(Yesilaltay et al. 2006b). Subsequent experiments showed a negative correlation
of follicular HDL cholesterol levels in women and embryo fragmentation during
in vitro fertilization (Browne et al. 2009). Taken together these data suggest a role
of HDL in oocyte development and embryogenesis. The SR-BI-mediated selective
uptake of the CE of HDL by the liver is a complex process and requires the
functions of a liver-specific protein, PDZK1, that contains four PDZ domains that
can recognize the C-terminal region of SR-BI. Interaction of PDZK1 with the
C-terminal region of SR-BI, posttranscriptionally, regulates localization and stabi-
lity of SR-BI (Fenske et al. 2009). Inactivation of hepatic PDZK1 significantly
affected plasma HDL metabolism and structure and caused occlusive atherosclero-
sis in double-deficient mice for apoE and PDKZ (Kocher et al. 2008; Yesilaltay
et al. 2009). The detailed mechanism of SR-BI-facilitated selective uptake of the
CE of HDL is not yet clear. It has been suggested that HDL binding to hepatic
SR-BI allows the entry of cholesteryl esters into a channel that is generated by
SR-BI and along which cholesteryl esters move down their concentration gradient
into the cell membrane. During this movement, HDL particles donate their CE to
hepatocytes without the simultaneous uptake and degradation of the whole HDL
particle.
Recent findings reviewed in Meyer et al. (2013) indicated that SR-BI-indepen-
dent cholesterol ester uptake processes may also operate in macrophages. Liver-
specific or whole-body ABCA1 deficiency in mice accelerated HDL catabolism in
plasma without changing the hepatic expression of SR-BI, suggesting that other
membrane proteins, such as those involved in the hepatic F1-ATPase/P2Y13 path-
way (Martinez et al. 2003) (see below for more detail) and CD36 (Brundert
et al. 2011), may be involved in the selective cholesteryl ester uptake. In a large-
scale human study, several CD36 SNPs were strongly associated with HDL choles-
terol levels, thus pointing to a potential role of CD36 in the regulation of human
HDL metabolism (Love-Gregory et al. 2008).
Interactions of HDL with SR-BI in endothelial cells trigger signaling
mechanisms that involve activation of eNOS and release of nitric oxide that causes
vasodilation (Mineo et al. 2003; Yuhanna et al. 2001; Li et al. 2002; Gong
et al. 2003).
Human subjects have been identified with a P297S substitution in SR-BI.
Heterozygote carriers for this mutation had increased HDL levels and decreased
adrenal steroidogenesis and dysfunctional platelets, but did not develop atheroscle-
rosis. HDL derived from these subjects had decreased ability to promote cholesterol
efflux from macrophages (Vergeer et al. 2011). A recent study has shown the
impact of SR-BI SNPs on female fertility (Yates et al. 2011).
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2.7 Role of Ecto-F1-ATPase/P2Y13 Pathway in Hepatic HDL
Clearance
Based on Biacore’s surface plasmon resonance studies of hepatic membranes,
Martinez and his colleagues (Martinez et al. 2003) demonstrated the presence of
a 50 kDa apoA-I binding protein that was identical to the subunit of the β-chain of
ATP synthase (Boyer 1997). The HDL-binding protein was identified as ecto-F1-
ATPase that recognizes apoA-I (Fig. 8d). The multi-subunit ATPase complex
consists of two major domains called F0 and F1 (Boyer 1997). The ecto-F1-ATPase
protein, which resides on cell membranes, hydrolyzes ATP to ADP and phosphate
and can be inhibited by the mitochondrial inhibitor protein IF1 (Cabezon
et al. 2003). It was recently shown that IF1 is present in the serum, and its
concentration correlates negatively with HDL-C levels and the risk for coronary
heart disease (Genoux et al. 2013). Binding of lipid-free apoA-I to the high affinity
side of ecto-F1-ATPase enhances binding of HDL to the low-affinity binding sites.
The apoA-I binding to the ecto-F1-ATPase also increases the production of ADP
that associates with its receptor, purinergic P2Y13 (Jacquet et al. 2005). The ecto-
F1-ATPase/P2Y13-mediated HDL uptake pathway is under careful control.
Adenylate kinase and niacin are important factors that regulate HDL metabolism
and plasma levels via ecto-F1-ATPase (Fabre et al. 2006; Zhang et al. 2008).
Inhibitors of ecto-F1-ATPase or adenylate kinase activity that consume ADP
generated by ecto-F1-ATPase downregulate holo-HDL particle uptake (Genoux
et al. 2013). In vivo studies using a P2Y13-deficient mouse model also indicated that
the P2Y13 ADP receptor may have an important role in HDL-mediated reverse
cholesterol transport (Fabre et al. 2010). It is possible that induction of hepatic ecto-
F1-ATPase/P2Y13 pathway might enhance hepatic HDL endocytosis and turnover
and accelerate cholesterol removal from cholesterol-laden macrophages and other
tissues and cells of the body.
2.8 Transcytosis of apoA-I and HDL by Endothelial Cells
It has been shown that endothelial cells have the ability to bind and transcytose
lipid-free apoA-I in a specific manner. This process depends on ABCA1 and leads
to the generation of a lipidated apoA-I particle that is secreted (Cavelier et al. 2006;
Rohrer et al. 2006). Endothelial cells can also transcytose HDL and this process
required the functions of SR-BI and ABCG1 (Rohrer et al. 2009). ApoA-I mutants
with defective C-terminal apoA-I[Δ(185-243)] and apoA-I[L218A/L219A/V221A/
L222A] had 80 % decreased specific binding and 90 % decreased specific transport
by aortic endothelial cells. Following lipidation of these mutants, the rHDL
particles formed were transported through endothelial cells by an ABCG1- and
SR-BI-dependent process. Amino and combined amino- and carboxy-terminal
apoA-I deletion mutants displayed increased nonspecific binding, but the specific
binding or transport remained absent (Ohnsorg et al. 2011). These data support the
model in which apoA-I is initially lipidated by ABCA1 and subsequently processed
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by ABCA1-independent mechanisms. Transcytosis of apoA-I and HDL may pro-
vide a mechanism for transfer of HDL into the subendothelial space.
2.9 The Role of Cubilin in apoA-I and HDL Catabolism
by the Kidney
It has been shown that in humans, impaired cubilin and amnionless function results
in the Imerslunds-Gräsbeck syndrome, which is characterized by intestinal vitamin
B12 malabsorption and proteinuria (Fyfe et al. 2004). Cubilin is a 460 kDa
endocytic receptor which is co-expressed with megalin, a 600 kDa multi-ligand
receptor belonging to the LDL receptor gene family. It is localized in the apical
membranes of epithelial cells in the proximal tubules in the kidney cortex
(Kozyraki 2001). In addition to co-localization of cubilin with megalin, the trans-
membrane protein amnionless is a renal protein that interacts with cubilin and
forms a large cubilin/amnionless complex. In this complex, cubilin plays a role as
a ligand-binding domain, whereas amnionless is essential for subcellular localiza-
tion and endocytosis of cubilin bound to its ligand (Strope et al. 2004; Fyfe
et al. 2004). An important function of cubilin is related to its ability to bind
apoA-I or HDL (Kozyraki et al. 1999). In the kidney, however, HDL particles are
too large to cross the glomerular filtration barrier, and therefore megalin and
cubilin/amnionless protein receptor system is only exposed to filtered lipid-free or
poorly lipidated apoA-I, thereby affecting the overall HDL metabolism (Kozyraki
et al. 1999; Moestrup and Nielsen 2005). In physiological terms, it is considered
that the kidney cortex is a major site of catabolism for lipid-free and poorly
lipidated apoA-I and that this uptake is a concerted action of glomerular filtration,
tubular reabsorption, and intracellular degradation of free apoA-I (Woollett and
Spady 1997). Graversen et al. (2008) analyzed urine samples from patients with
Fanconi syndrome. This is a rare renal proximal tubular reabsorption failure and
also includes dysfunction of cubilin. A high urinary excretion of both apoA-I and
apoA-IV but not apoA-II was evident. This study demonstrated that the human
kidney is a major site for filtered apoA-I and A-IV but not for HDL particles since
urinary excretion of all major lipid classes (phospholipids, triglycerides, choles-
terol, and cholesterol esters) in Fanconi patients was as low as in control subjects
(Graversen et al. 2008). Although the kidney is not considered a central organ in
lipoprotein catabolism, it plays an important role in the degradation of lipid-poor
apoA-I via the cubilin function.
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3 HDL Subclasses
3.1 The Origin and Metabolism of Preb-HDL Subpopulations
Several preβ- and α-HDL subpopulations exist in plasma and are generated as a
consequence of the pathway of biogenesis and remodeling of HDL. These
subpopulations can be separated based on different fractionation procedures
(Fielding and Fielding 1996; Chung et al. 1986; Nichols et al. 1986; Davidson
et al. 1994). The precursor-product relationship between preβ- and α-HDL particles
as well as the precise origin and functions of the preβ-HDL particles is still a matter
of investigation.
It has been reported earlier that preβ-HDL comprises approximately 5 % of total
plasma apoA-I level. It is heterogeneous in size and contains several species of 5–
6 nm in diameter (Fielding and Fielding 1995; Nanjee et al. 2000). The best
characterized species are preβ1 and preβ2 (Fielding and Fielding 1995). The
concentration of preβ1-HDL is increased in large lymph vessels (Asztalos
et al. 1993) and in aortic intima (Heideman and Hoff 1982).
Preβ-HDL particles can be formed by two different routes. The first is de novo
synthesis by the HDL biogenesis pathway (Fig. 8a). The second is generation of
preβ-HDL particles from α-HDL particles by reactions catalyzed by CETP, PLTP,
HL, EL, and apoM discussed earlier (Barrans et al. 1994; Maugeais et al. 2003c;
Arai et al. 2000; Huuskonen et al. 2001; Christoffersen et al. 2008b) (Fig. 8a–c).
Cell culture studies showed that lipid-free apoA-I added to a culture medium of
CHO cells can recruit phospholipids and cholesterol, initially to form small 73 Å
particles, and subsequently larger apoA-I-containing particles by the action of
LCAT that have a precursor-product relationship (Forte et al. 1993, 1995).
Subsequent studies showed that a large proportion of apoA-I is secreted from
HepG-2, CaCo-2, or apoA-I expressing CHO cells in lipid-free monomeric form,
with a Stokes radius of 2.6 nm and preα electrophoretic mobility that is unable to
promote efflux of phospholipids and cholesterol. It was suggested that in a reaction
dependent on ABCA1, the 2.6 nm form was converted into a 3.6 nm monomeric
apoA-I form with preβ electrophoretic mobility that was able to promote efflux of
phospholipids and cholesterol from cells and thus increase its size (Chau
et al. 2006). Expression of apoM in cells transfected with ABCA1 can also increase
the size of preβ-HDL (Mulya et al. 2010). Other studies have shown that some types
of preβ-HDL particles can be formed independently of apoA-I/ABCA1 interactions
in the plasma of humans with Tangier disease and the plasma of apoA-I-deficient
mice expressing mutant apoA-I forms (Chroni et al. 2007; Fotakis et al. 2013a;
Asztalos et al. 2001). Furthermore, inhibition of ABCA1 in HepG2 cells and
macrophage cultures by glyburide inhibited the formation of α-HDL particles but
did not affect the formation of preβ-HDL particles (Krimbou et al. 2005).
The presence of increased concentrations of preβ1-HDL in the vascular bed
suggests that these particles may be generated locally by gradual lipidation of lipid-
poor apoA-I (Heideman and Hoff 1982; Smith et al. 1984). Preβ-HDL particles are
typically lipid-poor and therefore they are efficient in promoting ABCA1-mediated
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cholesterol efflux. The ABCA1/preβ1-HDL interaction provides phospholipids and
cholesterol and thereby converts the preβ-HDL to α-HDL-migrating particles.
These particles may be enlarged further by recruitment of phospholipids and
cholesterol from cell membranes (Fielding and Fielding 2007). In addition, esterifi-
cation of the cholesterol of preβ1-HDL by LCAT contributes to their gradual
conversion into spherical HDL without prior formation of discoidal HDL particles
(Nakamura et al. 2004b; Fielding and Fielding 2007).
3.2 Complexity of HDL
Genome-wide association studies demonstrated that new genes and the
corresponding proteins affect plasma HDL levels by unknown mechanisms
(Holleboom et al. 2008; Kathiresan et al. 2008b, 2009; Sabatti et al. 2009;
Aulchenko et al. 2009; Teslovich et al. 2010; Richards et al. 2009; Willer
et al. 2008; Chasman et al. 2009; Waterworth et al. 2010; Laurila et al. 2013). In
parallel, proteomic analysis showed that a large number of plasma proteins can
associate with HDL and this may affect the HDL structure and functions (Fig. 9)
(Gordon et al. 2010). The proteins associated with HDL can be classified in six
major categories and include proteins involved in lipid, lipoprotein, and HDL
biogenesis and metabolism, acute phase proteins, protease inhibitors, complement
regulatory proteins, and a few others (albumin, fibrinogen a chain platelet basic
protein) (Vaisar et al. 2007; Davidson et al. 2009b). Differences were observed in
Fig. 9 Schematic representation of proteins associated with HDL and factors that may affect
HDL levels and functions
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the proteomic composition of HDL subpopulations derived from HDL particles of
different sizes (Davidson et al. 2009a). Furthermore the HDL proteome could be
altered by pharmacological treatments (Green et al. 2008).
The modulation of the concentration of various proteins associated with HDL
has been studied in more detail under conditions of infection, inflammation, or
tissue injury. Under these conditions, acute phase response is triggered that causes
huge alterations in hepatic protein synthesis in response to cytokines that alter HDL
protein composition (Rohrer et al. 2004; Shah et al. 2013). These changes include
the abrupt increase in serum amyloid A, apoJ, and secretory non-pancreatic phos-
pholipase A2 and a decrease in apoA-I, paraoxonase-1, LCAT, and PLTP. These
changes affect the capacity of HDL to promote cellular cholesterol efflux as well as
other HDL functions (Rohrer et al. 2004; Shah et al. 2013).
In addition to the variety of proteins, a variety of lipids are also carried by HDL,
and some of them are or can be transformed to potent bioactive molecules (Vickers
and Remaley 2014). Furthermore, HDL carries and transports fat soluble vitamins,
steroid hormones, carotenoids, as well as numerous more polar metabolites such as
heneicosanoic acid, pentitol, and oxalic acid which were found to be significantly
correlated with insulin resistance (Vickers and Remaley 2014). Finally, it has been
reported that HDL also transports small RNAs, including microRNAs, tRNA-
derived RNA fragments, and RNase P-derived RNA fragments (Vickers
et al. 2011). How all this protein decoration affects HDL metabolism and HDL
particle function remain to be studied.
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Abstract
HDL regulation is exerted at multiple levels including regulation at the level of
transcription initiation by transcription factors and signal transduction cascades;
regulation at the posttranscriptional level by microRNAs and other noncoding
RNAs which bind to the coding or noncoding regions of HDL genes regulating
mRNA stability and translation; as well as regulation at the posttranslational
level by protein modifications, intracellular trafficking, and degradation. The
above mechanisms have drastic effects on several HDL-mediated processes
including HDL biogenesis, remodeling, cholesterol efflux and uptake, as well
as atheroprotective functions on the cells of the arterial wall. The emphasis is on
mechanisms that operate in physiologically relevant tissues such as the liver
(which accounts for 80 % of the total HDL-C levels in the plasma), the
macrophages, the adrenals, and the endothelium. Transcription factors that
have a significant impact on HDL regulation such as hormone nuclear receptors
and hepatocyte nuclear factors are extensively discussed both in terms of gene
promoter recognition and regulation but also in terms of their impact on plasma
HDL levels as was revealed by knockout studies. Understanding the different
modes of regulation of this complex lipoprotein may provide useful insights for
the development of novel HDL-raising therapies that could be used to fight
against atherosclerosis which is the underlying cause of coronary heart disease.
Keywords
High-density lipoprotein • Regulation • Transcriptional • Posttranscriptional •
Posttranslational • miRNAs • Protein stability • Hormone nuclear receptors •
Hepatocyte nuclear factors • apoA-I • ABCA1 • ABCG1 • ABCG5 • ABCG8 •
apoE • SR-BI • CETP
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ARP-1 Apolipoprotein A-I-regulated protein 1
DHHC8 Asp-His-His-Cys 8
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
BIG1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1
JNK c-Jun N-terminal kinase
C/EBP CCAAT/enhancer-binding protein
CAV-1 Caveolin 1
CXCL Chemokine (C-X-C motif) ligand
COUP-TFI Chicken ovalbumin upstream promoter transcription factor I
CEH Cholesterol ester hydrolase
CETP Cholesterol ester transfer protein
3C Chromosome conformational capture
CLA Conjugated linoleic acid
CAR Constitutive androstane receptor
CREB Cyclic AMP response element-binding protein
DNase Deoxyribonuclease
DR4 Direct repeat with 4 nucleotides in the spacer region
DBD DNA-binding domain




ESCRT Endosomal sorting complex required for transport
ERα and β Estrogen receptors α and β
ERE Estrogen response element
ESRRG Estrogen receptor-related gamma
FXR Farnesoid X receptor
FXRE Farnesoid X receptor-responsive element
FF Fenofibrate
FOXA2 Forkhead box A2
FOXΟ1 Forkhead box Ο1
GF Gemfibrozil
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GR Glucocorticoid receptor
GSK3β Glycogen synthase kinase 3β
HNF-4 Hepatocyte nuclear factor-4
HDL High-density lipoprotein
HDL-C High-density lipoprotein cholesterol
Hcy Homocysteine
HRE Hormone response element
IRAK-1 IL-1 receptor-associated kinase 1




KLF4 Kruppel-like factor 4
LCAT Lecithin-cholesterol acyltransferase
LXR Liver X receptor
LXRE Liver X receptor response element
LRH-1 Liver receptor homologue-1
LBD Ligand-binding domain
LPS Lipopolysaccharide
LDLR Low-density lipoprotein receptor
LAL Lysosomal acid lipase
MCSF Macrophage colony-stimulating factor
miRNAs microRNAs
MEKK Mitogen-activated protein kinase/ERK kinase kinase




NHERF Na+/H+ exchanger regulator factor
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NFY Nuclear factor Y
ORP1S Oxysterol-binding protein-related protein 1S
PDZK1 PDZ domain-containing adaptor protein
PPAR Peroxisome proliferator-activated receptors
PPRE Peroxisome proliferator-activated receptor-responsive element
PMA Phorbol 12-myristate 13-acetate
PI3K phosphatidylinositol 3- kinase
PLD Phospholipase D
PGC-1 PPARgamma coactivator 1
PLTP Phospholipid transfer protein
pri-miRNA Primary long miRNA
PREB Prolactin regulatory element-binding
PEST Proline, glutamic acid, serine, threonine
PKC Protein kinase C
PCA Protocatechuic acid
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PCSK9 Proprotein convertase subtilisin/kexin type 9
RAR Retinoic acid receptor
RORα Retinoic acid receptor-related orphan receptor α
RXRα Retinoid X receptor α
RISC RNA-induced silencing complex
SR-BI Scavenger receptor class B type I
SPTLC1 Serine palmitoyltransferase 1
STAT Signal transducer and activator of transcription
SHP Small heterodimer partner
siRNAs Small interfering RNAs
SP1 Specificity protein 1
S1P Sphingosine 1 phosphate
SRC-1 Steroid receptor coactivator-1
SF-1 Steroidogenic factor-1
SREBP Sterol regulatory element-binding protein
SREs Sterol-responsive elements
TRβ Thyroid hormone receptor β
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TGFβ1 Transforming growth factor β1
TNFα Tumor necrosis factor α
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UTR Untranslated region
URE Upstream regulatory element
USF Upstream stimulatory factors
VDR Vitamin D receptor
WT Wild type
YY1 Yin Yang 1
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ZNF202 Zinc finger protein 202
1 Regulation of Genes Involved in HDL Metabolism
at the Transcriptional Level
A large body of work generated over the past four decades has revealed that
eukaryotic gene transcription is a remarkably intricate biochemical process that is
tightly regulated at many levels by the ordered assembly of multiprotein transcrip-
tion initiation complexes to specific regulatory regions in the promoters of genes
(Roeder 1998, 2005; Lemon and Tjian 2000). Despite the progress made, still
limited knowledge regarding the details exists. It is believed that specificity in
gene regulation is determined by the unique order of cis-acting regulatory regions
which are recognized by sequence-specific DNA-binding transcription factors.
Recent advances in gene regulation technologies including the powerful chromatin
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immunoprecipitation assay have enabled the monitoring in real time of the ordered
assembly and the disassembly of transcription factor complexes on the promoters
and the enhancers of genes in response to extracellular or intracellular cues
(Christova 2013; Rodriguez-Ubreva and Ballestar 2014). High-throughput
sequencing technologies have revolutionized the fields of genomics, epigenomics,
and transcriptomics and have provided novel insights into the transcription
signatures of human diseases (Churko et al. 2013). Furthermore, using new power-
ful methodologies such as chromosome conformation capture (3C) and its
derivatives, we are at a position to monitor dynamic intra- and interchromosomal
interactions that allow the optimal expression of genes at a given time and space
(Gavrilov et al. 2009; Wei et al. 2013).
Transcription factors may be constitutively active in a cell or work in an
inducible mode in response to various ligands and signal transduction pathways.
The cross talk between different signaling pathways which orchestrate the cellular
responses can be facilitated by the physical and functional interactions between
transcription factors, and these interactions can be monitored by various methods
both in vivo and in vitro. All known transcription factors are modular in nature and
contain a DNA-binding domain and a transcriptional activation domain (Mitchell
and Tjian 1989; Lemon and Tjian 2000). In addition, several factors contain a
dimerization domain that permits them to form homodimers and/or heterodimers. A
variety of nuclear receptors for steroids, thyroids, retinoids, etc. contain a ligand
binding site. Via their transcription activation domains, transcription factors appear
to facilitate the recruitment of the proteins of the coactivator complex and the basal
transcription complex to the transcription initiation site of each gene and thus
initiate transcription (Roeder 2005). Importantly, the activity of transcription
factors can be modulated by drugs against diseases such as cancer and cardio-
vascular disease as exemplified by the drugs that activate or repress the hormone
nuclear receptors (Gronemeyer et al. 2004).
It is beyond the scope of this chapter to provide a thorough review of the
different mechanisms of transcriptional regulation of eukaryotic genes or to
describe extensively the different classes of transcription factors, their structures,
and their mode of regulation. We will only focus on those classes of transcription
factors that have been shown to play key roles in the regulation of the genes
involved in lipid and lipoprotein metabolism and more specifically on those
involved in the metabolism of high-density lipoproteins (HDL) such as the hormone
nuclear receptors.
1.1 General Introduction to Hormone Nuclear Receptors
Hormone nuclear receptors belong to a superfamily of transcription factors that are
activated by steroid hormones (estrogens, androgens, glucocorticoids, etc.),
retinoids, thyroids, and products of intermediate metabolism such as bile acids,
fatty acids, and cholesterol derivatives, among others (Gronemeyer et al. 2004).
Some members of this family do not need ligand binding to regulate transcription
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and are classified as “orphans” (Blumberg and Evans 1998). Nuclear receptors are
structurally highly conserved. In terms of primary structure, the highest degree of
homology among family members is in the DNA-binding domain that contains two
zinc fingers (Helsen et al. 2012). Nuclear receptors also contain two transactivation
domains (TADs), one N-terminal ligand-independent TAD called activation func-
tion 1 (AF1) and a ligand-dependent TAD called AF2 located close to the ligand-
binding domain (LBD) (Rochel et al. 2011). Nuclear receptors bind to hormone
response elements (HREs) on the promoters of target genes either as homodimers or
as heterodimers with the retinoid X receptor (RXR). The HREs consist of direct
repeats (DRs), inverted repeats (IRs), or palindromic repeats (PRs) of the consensus
sequence 50 AG(G/T)TCA 30. The repeats are separated by 1, 2, 3, 4, or
5 nucleotides and are designated DR1, DR2, etc. (for the direct repeats); IR1,
IR2, etc. (for the inverted repeats); and PR1, PR2, etc. (for the palindromic repeats)
as described previously (Kardassis et al. 2007; Helsen et al. 2012). The HRE type
and inter-repeat spacing determine to a large degree the specificity in nuclear
receptor binding, but this rule is not strict at all. For instance, both LXR/RXR
and T3R/RXR heterodimers prefer to bind to DR4 HREs, whereas RAR/RXR
heterodimers bind to DR5. The direct repeats with one base spacing (DR1 type)
appear to be very promiscuous as they bind RXR, COUP-TFI, ARP-1, and HNF-4
homodimers and PPAR/RXR, RAR/RXR, COUP-TFI/RXR, and ARP-1/RXR
heterodimers (Nakshatri and Bhat-Nakshatri 1998). The elucidation of the three-
dimensional structure of the ligand-binding domain of several nuclear receptors by
X-ray crystallography in the absence and in the presence of ligands has allowed a
good understanding of the modulation of nuclear receptor action by ligands and the
development of very potent agonists and antagonists, some of which have been used
therapeutically (Bourguet et al. 2000). Chromatin immunoprecipitation studies
usually reveal that nuclear receptors are constitutively nuclear and bound to chro-
matin but they are transcriptionally silent in the absence of ligand. The binding of
the ligand to the LBD causes a major conformational change to this domain which
culminates in the recruitment of nuclear receptor coactivators such as PGC-1 and
CBP/p300 and the displacement of corepressors (Chen and Li 1998; Liu and Lin
2011). Nuclear receptors can cross talk with other transcription factors in a positive
or a negative manner as exemplified by the negative regulation of Jun or NF-κB
transcription factors by the glucocorticoid receptors during inflammation, a mecha-
nism termed trans-repression (Adcock and Caramori 2001).
1.2 Transcriptional Regulation of the apoA-I Gene in the Liver
The hypothesis that apolipoprotein (apo) A-I overexpression positively influences
plasma concentrations of HDL cholesterol (HDL-C) has been validated experi-
mentally in transgenic mice expressing human apoA-I under homologous or hetero-
logous regulatory sequences. These mice have significantly elevated plasma levels
of HDL-C and human apoA-I (Rubin et al. 1991; Kan et al. 2000). These “humanized”
apoA-I transgenic mice are valuable tools for the study of apoA-I gene regulation
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in vivo. Furthermore, it was demonstrated that the overexpression of apoA-I in apoE
KO or LDLR KO mice via transgene- or adenovirus-mediated gene transfer reduced
atherosclerosis development confirming the anti-atherogenic role of apoA-I
upregulation (Paszty et al. 1994; Belalcazar et al. 2003; Valenta et al. 2006).
In humans, the apoA-I gene is expressed abundantly in the liver and intestine and
to a lesser extent in other tissues (Zannis et al. 1985). Early studies had established
that the human apoA-I promoter containing 250 bp upstream from the transcription
start site of the gene is sufficient to drive liver-specific gene expression both in cell
cultures and in mice (Walsh et al. 1989; Tzameli and Zannis 1996; Hu et al. 2010a).
This promoter region is rich in nuclear factor binding sites and responds to various
intracellular as well as extracellular ligands (Zannis et al. 2001a; Haas and
Mooradian 2010). As shown in Fig. 1, prominent role in the regulation of the
apoA-I promoter play two hormone response elements (HREs) located at positions
210/190 and 132/120 that bind members of the hormone nuclear receptor
superfamily in a competitive manner (Tzameli and Zannis 1996).
One of the nuclear receptors that plays a prominent role in apoA-I gene regu-
lation in the liver and the intestine is the hepatocyte nuclear factor-4 (HNF-4).
HNF-4 was discovered as a rat liver nuclear protein that binds to the promoters
of liver-specific genes such as transthyretin and apolipoprotein C-III (Sladek 1994).
In the adult organism, HNF-4 is expressed in the liver, kidney, intestine, and
pancreas (Sladek 1994). The total disruption of the HNF-4 gene in mice leads to
an embryonic lethal phenotype due to the impairment of endodermal differentiation
and gastrulation (Chen et al. 1994). This early developmental arrest was rescued by
the complementation of the HNF-4α/ embryos with a tetraploid embryo-derived
Fig. 1 Regulatory elements and transcription factors that control the expression of the apoA-I
gene. Arrows and block lines denote activation and repression, respectively. The mechanisms are
described in detail in the text. Abbreviations: retinoic acid receptor (RAR); retinoid X receptor
(RXR); thyroid receptor β (TRβ); farnesoid X receptor (FXR); hepatocyte nuclear factor (HNF);
apoA-I regulatory protein 1 (ARP-1); forkhead box 2 (FOXA2); nuclear factor Y (NFY); CCAAT/
enhancer-binding protein (CEBP); liver receptor homologue-1 (LRH-1); small heterodimer part-
ner (SHP); specificity protein 1 (Sp1); tumor necrosis factor α (TNFα), interleukin-1 (IL-1);
lipopolysaccharide (LPS)
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wild-type visceral endoderm (Li et al. 2000). The analysis of the rescued mice
showed that the expression of the apoA-I gene as well as of other apolipoprotein
genes, shown previously to be regulated by HNF-4 including apoA-II, apoB, apoC-
III, and apoC-II, was abolished confirming the cell culture data (Li et al. 2000).
Experiments in mice in which the HNF-4 gene was disrupted in the adult liver using
Alb-Cre revealed that HNF-4 is essential not only for the establishment but also for
the maintenance of hepatic differentiation status (Hayhurst et al. 2001). Lipid and
lipoprotein analysis of plasma of these mice revealed a dramatic reduction in total
cholesterol, HDL cholesterol, and triglycerides as well as a dramatic increase in the
concentration of bile acids (Hayhurst et al. 2001). Furthermore, FPLC analysis
showed that HDL cholesterol from the HNF-4 Liv KO mice eluted later than that
from controls indicative of the presence of smaller HDL populations. Interestingly,
the expression of the two essential genes for HDL biogenesis, namely apoA-I and
ABCA1, was not affected in the livers of the HNF-4 Liv KO, suggesting that the
reduction in the plasma HDL levels was the result of altered HDL remodeling rather
than reduced biosynthesis. In agreement with this, the expression level of the HDL
receptor SR-BI gene was dramatically increased (Hayhurst et al. 2001).
Studies in transgenic mice expressing the human apoA-I gene under its own
regulatory sequences and clinical studies in humans have shown that fibrates have a
positive effect on apoA-I gene transcription as well as on plasma HDL levels. The
increase in human apoA-I gene transcription by fibrates is mediated by peroxisome
proliferator-activated receptor α (PPARα) which binds to a PPRE on the proximal
apoA-I promoter as a heterodimer with RXRα (Tzameli and Zannis 1996; Staels
and Auwerx 1998). This was confirmed by in vivo experiments performed in mice
that express human apoA-I under the control of its own promoter but lack the
expression of PPARα. When these mice were given fenofibrate (FF) or gemfibrozil
(GF) for 17 days, an increase in plasma HDL-C levels was observed by FF and to a
lesser extent by GF only in the mice that express endogenous PPARα (Duez
et al. 2005). The fibrate-treated mice had larger HDL particles possibly due to the
upregulation of phospholipid transfer protein and downregulation of SR-BI (Duez
et al. 2005). Interestingly, the apoA-I gene cannot be upregulated by fibrates in
rodents due to a three base pair difference in the PPRE rendering the rodent apoA-I
PPRE nonfunctional (Vu-Dac et al. 1994). In line with the above findings, liver-
specific inactivation of the PPARα heterodimer partner retinoid X receptor α
(RXRα) gene in mice was associated with increased expression of the apoA-I
gene (Wan et al. 2000).
In a clinical study involving 234 patients with combined hyperlipidemia, both
FF and GF reduced triglycerides and increased HDL-C to a similar extent, but only
FF treatment increased apoA-I plasma levels, and this was in agreement with the
previous clinical trials (Schaefer et al. 1996; Durrington et al. 1998; Sakai
et al. 2001; Duez et al. 2005).
A humanized apoA-I transgenic mouse model expressing human apoA-I under
its own regulatory sequences in a mouse apoA-I null background was recently used
to identify by global gene expression profiling candidate genes that affect lipid and
lipoprotein metabolism in response to fenofibrate treatment (Sanoudou et al. 2009).
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Bioinformatical analysis and stringent selection criteria (twofold change, 0 % false
discovery rate) identified 267 significantly changed genes. In contrast to the study
by Duez et al. discussed above (Duez et al. 2005), fenofibrates (FF) did not
significantly alter the levels of hepatic human apoA-I mRNA and plasma apoA-I
protein. This could be due to differences either in the mouse models used (for
instance, the humanized apoA-I mouse of Sanoudou et al. has 2.1 kb apoA-I
promoter fragment, whereas the model of Duez et al. has a 5.5 kb apoA-I promoter)
or the doses of fibrates (0.2 % w/w in the paper of Duez et al. and 0.03 % in the
paper by Sanoudou et al.). Despite the lack of apoA-I responsiveness, the FF
treatment increased cholesterol levels 1.95-fold mainly due to the increase in
HDL-C. The observed changes in HDL were associated with the upregulation of
genes involved in phospholipid biosynthesis and lipid hydrolysis, as well as in the
phospholipid transfer protein. The gene encoding the estrogen receptor-related
gamma (ESRRG) transcription factor was upregulated 2.36-fold by FF and had a
significant positive correlation with genes of lipid and lipoprotein metabolism and
mitochondrial functions, indicating an important role of this orphan receptor in
mediating the FF-induced activation of a specific subset of its target genes
(Sanoudou et al. 2009).
In addition to HNF-4 and PPARα, the two HREs of the proximal human apoA-I
promoter bind apoA-I regulatory protein 1 (ARP-1) and liver receptor homologue-1
(LRH-1) which repress and activate the apoA-I promoter, respectively, as illustrated
in Fig. 1 (Ladias and Karathanasis 1991; Delerive et al. 2004). LRH-1 is a member of
the fushi tarazu subfamily of nuclear receptors that is highly expressed in the liver,
intestine, pancreas, and ovary (Fayard et al. 2004). In the liver, LRH-1 plays a key
role in cholesterol homeostasis, through the control of the expression of genes that are
implicated in bile acid biosynthesis and enterohepatic circulation such as CYP7A1,
CYP8B1, and ABCG5/8 (del Castillo-Olivares and Gil 2000; Freeman et al. 2004;
Kir et al. 2012; Back et al. 2013), reverse cholesterol transport (SR-BI, apoA-I)
(Schoonjans et al. 2002; Delerive et al. 2004), and HDL remodeling (CETP) (Luo
et al. 2001). However, mice with targeted inactivation of the LRH-1 gene in the liver
are characterized by physiological levels of HDL cholesterol, LDL cholesterol, and
triglycerides but have a profound effect on bile acid composition in the liver which
leads to reduced intestinal reuptake of bile acids and to the enhanced removal of
lipids from the body (Mataki et al. 2007). Recent data suggest that LRH-1 functions
in a compensatory safeguard mechanism for adequate induction of bile salt synthesis
under conditions of high bile salt loss (Out et al. 2011).
The two HREs of the apoA-I promoter also mediate the response of apoA-I to
thyroids, retinoids, and bile acids via heterodimers of RXRα with thyroid hormone
receptor β (TRβ), retinoic acid receptor α (RARα), and farnesoid X receptor α
(FXRα), respectively (Rottman et al. 1991; Hargrove et al. 1999). Although
retinoids activate apoA-I gene expression, thyroids have dual effects on apoA-I
promoter activity, whereas bile acids inhibit apoA-I gene expression (Taylor
et al. 1996; Tzameli and Zannis 1996; Srivastava et al. 2000; Claudel
et al. 2002). As shown in Fig. 1, in response to bile acids, FXR downregulates
apoA-I gene transcription by two complementary mechanisms: (a) a direct binding
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to the apoA-I HRE and (b) an indirect mechanism via the induction of small
heterodimer partner (Bavner et al. 2005) which, in turn, represses the activity of
LRH-1 (Delerive et al. 2004).
The nuclear receptor constitutive androstane receptor (CAR) regulates the
detoxification of xenobiotics and endogenous molecules. In mice, the specific
CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) decreased
HDL cholesterol and plasma apoA-I levels in a CAR-specific manner (Masson
et al. 2008). In transient transfections, CAR decreased the activity of the human
apoA-I promoter in the presence of TCPOBOP, but the mechanism by which this
repression is facilitated remains unknown (Masson et al. 2008).
Ligands of the vitamin D receptor (VDR) were also shown to affect negatively
apoA-I gene expression in hepatic cells (Wehmeier et al. 2005). In VDR KO mice,
serum HDL-C levels were 22 % higher and the mRNA levels of apoA-I were
49.2 % higher compared with WT mice. The mechanisms by which VDR ligands
affect HDL levels remain unclear (Wang et al. 2009).
1.2.1 The Role of the Distal Enhancer in apoA-I Gene Transcription
In addition to its own promoter, optimal expression of the human apoA-I gene in
hepatic and intestinal cells requires the presence of a 200 bp transcriptional
enhancer element located downstream of the apoA-I gene, 500 bp upstream of
the first exon of the adjacent apoC-III gene. This regulatory region, which
coordinates the expression of all three genes of the apoA-I/C-III/A-IV cluster,
contains two hormone response elements that bind HNF-4 and different
combinations of ligand-dependent nuclear receptors as well as two binding sites
for the ubiquitous transcription factor specificity protein 1 (Sp1) (Kardassis
et al. 1997; Lavrentiadou et al. 1999). The mutagenesis of the HREs and of the
Sp1 sites reduced the activity of the apoA-I promoter/C-III enhancer cassette in cell
cultures and abolished the binding of the corresponding factors (Kardassis
et al. 1997; Lavrentiadou et al. 1999).
The contribution of the HREs and the Sp1 binding sites to the tissue-specific
expression of the apoA-I gene in vivo was addressed using transgenic mice bearing
the WT apoA-I/apoC-III gene cluster under the control of their regulatory regions
or the same cluster bearing mutations in different regulatory elements
(Georgopoulos et al. 2000; Kan et al. 2000, 2004). It was shown that mutations in
one of the two HREs of the enhancer (element I4) abolished the intestinal expres-
sion and reduced the hepatic expression of the adjacent apoA-I gene to 20 % of the
control. Mutations in the two HREs of the proximal apoA-I promoter reduced the
hepatic and intestinal expression of the apoA-I gene to approximately 15 % of the
control, whereas combined mutations in all three HREs totally eliminated the
intestinal and hepatic expression of the apoA-I gene (Kan et al. 2000). Studies in
cell cultures established that HNF-4 and Sp1 factors are both required for the
synergy between the apoA-I promoter and the enhancer by physically interacting
with each other and forming transcriptional complexes in order to facilitate the
recruitment of the basal transcriptional machinery (Kardassis et al. 2002). The
aforementioned mouse model that expresses human apoA-I under its own promoter
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and enhancer (Kan et al. 2000) is very useful for the in vivo characterization of the
mechanisms that regulate the expression of the apoA-I gene under physiological or
pathological conditions as well as for the identification and validation of novel
compounds that are designed to upregulate human apoA-I gene transcription and
serve as HDL-raising drugs. This is especially important in light of the differences
between the mouse and the human apoA-I promoters. For instance, the mouse gene
cannot be upregulated by fibrates due to a three base pair difference in the PPRE
compared to the human promoter which responds to 0.2 % fibrates but not to 0.03 %
fibrates as mentioned above.
1.2.2 Other Factors Regulating apoA-I Gene Transcription
Further upstream from the two apoA-I HREs, an insulin response core element
(IRCE) was identified and shown to bind Sp1 (Murao et al. 1998). Insulin-activated
signaling pathways including the Ras/raf and the phosphatidylinositol 3-kinase
(PI3K) have been shown to posttranslationally modify Sp1, and this leads to
increased apoA-I promoter activity (Mooradian et al. 2004).
Early growth response protein 1 (EGR-1) is another transcription factor that
regulates apoA-I expression via the proximal HREs (Kilbourne et al. 1995; Cui
et al. 2002). Mice with experimental nephrotic syndrome are characterized by a
fivefold increase in the levels of EGR-1, and these changes were associated with
high plasma apoA-I and HDL-C levels as well as apoA-I gene transcription in the
liver (Zaiou et al. 1998). In line with these findings, mice deficient in EGR-1 have
reduced plasma HDL-C and apoA-I as well as hepatic apoA-I mRNA levels (Zaiou
et al. 1998). EGR-1 was shown to mediate the response of the apoA-I promoter to
estrogens (Hargrove et al. 1999).
The proximal apoA-I promoter also contains one element that binds the basic
leucine zipper (bZip) factor CCAAT/enhancer-binding protein (C/EBP) and
nuclear factor Y (NFY) and another element that binds hepatocyte nuclear factor-
3β/FOXA2 (Papazafiri et al. 1991; Novak and Bydlowski 1997). Nuclear factor
HNF-3β was shown to mediate the response of the apoA-I promoter to
glucocorticoids (Hargrove et al. 1999).
Several natural compounds with antioxidant, pro-estrogenic, or other activities
were shown to affect apoA-I and HDL-C levels, and these studies are summarized
in Haas and Mooradian (2010).
Pro-inflammatory cytokines including tumor necrosis factor α (TNFα) and
interleukin-1β (IL-1β) were previously shown to inhibit apoA-I gene expression
both in cell cultures and in animals (Ettinger et al. 1994; Song et al. 1998).
Furthermore, plasma levels of HDL-C and apoA-I were shown to be highly
increased in mice deficient in the p50 subunit of the pro-inflammatory transcription
factor NF-κB (Morishima et al. 2003). In agreement with this observation, the
activation of NF-κB by lipopolysaccharide (LPS) caused a reduction in apoA-I
mRNA and protein levels in HepG2 cells, whereas the inhibition of NF-κB via
adenovirus-mediated overexpression of IκBα abolished the reduction (Morishima
et al. 2003). This IκBα-induced apoA-I increase was blocked by preincubation with
MK886, a selective inhibitor of peroxisome proliferator-activated receptor α, and
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mutations in the PPARα binding site in the apoA-I promoter abrogated these
changes (Morishima et al. 2003). In a recent study, it was shown that apoA-I
promoter activity in HepG2 cells is inhibited by TNFα in a c-Jun-dependent manner
but no AP1-responsive element within the apoA-I promoter was reported to mediate
this effect (Parseghian et al. 2013). The inhibition of the expression of apoA-I and
other HDL genes in hepatocytes during inflammation could also be mediated by
HNF-4 which was previously shown to be negatively regulated by the TNFα/NF-κB
signaling pathway by physically interacting with NF-κB (Nikolaidou-
Neokosmidou et al. 2006).
1.3 Transcriptional Regulation of the ABCA1 Gene
The gene encoding the ATP-binding cassette transporter A1 (ABCA1) is expressed
in the liver, small intestine, macrophages, kidney, and various other tissues
(Langmann et al. 1999, 2003; Kielar et al. 2001; Wellington et al. 2002). ABCA1
is an important regulator of HDL biogenesis in the liver and facilitates the removal
of excess cholesterol from macrophages.
ABCA1 is particularly abundant in macrophages (Langmann et al. 1999).
ABCA1 expression in macrophages has little influence on HDL-C plasma levels
(Haghpassand et al. 2001) but is an important factor in the prevention of cholesterol
accumulation in the macrophages found in the atherosclerotic plaque and their
transformation into foam cells (Aiello et al. 2002). ABCA1 mRNA and protein are
very unstable, having a half-life of 1–2 h in murine macrophages (Wang and Oram
2002). Fine-tuning regulatory mechanisms (transcriptional regulation as well as
posttranscriptional and posttranslational modifications) are involved to ensure the
constant and inducible ABCA1 expression in macrophages. In this section, we will
focus on the transcriptional regulation of the ABCA1 gene with emphasis on
macrophages. Posttranscriptional and posttranslational regulation of this gene will
be discussed in later sections.
The human ABCA1 gene mapped to chromosome 9q31.1 is composed of
50 exons, which encode 2261-amino-acid residues (Santamarina-Fojo
et al. 2000). The ABCA1 gene promoter contains a TATA box localized 24 bp
upstream of the transcription initiation site, essential for promoter activity in
macrophages as well as in hepatocytes (Langmann et al. 2002). The engagement
of alternative promoters and transcription initiation sites localized upstream of the
first exon or inside the first intron of the gene enables the inducible and tissue-
specific expression regulation of ABCA1 gene (Huuskonen et al. 2003; Singaraja
et al. 2005). In addition, other transcriptional response elements of the promoter
influence the constitutive and tissue-specific expression of ABCA1 (Fig. 2).
1.3.1 Upregulatory Mechanisms of ABCA1 Gene Expression
The major transcription factors that upregulate ABCA1 gene expression in
macrophages are the nuclear receptors liver X receptors α and β (LXRα and
LXRβ), both expressed by this cell type. LXRs heterodimerize with the retinoic
Regulation of HDL Genes: Transcriptional, Posttranscriptional, and. . . 125
X receptor (RXRα) to bind to the direct repeats separated by four nucleotides
(direct repeat 4; DR4 elements) found at position62/47 of the ABCA1 promoter
(Costet et al. 2000). Additional but not well-characterized LXREs are present at the
intron 1 promoter of the ABCA1 gene (Singaraja et al. 2001). Since the LXRα
promoter is subject to autoregulation, the LXR-mediated gene expression is auto-
amplified (Laffitte et al. 2001a). The natural ligands of LXR are several
hydroxylated derivatives of cholesterol (oxysterols) and include
27-hydroxycholesterol (Schwartz et al. 2000; Fu et al. 2001), 22(R)-
hydroxycholesterol (Costet et al. 2000), 20(S)-hydroxycholesterol (Schwartz
et al. 2000), and desmosterol (Yang et al. 2006). Among these ligands,
27-hydroxycholesterol which is endogenously produced by the action of
CYP27A1 enzyme represents the sensor of cholesterol loading in macrophages.
In addition to these natural ligands, synthetic LXR ligands such as TO901317 have
also been developed. These synthetic LXR agonists upregulate ABCA1 in cultured
macrophages more efficiently than cholesterol loading via modified LDL particles
(Sparrow et al. 2002).
LXR tissue-selective gene transcription is dependent on co-regulatory proteins.
For example, data showed that the activation of the ABCA1 promoter by LXRα/
RXRα heterodimers and their ligands require Sp1 (Thymiakou et al. 2007). The
overexpression of Sp1 increased ABCA1 mRNA level in HeLa cells and enhanced
cellular cholesterol and phospholipid efflux in RAW 246.7 macrophages. Gel shift
experiments revealed in vitro binding of Sp1 to 85/91 and 151/156 GC
Fig. 2 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the ABCA1 gene in macrophages
and other tissues. Arrows and block lines denote activation and repression, respectively. The
mechanisms are described in detail in the text. Abbreviations: retinoic acid receptor (RAR);
retinoid X receptor (RXR); liver X receptor (LXR); sterol regulatory element-binding protein
(SREBP); specificity protein 1 (Sp1); tumor necrosis factor α (TNFα), interleukin (IL); lipopoly-
saccharide (LPS); interferon γ (IFNγ); angiotensin II (AngII); nuclear factor kappa beta (NF-κB);
upstream stimulatory factor (USF); hypoxia-inducible factor (HIF); transforming growth factor β
(TGFβ); peroxisome proliferator-activated receptor (PPAR); Janus kinase (Jak); signal transducer
and activator of transcription (STAT)
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boxes. Moreover, it was shown that Sp3 competed with Sp1 for binding to the latter
GC box, acting as a repressor (Langmann et al. 2002). Physical interactions
between Sp1 and LXRα require the N-terminal region of LXRα, which includes
the DNA-binding domain and two different domains of Sp1: the transactivation
domain B and the DNA-binding domain (Thymiakou et al. 2007). LXR agonists,
such as the natural steroidal ligand 22(R)-hydroxycholesterol and the weak non-
steroidal ligand GSK418224, differentially recruit coactivators and corepressors
compared with full LXR agonists, such as the nonsteroidal ligand T0901317 (Albers
et al. 2006; Peng et al. 2008, 2011; Phelan et al. 2008). The synthetic oxysterol N,
N-dimethyl-3β-hydroxycholenamide (DMHCA) caused a differential induction of
the ABCA1 and the sterol regulatory element-binding protein (SREBP)-1c genes in
hepatic and macrophage cell lines, as well as in mice (Quinet et al. 2004). In
cholesterol-loaded or unloaded peritoneal macrophages, DMHCA increased
ABCA1 mRNA, whereas SREBP-1c mRNA levels were downregulated (Quinet
et al. 2004). Cineole, a small aromatic compound found in teas and herbs, consider-
ably stimulated the transactivation potential of LXRα and LXRβ and induced
ABCA1 expression in macrophages but significantly reduced the expression of
LXRα- and LXRα-responsive genes in hepatocytes (Jun et al. 2013). Another
LXR agonist, ATI-111, had a strong effect on ABCA1 expression in macrophages
as well as in the intestine and small effect on ABCA1 expression in the liver.
ATI-111 significantly stimulated SREBP-1c mRNA in some tissues but inhibited
the conversion of SREBP-1c precursor form into its active form (Peng et al. 2011).
These findings revealed that LXR agonists have a promising potential for the
upregulation of the ABCA1 transporter and the promotion of the cellular lipid
efflux capacity of macrophages. Due to the concomitant LXR-mediated
upregulation of two genes involved in the fatty acid biosynthesis, fatty acid
synthase (Joseph et al. 2002a), and SREBP-1c (Yoshikawa et al. 2001), the devel-
opment of LXR agonists for therapeutic uses has been limited by their adverse
effects that include hepatic steatosis and hypertriglyceridemia. In order to dissoci-
ate the positive effects of LXR agonists on cholesterol homeostasis from the
adverse effects on fatty acid metabolism, the next step will be the discovery of
new LXRβ-selective agonists and the synthesis of novel tissue-specific LXR
ligands with weaker transcriptional effects on SREBP-1c. SREBP-1a, a different
member of the SREBP family of proteins, binds to several sites present inside intron
1; however, the role of these elements in ABCA1 gene regulation is still unknown
(Thymiakou et al., unpublished observations) (Fig. 2).
Besides LXR, other nuclear receptors and transcription factors are involved in
ABCA1 gene regulation in macrophages. Retinoic acid receptor (RAR) activators
such as all-trans-retinoic acid and 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-1-propenyl]benzoic acid (arotinoid acid) were found to increase
ABCA1 mRNA and protein levels in macrophages (Costet et al. 2003).
Co-transfection experiments showed that the same DR4 promoter element of the
ABCA1 promoter binds RXR heterodimers in the following order: RARγ/RXRα
bound stronger and activated the human ABCA1 promoter, and RARα/RXRα
bound weaker, while no RARβ/RXRα binding was detected. However, in
Regulation of HDL Genes: Transcriptional, Posttranscriptional, and. . . 127
macrophages from RARγ/ mice, arotinoid acid still induced ABCA1 gene
expression and caused marked upregulation of RARα, suggesting that high levels
of RARα can compensate for the absence of RARγ (Costet et al. 2003).
Peroxisome proliferator-activated receptors α (PPARα) and γ (PPARγ) are both
expressed in human macrophages where they exert anti-inflammatory effects. The
hydroxylated derivative of linoleic acid, 13-hydroxy linoleic acid, a natural PPAR
agonist, and pioglitazone (PPARγ agonist) increased PPAR transcriptional activity
and induced ABCA1 gene expression in macrophages (Kammerer et al. 2011;
Ozasa et al. 2011). However, data suggest that these effects are indirect and most
probably are mediated by LXRα (Chinetti et al. 2001). PPARδ activators appeared
to induce ABCA1 gene expression and cholesterol efflux moderately and to
increase HDL levels in an obese-monkey model (Oliver et al. 2001).
Recent data showed that Clock, a key transcription factor that controls circadian
rhythm, is involved in ABCA1 regulation in macrophages (Pan et al. 2013). The
dominant-negative Clock mutant protein (ClockΔ19/Δ19) enhanced plasma
cholesterol and atherosclerosis. Mutant ClockΔ19/19/apoE/ mice had macro-
phage dysfunction, expressed low levels of ABCA1, and had higher levels of
scavenger receptors. Molecular studies revealed that Clock regulated ABCA1
expression in macrophages by modulating the activity of upstream stimulatory
factor 2 (Pan et al. 2013).
Experimental data showed that signaling molecules upregulate ABCA1 expres-
sion in macrophages, but the fine-tuning mechanism of modulation and the regu-
latory regions involved remain to be elucidated. Transforming growth factor β1
(TGFβ1) increased ABCA1 mRNA levels in cholesterol-loaded macrophages
(Argmann et al. 2001; Panousis et al. 2001). It was demonstrated that in THP-1
macrophage-derived foam cells, the LXRα pathway is involved in TGFβ-mediated
upregulation of ABCA1 expression (Hu et al. 2010b). Interleukin-6 (IL-6) signifi-
cantly increased ABCA1 at both the mRNA and protein levels. This effect was
abolished by selective inhibition of the JAK2/STAT3 signaling pathway (Frisdal
et al. 2011). ABCA1 mRNA levels were significantly increased by estradiol
treatment of macrophages for a short period of time, suggesting a direct activation
of the ABCA1 promoter via the estrogen receptor β (Schmitz and Langmann 2005).
Membrane-permeable analogues of cyclic adenosine monophosphate (cAMP)
induced the ABCA1 mRNA in macrophages and other cells by an unknown
mechanism (Lin and Bornfeldt 2002). Inhibitors that are able to block the action
of phosphodiesterase 4 on cAMP have been found to increase ABCA1 mRNA and
cellular cholesterol efflux (Lin and Bornfeldt 2002). Verapamil, a calcium channel
blocker, enhanced ABCA1 transcription by an LXR-independent process (Suzuki
et al. 2004). Toll-like receptor 2 agonist Pam(3)CSK(4) upregulated ABCA1 gene
expression in RAW 264.7 macrophages via the activation of the PKCη/phospho-
lipase D2 signaling pathway (Park et al. 2013). S-Allylcysteine, the most abundant
organosulfur compound in aged garlic extract, also elevated ABCA1 content in
human THP-1 macrophages (Malekpour-Dehkordi et al. 2013). The data showed
that stimulation with CXCL5 that has a protective role in atherosclerosis (Rousselle
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et al. 2013) induced ABCA1 expression in alternatively activated
(M2) macrophages but not in classically activated (M1) macrophages.
1.3.2 Negative Regulation of ABCA1 Gene Transcription
The thyroid hormone T3 strongly suppressed ABCA1 gene transcription
(Huuskonen et al. 2004). It was demonstrated that T3 significantly inhibited the
ability of oxysterols to activate LXR. Moreover, the TR/RXR heterodimers
competed with LXR/RXR for the DR4 element in the ABCA1 promoter
(Huuskonen et al. 2004). A reciprocal negative cross talk exists between LXRs
and STAT1 based on the competition for CREB-binding protein (Pascual-Garcia
et al. 2013). This may explain the IFNγ-mediated downregulation of ABCA1 in
cholesterol-loaded macrophages (Panousis and Zuckerman 2000; Argmann
et al. 2001; Ma et al. 2013). Moreover, TNFα downregulates ABCA1 as well as
LXRα expression in macrophages via a PKCθ-dependent pathway (Ma et al. 2013).
Unsaturated fatty acids decrease the expression of ABCA1 in RAW 264.7
macrophages by a mechanism that involves LXR/RXR binding to the promoter
(Uehara et al. 2007) and by modulation of the histone acetylation state
(Ku et al. 2012). In MCSF-activated human monocytes, linoleic acid decreases
ABCA1 gene expression (Mauerer et al. 2009). Geranylgeranyl pyrophosphate, a
product of the mevalonate pathway that is used for protein isoprenylation,
suppresses LXR-induced ABCA1 synthesis in two ways: as an antagonist of the
LXR interaction with the steroid receptor coactivator-1 (SRC-1) and as an activator
of Rho GTP-binding proteins (Gan et al. 2001).
Among the transcription factors that downregulate ABCA1 expression in
macrophages in an LXR-independent manner is the SCAN domain-containing
zinc finger transcription factor ZNF202 which binds to a GnT motif in the region
234/215 of the ABCA1 promoter (Porsch-Ozcurumez et al. 2001). High intra-
cellular levels of ZNF202 prevented LXR/RXR-mediated induction of the ABCA1
promoter in response to oxysterols (Porsch-Ozcurumez et al. 2001).
The conserved E-box at position 140 binds transcription factors that modulate
the ABCA1 gene expression. Experimental data indicated that upstream stimu-
latory factors (USF) 1 and 2, hepatocyte nuclear factor-1α (HNF-1α), and
fos-related antigen (Fra)2 bind to the intact E-box of the human ABCA1 promoter
and differentially modulate the gene expression: USF1 and USF2 enhanced and
Fra2 repressed ABCA1 promoter activity (Langmann et al. 2002; Yang et al. 2002).
The same E-box element also binds the sterol regulatory element-binding protein
2 (SREBP-2), a key regulator of cholesterol metabolism, which suppresses ABCA1
gene transcription in response to cholesterol depletion (73).
ABCA1 gene expression was severely decreased in the liver and peritoneal
macrophages of diabetic mice (Uehara et al. 2002). This observation was explained
using in vitro models in which it was revealed that acetoacetate downregulates
ABCA1 mRNA and protein in HepG2 hepatocytes and RAW 264.7 macrophages
(Uehara et al. 2002) and thus high glucose concentration decreases ABCA1 gene
expression in MCSF-activated monocytes (Mauerer et al. 2009). Data showed that
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the treatment of THP-1 macrophages with 100 nM dexamethasone, a potent
synthetic ligand of the glucocorticoid receptor, decreases the expression of the
ABCA1 gene (Sporstol et al. 2007).
LPS downregulates ABCA1 in macrophages; this inhibition was reverted by the
treatment with betulinic acid acting via the downregulation of miR-33 and suppres-
sion of NF-κB pathway (Zhao et al. 2013). IL-18 and IL-12 synergistically decrease
ABCA1 levels in THP-1 macrophage-derived foam cells through the IL-18 recep-
tor/NF-κB/ZNF202 signaling pathway (Yu et al. 2012). ABCA1 expression was
strongly suppressed by angiotensin (Ang) II at both mRNA and protein levels in a
dose-dependent manner in THP-1-derived macrophages, whereas ABCG1 expres-
sion was not affected. The effect of Ang II on ABCA1 expression could be
mediated by the angiotensin II type 1 (AT1) receptor (Chen et al. 2012a). It was
demonstrated that clinically relevant concentrations of homocysteine (Hcy)
decreased the mRNA and protein expression levels of ABCA1 in macrophages. It
was revealed that mRNA expression and the activity of DNA methyltransferase
were increased by Hcy, which may explain the higher DNA methylation level of
ABCA1 gene in macrophages incubated with Hcy (Liang et al. 2013).
1.4 Transcriptional Regulation of the ABCG1 Gene
ABCG1 mediates cholesterol removal from macrophages to HDL particles, but not
to lipid-free apoA-I (Kennedy et al. 2005; Fitzgerald et al. 2010). Although recent
data showed that the combined macrophage deficiency of ABCA1/G1 is
pro-atherogenic, probably by promoting plaque inflammation (Westerterp
et al. 2013), the data concerning the role of ABCG1 expression in macrophages is
controversial. Two independent groups reported that LDLR/ mice lacking
macrophage ABCG1 show decreased atherosclerotic lesions (Baldan et al. 2006;
Ranalletta et al. 2006), while others reported that the absence of macrophage
ABCG1 causes a modest increase in atherosclerotic lesions (Out et al. 2006).
These contradictory results may be explained by recent data showing that the
absence of ABCG1 leads to increased lesions in early stages of atherosclerosis
but causes retarded lesion progression in more advanced stages of atherosclerosis in
LDLR/ mice, suggesting that the influence of ABCG1 deficiency on lesion
development depends on the stage of atherogenesis (Meurs et al. 2012).
The human ABCG1 gene has been mapped to chromosome 21q22.3 and encodes
for a 678-amino-acid protein of 75.5 kDa molecular mass (Chen et al. 1996). The
ABCG1 gene spans more than 70 kb and includes 15 exons, each containing
between 30 and 1,081 bp, while the intron size is between 137 bp and more than
45 kb. All exon-intron boundaries display the canonical GT/AG sequences.
In contrast to the ABCA1 gene, the ABCG1 gene does not contain a canonical
TATA box in the promoter (Langmann et al. 2000).
130 D. Kardassis et al.
The regulation of ABCG1 expression has similarities with that of ABCA1
(Fig. 3). Thus, LXR plays an important role in ABCG1 promoter activation.
Experimental data indicated that various LXR ligands upregulate ABCG1 expres-
sion. ATI-111, a novel steroidal LXR agonist, induces ABCG1 mRNA expression
in peritoneal macrophages more potently than T0901317 and inhibits its expression
in the liver, suggesting tissue selectivity (Peng et al. 2011). Different natural
compounds, such as cineole and fucosterol that are LXR activators, are able to
increase ABCG1 levels in macrophages (Hoang et al. 2012; Jun et al. 2013). Recent
data showed that the knockdown of LXRα impaired cholesterol efflux in human
primary macrophages, while LXRβ silencing had no detectable impact on the
expression of LXR target genes such as ABCA1 and ABCG1 and did not affect
cholesterol efflux (Ishibashi et al. 2013). The indirect effects of LXR in ABCG1
regulation were recently shown. Adiponectin treatment significantly increased
ABCG1 mRNA and protein levels in macrophages from diabetic patients, whereas
the pharmacological or genetic inhibition of LXR abrogated this enhancement;
these data demonstrated that the mechanism of adiponectin-mediated upregulation
of ABCG1 includes LXRα (Wang et al. 2013b). Similar with ABCA1, TGFβ
upregulates the expression of ABCG1, while unsaturated fatty acids suppress
ABCG1 expression via the LXR pathway (Uehara et al. 2007; Hu et al. 2010b).
The analysis of potential regulatory elements in the promoter region carried out
using the MatInspector program identified multiple Sp1 sites at positions 184,
382, and 566, an AP2 binding site at position 222, a NF-κB site at position
338, an E-box motif at position 233, a sterol regulatory element at position
660, and the NFY binding site at position 198 in ABCG1 proximal promoter
(Langmann et al. 2000). A functional genetic variant of the ABCG1 promoter
associated with an increased risk of myocardial infarction and ischemic heart
disease in the general population was revealed (Schou et al. 2012). This study
Fig. 3 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the ABCG1 gene. Arrows and block
lines denote activation and repression, respectively. The mechanisms are described in detail in the
text. Abbreviations: conjugated linoleic acid (CLA); glycogen synthase kinase 3β (GSK3β); sterol
regulatory element-binding protein (SREBP); specificity protein 1 (Sp1)
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showed that the ABCG1 expression was decreased by approximately 40 % in
g.-376C>T heterozygotes versus noncarriers. This gene polymorphism is included
in a Sp1 binding site located at position382/373 in the ABCG1 promoter. Thus,
the presence of the 376 T allele reduced the binding and transactivation of the
promoter by Sp1, leading to a decreased ABCG1 expression (Schou et al. 2012).
ZNF202 was identified as a transcriptional repressor of ABCG1 gene which
binds at position 560 in the ABCG1 promoter (Porsch-Ozcurumez et al. 2001).
Recently, microbiotic and dietary factors were shown to regulate the ABCG1
expression. Protocatechuic acid (PCA), a gut microbiota metabolite of cyanidin-3
formed by 0-β-glucoside, exerts an anti-atherogenic effect partially through the
inhibition of miR-10b-mediated downregulation of ABCG1 expression (Wang
et al. 2012a). Extra-virgin olive oil intake has been shown to improve the capacity
of HDL to mediate cholesterol efflux and increased ABCG1 and ABCA1 expres-
sion in human macrophages (Helal et al. 2013). Conjugated linoleic acids (CLAs)
are minor components of the diet with many reported biological activities. It was
revealed that in MCSF-differentiated monocytes, trans-9,trans-11-CLA, but not
cis-9,trans-11-CLA and trans-10,cis-12-CLA, activated ABCG1 via SREBP-1c
(Ecker et al. 2007). In addition, it was demonstrated that palmitic acid upregulates
the ABCG1 gene, while high glucose concentration decreased ABCG1 gene
expression in MCSF-activated human monocytes (Mauerer et al. 2009).
Among the downregulators of ABCG1, low doses of LPS strongly reduce the
expression of ABCG1 in bone marrow-derived macrophages through IL-1 receptor-
associated kinase 1 (IRAK-1)/glycogen synthase kinase 3β (GSK3β)/retinoic acid
receptor α (RARα) signaling pathway (Maitra and Li 2013). HMG-CoA reductase
inhibitors, simvastatin and atorvastatin, decreased ABCG1-mediated cholesterol
efflux in human macrophages, despite the fact that the protein expression remained
unaltered (Wang et al. 2013c). In THP-1 monocytes, 100 nM dexamethasone, a
synthetic glucocorticoid, inhibited the mRNA expression of ABCG1, although the
glucocorticoid receptor expression was very low in this cell line (Sporstol
et al. 2007). IL-22, a member of the IL-10 cytokine family secreted primarily by
Th17 and Th22 subsets of T lymphocytes, was induced by S100/calgranulin and
impaired cholesterol efflux in macrophages by downregulation of ABCG1 (Chellan
et al. 2013).
1.5 Transcriptional Regulation of the Apolipoprotein E Gene
Apolipoprotein E (apoE), a glycoprotein of 35 kDa, plays an important role in
plasma cholesterol level regulation and in cholesterol efflux, as documented by
studies in patients and animal models with apoE deficiency or mutated apoE genes
(Nakashima et al. 1994; Linton et al. 1995; von Eckardstein 1996; Van Eck
et al. 1997; Grainger et al. 2004; Ali et al. 2005; Davignon 2005; Raffai
et al. 2005). ApoE is mainly synthesized by the liver but also by various cells and
peripheral tissues (Zannis et al. 2001b). ApoE is a marker for the developmental
state of macrophages; the culture of mouse bone marrow cells in vitro showed that
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mature macrophages, but not their monocytic precursors, synthesized apoE (Werb
and Chin 1983c). At the site of atherosclerotic lesion, apoE is provided by
infiltrated macrophages. Transgenic mice expressing apoE only in macrophages
are protected against atherosclerosis, even though the plasma levels of apoE are
exceedingly low and the animals are hypercholesterolemic (Bellosta et al. 1995). In
contrast, transgenic mice with normal levels of apoE in plasma, but not in
macrophages, are more susceptible to atherosclerosis (Fazio et al. 1997). ApoE
secreted by macrophages within the atherosclerotic plaque facilitates the choles-
terol efflux to exogenous acceptors (such as HDL), thus assisting the reverse
cholesterol transport to the liver. The uptake of acetylated LDL or cholesterol
ester-rich β-VLDL into peritoneal macrophages stimulates apoE synthesis and
secretion (Basu et al. 1981).
The human apoE gene is located on chromosome 19 at the 50 end of a cluster
containing also apoC-I, apoC-IV, and apoC-II genes (Myklebost and Rogne 1988;
Smit et al. 1988; Allan et al. 1995a, b). The regulation of apolipoprotein E gene
transcription is a highly complex process and requires the interaction of transcrip-
tion factors with the proximal promoters but also with the distal regulatory regions
(Fig. 4).
Fig. 4 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the apoE gene. Arrows and block
lines denote activation and repression, respectively. The mechanisms are described in detail in the
text. Abbreviations: glucocorticoid receptor (GR); signal transducer and activator of transcription
(STAT); Jun N-terminal kinase (JNK); retinoid X receptor (RXR); liver X receptor (LXR);
specificity protein 1 (Sp1); activator protein 2 (AP2); nuclear factor kappa beta (NF-κB); upstream
regulatory region 3 binding protein (URE3BP); lipopolysaccharide (LPS); multienhancer
2 (ME.2); transforming growth factor β (TGFβ)
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1.5.1 Proximal Regulatory Binding Sites Involved in the apoE Gene
Expression
The proximal apoE promoter is well conserved in humans and mice, having the
same localization of TATA box and GC box (Rajavashisth et al. 1985; Horiuchi
et al. 1989). Multiple positive and negative elements that modulate apoE gene
expression have been detected on the apoE promoter, using different in vitro
systems (Larkin et al. 2000; Zannis et al. 2001b). Smith et al. analyzed the apoE
promoter in both expressing (HepG2) and non-expressing (HeLa) cells (Smith
et al. 1988). Within the proximal 50-flanking sequence and the first intron, eight
regions were identified which had a positive effect and three regions with a negative
effect on apoE expression, in both HepG2 and HeLa cells (Smith et al. 1988). The
proximal apoE promoter contains a GC box transcriptional control element at 59/
45, a nonspecific enhancer element at 366/246, an upstream regulatory ele-
ment (URE1) at 193/124, and a downstream regulatory element at +44/+262
(Paik et al. 1988). Within URE1, a sequence spanning 161/141, defined as a
positive element for transcription, has the ability to act alone as an enhancer
element (Chang et al. 1990). This element interacts with Sp1 transcription factor
that constitutively binds the GC box motif, suggesting that Sp1 may play an
important role in the basal level of apoE expression, as well as in the activity of
this enhancer element. Another regulatory element, termed URE3, was identified at
position 101/89 and found to bind a 300 kDa protein from placental nuclear
extracts termed URE3 BP (Jo et al. 1995). DNase I footprinting revealed the
existence of two binding sites for recombinant AP2 in the regions from 48/74
and from 107/135 of the apoE promoter (Olaisen et al. 1982; Smith et al. 1988;
Garcia et al. 1996; Salero et al. 2001, 2003). Gel mobility-shift assays showed the
direct binding of LXRα/RXRα and LXRβ/RXRα to a low-affinity LXRE present in
the region 494/465 of the proximal promoter (Laffitte et al. 2001b). Other
studies revealed that USF binds to an atypical E-box located in the 101/91
region of the apoE promoter (Salero et al. 2003). The same group found that Zic1
and Zic2 transcription factors can bind to three binding sites located at 65/54,
136/125, and 185/174 in the apoE promoter and stimulate apoE gene
expression (Salero et al. 2001).
Bacterial endotoxin and other inflammatory agents decrease apoE production
(Werb and Chin 1983a, b; Gafencu et al. 2007). The apoE downregulation in
macrophages impaired the local beneficial effect of apoE during the plaque devel-
opment. As a result, despite the fact that macrophages are present in the lesion, their
ability to regress atherosclerosis is seriously compromised. We have previously
reported the mechanisms of apoE downregulation in macrophages exposed to
inflammatory conditions, similar to those found at the atherosclerotic site (Gafencu
et al. 2007). Tumor progression locus 2 (Tpl2) and mitogen-activated protein
kinase/ERK kinase kinase 1 (MEKK1) were identified as the kinases that are
primarily responsible for the downregulation of apoE promoter activity by LPS.
Tpl2 and MEKK1 signaling pathways converge to NF-κB and AP1, acting on the
apoE core promoter 55/+73 (Gafencu et al. 2007).
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1.5.2 Distal Regulatory Binding Sites That Modulate apoE Gene
Expression in Macrophages
Despite this complex transcription factor machinery that may be targeted to the
apoE promoter, the promoter itself lacks the ability to direct gene transcription
in vivo in any cells, in the absence of the distal enhancers (Shih et al. 2000). In
many tissues, cell-specific distal enhancers regulate the expression of genes in the
apoE/apoC-I/apoC-I0/apoC-IV/apoC-II gene cluster (Shih et al. 2000). The expres-
sion of apoE in macrophages is controlled by two homologous enhancers (95 %
identical in sequence), designated as multienhancer 1 (ME.1) and multienhancer
2 (ME.2), containing 620 and 619 nucleotides, respectively (Shih et al. 2000).
These enhancers are located at 3.3 and 15.9 kb downstream of the apoE gene,
respectively. We demonstrated by chromosome conformational capture (3C) and
transient transfections that both ME.1 and ME.2 can interact with the apoE pro-
moter only in phorbol 12-myristate 13-acetate (PMA)-differentiated macrophages,
but not in undifferentiated monocytes (Trusca et al. 2011). The results showed that
the interactions take place in antisense orientation of the promoter and ME.1/2. Our
data obtained using a series of deletion mutants of the promoter or of the ME.2
identified the fragment 100/+73 as the minimal region of the apoE promoter that
is activated by the ME.2. We showed that the entire sequence of ME.2 is necessary
for an optimal interaction with the apoE promoter, but the 50 region of ME.2 is more
important than 30 region for enhancing apoE promoter activity (Trusca et al. 2011).
The interaction of the apoE promoter with ME.1/2 facilitates the transcriptional
enhancement of the apoE gene by various transcription factors.
LXRα and LXRβ and their oxysterol ligands are key regulators of apoE expres-
sion in macrophages (Laffitte et al. 2001b; Joseph et al. 2002b; Mak et al. 2002b).
The ability of oxysterols and synthetic ligands to regulate apoE expression in
peritoneal macrophages as well as in adipose tissue is reduced in LXRα/ or
LXRβ/ mice and abolished in double knockouts. However, basal expression of
apoE is not compromised in LXR null mice, suggesting that LXRs mediate lipid-
inducible expression rather than tissue-specific expression of this gene (Laffitte
et al. 2001b). Data revealed that LXR/RXR binds to a low-affinity LXRE present in
the apoE promoter as well as a high-affinity site conserved in both human ME.1 and
ME.2 (Laffitte et al. 2001b). Experimental data revealed that the ligand activation
of the LXR/RXR heterodimer enhanced the activity of the reporter constructs under
the control of human ME.1 or ME.2 fused to the apoE proximal promoter (Laffitte
et al. 2001b). Oxysterol-binding protein-related protein 1S (ORP1S) translocates
from the cytoplasm to the nucleus in response to sterol binding and then binds to
LXRs, promoting the binding of LXRs to LXREs. Thus, ORP1S mediates the
LXR-dependent transcription via the ME.1 and ME.2 of the apoE gene (Lee
et al. 2012). An interesting finding was that the induction of apoE gene expression
by LXR agonists is attenuated by inhibitors of JNK and PI3K pathways (Huwait
et al. 2011). A similar inhibition was noticed in the case of TGFβ-induced expres-
sion of apoE, which was prevented by pharmacological inhibitors of JNK, p38
kinase, and casein kinase 2 (Singh and Ramji 2006).
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The synthetic glucocorticoid receptor (GR) ligand, dexamethasone, increased
apoE mRNA levels in mature macrophages up to sixfold over basal levels
(Zuckerman et al. 1993). In silico analysis of the ME.1 and ME.2 revealed some
transcription factor binding motifs for the GR (Shih et al. 2000). The presence of
these GR binding sites in the multienhancers may explain the apoE upregulation by
GR ligands, but the biological activity of these GR biding sites remains to be
revealed.
TRANSFAC analysis of the apoE promoter, ME.1, and ME.2 showed that
STAT1 transcription factor has a binding site only on the ME.2. Our data showed
that this binding site is biologically active and STAT1 specifically upregulates apoE
gene expression via ME.2, in macrophages, but not in hepatocytes. The STAT1
binding site was located in the 174/182 region of ME.2 (Trusca et al. 2011).
Interestingly, a simultaneous increase in the expression of apoE and STAT1 was
recorded after monocyte differentiation with PMA treatment (for 4 h). Our model
proposed that after DNA bending, which probably takes place during monocyte
differentiation, STAT1 bound on ME.2 interacts with the transcription initiation
complex, leading to the activation of apoE expression. In addition, STAT1 can
interact and cooperate with other transcription factors bound on the ME.2 or on the
apoE promoter, for the modulation of apoE gene expression. Recently, we have
revealed that STAT1 can interact with RXR and modulate gene expression of the
apoC-II gene (Trusca et al. 2012). Since RXRα binds to the ME.2, we can speculate
that apoE expression in macrophages may be modulated by the STAT1-RXRα
interactions, similarly with apoC-II.
1.6 Transcriptional Regulation of the Human apoM Gene
in the Liver
Apolipoprotein M (apoM) belongs to the lipocalin protein superfamily and differs
from typical water-soluble apolipoproteins by its tertiary structure (Dahlback and
Nielsen 2009; Nielsen et al. 2009). ApoM is secreted primarily by the liver and
associates with HDL particles through its retained N-terminal signal peptide (Axler
et al. 2008; Christoffersen et al. 2008). The silencing of the endogenous apoM gene
in mice showed a loss of pre-β-HDL particles and formation of large HDL particles
(Wolfrum et al. 2005). In addition to its role in HDL remodeling, it was shown that
apoM is the sole carrier of the bioactive lipid sphingosine 1 phosphate (S1P) in
HDL, thus mediating many of the atheroprotective properties of HDL in the
endothelium (Christoffersen et al. 2011; Arkensteijn et al. 2013; Christoffersen
and Nielsen 2013).
The expression of apoM in the liver is primarily controlled by hepatocyte
nuclear factor-1α (HNF-1α) (Richter et al. 2003). HNF-1α/ mice are
characterized by the complete absence of apoM from plasma. The plasma
concentrations of other apolipoproteins in HNF-1α/ mice were either similar
(apoA-II, apoB, apoC) or increased (apoA-I, apoE) compared to wild-type mice.
This was not due to the absence of apoM since restoration of apoM gene expression
136 D. Kardassis et al.
in the liver via adenovirus-mediated gene transfer could not rescue the abnormal
apolipoprotein profile (Wolfrum et al. 2005). The analysis of the plasma lipoprotein
profile of HNF-1α/ mice showed that similar to the apoM gene-silenced mice,
plasma cholesterol was primarily associated with the HDL fraction. In addition, an
abnormal large apoE-enriched HDL fraction that was identified as HDLc or HDL1
was observed, suggesting that this abnormal lipid profile in HNF-1α/ mice may
be caused by the lack of apoM (Shih et al. 2001). In humans, HNF-1α regulates
apoM gene expression through direct binding to a conserved DNA element located
in the proximal apoM promoter region between nucleotides 55 and 41 (Richter
et al. 2003).
ApoM gene expression in the liver is negatively regulated during inflammation
or infection via pro-inflammatory cytokines such as TNFα or IL-1β (Feingold
et al. 2008). The HNF-1α binding element in the proximal human apoM promoter
is a dual-specificity regulatory element that mediates the activation or repression of
apoM promoter activity by HNF-1 and by activator protein 1 (AP1) proteins (c-Jun
and JunB), respectively, in hepatic cells (Mosialou et al. 2011). Competition
experiments showed that the binding of Jun proteins and HNF-1α to the apoM
promoter is mutually exclusive and chromatin immunoprecipitation assays
established that AP1 activation leads to the recruitment of c-Jun and JunB proteins
to the proximal apoM promoter with the simultaneous displacement of HNF-1
(Mosialou et al. 2011). A similar mechanism of transcriptional repression via
dual-specificity AP1-/HNF-1-responsive elements has been demonstrated in the
case of the promoter of the human apolipoprotein A-II gene (Mosialou et al. 2011).
AP1 factors were shown to inhibit the promoters of the apolipoprotein C-III
(Hadzopoulou-Cladaras et al. 1998) and ABCA1 (Mosialou and Kardassis unpub-
lished) genes in hepatic cells suggesting a broader role of AP1 factors in lipoprotein
metabolism in the liver during inflammation.
Besides HNF-1α, apoM gene transcription in the liver has been shown to be
controlled positively by liver receptor homologue-1 (LRH-1) and forkhead box A2
(FOXA2) transcription factors which bind to distinct sites on the proximal apoM
promoter (Venteclef et al. 2008; Wolfrum et al. 2008). Bile acids suppress apoM
expression in vivo by inhibiting LRH-1 transcriptional activity via the recruitment
of small heterodimer partner (SHP) to the apoM promoter (Venteclef et al. 2008).
Insulin, insulin-like growth factor I (IGF-I), and IGF-I potential peptide
(IGF-IPP) were all shown to inhibit apoM gene expression in a dose- and time-
dependent manner in primary human and murine hepatocytes via a signal transduc-
tion pathway that involves the serial activation of phosphatidylinositol 3-kinase
(PI3K) and protein kinase B (PKB) and the inactivation of Foxa2 (Xu et al. 2006).
In HepG2 cells, glucose and insulin inhibited apoM gene expression in an additive
manner, while in hyperglycemic rats, serum apoM concentrations and hepatic
apoM mRNA levels were significantly reduced (Zhang et al. 2007).
The human apoM gene is under the control of various orphan- and ligand-
dependent nuclear receptors (Mosialou et al. 2010). The overexpression via adeno-
virus and silencing via siRNA established that HNF-4 is an important regulator of
apoM gene transcription in hepatic cells (Mosialou et al. 2010). In addition to
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HNF-4, homodimers of retinoid X receptor and heterodimers of retinoid X receptor
with receptors for retinoic acid, thyroid hormone, fibrates (peroxisome proliferator-
activated receptor), and oxysterols (liver X receptor) were shown to bind with
different affinities to the proximal HRE in vitro and in vivo (Mosialou
et al. 2010). These findings provide novel insights into the role of apoM in the
regulation of HDL by steroid hormones and into the development of novel
HDL-based therapies for diseases such as diabetes, obesity, metabolic syndrome,
and coronary artery disease that affect a large proportion of the population in
Western countries.
1.7 Transcriptional Regulation of the CETP Gene
The gene encoding the cholesterol ester transfer protein (CETP) plays an important
role in human HDL metabolism because it facilitates the transfer of cholesteryl
esters from mature spherical HDL particles to VLDL/IDL lipoproteins in exchange
of triglycerides and its activity determines the plasma levels of HDL cholesterol
(von Eckardstein et al. 2005; Tall et al. 2008).
The CETP gene is expressed mainly in the liver, adipose tissue, and spleen and at
lower levels in the small intestine, adrenal, kidneys, and heart (Jiang et al. 1991;
Radeau et al. 1995). Atherogenic diets were shown to increase CETP mRNA levels
in rabbits and in human CETP transgenic mice (Quinet et al. 1990; Jiang
et al. 1992). Both LXRs and SREBPs were shown to bind to regulatory elements
on the promoter of the CETP gene and regulate its transcription in response to
intracellular cholesterol levels (Gauthier et al. 1999; Luo and Tall 2000). It was
shown recently that synthetic LXR agonists enhanced plasma CETP activity and
decreased HDL-C levels in cynomolgus monkeys and human CETP transgenic
mice (Honzumi et al. 2010). The induction of CETP gene expression by the LXR
agonist was significantly reduced by knocking down the expression of LXRα but
not LXRβ both ex vivo and in mice (Honzumi et al. 2010). In another study, it was
shown that the LXR agonist T0901317 markedly increased CETP mRNA levels
and CETP production in human differentiated macrophages but not in human
peripheral blood monocytes (Lakomy et al. 2009). In inflammatory mouse and
human macrophages, LXR-mediated CETP gene upregulation was inhibited and
this inhibition was independent of lipid loading. It was concluded that
LXR-mediated induction of human CETP expression is switched on during
monocyte-to-macrophage differentiation and is abrogated in inflammatory
macrophages (Lakomy et al. 2009).
Other factors that regulate CETP promoter activity include Yin Yang 1 (YY1)
that binds to the same element as SREBPs (Gauthier et al. 1999), the LRH-1 that
potentiates the sterol-mediated induction of the CETP gene by LXRs (Luo
et al. 2001), the orphan nuclear receptor ARP-1 (Gaudet and Ginsburg 1995) that
inhibits CETP promoter activity, the retinoic acid receptor (RAR) which regulates
CETP gene expression in response to all-trans-retinoic acid (Jeoung et al. 1999),
and the CCAAT/enhancer-binding protein (C/EBP) which is an activator of CETP
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gene expression (Agellon et al. 1992). Binding sites for the ubiquitous transcription
factors SP1 and SP3 have been identified on the CETP promoter at positions 690,
623, and 37 and seem to be essential for the basal CETP promoter activity
(Le Goff et al. 2003).
CETP gene expression was shown recently to be under regulation by bile acids
and their nuclear receptor farnesoid X receptor (FXR) (Gautier et al. 2013). It was
shown that plasma CETP activity and mass was higher in patients with cholestasis
than controls and this was associated with lower HDL-C levels (Gautier et al. 2013).
In agreement with this observation, bile acid feeding of APOE3*Leiden mice
expressing the human CETP transgene controlled by its endogenous promoter
decreased HDL-C and increased plasma CETP activity and mass. An FXR response
element (FXRE) was identified in the first intron of the human CETP gene which
could be responsible for the upregulation of CETP gene expression in response to
bile acids (Gautier et al. 2013). In another study, it was shown that FXRα binds to
DR4 LXRE that is present in the proximal CETP promoter and represses
LXR-mediated transactivation of the CETP promoter by a competition mechanism
(Park et al. 2008).
1.8 Transcriptional Regulation of the PLTP Gene
Phospholipid transfer protein (PLTP) belongs to the lipopolysaccharide (LPS)
binding/lipid transfer gene family that includes the LPS-binding protein (LBP),
the neutrophil bactericidal/permeability-increasing protein (BPI), and the
cholesteryl ester transfer protein (CETP). PLTP is essential in the transfer of very
low-density lipoprotein phospholipids into HDL (Jiang et al. 2012).
PLTP is expressed ubiquitously, but the highest expression levels in human
tissues were observed in the ovary, thymus, placenta, and lung (Day et al. 1994).
Taking into account the organ size involved, the liver and small intestine appear to
be important sites for the overall PLTP expression. A high-fat, high-cholesterol diet
causes a significant increase in PLTP activity and in mRNA levels. Plasma PLTP
activity and PLTP mRNA levels in the liver and adipose tissues were significantly
decreased following LPS administration (Jiang and Bruce 1995).
An FXR-responsive element (FXRE) has been found in the proximal PLTP
promoter that binds FXRα/RXRα heterodimers and mediates the response of the
PLTP promoter to bile acids (Urizar et al. 2000). Fibrates were shown to increase
PLTP gene expression by activating PPARs which bind to three PPAR-responsive
elements on the PLTP promoter (Tu and Albers 1999; Bouly et al. 2001). Two of
these PPAR-responsive elements also seem to be responsible for the induction of
PLTP expression by high glucose (Tu and Albers 2001).
The human PLTP promoter contains at least two LXR-responsive elements, one
in the proximal and one in the distal region, that were shown to mediate PLTP gene
regulation by oxysterols ex vivo and in vivo (Cao et al. 2002; Mak et al. 2002a;
Laffitte et al. 2003). It was recently demonstrated that LXR agonists activate
triglyceride synthesis and PLTP gene transcription by activating SREBP-1c
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(Okazaki et al. 2010). In concert with the increase in triglyceride synthesis, the
increased PLTP caused triglyceride incorporation into abnormally large VLDL
particles which were removed from plasma by LDL receptors, whereas in the
absence of LDL receptors, the large VLDLs accumulated and caused massive
hypertriglyceridemia (Okazaki et al. 2010).
Recently, microarray analysis following alteration of p53 status in several
human- and mouse-derived cells identified a group of 341 genes whose expression
was induced by p53 in the liver-derived cell line HepG2 (Goldstein et al. 2012).
Twenty of these genes encode proteins involved in many aspects of lipid homeo-
stasis including PLTP (Goldstein et al. 2012).
1.9 Transcriptional Regulation of the Bile Acid Transporters
ABCG5/ABCG8
ATP-binding cassette half-transporters G5 and G8 (ABCG5 and ABCG8) play
important roles in the control of sterol excretion from the liver (Fitzgerald
et al. 2010; Tarling and Edwards 2012; Li et al. 2013; Yu et al. 2014). Mutations
in either of these transporters leads to β-sitosterolemia, an autosomal recessive
disease characterized by premature coronary atherosclerosis and elevated levels of
phytosterols in plasma (Fitzgerald et al. 2010; Tarling and Edwards 2012; Li
et al. 2013; Yu et al. 2014). Mice lacking ABCG5 and ABCG8 proteins have
decreased ability to secrete sterols into the bile (Yu et al. 2002a). The
overexpression of ABCG5 and ABCG8 in the liver increases biliary cholesterol
secretion and decreases dietary cholesterol absorption (Yu et al. 2002b). The human
ABCG5 and ABCG8 genes are oriented in a head-to-head configuration, they are
transcribed in opposite directions, and their transcription is coordinated by a short
374 bp bidirectional promoter in the intergenic region (Remaley et al. 2002).
The bidirectional promoter of ABCG5/ABCG8 genes contains a binding site for
LRH-1 at positions 134–142 which is required for the activity of both the ABCG5
and ABCG8 promoters (Freeman et al. 2004). Mutating this LRH-1 binding site
reduced promoter activity of the human ABCG5/ABCG8 intergenic region in
HepG2 and Caco2 cells. Bile acids such as deoxycholic acid repressed ABCG5
and ABCG8 promoters via the FXR-SHP-LXR pathway that was described above
(Sumi et al. 2007).
Dietary cholesterol feeding was shown to increase duodenal, jejunal, and hepatic
expression levels of ABCG5 and ABCG8 mRNA in wild-type mice (Berge
et al. 2000). The increase in ABCG5 or ABCG8 gene expression by diet was
compromised in mice lacking either LXRα or both LXRα and LXRβ (Repa
et al. 2002). Both the RXR-specific agonist LG268 and the LXR-specific agonist
T0901317 caused upregulation of ABCG5 and ABCG8 mRNA expression in the
liver and intestine of wild-type mice but not in LXRα/β/ mice (Repa et al. 2002).
To identify functional LXREs that control the expression of the ABCG5/ABCG8
genes in response to oxysterols, a recent study searched for evolutionarily
conserved regions (ECRs) between the human and the mouse genes and identified
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23 ECRs which were studied by luciferase assays for LXR responsiveness (Back
et al. 2013). Two ECRs were found to be responsive to the LXR and binding of
LXRα to these regions was verified (Back et al. 2013).
The bidirectional promoter of the ABCG5/G8 genes was shown to bind HNF-4
and GATA transcription factors and to be regulated by these factors in a coopera-
tive manner and independent of the orientation of the bidirectional promoter (Sumi
et al. 2007).
It was shown that the expression of both ABCG5 and ABCG8 genes is
upregulated in the livers of mice with genetic ablation of the insulin receptor
gene (LIRKO mice) both at the mRNA and the protein levels (Biddinger
et al. 2008). In agreement with these findings, insulin suppressed the expression
of ABCG5 and ABCG8 genes at subnanomolar concentrations and in a dose-
responsive manner in rat hepatoma cells (Biddinger et al. 2008). The observation
that the short intergenic region responded to insulin in both the ABCG5 and
ABCG8 orientations suggested the presence of an element in the intragenic region
of the ABCG5 and ABCG8 genes that responds to insulin. Using ex vivo and
in vivo approaches, it was shown that insulin resistance leads to the activation of the
forkhead box 1 (FOXO1) transcription factor which binds to the bidirectional
promoter and activates the transcription of both genes severalfold (Biddinger
et al. 2008).
1.10 Transcriptional Regulation of the HDL Receptor SR-BI
The gene encoding the HDL receptor scavenger receptor class B type I (SR-BI) is
expressed at high levels in the liver and steroidogenic tissues. Several transcription
factors have been shown to bind to the human or rodent SR-BI promoter and to
regulate SR-BI gene transcription in a positive or negative manner.
The steroidogenic factor-1 (SF-1) has been shown to regulate both the human
and rat SR-BI promoters and to serve as mediator of the cAMP-dependent regu-
lation of the SR-BI gene in response to steroidogenic hormones (Lopez et al. 1999).
Liver X receptors α and β and PPARα and γ were shown to bind to distal LXRE
and PPARE, respectively, on the human and rat SR-BI promoters and regulate the
expression of the human SR-BI gene in response to oxysterols and fibrates (Lopez
and McLean 1999; Malerod et al. 2002, 2003), whereas HNF-4 enhances the
PPARγ-mediated SR-BI gene transcription (Malerod et al. 2003; Zhang
et al. 2011). As discussed above, conditional inactivation of the HNF-4 gene in
the liver of adult mice was associated with a significant increase in hepatic SR-BI
mRNA levels and a decrease in plasma HDL-C levels, suggesting that HNF-4
influences negatively the expression of the HDL receptor (Hayhurst et al. 2001).
LRH-1 binds to a proximal response element on the human SR-BI promoter in
an overlapping manner with SF-1 and activates the SR-BI promoter (Schoonjans
et al. 2002). Retrovirus-mediated overexpression of LRH-1 in hepatic cells induced
SR-BI gene expression, and this was associated with histone H3 acetylation on the
SR-BI promoter. In agreement with these findings, the SR-BI mRNA levels were
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decreased in the livers of LRH-1(+/) animals providing evidence that LRH-1
regulates SR-BI gene expression in vivo (Schoonjans et al. 2002).
Estrogens regulate the activity of the rat SR-BI promoter via estrogen receptors
α and β (ERα and β) which bind to three different estrogen response elements (ERE)
on the SR-BI promoter (Lopez et al. 2002; Lopez and McLean 2006). In endothelial
cells, 17beta-estradiol (E2) increased the mRNA levels of the human SR-BI gene
and the activity of the hSR-BI promoter, and this upregulation was protein kinase C
(PKC) dependent since it was blocked by the PKC inhibitor bisindolylmaleimide I
and a dominant-negative mutant of PKC (Fukata et al. 2013).
The mRNA levels of the mouse SR-BI gene were decreased in mice lacking the
FXR nuclear receptor (FXR/ mice) (Lambert et al. 2003). When WT mice were
placed on a diet containing 0.4 % of the FXR agonist cholic acid, the hepatic SR-BI
mRNA and protein levels increased in the wild-type but not in the FXR/ mice,
indicating that bile acids positively regulate SR-BI gene expression via FXRs
(Lambert et al. 2003). In agreement with these findings, treatment of human
hepatoma HepG2 cells with FXR ligands resulted in the upregulation of SR-BI
both at the mRNA and protein levels via FXR binding to a novel FXRE, a direct
repeat 8 at position703/684 of the promoter (Chao et al. 2010). A natural ligand
of FXR administered to mice increased hepatic SR-BI expression (Chao
et al. 2010). However, in another study, it was reported that bile acids inhibit
SR-BI gene expression in the liver of mice and reduce the SR-BI promoter activity
(Malerod et al. 2005). It was proposed that this inhibition was due to the
FXR-mediated activation of SHP, which repressed the activity of LRH-1 that
binds to the proximal SR-BI promoter (Malerod et al. 2005).
The zinc finger transcription factor Kruppel-like factor 4 (KLF4) was shown to
bind to a putative KLF4 element on the SR-BI promoter at position342/329 and
upregulate its activity in peripheral blood mononuclear cells and
PMA-differentiated THP-1 cells treated with HDL (Yang et al. 2010).
Using high-throughput screening of 6,000 microbial secondary metabolite crude
extracts for the identification of compounds that upregulate the SR-BI promoter in
HepG2 cells, several putative SR-BI upregulators were identified: hoxyl-30,5,7-
hydroxyl isoflavone; (9R,13S)-7-deoxy-13-dihydrodaunomycinone; pratensein; the
isoflavones formononetin, genistein, and daidzein; and the histone deacetylase
inhibitor trichostatin A (Yang et al. 2007, 2009; Bao et al. 2009). Some of these
compounds were shown to increase the uptake of DiI-labeled HDL and the efflux of
cholesterol to HDL by cells.
In steroidogenic tissues, SR-BI supplies the cells with exogenous cholesterol for
storage or for the synthesis of steroid hormones. In these tissues, SR-BI expression
was shown to be upregulated by adrenocorticotropic hormone (ACTH) (Sun
et al. 1999). The suppression of ACTH by the synthetic corticosteroid dexametha-
sone (which inhibits the hypothalamic-pituitary axis and decreases ACTH secre-
tion) decreased SR-BI levels. However, the mechanism by which ACTH and
glucocorticoid regulate the expression of the SR-BI gene in steroidogenic tissues
is unclear. It was shown that the transcription of the human SR-BI gene is subject to
feedback inhibition by glucocorticoids in adrenal and ovarian cells. SR-BI mRNA
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levels were increased in adrenals from corticosterone-insufficient Crh/ mice,
whereas corticosterone replacement by oral administration inhibited SR-BI gene
expression in these mice (Mavridou et al. 2010). The glucocorticoid-mediated
inhibition of SR-BI gene transcription required de novo protein synthesis and the
glucocorticoid receptor (GR). No direct binding of GR to the SR-BI promoter could
be demonstrated in vitro and in vivo, suggesting an indirect mechanism of repres-
sion of SR-BI gene transcription by GR in adrenal cells (Mavridou et al. 2010).
In the rat ovary, the uptake of cholesterol by the theca-interstitial cells is
mediated by SR-BI. It was shown that insulin and the trophic hormone LH/cGH
stimulate the expression of SR-BI in theca-interstitial cells and increase intracellu-
lar cholesterol, which is subsequently mobilized for androgen biosynthesis
(Li et al. 2001; Towns et al. 2005).
In the adrenocortical cell line Y-1, adenovirus-mediated overexpression of
prolactin regulatory element-binding (PREB) protein, a transcription factor that
regulates prolactin expression in the anterior pituitary and is induced by cAMP,
increased the levels of SR-BI protein and the activity of the SR-BI promoter by
binding to a PREB-responsive cis-element of the SR-BI promoter. Using small
interfering RNA against PREB in Y-1 cells, the effects of cAMP on SR-BI
expression were attenuated. It was concluded that in the adrenal gland under
conditions of cAMP increase, PREB regulates the transcription of the SR-BI gene
(Murao et al. 2008).
Intracellular sterol levels regulate SR-BI gene expression via SREBP-1a which
binds to two sterol-responsive elements (SREs) present on the rat SR-BI promoter
(Cao et al. 1997; Lopez and McLean 1999). The ubiquitous transcription factors
SP1 and SP3 bind to several GC-rich boxes present on the proximal SR-BI
promoter and have been shown to be important for the basal activity as well as
the SREBP-1a-mediated transactivation of the SR-BI promoter (Shea-Eaton
et al. 2001).
The expression of the SR-BI gene is also subject to negative regulation by
transcription factors including the orphan nuclear receptor dorsal-sensitive sex
adrenal hypoplasia congenital critical region on the X chromosome gene
1 (DAX-1), which was shown to repress the rat SR-BI promoter by interfering
with the SF-1- and SREBP-1a-mediated transactivation of the this promoter (Lopez
et al. 2001). In addition, YY1 transcription factor binds directly to two sites on the
SR-BI promoter and downregulates its activity by interfering with the binding of
SREBP-1a to the SR-BI promoter (Shea-Eaton et al. 2001).
2 Posttranscriptional Regulation of HDL Genes
by Noncoding RNAs and microRNAs
According to the Encyclopedia of DNA Elements (ENCODE project), 76 % of the
human genome is transcribed (Bernstein et al. 2012; Djebali et al. 2012). While
novel promoter and enhancer regions have been described (Bernstein et al. 2012;
Sanyal et al. 2012), some of the newly described genes encode for noncoding RNAs
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including microRNAs (miRNAs), small interfering RNAs (siRNAs), piwi-
interacting RNAs (piRNAs), circular RNAs (circRNAs), long noncoding RNAs
(lncRNAs), trans-acting siRNAs (tasiRNAs), and several other noncoding RNAs.
Their abundance and their recognized roles in transcriptional and epigenetic gene
regulation and their involvement in several diseases suggest the existence of an
extensive regulatory network on the basis of RNA signaling (Mattick and Makunin
2005). An important class of these endogenous noncoding RNAs is miRNAs.
miRNAs are small noncoding RNAs (~22 nt) that have emerged as important
posttranscriptional regulators of different protein-coding genes (Bartel 2009)
including those related to HDL metabolism (Davalos and Fernandez-Hernando
2013).
2.1 miRNAs: Biogenesis and Function
Although originally described as regulators of developmental timing in
Caenorhabditis elegans (Lee et al. 1993; Wightman et al. 1993), miRNAs did not
receive special attention until their widespread identification in different species
(Lagos-Quintana et al. 2002; Reinhart et al. 2002) and their role in human diseases
was uncovered (Calin et al. 2002). miRNAs are important posttranscriptional
regulators of gene expression through sequence-specific complementary binding
to the 30 untranslated region (UTR) of the target mRNA (Bartel 2009), even though
certain miRNAs can interact with other target mRNA regions including the 50 UTR,
coding region, or intron–exon junction and even increase rather than decrease target
mRNA expression (Vasudevan et al. 2007; Orom et al. 2008; Tay et al. 2008;
Schnall-Levin et al. 2010). The interaction of a miRNA with its target mRNA
results in the inhibition of translation and/or degradation of mRNAs (Guo
et al. 2010; Krol et al. 2010).
miRNA biogenesis and function have been intensively studied in recent years
(Bartel 2009; Krol et al. 2010). Briefly, in most mammals, these small RNAs are
transcribed by RNA polymerase II into a primary long miRNA (pri-miRNA). The
pri-miRNA is then processed in the nucleus into an ~70 nucleotide precursor
hairpin (pre-miRNA) by a multiprotein complex containing different cofactors
and two core components, a ribonuclease III (Drosha) and a double-stranded
RNA-binding domain protein (DGCR8/Pasha). Some intronic miRNAs that bypass
Drosha-mediated processing are produced by splicing and debranching (miRtrons).
Pre-miRNAs are transported to the cytoplasm by Exportin 5 in a Ran-GTP-depen-
dent manner (Lund et al. 2004) where they are further cleaved by an RNAse III
enzyme called Dicer, generating the mature ~22 nt long miRNA/miRNA* duplex.
Dicer-independent miRNA biogenesis has also been described (Cifuentes
et al. 2010). The duplex miRNA is separated and one of the strands associates
with an argonaute protein (Ago) within the RNA-induced silencing complex
(RISC), guiding the complex to the complementary sites within the 30 UTR of the
target mRNA to induce mRNA repression and/or degradation. Although the
miRNA/miRNA* duplex is initially produced in equal amounts, the miRNA*
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strand (passenger strand) is usually degraded. However, it also contains target
recognition sites and is thus functional (Yang et al. 2011). Argonaute proteins are
major players in miRNA-mediated gene regulation (Meister 2013). Although
several aspects of miRNA biogenesis and function are well characterized, the
different factors that regulate their decay or turnover are not well known (Krol
et al. 2010).
Sequencing studies have identified ~2,000 miRNAs encoded in our human
genome, and prediction algorithms suggest that 60 % of human protein-coding
genes have conserved targets for pairing with miRNAs within their 30 UTR
(Friedman et al. 2009). Factors that influence miRNA target selection include the
“seed” sequence which consists of nucleotides 2–8 at the 50 end of the mature
miRNA (Bartel 2009) and tissue distribution or developmental stage, as certain
miRNAs are highly expressed or even restricted to certain cell types and can only
target their mRNA target if they are co-expressed in the same tissue at the same
time (Lagos-Quintana et al. 2002; Small and Olson 2011). In contrast to most plant
miRNAs, which bind with near perfect complementarity to their targets, most
mammalian miRNAs bind with mismatches and bulges and the mode of binding
determines the type of posttranscriptional repression (Carthew and Sontheimer
2009). Recent experimental data suggest that around 60 % of seed interactions
are noncanonical, containing bulged or mismatched nucleotides which are
accompanied by specific, non-seed base pairing (Helwak et al. 2013). Some
miRNA-mRNA interactions also involve the 30 end of the miRNA (Helwak
et al. 2013). Moreover, pseudogenes (Poliseno et al. 2010), long noncoding
RNAs (lncRNAs) (Cesana et al. 2011), and circular RNAs (Hansen et al. 2013)
that contain miRNA binding sites also influence miRNA activity, acting as com-
peting endogenous RNAs (ceRNAs) and thus sequestering miRNAs and preventing
them from binding to their mRNA targets (Salmena et al. 2011).
While the primary role of miRNAs seems to be the “fine-tuning” of gene
expression, their capacity to simultaneously bind and repress multiple target
genes and similarly the possibility of a single mRNA to be targeted by multiple
miRNAs provide a mechanism to synchronize the coordinated regulation of a large
number of transcripts that govern an entire biological process, thus resulting in
strong phenotypic output (Mendell and Olson 2012). The high redundancy among
related and non-related miRNAs in regulating gene expression reduces the impor-
tance of a particular miRNA under conditions of normal cellular homeostasis.
However, compelling evidence suggests that under conditions of stress the function
of miRNAs become especially pronounced (Mendell and Olson 2012) and their
pharmacological modulation represents a novel approach to treat disease by
modulating entire biological pathways as described in Davalos and Chroni (2014).
Compelling evidences have shown that miRNAs are present in the systemic
circulation and other human biological fluids associate with extracellular
microvesicles, exosomes (Valadi et al. 2007; Hunter et al. 2008), Ago2 complex
(Arroyo et al. 2011), or HDL (Vickers et al. 2011). Even exogenous miRNAs have
been described in our circulating plasma (Wang et al. 2012b; Zhang et al. 2012).
Although several circulating miRNAs have been implicated as disease biomarkers
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in several diseases (Allegra et al. 2012; Kinet et al. 2013) or secreted for intercellu-
lar communication (Chen et al. 2012b), the biological significance, the factors that
modulate their extracellular secretion, and the mechanisms by which they reach the
target tissue still remain elusive. HDL has been shown to transport and deliver
endogenous miRNAs to recipient cells with functional targeting capabilities
(Vickers et al. 2011). Although the HDL miRNA signature from normal subjects
was found to be different from hypercholesterolemic subjects (Vickers et al. 2011),
the extent by which HDL-bound miRNAs contribute to total circulating miRNAs
and thus regulate target cell gene function is not clear (Wagner et al. 2013).
In summary, miRNAs play a major role in almost every aspect of cellular
function by posttranscriptional regulation of gene expression. Whether other non-
coding RNAs (that modulate miRNA activity) or circulating or extracellular
miRNAs might modulate HDL metabolism is not known. However, it seems
obvious that by modulating miRNA activity, they might also have a role in HDL
metabolism.
2.2 Posttranscriptional Modulation of HDL Metabolism
by miRNAs
For normal function, mammalian cells must maintain cellular cholesterol levels
within tight limits. Thus, complex mechanisms have been evolutionarily developed
to control both cellular input from endogenous cholesterol biosynthesis or the
uptake from circulating lipoproteins and cellular output by controlling cholesterol
efflux. miRNAs have emerged as important regulators of HDL and cholesterol
metabolism, and their functions are summarized in Fig. 5 and described in detail
below. Although miRNAs have increased the complexity of HDL metabolism
regulation, our understanding of every single step in their regulation will provide
better opportunities to develop novel targets for their therapeutic modulation.
2.2.1 Targeting ABCA1 and ABCG1
ABCA1 is one of the most important proteins directly involved in the elimination of
excess cholesterol from cells (cholesterol efflux). As described in this chapter,
ABCA1 is regulated at the transcriptional, posttranscriptional, and posttranslational
level. Its regulation is in accordance with the cellular need to handle cholesterol
levels within tight limits, as excess of free cholesterol is deleterious to cells.
ABCA1 mRNA contains a particularly long 30 UTR (>3.3 kb) as compared to
other common genes involved in cholesterol and HDLmetabolism including LCAT
(20 bp), apoA-I (55 bp), ApoA-II (112 bp), CETP (178 bp), apoB (301 bp), PDZK1
(583 bp), ABCG1 (852 bp), SR-BI (959 bp), PCSK9 (1,269 bp), IDOL (1,496 bp),
CAV-1 (1,898 bp), LIPG (2,386 bp), and LDLR (2,513 bp) (Davalos and
Fernandez-Hernando 2013). This unusually long 30 UTR of ABCA1 clearly raises
the probability of posttranscriptional regulation by miRNAs (and probably other
noncoding RNAs). Different prediction algorithms indicate that ABCA1 can poten-
tially be targeted by ~100 miRs. Some of them have been experimentally validated
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Fig. 5 Overview of posttranscriptional regulation by miRNAs of proteins involved in cholesterol
efflux, RCT, and HDL metabolism. HDL metabolism and the role of individual proteins such as
plasma enzymes, membrane transporters, and receptors are described in the text and more
extensively in other chapters. Autophagy, the cell catabolism process through the lysosomal
machinery, has been proposed to participate in cholesterol efflux. The induction of SREBPs
induces the expression of miR-33 family. The induction of LXR induces the expression of
miR-144 and represses miR-26. The induction of FXR also induces miR-144. miRNAs in black
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for their importance in cholesterol efflux, reverse cholesterol transport, and cardio-
vascular disease, whereas other miRNAs still remain to be elucidated. Validated
miRNAs that directly target ABCA1 are miR-33 family, miR-758, miR-106b,
miR-26, miR-144, miR-10b, miR-128-2, and miR-145 (Fig. 5).
miR-33a and miR-33b play a crucial role in controlling cholesterol efflux and
HDL function in concert with their host genes, the SREBP transcription factors
(Najafi-Shoushtari et al. 2010; Horton et al. 2002; Horie et al. 2010; Marquart
et al. 2010; Rayner et al. 2010). While both mature miRNAs only differ in two
nucleotides, they are predicted to have largely overlapping sets of target genes in
rodents (Rayner et al. 2011b; Horie et al. 2012) and nonhuman primates (Rayner
et al. 2011a; Rottiers et al. 2013). The inhibition of the two miR-33 isoforms, either
genetically or therapeutically, resulted in increased cholesterol efflux, increased
HDL levels, increased reverse cholesterol transport, reduced atherosclerosis, and
reduced VLDL triglyceride levels. Although miR-33a and miR-33b target different
genes involved in lipid homeostasis, fatty acid β-oxidation, insulin signaling, and
biliary transporters (Gerin et al. 2010; Davalos et al. 2011; Rayner et al. 2011a;
Allen et al. 2012; Horie et al. 2013), their effects are mediated mainly by ABCA1.
The human 30 UTR of ABCA1 has three functional binding sites for miR-33. While
most of the studies have been performed in tissues/cells directly related to lipo-
protein metabolism and CVD (i.e., hepatocytes, macrophages), it is possible that
from these ~100 miRs that potentially target ABCA1 30 UTR, some of them might
be relevant to other cells and tissues as well.
Regarding other tissues, miR-106b (Kim et al. 2012) and miR-758 (Ramirez
et al. 2011) were found to regulate neuronal cholesterol excess. While miR-758
expression is particularly high in the brain and its expression is mediated by high
cholesterol levels, the expression of miR-106 in brain tissues is low. However, their
role in neuronal cholesterol efflux suggests that these miRNAs may contribute to
the regulation of cholesterol levels in the brain. miR-758 and miR-106 directly
target the 30 UTR of ABCA1 by binding to two sites and one site, respectively.
Moreover, miR-758 has other targets involved in neurological functions (Ramirez
et al. 2011). miR-106b also targets the amyloid precursor protein (APP) and
increases the amyloid β (Aβ) peptide secretion and clearance (Kim et al. 2012).
HDL metabolism is regulated by the LXRs which control the transcription of
several genes related to lipid metabolism in response to hydroxylated products of
cholesterol as described above (Calkin and Tontonoz 2012). Recent data suggest
that LXRs also regulate HDL metabolism posttranscriptionally (Sun et al. 2012; de
Aguiar Vallim et al. 2013; Ramirez et al. 2013; Vickers and Rader 2013). The
induction of LXR resulted in the repression of miR-26 and induction of miR-26-a-1,

Fig. 5 (continued) labels are validated miRNAs for HDL metabolism. miRNAs in red labels are
suggested miRNAs, but not fully validated, in HDL metabolism. All biological processes may not
necessarily happen in the same cell type. Abbreviations: endoplasmic reticulum (ER); early
endosome (EE); cholesterol ester hydrolase (CEH); multivesicular bodies (MVB); lysosomal
acid lipase (LAL) (Figure courtesy of Dr. Alberto Canfrán-Duque)
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and miR-144 that directly target the 30 UTR of ABCA1 and thus regulate choles-
terol efflux, RCT, and HDL levels. While having one binding site for miR-26-a-1
(Sun et al. 2012), the human 30 UTR of ABCA1 has several (up to seven) predicted
binding sites for miR-144 (Ramirez et al. 2013). miR-26-a-1 also targets the
ADP-ribosylation factor-like 7 (Arl7), which participates in cellular cholesterol
efflux (Engel et al. 2004). miR-144 expression is also induced by the nuclear
receptor FXR (Vickers and Rader 2013). By controlling bile acid levels, FXR
activation will not only repress the expression of ABCA1 posttranscriptionally
but will also induce the expression of SR-BI, thereby resulting in an increased
uptake of plasma HDL cholesterol and increased cholesterol biliary excretion via
ABCG5/ABCG8 (de Aguiar Vallim et al. 2013).
Evolutionarily, the dual effect of LXR activation on miR-144 induction and
mR-26-a-1 repression seems obvious, as cells must maintain cellular cholesterol
levels within tight limits and these miRNAs might work as buffers against deleteri-
ous variation in gene expression programs.
Other miRNAs including miR-10b, miR-128-2, and miR-145 also regulate
cellular cholesterol efflux by directly targeting the 30 UTR of ABCA1.
Protocatechuic acid, an intestinal microbiota metabolite of cyanidin-3-O-glucoside,
was found to repress miR-10b and thus regulate cholesterol efflux (Wang
et al. 2012a). While in hepatocytes the inhibition of miR145 increases cholesterol
efflux, in pancreatic islet beta cells it improves glucose-stimulated insulin secretion
(Kang et al. 2013). The proapoptotic miRNA miR-128-2 was also found to regulate
cholesterol efflux by targeting (one binding site) the 30 UTR of ABCA1 (Adlakha
et al. 2013). Recent data suggest that this miRNA family governs neuronal
excitability and motor behavior in mice (Tan et al. 2013) and that miR-128-
2 might control neuronal cholesterol levels. RXRα is also a direct target of
miR-128-2 (Adlakha et al. 2013). miR-27a and miR-148 were found to repress an
ABCA1 30 UTR luciferase reporter construct; however, their physiological role in
regulating cholesterol efflux has not been described (Kang et al. 2013).
ABCG1, the other member of the ATP-binding cassette transporter family,
which also participates in cellular cholesterol efflux to HDL, was found to be
directly regulated by some of these miRNAs. miR-33, miR-10b, and miR-128-
2 regulate cholesterol efflux by posttranscriptionally regulating ABCG1 through
binding to its 30 UTR (Rayner et al. 2010; Wang et al. 2012a; Adlakha et al. 2013).
2.2.2 Targeting SR-BI
Liver regulation of SR-BI is primarily achieved posttranslationally through a PDZ
domain-containing adaptor protein (PDZK1) (Kocher et al. 2003; Kocher and
Krieger 2009) as described in detail in a later section of this chapter. Increasing
evidence suggests that other posttranscriptional mechanisms, such as targeting by
miRNAs, also regulate SR-BI protein levels. Prediction miRNA analysis (www.
targetscan.org) suggests that ~25 miRNA families might target SR-BI, most of
which are poorly conserved among mammals and vertebrates. miR-125a and
miR-455 were found to repress the lipoprotein-supported steroidogenesis by
directly targeting the 30 UTR of SR-BI (Hu et al. 2012). In hepatic cells, where
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SR-BI is expressed at higher levels, the expression of miR-125a was also high and
its overexpression resulted in a reduced SR-BI-mediated selective cholesterol ester
uptake. In contrast, miR-455 did not show any effect on hepatic SR-BI expression
(Hu et al. 2012). miR-185, miR-96, and miR-223 were also found to directly target
the 30 UTR of SR-BI and to repress HDL cholesterol uptake in hepatic cells (Wang
et al. 2013a).
2.2.3 Targeting Other miRNAs Related to HDL Biogenesis
and Function
miR-27a was suggested to regulate apoA-I plasma levels, but the direct interaction
to its 30 UTR was not evaluated (Shirasaki et al. 2013). Several other miRNAs were
proposed to regulate genes involved in cholesterol efflux, RCT, or HDL meta-
bolism, including ABCG5 (Liu et al. 2012) or endothelial lipase (Kulyte et al. 2013),
but either their direct interaction with the 30 UTR of these genes or their physio-
logical effects on HDL metabolism were not directly assessed.
Autophagy is the catabolic process by which unnecessary or dysfunctional
cellular components are degraded in the lysosome. During starvation, this break-
down of cellular components contributes to the maintenance of cellular energy
levels. The hydrolysis of cytoplasmic cholesteryl ester of lipid droplets is normally
mediated by the action of neutral cholesteryl ester hydrolases. It has been recently
recognized that lipid droplets can also be delivered to lysosomes via autophagy,
where lysosomal acid lipase can hydrolyze lipid droplet cholesteryl esters to
generate free cholesterol for cholesterol efflux (Ouimet et al. 2011).
Several miRNAs have been described that regulate different targets in
autophagy (Frankel and Lund 2012). miRNAs that target key pathways in lipid-
loaded macrophage autophagy genes and/or cholesterol ester hydrolases might be
promising targets to promote cholesterol efflux (Davalos and Fernandez-Hernando
2013). Caveolin, the major protein coat of caveolae, has been proposed to contri-
bute to cellular cholesterol efflux (Truong et al. 2010; Kuo et al. 2011). There is
accumulating evidence that several miRNAs including miR-103, miR-107,
miR-133a, miR-192, miR-802, and others target caveolin (Nohata et al. 2011;
Trajkovski et al. 2011) but their contribution to cholesterol efflux, RCT, and
HDL metabolism and their real physiological contribution to HDL function remain
to be elucidated.
3 Posttranslational Mechanisms of HDL Regulation
3.1 ABCA1
In addition to the transcriptional and posttranscriptional mechanisms described
above, the expression of ABCA1 is also regulated at the posttranslational level.
Following its synthesis, ABCA1 is inserted into the ER where it undergoes proper
folding, N-glycosylation, dimerization, and disulfide bond formation and transport
to the plasma membrane via the ER-Golgi system (Fig. 6) (Kang et al. 2010).
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Transport from the ER to the Golgi is prevented when ABCA1 interacts with the
enzyme serine palmitoyltransferase 1 (SPTLC1) which participates in the biosyn-
thetic pathway of sphingomyelin, a major phospholipid component of membranes.
The ABCA1/SCPTL1 interaction may regulate the levels of intracellular pools of
sphingolipids when the cellular demands for these lipids are high. Pharmacological
inhibition of SPTLC1 with myriocin, an atypical amino acid and antibiotic derived
from thermophilic fungi (Miyake et al. 1995), increases both the ABCA1 levels at
the plasma membrane and the ABCA1-mediated cholesterol efflux (Tamehiro
et al. 2008). Mutations in ABCA1 that prevent normal glycosylation cause failure
Fig. 6 Overview of the mechanisms that regulate the expression of ABCA1, ABCG1, and SR-BI
genes at the posttranslational level. The mechanisms are described in the text. Abbreviations:
endoplasmic reticulum (ER); Asp-His-His-Cys 8 (DHHC8); serine palmitoyltransferase
1 (SPTLC1); guanine nucleotide-exchange protein 1 (BIG1); endosomal sorting complex required
for transport (ESCRT); Pro-GLu-Ser-Thr (PEST); calmodulin (Cam); lymphotoxin (LT); LT-β
receptor (LTβR); phospholipase D (PLD); protein kinase C δ (PKCδ); insulin receptor (IR);
phosphatidylinositol 3-kinase (PI3K); 12/15-lipoxygenase (12/15LO); PDZ-containing kidney
protein 1 (PDZK1); Na+/H+ exchanger regulator factor-3 (NHERF3); 4-hydroxy-2-nonenal
(4HNE); monocyte chemoattractant protein-1 (MCP-1)
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of ABCA1 to exit the ER (Singaraja et al. 2006). In the Golgi compartment,
ABCA1 undergoes palmitoylation at cysteine residues 3, 23, 1110, and 1111 by
the palmitoyltransferase Asp-His-His-Cys 8 (DHHC8) (Singaraja et al. 2009).
Inhibiting this enzyme by drugs or preventing ABCA1 palmitoylation by site-
specific mutagenesis reduced ABCA1 levels at the plasma membrane and
decreased efflux to apoA-I (Singaraja et al. 2009). The gene encoding
cathepsin D, a lysosomal protease, was identified by comparative transcriptomic
analysis to be associated with low HDL-C levels in humans (Haidar et al. 2006).
Blocking the activity or expression of cathepsin D reduced ABCA1 expression and
protein abundance as well as apoA-I-mediated lipid efflux by more than 70 % and
caused retention of ABCA1 in lysosomal compartments (Haidar et al. 2006). Very
recently, BIG1 (brefeldin A-inhibited guanine nucleotide-exchange protein 1) was
found to modulate ABCA1 trafficking and functions in the liver cells (Lin
et al. 2013). BIG1 depletion reduced surface ABCA1 on HepG2 cells and inhibited
by 60 % cholesterol efflux, whereas BIG1 overexpression had the opposite effects.
RNA interference with BIG1 dramatically decreased the internalization and
recycling of ABCA1. This novel function of BIG1 was dependent on the
guanine nucleotide-exchange activity and achieved through the activation of
ADP-ribosylation factor 1 (Lin et al. 2013).
The transport of ABCA1 to the plasma membrane is also facilitated by certain
members of the family of small GTPase including Rab8, Rab4A, and Rab4B
(Linder et al. 2009) (Jean and Kiger 2012).
Calpain, a cysteine protease, cleaves ABCA1 at the PEST (proline, glutamic
acid, serine, threonine) sequence (amino acids 1283–1306) that is located in the
cytosolic loop of the molecule, and this cleavage takes place at the early endosomes
(Fig. 6) (Yokoyama et al. 2012; Miyazaki et al. 2013). The deletion of the PEST
sequence increases ABCA1 levels on the plasma membrane and apoA-I binding
(Chen et al. 2005). The interaction with apoA-I stabilizes ABCA1 against this
degradation (Arakawa and Yokoyama 2002; Wang et al. 2003; Arakawa
et al. 2004). Importantly, the inhibition of calpain was shown to increase HDL
biogenesis in cultured cells, indicating that the inhibition of proteolytic degradation
of ABCA1 could be a promising strategy for increasing HDL (Lu et al. 2008). The
phosphorylation of the PEST sequence of ABCA1 at Thr-1286 and Thr-1305
regulates calpain-mediated proteolysis of ABCA1 since the ABCA1-T1286A/
T1305A mutant could not be degraded by calpain (Martinez et al. 2003). The
interaction of ABCA1 with apoA-I results in the dephosphorylation of the
ABCA1 PEST sequence and inhibition of calpain degradation, leading to an
increase of ABCA1 cell-surface expression (Martinez et al. 2003). Calmodulin
was also shown to interact with ABCA1 in the presence of Ca2+ and to protect
from calpain-mediated degradation (Iwamoto et al. 2010).
In addition to the calpain-mediated proteolytic degradation of ABCA1 described
above, ABCA1 is subject to ubiquitin-mediated proteolysis. The presence of
ubiquitinated ABCA1 in the plasma membrane of several cell lines was recently
demonstrated (Mizuno et al. 2011). In HuH-7 cells, the degradation of cell-surface-
resident ABCA1 was inhibited by the overexpression of a dominant-negative form
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of ubiquitin. Moreover, the disruption of the endosomal sorting complex required
for transport (ESCRT) pathway by the knockdown of hepatocyte growth factor-
regulated tyrosine kinase substrate (HRS) delayed the degradation of ABCA1
(Mizuno et al. 2011). These findings suggested that ubiquitination mediates the
lysosomal degradation of plasma membrane ABCA1 and thereby regulates the
expression and cholesterol efflux functions of ABCA1 independently of the
calpain-mediated pathway.
Unsaturated fatty acids such as oleate and linoleate were shown to destabilize
ABCA1 protein and to inhibit ABCA1-mediated cholesterol efflux in macrophages
by a mechanism that depends on the activity of the enzyme acyl-CoA synthetase
1 which is responsible for their activation to their CoA derivatives (Kanter
et al. 2012). At the same time, unsaturated fatty acids increase the Ser phosphory-
lation of ABCA1 via a phospholipase D (PLD)/protein kinase C δ pathway which
contributes to ABCA1 destabilization (Fig. 6) (Wang and Oram 2007).
Two additional proteins that were identified by two-hybrid screen to physically
interact with ABCA1 and to regulate ABCA1 intracellular localization and turnover
by interacting with its PDZ (PSD-95, Dlg, ZO-1) domain are the a1 and b1
syntrophins (Munehira et al. 2004). Given the short half-life of ABCA1
(t1/2 ¼ 1–2 h) (Wang et al. 2003), interfering with the accessory proteins or the
enzymes that posttranslationally modify ABCA1 may prove a valuable strategy to
regulate ABCA1-mediated HDL biogenesis in the liver and the intestine or to
enhance cholesterol efflux in peripheral cells.
Insulin enhances ABCA1 protein degradation in HepG2 cells via PI3K.
In addition, it inhibits ABCA1 activity by phosphorylation at Tyr1206 (Nonomura
et al. 2011). The kinase that is responsible for this Tyr phosphorylation of ABCA1
is not known, but it was hypothesized that it is the insulin receptor itself.
TNFα and lymphotoxin α (LT) are key inflammatory mediators which also
contribute to the atherogenic process (Schreyer et al. 1996, 2002; Pamir
et al. 2012). TNF induces ABCA1 mRNA and protein levels as well as cholesterol
efflux from cultured macrophages to apoA-I (Gerbod-Giannone et al. 2006). The
induction of ABCA1 by TNFα depended primarily on NF-κB (Gerbod-Giannone
et al. 2006). It was also shown that the expression of the two TNF receptors is
required to mediate full ABCA1 induction by TNFα. In addition, LT increased
ABCA1 protein levels by inhibiting protein degradation through the LT-β receptor
(LTβR) (Edgel et al. 2010).
ABCA1-mediated cholesterol efflux and ABCA1 protein levels were shown to
be decreased by interferon γ (IFNγ) in murine macrophages and macrophage-
derived foam cells (Panousis and Zuckerman 2000). This ABCA1 downregulation
was an early event in IFNγ-mediated activation of macrophages (Alfaro Leon
et al. 2005) and was dependent on signal transducer and activator of transcription
1 (STAT1) since similar effects were not observed in macrophages from STAT1
KO mice (Wang et al. 2002).
Additional protein kinases were shown to affect the activity and stability of
ABCA1 at the posttranslational level including protein kinase A (PKA), protein
kinase C (PKC), Janus kinase 2 (JAK2), and casein kinase (CK2) (Tang et al. 2004).
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ABCA1 activity was shown to be regulated by the nuclear receptor LXRβ by a
mechanism that is distinct from the transcriptional induction of the ABCA1 gene
caused by cholesterol accumulation. It was shown that at low cholesterol levels,
LXRβ binds to ABCA1 and the ABCA1-LXRβ complex is stably localized at the
plasma membrane but is unable to facilitate apoA-I-mediated cholesterol efflux.
Exogenously added LXR ligands, which mimic cholesterol accumulation, cause
LXRβ to dissociate from ABCA1, thus freeing ABCA1 for apoA-I binding and
subsequent cholesterol efflux (Hozoji et al. 2008; Hozoji-Inada et al. 2011).
3.2 ABCG1
Similar to ABCA1, the levels of ABCG1 transporter were shown to be subject to
regulation at the posttranslational level (Fig. 6) (Tarling and Edwards 2012). Recent
studies showed that the presence of additional 12 amino acids between the Walker
B motif and the first transmembrane domain of ABCG1 can affect ABCG1 protein
stability (Engel et al. 2006). It was shown that stable overexpression of 12/15-
lipoxygenase (12/15LO) in macrophages was associated with a 30 % reduction in
HDL-mediated cholesterol efflux and reduced ABCG1 protein expression (Nagelin
et al. 2008). Treatment of macrophages with the 12/15LO eicosanoid product
12SHETE increased serine phosphorylation of ABCG1 and affected the stability
of the protein (Nagelin et al. 2008). Proteasomal inhibitors blocked the
downregulation of ABCG1 and resulted in the accumulation of phosphorylated
ABCG1 (Nagelin et al. 2009). Macrophages that lack 12/15LO had enhanced
ABCG1 expression, reduced ABCG1 phosphorylation, and increased cholesterol
efflux. Conversely, macrophages that overexpress 12/15LO have reduced ABCG1
expression, increased transporter phosphorylation, and reduced cholesterol efflux
(Nagelin et al. 2009). It was also shown that 12/15LO regulates ABCG1 expression
and function through p38- and JNK2-dependent mechanisms (Nagelin et al. 2009).
The activation of adenosine monophosphate-activated protein kinase (AMPK) in
human aortic endothelial cells resulted in increased levels of ABCG1 protein via a
posttranscriptional mechanism that involved increased stability of ABCG1 mRNA
(Li et al. 2010a, b). The aminoimidazole carboxamide ribonucleotide (AICAR)-
dependent induction of ABCG1 was associated with increased efflux of cellular
cholesterol and 7-ketocholesterol to HDL and protected nitric oxide synthase
activity and vascular reactivity (Li et al. 2010a, b).
The protein levels of ABCG1 were shown to be controlled by palmitoylation in
both human embryonic kidney 293 cells and in mouse macrophage, J774
(Gu et al. 2013). Five cysteine residues located at positions 26, 150, 311, 390,
and 402 in the NH2-terminal cytoplasmic region of ABCG1 were shown to be
palmitoylated. The removal of palmitoylation at Cys311 by mutating the residue to
Ala (C311A) or Ser significantly decreased ABCG1-mediated cholesterol efflux.
On the other hand, the removal of palmitoylation at sites 26, 150, 390, and 402 had
no significant effect (Gu et al. 2013).
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3.3 SR-BI
The stability of the HDL receptor SR-BI in the hepatocyte plasma membrane is
very important for its functions and is subject to posttranscriptional regulation
(Fig. 6). SR-BI stability is primarily controlled by its adapter protein,
PDZ-containing kidney protein 1 (PDZK1 or NHERF3 for Na+/H+ exchanger
regulator factor-3), since PZK1-knockout mice exhibit a >95 % reduction in
hepatic SR-BI protein (but not mRNA) and are characterized by hypercholesterol-
emia and the presence of large cholesterol-rich HDL particles in the plasma
(Kocher et al. 2003). In adrenal cells where the PDZK1 levels are very low,
additional members of the NHERF family such as NHERF1 and NHERF2 (but
not NHERF4) were shown to specifically interact with SR-BI and reduce its protein
levels (Hu et al. 2013). The data showed that the downregulation of SR-BI by these
NHERF1/2 factors significantly inhibits both HDL-CE uptake and steroid hormone
production by adrenal cells. It was concluded that the PDZK1 homologues act as
physiological translational/posttranslational regulators of the functional expression
of SR-BI (Hu et al. 2013).
Feeding mice with an atherogenic diet was accompanied by a threefold post-
translational downregulation of hepatic SR-BI at the protein level (Niemeier
et al. 2009). A similar SR-BI downregulation was observed in transgenic mice
overexpressing SREBP-1a and SREBP-1c on chow diet, and it was associated with
a decrease in the expression levels of PDZK1 (Niemeier et al. 2009).
The levels of SR-BI protein were shown to be affected in two syndromes: the
nephrotic syndrome and the Rett syndrome. It was shown that animals with
nephrotic syndrome which is characterized by dyslipidemia, impaired high-density
lipoprotein (HDL)-mediated reverse cholesterol transport, and atherosclerosis
(Vaziri et al. 2003) exhibited severe hypercholesterolemia, hypertriglyceridemia,
reduced HDL/total cholesterol ratio, significant upregulation of the endocytic HDL
receptor ATP synthase mRNA and protein, and significant reduction of SR-BI
protein despite its normal mRNA abundance. The reduction in SR-BI protein levels
in animals with NS was accompanied by parallel reductions in PDZK1 mRNA and
protein levels (Vaziri et al. 2011). Rett syndrome, a genetic form of infantile autism,
is the second most common cause of mental retardation in women (Amir
et al. 1999). When compared to healthy subjects, patients with Rett syndrome
present with significant increases in total cholesterol (12 %), LDL cholesterol
(15 %), and HDL-C (18 %) (Sticozzi et al. 2013). Skin fibroblasts isolated from
patients with Rett syndrome exhibited low levels of SR-BI as a consequence of its
association with 4-hydroxy-2-nonenal (4HNE), a product of lipid peroxidation that
is increased in patients with Rett syndrome, and increased ubiquitination (Sticozzi
et al. 2013). The role of the proteasome in SR-BI stability was confirmed using the
proteasomal inhibitor (MG132). When Rett syndrome fibroblasts were pretreated
with MG132, the loss of SR-BI was reversed demonstrating that SR-BI is degraded
via the proteasome machinery (Sticozzi et al. 2013).
In hepatic cells and fibroblasts, SR-BI protein levels and SR-BI-mediated cho-
lesterol transport (export and uptake) were shown to be affected by the Ras/MEK/
ERK signaling cascade. This effect was mediated via PPARα-inducible
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degradation pathways (Wood et al. 2011). Metabolic labeling experiments in
primary hepatocytes from mice demonstrated that fenofibrate enhances the degra-
dation of SR-BI in a post-endoplasmic reticulum compartment (Lan and Silver
2005). Moreover, fenofibrate-induced degradation of SR-BI was independent of the
proteasome, the calpain protease, or the lysosome (Lan and Silver 2005).
In primary macrophages and cell lines derived from female but not from male
mice, tamoxifen and 4-hydroxytamoxifen increased SR-BI protein expression via
the estrogen receptor α (Dong et al. 2011). Because SR-BI mRNA expression and
promoter activity were not influenced by tamoxifen and 4-hydroxytamoxifen, it was
demonstrated that the regulation of SR-BI by these substances takes place at the
level of protein stability (Dong et al. 2011).
The phosphatidylinositol 3-kinase (PI3K) pathway was shown to affect posi-
tively the SR-BI-mediated HDL selective cholesterol ester uptake into human
HepG2 cells as this process was compromised in the presence of the PI3K inhibitors
wortmannin and LY294002 (Shetty et al. 2006). These inhibitors also blocked the
positive effect of insulin on the SR-BI-dependent selective uptake. HDL cell-
surface binding, receptor biotinylation studies, and confocal fluorescence micro-
scopy of HepG2 cells expressing green fluorescent protein-tagged SR-BI
demonstrated changes in SR-BI subcellular localization and cell-surface expression
as a result of PI3K activation (Shetty et al. 2006). These data indicate that PI3K
activation stimulates hepatic SR-BI function posttranslationally by regulating the
subcellular localization of SR-BI. It was recently shown that monocyte chemo-
attractant protein-1 (MCP-1), a protein expressed by endothelial cells under inflam-
matory conditions, decreases the cell-surface protein expression of ABCA1,
ABCG1, and SR-BI in a dose-dependent and time-dependent manner (Huang
et al. 2013). It was shown that PI3K activation corrected the MCP-1-induced
decreases in the cell-surface protein expression of the three transporters. MCP-1
decreased the lipid uptake by HepG2 cells and the ABCA1-mediated cholesterol
efflux to apoA-I, and this was reversed by the activation of PI3K. These data
suggested that MCP-1 impairs RCT activity in HepG2 cells by a PI3K-/AKT-
mediated posttranslational regulation of ABCA1, ABCG1, and SR-BI cell-surface
expression (Huang et al. 2013).
Finally, it was shown that hormones such as triiodothyronine (T3) and
thyromimetics and some pharmacological agents such as probucol increase SR-BI
levels posttranscriptionally (Leiva et al. 2011).
Conclusions
As discussed earlier in this chapter as well as in other chapters of this handbook,
plasma HDL cholesterol levels are determined by the relative rates of HDL
biogenesis and HDL catabolism which in turn are mediated by several lipid-
carrying proteins, plasma enzymes, and membrane transporters. The deregu-
lation of the activity or the expression of these proteins by mutations or during
diseases is associated with non-physiological levels of HDL cholesterol, HDL
dysfunction, and predisposition to coronary heart disease. Epidemiological
studies as well as experiments in genetically modified animals have provided
unequivocal proof that raising HDL cholesterol levels may be therapeutic. Drugs
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that could specifically increase the rates of HDL biogenesis by inducing the
levels of apoA-I, ABCA1, or LCAT are anticipated to be of great clinical benefit.
Other HDL proteins such as ABCG1, ABCG5/G8, CETP, and LPL could also
provide useful targets for HDL-based therapies that will interfere with HDL
maturation or catabolism without compromising HDL functionality. The devel-
opment of novel HDL-raising drugs that will capitalize on HDL biogenesis will
certainly require a thorough understanding of the mechanisms and the molecules
that are involved in HDL regulation at the transcriptional, posttranscriptional, or
posttranslational level in hepatic cells as well as in other physiologically relevant
cells such as the macrophages. For instance, understanding ABCA1 gene regu-
lation in the macrophage has led to the elucidation of the important role of LXRs
and their ligands in the reverse cholesterol transport and the development of
novel LXR ligands which however have severe lipogenic effects in the liver and
are thus of no clinical value today so the challenge here is to develop more
specific drugs that will avoid lipogenesis. Novel single- or dual-specificity
agonists of peroxisome proliferator-activated receptor isoforms are also
anticipated. Understanding how the levels of HDL proteins and their functional-
ity are affected by inflammatory factors will enable us to develop novel drugs to
restore HDL levels and functionality and thus reduce the atherosclerotic burden
in patients with chronic inflammatory diseases.
In summary, the current challenges in the HDL field are to develop novel
therapies that would raise HDL cholesterol levels without compromising HDL
functionality and to identify novel HDL-based biomarkers. The advances in the
field of HDL regulation may provide crucial insights and tools to achieve
this goal.
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Abstract
Both alterations of lipid/lipoprotein metabolism and inflammatory events con-
tribute to the formation of the atherosclerotic plaque, characterized by the
accumulation of abnormal amounts of cholesterol and macrophages in the artery
wall. Reverse cholesterol transport (RCT) may counteract the pathogenic events
leading to the formation and development of atheroma, by promoting the high-
density lipoprotein (HDL)-mediated removal of cholesterol from the artery wall.
Recent in vivo studies established the inverse relationship between RCT effi-
ciency and atherosclerotic cardiovascular diseases (CVD), thus suggesting that
the promotion of this process may represent a novel strategy to reduce athero-
sclerotic plaque burden and subsequent cardiovascular events. HDL plays a
primary role in all stages of RCT: (1) cholesterol efflux, where these lipoproteins
remove excess cholesterol from cells; (2) lipoprotein remodeling, where HDL
undergo structural modifications with possible impact on their function; and
(3) hepatic lipid uptake, where HDL releases cholesterol to the liver, for the final
excretion into bile and feces. Although the inverse association between HDL
plasma levels and CVD risk has been postulated for years, recently this concept
has been challenged by studies reporting that HDL antiatherogenic functions
may be independent of their plasma levels. Therefore, assessment of HDL
function, evaluated as the capacity to promote cell cholesterol efflux may offer
a better prediction of CVD than HDL levels alone. Consistent with this idea, it
has been recently demonstrated that the evaluation of serum cholesterol efflux
capacity (CEC) is a predictor of atherosclerosis extent in humans.
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1 Cholesterol Efflux as the First Step of Reverse Cholesterol
Transport (RCT)
Lipid accumulation within macrophages, leading to the formation of foam cells,
represents a main feature of atherogenesis (Wynn et al. 2013). Among the strategies
by which cells may counteract this process, the release of excess cholesterol to
extracellular lipid acceptors has been matter of several studies in the recent years.
Although cholesterol efflux from macrophages has a minor contribution to the
whole body cholesterol transported by plasma high-density lipoproteins (HDL), it
is the most important for the antiatherosclerotic extent. For this reason, the macro-
phage RCT concept has been proposed, and it was recently identified as a novel
therapeutic target (Rosenson et al. 2012).
Both active and passive mechanisms are responsible for cholesterol efflux, and
several components, such as cell cholesterol status, lipid transporter activity, and
the nature of extracellular acceptors, have been shown to impact its efficiency
(Zanotti et al. 2012).
The efflux process involves cholesterol localized on the plasma membrane that
in turn may derive from intracellular sites, such as the late endosomal/lysosomal
compartment and from the Golgi apparatus. Cholesterol localized in the endoplas-
mic reticulum originates from endogenous synthesis and can be delivered to
intracellular organelles mainly through a nonvesicular pathway involving protein
carriers. Cholesterol in endosomes and lysosomes derives from lipoprotein uptake
and undergoes hydrolyzation by acid hydrolase (Maxfield and Tabas 2005). This
lipoprotein-derived cholesterol is then rapidly released into the cytoplasm and
delivered throughout the cells by Niemann-Pick type C 1 and 2. These proteins,
expressed on the membrane of late endosomes and in lysosomes, respectively,
facilitate lipid mobilization from these compartments to the plasma membranes
via the trans-Golgi network (Boadu and Francis 2006). In physiological conditions
cholesterol content in intracellular locations is low, because most of it (about 80 %)
is transferred to the plasma membrane, where it establishes a dynamic equilibrium
with endoplasmic reticulum and the Golgi system pools (Huang et al. 2003). The
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plasma membrane bilayer contains distinct lipid environments in a steady state
equilibrium. Lipid rafts are characterized by a tightly packed, liquid-ordered state,
where cholesterol associates with sphingolipids and caveolin, playing a crucial role
in cell signaling (Gargalovic and Dory 2003). Several studies carried out in
macrophages, demonstrated that the major mechanisms of cholesterol efflux are
raft-independent (Gargalovic and Dory 2003). The non-raft membrane
microdomains serve as the principal source of cholesterol available for interaction
with extracellular acceptors and subsequent efflux via ATP-binding cassette trans-
porter A1 (ABCA1) that is localized in these portions of the membrane (Landry
et al. 2006; Vaughan and Oram 2005). Interestingly, RCT can be triggered also
from extracellular matrix-associated cholesterol microdomains, whose formation is
mediated by ATP-binding cassette transporter G1 (ABCG1) (Freeman et al. 2013).
Mechanisms accounting for cholesterol efflux include passive diffusion pro-
cesses as well as active pathways mediated by ABCA1, ABCG1, and scavenger
receptor class B type I (SR-BI). Aqueous diffusion mainly involves free cholesterol
in the plasma membrane and HDL as lipid acceptors. The nature of this process is a
matter of debate: whereas this mechanism appears to be a relevant contributor of
lipid removal in foam cell macrophages (Adorni et al. 2007), the involvement of a
still unknown transporter is not completely ruled out.
1.1 ABCA1-Mediated Lipid Efflux to Lipid-Poor apoA-I
ABCA1 is a 2,261-amino acid integral membrane protein, member of the large
superfamily of ABC transporters that use ATP as an energy source to transport
lipids across membranes. ABC transporters are characterized by the presence of
nucleotide-binding domains containing two conserved peptide motifs known as
Walker A and Walker B, a unique amino acid signature between the two Walker
motifs, which defines the family. ABC transporters are integrated into the mem-
brane by domains containing six transmembrane helices. The minimum require-
ment for an active ABC transporter is two nucleotide-binding and two 6-helix
transmembrane domains (Oram and Lawn 2001). At the cellular level ABCA1 is
localized both on the plasma membrane and intracellular compartments, the Golgi
complex, and the late endosome/lysosomes, cycling between these loci and pro-
moting a flow of intracellular cholesterol from the late endosomes/lysosomes,
through the trans-Golgi complex, to the plasma membrane (Boadu and Francis
2006). This movement produces an ABCA1-dependent depletion of intracellular
pools of cholesterol that affects both the “regulatory” pool of cholesterol and the
LDL-derived cholesterol. These activities result in the modulation of a number of
cellular events including: endogenous cholesterol synthesis, LDL receptor expres-
sion, cholesteryl ester turnover, and nascent HDL formation (Boadu and Francis
2006). The last process is driven by ABCA1-mediated removal of lipids from the
cell membrane to extracellular acceptors represented by lipid-free or lipid-poor
apolipoproteins. ABCA1 expression on the plasma membrane leads to the genera-
tion of non-raft microdomains and enlargement of cholesterol and phospholipid
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domains in the outer leaflet, thus facilitating the interaction with apoA-I and
subsequent cholesterol efflux. It is worth noting that these pools of cholesterol
created by ABCA1 are specific substrates for ABCA1-mediated lipid release
because they selectively interact with lipid-free or lipid-poor apolipoproteins
(Landry et al. 2006). ABCA1 exerts its function through a floppase activity,
which drives cholesterol and phospholipids from the inner leaflet of the membrane
to cell surface domains and eventually back to intracellular compartments. In
addition, ABCA1 promotes vesicular trafficking of cholesterol, phospholipids and
ABCA1 itself between the plasma membrane and intracellular compartments
(Landry et al. 2006). Cholesterol efflux via ABCA1 is related to the protein level,
in turn regulated by transcriptional or posttranslational mechanisms. Abca1 gene
expression is primarily induced by the stimulation of liver X receptor/retinoid X
receptor (LXR/RXR) axis, stimulated by cholesterol accumulation in the cells
(Larrede et al. 2009). Recently, the role of microRNAs in the inhibitory control
of Abca1 expression has emerged (Sun et al. 2012; Rayner et al. 2010; Ramirez
et al. 2011). The posttranscriptional regulation includes mechanisms that involve
(1) the stabilization of ABCA1 protein by apoA-I and (2) the acceleration of its
turnover by calpain-mediated proteolysis or polyunsaturated fatty acids (Oram and
Vaughan 2006).
1.2 Cholesterol Efflux to Lipidated HDL
ABCA1-mediated generation of nascent HDL particles may in turn promote cho-
lesterol efflux via ABCG1 and SR-BI. The former is a half-size ABC protein, where
the nucleotide-binding domain at the N-terminus is followed by six
transmembrane-spanning domains. Interestingly, various transcripts of ABCG1
have been detected in different cells, possibly arising from alternative splicing
events (Schmitz et al. 2001). Early studies reported many similarities between
ABCG1 and ABCA1, including the cellular localization, the translocation from
intracellular compartments to the plasma membrane, the floppase activity, and the
expression promoted by cholesterol enrichment via LXR. A main feature of
ABCG1-mediated efflux is the specific interaction with HDL and low-density
lipoproteins (LDL) thus accounting for the elimination of cholesterol and toxic
oxysterols from the macrophages (Vaughan and Oram 2005). It is important to note
that under physiologic conditions ABCA1 and ABCG1 can act in a sequential
fashion, with ABCA1 generating, which then promote lipid release via ABCG1
(Gelissen et al. 2006). However, recent data challenge these concepts, suggesting
that, unlike ABCA1, ABCG1 effluxes cellular cholesterol by a process that is not
dependent upon interaction with an extracellular protein (Tarling and Edwards
2012).
Although several cholesterol-responsive ABC transporters, other than ABCA1
and ABCG1, have been described in the macrophages, their potential relevance for
the process of foam cell formation and RCT needs further investigations
(Fu et al. 2013).
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SR-BI is an 82-kDa integral membrane protein, belonging to the CD36 family,
whose physiological role is related to the selective uptake of HDL cholesteryl ester,
the process by which the core cholesteryl ester is taken into the cell without the
endocytic uptake and degradation of the whole HDL. Since this pathway is the
major route for the delivery of HDL cholesteryl ester to the liver, the role of SR-BI
in determining the plasma levels of HDL is of major importance. Importantly,
SR-BI has shown to stimulate free cholesterol efflux facilitating the aqueous
diffusion pathway to phospholipid-enriched acceptors. Thus, the expression of
this receptor establishes a bidirectional flux between cells and HDL, whose net
effect will be related to cell cholesterol status, as well as the composition and
concentration of the acceptor in the extracellular environment. Differently from the
ABC transporters, SR-BI is localized in caveolae, a subset of lipid rafts, cell surface
invaginations enriched in free cholesterol (Rosenson et al. 2012). Despite the
significant role of SR-BI in cell cholesterol metabolism, its role in cholesterol
efflux from macrophages is still unclear. It is important to note that the relative
contribution of a single pathway to cholesterol export is species specific: whereas
ABCA1-mediated efflux is the predominant mechanism both in human and murine
cultured foam cells, the role of ABCG1 is elusive in the former, but not in the latter.
Conversely, SR-BI (Cla-1 in humans) plays a pivotal role in human, but not murine
cells (Adorni et al. 2007; Sun et al. 2012). Moreover, the antiatherosclerotic
properties of ABCA1 and ABCG1 have recently been challenged by the demon-
stration that some efflux-independent activities could be related to deleterious
effects on macrophage function (Adorni et al. 2011; Olivier et al. 2012).
A relevant role in cholesterol efflux from macrophages and RCT has been also
attributed to apolipoprotein E (apoE) (Zanotti et al. 2011a, b). This 34-kDa protein
is synthesized by many cell types, including macrophages, upon different stimuli,
such as differentiation, cytokines, and lipid enrichment. The last process activates
the LXR pathway, as described for ABCA1 and ABCG1. ApoE synthesis in the
endoplasmic reticulum is followed by its movement to the Golgi and trans-Golgi
network and incorporation into vesicular structures, before being transported to the
plasma membrane for the final secretion. Secreted apoE can be released into the
extracellular medium or alternatively can bind to the cell surface, particularly in
association with heparan sulfate proteoglycans. Cell surface pools may be
reinternalized and subsequently degraded, transported to the Golgi network for
posttranslational modifications, or released into the extracellular medium (Kockx
et al. 2008). When ApoE is secreted from cholesterol-enriched macrophages, this
process can promote cholesterol efflux in the absence of added cholesterol
acceptors or in presence of exogenous HDL, causing the generation of nascent
HDL particles. There is evidence that apoE can promote cholesterol release by both
ABCA1-dependent and independent mechanisms, whereas ABCG1 may contribute
by driving cholesterol efflux to apoE-enriched particles (Huang et al. 2001).
186 E. Favari et al.
2 HDL Quality and Cholesterol Efflux
HDL comprises several subclasses that differ in composition and size and exhibit a
series of atheroprotective and other properties, including the ability to efflux
cholesterol from various cell types, as well as antioxidative, anti-inflammatory,
anticoagulatory, and anti-aggregatory properties (Annema and von Eckardstein
2013; Vickers and Remaley 2014). These properties are exerted by the various
protein and lipid components of HDL (Annema and von Eckardstein 2013; Vickers
and Remaley 2014). It is increasingly accepted that the quality rather than quantity
of HDL is more relevant for its atheroprotective activity (see chapter “Dysfunc
tional HDL: From Structure-Function-Relationships to Biomarkers” for more
details).
As anticipated, the ability of HDL to promote cholesterol efflux from lipid-laden
macrophages is thought to be important for the atheroprotective function of HDL.
The capacity of HDL to promote cholesterol efflux from macrophages was shown
to have a strong inverse association with both carotid intima–media thickness and
the likelihood of angiographic coronary artery disease, independently of the HDL-C
level (Khera et al. 2011). As mentioned before, cellular cholesterol efflux is
mediated by a number of pathways, with the various HDL subpopulations to display
a varied capacity to promote cholesterol efflux via each of these pathways (Annema
and von Eckardstein 2013; Vickers and Remaley 2014). Therefore, the efficiency of
serum from an individual to accept cellular cholesterol can be affected by the
distribution and composition of HDL particles acting as cholesterol acceptors.
Indeed, it has been shown that apolipoprotein B (apoB)-depleted sera from subjects
with similar HDL-C or apoA-I can have higher total macrophage efflux capacity
due to significantly higher ABCA1-mediated efflux, and this efflux is significantly
correlated with the levels of preβ1-HDL (de la Llera-Moya et al. 2010; Calabresi
et al. 2009). Small discoidal preβ1-HDL particles are also efficient acceptors of cell
cholesterol via ABCG1 (Favari et al. 2009). In another study, apoB-depleted sera
from patients treated with the cholesteryl ester transfer protein (CETP) inhibitor
anacetrapib were shown to have enhanced ability to promote ABCG1-mediated
cholesterol efflux from macrophages, which was associated with increased lecithin-
cholesterol acyltransferase (LCAT) and apoE mass in HDL (Yvan-Charvet
et al. 2010).
The various components of HDL particles can undergo structural or chemical
modifications during atherogenesis or other pathologic processes, having as a result
adverse effects on HDL functionality, including the cholesterol efflux capacity. In
vitro and in vivo studies have shown that enzymatic oxidation, lipolysis, and
proteolysis can modify HDL and affect the HDL capacity to promote cellular
cholesterol efflux. HDL isolated from humans with established CVD was found
to contain higher levels of protein-bound 3-chlorotyrosine and protein-bound
3-nitrotyrosine compared to HDL from controls (Bergt et al. 2004; Pennathur
et al. 2004; Zheng et al. 2004). In addition, the levels of both 3-chlorotyrosine
and 3-nitrotyrosine were higher in HDL isolated from atherosclerotic lesions
compared with plasma HDL. One pathway that generates such species involves
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myeloperoxidase (MPO), a major constituent of artery wall macrophages (Bergt
et al. 2004; Pennathur et al. 2004; Zheng et al. 2004). It was proposed that apoA-I is
a selective target for MPO-catalyzed nitration and chlorination in vivo and that
MPO-catalyzed oxidation of HDL and apoA-I results in selective inhibition of
ABCA1-dependent cholesterol efflux from macrophages (Zheng et al. 2004).
More specifically, it was shown that chlorination of apoA-I impaired the ability
of the protein to promote cholesterol efflux by MPO, while nitration had a much
lesser effect (Bergt et al. 2004; Zheng et al. 2005; Shao et al. 2005) and that a
combination of Tyr-192 chlorination and methionine oxidation is necessary for
depriving apoA-I of its ABCA1-dependent cholesterol transport activity (Shao
et al. 2006). More recently it was suggested that oxidative damage to apoA-I by
MPO limits the ability of apoA-I to be liberated in a lipid-free form from HDL and
that this impairment of apoA-I exchange reaction may contribute to reduced
ABCA1-mediated cholesterol efflux (Cavigiolio et al. 2010).
Treatment of HDL3 with the reticulocyte-type 15-lipoxygenase-1 (15-LO-1),
which has been suggested to play a pathophysiological role in atherosclerosis,
induced HDL apolipoprotein cross-linking and reduced cholesterol efflux from
lipid-laden J774 cells (Pirillo et al. 2006). A reduced binding of 15-LO-modified
HDL3 to SR-BI explained, in part, the observed reduction of cholesterol efflux. In
addition, the ABCA1-mediated cholesterol efflux was also reduced, as a conse-
quence of loss of preβ-particles after HDL3 modification (Pirillo et al. 2006).
The capacity of HDL to promote cellular cholesterol efflux from lipid-loaded
mouse peritoneal macrophages was significantly decreased after treatment of HDL
with secretory phospholipase A2 (PLA2) group X or V (Zanotti et al. 2011a, b).
sPLA2-X and sPLA2-V that have been associated with the pathogenesis of athero-
sclerosis affect the capacity of HDL to promote cholesterol efflux by catalyzing the
hydrolysis of phosphatidylcholine in HDL without any modification of apoA-I
(Ishimoto et al. 2003).
Several proteases, including metalloproteinases, cathepsins, chymase, tryptase,
kallikrein, neutrophil elastase, and plasmin, that are secreted from various types of
cells of human atherosclerotic arterial intima can proteolytically modify HDL
in vitro (Lee-Rueckert et al. 2011). It has been shown that the various proteases
proteolyze apoA-I that is present in preβ-HDL and therefore reduce cholesterol
efflux from macrophage foam cells (Favari et al. 2004). A series of studies aiming
to elucidate the effect of proteolytic modification of HDL on cholesterol efflux and
RCT used mast cells and the neutral serine proteases chymase and tryptase, which
are secreted from mast cells. Treatment of HDL3 with human chymase resulted in
rapid depletion of preβ-HDL and a concomitant decrease in the efflux of cholesterol
and phospholipids by an ABCA1-dependent pathway, while aqueous or SR-BI-
facilitated diffusion of cholesterol was not affected (Favari et al. 2004). Further-
more, local activation of mast cells by the specific mast cell degranulating com-
pound 48/80 in the mouse peritoneal cavity, which causes acute release of active
chymase, resulted in a 90 % reduction of human apoA-I injected into the peritoneal
cavity. This reduction reflected the reduction in preβ-HDL particles and resulted in
attenuation of cholesterol efflux from intraperitoneally co-injected J774
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macrophages and a reduced rate of macrophage RCT. In addition, pretreatment of
apoA-I with chymase also fully abolished the stimulatory effect of untreated apoA-I
to promote the transfer of macrophage-derived cholesterol to the intestine
(Lee-Rueckert, Silvennoinen et al. 2011).
Proteolysis of lipid-free apoA-I or preβ-HDL- or HDL3-associated apoA-I by
intima proteases may result in the formation of carboxy-terminal truncated apoA-I
fragments. Specifically, it has been shown recently that lipid-free apoA-I is prefer-
entially digested by chymase at the C-terminus rather than the N-terminus and that
the Phe229 and Tyr192 residues are the main cleavage sites, while the Phe225 residue
is a minor cleavage site (Usami et al. 2013). C-terminally truncated apoA-I was
detected in normal human serum using a specific monoclonal antibody (16-4mAb)
recognizing C-terminally truncated apoA-I that has been cleaved after Phe225 by
chymase (Usami et al. 2011). In addition, it has been shown that proteolysis of
apoA-I in preβ-HDL by plasmin generated apoA-I fragments lacking the
C-terminal region (Kunitake et al. 1990). Such C-terminal truncation of apoA-I
can affect its capacity to promote ABCA1-mediated cholesterol efflux and the
biogenesis of HDL. Previous studies showed that when C-terminal segments that
contain residues 220–231 are deleted, the apoA-I cannot associate with ABCA1 and
has a diminished capacity to promote ABCA1-mediated phospholipid cholesterol
efflux (Favari et al. 2002; Chroni et al. 2003, 2004). In another study, the treatment
of lipid-free human apoA-I by chymase-containing lysate derived from mouse
peritoneal mast cells or recombinant human chymase generated apoA-I fragments,
lacking the C-terminal site (Usami et al. 2013), which had diminished capacity to
promote cholesterol efflux from mouse peritoneal macrophage foam cells
(Lee-Rueckert, Silvennoinen et al. 2011). Furthermore, adenovirus-mediated gene
transfer in apoA-I-deficient mice showed that the apoA-I mutants that lack
C-terminal residues 220–231 fail to form spherical αHDL in vivo (Chroni
et al. 2003, 2007).
Other proteolysis studies showed that apoA-I in HDL3 by various recombinant
metalloproteinases in vitro or by metalloproteinases secreted from macrophages
generated apoA-I fragments also lacking the carboxyl-terminal region (cleavage
after residues 213, 202, 215, 225,199, 191, or 188) (Lindstedt et al. 1999; Eberini
et al. 2002). In addition, chymase, in vitro, cleaves apoA-I in reconstituted HDL at
the C-terminus (after Phe225) (Lee et al. 2003). These C-terminal truncated
lipoprotein-associated apoA-I displayed diminished capacity to promote choles-
terol efflux from mouse macrophage foam cells (Lindstedt et al. 1999; Lee
et al. 2003). A recent study showed that reconstituted HDL containing the
C-terminal deletion mutants apoA-I(Δ(185–243)) or apoA-I(Δ(220–243)) had
strongly impaired capacity to promote ABCG1-mediated cholesterol efflux (Daniil
et al. 2013). In addition, limited proteolysis of rHDL containing wild-type apoA-I
by plasmin resulted in 66 % decrease of ABCG1-dependent cholesterol efflux
(Daniil et al. 2013). It is therefore possible that proteolysis of HDL-associated
apoA-I in vivo by proteases, which are present in the human arterial intima, could
yield apoA-I fragments similar to the apoA-I(Δ(185–243)) or apoA-I(Δ(220–243))
mutants and thus may impair their capacity to promote ABCG1-mediated
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cholesterol efflux from macrophages. The structure-function relationship seen in
this study between rHDL-associated apoA-I mutants and ABCG1-mediated cho-
lesterol efflux closely resembles that seen before in lipid-free apoA-I mutants and
ABCA1-dependent cholesterol efflux, suggesting that both processes depend on the
same structural determinants of apoA-I.
The levels, composition, and the antiatherogenic properties, including the
cholesterol efflux capacity, of HDL has been shown to be affected in patients
suffering from chronic inflammatory rheumatic diseases (Onat and Direskeneli
2012; Watanabe et al. 2012). Specifically, cholesterol efflux capacity of HDL was
impaired in rheumatoid arthritis and systemic lupus erythematosus patients with
high disease activity and was correlated with systemic inflammation, higher plasma
MPO activity, and HDL’s antioxidant capacity (Ronda et al. 2013; Charles-
Schoeman et al. 2012). In addition, HDL cholesterol efflux capacity was lower in
patients with psoriasis (Watanabe et al. 2012; Holzer et al. 2013), while
antipsoriatic therapy significantly improved the HDL cholesterol efflux capacity,
along with improved serum LCAT activity and without any effect on serum HDL
cholesterol levels (Holzer et al. 2013).
Overall, modifications of HDL particles have been demonstrated to affect the
atheroprotective properties of HDL, including its capacity to promote cellular
cholesterol efflux. Elucidation of the conditions and processes that affect the
compositional, structural, and functional intactness of HDL may become an impor-
tant tool for the assessment of cardiovascular risk and may provide us with novel
therapeutic approaches. In addition, monitoring of the capacity of HDL to promote
cholesterol efflux could be useful to evaluate novel therapeutic approaches for the
reduction of cardiovascular risk, as it will be discussed later.
3 RCT in Animal Models
3.1 Physiology
The term RCT summarizes the transport of cholesterol from macrophage foam cells
within atherosclerotic lesions through the aqueous compartment of the blood for
final excretion into the feces, which could either occur directly as cholesterol or
after metabolic conversion into bile acids (Annema and Tietge 2012). As detailed
above, cholesterol efflux from lipid-laden macrophages is mediated by the
transporters ABCA1, ABCG1, and SR-BI with HDL as acceptor, and this process
is facilitated by apoE. Within the blood HDL can be remodeled in several ways.
LCAT esterifies free cholesterol in the particles resulting in larger HDL and
increased plasma HDL-C levels (Annema and Tietge 2012). CETP transfers cho-
lesterol out of HDL toward apoB-containing lipoproteins in exchange for
triglycerides, which are then rapidly hydrolyzed by hepatic lipase (HL) (Annema
and Tietge 2012). Thereby CETP and also HL, either alone or in combination,
lower plasma HDL-C levels. Other HDL remodeling proteins that increase the
catabolic rate of HDL and lower circulating HDL-C are the phospholipid transfer
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protein (PLTP) (Annema and Tietge 2012) and the phospholipases endothelial
lipase (EL) (Annema and Tietge 2011) and group IIA secretory phospholipase A2
(sPLA2-IIA) (Rosenson and Hurt-Camejo 2012) . Uptake of HDL-C into
hepatocytes can be accomplished in two distinct ways, via selective uptake
mediated by SR-BI (Annema and Tietge 2012) or via holoparticle uptake in a
process that has not been fully elucidated yet (Vantourout et al. 2010). However, it
has been shown that via ectopic localization of the mitochondrial F1-beta-ATPase
on the cell membrane, ADP is generated which then stimulates via the ADP
receptor P2Y13 holoparticle uptake of HDL by still elusive receptor mechanisms;
thereby, HDL holoparticle uptake is fully dependent on the expression of the ADP
receptor P2Y13 (Vantourout et al. 2010). In hepatocytes, cholesterol is either
secreted directly into the bile, which is mediated in terms of mass mainly by
ABCG5/G8 and to a lesser extent by SR-BI, or following conversion into bile
acids, for which ABCB11 is the critical transporter into bile (Dikkers and Tietge
2010). Cholesterol can be reabsorbed in the intestine by Niemann-Pick type C like
1 (NPC1L1) but also (re)secreted by the ABCG5/G8 heterodimer, whereby a low
activity of NPC1L1 would increase and a low activity of ABCG5/G8 would
decrease cholesterol excretion into the feces (Annema and Tietge 2012). Bile
acids can be reabsorbed in the terminal ileum by ASBT (Dawson 2011). In addition
to its role in sterol absorption, the intestine has also been indicated to mediate direct
secretion of cholesterol, a process termed transintestinal cholesterol excretion
[TICE, current knowledge summarized in Tietge and Groen (2013)]. All different
steps discussed in this paragraph have the potential to impact on and modulate RCT.
3.1.1 Methodological Approaches to Quantify RCT In Vivo
The key methodological problem for quantifying RCT specifically from
macrophages, which is most relevant for atherosclerotic disease, is that the macro-
phage cholesterol pool is rather small. Initially employed techniques such as mass
determinations of centripetal cholesterol fluxes to the liver or isotope dilution
methods were therefore not able to accurately allow a conclusion of specific
cholesterol fluxes from macrophages (Annema and Tietge 2012). Recently, a now
widely used and accepted technique had been developed that overcomes such
methodological drawbacks (Zhang et al. 2003). Thereby, macrophages, either
primary or cell lines, are loaded with radiolabeled cholesterol and then injected
intraperitoneally into recipient animals. After injection, the appearance of the tracer
is determined in plasma at different time points and, most importantly, in the feces
that are collected continuously. The time course of such experiments is usually
24–48 h; in the feces distinguishing between labels in neutral sterols and bile acids
is in our view preferable.
Although this method allows tracing of cholesterol from macrophages to feces,
there are certain limitations that need to be taken into account when interpreting
results from such studies. One is that in the assay a potential influx of cholesterol
from the plasma compartment into the macrophage is not taken into account. As
first steps to overcome this, two approaches were reported, in which the application
procedure of the labeled macrophages is modified in a way that allows reisolation of
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the cells to measure label as well as mass cholesterol content. One of these
approaches makes use of Matrigel plugs that are implanted subcutaneously
(Malik and Smith 2009), while the other another, entrapment of the macrophages
in semipermeable holofibers (Weibel et al. 2011). Another limitation of in vivo
RCT assays is that all approaches place the labeled macrophages outside the
vascular compartment, which supposedly is a good surrogate but might also not
accurately reflect the situation in an atherosclerotic lesion in terms of oxygen
tension, pH, or accessibility by the HDL particles. In the following, results obtained
from the above-described method will be summarized. It is relevant to point out that
although initial steps toward a macrophage RCT assay in humans have been
reported at conferences (Dunbar et al. 2013), current knowledge on the regulation
of in vivo RCT is based on studies in animal models that differ in several aspects of
their lipoprotein metabolism.
3.1.2 Factors Impacting In Vivo RCT
Looking at the level of the macrophage, available studies consistently indicate that
expression of ABCA1 and ABCG1 is associated with increased RCT (Wang
et al. 2007a, b; Out et al. 2008). However, SR-BI deficiency in macrophages does
not impact RCT (Wang et al. 2007b; Zhao et al. 2011). On the other hand,
macrophage apoE was shown to stimulate RCT (Zanotti et al. 2011a, b).
Regarding plasma proteins that have a role in HDL metabolism, for LCAT
surprisingly no consistent effects on RCT were observed using several different
models and overexpression as well as knockout strategies resulting in the conclu-
sion that LCAT only minimally contributes to RCT although it has a major role in
determining plasma HDL-C levels (Tanigawa et al. 2009). In the case of the lipid
transfer proteins, PLTP overexpression resulted in increased RCT (Samyn
et al. 2009), while for CETP (over)expressing models, either an increase (Tchoua
et al. 2008; Tanigawa et al. 2007), dependent on functional expression of the LDL
receptor (Tanigawa et al. 2007), or no effect (Rotllan et al. 2008) was observed.
With respect to (phospho)lipases, sPLA2-IIA had no impact on RCT (Annema
et al. 2010). In case of HL and EL, conflicting data have been reported. While
one group found no effect of knocking out either lipase separate or both in
combination (Brown et al. 2010), others reported increased RCT for EL as well
as HL (Escola-Gil et al. 2013). In contrast to apoE expression in macrophages,
systemic overexpression of apoE had no effect on RCT either in wild-type or CETP
transgenic mice (Annema et al. 2012).
In the case of the hepatic component of RCT, SR-BI expression in hepatocytes
has a clear increasing effect on RCT as indicated in studies using both knockout and
overexpression (Zhao et al. 2011; El Bouhassani et al. 2011; Zhang et al. 2005).
Interestingly, it has been shown that in the liver the impact of SR-BI is independent
of ABCG5/G8 expression, since double-knockout mice for both transporters had a
significant decrease in RCT compared with ABCG5 knockout mice alone (Dikkers
et al. 2013). ABCG5/G8 knockouts on the other hand exhibited no change in RCT
(Calpe-Berdiel et al. 2008). In addition, also the consequences of abolishing
functional HDL holoparticle uptake into hepatocytes on RCT were assessed. In
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P2Y13 knockout mice, this pathway is completely absent translating into a signifi-
cant reduction in macrophage-to-feces RCT (Fabre et al. 2010; Lichtenstein
et al. 2013). These combined studies indicate that both selective uptake and
holoparticle uptake of HDL are critical for RCT. Regarding expression of
ABCA1 in hepatocytes, liver supposedly contributes around 70 % to total HDL
formation (Timmins et al. 2005); the picture is not so clear. While in wild-type and
SR-BI knockout mice blocking hepatic ABCA1 with probucol enhanced RCT
(Annema et al. 2012; Yamamoto et al. 2011), no such effect was seen in liver-
specific ABCA1 knockout mice on a LDLR-deficient background (Bi et al. 2013).
With respect to the final step of RCT, sterol excretion from the body, the
differential contribution of the biliary pathway and the intestine is a subject of
active study; it might be important to note that no unequivocally established
concept has emerged thus far. The classical view on the RCT pathway puts biliary
secretion of RCT-relevant cholesterol central (Annema and Tietge 2012). This view
is supported by studies using either surgical disruption of biliary secretion or Abcb4
knockout mice that have a genetic defect in cholesterol secretion into the bile
secondary to their inability to secrete phospholipids and form mixed micelles
(Nijstad et al. 2011). In the surgical model RCT was virtually absent, while in the
genetic model, RCT was strongly reduced (Nijstad et al. 2011). Studies in
ezetimibe-treated mice that express NPC1L1 only in hepatocytes reached a similar
conclusion, namely, that functional RCT in this model depended on efficient biliary
sterol secretion (Xie et al. 2013). On the other hand, RCT studies in NPC1L1 liver-
transgenic mice on a wild-type background as well as a short-term experiment in
bile-diverted mice resulted in opposite findings, namely, that RCT can proceed
when the biliary secretion pathway is impaired (Temel et al. 2010). Further studies
are clearly required to assess the role of the intestine and a possible contribution of
TICE to macrophage RCT. However, currently such experiments are hampered by
the lack of information how TICE is precisely mediated (Tietge and Groen 2013).
Commonly accepted on the other hand is the role of intestinal sterol absorption in
RCT, and several pharmacological intervention studies were carried out to show
that blocking sterol absorption increases RCT (for details please see Table 1 and
text above).
In addition, there are also more complex systemic pathophysiological states that
are clinically associated with an increased atherosclerosis incidence and in which
also alterations in RCT have been observed in mouse models. One example is an
inflammatory response. Consistently, RCT was severely impaired in LPS- (Annema
et al. 2010; McGillicuddy et al. 2009) and zymosan-induced (Malik et al. 2011)
models of acute inflammation. Another example is diabetes. In both, an insulin-
deficient model of type 1 diabetes (de Boer et al. 2012) as well as in db/db mice
(Low et al. 2012), which lack the leptin receptor and serve as model of type
2 diabetes, RCT was decreased. Interestingly, the first study indicated that the
selective uptake step of HDL into the liver is defective in type 1 diabetic mice
(de Boer et al. 2012), while the latter study provided evidence that advanced
glycation end products are not likely to be pathophysiologically involved (Low
et al. 2012). Furthermore, acute psychological stress has been shown to increase








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cholesterol Efflux and Reverse Cholesterol Transport 195
RCT in mice, mainly by a corticosterone-mediated downregulation of NPC1L1 and
subsequent reduction in intestinal cholesterol absorption (Silvennoinen et al. 2012).
These data underline the important role of intestinal NPC1L1 in RCT but are
counterintuitive to the increased atherosclerosis risk attributed to psychological
stress in clinical settings.
Finally, two recent additions of pathways that are linked to RCT have emerged
which are not so obvious given the classical view on the RCT pathway but are
worth mentioning. On the one hand, red blood cells were shown to contribute to
RCT in a way that functional RCT was decreased in anemic mice (Hung
et al. 2012). On the other hand, lymphatic drainage has been indicated to be
involved in RCT (Martel et al. 2013; Lim et al. 2013). Hereby, blocking lymphatic
transport or lymph vessel regrowth inhibited RCT, while enabling it increased RCT
(Martel et al. 2013; Lim et al. 2013). Interestingly, for this route of RCT,
transcytosis of HDL through lymphatic endothelium in a SR-BI-dependent fashion
was critical (Lim et al. 2013), findings very similar to the role of SR-BI in HDL
transcytosis through vascular endothelial cells (Rohrer et al. 2009).
3.2 Pharmacology
RCT-enhancing therapies are currently considered a promising strategy for the
prevention and treatment of atherosclerotic CVD. An important number of
RCT-targeted drugs have been used in preclinical animal models (mainly mice
and hamsters) to test their effects on in vivo RCT from labeled cholesterol
macrophages to feces. These RCT-targeted drugs can be classified among four
different therapeutic approaches: CETP inhibition, nuclear receptors activation,
cholesterol absorption inhibition, and directly augmenting or mimicking apoA-I.
Most of these drugs are being used in clinical practice or tested in clinical trials in
phases I, II, or III. This section discusses recent findings indicating that some of
these therapies may be atheroprotective by promoting RCT in vivo (Table 1 shows
a summary of available data).
3.2.1 CETP Inhibitors
CETP inhibition presents a preferential target for raising HDL-C and enhancing
RCT. However, available data on the effect of the CETP inhibitors torcetrapib,
dalcetrapib, and anacetrapib in macrophage-to-feces RCT have produced divergent
results (Tchoua et al. 2008; Briand et al. 2011; Niesor et al. 2010; Castro-Perez
et al. 2011). These controversial effects, together with the disappointing results of
two large clinical trials using torcetrapib and dalcetrapib, have raised reasonable
doubts regarding the clinical use of CETP inhibitors (Barter and Rye 2012). The
positive effects of CETP antisense oligonucleotides on macrophage RCT (Bell
et al. 2013) open up an alternative pathway to further evaluate whether the inhibi-
tion of CETP may improve cardiovascular risk.
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3.2.2 Nuclear Receptor Activation
Liver X receptor (LXR) is considered an attractive target for therapeutic strategies
aimed at stimulating RCT since it promotes HDL biogenesis, macrophage choles-
terol efflux, and biliary cholesterol excretion. A considerable number of studies
tested the effect of systemic LXR agonists T0901317 and GW3965 on macrophage-
to-feces RCT and consistently found a higher flux through this pathway (Naik
et al. 2006; Zanotti et al. 2008; Calpe-Berdiel et al. 2008; Yasuda et al. 2010;
Nijstad et al. 2011; Briand et al. 2010). However, systemic LXR activators have
detrimental consequences for the liver such as the induction of lipogenesis. As
discussed in Sect. 3.1.2, multiple evidences indicate that excretion of macrophage-
derived cholesterol can be modulated in the last step of RCT pathway which occurs
in the small intestine. Indeed, intestine-specific LXR activator GW6340 also
enhances macrophage RCT but avoids the lipogenic toxicity associated with liver
LXR activation in mice (Yasuda et al. 2010). Peroxisome proliferator-activated
receptor (PPAR) α agonists such as GW7647 and fenofibrate promote macrophage
RCT (Rotllan et al. 2011; Nakaya et al. 2011). This effect is strongly correlated with
the positive effects on apoA-I levels; more importantly, macrophage PPARα and
LXR expression are required for the PPARα-mediated enhancement of macrophage
RCT (Nakaya et al. 2011). ABCA1 and G1 are targeted for degradation by
microRNA (miR)-33, an intronic microRNA located within the SREBF2 gene;
anti–miR-33 therapy enhances macrophage RCT (Rayner et al. 2011). In contrast,
the PPARγ agonist GW7845 reduces macrophage RCT. The authors hypothesize
that GW7845 redirects macrophage-derived cholesterol to adipose tissue via
SR-BI, thereby reducing its biliary excretion (Toh et al. 2011). Beyond PPAR-
LXR activation, the farnesoid X receptor (FXR) agonist GW4064 also promotes
macrophage-to-feces RCT; this effect is related to liver SR-BI upregulation and
reduced intestinal cholesterol absorption (Zhang et al. 2010).
3.2.3 Cholesterol Absorption Inhibitors
Interventions that inhibit cholesterol absorption including ezetimibe administration
and PPAR β/δ activation with GW0742 increase the excretion of macrophage-
derived cholesterol in feces by reducing intestinal NPC1L1 activity (Briand
et al. 2009; Sehayek and Hazen 2008; Silvennoinen et al. 2012; Maugeais
et al. 2013). The bile acid sequestrant cholestyramine also promotes macrophage-
to-feces RCT (Maugeais et al. 2013).
3.2.4 Augmenting or Mimicking apoA-I
The use of apoA-I and its different forms for the prevention and treatment of
atherosclerosis is a long-term goal of many laboratories. The full-length apoA-I,
reconstituted apoA-I-containing HDL, or apoA-I mimetics D4-F, ATI-5261, and
5A have been demonstrated to be effective for enhancing macrophage-to-feces
RCT in different mouse models (Maugeais et al. 2013; Lee-Rueckert and Kovanen
2011; Navab et al. 2004; Bielicki et al. 2010; Amar et al. 2010). The upregulation of
liver apoA-I production, as occurred with the thienotriazolodiazepine Ro 11-1464,
also enhances macrophage RCT (Zanotti et al. 2011a, b).
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4 Serum Cholesterol Efflux Capacity (CEC)
Several epidemiological studies define HDL as the most powerful plasmatic factor
with atheroprotective activity in humans (Di Angelantonio et al. 2009); a 1 mg/dl
increase of plasma HDL-C is associated with a 3–4 % reduction in cardiovascular
mortality (Assmann et al. 2002). Some post hoc analyses from randomized con-
trolled trials also suggest that raising HDL-C beneficially affects the risk of CVD
(Toth et al. 2013). However, the clinical efficacy of raising plasma HDL-C levels to
achieve cardiovascular risk reduction has been difficult to prove. Recently
published outcome trials involving the addition of niacin or dalcetrapib to standard
low-density lipoprotein cholesterol reduction therapy failed to demonstrate clinical
benefit despite increases in HDL-C ((AIM-HIGH) trial 2011; Schwartz et al. 2012).
Furthermore, genetic variants associated with increased HDL-C, thus conferring
lifelong exposure to higher circulating levels, are not consistently associated with
improved vascular outcomes (Voight et al. 2012). These findings have reinforced
the idea that changes in HDL-C levels are an inadequate surrogate for therapeutic
use. Therefore, an emerging concept is that of the quality of HDL, which are
heterogeneous in terms of size, charge, and lipid content (Calabresi et al. 2010)
and display functional differences, such as cell cholesterol efflux promotion.
Animal studies have suggested that HDL-mediated cholesterol flux through the
different RCT steps is a better predictor of the atherosclerotic impact of various
genetic and pharmacological perturbations than static, mass-based quantification of
circulating HDL-C (Rader et al. 2009). The efficacy of such HDL function in a
single individual may be estimated by measuring the cholesterol efflux capacity
(CEC) using widely standardized techniques that allow distinguishing between the
various mechanisms involved (Adorni et al. 2007). Several lines of evidence
suggest that CEC is sensitive to HDL composition rather than HDL-C plasma
levels; for instance, it has been shown that the serum capacity to promote choles-
terol efflux via ABCA1 strictly depends on the nascent (preβ) HDL plasma levels
(de la Llera-Moya et al. 2010; Favari et al. 2004). Subjects with the apoA-IMilano
mutation or LCAT deficiency have high levels of circulating particles and efficient
serum ability to induce macrophage cholesterol depletion despite very low HDL
levels (Favari et al. 2007; Calabresi et al. 2009). Thus, there is increasing evidence
that the measure of HDL functionality in different populations may be a better
predictor of coronary artery disease than the measure of absolute HDL-C levels
(Khera et al. 2011). As mentioned before, this concept is consistent with studies
revealing that subjects affected by CVD not only have HDL deficiency but also
major rearrangements of their composition (Campos et al. 1995; Sweetnam
et al. 1994) and consequently function. The role of serum CEC as an index of
cardiovascular protection has been suggested by a recent study demonstrating that
in two distinct cohorts of subjects, the CEC variable has a stronger predictive power
of the carotid intima-media thickness, an index of subclinical atherosclerosis, than
plasma HDL-C levels (Khera et al. 2011). In addition, in a population of healthy
subjects, ABCA1-mediated serum CEC was inversely correlated with pulse wave
velocity, an index of arterial stiffness, independent of HDL-C serum levels (Favari
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et al. 2013). A work measuring the flow-mediated dilation, as a parameter of
endothelial function, showed a positive correlation with the ABCA1-mediated
efflux pathway confirming the concept that the functional measures of HDL
might be a better marker for cardiovascular risk rather than HDL cholesterol levels
(Vazquez et al. 2012). Recently, Li and colleagues provided data indicating that
individuals in the top tertile of CEC had a moderately increased risk of a composite
cardiovascular end point of incident myocardial infarction, stroke, or death during
3 years of follow-up (Li et al. 2013). However, in the same study, CEC was
inversely associated with coronary artery disease. The reasons for this apparently
contradictory findings require further evaluation, but may be related to the
characteristics of the population involved in the study (Khera and Rader 2013).
Overall, the available data suggest that evaluation of CEC may better correlate with
coronary artery diseases than HDL-C; however, further studies are required to
demonstrate its role as predictor of cardiovascular event risk.
Conclusions
RCT provides a physiological strategy of protection from atherosclerosis. HDL
plays a leading role by promoting the removal of excess cholesterol in the arterial
wall through the induction of cellular cholesterol efflux from cells. Cholesterol
efflux represents the first and perhaps most important step of RCT. The ability of
HDL to promote cholesterol efflux depends on their quality and the pathologic
processes that induce their modifications. Many of the available data on the
physiology and pharmacology of RCT depend on studies in animal models that
have demonstrated that the enhancement of RCT is inversely correlated with the
development of atherosclerosis. In humans, the efficiency of the RCT can be
evaluated with the surrogate parameter of serum cholesterol efflux capacity
(CEC) that indicates the ability of HDL to promote efflux of cholesterol in the
individual patient. Recent clinical data suggest that the evaluation of CEC is a
strong predictor of atherosclerosis extent in humans and may represent in the
future a useful biomarker of cardiovascular risk.
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Abstract
High-density lipoproteins (HDL) are complexes of multiple talents, some of
which have only recently been recognised but all of which are under active
investigation. Clinical interest initially arose from their amply demonstrated role
in atherosclerotic disease with their consequent designation as a major cardio-
vascular disease (CVD) risk factor. However, interest is no longer confined to
vascular tissues, with the reports of impacts of the lipoprotein on pancreatic,
renal and nervous tissues, amongst other possible targets. The ever-widening
scope of HDL talents also encompasses environmental hazards, including infec-
tious agents and environmental toxins. In almost all cases, HDL would appear to
have a beneficial impact on health. It raises the intriguing question of whether
these various talents emanate from a basic ancestral function to protect the cell.
The following chapter will illustrate and review our current understanding of
some of the functions attributed to HDL. The first section will look at the
antioxidative functions of HDL and possible mechanisms that are involved.
The second section will focus specifically on paraoxonase-1 (PON1), which
appears to bridge the divide between the two HDL functions discussed herein.
This will lead into the final section dealing with HDL as a detoxifying agent
protecting against exposure to environmental pathogens and other toxins.
Keywords
HDL • Lipoproteins • Oxidative stress • Paraoxonase • Organophosphates •
Bacterial pathogen • Antiviral activity • Nanoparticles • Bisphenol
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AAPH Azo-initiator (2,20-azobis-(2-amidinopropane) hydrochloride)
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HBV Hepatitis B virus
HDL High-density lipoproteins
HETE Hydroxy-eicosatetraenoic acid
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NADPH Nicotinamide adenine dinucleotide phosphate
NLF Nasal lavage fluid
OP Organophosphate




PLTP Phospholipid transfer protein
PON1 Paraoxonase-1
POP Persistent organic pollutant
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
rHDL Reconstituted HDL
SAA Serum amyloid A
SRA Serum resistance-associated
SR-BI Scavenger receptor class B-I
TLF Trypanolytic factor
TLR Toll-like receptor
TNF Tumour necrosis factor
Tyr Tyrosine
VLDL Low-density lipoproteins
1 High-Density Lipoproteins and Oxidative Stress
The role of high-density lipoproteins (HDL) in the vascular system has been the
primary focus of clinical interest. It arose from early studies of the influence of the
lipoprotein on cholesterol metabolism and atherosclerosis. With increasing under-
standing of the complexity of the atherosclerotic process and involvement of other
pathological mechanisms, attention has logically progressed to the impact of HDL
on such mechanisms. One process is oxidative stress and there is now persuasive
evidence that the lipoprotein can attenuate its consequences by a number of
mechanisms. These are discussed in this section.
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1.1 High-Density Lipoproteins: Antioxidative Function
The response-to-retention hypothesis of atherosclerosis (Williams and Tabas 1995)
postulates that cholesterol-rich lipoproteins, primarily low-density lipoproteins
(LDL), are retained in the arterial wall and oxidatively modified under the action
of resident cells (Stocker and Keaney 2004). Oxidation in the arterial intima results
from local oxidative stress, which represents an imbalance between prooxidants and
antioxidants in favour of the former. Cellular oxidative systems involved in vivo
include myeloperoxidase (MPO), NADPH oxidase, nitric oxide synthase and
lipoxygenase. They produce a variety of reactive chlorine, nitrogen and oxygen
species in the form of one-electron (free radical) and two-electron oxidants (Gaut
and Heinecke 2001).
HDL can protect LDL and other lipoproteins from oxidative stress induced by
both one- and two-electron species. It can be observed in vitro on their
co-incubation (Parthasarathy et al. 1990) and in vivo upon HDL supplementation
(Klimov et al. 1993). One-electron oxidants modify both lipid and protein moieties
of HDL with formation of lipid and protein radicals. It is followed by accumulation
of primary oxidation products, initially lipid hydroperoxides (LOOH), which in
turn propagate further oxidation of HDL components to stable termination products
(Stocker and Keaney 2004). HDL particles potently protect both lipid and protein
moieties of LDL from free radical-induced oxidation, inhibiting accumulation of
both primary and secondary oxidation products (Kontush and Chapman 2010). The
following overview will focus on the impact of HDL on lipid hydroperoxides and
other primary products of lipid peroxidation.
1.2 Mechanisms of Protection
HDL potently inhibits accumulation of LOOH in LDL. Removal of LOOH from
LDL (or cells) represents a key step of HDL-mediated protection from oxidative
damage induced by free radicals. Indeed, phospholipid hydroperoxides (PLOOHs)
are rapidly transferred from LDL to HDL upon their co-incubation (Zerrad-Saadi
et al. 2009). Addition of a hydroperoxyl group to a phospholipid or cholesteryl ester
molecule strongly increases hydrophilicity. As a result, LOOH molecules are more
surface active than their non-peroxidised counterparts (Nuchi et al. 2002). Their
exposure to the aqueous phase at the HDL surface facilitates their removal from the
lipoprotein. Transfer from LDL to HDL can occur directly between lipoprotein
phospholipid monolayers, either spontaneously or mediated by lipid transfer
proteins, including cholesterol ester transfer protein (CETP). The latter can accel-
erate the transfer of both cholesteryl ester hydroperoxides (CEOOHs) and PLOOHs
(Christison et al. 1995). Thus, CETP can enhance the antioxidative activity of HDL
towards LDL-derived LOOH. Removal of LOOH molecules from LDL can also be
mediated by lipid-free apoA-I. As a consequence, HDL particles constitute a major
transport vehicle of LOOH in human plasma, effectively functioning as a “sink” for
oxidised lipids (Bowry et al. 1992). They can accumulate in the particle when its
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LOOH-inactivating capacity is overwhelmed. Furthermore, HDL represents a
major plasma carrier of F2-isoprostanes, stable final products of lipid peroxidation
(Proudfoot et al. 2009). The ability of HDL to remove LOOH from cell membranes
of erythrocytes and astrocytes has also been reported (Ferretti et al. 2003; Klimov
et al. 2001). Thus, the accumulation of oxidised lipids in HDLmost probably results
not only from their transfer from LDL but also from remnant triglyceride-rich
lipoproteins and/or arterial wall cells, mediated in part by lipid transfer proteins
(Christison et al. 1995). Subsequently, LOOHs and their corresponding hydroxides
can be rapidly removed from HDL via scavenger receptor class B-I (SR-BI)-
mediated selective uptake by the liver (Christison et al. 1996). This pathway may
significantly contribute to the removal of toxic, oxidised lipids from the body. As
CEOOH are removed from the circulation more rapidly than the corresponding
nonoxidised cholesteryl ester, addition of a hydroperoxyl group may accelerate
cholesterol excretion. Following their transfer, HDL-associated LOOH are
inactivated by reduction to the corresponding hydroxides in a two-electron redox
reaction with HDL proteins (Garner et al. 1998; Zerrad-Saadi et al. 2009). ApoA-I
plays a central role in redox inactivation of LOOH and may account for a large part
of the antioxidation effects of the lipoprotein. ApoA-I Met residues 112 and
148 reduce LOOH to redox-inactive lipid hydroxides, thereby terminating chain
reactions of lipid peroxidation (Garner et al. 1998; Zerrad-Saadi et al. 2009).
Simulation by molecular dynamics shows interaction of Met112 and Met148 with
Tyr115, creating a microenvironment unique to human apoA-I (Bashtovyy
et al. 2011) that may be optimal for such redox reactions. LOOH is also inactivated
by apoA-II, although to a lesser extent. The key role of apoA-I in the
HDL-mediated protection of LDL from one-electron oxidants is supported by the
observation that reconstituted HDL (rHDL) containing only purified apoA-I and
phospholipid (POPC), but devoid of other protein and lipid components, are
comparable to natural, small, dense HDL3b + 3c subfractions in their capacities to
delay lipid peroxidation (Zerrad-Saadi et al. 2009). Concentrations of redox-active
Met residues in apoA-I and of PLOOH suggest a 1:1 reaction stoichiometry (Garner
et al. 1998; Zerrad-Saadi et al. 2009). HDL content of apoA-I and oxidative status
of apoA-I Met residues are therefore important determinants of the capacity of HDL
to inactivate LOOH and protect LDL from free radical-induced oxidation (Zerrad-
Saadi et al. 2009). The redox reaction between HDL Met residues and LOOH is
paralleled by the formation of oxidised forms of apoA-I and apoA-II which contain
methionine sulfoxides. These methionine sulfoxide moieties can be reduced back to
methionine by methionine sulfoxide reductases. In addition to Met, Cys residues
may be important for the antioxidative properties of apoA-I, as demonstrated by the
elevated inhibitory potency of the N74C mutant of apoA-I towards LDL oxidation
(Zhang et al. 2010). His residues may also contribute to the apoA-I-mediated
inhibition of LOOH accumulation in LDL, as a result of their metal-chelating
properties (Nguyen et al. 2006). Indeed, transition metal ions are well-established
catalysers of lipid peroxidation.
HDL particles contain other apolipoproteins that may contribute to inhibition of
LOOH accumulation (Davidson et al. 2009; Ostos et al. 2001). Such antioxidative
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properties have been reported for apoA-IV (Ostos et al. 2001) and apoE (Miyata
and Smith 1996). In addition, apoM displays antioxidative properties in transgenic
mice where possible mechanisms may involve binding of oxidised phospholipids,
including LOOH (Elsoe et al. 2012). Enzymatic components potentially
contributing to antioxidative properties of HDL include paraoxonase-1 (PON1),
platelet-activating factor acetylhydrolase (PAF-AH) and lecithin-cholesterol
acyltransferase (LCAT), all of which have been proposed to hydrolyse oxidised
phospholipids (Kontush and Chapman 2006). In addition, HDL carries glutathione
peroxidase (GSPx) which can detoxify LOOH by reducing them to the
corresponding hydroxides (Maddipati and Marnett 1987). Finally, the trypanosome
lytic factor present in very high-density subpopulations of human HDL exhibits a
peroxidase-like activity (Molina Portela et al. 2000) that may provide a minor
contribution to LOOH-inactivating properties of HDL. With respect to PON1,
PAF-AH and LCAT, these are weakly reactive towards LOOH (Goyal
et al. 1997; Kriska et al. 2007; Teiber et al. 2004). HDL-associated PON1, which
has been attributed a major antioxidant role in HDL (see Sect. 2.1), does not appear
to contribute significantly to the inactivation of LDL-derived PLOOH (Garner
et al. 1998; Zerrad-Saadi et al. 2009). Such activity that has been previously
reported has been ascribed to the presence of detergents or unidentified proteins
(Teiber et al. 2004). The major activity of PON1 is that of a calcium-dependent
lactonase rather than a peroxidase (Khersonsky and Tawfik 2005); its affinity for
LOOH is several orders of magnitude lower than its affinity for lactones (see
Sect. 2.1 for further discussion of PON1). It is more probable that PAF-AH, rather
than PON1, represents the hydrolase for PLOOH in HDL (Kriska et al. 2007).
LCAT may equally hydrolyse PLOOH generated during lipoprotein oxidation
(Goyal et al. 1997). In addition, it can delay LDL oxidation, acting as a chain-
breaking antioxidant, most likely via its Cys residues (McPherson et al. 2007).
Inhibition of LCAT does not, however, significantly influence HDL-mediated
inactivation of LDL-derived PLOOH (Zerrad-Saadi et al. 2009), thereby indicating
that the enzyme is at most a minor factor in PLOOH inactivation. Irrespective of the
enzyme involved, PLOOH hydrolysis releases lysophosphatidylcholine and a free
fatty acid hydroperoxide. Interestingly, PAF-AH is capable of hydrolysing PLOOH
within oxidised LDL; in this case, free fatty acid hydroperoxides are transferred to
HDL for subsequent two-electron reduction to corresponding hydroxides by apoA-I
(Kotosai et al. 2013). As a result of elevated hydrophilicity, free fatty acid
hydroperoxides, as compared to PLOOH and CEOOH (Kotosai et al. 2013), are
preferentially transported to HDL and reduced to hydroxides.
In contrast to its effects on free radical-induced oxidation, HDL weakly protects
LDL from oxidation by two-electron oxidants, such as hypochlorite, which mainly
modify the protein moiety of LDL. Such antioxidative action appears largely
unspecific, reflecting direct oxidant scavenging by HDL. A rare example of
HDL-mediated protection from two-electron oxidants is inactivation by enzymes
such as PAF-AH and/or PON1 with participation of apoA-I (Ahmed et al. 2001), of
phospholipid core aldehydes generated upon HDL oxidation by peroxynitrite.
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Finally, HDL lipids can significantly modulate antioxidative activities displayed
by the protein components. First, HDL carries small amounts of lipophilic
antioxidants, primarily tocopherols, which may provide a minor contribution to
its LOOH-inactivating properties (Bowry et al. 1992; Goulinet and Chapman
1997). Second, the rigidity of the phospholipid monolayer of HDL particles is a
key negative modulator of PLOOH transfer efficiency from LDL and cell
membranes (Vila et al. 2002; Zerrad-Saadi et al. 2009). The surface monolayer
rigidity of HDL is primarily determined by the relative content of such lipids
(sphingomyelin, free cholesterol, and saturated and monounsaturated fatty acids).
Increasing the content of each rigidifies the surface monolayer of HDL particles at a
given protein/lipid ratio (Zerrad-Saadi et al. 2009).
1.3 Heterogeneity of Antioxidant Activity of HDL Particles
Apolipoproteins, enzymes and lipids which determine the antioxidative activities of
HDL are non-uniformly distributed across the spectrum of HDL subpopulations.
ApoA-I, the major protein component of HDL participating in the reduction of
LOOHs, is enriched relative to apoA-II in small, dense HDL3c and in large, less
dense HDL2b as compared to HDL2a, 3a and 3b subpopulations (Kontush
et al. 2007). LCAT, PAF-AH, PON1 (Kontush et al. 2003) and apoA-IV (Bisgaier
et al. 1985) are enriched in small, dense HDL. As a consequence, HDL particles are
heterogeneous in their capacity to protect LDL from oxidative damage induced by
one-electron oxidants. Small, dense, protein-rich HDL particles in particular
potently protect LDL from mild oxidative stress induced by azo-initiator (2,2-
0-azobis-(2-amidinopropane) hydrochloride; AAPH) or Cu2+ (Kontush et al. 2003;
Yoshikawa et al. 1997). It involves inactivation of LOOHs via a two-step mecha-
nism with transfer of LOOHs to HDL (facilitated by enhanced fluidity of the HDL
surface lipid monolayer) and subsequent reduction to redox-inactive hydroxides by
Met residues of apoA-I (Christison et al. 1995; Garner et al. 1998; Zerrad-Saadi
et al. 2009). Small, dense HDL3 may be superior to large, less dense HDL2 in terms
of their capacity to remove oxidised lipids from other lipoproteins and cellular
membranes. Structural defects in the packing of surface lipids, which allow inser-
tion of exogenous molecules, become more pronounced with decreasing HDL
particle size and may account for this property (Kumpula et al. 2008). Consistent
with this possibility, small discoid rHDL complexes appear to remove negatively
charged lipids from oxidised LDL to a greater degree than native, spherical HDL
(Miyazaki et al. 1994). In addition, a diminished content of sphingomyelin and free
cholesterol in small, dense HDL may result in an increased fluidity of the surface
lipid monolayer, thereby facilitating incorporation of oxidised lipids of exogenous
origin (Kontush and Chapman 2010).
Inactivation of oxidised lipid molecules following their transfer to HDL may
also occur more rapidly in small, dense particles. First, reduction of LOOHs to
hydroxides is more efficient in HDL3 as compared to HDL2 (Zerrad-Saadi
et al. 2009). Relative enrichment of small, dense HDL in apoA-I may underlie
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this feature (Kontush et al. 2007). Moreover, the distinctly low lipid content of
small, dense HDL can induce conformational changes in apoA-I relative to large,
less dense HDL. It results in enhanced exposure to the aqueous phase, as reflected in
modified reactivity towards monoclonal antibodies (Sparks et al. 1995), which
might in turn facilitate the redox reaction between Met residues of apoA-I and
LOOHs. Second, LOOH hydrolysis by HDL-associated hydrolytic enzymes
appears to be predominantly associated with small, dense HDL3 (Kontush
et al. 2003). Preferential localisation of enzymatic activities of PAF-AH within
HDL3 is probably responsible for such association. Furthermore, enzymatic
activities might be beneficially influenced by the lipidome of small, dense HDL3,
which is distinct in displaying a low sphingomyelin to phosphatidylcholine ratio
(Kontush et al. 2007). Indeed, sphingomyelin belongs to a class of structural lipids
that exert a positive impact on surface rigidity and a negative impact on LCAT
activity (Subbaiah and Liu 1993).
Finally, the unique proteome of HDL3c may have implications for its
antioxidative activity. Several proteins, including apoJ, apoM, serum amyloid A4
(SAA4), apoD, apoL-1, PON1 and PON3 and phospholipid transfer protein (PLTP)
occur predominantly in this subfraction (Davidson et al. 2009). Indeed, PLTP is
present on HDL together with apoJ, apoL-I, apoD, apoA-I, apoA-II and several
other proteins, suggesting a direct, functional interaction between them.
2 High-Density Lipoproteins, Paraoxonase-1
PON1 is an intriguing example of the functional flexibility of HDL components as
it bridges the apparent divide between systemic oxidative stress and environmental
toxicology. Originally identified as an enzyme neutralising environmental toxins, it
progressed to an antioxidant role before revealing its capacity to combat pathogens:
the functional complexity and versatility of HDL reflected in a single, peptide
component. This section will focus on two aspects of PON1 function. It will expand
on the antioxidant capacity of PON1 that was referred to in the preceeding section.
Subsequently the ability of PON1 to limit bacterial virulence, notably with respect
to Pseudomonas aeruginosa, will be addressed.
2.1 PON1 as an Antioxidant
Early, in vitro studies suggested that purified PON1 and HDL-associated PON1
could protect LDL from oxidation (Mackness et al. 2003), although these
conclusions were questioned in subsequent reports (James 2006). However, studies
from several animal models (James 2006) have provided much stronger support for
the conclusion that PON1 protects against atherosclerotic disease by a process that
involves reduction of oxidative stress. Thus PON1 knockout in mice was associated
with a significant increase in the development of atherosclerotic lesions, whilst
HDL from such mice were less able to protect LDL from oxidation (Shih
214 H. Karlsson et al.
et al. 1998, 2000). The latter was corrected by addition of purified PON1 to the
HDL. Conversely, over-expression of PON1 protected against lesion development,
with HDL showing a greater capacity to protect against oxidative stress (Tward
et al. 2002). A consistent observation from these animal models is that PON1
activity is a negative correlate of markers of oxidative stress.
Studies in man are also consistent with a protective role of PON1, involving an
impact on oxidative stress. In a number of disease states that increase risk of
atherosclerotic disease and where increased oxidative stress is noted, PON1
serum activity is significantly reduced. These include diabetes, the metabolic
syndrome, familial hypercholesterolaemia and renal dysfunction (Abbott
et al. 1995; James 2006). Enzyme activity was also reduced in coronary disease
patients, with the extent of coronary lesions correlating inversely with the PON1
activity (Graner et al. 2006). The relationship was independent of other risk factors.
Other case-control investigations confirm that PON1 is a risk factor for coronary
disease (Soran et al. 2009), although it is not a consistent observation (Troughton
et al. 2008). Whilst the above studies focus on enzyme activity, there have also been
a number of studies examining the relationship of PON1 coding region
polymorphisms to coronary risk. The rationale is that a polymorphism at amino
acid 192 gives rise to two isoforms with strikingly different activities towards
paraoxon, one of the substrates used to analyse PON1 activity. Such studies have
given somewhat equivocal results, as illustrated in a meta-analysis by Wheeler
et al. (2004). However, this data should be interpreted with reserve as the range of
activities is wide within each isoform. Moreover, the isoforms manifest much
smaller differences in activities towards a second substrate, phenylacetate, fre-
quently used to analyse PON1. It has led to suggestions that PON1 phenotype
should be used to analyse the relationship of the enzyme to vascular risk (Jarvik
et al. 2000).
More persuasive evidence of a role for PON1 in CVD comes from prospective
studies. In the Caerphilly prospective study, serum PON1 activity was shown to be
an independent determinant of future coronary events (Mackness et al. 2003). No
measures of oxidative stress were undertaken. In two prospective studies, Hazen
and colleagues (Bhattacharyya et al. 2008; Tang et al. 2012) firmly established
PON1 as an independent risk factor for vascular disease, in both primary and
secondary disease settings. They also analysed an impressive range of systemic
indices of lipid oxidation (HETE, HODE, isoprostane) and showed a strong nega-
tive correlation between PON1 activity and serum concentrations of these markers.
These studies clearly suggest that it is the ability of PON1 to limit systemic
oxidative stress and the generation of oxidised lipids that underlies its links to
atherosclerotic disease. Alternative or complementary mechanisms by which PON1
could reduce risk have also been proposed (Aviram 2012; Rosenblat et al. 2013).
The authors suggest that the enzyme can increase the free radical scavenging
capacity of monocyte/macrophages and lower oxidative stress. The same group
also proposed that PON1 increased the ability of HDL to remove cholesterol from
macrophages (Rosenblat et al. 2011). The latter is thought to be an important step in
reverse cholesterol transport. Data from the same study indicated that PON1 may
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increase the ability of HDL to prevent macrophage-mediated oxidation of LDL. In
another study, the group proposed that PON1 could reduce the risk of diabetes, a
potent CVD risk factor (Koren-Gluzer et al. 2011). The antioxidant function, acting
via sulphydryl groups PON1, was suggested to play a role, but not enzyme activity.
Whilst there is persuasive evidence that PON1 prevents systemic lipid oxidation,
how and what substrates it may act on are still unclear. As discussed above
(Sect. 1.2), LOOHwould appear to be poor substrates for the enzyme. Nevertheless,
a feature of the PON1 knockout mice was an accumulation of LOOH in HDL (Shih
et al. 1998; Tward et al. 2002). It is possible that short-chain oxidised phospholipids
may be a better substrate for the enzyme. Increased lipoperoxides as well as lipid
oxidation end products were also a feature of reduced PON1 activity in human
studies (Bhattacharyya et al. 2008; Tang et al. 2012). One possible explanation may
be furnished by a recent, intriguing proposal that PON1 can modulate the activity of
myeloperoxidase (MPO). The latter is an important source of reactive oxygen
species and is associated with HDL. Huang et al. (2013) reported that PON1 and
MPO form a ternary complex with HDL. In this constellation, PON1 was able to
modulate MPO activity (and conversely MPO inhibited PON1). Confirmation was
obtained in vitro by showing that adding PON1 to active MPO significantly reduced
lipid peroxidation by the latter.
At present, the question remains open as to how exactly PON1 functions, with
possible explanations being prevention of ROS formation, curtailing propagation of
ROS or hydrolysing oxidised lipids.
2.2 PON1 and Bacterial Pathogens
A major advance in our appreciation of the physiological relevance of PON1 was
the demonstration that its principal enzyme activity is that of a lactonase
(Khersonsky and Tawfik 2005). Indeed, lactonase activity would appear to be the
initial, ancestral enzyme activity of the PON gene family. These observations
considerably broadened the scope of HDL functions as lactonases are instrumental
in neutralising bacterial virulence factors.
Pseudomonas aeruginosa is an opportunist bacterium and a common cause of
disease in immunocompromised patients. It is also a major contributor to nosoco-
mial infections. Bacterial virulence is governed by homoserine lactones (HSL)
synthesised and secreted by the bacterium. They are central to the phenomenon
of quorum sensing that allows communication between bacteria. The HSLs give a
measure of bacterial density and when a threshold bacteria count is achieved, they
activate gene programmes that greatly increase the rate of Pseudomonas infection
(Juhas et al. 2005). The ability of the PON enzymes to hydrolyse the HSL interrupts
bacterial communication and reduces virulence. Whilst the intracellular PON2
variant shows the strongest lactonase activity, PON1is also active towards HSL
(Ozer et al. 2005) and is able to protect against Pseudomonas infection (Stoltz
et al. 2008). Indeed, PON1 is the major source of HSL neutralising activity in serum
(Teiber et al. 2008).
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Discovery of its role in combating bacterial infection and knowledge that the
paraoxonases are a highly conserved gene family have led to suggestions that they
may play a role in innate immunity (Shih and Lusis 2009).
3 High-Density Lipoproteins, Environmental Pathogens
and Toxins
In recent studies, the molecular composition of the HDL particle has been assigned
significant, functional importance (Besler et al. 2012), which is of particular
relevance with respect to reported changes in HDL composition in disease. Inter-
estingly, alterations in HDL composition have also been observed in man during
endotoxemia (Levels et al. 2011) and in endotoxin-treated mice (Chiba et al. 2011).
As suggested above, data indicate that HDL has an important role in neutralising
and detoxifying invading pathogens to prevent systemic inflammatory responses or
sepsis, which is the leading cause of death in intensive care units (ICUs) of high-
income countries (Levels et al. 2011; Russell 2006). Concurrently, the interaction
of HDL with viruses, parasites and environmental toxins has also been a focus of
recent interest. This is reflected in reviews of the impact of gram-positive and gram-
negative bacterial toxins in sepsis (Ramachandran 2013), the role of HDL in innate
immunity (Feingold and Grunfeld 2011) and the immune system (Kaji 2013) and
xenobiotic metabolism, disposition and regulation of receptors (Omiecinski
et al. 2011) to which the reader is referred. In this chapter, the role(s) of HDL as
a detoxifying agent during exposure to different environmental pathogens or toxins
will be discussed.
3.1 Bacterial Pathogens
Multiple alterations in lipid and lipoprotein metabolism occur during the acute
phase response. Within HDL, apoA-I, cholesterol and phospholipid levels decrease,
as do certain enzyme activities, e.g. PON1 (Khovidhunkit et al. 2004), whilst free
apoA-I (Cabana et al. 1997) and triglyceride levels increase (Cabana et al. 1996).
As a consequence, reverse cholesterol transport decreases, accompanied by
increased cholesterol delivery to immune cells. Such alterations initially protect
the host from the harmful effects of invading pathogens but will contribute to
atherogenesis if prolonged (Khovidhunkit et al. 2004).
A crucial factor in the detoxifying properties attributed to HDL is the ability to
neutralise the invading pathogen. A number of human studies have shown that
circulating lipoproteins, principally HDL, are able to bind lipopolysaccharides
(LPS) from gram-negative bacteria as well as lipoteichoic acid (LTA) from gram-
positive bacteria (Khovidhunkit et al. 2004; Levels et al. 2003, 2011). Binding to
HDL inhibits LPS interaction with cell surface toll-like receptor 4 (TLR-4)
(Underhill and Ozinsky 2002) and LTA interaction with TLR-2 (Flo et al. 2000),
receptors known to mediate inflammatory responses (macrophage activation,
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cytokine release). These neutralising effects of HDL have been confirmed in
humans with low HDL levels who show a more robust inflammatory response to
LPS administration (Birjmohun et al. 2007).
During the acute phase response, HDL protein and lipid compositions change
(Khovidhunkit et al. 2004). Observations indicate that apoA-I can be replaced by
the positive acute phase protein SAA (Artl et al. 2000). SAA is able to influence
HDL-mediated cholesterol metabolism through its inhibitory effects on SR-BI-
mediated selective cholesterol uptake (Cai et al. 2005). It has recently been
suggested to facilitate the binding of HDL, isolated from mice injected with LPS,
to vascular proteoglycans (Chiba et al. 2011). The relevance of these observations is
important when taken together with the up to 1,000-fold increase in concentrations
of plasma SAA during acute phase reactions such as inflammation or infection. In
addition, several isoforms of SAA, still with unknown functions, have recently been
detected in acute phase HDL (Levels et al. 2011).
The neutralising effects of HDL during LPS exposure are dependent on
phospholipids as well as proteins. ApoA-I is suggested to be the major neutralising
factor (Massamiri et al. 1997). Thus, direct interaction between LPS and the
C-terminus of apoA-I can decrease TNF-α release from macrophages in vitro
(Henning et al. 2011). The role of apoA-I as a neutralising agent is further
strengthened by the beneficial effects of apoA-I on LPS-induced acute lung injury
and endotoxemia, as shown in mice (Yan et al. 2006).
The HDL receptor, SR-BI, is highly expressed in hepatocytes and steroid-
producing cells and has an important role regarding the fate of the neutralised
pathogens. In mice, it is suggested to protect against endotoxemia through its roles
in facilitating glucocorticoid production as well as hepatic clearance of LPS. In this
respect, SR-BI has been suggested to mediate the binding and uptake of LPS as well
as LTA (Vishnyakova et al. 2006). Additionally, an alternatively spliced variant,
SR-BII, has been shown to bind directly a variety of bacteria suggesting a
conserved role of these receptors in pattern recognition and innate immunity
(Webb et al. 1998).
3.2 Parasites
Several species of African trypanosomes cause fatal disease in livestock, but most
are unable to infect humans due to innate trypanolytic factors (TLFs). It has been
shown that in human serum, TLFs consist of two minor HDL subfractions
characterised by the presence of haptoglobin-related protein (Hpr) and apoL-I
(Vanhamme et al. 2003). The underlying mechanisms of TLFs action during
parasite infection involve their endocytosis by trypanosomes where, subsequently,
apoL-I forms membrane pores within the acidic lysosome resulting in ion
dysregulation that leads to osmotic imbalance, parasite swelling and lysis
(Molina-Portela Mdel et al. 2005). Endocytosis of apoL-I is facilitated by a
complex formed by Hpr and haemoglobin that interacts with the haptoglobin-
haemoglobin receptor on the trypanosome cell surface (Vanhollebeke
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et al. 2008). However, Trypanosoma brucei rhodesiense, carried by tsetse flies and
causing sleeping sickness in man, is able to escape lysis by TLFs. It is achieved
mainly by the expression of the serum resistance-associated (SRA) protein, which
binds to and neutralises apoL-I (Vanhamme et al. 2003). It should be noted however
that recent population-based observations, focused on individual variations in Hpr,
indicate that a more dynamic view of the relative roles of Hpr and Hpr-Hb
complexes needs to be considered for understanding innate immunity to African
trypanosomes. Other pathogens including the newly discovered Plasmodium (Imrie
et al. 2012) should possibly be considered.
3.3 Hepatitis, Dengue and Other Viruses
HDL account for part of the broad, non-specific antiviral activity in human serum
(Singh et al. 1999). Thus, apoA-I was found to prevent cell penetration by inhibiting
fusion of the herpes virus as well as the human immunodeficiency virus (HIV)
(Srinivas et al. 1990). Interestingly, HIV infection has also been linked to dysfunc-
tional HDL with reduced antioxidant properties, which may be associated to
progression of subclinical atherosclerosis (Kelesidis et al. 2013). In addition,
enhanced levels of human apoM, which is mainly associated with HDL, were
observed during hepatitis B virus (HBV) infection and may reflect feedback
suppression of HBV replication (Gu et al. 2011). Conversely, HDL may also
promote virulence by facilitating virus entry via the SR-BI receptor. This was
first demonstrated for the hepatitis C viruses (Voisset et al. 2006) and recently
extended to dengue viruses that directly associate with apoA-I of HDL
(Li et al. 2013). It is perhaps unsurprising that SR-BI has recently been proposed
as a therapeutic target that warrants further research, based on reports indicating its
involvement in the capture and cross-presentation of antigens from viruses, bacteria
and parasites.
3.4 Metal Oxides, Carbon Nanotubes and PLGA Nanoparticles
Nanotechnology is an emerging industry that involves the creation of new materials
with a variety of useful functions. However, concerns are growing that some of
themmay have toxic effects. This has promoted interest in the role of HDL both as a
neutralising agent and carrier of nanosize particles. Thus the biodistribution of
nanoparticles is significantly influenced by their interaction with plasma proteins,
notably HDL proteins apoA-I and apoE. These, amongst others, have been found to
recognise and interact with carbon nanotubes, a number of metal oxides (Karlsson
et al. 2012) and PLGA (poly(lactic-co-glycolic acid)) nanoparticles (Sempf
et al. 2013) in in vitro plasma models. There are, as yet, no detailed studies
confirming HDL neutralisation and clearance of engineered nanoparticles. How-
ever, the concept of incorporating lipophilic drugs assembled with apoA-I and
phospholipids into soluble, HDL-like nanoparticles for drug delivery is presently
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widely explored (Marrache and Dhar 2013; Shin et al. 2013). They could serve a
number of therapeutic purposes, for example, targeting tissues expressing high
amounts of SR-BI, such as cancer cells (Marrache and Dhar 2013; Shin et al. 2013).
3.5 PON1 and Organophosphates
A crucial function of HDL-associated PON1, in addition to its potential antioxidant
role, is neutralisation of toxic organophosphate (OP) derivatives. Such an activity
was described in human serum many years ago (Aldridge 1953). The activity was
attributed to the enzyme PON1, a name derived from the substrate paraoxon,
initially employed in such studies. Its involvement in the detoxification of OPs
has since been well documented, encompassing chlorpyrifos, oxon and diazoxon as
well as nerve agents (Costa et al. 2013). Indeed, HDL-associated PON1 has been
shown to be a key determinant in detoxification of OPs (Shih et al. 1998) in mouse
models. Intriguingly, PON1 was shown to be associated with HDL at a time when
its antioxidant activity was unknown (James 2006).
A growing area of research is the importance of PON1 in environment toxicol-
ogy and its role in susceptibility to OP exposure. Serum concentrations of the
enzyme, as well as certain polymorphisms affecting activity, appear important for
risk prediction (Androutsopoulos et al. 2011; Costa et al. 2013). Consequently,
children may be more sensitive to environmental OPs since they have reportedly
lower PON1 levels than adults (Huen et al. 2009). Finally, its impact on environ-
mental toxins, as well as its antioxidant function, has led to suggestions that PON1
is linked to neurological disorders (Androutsopoulos et al. 2011), an area that
requires considerably more research.
3.6 Detoxification of Plasma and External Fluids
As discussed in previous sections, HDL and apo A-I have a role in recognition,
neutralisation and elimination of xenobiotics. Thus, elevated levels of plasma
apoA-I in female rats have been found after exposure to the plastic chemical
bisphenol A (BPA) (Ronn et al. 2013). The molecular mechanisms behind the
increase in apoA-I may reflect the effects of estrogens, although conflicting data
have been reported (Teeguarden et al. 2013). It could also be related to apoA-I/
HDL-controlled clearance mechanisms that involve transport of xenobiotics to the
liver. Interestingly, an increase in liver somatic index (LSI) accompanied the apoA-
I increase in the exposed rats, indicating less favourable metabolic alterations.
Since the structure of BPA is very similar to a number of recently proposed
apoA-I enhancing drugs (Du et al. 2012), it may be relevant to investigate these
mechanisms further.
Another group of environmental contaminants, present at low levels in most
living organisms, are persistent organic pollutants (POPs). Due to their hydrophobic
character, they can be transported by lipoprotein particles. Interestingly, long-term
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effects of POPs in human plasma have recently been highlighted in a number of
epidemiological studies (Lind et al. 2012). In a recent study of an exposed Swedish
population, significantly higher concentrations of POPs were found amongst
individuals with CVD or cancer compared to controls (Ljunggren et al. 2014).
Principal component analyses showed that POP concentrations in HDL were more
associated with CVD, whilst POP concentrations in LDL/VLDL were more
associated with cancer. Interestingly, PON-1 activity was negatively correlated to
the sum of polychlorinated biphenyls (PCBs), and covariation between decreased
arylesterase activity, increased PCB concentrations and CVD was found.
To expand the knowledge regarding the role of HDL as detoxifier, it may be
beneficial exploring external fluids. Lipids are present in human tears (Rantamaki
et al. 2011), and apoA-I has been detected in nasal lavage fluid (NLF) (Ghafouri
et al. 2002) and saliva (Ghafouri et al. 2003). Interestingly, in NLF, apoA-I was
shown to increase in hairdressers after 20 min of exposure to persulphates (Karedal
et al. 2010), whilst apoA-I in gingival crevicular fluid has been suggested to be a
novel periodontal disease marker (Tsuchida et al. 2012). In addition, decreased
levels of apoA-I have been reported in bronchio-alveolar lavage fluids of patients
with idiopathic pulmonary fibrosis compared to healthy controls (Kim et al. 2010).
Together with lipocalin, apoA-I has been suggested as a potential biomarker for
chronic obstructive pulmonary disease (Nicholas et al. 2010). The origin of apoA-I
in fluids of the airways has not been extensively studied, but trans-endothelial
transport has been investigated (Ohnsorg et al. 2011). The presence, composition
and possible function of apoA-I containing lipoprotein particles in external fluids
remain to be investigated.
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Abstract
Numerous epidemiologic studies revealed that high-density lipoprotein (HDL) is
an important risk factor for coronary heart disease. There are several well-
documented HDL functions such as reversed cholesterol transport, inhibition
of inflammation, or inhibition of platelet activation that may account for the
atheroprotective effects of this lipoprotein. Mechanistically, these functions are
carried out by a direct interaction of HDL particle or its components with
receptors localized on the cell surface followed by generation of intracellular
signals. Several HDL-associated receptor ligands such as apolipoprotein A-I
(apoA-I) or sphingosine-1-phosphate (S1P) have been identified in addition to
HDL holoparticles, which interact with surface receptors such as ATP-binding
cassette transporter A1 (ABCA1); S1P receptor types 1, 2, and 3 (S1P1, S1P2,
and S1P3); or scavenger receptor type I (SR-BI) and activate intracellular
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signaling cascades encompassing kinases, phospholipases, trimeric and small
G-proteins, and cytoskeletal proteins such as actin or junctional protein such as
connexin43. In addition, depletion of plasma cell cholesterol mediated by
ABCA1, ATP-binding cassette transporter G1 (ABCG1), or SR-BI was
demonstrated to indirectly inhibit signaling over proinflammatory or
proliferation-stimulating receptors such as Toll-like or growth factor receptors.
The present review summarizes the current knowledge regarding the
HDL-induced signal transduction and its relevance to athero- and
cardioprotective effects as well as other physiological effects exerted by HDL.
Keywords
High-density lipoprotein (HDL) • Apolipoprotein A-I (apoA-I) • ATP-binding
cassette transporter A1 (ABCA1) • Scavenger receptor type I (SR-BI) •
Sphingosine-1-phosphate (S1P) • Signal transduction
Abbreviations
ABCA1 ATP-binding cassette transporter A1
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AMPK AMP-activated protein kinase
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CAMK Calcium/calmodulin-dependent protein kinase
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Cdc42 Cell division control protein 42
CHD Coronary heart disease





eNOS Endothelial nitric oxide synthase
GLUT4 Glucose transporter type 4
GM-CSF Granulocyte macrophage colony-stimulating factor
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HSPC Hematopoietic stem progenitor cells
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JAK2 Janus kinase 2





MAPK Mitogen-activated protein kinase
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PC Phosphatidylcholine
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PC-PLD PC-specific phospholipase D
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SR-BI Scavenger receptor type I
STAT3 Signal transducer and activator of transcription 3
TGFβ Transforming growth factor-β
TLR Toll-like receptor
TNFα Tumor necrosis factor α
β-ATPase F1F0 ATP synthase β-subunit
1 Introduction
Innumerable epidemiological studies document the inverse relationship between
plasma levels of high-density lipoprotein (HDL) cholesterol and cardiovascular
risk. The first hypothesis aiming to mechanistically explain this relationship has
been formulated by John Glomset (1968), who proposed that HDL particles take up
excess cholesterol in peripheral tissues including atherosclerotically changed arte-
rial walls and transport it to the liver for excretion with bile. The first step in this
process termed reverse cholesterol transport encompassed direct interaction
between HDL and cell membrane with the subsequent efflux of cholesterol to
lipoprotein particles. Early concepts envisioned cholesterol efflux as a purely
physicochemical phenomenon with the unidirectional flux of free cholesterol
perpetuated by a steady concentration gradient maintained by the activity of
lecithin:cholesterol acyltransferase (LCAT) in HDL particles. John F. Oram was
the first to note that HDL binding to specific binding sites precedes cholesterol
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efflux and is required for the effective mobilization of free cholesterol from internal
pools and its transport to the plasma membrane, where it is available for further
transfer to lipoprotein particles (Graham and Oram 1987; Slotte et al. 1987). The
seminal discovery of Oram put HDL function in a fully new perspective: ever since
then HDL has been perceived not only as a cholesterol transporter but also as
hormone-like particle exerting its activities through binding to specific receptors.
Signal transduction occurs when an extracellular signaling molecule activates a
surface receptor, which in turn alters intracellular molecules creating a response,
which ultimately modifies cellular functions. The recognition of specific HDL
binding sites raised immediately a question, whether HDL-cell interaction is linked
to signaling events relevant to intracellular cholesterol transport and/or cholesterol
efflux. It was Oram again who demonstrated that the exposure of fibroblasts to HDL
causes activation of protein kinase C (PKC), which in turn contributes to transloca-
tion of free cholesterol between intracellular membranes and plasmalemma
(Mendez et al. 1991). This finding opened a new field of research focusing on
dissection of intracellular signaling pathways that are induced by HDL or its
constituents and mediate cellular responses to lipoprotein particles. In the following
years, several ligands present in HDL and their receptors expressed on the cell
surface could be identified that mediate one or more physiological effects attributed
to this lipoprotein. In addition, the interaction of HDL with the cell membrane was
found to potently modify signal transduction induced by other ligands such as
pathogen-associated molecular patterns (PAMPs) or growth factors. This review
attempts to summarize the current state of knowledge on HDL-induced signal
transduction and its physiological relevance.
2 ApoA-I-Induced Cell Signaling Directly Mediated
by ABCA1
ATP-binding cassette transporter A1 (ABCA1) has been originally identified as a
protein defective in familial HDL deficiency (Tangier disease), which is
characterized on the molecular level by the failure of apoA-I to mobilize cholesterol
from intracellular stores, to induce cholesterol and phospholipid efflux from cells,
and ultimately to initiate the maturation of HDL particles and the HDL-mediated
reversed cholesterol transport (Bodzioch et al. 1999; Brooks-Wilson et al. 1999;
Rust et al. 1999). Early models explaining ABCA1-mediated lipid efflux from cells
assumed that this transporter facilitates translocation of cholesterol and
phospholipids to the exofacial leaflet of the cell membrane, where they became
accessible for the passive transfer to apoA-I. Further studies, however, provided
several pieces of evidence suggesting that apoA-I may directly interact with
ABCA1 for the effective unloading of cell cholesterol. For instance, cells obtained
from patients with Tangier disease displayed reduced number of apoA-I binding
sites, whereas increased apoA-I binding to the cell surface could be observed in
cells overexpressing full-length cDNA of ABCA1 (Francis et al. 1995; Wang
et al. 2000). Moreover, studies utilizing chemical cross-linking indicated that
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apoA-I and ABCA1 are in a very close proximity (<7 Å) characteristic of ligand-
receptor interaction, while naturally occurring mutations in extracellular ABCA1
loops profoundly impaired the cross-linking efficiency (Wang et al. 2000;
Fitzgerald et al. 2002, 2004; Chroni et al. 2004). The binding of apoA-I to
ABCA1 was subsequently found to increase the cell content of ABCA1 protein
but not the ABCA1 mRNA abundance suggesting that apoA-I-ABCA1 interaction
might be critical to ABCA1 stabilization (Wang et al. 2003). Actually, apoA-I was
found to promote both the dephosphorylation of the proline-, glutamic acid-, serine-,
and threonine-rich (PEST) sequence in the cytoplasmatic domain of ABCA1 and the
recruitment of calmodulin to the specific 1-5-8-14 binding motif localized in a close
vicinity to the PEST sequence (Wang et al. 2003; Martinez et al. 2003a; Iwamoto
et al. 2010). In this manner, apoA-I binding appears to protect ABCA1 against
calpain-mediated proteolysis. In addition, lipid-free apoA-I was found to retard
ABCA1 degradation mediated by thiol proteases and thereby to facilitate ABCA1
accumulation on the cell surface (Arakawa and Yokoyama 2002).
The recognition of the apoA-I-ABCA1 complex formation and its stabilization
as a mechanism protecting against protease-mediated degradation gave rise to the
hypothesis that the interaction of apoA-I with ABCA1 may trigger intracellular
signaling cascades that modulate ABCA1 levels and/or ABCA1-mediated lipid
transport activity in a posttranslational manner (see Fig. 1 for schematic presenta-
tion of ABCA1-induced signaling). Early studies documented that apoA-I enhances
phosphatidylcholine (PC) turnover in a specific process mediated by a G-protein-
dependent activation of PC-specific phospholipases C and D (PC-PLC and
PC-PLD) (Walter et al. 1995, 1996). Later investigations attributed the apoA-I-
mediated activation of PC-PLC rather to ABCA1-dependent efflux of
sphingomyelin (SPM) and the unspecific depletion of plasma membrane SPM
content (Yamauchi et al. 2003). In both cases, stimulation of PC-PLC liberates
diacylglycerol (DAG), which is the primary physiological activator of PKC. The
activation of both PC-specific phospholipases and PKC seems to be critical for
ABCA1-mediated lipid transport. Actually, pharmacological interference with
PC-PLC and PC-PLD activation reduced apoA-I-induced cholesterol efflux,
whereas exogenous application of their products DAG or phosphatidic acid
(PA) partially corrected the cholesterol efflux defect in cells obtained from patients
with Tangier disease (Walter et al. 1996; Haidar et al. 2001). Similarly, PKC
inhibitors and activators were found, respectively, to block or to enhance apoA-I-
induced cholesterol efflux from various cell types including macrophages, smooth
muscle cells, and fibroblasts (Mendez et al. 1991; Li and Yokoyama 1995; Li
et al. 1997). More recently, it has been suggested that PKC specifically controls
the translocation of cholesterol from acylCoA:cholesterol acyltransferase (ACAT)-
accessible pools to the as yet poorly defined intracellular cholesterol compartment,
where it is available for the ABCA1-mediated release (Yamauchi et al. 2004). In
addition, PKC isoform alpha (PKCα) was found to increase ABCA1 phosphoryla-
tion at as yet unknown serine sites and thereby to enhance it protection against
calpain-mediated proteolysis (Yamauchi et al. 2003). Apelin, a bioactive peptide
modulating vascular tone and blood pressure and displaying strong antiatherogenic
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properties, has been recently found to phosphorylate serine residues in ABCA1
through the PKCα pathway and to inhibit calpain-mediated proteolysis, thereby
promoting cholesterol efflux and reducing foam cell formation (Liu et al. 2013a).
ABCA1 is well known to be regulated by cyclic adenosine monophosphate
(cAMP) at the transcriptional level, and cAMP responsive elements have been
localized in the ABCA1 promoter. The interaction of apoA-I with ABCA1, in turn,
was demonstrated to activate adenylate cyclase and to increase cAMP content,
while severely reduced apoA-I-induced cAMP production was found in cells
obtained from carriers of ABCA1 mutations (Haidar et al. 2004). These
observations strongly suggested that cAMP and its downstream target protein
kinase A (PKA) may represent an important component of apoA-I/ABCA1-induced
signaling cascade regulating intracellular lipid translocation and/or their removal
from cells. Actually, PKA phosphorylation sites were identified in the nucleotide
binding domains of ABCA1, and the targeted mutation of one of these sites, S2054,
significantly impaired apoA-I-mediated lipid efflux (See et al. 2002). Moreover,
PC-PLC
PC-PLD AC JAK2Cdc42 Ca2+
PKC PKA STAT3JNK CalcineurinActin





















Fig. 1 ApoA-I-induced cell signaling mediated by ABCA1. The binding of apolipoprotein A-I
(apoA-I) to lipid transporter ABCA1 induces the trimeric G-protein-mediated activation of
phosphatidylcholine-specific phospholipases C and/or D (PC-PLC, PC-PLD) and adenylate
cyclase (AC) and the ensuing activation of protein kinases C and A (PKC, PKA). Direct interaction
of the small G-protein Cdc42 with ABCA1 induces activation of protein kinase JNK and actin
polymerization. Direct interaction of Janus kinase-2 (JAK2) with ABCA1 leads to its
autophosphorylation and activation as well as activation of transcription factor signal transducer
and activator of transcription 3 (STAT3). These effects account for cholesterol efflux-inducing,
anti-inflammatory, and ABCA1-stabilizing properties of apoA-I. In addition, ABCA1-mediated
cholesterol efflux to apoA-I exerts indirect negative effect on signal transduction mediated by
proinflammatory Toll-like receptors and the resulting activation of the transcription factor NF-κB
and expression of cyto- and chemokines. PAMP Pathogen-associated molecular patterns
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pharmacological modulation of cAMP/PKA signaling pathway exerted profound
effects on apoA-I-induced cholesterol efflux. For instance, forskolin, an adenyl
cyclase activator, and 8-Br-cAMP, a stable cAMP analog, substantially increased
both ABCA1 phosphorylation and cholesterol efflux to apoA-I in wild-type cells
and partly corrected the impaired efflux in cells obtained from patients with Tangier
disease (Haidar et al. 2002). Similar effects were more recently observed in
macrophages treated with Ht31, a PKA-anchoring inhibitor, which robustly ele-
vated PKA activity in the cytoplasm, elevated ABCA1-dependent cholesterol
export from cells, and completely reversed foam cell formation (Ma et al. 2011).
Conversely, interference with cAMP/PKA signaling accomplished by treating cells
with adenyl cyclase inhibitors, PKA inhibitors, or eicosapentaenoic acid, which
decreased both cAMP levels and PKA activity, led to concomitant reduction of
ABCA1 phosphorylation and ABCA1-mediated cholesterol efflux (Haidar
et al. 2002, 2004; Hu et al. 2009). The molecular mechanisms underlying the
stimulatory effect of PKA-mediated ABCA1 phosphorylation on the function of
this transporter remain unclear. In contrast to PKC, PKA neither improves ABCA1
stability nor increases apoA-I binding. It seems more likely that phosphorylation of
ABCA1 by the cAMP/PKA pathway allows the transporter to assume the confor-
mation favoring more effective lipid translocation across the cell membrane (See
et al. 2002).
Janus kinase 2 (JAK2) represents the third kinase, the activity of which is
induced by ApoA-I/ABCA1 interaction. Even short exposure of cells expressing
ABCA1 to apoA-I produces substantial autophosphorylation of JAK2, which is a
prerequisite for further signal transmission to downstream located targets (Tang
et al. 2004). Active JAK2 does not seem to directly phosphorylate ABCA1, and it is
more likely that it targets an as yet unknown ABCA1 partner protein. Nevertheless,
several experimental approaches clearly documented that JAK2 signaling is
required for ABCA1 to effectively mediate lipid export from cells. For instance,
JAK2-specific inhibitors substantially reduced apoA-I-induced cholesterol efflux,
and mutant cells lacking JAK2 exhibited a severely impaired lipid transport (Tang
et al. 2004, 2006). In addition, studies exploiting various ABCA1 variants revealed
close interdependency between lipid export and JAK2 activation (Vaughan
et al. 2009). In contrast to PKC and PKA, JAK2 activation by apoA-I neither
promotes ABCA1 stability nor enhances intrinsic lipid translocase activity of the
transporter. However, JAK2 activation seems to be critical for the optimum forma-
tion of apoA-I/ABCA1 complex, as JAK2-deficient cells exhibit severely impaired
apoA-I binding despite normal ABCA1 protein levels (Tang et al. 2006).
JAK2 autophosphorylation is commonly followed by phosphorylation of several
downstream targets, out of which signal transducer and activator of transcription
3 (STAT3) represents its canonical target. As ABCA1 possesses STAT3 docking
sites, this molecule was an obvious candidate for linking JAK2 with ABCA1
activation. As a matter of fact, apoA-I induces STAT3 phosphorylation (which is
tantamount to its activation) in an ABCA1-dependent fashion, and this effect is
attenuated in cells expressing ABCA1, in which STAT3 docking sites have been
mutated (Tang et al. 2009). However, neither complete STAT3 deficiency nor
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interruption of ABCA1-STAT3 interaction altered ABCA1 capacity to bind apoA-I
and to efflux cholesterol from cells (Tang et al. 2009). Hence, apoA-I-induced
STAT3 activation seems dispensable for the ABCA1-mediated lipid export.
STAT3 represents an intracellular target of IL-10—a cytokine with well-
established anti-inflammatory properties—and activation of STAT3 was
demonstrated to suppress several aspects of inflammatory macrophage activation.
These observations raised the interesting possibility that apoA-I might produce
anti-inflammatory effects by activating STAT3 in ABCA1-dependent fashion.
Actually, exposure of ABCA1-expressing macrophages to apoA-I suppressed
lipopolysaccharide (LPS)-induced production of proinflammatory cytokines such
as interleukin-6 (IL-6), and this effects were abolished after pharmacological
STAT3 blockade or knocking down STAT3 expression with siRNA (Tang
et al. 2009). Further investigations demonstrated that the suppressing effect of
apoA-I on LPS-induced cytokine production was mediated by mRNA destabiliza-
tion brought about by mRNA-destabilizing protein tristetraprolin, the expression of
which was induced in cells exposed to apoA-I in an ABCA1- and JAK2/STAT3-
dependent manner (Yin et al. 2011). Recently, apoA-I was demonstrated to promote
cyclooxygenase-2 (COX-2) activation and prostacyclin (PGI2) production in endo-
thelial cells, and these anti-inflammatory effects were also found to depend on
ABCA1 and JAK2 activation (Liu et al. 2011).
Cell division control protein 42 (Cdc42) is a member of a small G-protein family
involved in the regulation of cytoskeleton organization and intracellular vesicular
trafficking. Early studies revealed decreased Cdc42 expression and abnormal cyto-
skeleton architecture in cells obtained from Tangier patients (Hirano et al. 2000).
Moreover, impaired cholesterol efflux observed in aged human fibroblasts as well
as fibroblasts from Werner syndrome characterized by the early onset of senescent
phenotypes including premature atherosclerotic cardiovascular disease could be
corrected by forced expression of wild-type Cdc42 (Tsukamoto et al. 2002; Zhang
et al. 2005). Expression of constitutively active Cdc42 variant in normal Madin-
Darby canine kidney (MDCK) cells potentiated apoA-I-induced cholesterol efflux,
whereas expression of dominant negative Cdc42 variants in normal MDCK cells or
fibroblasts exerted opposite effects (Hirano et al. 2000; Nofer et al. 2003). ApoA-I-
induced cholesterol efflux was also reduced in cells pretreated with Clostridium
difficile toxin, which irreversibly modifies and disables Cdc42 (Nofer et al. 2003).
Both Cdc42 and ABCA1 were found to co-segregate into lubrol-insoluble, triton-
soluble lipid rafts (Drobnik et al. 2002). In addition, Cdc42 could be immunopre-
cipitated with wild-type ABCA1, but not with C-terminally truncated variant of this
transporter indicating that both proteins interact with each other and suggesting that
C-terminus of ABCA1 harbors a potential docking site for Cdc42 (Tsukamoto
et al. 2001; Nofer et al. 2006). Exposure of cells expressing wild-type ABCA, but
not cells obtained from Tangier patients or expressing C-terminally truncated
variant of ABCA1 to apoA-I, induced Cdc42 activation and subsequent actin
polymerization (Nofer et al. 2006). Taken together, these findings suggest that
apoA-I signals through ABCA1 to activate Cdc42 and thereby to promote choles-
terol efflux. How exactly Cdc42 activation promotes lipid export from cells remains
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to be elucidated. One possibility is that Cdc42 modulates intracellular vesicular
traffic and thereby helps to supply cholesterol and/or phospholipids to an intracel-
lular compartment, where they are available for the ABCA1-mediated release. The
retardation of intracellular lipid transport in cells with reduced Cdc42 levels and its
intensification after enforced expression of Cdc42 appears to support this concept
(Tsukamoto et al. 2002). Alternatively, components of the signaling machinery
localized downstream to Cdc42 might accelerate intracellular lipid transfer or the
ABCA1-dependent lipid translocation across the cell membrane. Actually, apoA-I
was demonstrated to produce consecutive activation of two serine/threonine
kinases, namely, p21-activated kinase 1 (PAK1) and c-Jun N-terminal kinase
(JNK) in ABCA1- and Cdc42-dependent manner (Nofer et al. 2003). The potential
involvement of these two kinases in the processes of lipid export from cells has
been not clarified to date.
Mobilization of intracellular Ca(2+) from intracellular stores or Ca(2+) influx
from extracellular space represents an integral component of diverse intracellular
signaling pathways. In one single report, evidence has been provided that apoA-I
provokes extracellular Ca(2+) influx in an ABCA1-dependent manner and that
inhibition of calcineurin, the downstream target of Ca(2+) influx, with cyclosporine
A or FK506 completely abolished apoA-I lipidation and also interfered with JAK2
phosphorylation (Karwatsky et al. 2010). However, other authors failed to observe
Ca(2+) mobilization in fibroblasts or smooth muscle cells after exposure to apoA-I
or other apolipoproteins (apoA-II, apoC-III) (Nofer et al. 2000 and unpublished
observations). Further studies are necessary, therefore, to fully understand the
contribution of Ca(2+) mobilization to ABCA1-mediated signaling and lipid
export.
3 ApoA-I-Induced Cell Signaling Indirectly Mediated
by b-ATPase and P2Y12/13 ADP Receptor
F1F0 ATP synthase is the terminal enzyme of the oxidative phosphorylation
pathway responsible for the lion part of ATP synthesis in humans and other living
being except in Archaea and present in mitochondria, chloroplasts, and prokaryotic
membranes. Unexpectedly, the F1F0 ATP synthase (with F1 domain facing out-
side) has been found on the surface of several cells including hepatocytes,
adipocytes, and endothelial cells, and its β-chain (β-ATPase) has been characterized
as a receptor for apoA-I (Martinez et al. 2003b; Fabre et al. 2006; Radojkovic
et al. 2009; Howard et al. 2011). The binding of apoA-I to β-ATPase induces ATP
hydrolysis and promotes extracellular ADP generation, which in turn stimulates
intracellular signaling by activating purinergic receptors, which belong to the
family of G-protein-coupled receptors stimulated by extracellular nucleotides
(Martinez et al. 2003b; Fabre et al. 2006). In hepatocytes, the β-ATPase/P2Y13-
induced signaling was reported to activate the small G-protein RhoA and the
downstream-located Rho-associated protein kinase (ROCK-I) and thereby to pro-
mote HDL endocytosis by as yet poorly defined mechanism (Fabre et al. 2006;
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Malaval et al. 2009). In endothelial cells, binding of apoA-I to β-ATPase and the
subsequent generation of extracellular ADP stimulated endothelial proliferation
and survival, but components of intracellular signaling cascade responsible for
these effects remained uncharacterized (Radojkovic et al. 2009). In a recent
study, the activation of β-ATPase/P2Y12 was found to precede HDL binding and
cell association as well as ABCG1- and SR-BI-dependent internalization, and
transcytosis in endothelial cells (Cavelier et al. 2012). The identity of intracellular
signaling pathway linking P2Y12 activation to HDL internalization has not been
addressed in this study.
4 ApoA-I- and HDL-Induced Cell Signaling Indirectly
Mediated by ABCA1 and/or ABCG1
ABCA1 is unique among ABC transporters in that it requires the direct binding of
acceptors for the transported substances. ATP-binding cassette transporter G1
(ABCG1) was also found to be a crucial mediator of lipid export. Studies by
Wang et al. demonstrated that ABCG1 promotes efflux to a variety of acceptors,
including HDL, low-density lipoprotein (LDL), phospholipid vesicles, and cyclo-
dextrin (Wang et al. 2004, 2006). In major contrast to ABCA1, ABCG1 does not
engage into direct interaction with lipid acceptors and for this reason cannot serve
as a triggering element of intracellular second messenger cascade. However, recent
studies document that ABCG1 (and to lesser extent ABCA1) profoundly impacts on
signaling processes taking place in contiguity. Several studies showed that ABCA1
regulates cholesterol distribution between raft and non-raft membrane fractions and
pointed to increased lipid raft formation in macrophages and other cells deficient in
ABCG1 and ABCA1 (Landry et al. 2006; Sano et al. 2007; Koseki et al. 2007; Zhu
et al. 2008a, Yvan-Charvet et al. 2008). Lipid rafts provide a molecular platform
securing efficient signal transduction through several receptor families including
proinflammatory Toll-like receptors (TLRs). Not surprisingly, therefore, both
ABCA1-deficient cells and ABCG1-deficient cells, and in particular cells lacking
both ABC transporters, exhibited increased cell surface expression of TLR4 and
sensitivity to LPS stimulation (Koseki et al. 2007; Zhu et al. 2008a, Yvan-Charvet
et al. 2008; Mogilenko et al. 2012). Also the NF-κB activation-dependent cytokine
and chemokine release in response to stimulation with agonists of other TLR
receptors (TLR2, TLR3) or other proinflammatory receptors (CD40) revealed to
be increased in macrophages deficient in ABCA1 and/or ABCG1 (Sun et al. 2009;
Yin et al. 2012). Such cells were also found to be prone to apoptosis during
efferocytosis (phagocytosis of apoptotic cells) as compared to wild-type cells
(Yvan-Charvet et al. 2010a). The enhanced apoptotic response observed in
ABCA1- and ABCG1-deficient macrophages was dependent on an excessive
assembly of NADPH oxidase/NOX2 complexes within lipid rafts followed by
oxidative burst and ensuing sustained JNK activation, which turned on the apopto-
tic cell death program. It is very likely that similar mechanisms consisting in
amplification of transmembrane signaling under conditions of decreased ABCG1
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and/or ABCA1 activity and the resulting accumulation of lipid rafts may substan-
tially contribute to the enhancement of several proinflammatory processes. For
instance, cholesterol accumulation within lipid rafts was suggested to enhance
monocyte adhesion and neutrophil activation, and both processes could be reversed
by cholesterol removal from cells carried out either with help of synthetic choles-
terol acceptors (e.g., cyclodextrin) or through induction of ABCA1-dependent
cholesterol efflux (Murphy et al. 2008, 2011). In addition, ABCG1- and ABCA1-
dependent modulation of cell membrane cholesterol content was demonstrated to
critically regulate cellular signaling related to proliferatory responses. For instance,
mice deficient in ABCG1- and ABCA1 developed severe monocytosis and
neutrophilia, which was dependent on uncontrolled proliferation and expansion of
hematopoietic stem progenitor cells (HSPC) (Yvan-Charvet et al. 2010b). The
mechanistic analysis revealed increased plasma membrane lipid raft formation in
these cells accompanied by elevated cell surface presence of interleukin IL-3/
granulocyte macrophage colony-stimulating factor (GM-CSF) receptor. Addition
of IL-3 or GM-CSF to ABCA1/G1-deficient bone marrow led to increased prolif-
eration of HSPCs, reflecting activation of signaling pathways downstream of the
IL-3/GM-CSF receptor. Similarly, defects in cholesterol efflux pathways in
macrophages and dendritic cells in spleens of ABCA1/G1-deficient mice led
to increased production of IL-23 and activation of a proinflammatory and
proatherogenic signaling axis involving IL-23/IL-17 (Westerterp et al. 2012).
Other studies showed increased lipid raft content in plasma membrane and
enhanced proliferation in response to anti-CD3 antibody stimulation in T cells
obtained from ABCG1-deficient animals (Bensinger et al. 2008). Similar increase
in lymph node T-cell proliferation has been noted after disruption of cholesterol
efflux pathway by deletion of apoA-I on a hypercholesterolemic background
(Wilhelm et al. 2009).
5 HDL-Induced Cell Signaling Mediated by SR-BI
Scavenger receptor type I (SR-BI) is a cell surface glycoprotein originally identified
by its homology to the scavenger receptor CD36 and capacity to bind acetylated
LDL. Later studies in vitro revealed that SR-BI serves as the binding partner for a
variety of ligands including native and oxidized LDL, very-low-density
lipoproteins (VLDL), Lp(a), modified serum proteins such as maleylated albumin,
lipid vesicles containing negatively charged phospholipids, apoptotic cells, and
HDL. Despite this promiscuous binding behavior SR-BI is believed to primarily
function as a physiologically relevant HDL receptor because of its tissue expression
pattern reflecting sites of HDL cholesterol uptake and because of the profound
impact of complete or tissue-specific SR-BI deficiency on HDL metabolism. The
classic cellular function of SR-BI is to mediate the selective uptake of lipids from
HDL and to transfer them into cells. Cholesteryl esters represent the primary
substrate for SR-BI, but this receptor also facilitates transfer of various other lipid
species including unesterified cholesterol, phospholipids, triglycerides, and lipid-
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soluble vitamins. SR-BI also mediates the efflux of cholesterol from cells to HDL,
which in contrast to ABCA1- and ABCG1-mediated efflux is a passive, concentra-
tion gradient-dependent, and energy-independent process. Importantly, SR-BI-
mediated lipid transfer from and to HDL occurs in the absence of consecutive
internalization and degradation of HDL particle, which is a precedent condition for
effective signal transduction (for recent reviews, see Hoekstra et al. 2010; Mineo
and Shaul 2012).
Binding of HDL to SR-BI has been demonstrated to trigger several intracellular
signaling events (see Fig. 2). The recruitment of non-receptor tyrosine kinase src to
the C-terminal cytoplasmic tail of SR-BI followed by src autophosphorylation and
phosphorylation and activation of AMP-activated protein kinase (AMPK) mediated
through calcium/calmodulin-dependent protein kinase (CAMK) and/or serine/thre-








































Fig. 2 HDL-induced cell signaling mediated by SR-BI. The binding of HDL to scavenger
receptor type 1 (SR-BI) induces activation of protein kinases src, liver kinase B1 (LKB1), and
calcium calmodulin-dependent protein kinase (CAMK) in a process dependent on an adapter
protein PDZK1 (CLAMP). The resulting activation of AMP-activated protein kinase (AMPK) and
protein kinase Akt as well as mitogen-activated protein kinase (MAPK) transduces signal to
downstream effectors including endothelial nitric oxide synthase (eNOS) generating NO,
cyclooxygenase-2 (COX-2) producing prostacyclin (PGI2), glucose transporter GLUT4 mediating
cellular glucose uptake, ubiquitin ligases Siah 1 and 2 stabilizing hypoxia-inducible factor-1α
(HIF-1α), and small G-protein Rac-1 regulating formation of lamellipodia. These effects account
for vasodilatory, insulin-sensitizing, proangiogenic, and endothelial regenerating properties of
HDL. In addition, SR-BI-mediated cholesterol efflux to HDL exerts indirect negative effects on
signal transduction mediated by proinflammatory Toll-like receptors and the resulting activation
of the transcription factor NF-κB and expression of cyto- and chemokines. Pathogen-associated
molecular patterns (PAMP)
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(Mineo et al. 2003; Kimura et al. 2010). Detailed studies revealed that phosphor-
ylations of src (though not its interaction with SR-BI) and AMPK are critically
dependent on the presence of the PDZ domain-containing adaptor protein, PDZK1
(also termed CLAMP), which interacts with extreme C-terminal residues of SR-BI
and is essential for its stability in the plasma membrane (Kimura et al. 2010;
Assanasen et al. 2005; Zhu et al. 2008a, b). Src and AMPK activations lead to the
activation of phosphatidylinositol 3-kinase (PI3K), which in turn induces parallel
activation of protein kinase B (Akt) and mitogen-activated protein kinase (MAPK)
(Kimura et al. 2010; Assanasen et al. 2005; Zhu et al. 2008b). The latter event
seems to be required for the subsequent stimulation of the activity of small
G-protein Rac1, which promotes formation of lamellipodia and induces cell
shape change (Seetharam et al. 2006). It remains currently unclear, whether SR-
BI-mediated lipid transfer is required for the effective initiation of signaling by
HDL. The C-terminal transmembrane domain of SR-BI contains a cholesterol-
binding site, which interacts with plasma cholesterol, as could be documented in
photocholesterol binding experiments (Assanasen et al. 2005). Studies utilizing
SR-BI/CD36 chimeras showed that only transfer of both C-terminal domains
(cytoplasmatic and transmembrane) endows CD36 with signaling properties of
SR-BI, whereas the transfer of the C-terminal cytoplasmatic domain only is insuf-
ficient (Assanasen et al. 2005). In addition, introduction of mutations into the
transmembrane C-terminal domain severely impeded SR-BI-mediated signal trans-
duction (Saddar et al. 2013). Other studies pointed to the enhancement of SR-BI
signaling in the presence of extracellular cholesterol acceptors such as
cyclodextrins or reconstituted HDL particles containing 2 molecules of apoA-I
but not cholesterol (Assanasen et al. 2005). Furthermore, HDL enriched in phos-
phatidylcholine, which increases its cholesterol acceptor capacity, induces signal
transduction at concentrations that are otherwise insufficient to invoke signaling.
Collectively, these observations suggest that SR-BI-mediated cholesterol efflux
exerts at least potentiating effects on HDL-triggered signaling transduced by this
receptor. Recently, Al-Jarallah and Trigatti hypothesized that SR-BI-mediated
removal of cholesterol from caveolae might suppress the activity of high molecular
weight phosphatase complex, which would in turn help to maintain protein kinase
targets such as MAPK in the phosphorylated state and to prolong their activation
(Al-Jarallah and Trigatti 2010). Whether this mechanism indeed contributes to
HDL-induced signaling mediated by SR-BI remains to be clarified.
The concerted activation of both Akt and MAPK appears to constitute the
centerpiece of SR-BI-triggered signaling cascades. Both kinases are required for
phosphorylation and full activation of endothelial nitric oxide synthase (eNOS),
nitric oxide generation, and vasorelaxation, which are observed in endothelial cells
or isolated aortas in the presence of HDL (Yuhanna et al. 2001; Mineo et al. 2003;
Assanasen et al. 2005). In addition, PI3K/Akt/eNOS signaling was found to be
involved in the HDL-induced COX-2 expression and PGI2 release in endothelial
cells (Zhang et al. 2012). The proliferation of bone-derived mesenchymal stem cells
in response to HDL was likewise mediated via its binding to scavenger receptor-B
type I and activation of PI3K/Akt/MAPK pathways (Xu et al. 2012). Activation of
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MAPK but not Akt with subsequent induction of Rac1-GTPase was demonstrated
to promote HDL-induced endothelial cell migration, which is critical for carotid
artery reendothelialization after perivascular electric injury (Seetharam et al. 2006).
Conversely, activation of Akt but not MAPK was necessary to sustain the migration
and the proliferation of breast cancer cells (Danilo et al. 2013). In adipocytes, SR-
BI-mediated activations of Akt and AMPK were found to promote glucose uptake
and translocation of the glucose transporter GLUT4 to the plasma membrane
suggesting that SR-BI signaling might contribute to insulin-sensitizing effects of
HDL (Zhang et al. 2011). Finally, augmentation of hypoxia-induced angiogenesis,
which is observed in the presence of HDL, was demonstrated to depend on SR-BI-
mediated activation of Akt linked to increased expression of E3 ubiquitin ligases
Siah1 and Siah2 and accelerated degradation of prolyl hydroxylases (PHD1-PHD3)
combined with stabilization of hypoxia-inducible factor 1α (HIF-1α) (Tan
et al. 2013). Recent studies provide evidence that similar to ABCG1 also SR-BI
may indirectly affect proinflammatory signaling by reducing membrane cholesterol
content. Actually, macrophages obtained from SR-BI-deficient animals were
characterized by increased inflammatory responses to Toll-like receptor agonists
(Guo et al. 2009; Cai et al. 2012). Feng et al. found that SR-BI deficiency enhanced
lymphocyte proliferation, caused imbalanced interferon-γ (IFNγ) and IL-4 produc-
tion in lymphocytes, and led to elevated inflammatory cytokine production in
macrophages (Feng et al. 2011). Umemoto et al. demonstrated that HDL-induced
disruption of lipid raft in adipocytes, which is accompanied by reduced activation
of NADPH oxidase and production of monocyte chemotactic protein 1 (MCP1),
was reversed by silencing both ABCG1 and SR-BI expression (Umemoto
et al. 2013).
It is well established that HDL inhibits the activation of platelets by strong
agonists such as thrombin and collagen (for review, see Nofer and van Eck 2011).
The presence of SR-BI has been identified on platelet surface (Imachi et al. 2003).
Recent investigations demonstrated that HDL binding to platelets was reduced in a
concentration-dependent fashion by SR-BI ligands such as negatively charged
liposomes, which in addition potently inhibited thrombin-induced platelet aggre-
gation, granule secretion, fibrinogen binding, and mobilization of intracellular Ca2+
(Nofer et al. 2011). Furthermore, both native HDL and other SR-BI ligands failed to
inhibit thrombin-induced activation of platelets obtained fromSR-BI-deficientmice.
These findings together with the results of Imachi et al. (2003), who observed an
inverse relationship between the levels of SR-BI expression and the platelet aggre-
gation in response to ADP, corroborate the hypothesis that SR-BI is a true functional
HDL receptor on platelets. The likely consequence of the HDL binding to SR-BI on
platelets is the induction of intracellular second messenger cascade. It has been
previously demonstrated that incubation of platelets with HDL leads to the release of
DAG from the plasma membrane phosphatidylcholine and to subsequent activation
of PKC, which in turn stimulates the Na+/H+ antiport, promotes the alkalization of
the cytoplasmic compartment, and inhibits the release of calcium ions from intra-
cellular storage sites (Nofer et al. 1996). In addition, activation of PKC inhibits the
activity of phosphatidylinositol-specific phospholipase C (PI-PLC), which is one of
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the most important signal transduction mediators of agonists such as thrombin and
collagen (Nofer et al. 1998). It is conceivable that this signaling cascade is launched
by interaction of HDL with SR-BI on platelet surface.
6 HDL-Induced Cell Signaling Mediated by S1P
Early studies on HDL-induced signal transduction focused on apoA-I or other
apolipoproteins as potential binding partners for HDL receptor responsible for
initiating the cascade of intracellular signaling events. However, it has soon become
clear that neither apoA-I nor other proteins encountered in HDL particles can
exclusively account for HDL signaling activities. Studies utilizing fibroblasts
demonstrated that PI-PLC activation, which is observed in cells exposed to HDL
and accompanied by increased phosphatidylinositol bisphosphate (PIP2) turnover
and the mobilization of intracellular calcium, is not emulated by purified apoA-I or
apoA-I-containing proteoliposomes, but occurs in the presence of lipids extracted
from HDL holoparticles (Nofer et al. 2000). Likewise, certain cellular responses
triggered by HDL in fibroblasts of smooth muscle cells such as cell proliferation or
proliferation-linked activation of MAPK could be observed in the presence of HDL
lipids orHDLparticles, inwhich proteins were covalentlymodified or enzymatically
degraded, but not in the presence of proteins isolated from HDL (Deeg et al. 1997;
Sachinidis et al. 1999; Nofer et al. 2001a). The intense search for lipid species
accounting for the signal-inducing capacity of HDL revealed that these lipoproteins
serve as a carrier for bioactive lysosphingolipids such as sphingosine-1-phosphate
(S1P), sphingosylphosphorylcholine (SPC), and lysosulfatide (LSF) and that signal-
ing events observed in cells exposed to native HDL or isolated lysosphingolipids
largely overlap (Sachinidis et al. 1999; Nofer et al. 2000, 2004; Kimura et al. 2001).
S1P is the most prominent and best characterized member of the lysosphingolipid
family. It is produced by phosphorylation of sphingosine by sphingosine kinases
1 and 2 (SK1 and SK2) in response to a variety of stimuli and degraded to
phosphoethanolamine and hexadecanal by S1P-lyase or to sphingosine and organic
phosphate by S1P phosphatase. S1P interacts with five related G-protein-coupled
receptors termed S1P1–5, which regulate a wide spectrum of cellular functions,
including proliferation and survival, cytoskeletal rearrangements, and cell motility,
and exert potent cytoprotective effects. In the vasculature, S1P receptors were
identified on endothelial and smooth muscle cells, and S1P provides essential contri-
bution to the new vessel formation and the maintenance of vascular barrier integrity.
In addition, S1P was demonstrated to interfere with proliferation, migration, and
activation of monocytes/macrophages and to regulate their recruitment to sites of
inflammation (for recent reviews, see Maceyka et al. 2012; Levkau 2013).
Erythrocytes and platelets are major sources of S1P in plasma, where it is preferen-
tially (up to 60 %) associated with HDL subfraction rich in apolipoprotein M (apoM)
(Dahm et al. 2006; Hänel et al. 2007; Christoffersen et al. 2011). Recent studies
demonstrate that apoM specifically binds S1P and stimulates its biosynthesis for
secretion (Liu et al. 2013b). There is substantial evidence suggesting that S1P may
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directly contribute to atheroprotective effects attributed to HDL. For instance, S1P
closely correlates with HDL in a concentration range, in which HDL most effectively
protects against atherosclerosis, and decreased HDL-bound S1P levels were noted in
patients with coronary artery disease and myocardial infarction (Karuna et al. 2011;
Sattler et al. 2010; Argraves et al. 2011). In addition, S1P was found to emulate
in vitro several atheroprotective effects of HDL, which themselves could be
attenuated by interrupting signaling through S1P receptors (Levkau et al. 2013).
Protein kinases MAPK, AMPK, and Akt are critical for the S1P-dependent
signaling cascade, which unfolds in endothelial cells in the presence of HDL (see



















































Fig. 3 HDL-induced cell signaling mediated by S1P. The binding of HDL to scavenger receptor
type I (SR-BI) may provide a molecular platform for efficient receptor stimulation by sphingosine-
1-phosphate (S1P) present in HDL molecule. Activation of AMP-activated protein kinase
(AMPK) and protein kinase Akt via S1P1 and/or S1P3 receptors leads to the stimulation of focal
adhesion kinase (FAK), the inactivation of proapoptotic protein BAD and the inhibition of
caspases 9 and 3, the inhibition of the transcription factor NF-κB and the expression of adhesive
molecules E-selectin and vascular cell adhesion molecule 1 (VCAM-1), as well as the activation of
endothelial nitric oxide synthase (eNOS) and the generation of NO. Activation of the mitogen-
activated protein kinase p38MAPK results in activation of cyclooxygenase-2 (COX-2) and
production of prostacyclin (PGI2). Increased expression of transforming growth factor β (TGFβ)
contributes to the increased activation of transcription factors Smad 2 and 3, which suppress
production of proinflammatory matrix metalloproteinases such as MMP9 as well as phospholipase
A2 (PLA2). Inhibition of small G-protein Rac1 suppresses activity of NADPH oxidase and
generation of reactive oxygen species. Inhibition of Toll-like receptor 2 (TLR2) reduces NF-κB
activation and production of proinflammatory cytokines. These effects account for endothelial
barrier-enhancing, anti-inflammatory, antiapoptotic, anti-adhesive, and vasodilatory properties of
HDL. Activation of protein kinase src and transcription factor signal transducer and activator of
transcription 3 (STAT3) via S1P2 protects against cardiomyocyte apoptosis. Activation of the
small G-protein RhoA via S1P2 leads to inhibition of the small G-protein Rac1, which regulates
smooth muscle cell migration
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colleagues demonstrated that activation of MAPK is essential for endothelial
proliferation and survival mediated by HDL-associated lysosphingolipids (Kimura
et al. 2001). Using antisense oligonucleotides and siRNA strategy combined with
application of pharmacological G-protein inhibitors, they further show that S1P
receptor types 1 and 3 and inhibitory G-protein (Gi) contribute to HDL-mediated
induction of endothelial migration, whereas the augmentation of endothelial sur-
vival in endothelial cells exposed to HDL is exclusively dependent on S1P1. Miura
et al. demonstrated that HDL promotes endothelial cell tube formation via activa-
tion of MAPK and suggested that this effect is mediated by S1P present in HDL
particles (Miura et al. 2003). Later these authors showed that reconstituted HDL
particles enriched in S1P are particularly effective in stimulating angiogenic
response (Matsuo et al. 2007). HDL-like lipoproteins are also present in follicular
fluid and induce angiogenesis in the S1P- and MAPK-dependent manner (von Otte
et al. 2006). The activation of AMPK, which itself was entirely dependent on the
parallel activation of CAMK, was localized upstream to Akt in the signaling sequel
(Kimura et al. 2010). The stimulation of Akt by HDL-associated lysosphingolipids
was—depending on the experimental system used—mediated by either S1P1 or
S1P3 and controlled an array of important antiatherogenic activities attributed to
HDL. Nofer et al. (2001b) found that activation of Akt by HDL and its associated
lysosphingolipids disabled a proapoptotic protein BAD and thereby inhibited the
collapse of mitochondrial potential, the cytochrome C release from mitochondria,
and the ensuing activation of apoptosis-executing caspases 3 and 9. Nofer
et al. (2004) and Kimura et al. (2006) demonstrated that the S1P content in HDL
at least partially accounts for the HDL-stimulated activation of eNOS, generation of
NO, and vasorelaxation. Stimulation of endothelial cells with statins such as
pitavastatin or simvaststin increased the expression of S1P1 and potentiated the
stimulatory effect of HDL on eNOS activation (Igarashi et al. 2007; Kimura
et al. 2008). Likewise, upregulated S1P1 and S1P3 expression and increased Akt
and eNOS activation were found in fenofibrate-treated mice, which were
characterized by elevated plasma levels of HDL and S1P (Krishna et al. 2012).
Kimura et al. (2006) reported that signaling through S1P1 receptor partly accounts
for the inhibitory effects exerted by HDL on tumor necrosis factor α (TNFα)-
induced NF-κB activation as well as endothelial expression of adhesins such as
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-
1 (ICAM-1). Argraves et al. (2008) found that HDL increased endothelial barrier
integrity as measured by electric cell substrate impedance sensing in a process that
was entirely dependent on S1P, S1P1 expression, and Akt activation. The favorable
effect of S1P on endothelial barrier was sustained for considerably longer time with
HDL-associated rather than albumin-associated S1P, and this was related to the
inhibitory effect of HDL on S1P1 degradation (Wilkerson et al. 2012). Norata
et al. reported that HDL potently stimulates endothelial expression of long
pentraxin 3—a key component of innate immunity—as well as transforming
growth factor-β (TGFβ), a compound with potent anti-inflammatory and immuno-
modulatory activities, in Akt-dependent manner. They attributed these effects to the
presence of S1P and SPC in HDL particles and S1P1 and S1P3 receptors on
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endothelial cells (Norata et al. 2005, 2008). Increased activation of Smad 2/3, a
transcription factor controlled by TGFβ, found in the latter study suggests that
HDL-associated S1P may transactivate TGFβ signaling pathways in an autocrine
fashion. Most recently, Tatematsu et al. reported that endothelial lipase (EL) is a
critical determinant of HDL-stimulated S1P-dependent signaling (Tatematsu
et al. 2013). Actually, HDL-induced endothelial cell migration and angiogenic
responses as well as Akt activation were markedly decreased in EL-deficient
endothelial cells, but restored in the presence of exogenous S1P. Basing on appli-
cation of pharmacological inhibitors, Tatematsu and colleagues concluded that the
effects of HDL on endothelial cell migration and Akt activation are mediated
by S1P1.
As pointed out above, HDL is strongly mitogenic for smooth muscle cells, and
HDL-associated lysosphingolipids appear to account for this effect. On the other
hand, HDL was identified as a potent inhibitor of smooth muscle cell migration,
which is a hallmark of the development of advanced atherosclerotic plaque and
restenosis (Tamama et al. 2005; Damirin et al. 2007). The inhibitory effect of HDL
was likely mediated by its S1P content, as it was abolished in the presence of S1P2-
specific siRNA and following desensitization of S1P receptors and much enhanced
in cells overexpressing S1P2 receptor. Further effects exerted by HDL on smooth
muscle cell through its S1P content include modulation of the activity of several
vasoactive factors. Chrisman et al. found that HDL-associated S1P desensitizes
guanylyl cyclase B, a receptor for C-type natriuretic peptide (CNP), and thereby
inhibits CNP-induced cyclic guanosine monophosphate (cGMP) accumulation in
vascular smooth muscle cells (Chrisman et al. 2003). Gonzalez-Diez and colleagues
demonstrated induction of COX-2 expression and PGI2 production in vascular
smooth muscle cells exposed to HDL, which was mediated through S1P receptors
2 and 3 and protein kinase p38MAPK (González-Dı́ez et al. 2008). They have also
shown that simvastatin potentiates the HDL- and S1P-induced COX-2 expression
by upregulating cellular levels of S1P3. Finally, HDL-associated lysosphingolipids
S1P and SPC were found to suppress the proinflammatory activation of smooth
muscle cells brought about by stimulation with thrombin and characterized by the
increased release of inflammatory cyto- and chemokines such as MCP1 (Tölle
et al. 2008). The detailed examination of signaling pathways accounting for inhibi-
tory effects exerted by HDL-associated lysosphingolipids revealed that they were
related to the inhibition of Rac1-mediated activation of NADPH oxidase and
generation of reactive oxygen species. S1P3 was identified to mediate anti-
inflammatory effects of HDL, S1P, and SPC in smooth muscle cells.
Cardiomyocytes express several S1P receptors, and HDL was found to exert
protective effects on these cells through its S1P content. HDL and S1P showed
potent capacity to protect cardiomyocytes against hypoxia-reoxygenation- or
doxorubicin-induced apoptosis, and these effects were attributed to the induction
of protein kinases Src, MAPK, and Akt and the transcription factor STAT3
(Frias et al. 2009, 2010; Tao et al. 2010). However, investigations concerning the
identity of receptor-mediating protective effects of HDL-associated S1P were
inconclusive, and equally supportive evidence for the involvement of either S1P2
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or S1P1 and S1P3 has been provided. Recently, short-term treatment of
cardiomyocytes with HDL or S1P was found to induce a PKC-dependent phos-
phorylation of connexin43, which is a gap junction protein present in ventricular
cardiomyocytes and involved in cardioprotection by modulating ischemic
preconditioning (Morel et al. 2012). In addition, HDL and S1P improved gap
junctional communication, but only incrementally affected conduction velocities
in cardiomyocytes. The physiological relevance of these effects has been clearly
documented using an ex vivo approach, in which both HDL and S1P protected
perfused hearts against ischemia/reperfusion-induced cell death.
Several other cell types were found to be responsive to stimulation with
HDL-associated lysosphingolipids, but the physiological relevance of these effects
remains obscure. For instance, HDL and S1P were demonstrated to stimulate
prostate cancer cell migration and invasion through S1P receptors 2 and 3 and
activation of MAPK and STAT3, to stimulate plasminogen activator inhibitor-1
(PAI-1) release from adipocytes through S1P2 and activation of PKC and Rho
kinase, and to promote release of fibroblast growth factor-2 (FGF2), a potent
neurotrophic factor, from astroglial cells through activation of PI-PLC and
MAPK (Malchinkhuu et al. 2003; Lee et al. 2010; Sekine et al. 2011). HDL
particles isolated from body fluids other than plasma were also found to contain
S1P and to stimulate intracellular signaling through their S1P content. For instance,
HDL-like particles obtained from cerebrospinal fluid stimulated astrocyte migra-
tion and oligodendrocyte retraction in a manner sensitive to inhibitors of S1P
receptors 1 and 3 (Sato et al. 2007). Follicular fluid-derived HDL was found to
promote human granulosa lutein cell migration through S1P3 and activation of
small G-protein Rac1 (Becker et al. 2011). Despite the prominent role played by
monocytes and macrophages in the pathogenesis of atherosclerosis, very little is
known about the modulatory effects exerted by S1P cargo of HDL particles on these
cells. In one study, both HDL and S1P were found to blunt monocyte activation
induced by agonists of TLR2, but the attribution of this effect to the
HDL-associated S1P was not unequivocally demonstrated (Dueñas et al. 2008).
7 HDL-Induced Cell Signaling: Future Challenges
and Opportunities
HDL constitutes a large and heterogenous macromolecule carrying more than
50 proteins, several amphipathic peptides, miRNAs, and hundreds of lipid species
representing almost all known lipid classes. Several proteins and lipids identified in
HDL—among others, apolipoprotein H, haptoglobin, and steroid hormones—are
recognized receptor ligands and inductors of intracellular signaling events. How-
ever, the rigid evidence demonstrating that these proteins or lipids contribute to the
HDL-induced signaling governing diverse functional responses to this lipoprotein
has been not provided to date or is at best equivocal. For instance, several studies
documented that HDL carries estradiol in the form of fatty acyl esters produced in a
reaction catalyzed by LCAT. HDL-derived estradiol esters are internalized via SR-
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BI-mediated mechanisms and subsequently hydrolyzed intracellularly to unfold
their effects. However, the specific signaling events and/or physiological effects
clearly attributable to the estradiol content in HDL particles have not been unequiv-
ocally defined. In one study, HDL-associated estradiol was found to stimulate
eNOS and vasodilation in an SR-BI- and Akt-dependent manner, but these results
were questioned by others (Gong et al. 2003; Nofer et al. 2004). In other study,
dehydroepiandrosterone (DHEA) fatty acyl esters once incorporated in HDL were
found to induce stronger vasodilatory response, and this effect appeared also to be
mediated by SR-BI (Paatela et al. 2011). However, no clear signaling link between
the HDL-associated DHEA and vasodilation has been established in this study.
These two examples clearly show that the assignment of ligands present in HDL to
the appending signaling machinery and to various functions exerted by these
lipoproteins in physiology will be a major challenge in the future.
The composition of HDL particles is variable and influenced both by normal
metabolism and in various states of pathology. For instance, HDL particles isolated
from subjects suffering from acute or chronic inflammatory diseases were found to
lose proteins and enzymes with established or presumed antiatherogenic function
such as apoA-I or LCAT and to concomitantly acquire proinflammatory or
prooxidative factors such as serum amyloid A (SAA), ceruloplasmin, lipoprotein-
specific phospholipase A2, or myeloperoxidase. Not surprisingly, such inflamma-
tory HDL particles are severely impeded in their capacity to trigger certain signal-
ing pathways, but at the same time may acquire new ligands and thereby alter their
signaling properties. For instance, the relatively high content of apolipoprotein J
(apoJ) in HDL particles obtained from healthy subjects endowed them with impor-
tant antiatherogenic property to promote endothelial survival by stimulation of the
expression of antiapoptotic protein Bcl-XL (Riwanto et al. 2013). By contrast, HDL
particles isolated from patients with stable coronary heart disease (CHD) or acute
coronary syndromes were found to be poor in apoJ, but instead enriched in apoC-I
or apoC-III (McNeal et al. 2013; Riwanto et al. 2013). Furthermore, the increased
content of these apolipoproteins turned HDL particles into potent apoptosis
inducers in vascular smooth muscle and endothelial cells by virtue of stimulating
the expression of proapoptotic protein tBid. In addition to CHD, dysfunctional HDL
is also encountered in chronic conditions such as chronic kidney disease (CKD).
Abnormal HDL composition characterized primarily by increased serum amyloid A
and apoC-III content as well as compromised HDL functionality has been repeat-
edly reported in uremic patients (Holzer et al. 2011; Weichhart et al. 2012). In one
recent study, SAA-enriched HDL encountered in CKD was found to induce pro-
duction of a proinflammatory chemokine MCP1 in smooth muscle cells by interac-
tion with formyl peptide receptor 2 (FPR2) (Tölle et al. 2012). In other study
conducted in CKD patients, accumulation of symmetric dimethylarginine
(SDMA) in HDL was found to turn this lipoprotein into a noxious particle reducing
NO bioavailability, evoking endothelial dysfunction, and subsequently increasing
arterial blood pressure. The deleterious effects of SDMA-modified HDL were
attributed to the noncanonical activation of TLR2 (Speer et al. 2013). This
exemplifies another challenge facing HDL research in the future, namely,
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identification of ligands, receptors, and signaling cascades attributable to HDL in
various states of pathology.
Notwithstanding the physiological or pathological character of HDL-induced
signal transduction, its elucidation may open new opportunities for the develop-
ment of antiatherogenic, anti-inflammatory, or antithrombotic drugs. Several inter-
ventional studies conducted recently and aiming at cardiovascular risk reduction
through simple elevation of plasma HDL cholesterol fall through. This epic failure
emphasizes the necessity to develop more sophisticated strategies based on targeted
exploitation of selected antiatherogenic or anti-inflammatory activities exerted by
HDL particles. The proper understanding of HDL-induced signaling may help to
specifically enhance beneficial physiological or to disable harmful pathological
effects of HDL and thereby to design more efficacious therapeutic approaches for
cardiovascular and other inflammatory diseases.
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Abstract
Epidemiological studies have shown an inverse association between high-
density lipoprotein cholesterol (HDL-C) levels and risk of ischemic heart dis-
ease. In addition, a low level of HDL-C has been shown to be a risk factor for
other diseases not related to atherosclerosis. However, recent studies have not
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supported a causal effect of HDL-C in the development of atherosclerosis.
Furthermore, new drugs markedly elevating HDL-C levels have been disap-
pointing with respect to clinical endpoints. Earlier, most studies have focused
almost exclusively on the total HDL-C without regard to the chemical composi-
tion or multiple subclasses of HDL particles. Recently, there have been efforts to
dissect the HDL fraction into as many well-defined subfractions and individual
molecules of HDL particles as possible. On the other hand, the focus is shifting
from the structure and composition to the function of HDL particles. Biomarkers
and mechanisms that could potentially explain the beneficial characteristics of
HDL particles unrelated to their cholesterol content have been sought with
sophisticated methods such as proteomics, lipidomics, metabonomics, and func-
tion studies including efflux capacity. These new approaches have been used in
order to resolve the complex effects of diseases, conditions, environmental
factors, and genes in relation to the protective role of HDL but high-throughput
methods are still needed for large-scale epidemiological studies.
Keywords
High-density lipoproteins • Cholesterol • Atherosclerosis • Coronary heart
disease • Apolipoproteins • Cholesterol efflux • Diabetes • Obesity • Cancer •
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Low levels of high-density lipoprotein (HDL) particles in the plasma of patients
with coronary heart disease (CHD) were observed already in the early 1950s (Barr
et al. 1951; Nikkilä 1953). At that time the lipoprotein fraction was called alpha
lipoprotein as electrophoresis methods were used. Twenty years later the same
relationship was confirmed in large epidemiological studies using ultracentrifuga-
tion or precipitation methods. The new interest for HDL research was then
stimulated by the reverse cholesterol transport hypothesis (Glomset et al. 1966)
and a Lancet review written by Miller and Miller (1975). These authors proposed
that low plasma HDL concentration accelerates the development of atherosclerosis
by impairing the clearance of cholesterol from the arterial wall.
1 Protective Role of HDL: Evidence from Epidemiological
Studies
The protective role of HDL has been well established in several epidemiological
studies. An increment of 2.5 % corresponding to 1 mg/dl or 0.04 mmol/l is
associated with a 2 and 3 % reduction in CHD risk in men and women, respectively
(Gordon et al. 1989; Jacobs et al. 1990). So far, it is mainly the total cholesterol
concentration in HDL particles that has been determined using standardized
methods applicable also to routine clinical work. However, cholesterol represents
only a small fraction, approximately 15 %, of the HDL particle mass. Furthermore,
the proportion of free cholesterol to esterified cholesterol varies between lipopro-
tein particles.
The relationship between HDL-C and CHD is complex and HDL-C may not be
an appropriate indicator of the impact of this lipoprotein fraction on cardiovascular
risk. This has been demonstrated, e.g., by the fact that carotid intima media
thickness is not increased in apoA-I(Milano) mutation carriers with very low levels
of HDL-C (Sirtori et al. 2001). Moreover, recently, drugs that increase HDL
cholesterol (HDL-C) level have failed to reduce cardiovascular risk, and Mendelian
randomization studies have failed to show a causal relationship between HDL-C
and cardiovascular diseases (van Capelleveen et al. 2013).
Despite this controversy, the hard evidence for low HDL-C level as a risk factor
of atherosclerosis will be described in the first part of this presentation. It is
noteworthy that the cholesterol concentration in HDL fraction is not necessarily
associated with the antiatherogenic properties of HDL. Therefore, later in this
chapter, other potential HDL-related biomarkers for the prevention of atheroscle-
rosis by HDL will be presented. These include not only the other major lipid and
apolipoprotein components of HDL but also minor bioactive lipid molecules
residing in the HDL particles. Furthermore, the physicochemical characteristics
of various subfractions of HDL as well as the large number of molecules circulating
more or less firmly bound to HDL particles may contribute to the antiatherogenic
potential of HDL via antioxidative and anti-inflammatory effects or cholesterol
transport capacity.
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2 HDL Cholesterol as a Risk Factor for Atherosclerosis
and Its Complications
Until recently, the clinical evaluation of HDL as a risk factor has focused almost
exclusively on the total HDL-C without regard to the chemical composition or
multiple subclasses of HDL particles. A large body of epidemiological research has
shown a solid inverse and independent relationship between HDL-C and the risk of
cardiovascular disease (Toth et al. 2013).
Gofman et al. first reported an inverse association between HDL-C levels and the
risk of ischemic heart disease (Gofman et al. 1966). This was shown in case–control
studies from Framingham and Livermore cohorts with 10–12 years of follow-up.
Later, the inverse relationship has been observed also in several larger studies in the
USA (the Honolulu Heart Program, Rhoads et al. 1976, and the Framingham Heart
Study, Gordon et al. 1977), in Norway (the Tromsø Heart Study, Miller et al. 1977),
in Germany (the Prospective Cardiovascular Münster Study, Assmann et al. 1996),
and in Israel (the Israeli Ischemic Heart Disease Study, Goldbourt et al. 1997).
Recent meta-analyses have corroborated the relationship between HDL-C and
atherosclerosis and its complications (Chirovsky et al. 2009; Boekholdt
et al. 2013; Touboul et al. 2014). The association is independent of triglyceride
levels and other risk factors (Goldbourt et al. 1997). Many CHD risk algorithms
have included HDL-C as a factor to improve the prediction of CHD events (Cooper
et al. 2005; Halcox et al. 2013; Hippisley-Cox et al. 2013; Tehrani et al. 2013).
Recently, the picture has become less clear. Mendelian randomization studies
have not supported a causal effect of HDL-C in the atherosclerotic disease process
(Voight et al. 2012; Holmes et al. 2014). Moreover, statin trials have shown that
HDL-C is predictive among patients treated with statin even at low LDL levels
(Barter et al. 2007), whereas it is not predictive among patients taking placebo
(Ridker et al. 2010; Mora et al. 2012). Further research is needed to clarify the role
of HDL-C as a risk factor. It is possible that other characteristics of HDL particles
may be more important in this respect than the total cholesterol concentration.
In patients with CHD, the protective role of HDL-C is controversial (Silbernagel
et al. 2013). Some studies have shown that low HDL-C is associated with athero-
sclerotic progression in myocardial infarction survivors (Johansson et al. 1991;
Duffy et al. 2012; Liosis et al. 2013), provides additional prognostic value also in
patients with acute coronary syndrome (Correia et al. 2009), and reduces the risk
after coronary interventions (Sattler et al. 2009), whereas some studies have shown
that HDL-C has no protective role in the secondary prevention of CHD after bypass
operation (Angeloni et al. 2013).
3 HDL Cholesterol as a Risk Factor for Other Diseases
The low level of HDL-C has been shown to be a risk factor for other diseases not
related to atherosclerosis. Recent reports have shown that HDL-C may be a
biomarker for diseases like psoriasis (Holzer et al. 2012), rheumatoid arthritis
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(Raterman et al. 2013), and liver fibrosis in hepatitis C patients (Gangadharan
et al. 2012). Alterations in HDL composition have been observed also in hemodial-
ysis patients (Mangé et al. 2012).
Special interest has been recently focused on HDL in cancer patients. Several
epidemiological studies have shown that low HDL-C level may be a risk and/or
prognostic factor of biliary tract cancers (Andreotti et al. 2008), prostate cancer
(Mondul et al. 2011; Kotani et al. 2013), colon cancer (van Duijnhoven et al. 2011),
breast cancer (Furberg et al. 2005, Melvin et al. 2012) and gastric cancer (Tamura
et al. 2012), but not that of endometrial cancer (Cust et al. 2007; Esposito
et al. 2014) or rectal cancer (van Duijnhoven et al. 2011). Confounding factors
related to obesity and metabolic syndrome may be more strongly associated with
the latter cancer types (Kotani et al. 2013).
The association with low HDL-C levels is shared among many types of cancer,
and it is mainly linked to obesity and inflammation, suggesting a common pathway
(Melvin et al. 2013; Vı́lchez et al. 2014). The mechanism of cancer protection is not
known. Lipoprotein particles may carry cancerogenic molecules but at least one
small study has shown that persistent organogenic pollutants in HDL particles are
more associated with CVD than cancer (Ljunggren et al. 2014).
The potential importance of HDL particles in cancer protection has recently led
to attempts to develop cancer treatments by HDL-mimetic synthetic nanoparticles
(Zheng et al. 2013; Yang et al. 2013). These interesting approaches need to be
followed closely in the future.
4 Total HDL-C in Various Populations
Racial differences. Several studies have shown differences in HDL-C between
various ethnic groups (Thelle et al. 1982; Heiss et al. 1984; Haffner et al. 1986;
Saha 1987). The differences may in part be due to genetic factors but the role of
behavioral and anthropometric variables seem to affect the HDL-C (Thelle
et al. 1982; Haffner et al. 1986). Environmental factors such as diet, smoking,
and alcohol use may confound the differences observed between ethnic groups.
In the USA, the African-American population has higher HDL-C than
Caucasians after adjustment for weight, smoking, and alcohol consumption than
Caucasians (Heiss et al. 1984), while people originating from India have lower
HDL-C than Europeans or many other populations (Saha 1987; de Munter
et al. 2011). Differences in HDL-C and other lipoproteins between various ethnic
groups can be observed already in children (van Vliet et al. 2011). Even at an early
age, the HDL-C levels are confounded by other cardiovascular risk factors includ-
ing blood pressure, overweight, and obesity.
Gender differences. Women have higher HDL-C levels than men (Heiss
et al. 1980; Seidell et al. 1991), and significantly increased CHD risk is defined at
levels below 50 mg/dl (1.29 mmol/l) and 40 mg/dl (1.03 mmol/l), respectively. The
reason for the gender difference may mainly be sex hormones but the fat distribu-
tion seems to play a central role since adjustment for waist/thigh ratio almost totally
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removed the gender difference in HDL cholesterol (Seidell et al. 1991). In women
HDL-C levels decline after menopause (Heiss et al. 1980) but the sex difference
remains significant even in the seventh decade of life (Ostlund et al. 1990).
Age-related differences. Lipoprotein levels are very low at birth and then
increase during childhood. HDL-C levels decrease in males during puberty and
early adulthood and thereafter remain lower than those in women (Kreisberg and
Kasim 1987; Walter 2009). HDL-C levels decline with age and low HDL choles-
terol remains a powerful risk predictor into old age (Kreisberg and Kasim 1987;
Walter 2009). A selection bias by HDL-lowering genetic variation may explain
why HDL deficiency is rare among very old people (Kervinen et al. 1994; Baggio
et al. 1998).
5 Total HDL-C Modulated by Environmental Factors
Alcohol consumption in moderation is associated with a reduced risk for cardiovas-
cular diseases. Alcohol consumption increases the concentration of HDL-C, possi-
bly secondary to an inhibition of CETP (cholesteryl ester transfer protein)
(Savolainen et al. 1990; Hannuksela et al. 1992). A common polymorphism in
the CETP gene (TaqIB2) modifies the relationship of alcohol intake with HDL-C
suggesting a gene-environment interaction on the risk of CHD (Jensen et al. 2008).
However, it has not been definitely shown whether the HDL-C elevation associated
with alcohol consumption is cardioprotective.
The quantity of alcohol needed to increase HDL-C by 0.1 mmol/l (3.87 mg/dl) is
about 30 g/d (Brien et al. 2011). Therefore, alcohol drinking cannot be
recommended as a method to raise low HDL-C levels. The alcohol-induced
increase in HDL-C occurs commonly without significant changes in other lipids
although alcohol may increase triglyceride levels especially in subjects with ele-
vated triglyceride concentration.
The death rate from CHD among moderate alcohol users is lower than in total
abstainers or heavy drinkers (Rimm et al. 1999; Brien et al. 2011; Bergmann
et al. 2013). Even very low alcohol consumption, e.g., a couple of drinks per
week, seems to protect from CHD even though it does not have any significant
effect on HDL-C. To explain this fact, it has been suggested that ethanol metabo-
lism may produce specific bioactive lipids, e.g., phosphatidylethanol, that could
serve as a memory molecule in the body (Liisanantti et al. 2004). If HDL particles
of alcohol drinkers contain this bioactive lipid, it could circulate for several days
even without daily alcohol drinking, and when HDL enters into the endothelial cell,
it could then exert its positive effects on the vascular endothelium (Liisanantti and
Savolainen 2005). However, the concentration of phosphatidylethanol in HDL may
be in the low nanomolar range which makes the analysis challenging and may
hamper its determination of epidemiological studies.
Smoking reduces HDL-C level and smoking cessation is associated with an
increase in the plasma concentration of HDL-C (Maeda et al. 2003). The mecha-
nism by which smoking reduces HDL-C is not known. It is noteworthy that in many
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cases smoking is associated with alcohol drinking and therefore smoking could
attenuate the alcohol-induced increase in HDL-C.
Physical activity is associated with high HDL-C (Marti 1991). Low level of
physical activity is very common in the developed countries, and therefore, increas-
ing the level of exercise might be more beneficial for HDL-C than any other
preventive measure.
Education and socioeconomic status. HDL-C levels increase with income and
educational attainment after controlling diet, exercise, and other risk factors for
elevated cholesterol (Muennig et al. 2007). The mechanisms are not clear. It has
been suggested that stress differences by social class may play a role (Muennig
et al. 2007). However, several lifestyle factors including leisure-time physical
activity, smoking, alcohol drinking, and dietary habits correlate with the socioeco-
nomic status, classified as the degree of educational level (Schröder et al. 2004).
Dietary carbohydrates affect the lipoprotein profile. The epidemiological stud-
ies can be divided into three categories. First, the type of carbohydrate modulates
the impact of carbohydrates on plasma lipoproteins. The intake of refined
carbohydrates has increased in Western societies, and they have more deleterious
effects on abdominal obesity and consequently on insulin resistance and hepatic
lipogenesis in comparison with complex carbohydrates or starches (Ma et al. 2012;
Stanhope et al. 2009). The end result of high intake of refined carbohydrates is a low
HDL-C level (Heiss et al. 1980; Sonestedt et al. 2012).
Second, trials focusing on dietary carbohydrate restriction have shown modula-
tion of atherogenic dyslipidemia. The effect on HDL-C is modest but commonly
greater than that on total cholesterol, and thus, the atherogenic burden is improved.
Results from epidemiological studies are difficult to interpret due to differences in
diets.
The third type of studies involves the replacement of carbohydrate with different
fats in order to maintain isocaloric intake of macronutrients. A classic meta-
analysis of 60 trials (Mensink et al. 2003) showed that replacement of 10 % of
energy from carbohydrate with saturated fat, monounsaturated fat, and polyunsatu-
rated fat increased HDL-C by 4.7, 3.4, and 2.8 mg/dl (0.12, 0.09, and 0.07 mmol/l),
respectively. However, LDL cholesterol increased by 13 mg/dl (0.34 mmol/l) with
saturated fat substitution and decreased by 3.3 mg/dl (0.09 mmol/l) with polyunsat-
urated fat substitution while the substitution with monounsaturated fat had no effect
on LDL-C. Thus, the atherogenicity of the plasma lipoprotein profile improved with
the unsaturated fat substitution of carbohydrate.
The effects of dietary carbohydrates on HDL-C and CHD risk have been
analyzed also on the basis of their glycemic index (GI, the effect on blood glucose
level) or glycemic load (GL, including carbohydrate content and intake of foods in
addition to GI). High GL and GI were associated with significant increased risk of
CVDs, specifically for women. Several cross-sectional studies have reported
inverse associations of low GI and GL diets with HDL-C, but meta-analyses
(Kelly et al. 2004; Goff et al. 2013) have not found any effect on HDL-C.
Fatty acids and especially omega-3 fatty acids have been the focus of many
epidemiological studies. The most important omega-3 fatty acids in this respect are
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eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that increase
HDL-C by 1–3 % (Balk et al. 2006).
6 HDL-C in Diseases and Conditions
Type 2 diabetes. Patients with type 2 diabetes may have various types of
dyslipidemias that usually are accompanied with a low concentration of HDL-C
(Chehade et al. 2013; Morgantini et al. 2014). Low HDL-C contributes to diabetes-
related CHD risk more in women than in men, the diabetes-related hazard ratio for a
major CHD event being 3 times higher in women after adjustment for other
cardiovascular risk factors (Juutilainen et al. 2004). On the other hand, lipid
composition of HDL particles is associated with the development of metabolic
syndrome (Abbasi et al. 2013; Onat et al. 2013).
Dyslipidemias. Traditionally, dyslipidemia has been characterized by an eleva-
tion in plasma triglycerides and total or LDL cholesterol and reduction in HDL-C.
This is commonly referred to as the atherogenic triad. LDL particles are small and
dense (Mooradian 2009). Genetic studies have indicated linkage of apoB gene to
peak LDL size and plasma triglycerides, HDL-C, and apoB levels.
Obesity. Overweight and obese subjects usually have low HDL-C concentrations
(Seidell et al. 1991). The underlying cause may be insulin resistance that promotes
free fatty acid flux to the liver, stimulates hepatic lipogenesis, and finally enhances
the secretion of triglyceride-rich apoB-containing lipoproteins from the liver. The
excess triglyceride-rich particles also enhance the CETP-mediated exchange of
cholesteryl esters from HDL to apoB-containing lipoprotein particles and simulta-
neous transfer of triglycerides into HDL (Mann et al. 1991; Liinamaa et al. 1997).
This may further reduce HDL-C levels.
Weight reduction is an important modulator of the lipoprotein profile and long-
term weight reduction increases HDL-C levels especially in subjects with type
2 diabetes. It is noteworthy that the effect of weight reduction on HDL-C is
different in the initial weight loss period compared with the weight maintenance
phase. A meta-analysis has shown that HDL-C is increased by 0.35 mg/dl
(0.009 mmol/l) per kilogram weight lost during the stable weight reduction. During
active weight loss, however, HDL-C is reduced by 0.27 mg/dl (0.007 mmol/l) for
every kilogram of weight lost (Browning et al. 2011). Theoretically, an increase in
HDL-C of 2.45 mg/dl (0.06 mmol/l) could be expected during the stable weight
maintenance stage after a weight reduction of 7 % in an individual with an initial
weight of 100 kg. Furthermore, this would translate into 7.4 % reduction in CHD
risk in women.
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7 High HDL Levels Do Not Add to the Protection
While low levels of HDL-C are associated with increased CHD risk, high HDL-C
levels are not uniformly atheroprotective. At higher concentrations the curve of
CHD risk gradually tapers off as depicted in Fig. 1 which is based on the results
from the Framingham Heart Study (Gordon et al. 1977), and there is no additional
effect of higher HDL-C levels compared with average HDL-C concentrations.
8 Effect of HDL on Stroke
In contrast to the role of HDL-C as a major risk factor of CHD, the role of HDL-C in
the pathogenesis of ischemic stroke is less clear. Epidemiological studies of carotid
intima media thickness and stroke protection have provided conflicting results.
Even in the studies reporting positive results, the effect of HDL-C on protection
of stroke is modest (a 10 mg/dl or 0.38 mmol/l increase in HDL-C reduces stroke
risk by 11–15 %) compared with its protective effect on CHD. The discordant
results in prospective cohort studies as well as in case-control studies may be due to
the heterogeneity of stroke, since dyslipidemia including low HDL-C levels may
not be involved in the pathogenesis of some subtypes such as lacunar and
cardioembolic strokes (Amarenco et al. 2008).
Fig. 1 Potential differences in the functions of HDL particles. HDLaa depicts a theoretical
subclass of particles comprising the bulk of plasma HDL-C concentration but without any
significant role in reverse cholesterol transport or pleiotropic effects of HDL, whereas HDLbb
may be a smaller fraction but more active in reverse cholesterol transport. HDLcc could be a small
subclass without any significant contribution to the HDL-C quantity. These particles may, how-
ever, have many pleiotropic effects on cytokines, growth factors, etc. [Modified from Hannuksela
et al. (2004)]
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9 Time Trends in Total HDL-C
During the last decades, favorable trends in HDL-C levels have occurred in US
adults and youths aged 6–19 years despite changes in physical activity, obesity, and
diabetes (Carroll et al. 2012; Kit et al. 2012). Similar trends have been observed
also in Europe and India (Muntoni et al. 2009; Gupta et al. 2012).
10 Are There Other Biomarkers than the Total HDL-C?
The cholesterol in HDL (i.e., HDL-C) may reflect the rate of reverse cholesterol
transport from the peripheral tissues to liver. However, it may be that the bulk of
HDL cholesterol does not necessarily represent the particles that are involved in the
reverse cholesterol transport or any other potentially antiatherogenic activity of
HDL (Fig. 1).
HDL particles comprise a heterogeneous fraction of lipoprotein which vary by
the apolipoprotein and lipid content and consequently also in density, shape, size,
and charge. Various subfractions can be analyzed, e.g., by ultracentrifugation
(density), electron microscopy (shape), nondenaturing gel electrophoresis, gel
filtration or nuclear magnetic resonance (NMR) spectroscopy (size), NMR or
immunoaffinity (composition), and 2-dimensional electrophoresis (charge).
11 HDL Fractions
Analytic ultracentrifugation was first used to separate subclasses of HDL (DeLalla
et al. 1954). Later, the sequential ultracentrifugation and various precipitation
methods enabled the analysis of larger series in epidemiological studies.
Sequential ultracentrifugation methods have enabled separation of two major
HDL subfractions, namely, HDL2 and HDL3, while the isolation of further
subclasses has required more tedious methods such as gradient ultracentrifugation.
Nuclear magnetic resonance (NMR) spectroscopy has simplified the differentiation
into five subclasses. However, the nomenclature has varied and it is generally quite
difficult to compare HDL subclasses separated by different methods. Recently, a
unified nomenclature for a simplified differentiation into 5 subclasses according to
particle size (very small, small, medium, large, and very large HDL) has been
proposed (Rosenson et al. 2011).
Controversial results have been obtained in studies aimed at distinguishing
cardiovascular differences between HDL subclasses separated by density (Superko
et al. 2012; Pirillo et al. 2013). A majority of the studies, however, have found
HDL2-C to be more predictive of CHD risk than total HDL-C or HDL3-C
(Johansson et al. 1991; Drexel et al. 1992; Lamarche et al. 1997). A recent study
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with 29-year follow-up of the Gofman’s Livermore cohort showed that HDL2 and
HDL3 are independently related to CHD risk (Williams and Feldman 2011).
12 HDL Particle Size
Further characterization of HDL subfractions by nondenaturing polyacrylamide
gels has identified three HDL3 and two HDL2 subclasses. Very large HDL particles
(HDL2b subfraction with diameter between 9.7 and 12.9 nm) are strongly
correlated with the total HDL-C concentration and most strongly inversely related
to CHD risk in normotriglyceridemic subjects (Johansson et al. 1991). On the other
hand, an increased concentration small HDL particles (HDL3b subfraction, 7.8–
8.2 nm) is associated with an atherogenic lipoprotein profile characterized by low
HDL2b levels, high plasma triglyceride concentration, and increased level of small,
dense LDL particles (Berneis and Krauss 2002). Low concentration of HDL2b
subclass has also been shown in patients with T2DM (Xian et al. 2009).
13 HDL Particle Number
The complexity of HDL metabolism leads to the formation of multiple HDL
subpopulations with varying density, size, charge, and chemical composition.
Two individuals with the same HDL-C concentration may have HDL particles of
different size distribution, and consequently, the particle number is different.
Recently, NMR methods have enabled high-throughput determination of HDL
particle concentration. Plasma levels of large particles and low particle number
are consistently associated with low CHD prevalence (Mora et al. 2012).
14 HDL Lipids
Some of the effects of HDL on cellular functions are mediated by sphingomyelin-1-
phosphate (S1P) that is a bioactive lipid in HDL. Alterations in S1P content in HDL
particles could explain the dysfunction of HDL since the HDL-associated S1P
seems to be responsible for many of the pleiotropic effects of HDL by activating
special S1P receptors. In epidemiological studies low levels of S1P in HDL has
been associated with coronary heart disease (Argraves et al. 2011). Sphingomyelin
content in HDL particles has been associated with coronary heart disease in
postmenopausal women (Horter et al. 2002). Sphingomyelin has also been
associated with kidney disease in patients with type 1 diabetes (Mäkinen
et al. 2012).
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15 HDL Apolipoproteins
The structure of HDL particles is very complex, apoA-I and apoA-II being the
major protein components. ApoA-I accounts for about two-thirds of the protein
content of HDL and is also functionally important since it is the acceptor in the
efflux of phospholipids and free cholesterol from peripheral cells. The measurement
of apolipoprotein levels is more expensive and time-consuming than that of lipid
concentrations. To circumvent this, data from large epidemiological cohorts was
recently used for the development of computer software that enables accurate
estimation of apolipoprotein levels on the basis of lipid measurements (Raitakari
et al. 2013).
High plasma levels of apoA-I are protective against atherosclerosis in some
studies (Arsenault et al. 2011; Emerging Risk Factor Collaboration 2012). It has
been proposed that apoA-I concentration could even be a better predictor of
atherosclerosis development than HDL-C. A recent study reported that adjustment
for apoA-I changes the direction of the association between HDL-C and the severity
of atherosclerotic lesions as determined with coronary artery calcium score (Sung
et al. 2013). Among patients treated with statin therapy, apoA-I levels are strongly
associated with a reduced cardiovascular risk, even among those achieving very
low LDL-C level (Boekholdt et al. 2013).
ApoA-II is the second major apolipoprotein in HDL particles. It is present in
most but not all particles and the clinical significance of apoA-II-containing and
apoA-II-free particles is controversial (Rosenson et al. 2011).
Some studies have reported enrichment with apoC-III in the HDL of patients
with CHD (Vaisar et al. 2010; Kavo et al. 2012; Jensen et al. 2012). Interestingly,
Jensen and coworkers found that HDL particles without apoC-III were inversely
associated with the risk of CHD while apoC-III-containing HDL particles were
directly associated with increased risk of CHD (Jensen et al. 2012). HDL with
apoC-III comprised about 13 % of the total HDL-C.
16 HDL Proteomics
Several proteins circulate attached to HDL particles although most of them in much
lower numbers than apolipoproteins mentioned above. The protein content of HDL
particles has been characterized recently using various methods commonly
described as proteomics. It has been shown that HDL2 fraction of CHD patients
carries a distinct protein cargo (Vaisar et al. 2010; Gordon et al. 2010; Kavo
et al. 2012; Alwaili et al. 2012).
Proteomics as a new promising approach for detecting biomarkers and
mechanisms could potentially explain the beneficial characteristics of HDL
particles unrelated to their cholesterol content. To this end, novel sophisticated
methods have been recently developed (Gordon et al. 2010; Mazur et al. 2010;
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Burillo et al. 2013; Hoofnagle et al. 2012; Mazur and Cardasis 2013; Riwanto
et al. 2013). High-throughput methods are urgently needed for large-scale epidemi-
ological studies.
17 HDL Function
Cholesterol efflux is the first step of reverse cholesterol transport. Excess cellular
cholesterol from peripheral tissues is effluxed to extracellular HDL-based acceptor
particles through the action of active transporters and passive diffusion. Recently, it
was reported that the cholesterol efflux measured from cultured macrophages
enriched with free cholesterol to apoB-depleted serum as cholesterol acceptor
was inversely associated with the history of CHD independent of HDL-C levels
(Khera et al. 2011). However, more recently, enhanced efflux has been associated
with high cardiovascular risk (Li et al. 2013). Further studies are urgently needed to
resolve the issue with conflicting results.
Antioxidative properties of HDL are mainly attributed to apoA-I although
paraoxonase 1 (PON1) may also play an important role. Antioxidative activity of
HDL subfractions increases with increment in density as follows:
HDL2b<HDL2a<HDL3a<HDL3b<HDL3c (Kontush et al. 2003). The determi-
nation of the antioxidative capacity of HDL particles is technically challenging, and
therefore, indirect approaches measuring arylesterase or paraoxonase activities
have been used in larger cohorts.
Molecules carried by HDL particles. Recent studies have shown that short
noncoding RNAs (microRNAs, miRNAs) are present in the circulation as a result
of cellular damage or secretion (Laterza et al. 2009). miRNAs are ideal biomarkers
since they are stable and their sequences can be easily amplified. Alterations in
circulating miRNA profiles have been associated with cardiovascular risk factors
such as hypertension, diabetes, and dyslipidemias as well as with cardiovascular
diseases such as coronary heart disease, myocardial infarction, and heart failure
(Fichtlscherer et al. 2011; de Rosa et al. 2011). However, this association has not
been found in all studies (Wagner et al. 2013).
Several proteins are also attached to HDL particles. Paraoxonase 1 (PON1) is an
HDL-associated enzyme that has been suggested to mediate many antiatherogenic
and cardioprotective effects of HDL particles (Mackness et al. 2004; Aviram and
Vaya 2013).
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18 Pleiotropy
In addition to the antioxidative properties HDL particles have also other functions
independent of the effects of HDL particles on cholesterol homeostasis. These
include anti-inflammatory, anti-infective, antithrombotic, and endotoxin-
neutralizing effects as well as effects on endothelial function. These pleiotropic
effects have been recently reviewed (Annema and von Eckardstein 2013). The
laboratory assays used for analyzing the pleiotropic effects of HDL are demanding
and need to be standardized before they can be used in large epidemiological
studies in order to improve the CHD risk assessment.
19 Future Approaches of Epidemiological Studies
New approaches have been used in order to resolve the complex effects of diseases,
conditions, environmental factors, and genes in relation to the protective role of HDL.
On one hand, there have been efforts to dissect the HDL fraction into as many well-
defined subfractions and individual molecules of HDL particles as possible. On the
other hand, as discussed above, the focus has been shifted from the structure and
composition to the function of HDL particles (Fig. 2). Moreover, recent development
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Fig. 2 Relation between HDL-C and risk of myocardial infarction. The solid curve shows the
average risk level by HDL-C concentration. The risk of individuals, however, may vary substan-
tially, and even at the same HDL-C level, the CHD risk could be anywhere between the dotted
lines. Furthermore, the nearly horizontal arrow depicts how previous approaches have attempted
to improve the atheroprotective capacity of HDL by increasing the quantity of HDL-C. Nowadays,
several studies have suggested that it might be more important to change the quality of HDL
particles as shown by the arrow down. Various biomarkers and function assays have been
commonly used to determine the improved quality that ultimately could lead to lower risk of
myocardial infarction
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the analysis of more holistic patterns on lipoproteins and subfractions and their
relation to the risk of CHD (Ala-Korpela 2008; Rosenson et al. 2011; Würtz
et al. 2012).
Dietary patterns have been used as a complementary approach to the traditional
single-nutrient analysis (Randall et al. 1990; Bogl et al. 2013). Dietary patterns are,
e.g., “fruit and vegetables,” “meat,” “sweets and desserts,” “junk food,” and “fish.”
The “junk food” pattern is characterized by higher intakes of energy-dense nutrient-
poor foods, such as hamburger, pizza, French fries, salty snacks, and liquorices and
lower intakes of porridge, rye bread, and fruit. The “junk food” pattern
distinguishes from the commonly used definition of “Western pattern” in that
“junk food” does not contain high amounts of meat, eggs, or high-fat dairy. The
healthy diet pattern has been associated with higher levels of HDL-C, whereas the
fast-food dietary pattern, high in saturated fat, did not have this effect (Hamer and
Mishra 2010).
The idea of analyzing the whole diet through dietary patterns is based on the fact
that people do not eat single purified nutrients or simple foods, but mixed meals
consisting of several foods and nutrients at a time. The term “nutritional epidemi-
ology” depicting food patterns was coined already in the 1970s (Krehl 1977) but has
only recently used more frequently.
The Mediterranean diet refers to a dietary profile commonly available in the
early 1960s in the Mediterranean regions and characterized by a high consumption
of fruit, vegetables, legumes, and complex carbohydrates, with a moderate con-
sumption of fish, and the consumption of olive oil as the main source of fats and a
low-to-moderate amount of red wine during meals (Sofi et al. 2010). A recent meta-
analysis of 50 studies summarized the impact of the Mediterranean diet on CHD
risk factors (Kastorini et al. 2011). The diet is associated with a 3 % increase in
HDL-C, but many other lipid and non-lipid risk factors such as hypertrigly-
ceridemia, blood pressure, glucose, insulin resistance, and abdominal obesity are
also affected.
Conclusion
HDL-C is a strong and independent predictor of major cardiovascular events in a
wide range of populations, in men and women with or without preceding CHD.
As molecular biology and related approaches have revealed new biomarkers or
profiles in HDL structure and function, the epidemiological research is also
moving from the classical determination of total HDL-C to structure-function
analyses. Recent methodological breakthroughs in HDL structure analyses have
enabled their use also in large cohorts. In the future, further investigations are
urgently needed for validation and clinical applications of HDL function assays.
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Abstract
There is unequivocal evidence that high-density lipoprotein (HDL) cholesterol
levels in plasma are inversely associated with the risk of cardiovascular disease
(CVD). Studies of families with inherited HDL disorders and genetic association
studies in general (and patient) population samples have identified a large
number of factors that control HDL cholesterol levels. However, they have not
resolved why HDL cholesterol and CVD are inversely related. A growing body
of evidence from nongenetic studies shows that HDL in patients at increased risk
of CVD has lost its protective properties and that increasing the cholesterol
content of HDL does not result in the desired effects. Hopefully, these insights
can help improve strategies to successfully intervene in HDL metabolism. It is
clear that there is a need to revisit the HDL hypothesis in an unbiased manner.
True insights into the molecular mechanisms that regulate plasma HDL choles-
terol and triglycerides or control HDL function could provide the handholds that
are needed to develop treatment for, e.g., type 2 diabetes and the metabolic
syndrome. Especially genome-wide association studies have provided many
candidate genes for such studies. In this review we have tried to cover the
main molecular studies that have been produced over the past few years. It is
clear that we are only at the very start of understanding how the newly identified
factors may control HDL metabolism. In addition, the most recent findings
underscore the intricate relations between HDL, triglyceride, and glucose metab-
olism indicating that these parameters need to be studied simultaneously.
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Ever since plasma HDL cholesterol concentration was found to be inversely
correlated with the risk of cardiovascular disease (CVD), there has been a strong
interest in the biological mechanisms that can explain this correlation. From a large
number of studies in humans, animals, and tissue culture, it has become clear that
HDL exerts many beneficial functions with prominent roles in cellular cholesterol
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efflux and protection against inflammation. For recent overviews on this topic, see
Luscher et al. (2014) and Rye and Barter (2014).
Paradoxically and not always recognized, however, is that rare inborn errors of
HDL metabolism have illustrated that an almost complete loss of HDL or very high
HDL cholesterol levels do not automatically translate in accelerated or protection
from atherosclerosis, respectively. These observations may be related to the small
numbers of patients available for studies or the absence/presence of concomitant
established risk factors for CVD (such as increased LDL cholesterol, smoking, etc.)
in these individuals. However, these findings by themselves indicate that the
relation of HDL cholesterol with atherosclerosis is not as straightforward as for
LDL cholesterol since in this case increases and decreases are always associated
with increased and decreased risk, respectively.
Genetic approaches are frequently used to study whether changes in plasma
HDL cholesterol concentration affect atherosclerosis. Such studies are conducted in
families, larger patient population samples sharing large-impact mutations in HDL
genes, as well as general population samples. Using candidate gene approaches,
these studies mostly generated contrasting or confusing results [a short summary of
these findings can be found in Chapman et al. (2011)]. Illustrative in this regard
were investigations into variation at the locus encoding for the ATP-binding
cassette transporter A1 (ABCA1). While a complete loss of ABCA1 function
causes near HDL deficiency and often accelerated atherosclerosis in Tangier
patients who are referred to the clinic, studies in general population samples
indicated that ABCA1 gene variation is not necessarily related with plasma HDL
cholesterol concentration and risk of CVD (for review, see Frikke-Schmidt (2011)).
More recently, it has become possible to study the impact of whole-genome
variation on complex diseases which has shed light on our understanding whether
or not genes and their products are related to plasma lipid traits and the risk of CVD.
In this regard, particularly Mendelian randomization studies showed that genetic
variation associated with increased HDL cholesterol does not protect from athero-
sclerosis (Voight et al. 2012). In this case, it concerned a study of common variants
in HDL candidate genes; however, more recently, it was also shown that
low-frequency coding variants (frequencies between 0.1 and 2 %) with relatively
large effects on HDL cholesterol and/or triglycerides were also not associated with
risk for coronary heart disease (Peloso et al. 2014).
These and other studies have placed HDL cholesterol as a pharmaceutical target
under heavy fire especially in the context of several large clinical trials that tested
drugs which increased HDL cholesterol but did reduce atherosclerosis (for reviews
on CETP inhibitors and the use of niacin: Ginsberg and Reyes-Soffer 2013; Rader
and Degoma 2014). While there is still hope for HDL-related interventions as
outlined in a recent review (van Capelleveen et al. 2014), it is clear that there is a
need to revisit the mechanisms that have been put forward to explain the unequivo-
cal relation between HDL cholesterol and risk of CVD in epidemiological studies.
To date, it is repeatedly been pointed out that a focus on the cholesterol content
of HDL should maybe be replaced by a focus on the functions that are associated
with this lipoprotein (Feig et al. 2014; Peloso et al. 2014; Luscher et al. 2014;
Riwanto and Landmesser 2013), but unfortunately, HDL functionality studies have
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thus far not provided a solution to the problems encountered. So far it is not clear
which of HDL properties should and could be targeted. There is evidence for a
focus on HDL as an acceptor of cholesterol (Khera et al. 2011) but later studies
were not able to confirm this (Li et al. 2013a, b). In other words, the association with
CVD risk has only been firmly established for the concentration of cholesterol in
HDL while at the same time there is little evidence of a causal relation between
HDL and CVD (Vergeer et al. 2010). Thus, it is possible that HDL cholesterol is a
proxy for an unknown correlating factor. A renewed focus on the clinical applica-
tion of HDL-based strategies for certain indications on the basis of functional
properties of HDL but also on significant preclinical and clinical data, as was
recently suggested, may hopefully bring relief (Gordts et al. 2013).
In this light, the current chapter focuses on recent studies that have shed new
light on how genes and/or their products affect HDL metabolism. The first section
shortly describes established regulators of HDLmetabolism as a general framework
to help understand the new insights that are described in the second section.
2 Determinants of Plasma HDL Cholesterol Levels
Twin studies have indicated that genetic and environmental parameters equally
contribute to the levels of cholesterol in HDL in the blood (Goode et al. 2007). This
paragraph only shortly describes the major primary and secondary regulators of
HDL cholesterol. It is important to underscore, however, that changes in HDL
cholesterol without changes in other plasma lipid traits are very rare. They are
mostly seen in the context of changes in plasma triglycerides. At the population
level, genome-wide association (GWA) studies have recently confirmed that in
many cases, genetic variation is associated with changes in more than one lipid trait
(Teslovich et al. 2010; Willer et al. 2013).
2.1 Established Primary Regulators of Plasma HDL Cholesterol
For the de novo production of HDL, the small intestine and liver need to produce
apolipoprotein (apo) A-I, ATP-binding cassette protein A1, and lecithin–cholesterol
acyltransferase encoded by the APOAI, ABCA1, and LCAT genes, respectively. When
the production of any of these proteins is attenuated (through functional large-impact
mutations), it immediately translates into a reduction of HDL cholesterol in the
circulation. Other established modulators of HDL are cholesteryl ester transfer
protein (encoded by CETP) and scavenger receptor class B member 1 (SRB1,
encoded by SCARB1). While CETP mediates the transfer of cholesterol ester from
HDL to triglyceride-rich lipoproteins in exchange for triglycerides (thereby
controlling the levels of cholesteryl ester in HDL), SRB1 mediates the selective
cellular uptake of cholesteryl ester in the liver and steroidogenic organs. Figure 1
gives a schematic representation of how the above genes relate to HDL biology.
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2.2 Established Secondary Regulators of Plasma HDL Cholesterol
There are a large number of other factors that affect HDL cholesterol concentration
through modulating the lipolysis of plasma triglycerides [reviewed in Oldoni
et al. (2014)]. Figure 2 only illustrates the major players. Most of these regulate
the activity of lipoprotein lipase (LPL), the sole enzyme capable of breaking down
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Fig. 1 A schematic presentation of factors that control HDL synthesis/binding and/or
HDL-mediated cellular cholesterol homeostasis. The genes in the white boxes encode for key
HDL proteins and enzymes, while the genes in the blue boxes encode for less established (new)
factors that affect HDL metabolism. The roles of the genes in the gray boxes are addressed but
solid evidence has not yet been provided. Abbreviations (proteins encoded by the gene names):
ABCA1 ATP-binding cassette A1, ABCG1 ATP-binding cassette G1, APOAI apolipoprotein A-I,
APOF apolipoprotein F, APOM apolipoprotein M, BMP1 bone morphogenetic protein-1, GLCE
glucuronic acid epimerase, LCAT lecithin–cholesterol acyltransferase, PCPE2 procollagen
C-proteinase enhancer 2, PCYT1 CTP:phosphocholine cytidylyltransferase alpha, SCARB1
encoding for scavenger receptor class B member 1
Beyond the Genetics of HDL: Why Is HDL Cholesterol Inversely Related to. . . 289
(VLDL)) in the circulation. These include genes that encode for LPL’s cofactor
apoC-II (APOCII) as well as apoA-V (APOAV) and inhibitors of the LPL reaction
(APOCIII, ANGPTL3, ANGPTL4). More recently, also GPI-anchored HDL-binding
protein 1 (GPIHBP1) was shown to affect HDL concentration through ultimately its
effect on LPL activity. In addition, hepatic lipase (encoded by LIPC) and endothe-
lial lipase (LIPG) also exert marked effects on HDL cholesterol concentration
mainly through modulating HDL phospholipids and HDL triglycerides,
respectively.
2.3 Missing Heritability
So far, studies of over 40 genes have provided solid evidence that their products
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Fig. 2 A schematic
presentation of factors that
affect HDL through roles in
the conversion and
remodeling of HDL or
through effects on
triglyceride/glucose
metabolism. The genes in the
white boxes encode for
established factors of HDL
conversion/remodeling or
plasma TG hydrolysis. The
genes in the blue boxes
encode for less established
(new) factors. Abbreviations
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may expect these accounting for the estimated 50 % heritability of this trait. This
appears however not to be the case when GWA data are analyzed with the current
statistical methods and datasets: The most recent of meta-analysis indicates that
common genetic variation can only explain 12 % variation of HDL cholesterol
levels while in this study, both variations in established loci as well as newly
identified loci (n¼ 46) were taken into account (Willer et al. 2013). However, in
these calculations, gene–gene and gene–environment interactions are not for. In
addition, the estimated impact of gene variation on the phenotype is based on the
presence and frequency of such variations and these are not constant factors over
the genome.
From a different angle, candidate gene resequencing studies in individuals with
very high or low HDL cholesterol (selected from the general population) have
shown that apparent functional mutations are only found in a few percent of the
cases (Cohen et al. 2004; Haase et al. 2012). Also in individuals that were referred
to the clinic because of extreme levels of HDL cholesterol, resequencing studies of
candidate genes only provided satisfying clues in a minority of the subjects studied
(Candini et al. 2010; Holleboom et al. 2011a, b; Kiss et al. 2007). It may be noted,
however, that most studies conducted thus far focused only on APOAI, LCAT, and
ABCA1 leaving ample room for large-effect variants in other genes. Another study
focused on the origin of high HDL cholesterol levels through sequencing CETP,
LIPG, and GALNT, showed an enrichment of rare coding and splicing mutations in
171 probands (Tietjen et al. 2012). A second study conducted a search for mutations
in 197 lipid-related genes in 80 individuals with extreme HDL cholesterol
phenotypes. The outcome was that multiple mutations in different genes combined
could be responsible for extreme low or high HDL cholesterol levels (Motazacker
et al. 2013). Although a polygenic origin of a complex trait like HDL cholesterol
level appears logical, especially in view of similar studies for plasma triglycerides
(Johansen et al. 2010) or LDL cholesterol (Talmud et al. 2013), this needs to be
confirmed. Larger comprehensive resequencing efforts are warranted to study to
what extent large-impact mutations in established and candidate genes can explain
HDL cholesterol concentration in plasma and how such mutations relate to
CVD risk.
3 Novel Insight into HDL Biology
As indicated above, GWA studies have identified many genomic regions that affect
plasma lipid traits. One of the most famous papers in this regard published in 2010
(Teslovich et al. 2010) already listed 38 loci with HDL cholesterol as lead trait.
Importantly, these and many other GWA studies rediscovered many of the
established “HDL genes” which underscored the potential importance of the
newly identified loci. The most comprehensive meta-analysis in this field of
research to date lists an additional 46 loci that are associated with HDL cholesterol
(Willer et al. 2013). This section tries to capture the novel molecular insights that
have been published over the last few years. Many studies focused on genes that on
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the basis of their proximity to genetic markers in GWA studies were “annotated as
HDL genes.” In addition, other studies (not initiated through genetic insight) which
produced interesting novel insight in HDL biology are shortly discussed.
3.1 De Novo Synthesis of HDL and HDL Binding
3.1.1 Bone Morphogenetic Protein-1 and Procollagen
C-Proteinase Enhancer-2
In 2007, bone morphogenetic protein-1 encoded by BMP-1 (aliases OI13, PCOLC,
PCP, PCP2, TLD) was identified as the metalloproteinase that stimulates the
conversion of newly secreted proapoA-I to its phospholipid-binding form (Chau
et al. 2007). While these results were obtained through in vitro studies, early genetic
association studies showed the possible involvement of procollagen C-proteinase
enhancer-2 (encoded by PCPE2 or PCOLCE2) in modulating HDL cholesterol
levels (Hinds et al. 2004). It was subsequently shown that PCPE2 together with
BMP1 and proapoAI forms a ternary complex and that it is involved in the
regulation of apoA-I posttranslational processing (Zhu et al. 2009). In a later
study, it was shown that Pcpe2 KO mice have strongly increased plasma apoA-I
and HDL cholesterol levels compared with wild-type littermates, regardless of
gender or diet (Francone et al. 2011). Changes in HDL particle size and electropho-
retic mobility observed in Pcpe2 KO mice suggest that the presence of proapoA-I
impairs the maturation of HDL. Although initially picked up by GWA studies,
PCPE2 is not listed in the subsequent respective meta-analyses (Teslovich
et al. 2010; Willer et al. 2013), while BMP1 is also not listed in the latter studies.
So far, the role of BMP1 or PCPE2 in posttranslational processing in humans has
not been reported which in the light of the larger GWA studies performed is now
dependent on the identification of large-impact mutations in individuals with HDL
disorders.
3.1.2 Apolipoprotein M
Originally identified as a protein associated with HDL in 1999 (Xu and Dahlback
1999), apoM was later implicated to play a role in the generation of prebeta-HDL
and cholesterol efflux mediated by HDL (Wolfrum et al. 2005). These results have
recently been supported by evidence in plasma of humans (Plomgaard et al. 2009)
while others have found that human APOM gene variation affects HDL cholesterol
(Park et al. 2013; Aung et al. 2013). Through carrying sphingosine-1-phosphate
with effects on angiogenesis, endothelial cell migration, and inflammation, apoM
(Christoffersen and Nielsen 2013) may be a link to many of the functions that are
attributed to HDL. While there is thus substantial evidence for a role of apoM in
human HDL metabolism, the gene has thus far not been picked up by GWA studies,
while large-impact mutations in this gene have so far not been reported either.
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3.1.3 CTP:Phosphocholine Cytidylyltransferase Alpha (CT Alpha)
Through an interest in the synthesis of phosphatidylcholine (the primary phospho-
lipid in cellular membranes but also of HDL), the group of Dennis Vance studied a
conditional PCTY1 knockout mouse and showed in 2004 that hepatic CTP:
phosphocholine cytidylyltransferase alpha reduces HDL cholesterol and apoA-I
while it also affected VLDL (Jacobs et al. 2004). In 2008, the same investigators
subsequently showed that in hepatocytes isolated from these mice, ABCA1 expres-
sion was reduced. Other findings included normalization of plasma HDL and
VLDL in these mice after adenoviral delivery of CT alpha which clearly implicated
its importance in HDL genesis (Jacobs et al. 2008).
3.1.4 Apolipoprotein F
In proteomic studies, apoF has been identified to be associated with HDL. This
protein is also known as lipid transfer inhibitor protein which is able to inhibit
CETP. Plasma apoF levels were found to be positively associated with HDL
cholesterol in males but not in females (Morton et al. 2008). The Rader group
subsequently showed that overexpression of apoF in mice reduced HDL cholesterol
levels by accelerating clearance from the circulation (Lagor et al. 2009). A later
study showed that a murine apoF knockout model had no substantial effect on
plasma lipid concentrations, HDL size, lipid, or protein (Lagor et al. 2012) although
a reduced ability to promote cholesterol efflux was observed. Until now, no other
studies on apoF have been published.
3.1.5 Glucuronic Acid Epimerase
Through studies in Turkish families, a linkage peak with low HDL cholesterol was
identified on chromosome 15 which was>20 cM wide including the gene encoding
hepatic lipase (LIPC), which has important functions in HDL metabolism. How-
ever, the same investigators suspected that variations in LIPC might not fully
explain this linkage peak and sought additional gene(s) that might contribute to
the peak. This is how they identified GLCE encoding glucuronic acid epimerase, a
heparan sulfate proteoglycan biosynthetic enzyme (Hodoglugil et al. 2011). So far,
no other studies on the role of this enzyme in HDL metabolism have been
conducted while the gene was not found associated with HDL cholesterol levels
in the latest meta-analyses GWA study (Willer et al. 2013).
3.1.6 Beta-Chain of ATP Synthase
In 2003, beta-chain of ATP synthase (encoded by ATPB5), a principal protein
complex of the mitochondrial inner membrane, was surprisingly identified as a
high-affinity HDL receptor for apoA-I receptor with a role in hepatic HDL endocy-
tosis (Martinez et al. 2003). A subsequent study demonstrated a major role of
cytoskeleton reorganization in F(1)-ATPase/P2Y(13)-dependent HDL endocytosis
under the control of the small GTPase RhoA and its effector ROCK I (Malaval
et al. 2009). Others showed that binding of HDL to this receptor triggers the
generation of ADP, which via the activation of the purinergic receptor P2Y13
stimulates the uptake and transport of HDL and initially lipid-free apoA-I by
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endothelial cells (Cavelier et al. 2012). So far, there is no genetic support for the
involvement of beta-chain of ATP synthase and/or P2Y(13), but even mild
mutations could have in the case of ATPB5 lethal consequences. Most recently, it
was reported that there may be a role for beta-chain of ATP synthase in regulating
HDL cholesterol levels as mitochondrial inhibitor factor 1, which inhibits ATPB5
and can be measured in serum, is associated with HDL cholesterol levels (Genoux
et al. 2013).
3.2 HDL Conversion and Remodeling
3.2.1 Angptl Family of Proteins
In the year 2000, ANGPTL4 was identified as a peroxisome proliferator-activated
receptor α response gene (Kersten et al. 2000) while ANGPTL3 is since 2002 known
for its effects on glucose and lipid metabolism through a hypolipidemic mouse
strain (Koishi et al. 2002). Both Angptl3 and Angptl4 are known to inhibit LPL,
thereby having an indirect effect on HDL cholesterol concentration in plasma, but
Angptl3 may also exert direct effects on HDL remodeling through inhibition of
endothelial lipase (Shimamura et al. 2007). In GWA studies published in 2008 and
2010, ANGPTL3 was shown to be associated primarily with triglycerides
(Kathiresan et al. 2008; Teslovich et al. 2010) while more recently it was shown
that human ANGPTL3 deficiency also causes marked reduction in HDL cholesterol
(Musunuru et al. 2010). In 2010, ANGPTL4was reported to be associated with HDL
cholesterol as primary trait (Teslovich et al. 2010) while later on ANGPTL4 variants
were found associated with lower triglycerides and elevated HDL cholesterol
(Romeo et al. 2007). Another study showed that mutant alleles of ANGPTL3 and
ANGPTL4 that were associated with low plasma triglyceride levels interfered either
with the synthesis or secretion of the protein or with the ability of the ANGPTL
protein to inhibit LPL (Romeo et al. 2009). More recently, ANGPTL8 (also known
as betatrophin) was shown to also affect HDL cholesterol through affecting the
activity of Angpl3 (Quagliarini et al. 2012). In addition, low-frequency variants in
ANGPTL8 were shown to affect HDL cholesterol levels (Peloso et al. 2014). For a
recent review on the current eight Angptl proteins, please see Santulli (2014).
3.2.2 Tribbles Homolog 1
Variation at the TRIB1 gene locus has been reported to be associated with
triglycerides (as lead trait), HDL cholesterol, total cholesterol, and LDL cholesterol
(Kathiresan et al. 2008; Teslovich et al. 2010). It is one of the few genes subse-
quently studied in depth in mouse models, in vitro experiments, and further human
genetic association studies. Viral-mediated overexpression in the liver of mice
simultaneously reduced plasma triglycerides and cholesterol of all major
lipoproteins (including HDL). On the other hand, TRIB1 knockout mice showed
elevated levels of triglycerides (Burkhardt et al. 2010) without statistically signifi-
cant effects on HDL cholesterol. These effects were related to an on VLDL
production but it is not known what mechanisms are responsible. Further
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epidemiological studies confirmed that TRIB1 is associated with HDL cholesterol
but interestingly without affecting apoA-I concentration (Varbo et al. 2011). More
recently it was shown that Trib1 is important to adipose tissue maintenance and
suppression of metabolic disorders by controlling the differentiation of tissue-
resident M2-like macrophages (Satoh et al. 2013). In addition, a TRIB1 single-
nucleotide polymorphism was found associated with nonalcoholic fatty liver dis-
ease in humans while the same investigators showed that TRIB1 expression affects
hepatic lipogenesis and glycogenesis through multiple molecular interactions
(including a molecular interaction with MLXIPL or CHREBP, a hepatic lipogenic
master regulator) (Ishizuka et al. 2014). In addition to a role in lipid metabolism,
there is a substantial literature on the role of tribbles in cancer (Liang et al. 2013).
3.2.3 Tetratricopeptide Repeat Domain/Glycogen-Targeting PP1
Subunit G(L)
TTC39B was discovered through GWA studies in 2009 (Kathiresan et al. 2009).
When knocked down in mice (using a viral-mediated strategy), it was shown to
increase HDL cholesterol levels (Teslovich et al. 2010). However, no studies have
since revealed insight into how tetratricopeptide repeat domain 39B may affect
lipid metabolism while another GWA study could not replicate the effect of
TTC39B variation on plasma lipid levels (Dumitrescu et al. 2011).
PPP1R3B was also found to be associated with HDL cholesterol as primary trait
(Teslovich et al. 2010), and in the same paper, viral-mediated overexpression was
shown to reduce HDL cholesterol levels in mice. The gene encoding for glycogen-
targeting PP1 (protein phosphatase 1) subunit G(L) has also been associated with
type 2 diabetes and maturity-onset diabetes of the young but sequence variants at
the PPP1R3B locus were not found to be related to diabetes in mostly Caucasian
families (Dunn et al. 2006). Other studies proposed a role for this gene in inflam-
mation (Dehghan et al. 2011), Alzheimer’s disease (Kamboh et al. 2012), and
hepatic steatosis (Palmer et al. 2013). As for TTC39B, there are no mechanistic
studies that have revealed insight into how PPP1R3B gene products may affect
lipid metabolism.
3.2.4 ppGalNAc-T2
Variation at the GALNT2 locus was also shown to be associated with HDL choles-
terol (Teslovich et al. 2010). Viral-mediated overexpression and knockdown were
shown to decrease and increase HDL cholesterol levels in mice, respectively. In a
later study a rare functional GALNT2 variant, identified in two index cases with very
high HDL cholesterol, was reported to affect HDLmetabolism indirectly via an effect
on the lipolysis of triglycerides (Holleboom et al. 2011a, b). This was suggested to be
in part due to attenuated glycosylation of apoC-III which impaired its capacity to
inhibit LPL in the catabolism of triglycerides. Other investigators reported that
GALNT2 regulates plasma lipid levels through the glycosylation of ANGTPL3,
another inhibitor of the LPL reaction (Schjoldager et al. 2010). Recently,
ppGalNAc-T2 was identified as a novel regulator of insulin signaling (Marucci
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et al. 2013) while there appears to be a role for GALNT2 in hypertension too
(Pendergrass et al. 2013; McDonough et al. 2013).
3.2.5 Glucokinase (Hexokinase 4) Regulator
GCKR (also known as GKRP) encodes for a regulatory protein that inhibits
glucokinase in the liver and pancreatic islet cells by binding non-covalently to
form an inactive complex with the enzyme. This gene is considered a susceptibility
gene candidate for a form of maturity-onset diabetes of the young. GCKR was
picked up in both GWA studies with a focus on plasma lipids but also with type
2 diabetes (van de Bunt and Gloyn 2010). Varbo et al. showed that a GCKR SNP
was associated with increased triglycerides, decreased HDL cholesterol, and
remarkably increased apoA-I (Varbo et al. 2011). Several genetic association
studies have shown that GCKR variants are associated with triglycerides, insulin
resistance (Shen et al. 2013), type 2 diabetes fasting plasma glucose (Li et al. 2013a,
b), hyperglycemia (Stancakova et al. 2012), and nonalcoholic fatty liver disease
(Lin et al. 2014). In 2013, the crystal structure was resolved (Pautsch et al. 2013)
while two potent small-molecule GK–GKRP disruptors were recently reported to
normalize blood glucose levels in several rodent models of diabetes (Lloyd
et al. 2013).
Conclusions and Perspectives
The harvest of screening the most recent published literature for novel HDL
influencing genes is extensive. However, it also shows that there are only very
few mechanistic clues on how “the new kids on the block” (primarily identified
through GWA studies) affect HDL cholesterol or HDL function.
It is interesting that none of the genes encoding for the proteins and enzymes
that have been discussed in the section on the de novo synthesis of HDL are
listed in the current largest GWA studies. This may be surprising in light of the
evidence for the roles of especially bone morphogenetic protein-1, procollagen
C-proteinase enhancer 2, apoM, and CT alpha in HDL metabolism. It shows that
GWA strategies, like any approach, come with limitations. Thus, prioritizing
research interest on the basis of the top ranking GWA hits is not necessarily the
most promising route to go.
In the section on (new) insights in HDL conversion and remodeling, it is clear
that the factors discussed are only indirectly associated with HDL cholesterol
levels through effects on triglyceride and/or glucose metabolism. It may be
noted in this regard that HDL cholesterol was proposed to be the lead trait for
ANGPTL4, TTC39B, PPP1R3B, and GALNT2, in GWA studies which highlights
a need for more comprehensive studies with focus on the mechanistic relations
between HDL cholesterol, triglycerides, and glucose metabolism. Such studies
may need the use of genome-scale metabolic maps.
Finally, this review underlines an urgent need of mechanistic studies. But
where to start? Answering this question is today’s challenge as evidence-based
prioritization tools and high-throughput functional studies are yet to come.
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Abstract
High-density lipoprotein (HDL) is considered to be an anti-atherogenic lipopro-
tein moiety. Generation of genetically modified (total body and tissue-specific
knockout) mouse models has significantly contributed to our understanding of
HDL function. Here we will review data from knockout mouse studies on the
importance of HDL’s major alipoprotein apoA-I, the ABC transporters A1 and
G1, lecithin:cholesterol acyltransferase, phospholipid transfer protein, and scav-
enger receptor BI for HDL’s metabolism and its protection against atherosclero-
sis in mice. The initial generation and maturation of HDL particles as well as the
selective delivery of its cholesterol to the liver are essential parameters in the life
cycle of HDL. Detrimental atherosclerosis effects observed in response to HDL
deficiency in mice cannot be solely attributed to the low HDL levels per se, as
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the low HDL levels are in most models paralleled by changes in non-HDL-
cholesterol levels. However, the cholesterol efflux function of HDL is of critical
importance to overcome foam cell formation and the development of atheroscle-
rotic lesions in mice. Although HDL is predominantly studied for its
atheroprotective action, the mouse data also suggest an essential role for HDL
as cholesterol donor for steroidogenic tissues, including the adrenals and ovaries.
Furthermore, it appears that a relevant interaction exists between HDL-mediated
cellular cholesterol efflux and the susceptibility to inflammation, which
(1) provides strong support for the novel concept that inflammation and metabo-
lism are intertwining biological processes and (2) identifies the efflux function of
HDL as putative therapeutic target also in other inflammatory diseases than
atherosclerosis.
Keywords
Knockout mice • High-density lipoprotein • Reverse cholesterol transport • Ath-
erosclerosis • Steroidogenesis • Inflammation • ABC transporters • Scavenger
receptor BI • Apolipoprotein • Lecithin-cholesterol acyltransferase • Phospho-
lipid transfer protein
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1 Introduction
High levels of low-density lipoprotein (LDL) cholesterol are associated with an
increased risk for cardiovascular disease. In contrast, plasma levels of cholesterol
associated with high-density lipoprotein (HDL) are inversely correlated with the
risk of cardiovascular disease (Gordon et al. 1977). Since standard treatment with
statins to lower plasma levels of LDL cholesterol only reduces the risk of cardio-
vascular disease by ~30 % (Cholesterol Treatment Trialists’ (CTT) Collaboration
et al. 2010; Cholesterol Treatment Trialists’ (CTT) Collaborators et al. 2012),
raising plasma levels of HDL cholesterol has been considered a potential additional
therapeutic strategy to overcome disease.
The term HDL refers to a class of alpha-migrating protein/lipid complexes that
differ in size (5–12 nm), shape, and lipidation pattern. In order to be able to
effectively modulate plasma HDL-cholesterol levels, it is of critical importance
to understand the anti-atherogenic potential and metabolism of the different HDL
particles. Due to the large biological/genetic variation and lifestyle of people, it is
difficult to gain clear insight into the relation between the flux of cholesterol
through the HDL pathway and the development of atherosclerosis—the primary
underlying cause of cardiovascular disease—in the general human population.
Small animal models, in particular mice, have been proven valuable tools to
increase the understanding of the complexity of HDL metabolism and the
consequences of interfering in specific pathways or atherosclerosis susceptibility.
Here we will review data from several genetically modified (total body and tissue-
specific knockout) mouse models to (1) show the importance of specific gene
products in the life cycle of HDL and their contribution to HDL’s primary function,
reverse cholesterol transport, i.e., the flux of cholesterol from peripheral cells back
to the liver for subsequent excretion, and (2) highlight the potential of modulation
of HDL metabolism as an approach to lower atherosclerotic disease burden.
2 Apolipoprotein A-I
Apolipoprotein A-I (apoA-I) is produced by the liver (Zannis et al. 1983) and
intestine (Gordon et al. 1982) and represents the primary apolipoprotein constituent
of HDL particles (Scanu et al. 1969). Several mutations in the apoA-I gene have
been causally linked to HDL deficiency in humans (Tilly-Kiesi et al. 1995; Leren
et al. 1997; Matsunaga et al. 1999; Hovingh et al. 2004; Dastani et al. 2006; Wada
et al. 2009; Berge and Leren 2010; Lee et al. 2013).
The groups of Nobuyo Maeda (Williamson et al. 1992) and Jan Breslow (Plump
et al. 1997) both inactivated the apoA-I gene in mice using dedicated homologous
recombination strategies, leading to the absence of detectable amounts of apoA-I
protein in plasma. In accordance with an important function for apoA-I in the
formation and stability of HDL particles, genetic disruption of apoA-I in mice is
associated with an 83 % decrease in the level of HDL cholesterol, contributing to a
68 % decrease in plasma total cholesterol levels (Williamson et al. 1992). The
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limited amount of HDL cholesterol present in apoA-I knockout mice is carried by
particles that are enriched in triglycerides (Plump et al. 1997). However, HDL
particle size and shape are similar to that of wild-type controls. ApoA-I-deficient
HDL particles display increased levels of other apolipoprotein subspecies, includ-
ing apolipoprotein A-II (apoA-II), apolipoprotein E (apoE), and apolipoprotein
A-IV (apoA-IV) (Li et al. 1993; Plump et al. 1997; Moore et al. 2003). Homozy-
gous apoA-I deficiency in mice not only lowers plasma levels of HDL cholesterol,
but also decreases levels of cholesterol associated with apoB-containing very-low-
density lipoproteins (VLDL) (Plump et al. 1997). The cholesterol ester to
unesterified cholesterol ratio is lower in plasma of apoA-I-deficient mice, which
can be attributed to a reduced endogenous cholesterol esterification rate (Parks
et al. 1995). Furthermore, the cholesterol ester fatty acid composition of plasma is
markedly different between the different genotypes, with apoA-I knockout mice
displaying a higher degree of fatty acid saturation as compared to wild-type mice
(Parks et al. 1995). ApoA-I, in addition to its structural role, thus also serves as an
essential activator of the enzyme lecithin-cholesterol acyltransferase (LCAT) that
esterifies cholesterol.
ApoA-I deficiency in mice does, in general, not affect tissue cholesterol levels
(Plump et al. 1997). In the liver, decreased delivery of cholesterol esters to
hepatocytes is compensated by a concomitant decrease in bile acid formation as
judged from a decrease in hepatic mRNA expression levels of cholesterol 7alpha-
hydroxylase (CYP7A1) in apoA-I knockout mice (Plump et al. 1997). In contrast,
the adrenals are not able to cope with the diminished plasma cholesterol flux due to
the lack of apoA-I. Cortical cells located in the zona glomerulosa and zona
fasciculata from the adrenals of wild-type mice are filled with large lipid droplets
containing cholesterol esters, while adrenals from apoA-I-deficient mice
completely lack cholesterol esters and display a parallel decrease in microvillar
channel width (Plump et al. 1996). Importantly, apoA-I-deficient mice show a
diminished adrenal glucocorticoid output in response to steroidogenic triggers
(Plump et al. 1996), suggesting that a lack of apoA-I-containing HDL particles
impairs normal adrenal function in mice. Although the cholesterol ester content of
the testis is similar between apoA-I knockout and wild-type mice, interstitial and
theca cells within the ovaries of apoA-I knockout mice are similarly deprived of
cholesterol esters (Plump et al. 1996). Currently no evidence is present for an
altered female fertility, despite the clear ovarian cholesterol depletion phenotype.
Combined, these findings indicate that apoA-I-containing HDL particles act as
important cholesterol donors for several, but not all, steroidogenic tissues.
Human apoA-I mutation carriers may develop premature atherosclerosis
(Hovingh et al. 2004; Dastani et al. 2006). The formation of atherosclerotic lesions
in normolipidemic mice can be induced by feeding them a cholic acid-containing
diet enriched in cholesterol and fat that increases levels of pro-atherogenic apoB-
containing lipoproteins (Paigen et al. 1987; Ishida et al. 1991). Strikingly, deletion
of apoA-I in wild-type mice does not alter the incidence or extent of atherogenic
diet-induced lesion formation (Li et al. 1993). This may be explained by the fact
that, under cholic acid-containing diet feeding conditions, levels of anti-atherogenic
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HDL as well as levels of pro-atherogenic VLDL/LDL are lower in apoA-I knockout
mice as compared to wild-type controls (Li et al. 1993). To further determine the
impact of apoA-I deficiency on atherosclerosis susceptibility, apoA-I knockout
mice have been crossbred with genetically hyperlipidemic low-density lipoprotein
receptor (LDLr) knockout mice that spontaneously develop atherosclerotic lesions
on a chow diet, albeit at a slow rate (Ishibashi et al. 1994). Chow diet-fed apoA-I x
LDLr double knockout (DKO) mice as compared to LDLr single knockout controls
exhibit an increase in the plasma non-HDL-cholesterol to HDL-cholesterol ratio.
This can be attributed to a marked increase in VLDL-cholesterol levels and a
decrease in plasma HDL-cholesterol levels (Moore et al. 2003; Zabalawi
et al. 2003). In accordance with the more atherogenic lipoprotein profile (higher
VLDL cholesterol and lower HDL cholesterol), atherosclerotic lesion burden is
increased in chow diet-fed apoA-I x LDLr DKO mice, as measured by en face
analysis of the aorta, irrespective of the age of the mice (Moore et al. 2003).
Feeding a Western-type high fat/high cholesterol diet induces a rapid progression
of atherosclerotic lesion development in LDLr knockout mice (Ishibashi
et al. 1994). In great contrast with the chow diet findings, the extent of atheroscle-
rotic lesion formation was not significantly different between LDLr KO and apoA-I
x LDLr DKO mice upon feeding an atherogenic diet containing 10 % saturated fat
from palm oil and 0.1 % cholesterol for 16 weeks (Zabalawi et al. 2003). However,
it should be noted that apoA-I x LDLr DKO mice show a much lower diet-induced
increase in VLDL-cholesterol levels. Identical aortic cholesterol contents are thus
found in the context of a ~70 % lower plasma total cholesterol level (Zabalawi
et al. 2003). It therefore appears that ablation of apoA-I function and the concomi-
tant decrease in plasma HDL-cholesterol levels do predispose for atherosclerotic
lesion development in mice, but only after correcting for apoA-I genotype-
associated changes in VLDL-cholesterol levels.
ApoA-I x LDLr DKO mice develop severe (fatal) skin lesions containing lipid-
filled macrophages upon feeding the high cholesterol/high fat diet (Zabalawi
et al. 2003). In addition, B-cells, T-cells, and dendritic cells within lymph nodes
of apoA-I x LDLr DKO mice are enriched in cholesterol esters (Wilhelm
et al. 2009). This is associated with an autoimmune phenotype characterized by
relatively high autoantibody titers in plasma upon feeding an atherogenic high
fat/high cholesterol diet (Wilhelm et al. 2009). ApoA-I-containing HDL particles
thus also play an essential role in maintaining cholesterol homeostasis in the skin as
well as in cells from the lymphoid system.
3 ATP-Binding Cassette Transporter A1
The cholesterol used to transform pre-beta1HDL into discoidal alpha-migrating
HDL particles can be supplied through passive diffusion driven by a concentration
gradient. However, it has become clear that energy-dependent flux of cholesterol
and phospholipid across the membrane facilitated by members of the ATP-binding
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cassette (ABC) family of transporters contributes significantly to the lipidation of
apoA-I.
Human carriers of a mutation in the full size ABC transporter ABCA1 gene
suffer from familial HDL deficiency (Brooks-Wilson et al. 1999; Bodzioch
et al. 1999; Hong et al. 2002). In accordance with a prominent role for ABCA1 in
the control of HDL biogenesis, total body ABCA1-deficient mice are characterized
by an almost complete lack of HDL cholesterol (>90 % decrease) in the context of
similar levels of triglyceride-rich lipoproteins (Christiansen-Weber et al. 2000;
Orsó et al. 2000; Calpe-Berdiel et al. 2005; Brunham et al. 2006). Mature alpha-
migrating HDL particles are virtually absent in ABCA1 knockout mice. The
remaining HDL cholesterol is carried by pre-beta HDL particles that are relatively
enriched in triglycerides and exhibit an altered phospholipid species distribution
(Orsó et al. 2000; Francone et al. 2003). ABCA1 knockout mice display a dimin-
ished LCAT activity (Francone et al. 2003), which highlights that lipidation of
apoA-I via ABCA1 is required for LCAT activity and maturation of HDL.
Adrenocortical cells (Orsó et al. 2000) and testical Sertoli cells (Christiansen-
Weber et al. 2000) of mice lacking ABCA1 show distinct accumulation of choles-
terol esters. This can possibly be attributed to the observed increase in the activity
of the cholesterol synthesis gene HMG-CoA reductase (Drobnik et al. 2001). How-
ever, ABCA1 may also act as a local regulator of steroidogenic tissue cholesterol
homeostasis. In further support of a crucial role of ABCA1 in the control of normal
steroidogenesis and development, pregnant ABCA1-deficient females exhibit
lower plasma progesterone and estrogen levels (Christiansen-Weber et al. 2000).
Furthermore, placentas of ABCA1 knockout mice often show malformations,
which translates into a diminished birth and survival rate of ABCA1 knockout
pups (Christiansen-Weber et al. 2000).
Livers and intestines of ABCA1 knockout mice are depleted of cholesterol esters
(Orsó et al. 2000). Within the liver of wild-type mice, relatively high mRNA and
protein expression levels of ABCA1 are found in hepatocytes and tissue
macrophages (Kupffer cells) (Lawn et al. 2001; Hoekstra et al. 2003), while in
the intestine ABCA1 expression seems to be mostly restricted to macrophages in
the lamina propria of villi (Lawn et al. 2001). Dedicated gene targeting strategies
have been employed to delineate the contribution of the different cell compartments
to plasma HDL-cholesterol levels and total body cholesterol homeostasis. Condi-
tional disruption of ABCA1 function specifically in parenchymal liver cells with
the use of the Cre/Flox gene targeting system impairs the apoA-I-mediated efflux of
cholesterol and phospholipid from hepatocytes without altering the efflux of cho-
lesterol from macrophages to apoA-I (Timmins et al. 2005). Plasma
HDL-cholesterol levels are ~80 % lower as a result of liver-specific ABCA1
deficiency (Timmins et al. 2005). Liver-specific deletion of ABCA1 is also
associated with hypercatabolism of apoA-I by the kidneys resulting in an increased
turnover of HDL particles and a marked decrease in steady-state plasma apoA-I
levels (Timmins et al. 2005; Singaraja et al. 2006). Although no data on the effect of
general ABCA1 deficiency in mice on apoA-I flux have been described, it can be
assumed total body ABCA1 knockout mice similarly show an increased catabolism
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and clearance of apoA-I by the kidneys. ABCA1 deficiency in hepatocytes is
associated with a rise in plasma levels and size of triglyceride-rich VLDL particles,
which can be attributed to an increase in hepatic VLDL secretion and a parallel
decrease in lipoprotein lipase (LPL)-mediated catabolism of triglycerides (Sahoo
et al. 2004; Chung et al. 2010). ABCA1-mediated transport of cholesterol from
hepatocytes to the plasma compartment thus not only controls HDL biogenesis, but
also impacts on the synthesis and catabolism of non-HDL particles. Deletion of
ABCA1 specifically in intestinal epithelial cells is associated with an accumulation
of cholesterol esters in the intestine, a lower plasma apoA-I concentration, and a
~30 % decrease in plasma HDL-cholesterol levels (Brunham et al. 2006). In
contrast to total body and hepatocyte-specific knockout mice, intestinal-specific
ABCA1 knockout mice do not show major changes in non-HDL-cholesterol and
plasma triglyceride levels (Brunham et al. 2006), which further highlights the role
of hepatocyte ABCA1 in the control of plasma triglyceride levels. Importantly,
mice genetically lacking ABCA1 in both the liver and intestine show a greater
decrease in plasma HDL-cholesterol levels as compared to their single tissue
knockout controls, almost reaching similarly low levels as those found in total
body ABCA1 knockout mice (Brunham et al. 2006). Hepatocytes and the intestinal
epithelium can thus be considered the primary cellular sources of the cholesterol
that is used for lipidation of apoA-I and generation of HDL.
Loss-of-function mutations in the ABCA1 gene could not be associated with
increased coronary heart disease in the general population (Frikke-Schmidt
et al. 2008a). However, several studies have suggested that premature atheroscle-
rosis and cardiovascular disease are a common finding in human carriers of
functional mutations in the ABCA1 gene (Huang et al. 2001; Hong et al. 2002;
Frikke-Schmidt et al. 2008b). In contrast, total body ABCA1 deficiency does not
alter the susceptibility to atherosclerosis in hyperlipidemic apoE knockout and LDL
receptor (LDLr) knockout mice fed either regular chow or an atherogenic high
fat/high cholesterol diet (Aiello et al. 2002). However, deletion of ABCA1 function
in the context of genetic hyperlipidemia is not only associated with HDL deficiency
but also with a significant decrease in the plasma concentration of cholesterol
carried by pro-atherogenic VLDL/LDL (Aiello et al. 2002). As is also the case
for apoA-I, normal ABCA1 function in mice thus only protects against atheroscle-
rosis after correcting for ABCA1 genotype-associated confounding differences in
atherogenic lipoprotein levels. The atheroprotective effect of ABCA1 may be
attributed to its general impact on plasma HDL-cholesterol levels or specifically
due to its potential role in the efflux of cholesterol from macrophages. Lipid-filled
foam cells can be found in all macrophage-rich tissues of hyperlipidemic total body
ABCA1 knockout mice (Aiello et al. 2002), which already hints to an important
in vivo role for ABCA1 in macrophage cholesterol efflux. The capacity of ABCA1
knockout mice to facilitate reverse cholesterol transport, the transport from periph-
eral cells—i.e., macrophages—back to the liver for subsequent excretion, has been
validated by measuring the recovery in the plasma compartment and feces of
radiolabeled cholesterol from intraperitoneal administered macrophages. In line
with the hypothesis that ABCA1-mediated cholesterol efflux is an important
Mouse Models of Disturbed HDL Metabolism 307
determinant of reverse cholesterol transport, a lower amount of radiolabeled cho-
lesterol is excreted under the condition of both total body and macrophage-specific
ABCA1 deficiency (Calpe-Berdiel et al. 2005; Wang et al. 2007).
Aiello et al. (2002) and Van Eck et al. (2002) utilized bone marrow transplanta-
tion to explore the specific effect of ABCA1-dependent macrophage cholesterol
efflux on atherosclerosis susceptibility. In accordance with a negligible impact of
macrophage ABCA1 on total HDL biogenesis, bone marrow ABCA1 deficiency
does not alter plasma HDL-cholesterol levels (Haghpassand et al. 2001; Aiello
et al. 2002; Van Eck et al. 2002). Atherosclerotic lesion development in apoE
knockout mice is markedly enhanced—at multiple sites—in response to disruption
of ABCA1 expression in bone marrow (Aiello et al. 2002). Transplantation of
ABCA1 knockout bone marrow into lethally irradiated LDLr knockout mice
similarly stimulates atherosclerotic lesion development (Van Eck et al. 2002).
ABCA1-mediated efflux of cholesterol from leukocytes is thus an important pro-
tective mechanism to inhibit macrophage foam cell formation and atherosclerosis
in mice. Remarkably, macrophage-specific ABCA1 deficiency does not affect the
extent of atherosclerosis in LDLr knockout mice (Brunham et al. 2009). It can
therefore be concluded that ABCA1’s function in macrophages does not confer
protection against atherosclerosis, but that rather an efficient efflux of cholesterol
from lymphocytes or other immune cells is essential to overcome disease.
Relative HDL deficiency in liver-specific ABCA1 knockout mice on a
hyperlipidemic LDLr knockout background is not associated with any enhanced
susceptibility for the initial development of macrophage-rich atherosclerotic
lesions, while the development of more advanced (collagen-containing) plaques
is inhibited (Bi et al. 2013). In accordance with a prominent role for macrophage
ABCA1 in reverse cholesterol transport, no change is observed in the flux of
cholesterol from macrophages to the feces in LDLr knockout mice lacking
ABCA1 function only in hepatocytes (Bi et al. 2013). Strikingly, apoE knockout
mice that contain hepatocyte-specific ABCA1 deficiency do show an increased
susceptibility to atherosclerosis, despite lowered plasma VLDL/LDL-cholesterol
levels (Brunham et al. 2009). A critical review of these data has suggested that the
discrepancy in the atherosclerosis findings from liver-specific ABCA1 knockout
mice may be attributed to differences in inflammatory status of the two
hyperlipidemic mouse models (Van Eck and Van Berkel 2013), which makes
proper interpretation of the findings difficult. However, due to the inconsistency
of the aforementioned results, it seems clear that the decrease in plasma
HDL-cholesterol levels due to deletion of ABCA1 function should not be consid-
ered the driving force for the increase in atherosclerosis in total body ABCA1
knockout mice.
A consistent decrease in plasma VLDL-cholesterol levels is observed in LDLr
knockout mice that have been transplanted with ABCA1-deficient bone marrow
upon feeding an atherogenic Western-type diet (Van Eck et al. 2002; Lammers
et al. 2011, 2012). This finding suggests that modulation of the leukocyte choles-
terol efflux rate can directly impact on the metabolism of VLDL particles in vivo.
However, to date, the mechanism underlying this effect remains to be resolved. It is
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becoming more and more evident that immunology and metabolism are not just two
separate disciplines, but that they intervene and impact each other at multiple levels
(Mathis and Shoelson 2011). ABCA1-deficient macrophages display a higher
sensitivity to the bacterial membrane component lipopolysaccharide (LPS) (Zhu
et al. 2008; Yvan-Charvet et al. 2008) and myeloid cell-specific ABCA1 knockout
mice are protected against bacterial infection (Zhu et al. 2012). Furthermore,
ABCA1 deficiency in bone marrow is associated with an increase in blood leuko-
cyte counts (Van Eck et al. 2002). Given the apparent link between ABCA1 and
immune function in vivo, future research should be aimed at uncovering to what
extent ABCA1 contributes to the interplay between inflammation and cholesterol
metabolism.
4 ATP-Binding Cassette Transporter G1
ABCG1, formerly known as the ABC8/white gene, belongs to the family of ABC
half transporters that need to dimerize to execute their function. ABCG1 expression
is mostly restricted to macrophage-rich tissues, including liver, spleen, and lung
(Klucken et al. 2000), where it acts as an intracellular sterol transporter (Tarling and
Edwards 2011). ABCG1 mRNA expression can actually be used as a measure for
the hepatic macrophage content in rodent livers, despite detectable levels of
ABCG1 expression in hepatocytes (Hoekstra et al. 2003; Ye et al. 2008; Li
et al. 2012). The capacity to efflux cholesterol to HDL is diminished in ABCG1-
deficient macrophages, while the apoA-I-mediated cholesterol efflux rate is similar
as compared to wild-type macrophages (Out et al. 2006). ABCG1 and ABCA1 thus
interact with different HDL subspecies (mature HDL vs. pre-beta HDL) to facilitate
their cholesterol efflux function. To date, no association between ABCG1
mutations and HDL-cholesterol levels has been described in humans, suggesting
that ABCG1 does not significantly contribute to HDL biogenesis. In accordance,
under basal chow diet feeding conditions, ABCG1 knockout mice do not exhibit a
change in plasma total or HDL-cholesterol levels (Out et al. 2007; Wiersma
et al. 2009).
Chow-fed ABCG1-deficient mice exhibit a severe pulmonary lipidosis pheno-
type, starting from the age of ~6 months, which is characterized by accumulation of
phospholipids, cholesterol crystals, and inflammatory infiltrates in sub-pleural areas
of the lung (Baldán et al. 2006a, 2008; Wojcik et al. 2008). The distinct lung
phenotype in total body ABCG1 knockout mice can be specifically attributed to the
lack of ABCG1 in bone marrow-derived cells, presumably macrophages. Lethally
irradiated normolipidemic mice transplanted with ABCG1-deficient bone marrow
also show inflammatory cell infiltrates in their lungs, while normalization of
macrophage ABCG1 function prevents the occurrence of pulmonary lipidosis in
total body ABCG1 knockout mice (Wojcik et al. 2008). Alveolar macrophages
from ABCG1 knockout mice have a foamy appearance and display compensatory
upregulation of the cholesterol efflux gene ABCA1 (Baldán et al. 2006a). In vitro
cultured macrophages lacking ABCG1 are more susceptible to surfactant-induced
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cholesterol accumulation (Baldán et al. 2006a). ABCG1-mediated cholesterol
efflux to HDL is thus essential for the protection against specifically surfactant-
induced foam cell formation under normolipidemic conditions, since no accumula-
tion of lipid has been noted in other macrophage-rich tissues in chow-fed ABCG1-
deficient mice (Out et al. 2008a). The pulmonary lipidosis phenotype is exacerbated
upon challenging the mice with a cholic acid-containing atherogenic diet (Out
et al. 2007). Under atherogenic diet feeding conditions, ABCG1 knockout mice
also show marked lipid accumulation in cells within and surrounding the germinal
centers of the spleen (Out et al. 2007). This finding highlights that ABCG1 is not
solely involved in maintaining cholesterol homeostasis locally within the lungs.
Variations in the human ABCG1 gene have been linked to an altered risk for
atherosclerotic disease that cannot be explained by changes in lipoprotein levels
(Furuyama et al. 2009). In accordance with a role for murine ABCG1 in the
protection against atherosclerosis, a higher extent of lesion formation, in the context
of similar plasma lipoprotein levels, is detected in ABCG1 knockout mice as
compared to wild-type littermate controls upon feeding atherogenic diet (Out
et al. 2007). The bone marrow transplantation technique has been applied to
elucidate the specific contribution of macrophages in the atheroprotective effect
of ABCG1. In line with the prominent role of macrophage ABCG1 in the preven-
tion of pulmonary lipidosis, extensive lipid accumulation is observed also in lungs
of hyperlipidemic mice transplanted with ABCG1 knockout bone marrow (Out
et al. 2006; Baldán et al. 2006b). However, contrasting effects on atherosclerosis
outcome have been noted upon bone marrow-specific ABCG1 deletion. Macro-
phage ABCG1 appears to protect against atherosclerosis in LDLr knockout mice as
evident from the initial studies by Out et al. (2006). In marked contrast, similar
studies by Baldán et al. in LDLr and apoE knockout mice (Baldán et al. 2006b) and
Ranalletta et al. in LDLr-deficient mice (Ranalletta et al. 2006) have identified
macrophage ABCG1 as being a pro-atherogenic factor. Importantly, following
critical review of all the present data and additional bone marrow transplantation
studies, Meurs et al. have been able to clarify the evident discrepancy in the findings
regarding the role of macrophage ABCG1 in atherosclerosis. The effect of disrup-
tion of ABCG1 function in macrophages on atherogenesis appears to be highly
dependent on the stage of lesion development (Meurs et al. 2012). Diminished
ABCG1-mediated efflux of cholesterol to HDL stimulates the formation of foam
cells and accelerates lesion development in initial plaques that primarily contain
macrophages. During later stages of the disease, macrophage ABCG1 deficiency
inhibits plaque progression as a result of activation of compensatory
atheroprotective mechanisms, i.e., hypersecretion of apoE from macrophages
(Ranalletta et al. 2006), and/or an increased apoptosis rate of lipid-laden macro-
phage foam cells (Baldán et al. 2006b).
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5 Lecithin-Cholesterol Acyltransferase
Discoidal small HDL particles are able to carry a relatively limited load of choles-
terol. In order for nascent HDL species to become fully enriched in cholesterol, the
unesterified cholesterol acquired upon cellular efflux has to be esterified for
subsequent storage in the core of more mature spherical HDL particles. The
hepatocyte-derived enzyme lecithin-cholesterol acyltransferase (LCAT) is consid-
ered to be the sole mediator of cholesterol esterification in HDL in humans, since
familial LCAT deficiency is characterized by a >95 % decrease in plasma
HDL-cholesterol ester levels (Glomset et al. 1970). As such, homozygous carriers
of loss-of-function mutations in LCAT present with HDL deficiency, while half of
normal HDL-cholesterol values are observed in heterozygous carriers
(Santamarina-Fojo et al. 2000; Hovingh et al. 2005). Two different strains of
LCAT knockout mice have been generated through genetic deletion of respectively
exon 1 or exons 2–5. In accordance with a major role for LCAT in the maturation of
HDL, both types of LCAT-deficient mice show severe HDL-cholesterol deficiency
(>90 % decreased; Ng et al. 1997; Sakai et al. 1997). This coincides with a
significant decrease in plasma apoA-I levels (Ng et al. 1997), probably as a result
of apoA-I hypercatabolism by the kidneys. The remaining plasma HDL cholesterol
in LCAT knockout mice is contained in its unesterified form (Ng et al. 1997; Sakai
et al. 1997).
Besides the clear HDL deficiency phenotype, LCAT knockout mice display
significant changes in the metabolism of triglyceride-rich lipoproteins. Homozy-
gous LCAT-deficient mice show hypertriglyceridemia and an increase in plasma
VLDL-cholesterol levels on a chow diet (Sakai et al. 1997; Lambert et al. 2001; Ng
et al. 2002). This phenotype is preserved when mice are fed a Western-type diet
enriched in fat (Li et al. 2007). Furthermore, extensive triglyceride deposition can
be observed within livers of LCAT knockout mice upon Western-type diet feeding
(Li et al. 2007). Mechanistic studies in LCAT x LDLr double knockout mice have
indicated that the hypertriglyceridemia can be attributed to an increase in secretion
of triglyceride-rich VLDL particles and a decrease in the LPL-mediated lipolysis
rate (Ng et al. 2004). As evidenced by lower fasting glucose and insulin levels,
LCAT knockout mice exhibit an improved glucose tolerance and insulin sensitivity
when crossbred onto the hyperlipidemic LDLr knockout background
(Ng et al. 2004; Li et al. 2007). LCAT-mediated cholesterol ester formation thus
not only contributes to the formation of mature HDL particles, but also (indirectly)
impacts on fatty acid and glucose metabolism.
A genetic defect in LCAT does, in general, not affect the tissue cholesterol
balance in mice (Ng et al. 1997). However, adrenals of LCAT knockout mice show
gross morphological changes associated with neutral lipid depletion, i.e., they have
a more red/brownish color instead of the normal white appearance after perfusion
(Ng et al. 1997). Specifically adrenocortical cells within the zona fasciculata, but
not zona glomerulosa, are deprived from neutral lipid stores (Hoekstra et al. 2013a).
This results in an overall ~80 % decrease in adrenal cholesterol ester content
(Ng et al. 1997). Probably as a compensatory response to overcome cholesterol
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insufficiency, marked increases in the expression of genes involved in the de novo
synthesis and extracellular acquisition of cholesterol can be detected in LCAT
knockout adrenals (Ng et al. 1997). Importantly, in support of the notion that
HDL act as cholesterol donors for the synthesis of glucocorticoids by the adrenals,
LCAT knockout mice display a 40–50 % reduction in the maximal glucocorticoid
output (Hoekstra et al. 2013a). A minor decrease in tissue cholesterol content is also
noted in ovaries, but not testis, in response to LCAT deficiency in mice (Tomimoto
et al. 2001), which does not translate into apparent changes in female fertility.
LCAT knockout mice on a normolipidemic background are virtually protected
against cholic acid containing diet-induced formation of atherosclerotic lesions
(Lambert et al. 2001). Chow diet-fed LCAT x apoE double knockout mice also
display a decrease in atherosclerotic lesion formation, as compared with apoE
single knockout controls (Lambert et al. 2001; Ng et al. 2002). Ablation of LCAT
function is associated with marked HDL deficiency under all hyperlipidemic
conditions. Strikingly, mixed results on the effect of LCAT deficiency on athero-
sclerosis susceptibility, however, have been noted in hyperlipidemic mice upon
feeding diets enriched in fat. LCAT x LDLr double knockout mice display a lower
atherosclerotic lesion burden upon feeding a cholic acid-containing diet (Lambert
et al. 2001). In contrast, LCAT deficiency stimulates the formation of atheroscle-
rotic lesions feeding in LDLr knockout mice upon feeding a Western-type diet
devoid of cholic acid, as judged by the aortic cholesterol content (Furbee
et al. 2002; Lee et al. 2004). Furthermore, LCAT x apoE double knockout mice
also exhibit an increase in their aortic cholesterol content upon feeding the
Western-type high fat diet (Furbee et al. 2002). Importantly, lower plasma levels
of non-HDL cholesterol are found in the hyperlipidemic LCAT knockout mice
under cholic acid-containing diet feeding conditions (Lambert et al. 2001), while
non-HDL-cholesterol levels are actually increased in response to LCAT deficiency
upon Western-type diet feeding (Furbee et al. 2002; Lee et al. 2004). It thus seems
that the diverse effects of LCAT deficiency on atherosclerosis outcome in the
different mouse models cannot be attributed to the HDL deficiency, but are rather
a consequence of the genotype-associated changes in plasma levels of apoB-
containing lipoproteins (Kunnen and Van Eck 2012).
6 Phospholipid Transfer Protein
Transfer of cholesterol esters generated by LCAT to the core of the HDL particles
and the subsequent maturation of the HDL particles require the action of phospho-
lipid transfer protein (PLTP), which supplies phospholipids allowing surface
expansion of the shell of the particles. The phospholipids are liberated during the
lipolysis of triglycerides in the core of apoB-containing lipoproteins by the action of
lipoprotein lipase (Tall et al. 1985). In addition, PLTP facilitates the fusion of
HDL3 particles to enlarged particles (Lusa et al. 1996). During this process lipid-
poor apoA-I particles are released that can act as substrate for ABCA1-mediated
cholesterol efflux from macrophages. In humans, common variants of PLTP have
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been identified that are associated with alterations in serum HDL cholesterol and
the accumulation of small HDL particles (Albers et al. 2012). Furthermore, PLTP
expression and activity is regulated during several diseases, including sepsis,
multiple sclerosis, cancer, and cardiovascular disease (Albers et al. 2012), but it
is largely unknown if the regulation of PLTP is a causative factor or simply a
consequence of the processes underlying the diseases. The generation of PLTP
knockout mice by the group of Alan Tall 15 years ago has greatly contributed to the
general understanding of the role of PLTP in HDL metabolism. PLTP was
inactivated in mice by replacing exon 2 containing the translation initiation
codon, the signal peptide, and the first 16 amino acids of mature PLTP with a
neomycin-resistant gene (Jiang et al. 1999). The plasma transfer activity of the
major phospholipids, including phosphatidylcholine, phosphatidylethanolamine,
phosphatidylinositol, and sphingomyelin into HDL, was completely blocked,
while also the transfer of free cholesterol was impaired in PLTP knockout mice.
Deletion of PLTP in mice led to markedly decreased levels of HDL phospholipids
and cholesterol (65–70 %), illustrating the importance of transfer of surface
phospholipids from apoB-containing lipoproteins by PLTP for maintaining HDL
levels (Jiang et al. 1999). Furthermore, similarly as described for LCAT knockout
mice the decrease in HDL cholesterol coincided with a significant decrease in
plasma apoA-I levels. Hepatocytes isolated from PLTP knockout mice synthesized
normal amounts of apoA-I, albeit with reduced amounts of phosphatidylcholine
(Siggins et al. 2007), indicating that the reduced plasma apoA-I levels were not due
to impaired production. Qin et al. showed by in vivo turnover studies using
autologous HDL that the reduced apoA-I levels are likely the consequence of
increased catabolism of HDL in the PLTP knockout mice (Qin et al. 2000).
On regular chow diet, PLTP-deficient mice absorb less cholesterol in the intes-
tine (Liu et al. 2007), while hepatic phospholipids are increased and triglycerides
are reduced in mice lacking PLTP (Siggins et al. 2007).
Feeding the mice a high saturated fat diet, containing 20 % hydrogenated
coconut oil and 0.15 % cholesterol, led to the accumulation of surface components
of apoB-containing lipoproteins as evidenced by a massive increase in VLDL and
LDL phospholipids and cholesterol in the absence of changes in apoB (Jiang
et al. 1999). Subsequent studies showed that the animals accumulated phospholipid
and free cholesterol-rich lamellar particles containing apoA-IV and apoE (Qin
et al. 2000). The accumulation of the lamellar particles specifically in coconut
oil-fed PLTP knockout mice has been attributed to markedly reduced removal of
these particles via scavenger receptor BI (SR-BI) by parenchymal liver cells
(Kawano et al. 2002) and impaired secretion of biliary cholesterol and phospholipid
(Yeang et al. 2010). Interestingly, these particles did not accumulate in the circula-
tion when the mice were fed regular chow diet or a Western diet, containing 20 %
milk fat and 0.15 % cholesterol (Kawano et al. 2002). In contrast, while feeding a
Western diet, containing milk fat and 0.15 % cholesterol, PLTP deficiency was
associated with an attenuated diet-induced hypercholesterolemia due to twofold
lower concentrations of cholesterol transported by apoB-containing lipoproteins
and HDL. Hepatic and intestinal lipid levels were not affected under these
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conditions, but cholesterol absorption in the intestine was reduced (Shelly
et al. 2008).
Both on chow and while feeding the milk fat Western diet, PLTP knockout mice
display reduced systemic inflammation as evidenced by lower levels of interleukin
6 and reduced expression of intercellular adhesion molecule 1 (ICAM1) and
vascular adhesion molecule 1 (VCAM1) in aorta, indicating that mice lacking
PLTP might have a reduced atherosclerosis susceptibility (Shelly et al. 2008).
To study the effect of PLTP deficiency on atherosclerotic lesion development,
PLTP knockout mice were crossbred with human apoB transgenic mice, apoE
knockout mice, and LDLr knockout mice (Jiang et al. 2001). Both in the apoB
transgenic and the apoE knockout background, PLTP deficiency led, on top of the
reduction in HDL lipids, to substantially lower VLDL lipid levels. Interestingly,
this effect on VLDL lipids was not found in the LDLr knockout background,
indicating the involvement of the LDLr in the lowering of VLDL lipids. In line,
apoB production was reduced in the apoB transgenic and apoE knockout back-
ground, but not in the LDLr knockout background (Jiang et al. 2001). The content
of the antioxidant vitamin E was significantly increased in all three backgrounds in
the absence of PLTP, while autoantibodies to oxidized LDL were largely decreased
(Jiang et al. 2002). HDL isolated from PLTP knockout mice crossbred to both the
apoB transgenic and the LDLr knockout background displayed improved anti-
inflammatory properties and reduced the ability of LDL to induce monocyte
chemotaxis (Yan et al. 2004). After 6 months of feeding apoB transgenic mice
Western diet and after feeding apoE knockout mice chow for 3 months, atheroscle-
rotic lesion size was reduced fivefold in mice lacking PLTP. In contrast, in LDLr
knockout mice PLTP deficiency led to a twofold reduction in atherosclerotic lesion
size after 8 weeks Western diet, whereas no significant effects were observed after
12 weeks Western diet feeding (Jiang et al. 2001). Thus, while PLTP deficiency can
reduce early atherosclerotic lesion development in mice lacking the LDLr, the
pro-atherogenic effects of PLTP should be primarily attributed to its effects on
the production of apoB-containing lipoproteins in mice fed regular chow or a
Western diet. Notably, when apoE knockout mice lacking PLTP were challenged
with a coconut oil-enriched, high fat diet for 7 weeks plasma levels of free
cholesterol were 23 % higher due to the accumulation of the lamellar free choles-
terol and phospholipid-rich particles. Under these conditions no effects on athero-
sclerotic lesion development were found (Yeang et al. 2010).
PLTP is widely distributed with expression in placenta > pancreas > lung >
kidney > heart > liver > skeletal muscle > brain (Day et al. 1994). In addition,
PLTP is found in endothelial cells (Day et al. 1994) and in smooth muscle cell and
macrophage foam cells in atherosclerotic lesions (Desrumaux et al. 2003; Laffitte
et al. 2003; O’Brien et al. 2003). Interestingly, Vikstedt and colleagues showed that
the expression of PLTP is sixfold higher in Kupffer cells, macrophages of the liver
as compared to hepatocytes (Vikstedt et al. 2007). Mice with a hepatocyte-specific
deletion of PLTP were generated by injection of PLTP-flox/flippase animals with
adenovirus-associated virus expressing Cre-recombinase under control of the thy-
roxine binding globulin promoter (Yazdanyar et al. 2013). PLTP activity was
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reduced by approximately 25 % in these animals with a hepatocyte-specific deletion
of PLTP, leading to a 20 % reduction of HDL cholesterol. In addition, non-HDL
cholesterol was 29 % lower due to an impaired production of apoB-containing
lipoproteins (Yazdanyar et al. 2013). Conversely, liver-specific expression of PLTP
in a PLTP knockout background promoted the secretion of apoB-containing
lipoproteins by the liver (Yazdanyar and Jiang 2012). The contribution of macro-
phage PLTP to plasma PLTP activity was determined by bone marrow transplanta-
tion studies in LDLr knockout mice. Selective deletion of PLTP in bone marrow-
derived cells led to a decrease in plasma PLTP activity on chow and Western diet
(Vikstedt et al. 2007). Vikstedt et al. showed that after 9 weeksWestern diet feeding
atherosclerotic lesion size was 29 % smaller in LDLr knockout mice transplanted
with PLTP-deficient bone marrow, which coincided with decreased serum VLDL-
cholesterol and phospholipid levels, while HDL phospholipid and apoA-I were
increased (Vikstedt et al. 2007). In contrast, Valenta et al. also found lower levels of
cholesterol in apoB-containing lipoproteins upon disruption of PLTP in bone
marrow-derived cells of LDLr knockout mice, but surprisingly atherosclerotic
lesion development was increased (Valenta et al. 2006). No effect on atherosclero-
sis was observed upon transplantation of PLTP-deficient bone marrow into LDLr
knockout mice overexpressing human apoA-I (Valenta et al. 2006). The studies by
Valenta et al. suggest that locally in the arterial wall PLTP produced by
macrophages can be anti-atherogenic. A possible explanation is that PLTP produc-
tion by macrophages promotes ABCA1-mediated cholesterol efflux, as evidenced
by decreased efflux to apoA-I from PLTP-deficient macrophages (Lee-Rueckert
et al. 2006). In agreement, macrophages isolated from PLTP knockout mice were
shown to accumulate more cholesterol upon incubation with native or acetylated
LDL (Ogier et al. 2007). Importantly, the higher levels of lipid-poor apoA-I in
LDLr knockout mice overexpressing human apoA-I can overcome the
pro-atherogenic effects of deletion of PLTP in macrophages, probably by
stimulating the cholesterol efflux capacity of the macrophages.
In summary, the effects of PLTP on atherosclerotic lesion development are
determined by a balance between systemic effects influencing the levels of anti-
atherogenic HDL and pro-atherogenic apoB-containing lipoproteins and the anti-
oxidant vitamin E and local effects of PLTP produced by macrophages in the
arterial wall influencing macrophage apoE production and ABCA1-mediated cho-
lesterol efflux.
7 Scavenger Receptor BI
During the final step of the reverse cholesterol transport process, mature HDL
particles deliver their cholesterol load to the liver for subsequent excretion via the
bile. The transmembrane glycoprotein scavenger receptor BI (SR-BI) is considered
to be the sole mediator of selective uptake of cholesterol esters from HDL by
hepatocytes in mice (Out et al. 2004). Several genetic variations at the SR-BI
locus—either translating in an altered SR-BI protein expression or
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functionality—have been associated with a change in plasma HDL-cholesterol
levels (Hsu et al. 2003; West et al. 2009; Vergeer et al. 2011; Brunham
et al. 2011; Chadwick and Sahoo 2012), which highlights the crucial role for
SR-BI in human HDL metabolism. To uncover the role of SR-BI in lipoprotein
metabolism, the group of Monty Krieger developed a mouse model carrying a
targeted mutation in the SR-BI gene that leads to complete absence of functional
SR-BI protein in all tissues (Rigotti et al. 1997). In addition, a strain of SR-BIatt
mice has been generated by the group of Dennis Huszar in which the SR-BI
promoter is mutated, resulting in a lowered protein expression of SR-BI in liver,
testis, and adrenals (Varban et al. 1998). Furthermore, hypomorphic SR-BI knock-
out mice have been constructed that do not suffer from complete SR-BI deficiency,
but show a restricted expression pattern of the protein in liver, kidney, aorta, and
steroidogenic tissues (Huby et al. 2006).
Total body SR-BI knockout mice are characterized by a diet-independent hyper-
cholesterolemia, which can be primarily attributed to a marked rise in plasma
HDL-cholesterol levels (Rigotti et al. 1997; Van Eck et al. 2003, 2008). The
fractional catabolic rate, plasma decay, and subsequent uptake of
HDL-cholesterol esters by the liver are diminished in SR-BI knockout mice (Out
et al. 2004). SR-BIatt mice similarly show a diminished fractional catabolic rate
and hepatic selective uptake of HDL-associated cholesterol, also leading to a higher
steady-state level of HDL cholesterol in the plasma of these mice (Varban
et al. 1998; Ji et al. 1999). In accordance with a role for hepatic SR-BI in the
regulation of plasma HDL-cholesterol levels, both total body and hepatocyte-
specific restriction of SR-BI expression in hypomorphic SR-BI knockout mice is
also associated with an increase in plasma HDL-cholesterol levels (Huby
et al. 2006). Although SR-BI is thought to primarily mediate the uptake
HDL-cholesterol esters, in particular free cholesterol levels are higher in plasma
in the different SR-BI-deficient mice (Van Eck et al. 2003; Huby et al. 2006; El
Bouhassani et al. 2011). The increase in plasma free cholesterol to cholesterol ester
ratio underlies anemia and thrombocytopenia phenotypes in SR-BI knockout mice
(Holm et al. 2002; Meurs et al. 2005; Dole et al. 2008; Korporaal et al. 2011) and
can be attributed to a reduction in the LCAT activity (El Bouhassani et al. 2011). As
judged by the unchanged plasma apoA-I levels in total body SR-BI knockout mice,
only the size and cholesterol content but not the absolute number of HDL particles
is increased in response to SR-BI deficiency (Rigotti et al. 1997). The enlarged
HDL particles observed in plasma of SR-BI knockout mice are highly enriched in
apoE. In contrast, apoA-II cannot be detected in the HDL fraction of SR-BI-
deficient mice, which suggests a generally altered apolipoprotein composition
(Rigotti et al. 1997). In line with the notion that SR-BI facilitates HDL-mediated
reverse cholesterol transport, the recovery of radiolabeled cholesterol in feces upon
injection of either peritoneal or J774 macrophages is lower in SR-BI knockout mice
as compared to their wild-type littermate controls, despite an increased appearance
of radioactivity in the plasma (HDL) compartment (Zhang et al. 2005a; Zhao
et al. 2011).
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SR-BI knockout mice also display a significant increase in non-HDL-cholesterol
levels (Rigotti et al. 1997; Van Eck et al. 2003, 2008). Hepatic VLDL secretion and
LPL-mediated lipolysis rates are not affected by SR-BI deficiency (Van Eck
et al. 2008). SR-BI has been shown to be directly involved in the selective uptake
of cholesterol esters from LDL and VLDL particles by hepatocytes (Rhainds
et al. 2003; Van Eck et al. 2008). It can therefore be anticipated that the increase
in the level of cholesterol associated with apoB-containing lipoproteins in SR-BI
knockout mice is directly resulting from a diminished clearance by the liver.
Two variations in the SR-BI gene have been linked to changes in fertility in
humans (Yates et al. 2011). Without dietary addition of the lipid-lowering drug
probucol, SR-BI knockout female mice are virtually sterile, with a ~90 % reduction
in fertility and pup yield as compared to wild-type controls (Miettinen et al. 2001).
The development of SR-BI knockout embryos is impaired in ex vivo cultures
(Trigatti et al. 1999). Furthermore, developmental abnormalities are also observed
in SR-BI knockout embryos in vivo (Santander et al. 2013). Although steroidogenic
tissues, i.e., ovaries and adrenals, from SR-BI knockout mice exhibit an apparent
decrease in their cholesterol ester stores (Rigotti et al. 1997; Trigatti et al. 1999),
levels of the steroid hormone progesterone as well as the number of oocytes and
cyclic activity are unaffected by murine SR-BI deficiency (Trigatti et al. 1999). The
lack of pups generated from SR-BI-deficient breedings can thus rather be attributed
to embryonic defects than to infertility of the mothers.
Human carriers of functional mutations in the SR-BI gene exhibit a decrease in
their adrenal steroidogenesis rate (Vergeer et al. 2011). Similarly, depletion of
adrenocortical cholesterol stores due to SR-BI deficiency translates into a signifi-
cant change of the adrenal steroid function in mice. Basal glucocorticoid levels in
plasma are similar between SR-BI knockout and wild-type mice (Hoekstra
et al. 2008). However, total body SR-BI deficiency is associated with primary
glucocorticoid insufficiency. Total body SR-BI knockout mice display increased
plasma ACTH levels and are unable to increase their adrenal glucocorticoid output
in response to established steroidogenic triggers (Cai et al. 2008; Hoekstra
et al. 2008, 2009). It appears that SR-BI-mediated uptake of HDL-cholesterol esters
by the adrenals is necessary for a proper steroid output, since the glucocorticoid
function is also impaired in adrenocortical cell-specific SR-BI knockout mice
(Hoekstra et al. 2013b). In further support, hepatocyte-specific SR-BI deficiency
does not lower adrenal cholesterol levels or impair the adrenal corticosterone
response to fasting (El Bouhassani et al. 2011).
No atherosclerotic lesion development is normally observed in normolipidemic
wild-type mice upon feeding a regular chow diet or a high cholesterol high fat
Western-type diet that does not contain cholic acid. No atherosclerotic plaques can
also be detected in the aortic root of chow-fed SR-BI knockout mice (Zhao
et al. 2011). In contrast, SR-BI knockout mice with increased HDL-cholesterol
levels do readily develop macrophage-rich fatty streak lesions after 20 weeks of
Western-type diet feeding (Van Eck et al. 2003). SR-BI knockout mice display an
increase in non-HDL cholesterol under these feeding conditions (Van Eck
et al. 2003). However, the measured levels of apoB-containing lipoproteins upon
Mouse Models of Disturbed HDL Metabolism 317
Western-type diet feeding are still considered to be too low to stimulate the
formation of atherosclerotic lesions. This suggests that other SR-BI-related
mechanisms may underlie the susceptibility for Western-type diet-induced athero-
genesis in SR-BI knockout mice. Follow-up studies in liver-specific hypomorphic
SR-BI knockout mice have indicated that the SR-BI-mediated atheroprotection
originates from both hepatic and peripheral cell sources (Huby et al. 2006; El
Bouhassani et al. 2011). A similarly increased susceptibility for atherosclerosis
upon ablation of total body SR-BI function has been noted in response to feeding a
cholic acid-containing atherogenic diet (Zhang et al. 2005b). In accordance with a
role for SR-BI in the clearance of apoB-containing lipoproteins, high fat diet-fed
SR-BIatt x LDLr knockout mice exhibit higher plasma LDL-cholesterol levels and
an increased extent of atherosclerosis as compared to LDLr knockout controls
(Huszar et al. 2000). In contrast, total body SR-BI deficiency in high fat diet-fed
LDLr knockout mice is associated with lower VLDL/LDL levels, but a similarly
enhanced formation of atherosclerotic lesions in the context of a higher plasma
HDL-cholesterol concentration (Covey et al. 2003). Loss of total body SR-BI
function in chow diet-fed hyperlipidemic apoE knockout mice is associated with
severe cardiac dysfunction, i.e., a reduced contractility and ejection fraction, and
occlusion of the coronary arteries, leading to premature death of these animals at
the age of 6–8 weeks (Braun et al. 2002). Occlusive coronary atherosclerosis and an
increased extent of atherosclerosis in the aortic root are also seen upon genetic
deletion of SR-BI in atherogenic diet-fed hypomorphic APOER61h/h mice (Zhang
et al. 2005b). An optimal total body SR-BI function thus protects against athero-
sclerosis and myocardial infarction, through (1) its role in hepatic uptake of
lipoprotein-derived cholesterol and (2) via its action extrahepatic/peripheral cells.
In rodents, high expression of SR-BI is not only found in liver and steroidogenic
tissues (Acton et al. 1996), but also in tissue macrophages such as liver Kupffer
cells (Fluiter et al. 1998; Malerød et al. 2002; Hoekstra et al. 2003), which suggests
that SR-BI can also contribute to macrophage cholesterol homeostasis locally
within atherosclerotic lesions. Studies using isolated SR-BI-deficient peritoneal
macrophages have suggested that SR-BI may facilitate cholesterol efflux to mature
HDL (Van Eck et al. 2004). However, macrophage SR-BI does not contribute to
reverse cholesterol in vivo, based upon radiolabeled cholesterol recovery studies
(Wang et al. 2007). Bone marrow transplantation studies have been executed to
delineate the specific role of macrophage SR-BI in the protection against athero-
sclerosis. Transplantation of SR-BI knockout bone marrow into LDLr knockout
mice stimulates atherogenesis without altering plasma lipoprotein cholesterol levels
(Covey et al. 2003; Van Eck et al. 2004). Inactivation of macrophage SR-BI also
promotes the development of atherosclerotic plaques in the context of unchanged
lipid levels in apoE knockout mice (Zhang et al. 2003). In addition, the cardiac
hypertrophy and dysfunction and coronary atherosclerosis development are
attenuated upon restoration of macrophage SR-BI function in apoE x SR-BI double
knockout mice (Pei et al. 2013). Strikingly, in marked contrast to the findings from
hyperlipidemic mice, disruption of macrophage SR-BI expression in
normolipidemic C57BL/6 mice results in a lower susceptibility for atherosclerosis
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upon feeding a cholic acid-containing atherogenic diet (Van Eck et al. 2004).
C57Bl/6 mice fed a cholic acid-containing atherogenic diet develop small initial
atherosclerotic lesions, suggesting that SR-BI might be pro-atherogenic in this early
stage of lesion development. In line, early atherosclerotic lesion development in
LDLr knockout mice challenged with Western diet for only 4 weeks was reduced
upon disruption of SR-BI in bone marrow-derived cells. These combined studies
suggest that macrophage SR-BI plays a dual role in foam cell formation and
atherogenesis, which may be dependent on the stage of atherosclerotic lesion
development.
8 Insights from Intercrossing of the Different Knockout Mice
Since some of the aforementioned proteins execute both different and overlapping
functions in the formation of HDL particles and reverse cholesterol transport, it is
conceivable that they may act synergistically and/or be able to compensate for each
other’s loss. To uncover interactions between specific gene products several double
knockout mice have been generated via intercrossing. In line with a differential role
in HDL formation and maturation, studies in mice lacking both ABCA1 and LCAT
function have suggested that these two proteins act synergistically. Hepatic choles-
terol accumulation is higher, while peripheral tissue cholesterol levels are lower in
ABCA1 x LCAT double knockout mice as compared to the respective single
knockout mice, despite an even higher HDL fractional catabolic rate (Hossain
et al. 2009). In parallel, probucol-induced inhibition of ABCA1 function further
lowers adrenal cholesterol levels in LCAT knockout mice (Tomimoto et al. 2001).
The ABCA1-mediated formation of HDL particles rather than the SR-BI-mediated
cholesterol uptake is the driving force in the maintenance of plasma
HDL-cholesterol levels, as HDL-cholesterol levels in ABCA1 x SR-BI double
knockout mice are still close to zero (Zhao et al. 2011). In contrast, ablation of
either ABCA1 or SR-BI function is equally effective in lowering the rate of in vivo
macrophage reverse cholesterol transport (Zhao et al. 2011). The mild pulmonary
lipidosis phenotype of ABCA1 knockout mice is severely aggravated in response to
deletion of SR-BI function, which suggests that macrophage SR-BI is able to
partially compensate for the inability of ABCA1 to mediate cholesterol efflux
(Zhao et al. 2011). In accordance, specific disruption of both ABCA1 and SR-BI
in bone marrow-derived cells of LDLr knockout mice leads to an added increase in
(tissue) macrophage foam cell formation and Western-type diet-induced athero-
sclerotic lesion development, in the context of lower plasma cholesterol levels,
when compared to both single knockout bone marrow transplanted controls (Zhao
et al. 2010). Importantly, ABCG1 seems to play a more essential role in the
compensatory response to macrophage ABCA1 deficiency. Mass efflux of choles-
terol from macrophages to both apoA-I and HDL is virtually absent as a result of
combined deletion of ABCA1 and ABCG1 (Out et al. 2008a). Already on a chow
diet ABCA1 x ABCG1 double knockout mice display marked accumulation of
cholesterol not only within the lungs (reminiscent of the ABCG1 knockout
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phenotype), but also in primary and secondary lymphoid organs and macrophage-
rich areas of the liver and intestine (Out et al. 2008a). Furthermore, the double
deletion exacerbates high fat diet-induced lymphocytosis (Yvan-Charvet
et al. 2008). Transplantation of bone marrow from ABCA1 x ABCG1 double
knockout mice into LDLr knockout mice is associated with resistance to
Western-type diet-induced hyperlipidemia (Out et al. 2008b). However, despite
the rather low plasma cholesterol levels under Western-type diet feeding
conditions, ABCA1 x ABCG1 double knockout bone marrow recipient mice
show significant plaque development and exhibit distinct lipid deposition in
macrophage-rich tissues (Out et al. 2008b). This highlights the necessity for these
transporters to overcome macrophage foam cell formation and atherosclerosis.
Subsequent bone marrow transplantations into mice with a heterozygous mutation
in the LDLr gene (LDLr+/) have validated the increased susceptibility to macro-
phage cholesterol accumulation and atherosclerosis in response to the combined
deficiency in macrophage ABCA1 and ABCG1 upon challenge with a cholate-
containing diet (Yvan-Charvet et al. 2007). Furthermore, these studies have
suggested that the combined deficiency of these ABC transporters in bone marrow
also impacts on the inflammatory function and susceptibility to apoptosis of
macrophages as well as the cyclic activity of hematopoietic stem cells (Yvan-
Charvet et al. 2008, 2010a).
9 Conclusions from the Gene Knockout Mouse Studies
Generation of the different knockout mice has significantly contributed to our
understanding of HDL’s metabolism and function (see Fig. 1 for overview). It
has become clear that the initial generation and maturation of HDL particles as well
as the selective uptake of its cholesterol by the liver are important parameters in the
life cycle of HDL. In line with the proposed atheroprotective function of HDL,
murine HDL deficiency consistently predisposes to the development of atheroscle-
rotic lesions. However, it should be noted that many of the detrimental atheroscle-
rosis effects observed in response to HDL deficiency in mice cannot be solely
attributed to the low HDL levels per se, as the low HDL levels are in most models
paralleled by changes in non-HDL-cholesterol levels. Although in the human
setting, low HDL-cholesterol levels predict increased cardiovascular risk at all
plasma non-HDL-cholesterol levels, the mouse data firmly establish that HDL
and non-HDL metabolism are heavily intertwined.
Based upon the bone marrow transplantation studies in hyperlipidemic mice, it
appears that the cholesterol efflux function of HDL is of critical importance to
overcome foam cell formation and the development of atherosclerotic lesions. We
therefore consider it therapeutically highly relevant to increase the expression
and/or activity of the cholesterol transporters in macrophages. In this regard, special
focus should be given to macrophage ABCA1 as this transporter seems to be the
driving force in the atheroprotection.
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Although HDL is predominantly studied for its atheroprotective action, it can be
appreciated that the mouse data suggest an essential role for HDL as cholesterol
donor for steroidogenic tissues, including the adrenals and ovaries. Furthermore, it
appears that a relevant interaction exists between HDL-mediated cellular choles-
terol efflux and the susceptibility to inflammation, which (1) provides strong
support for the novel concept that inflammation and metabolism are intertwining
biological processes and (2) identifies the efflux function of HDL as putative
therapeutic target also in other inflammatory diseases than atherosclerosis, includ-
ing sepsis and diabetes.
10 Cholesterol Ester Transfer Protein Transgenic Mice
Despite the fact that a great deal regarding the function of specific gene products
has been learned from the murine transgenic studies it should be acknowledged that
one should take care when directly translating the data to the human situation.
Humans, in contrast to mice, naturally express cholesterol ester transfer protein
(CETP) that plays a major role in total body cholesterol homeostasis as it is able to
exchange cholesterol esters and triglycerides between cholesterol-rich HDL and
ApoA-I knockout
- Plasma HDL-C ↓↓↓
- Adrenal cholesterol ↓;  adrenal funcon ↓
- Ovarian cholesterol ↓;  female ferlity =
- Atherosclerosis  ↑ (LDLr  KO on chow); plasma VLDL-C ↑ 
- Atherosclerosis  =  (LDLr KO on Western diet); plasma VLDL-C ↓
- Development of skin lesions containing lipid-filled macrophages
- Cholesterol in B and T cells of lymph nodes ↑
ABCG1 knockout
- Plasma HDL-C =
- Adrenal funcon ?
- Female ferlity =
- Pulmonary lipidosis
- Inial atherosclerosis↑
- Advanced atherosclerosis ↓
- Similar effects in general KO’s
and bone marrow deleon
ABCA1 knockout
- Plasma HDL-C ↓↓↓
- Adrenal cortex cholesterol esters  ↑
- Female ferlity  ↓;  steroid hormones ↓ ;  placenta malformaons
- Atherosclerosis =;  plasma VLDL-C  ↓
- Bone marrow deleon: atherosclerosis ↑,  blood leukocytes  ↑
- Macrophage/Neutrophil deleon: atherosclerosis  =
- Liver deleon:  atherosclerosis  =  (LDLr KO), atherosclerosis  ↑ (apoE KO)
LCAT knockout
- Plasma HDL-C ↓↓↓ 
- Adrenal cholesterol ↓;  adrenal funcon ↓ 
- Female ferlity  =
- Plasma TG ↑ and VLDL-C ↑
- Atherosclerosis  =↓↑ (depending on the
genec background, diet and effects on
plasma VLDL-C)
PLTP knockout
- Plasma HDL-C ↓↓
- Adrenal funcon ?
- Female ferlity  =
- PL and FC-rich lamellar parcles  ↑ (saturated fat-rich diet)
- Atherosclerosis ↓=  (depending on the genec background, diet
and effects on plasma VLDL-C)
- Bone marrow deleon:  atherosclerosis ↓↑;  plasma VLDL-C ↓
SR-BI knockout
- Plasma HDL-C ↑↑
- Plasma VLDL-C ↑
- Adrenal cholesterol ↓;  adrenal funcon ↓ 
- Female ferlity ↓; abnormal embryo development
- Atherosclerosis  ↑
- Severe cardiac dysfuncon and premature death in apoE KO’s
- Bone marrow deleon: inial lesions ↓,  advanced lesions  ↑
Fig. 1 Major phenotypic changes in mouse models of disturbed HDLmetabolism. An overview is
given of the effects of deletion of apolipoprotein A-I (apoA-I), the ABC transporters A1 (ABCA1)
and G1 (ABCG1), lecithin-cholesterol acyltransferase (LCAT), phospholipid transfer protein
(PLTP), and scavenger receptor BI (SR-BI) for HDL’s metabolism, adrenal function, female
fertility, and its protection against atherosclerosis in mice. ¼ no effect, # decreased, " increased,
C cholesterol, PL phospholipids, TG triglycerides, KO knockout
Mouse Models of Disturbed HDL Metabolism 321
triglyceride-rich VLDL/LDL particles. In agreement with a major role for CETP in
the modulation of plasma HDL-cholesterol levels, genetic CETP deficiency is
associated with marked hyperalphalipoproteinemia, i.e., relatively high
HDL-cholesterol levels, in humans (Rhyne et al. 2006; Calabresi et al. 2009). To
overcome this apparent discrepancy between mice and humans in studies dealing
with lipoprotein metabolism, the group of Alan Tall generated a mouse line
(NFR-CETP) expressing the human CETP transgene under the control of its natural
flanking regulatory elements (Jiang et al. 1992). Initial cloning studies (Drayna
et al. 1987) indicated that CETP is primarily derived from liver, small intestine,
adrenals, and spleen in humans. In accordance, relatively high CETP mRNA levels
are found in liver, spleen, and small intestine of human NFR-CETP transgenic mice
(Jiang et al. 1992). Of note, the Tall group also generated a transgenic mouse line
expressing CETP under control of the methallothionein-I (MT) gene (Jiang
et al. 1992). In MT-CETP transgenic mice, additional high expression of CETP
can be detected in kidney, adipose tissue, and heart. Importantly, the expression of
CETP in MT-CETP transgenic is not responsive to high cholesterol/high fat diet
feeding, which contrasts the findings from NFR-CETP transgenic mice (Jiang
et al. 1992) and species naturally expressing CETP, i.e., monkeys and rabbits
(Quinet et al. 1990; Pape et al. 1991). Given the apparent limitations of
MT-CETP transgenic mice, in our opinion the NFR-CETP mouse model should
preferentially be used in studies aimed at translation to the human situation.
Therefore, findings from NFR-CETP transgenic mice will only be reviewed in
the next part.
Chow-fed CETP transgenic mice exhibit a ~15 % lower plasma total cholesterol
level as compared to non-transgenic controls (Masucci-Magoulas et al. 1996;
Harada et al. 2007). In contrast, plasma triglyceride levels are marginally increased
in CETP carrying mice upon feeding chow diet (Zhou et al. 2006; Harada
et al. 2007) due to a slightly diminished clearance of triglyceride-rich lipoproteins
(Salerno et al. 2009). The decrease in total cholesterol in CETP transgenic mice can
primarily be attributed to lower levels of cholesterol associated with HDL (Zhou
et al. 2006). The fractional catabolic rate and uptake of HDL-cholesterol esters by
the liver, adrenals, and adipose tissue are increased in CETP transgenic mice, which
is associated with an increase in hepatic cholesterol stores (Harada et al. 2007). As a
result, CETP transgenic mice exhibit a rise in the plasma total cholesterol over
HDL-cholesterol ratio (Clee et al. 1997). The decrease in HDL-cholesterol levels
cannot be attributed to a change in LCAT levels. Intriguingly, the presence of CETP
actually enhances the saturation level of the LCAT-mediated cholesterol esterifica-
tion reaction (Oliveira et al. 1997). This suggests that CETP generates particles that
can serve as optimal substrates for LCAT.
Despite the marked increase in plasma HDL-cholesterol levels associated with
complete CETP deficiency, variable effects on atherosclerosis and cardiovascular
disease risk in response to genetic variations in the CETP gene have been noted in
the human setting (Zhong et al. 1996; Agerholm-Larsen et al. 2000; Curb
et al. 2004; Zheng et al. 2004; Rhyne et al. 2006). To provide clear insight into
the contribution of CETP to atherosclerotic lesion development, NFR-CETP
322 M. Hoekstra and M. Van Eck
transgenic mice have been bred onto several different atherosclerosis-susceptible
mouse backgrounds. CETP expression in heterozygous LDLr knockout mice on a
cholic acid-containing atherogenic diet does not significantly alter plasma HDL- or
non-HDL-cholesterol levels. As a result, CETP does not impact on the susceptibil-
ity to atherosclerosis in heterozygous LDLr knockout mice (Casquero et al. 2006).
In contrast, CETP executes a clear pro-atherogenic effect in hyperlipidemic apoE
knockout and homozygous LDLr knockout mice (Plump et al. 1999). CETP lowers
plasma HDL-cholesterol levels in chow-fed apoE knockout mice without changing
levels of cholesterol associated with non-HDL particles. In addition, triglyceride
levels are increased in the plasma of CETP-expressing apoE knockout mice. CETP
expression does not alter plasma HDL-cholesterol levels in LDLr knockout mice
challenged with a Western-type high fat/high cholesterol diet. However, levels of
cholesterol associated with pro-atherogenic apoB-containing lipoproteins are mark-
edly increased in response to CETP expression in LDLr knockout mice. It thus
appears that the increased atherosclerotic lesion development in apoE and LDLr
knockout mice upon CETP expression can be directly related to an increased
atherogenic index of the plasma compartment (higher non-HDL/HDL ratio) in
both types of hyperlipidemic mice. In further support, a marked increase in plasma
non-HDL-cholesterol levels and atherosclerotic lesion development—in the con-
text of a marginal but significant decrease in HDL-cholesterol levels—was noted
when we expressed CETP only in bone marrow-derived cells of LDLr knockout
mice through bone marrow transplantation (Van Eck et al. 2007).
A clear drawback of using LDLr and apoE knockout mice for studies regarding
lipoprotein metabolism is that they do not exhibit a normal clearance of apoE-
containing VLDL/LDL particles. To determine the effect of CETP expression on
lipoprotein metabolism and atherosclerosis development in a more relevant
“humanized” setting, CETP transgenic mice have also been crossbred with
hyperlipidemic apoE*3-Leiden mice. Transgenic apoE*3-Leiden mice express a
mutation of the human apoE3 gene resulting in a slightly attenuated clearance of
apoB-containing particles via the LDLr pathway (van den Maagdenberg
et al. 1993). As a result, these mice (1) exhibit a lipoprotein cholesterol distribution
profile that is highly similar to that found in humans (van den Maagdenberg
et al. 1993; van Vlijmen et al. 1994), (2) are susceptible to atherosclerotic lesion
development when fed a high fat/high cholesterol Western-type diet devoid of
cholic acid (van Vlijmen et al. 1994), and (3) show a similar plasma lipid response
as human subjects to several drug interventions (van der Hoogt et al. 2007; de Haan
et al. 2008a; van der Hoorn et al. 2008). ApoE*3-Leiden x CETP double transgenic
mice as compared to apoE*3-Leiden controls display a significant increase in
plasma total cholesterol levels on both chow and under Western-type diet feeding
conditions (Westerterp et al. 2006). Under these dietary conditions, VLDL-
cholesterol levels are increased twofold, while HDL-cholesterol levels as well as
plasma apoA-I levels are 25 % lower in apoE*3-Leiden x CETP transgenic mice
(Westerterp et al. 2006). Importantly, apoE*3-Leiden x CETP transgenic mice
exhibit increased atherosclerotic lesion development in the aortic root as compared
Mouse Models of Disturbed HDL Metabolism 323
to apoE*3-Leiden controls (Westerterp et al. 2006). Based upon these combined
findings, CETP should clearly be considered a pro-atherogenic protein moiety.
In the last decade, therapeutic strategies have focused on inhibiting CETP
activity through the use of a variety of CETP-binding drugs, i.e., torcetrapib, that
form an inactive complex between CETP and HDL. Studies in apoE*3-Leiden x
CETP transgenic mice have suggested that the HDL increase associated with
torcetrapib treatment does not add to the beneficial impact of statin-induced lipid-
lowering on atherosclerosis (de Haan et al. 2008b). Importantly, the ILLUMINATE
and dal-OUTCOMES trials also failed to show the beneficial effect of CETP
inhibition in statin-treated cardiovascular disease patients (Barter et al. 2007;
Schwartz et al. 2012). Combination treatment with torcetrapib and statin increases
the macrophage content in atherosclerotic lesions in apoE*3-Leiden x CETP
transgenic mice as compared to statin treatment alone (de Haan et al. 2008b). A
higher lesional macrophage content is generally associated with an increased
susceptibility for plaque rupture and future cardiovascular events in the human
situation (Redgrave et al. 2006; Marnane et al. 2014). An effect of CETP inhibition
on plaque stability may therefore possibly have contributed to the negative outcome
of the aforementioned torcetrapib and dalcetrapib trials.
Concluding Remark
The use of dedicated knockout and transgenic mouse models has significantly
increased our knowledge on the different functions and metabolism of HDL.
However, as evident from the recent failures of the CETP inhibition-based
clinical trials, more research is clearly needed to better understand how we can
use HDL as target in the treatment of patients at risk of cardiovascular disease
and other immune-related disorders. The generation of “humanized” mouse
models such as the apoE*3-Leiden x CETP transgenic mice will hopefully aid
in the development of novel therapeutic approaches beneficially impacting on
HDL functionality and atherosclerosis outcome also in the clinical setting.
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Büchler C, Porsch-Ozcürümez M, Kaminski WE, Hahmann HW, Oette K, Rothe G,
Aslanidis C, Lackner KJ, Schmitz G (1999) The gene encoding ATP-binding cassette trans-
porter 1 is mutated in Tangier disease. Nat Genet 22:347–351
Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M,
Krieger M (2002) Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic
coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and
premature death in apolipoprotein E-deficient mice. Circ Res 90:270–276
Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C,
Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ,
Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B,
Pimstone S, Kastelein JJ, Genest J Jr, Hayden MR (1999) Mutations in ABC1 in Tangier
disease and familial high-density lipoprotein deficiency. Nat Genet 22:336–345
Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B,
Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR (2006) Intestinal ABCA1 directly
contributes to HDL biogenesis in vivo. J Clin Invest 116:1052–1062
Mouse Models of Disturbed HDL Metabolism 325
Brunham LR, Singaraja RR, Duong M, Timmins JM, Fievet C, Bissada N, Kang MH, Samra A,
Fruchart JC, McManus B, Staels B, Parks JS, Hayden MR (2009) Tissue-specific roles of
ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol 29:548–554
Brunham LR, Tietjen I, Bochem AE, Singaraja RR, Franchini PL, Radomski C, Mattice M,
Legendre A, Hovingh GK, Kastelein JJ, Hayden MR (2011) Novel mutations in scavenger
receptor BI associated with high HDL cholesterol in humans. Clin Genet 79:575–581
Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR (2008) SR-BI protects against
endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J
Clin Invest 118:364–375
Calabresi L, Nilsson P, Pinotti E, Gomaraschi M, Favari E, Adorni MP, Bernini F, Sirtori CR,
Calandra S, Franceschini G, Tarugi P (2009) A novel homozygous mutation in CETP gene as a
cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 205:506–511
Calpe-Berdiel L, Rotllan N, Palomer X, Ribas V, Blanco-Vaca F, Escolà-Gil JC (2005) Direct
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JW, Van Berkel TJ, Kuiper J, Van Eck M (2011) Deletion of the high-density lipoprotein
receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly
affects platelet function by elevation of plasma free cholesterol. Arterioscler Thromb Vasc Biol
31:34–42
Kunnen S, Van Eck M (2012) Lecithin:cholesterol acyltransferase: old friend or foe in atheroscle-
rosis? J Lipid Res 53:1783–1799
Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P
(2003) The phospholipid transfer protein gene is a liver X receptor target expressed by
macrophages in atherosclerotic lesions. Mol Cell Biol 23:2182–2191
Lambert G, Sakai N, Vaisman BL, Neufeld EB, Marteyn B, Chan CC, Paigen B, Lupia E,
Thomas A, Striker LJ, Blanchette-Mackie J, Csako G, Brady JN, Costello R, Striker GE,
Remaley AT, Brewer HB Jr, Santamarina-Fojo S (2001) Analysis of glomerulosclerosis and
atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem
276:15090–15098
Lammers B, Zhao Y, Hoekstra M, Hildebrand RB, Ye D, Meurs I, Van Berkel TJ, Van Eck M
(2011) Augmented atherogenesis in LDL receptor deficient mice lacking both macrophage
ABCA1 and ApoE. PLoS ONE 6:e26095
Lammers B, Zhao Y, Foks AC, Hildebrand RB, Kuiper J, Van Berkel TJ, Van Eck M (2012)
Leukocyte ABCA1 remains atheroprotective in splenectomized LDL receptor knockout mice.
PLoS ONE 7:e48080
Lawn RM, Wade DP, Couse TL, Wilcox JN (2001) Localization of human ATP-binding cassette
transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol
21:378–385
Lee RG, Kelley KL, Sawyer JK, Farese RV Jr, Parks JS, Rudel LL (2004) Plasma cholesteryl
esters provided by lecithin: cholesterol acyltransferase and acyl-coenzyme a:cholesterol
acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95:998–1004
Lee EY, Klementowicz PT, Hegele RA, Asztalos BF, Schaefer EJ (2013) HDL deficiency due to a
new insertion mutation (ApoA-INashua) and review of the literature. J Clin Lipidol 7:169–173
Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M (2006) Absence of
endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol
from macrophage foam cells. J Lipid Res 47:1725–1732
Leren TP, Bakken KS, Daum U, Ose L, Berg K, Assmann G, von Eckardstein A (1997)
Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high
density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of
HDL-subclass LpA-I. J Lipid Res 38:121–131
Mouse Models of Disturbed HDL Metabolism 329
Li H, Reddick RL, Maeda N (1993) Lack of apoA-I is not associated with increased susceptibility
to atherosclerosis in mice. Arterioscler Thromb 13:1814–1821
Li L, Naples M, Song H, Yuan R, Ye F, Shafi S, Adeli K, Ng DS (2007) LCAT-null mice develop
improved hepatic insulin sensitivity through altered regulation of transcription factors and
suppressors of cytokine signaling. Am J Physiol Endocrinol Metab 293:E587–E594
Li Z, Wang Y, van der Sluis RJ, van der Hoorn JW, Princen HM, Van Eck M, Van Berkel TJ,
Rensen PC, Hoekstra M (2012) Niacin reduces plasma CETP levels by diminishing liver
macrophage content in CETP transgenic mice. Biochem Pharmacol 84:821–829
Liu R, Iqbal J, Yeang C, Wang DQ, Hussain MM, Jiang XC (2007) Phospholipid transfer protein-
deficient mice absorb less cholesterol. Arterioscler Thromb Vasc Biol 27:2014–2021
Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C (1996) The mechanism of human
plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein
particles: evidence for particle fusion. Biochem J 313:275–282
Malerød L, Juvet K, Gjøen T, Berg T (2002) The expression of scavenger receptor class B, type I
(SR-BI) and caveolin-1 in parenchymal and nonparenchymal liver cells. Cell Tissue Res
307:173–180
Marnane M, Prendeville S, McDonnell C, Noone I, Barry M, Crowe M, Mulligan N, Kelly PJ
(2014) Plaque inflammation and unstable morphology are associated with early stroke recur-
rence in symptomatic carotid stenosis. Stroke 45:801–806
Masucci-Magoulas L, Plump A, Jiang XC, Walsh A, Breslow JL, Tall AR (1996) Profound
induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein
E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals
changes in plasma cholesterol levels. J Clin Invest 97:154–161
Mathis D, Shoelson SE (2011) Immunometabolism: an emerging frontier. Nat Rev Immunol 11:81
Matsunaga A, Sasaki J, Han H, Huang W, Kugi M, Koga T, Ichiki S, Shinkawa T, Arakawa K
(1999) Compound heterozygosity for an apolipoprotein A1 gene promoter mutation and a
structural nonsense mutation with apolipoprotein A1 deficiency. Arterioscler Thromb Vasc
Biol 19:348–355
Meurs I, Hoekstra M, van Wanrooij EJ, Hildebrand RB, Kuiper J, Kuipers F, Hardeman MR, Van
Berkel TJ, Van Eck M (2005) HDL cholesterol levels are an important factor for determining
the lifespan of erythrocytes. Exp Hematol 33:1309–1319
Meurs I, Lammers B, Zhao Y, Out R, Hildebrand RB, Hoekstra M, Van Berkel TJ, Van Eck M
(2012) The effect of ABCG1 deficiency on atherosclerotic lesion development in LDL receptor
knockout mice depends on the stage of atherogenesis. Atherosclerosis 221:41–47
Miettinen HE, Rayburn H, Krieger M (2001) Abnormal lipoprotein metabolism and reversible
female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest 108:1717–1722
Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A,
Collins R, Baigent C, Cholesterol Treatment Trialists’ (CTT) Collaborators (2012) The effects
of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-
analysis of individual data from 27 randomised trials. Lancet 380:581–590
Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, Rader DJ (2003)
Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking
the LDL receptor. Arterioscler Thromb Vasc Biol 23:1914–1920
Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM (1997) Disruption of the
murine lecithin: cholesterol acyltransferase gene causes impairment of adrenal lipid delivery
and up-regulation of scavenger receptor class B type I. J Biol Chem 272:15777–15781
Ng DS, Maguire GF, Wylie J, Ravandi A, XuanW, Ahmed Z, Eskandarian M, Kuksis A, Connelly
PW (2002) Oxidative stress is markedly elevated in lecithin: cholesterol acyltransferase-
deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in
association with a reduction in atherosclerosis. J Biol Chem 277:11715–11720
Ng DS, Xie C, Maguire GF, Zhu X, Ugwu F, Lam E, Connelly PW (2004) Hypertriglyceridemia in
lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of
330 M. Hoekstra and M. Van Eck
triglycerides, increased lipogenesis, and improved glucose tolerance. J Biol Chem
279:7636–7642
O’Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, Wight TN,
Chait A, Albers JJ (2003) Cell-associated and extracellular phospholipid transfer protein in
human coronary atherosclerosis. Circulation 108:270–274
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Abstract
Reduced plasma levels of HDL-C are associated with an increased risk of CAD
and myocardial infarction, as shown in various prospective population studies.
However, recent clinical trials on lipid-modifying drugs that increase plasma
levels of HDL-C have not shown significant clinical benefit. Notably, in some
recent clinical studies, there is no clear association of higher HDL-C levels with
a reduced risk of cardiovascular events observed in patients with existing CAD.
These observations have prompted researchers to shift from a cholesterol-centric
view of HDL towards assessing the function and composition of HDL particles.
Of importance, experimental and translational studies have further
demonstrated various potential antiatherogenic effects of HDL. HDL has been
proposed to promote macrophage reverse cholesterol transport and to protect
endothelial cell functions by prevention of oxidation of LDL and its adverse
endothelial effects. Furthermore, HDL from healthy subjects can directly stimu-
late endothelial cell production of nitric oxide and exert anti-inflammatory and
antiapoptotic effects. Of note, increasing evidence suggests that the vascular
effects of HDL can be highly heterogeneous and HDL may lose important anti-
atherosclerotic properties and turn dysfunctional in patients with chronic inflam-
matory disorders. A greater understanding of mechanisms of action of HDL and
its altered vascular effects is therefore critical within the context of
HDL-targeted therapies.
Keywords
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1 Introduction
It was shown in multiple large prospective studies of cardiovascular risk factors that
reduced plasma levels of HDL-cholesterol (HDL-C) are associated with an
increased risk of coronary artery disease (CAD) (Castelli et al. 1986; Cullen
et al. 1997; Di Angelantonio et al. 2009; Gordon et al. 1977; Sharrett et al. 2001).
Multiple biological functions of HDL have been identified, whereby HDL may
exert antiatherogenic effects (Annema and von Eckardstein 2013; Barter
et al. 2004; Mineo et al. 2006; Rader 2006; Riwanto and Landmesser 2013), e.g.,
HDL from healthy subjects has been shown to directly promote endothelial
antiapoptotic, anti-inflammatory, and antithrombotic effects (Mineo et al. 2006;
Nofer et al. 2004; Rye and Barter 2008; Tall et al. 2008; Yuhanna et al. 2001).
Accordingly, interventions to improve HDL-C levels and/or HDL function are
being intensely evaluated as a potential therapeutic strategy to reduce cardiovascu-
lar risk. However, increasing evidence suggests that the endothelial and vascular
effects of HDL are highly heterogeneous and vasoprotective properties of HDL are
impaired in patients with diabetes, CAD, or chronic kidney dysfunction (Besler
et al. 2011; Khera et al. 2011; Riwanto et al. 2013; Sorrentino et al. 2010).
Intriguingly, several recent clinical trials testing the effects of HDL-C-raising
therapies have failed to demonstrate cardiovascular risk reduction in patients with
CAD. The Investigation of Lipid Level Management to Understand its Impact in
Atherosclerotic Events (ILLUMINATE) trial testing the impact of the CETP
inhibitor torcetrapib on clinical outcome showed increased risk of mortality and
morbidity in patients at high risk for coronary events, despite a substantial increase
of HDL-C levels (Barter et al. 2007). Dalcetrapib, another CETP inhibitor, mod-
estly increased HDL-C levels, but the phase 3 trial dal-OUTCOMES study was
terminated before completion to a lack of efficacy (Schwartz et al. 2012). More
recently, the HPS2-THRIVE trial results showed that adding extended-release
niacin/laropiprant, another HDL-cholesterol-raising agent, to statins did not reduce
the risk of cardiovascular event (Haynes et al. 2013). Taken together, these
observations strongly suggest that plasma HDL-C levels per se are not an optimal
therapeutic target.
Of note, accumulating evidence suggests that the vascular effects of HDL can be
highly heterogeneous and may turn dysfunctional. HDL loses potential anti-
atherosclerotic properties in patients with chronic inflammatory disorders, such as
the antiphospholipid syndrome (Charakida et al. 2009), systemic lupus
erythematosus and rheumatoid arthritis (McMahon et al. 2006), scleroderma
(Weihrauch et al. 2007), metabolic syndrome (de Souza et al. 2008), diabetes
(Persegol et al. 2006; Sorrentino et al. 2010), and CAD (Ansell et al. 2003; Besler
et al. 2011; Riwanto et al. 2013). In a study of 189 patients with chronic kidney
disease on hemodialysis, an impaired anti-inflammatory capacity of HDL was
correlated with a poor clinical outcome (Kalantar-Zadeh et al. 2007). Furthermore,
HDL isolated from subjects with type 1 or type 2 diabetes mellitus or abdominal
obesity had reduced capacity to reverse the inhibition of aortic ring endothelium-
dependent relaxation by oxLDL as compared to HDL from healthy control subjects
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(Persegol et al. 2006, 2007). Importantly, the heterogeneity of the vascular effects
of HDL may be attributed to changes in the HDL-associated proteome and
lipidome, i.e., changes in the amount and type of proteins and lipids bound to the
HDL particle and also posttranslational modifications. In particular, HDL is known
to be susceptible to modification in vitro by a variety of oxidants, such as metal
ions, peroxyl and hydroxyl radicals, aldehydes, various myeloperoxidase (MPO)-
generated oxidants, lipoxygenase, phospholipase A2, elastase, nonenzymatic
glycation, and homocysteinylation (Ferretti et al. 2006). These oxidative
modifications may contribute to the generation of dysfunctional
proinflammatory HDL.
2 HDL and Reverse Cholesterol Transport
2.1 Mechanisms Under Physiological Conditions
One of the antiatherogenic effects of HDL has been attributed to its function in
macrophage reverse cholesterol transport (RCT), i.e., the removal of excess choles-
terol from lipid-laden macrophage foam cells in the atherosclerotic plaque and its
transport to the liver for excretion in the bile (Rader 2006). The first step of
macrophage RCT involves the hydrolysis of cytoplasmic cholesteryl ester into
free cholesterol followed by the efflux of the free cholesterol to mature HDL or
extracellular lipid-poor apoA-I. Macrophage cholesterol efflux is mediated by
active transport systems, which include the ATP-binding cassette transporters
ABCA1 and ABCG1 (Rader 2006; Tall et al. 2008). Studies in macrophages
from ABCA1-knockout or ABCA1-overexpressing mice have shown that
ABCA1 primarily mediates the cholesterol efflux to lipid-poor apoA-I (Bortnick
et al. 2000; Haghpassand et al. 2001). In contrast, ABCG1 largely mediates
cholesterol efflux from macrophages to mature HDL (Tall et al. 2008).
A study by Wang et al. quantitatively assessed the roles of SR-BI, ABCA1, and
ABCG1 in macrophage RCT in mice in vivo (Wang et al. 2007a). Using primary
macrophages lacking SR-BI, the authors demonstrated that SR-BI did not promote
macrophage RCT in vivo after intraperitoneal injection. In contrast, both ABCA1
and ABCG1 contributed to macrophage RCT in vivo. The study also demonstrated
that transplantation of bone marrow from ABCA1/ABCG1-deficient mice
accelerated atherosclerotic lesion formation in LDL receptor-deficient mice
(Wang et al. 2007a). Interestingly, Yvan-Charvet et al. also demonstrated that
SR-BI failed to stimulate net cholesterol efflux from HEK293 cells to plasma
HDL and inhibited ABCG1-mediated cholesterol efflux, which was at least in
part due to the increased uptake of HDL cholesteryl esters into these cells (Yvan-
Charvet et al. 2008).
HDL-associated cholesterol is subsequently esterified by LCAT which transfers
a fatty acyl residue from phospholipids to the 3-beta-hydroxy group of cholesterol.
The final steps of RCT involve the uptake of HDL-C by the liver and its excretion in
the bile. Cholesterol esters and free cholesterol in HDL can either be directly taken
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up by the liver via SR-BI or transferred to apoB containing lipoproteins in a process
mediated by CETP (Cuchel et al. 2009). In the latter pathway, cholesterol esters are
taken up by the liver via the LDL receptor and then hydrolyzed to free cholesterol
which can be excreted directly into the bile or following conversion to bile acid.
2.2 Alterations of the Cholesterol Efflux Capacity of HDL
in Cardiovascular Disease
A case-control study by Khera et al. showed that the cholesterol efflux capacity of
apoB-depleted serum was inversely related to carotid IMT in healthy volunteers
and to the likelihood of angiographic CAD, even after adjustment for HDL-C and
apoA-I levels (Khera et al. 2011). In a separate study, enhanced cholesterol efflux
activity from ABCA1-stimulated macrophages was associated with reduced risk of
prevalent CAD in unadjusted models in two case-control cohorts: an angiographic
cohort comprising stable subjects undergoing elective diagnostic coronary angiog-
raphy and an outpatient cohort (Li et al. 2013). However, the inverse risk relation-
ship remained significant after adjustment for traditional CAD risk factors only
within the outpatient cohort (Li et al. 2013). Surprisingly, higher cholesterol efflux
activity was associated with an increase in prospective 3-year risk of myocardial
infarction/stroke and major adverse cardiovascular events. The authors further
observed that the HDL fraction (1.063< d< 1.21) contained only a minority
(40 %) of [(14)C] cholesterol released, with the majority found within the
lipoprotein particle-depleted fraction, where 60 % was recovered after apoA-I
immunoprecipitation. This is in agreement with previous findings on plasmas from
patients with apoA-I deficiency, such as Tangier disease and LCAT deficiency,
whereby the cholesterol efflux capacity amounted to at least 40 and 20 % of total
and apoB-depleted plasmas from healthy controls, respectively (von Eckardstein
et al. 1995a). However, in these studies the considerable residual cholesterol efflux
capacity of HDL-free or HDL-poor plasma was explained by the abundance of
apoA-I-free HDL particles containing apoA-IV, apoA-II, or apoE rather than by
albumin (Huang et al. 1994, 1995; von Eckardstein et al. 1995a, b).
Importantly, impaired cholesterol efflux capacity of HDL has been associated
with structural changes of the HDL components. Two groups independently
demonstrated that oxidative modification of apoA-I, particularly by oxidation of
methionine, tyrosine, or tryptophan residues through the myeloperoxidase pathway,
dramatically reduced the ability of apoA-I to promote cholesterol efflux through the
ABCA1 pathway (Bergt et al. 2004; Huang et al. 2014; Shao et al. 2006, 2010).
Both groups also demonstrated that apoA-I in patients with cardiovascular disease
was oxidatively modified and defective in promoting cholesterol efflux from
macrophages via ABCA1 (Bergt et al. 2004; Shao et al. 2012; Zheng et al. 2004).
Of note, the cholesterol efflux capacity as determined by the assay protocol of
Khera et al. which is widely used after its prominent publications is potentially
confounded by several HDL-independent factors: the 4-h long incubation with cells
raises the possibility that serum components deregulate the activity of ABCA1 and
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ABCG1. For example, free fatty acids and cytokines are known to alter the
expression of ABCA1 and ABCG1 on both the transcriptional and posttranslational
level. The use of serum instead of plasma implies the activation of thrombin and
other proteases which are known to degrade prebeta-HDL (Eckardstein 2012).
3 Effects of HDL on LDL Oxidation
3.1 Mechanisms Under Physiological Conditions
The antioxidative properties of HDL were first reported by Bowry (Bowry
et al. 1992). It has been suggested that HDL limits the formation of oxidized
LDL (oxLDL) and oxidation of LDL has been proposed for decades to be a key
event in atherogenesis (Heinecke 1998; Witztum and Steinberg 1991). LDL
accumulates in the subendothelial space where it is oxidized by different pathways
such as lipoxygenase, myeloperoxidase, or NADPH oxidase pathways (Diaz
et al. 1997). OxLDL induces the expression of various proinflammatory cytokines,
chemokines, and adhesion molecules (Navab et al. 1996). In addition, it promotes
monocyte chemotaxis, their differentiation into macrophages, and the subsequent
oxLDL uptake that convert them into foam cells, a hallmark of atherosclerotic
plaques (Chisolm et al. 1999).
HDL is a major carrier of lipid oxidation products and specifically apoA-I, the
main protein constituent of HDL, binds to and removes lipid hydroperoxides of
LDL in vitro and in vivo (Navab et al. 2000b). In addition, apoA-I may directly
reduce cholesteryl ester hydroperoxides and phosphatidylcholine hydroperoxides
by oxidation of specific Met residues in the protein (Garner et al. 1998). Interest-
ingly, the resulting oxidized HDL is more rapidly and selectively removed by
hepatocytes than native HDL (Garner et al. 1998). Treatment of human artery
wall cells with apoA-I but not apoA-II, or by addition of native HDL, apoA-I
peptide mimetics, or paraoxonase, prevents the cells from oxidizing LDL in vitro
(Navab et al. 2000a). The antioxidative function of apoA-I was corroborated by the
finding that recombinant HDL containing only apoA-I and 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC) was as effective as native HDL in preventing LDL
oxidation. In addition, in vivo studies have demonstrated that apoA-I can act as an
antioxidative, anti-inflammatory, and anti-atherosclerotic agent (Nicholls
et al. 2005a, b; Paszty et al. 1994). This further underlines a key antioxidant role
for the HDL major protein apoA-I (Zerrad-Saadi et al. 2009).
Several other HDL-associated apolipoproteins have also been shown to contrib-
ute to its antioxidant effects. ApoE has been demonstrated to show isoform-
dependent antioxidant activity (Miyata and Smith 1996). ApoE2 stimulates endo-
thelial NO release and exerts anti-inflammatory effects (Sacre et al. 2003). In
contrast, apoE4 has been suggested to be proinflammatory (Ophir et al. 2005).
Another HDL-associated protein, apoA-IV, showed anti-atherosclerotic, anti-
inflammatory, and antioxidant actions in vivo (Ostos et al. 2001; Recalde
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et al. 2004; Vowinkel et al. 2004). In addition, apoJ, also called clusterin, has been
reported to block LDL oxidation by artery wall cells (Navab et al. 1997).
Furthermore, ApoA-II-enriched HDL isolated from transgenic human apoA-II
mice protected VLDL from oxidation more efficiently than control HDL (Boisfer
et al. 2002). In contrast, in other studies, dyslipidemic mice overexpressing human
apoA-II showed accelerated atherosclerosis and reduced antioxidative activity of
HDL, which may be attributed to the displacement of apoA-I and PON1 by apoA-II
in HDL particles (Ribas et al. 2004; Rotllan et al. 2005). Notably, in apparently
healthy subjects from the prospective EPIC-Norfolk (European Prospective Inves-
tigation into Cancer and Nutrition-Norfolk) cohort, apoA-II was found to be
associated with a decreased risk of future CAD in a nested case-control study
(Birjmohun et al. 2007).
Importantly, HDL carries antioxidant enzymes that have the capacity to prevent
lipid oxidation or degrade lipid hydroperoxides such as serum paraoxonase/
arylesterase 1 (PON1), lecithin/cholesterol acyltransferase (LCAT), and platelet-
activating factor acetylhydrolase (PAF-AH). Specifically PON1 has been suggested
to be an important regulator of the potential antiatherogenic capacity of HDL (Shih
et al. 1998; Tward et al. 2002). It is secreted from the liver and associates with HDL
in the plasma. Many studies revealed that PON1 degrades oxidized
proinflammatory lipids, measured as a reduction in lipid peroxides (Mackness
et al. 1991; Shih et al. 2000; Watson et al. 1995). Higher PON1 activity has been
reported to be associated with a lower incidence of major cardiovascular events in
human. Conversely, reduced activity of PON1 has been associated with pathologi-
cal conditions such as diabetes, chronic renal failure rheumatoid arthritis, and
various dementia (Soran et al. 2009).
LCAT is another HDL-associated enzyme with antioxidative properties. The
antioxidant role of LCAT is thought to be its capacity to hydrolyze oxidized acyl
chains from phosphatidylcholine-based oxidized phospholipids and oxidized free
fatty acids (Goyal et al. 1997; Subramanian et al. 1999). Genetics and biochemical
characterizations of HDLs from patients with low HDL disorders demonstrated that
HDL-LCAT activity was reduced in all LCAT mutation carriers as well as in
patients with HDL deficiency due to mutation in APOA1 or ABCA1 (Soran
et al. 2009; von Eckardstein et al. 1995a). In vivo study in mice deficient for
LDL receptor and leptin revealed that LCAT overexpression decreased
autoantibodies to oxLDL (Mertens et al. 2003). Besides LCAT and PON1,
PAF-AH, another HDL-associated enzyme, nowadays also known as lipoprotein-
associated phospholipase A2 (LpPLA2), is able to hydrolyze oxidized
phospholipids (Marathe et al. 2003; Noto et al. 2003). The local expression of
PAF-AH in arteries of non-hyperlipidemic rabbits reduced the accumulation of
oxidatively modified LDL without changing plasma levels of PAF-AH and reduced
the expression of endothelial cell adhesion molecules (Arakawa et al. 2005).
PAF-AH deficiency caused by a missense mutation in the gene has been indicated
to be an independent risk factor for CAD in Japanese men (McIntyre et al. 2009). In
contrast to this both activity and mass concentration of LpPLA2 in total serum has
been associated with increased rather than decreased cardiovascular risk
(Lp et al. 2010). However, recently HDL-associated LpPLA2 was found to be
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inversely related to risk of coronary events in stable CAD patients (Rallidis
et al. 2012). Hence, the lipoprotein distribution of LpPLA2 may determine the
pro- or antiatherogenic role of PAF-AH/LpPLA2. Furthermore, plasma levels of
PAF-AH are also shown to be an independent risk marker of CAD (Garza
et al. 2007). However, a study by Holleboom et al. showed that the reduction in
LCAT and PAF-AH activites due to LCAT mutations was not associated with
increased plasma lipid peroxidation (Holleboom et al. 2012).
3.2 Impairment of the Anti-Oxidative Effects of HDL in Patients
After Surgery and With Cardiovascular Disease
In the acute phase response to surgery, van Lenten et al. demonstrated that the
serum amyloid A (SAA) levels in HDL was increased and the activities of PON1
and PAF-AH were reduced (Van Lenten et al. 1995). Concomitant with these
changes the anti-inflammatory capacity of HDL was lost in both humans and rabbits
(Van Lenten et al. 1995). Isolated HDL from patients before and immediately after
surgery were compared for the effects of HDL on LDL-induced monocyte transmi-
gration and lipid hydroperoxide formation (Van Lenten et al. 1995). Prior to
surgery, HDL completely inhibited the LDL-induced increase in monocyte trans-
migration and lipid hydroperoxide formation. In marked contrast, the “acute phase”
HDL obtained from the same patients 2–3 days after surgery revealed a significant
LDL-induced monocyte transmigration and was less effective in inhibiting lipid
hydroperoxide formation. In other words, HDL in the same patient had been
transformed from anti-inflammatory towards proinflammatory particles (Van
Lenten et al. 1995). Similarly findings were reported in mice infected with influenza
A or Chlamydia pneumonia. HDL isolated from virus-infected wild-type mice had
impaired capacity to block LDL oxidation as well as LDL-induced monocyte
chemotactic activity in human artery wall cell co-cultures (Van Lenten
et al. 2001). The mice infected with C. pneumoniae had decreased PON1 activity
and reduced HDL capacity to prevent LDL oxidation at days 2 and 3 postinfection
(Campbell et al. 2010). Of note, studies by Navab et al. showed that HDL isolated
from patients with CAD failed to prevent LDL oxidation by human artery wall cells
(Navab et al. 2000a) and had impaired capacity to inhibit LDL-induced monocyte
chemotactiy activity (Navab et al. 2001b). Similar results were obtained with HDL
isolated from mice genetically predisposed to diet-induced atherosclerosis; it
became proinflammatory when the mice were fed an atherogenic diet (Navab
et al. 2001a). A subsequent small study by Ansell et al. suggested that the capacity
of HDL to alter LDL-induced monocyte chemotactic activity in patients with CAD
was somewhat improved after 6 weeks of simvastatin therapy (Ansell et al. 2003).
However, HDL from patients with CAD on statin therapy remained
proinflammatory when compared to HDL from healthy subjects, despite a signifi-
cant improvement in plasma lipid levels.
Interestingly, impaired antioxidant properties and increased oxidized fatty acids
content were found in HDL from patients with type 2 diabetes (Morgantini
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et al. 2011). The authors speculated that the elevated levels of oxidized fatty acids
in HDL from these patients may account for the impaired antioxidant properties of
the lipoprotein (Morgantini et al. 2011). Moreover, in a different study, the ability
of HDL to prevent LDL oxidation was found to be reduced in patients with acute
coronary syndrome but not in patients with stable coronary artery syndrome (Patel
et al. 2011). The antioxidative and cholesterol efflux capacities of HDL were also
found to be reduced in ischemic cardiomyopathy (Patel et al. 2013).
4 Effects of HDL on Endothelial Nitric Oxide Bioavailability
4.1 Mechanisms Under Physiological Conditions
Endothelial nitric oxide plays a crucial role in the regulation of vascular tone,
platelet aggregation, and angiogenesis. Endothelial nitric oxide synthase (eNOS)-
derived nitric oxide (NO) has been shown to exert a variety of atheroprotective
effects in the vasculature, such as anti-inflammatory and antithrombotic effects
(Landmesser et al. 2004). Consequently, reduced endothelial NO bioavailability
has been proposed to promote initiation and progression of atherosclerosis
(Landmesser et al. 2004).
It was shown that HDL can directly stimulate eNOS-mediated NO production
(Yuhanna et al. 2001). There have been several studies that consistently
demonstrated the capacity of HDL to modulate eNOS expression and to stimulate
endothelial NO production in vitro and in vivo (Besler et al. 2011; Kuvin
et al. 2002; Mineo et al. 2003; Nofer et al. 2004; Ramet et al. 2003; Sorrentino
et al. 2010). Furthermore, administration of reconstituted HDL (rHDL) has been
shown to improve endothelial function in patients with hypercholesterolemia or in
subjects with isolated low HDL due to heterozygous loss-of-function mutations in
the ABCA1 gene locus (Bisoendial et al. 2003; Spieker et al. 2002). Several
mechanisms have been proposed to account for the endothelial NO-stimulating
capacity of HDL. Early studies have demonstrated that HDL prevents oxLDL-
mediated eNOS displacements from caveolae and restores enzyme stimulation
(Uittenbogaard et al. 2000). Yuhanna et al. demonstrated that HDL binding to
endothelial SR-BI is required for eNOS activation (Yuhanna et al. 2001). This
binding activates the phosphatidylinositol-3-kinase/Akt signaling pathway and the
MAP kinase/extracellular signal-regulated kinase pathway (Mineo et al. 2003).
Activation of endothelial Akt by HDL stimulates phosphorylation of eNOS at
serine residue 1177 (Mineo et al. 2003; Nofer et al. 2004), which is known to be
an important regulatory mechanism leading to eNOS activation (Dimmeler
et al. 1999).
There are many different components of HDL known to play a role in the
endothelial NO-stimulating capacity. The potential interaction of apoA-I with
eNOS in cultured endothelial cells has been previously reported (Ramet
et al. 2003). However, lipid-free apoA-I failed to activate eNOS despite being the
ligand for SR-BI, suggesting that other HDL components may be important or are
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required to support the conformation of apoA-I to allow its interaction with SR-BI
and to stimulate eNOS (de Beer et al. 2001). In isolated endothelial cell plasma
membranes, anti-apoA-I antibody blocks eNOS activation by HDL in vitro
(Yuhanna et al. 2001). In contrast anti-apoA-II antibody further enhances eNOS
stimulation by HDL (Yuhanna et al. 2001). Furthermore, lysophospholipids may
play a role in eNOS activation as demonstrated in several studies. A study by Nofer
et al. suggested that HDL-associated sphingolipids such as sphingosylphosphor-
ylcholine, sphingosine-1-phosphate, and lysosulfatide caused eNOS-dependent
relaxation of precontracted aortic rings from mice by binding to the
lysophospholipid receptor S1P3 expressed in endothelial cells (Nofer et al. 2004).
However, the vasodilatory response of HDL was not completely abolished in S1P3-
deficient mice (Nofer et al. 2004).
Recently, we demonstrated that the HDL-associated enzyme PON1 is
participating in HDL’s capacity to stimulate endothelial NO production and to
exert NO-dependent endothelial atheroprotective effects (Besler et al. 2011). Inhi-
bition of PON1 in HDL from healthy subjects impaired the capacity of HDL to
stimulate endothelial NO production in human aortic endothelial cells. In addition
HDL isolated from PON1-deficient mice failed to stimulate NO production in
mouse aortic endothelial cells (Besler et al. 2011). Furthermore, inhibition of
eNOS-mediated NO production by the pharmacological inhibitor L-NAME
prevented the inhibitory effects of HDL from healthy subjects on nuclear factor
κB (NF-κB) activity, vascular cell adhesion molecule (VCAM)-1 expression, and
endothelial monocyte adhesion. These clearly indicate that the capacity of HDL to
stimulate endothelial NO production is important for these endothelial anti-
inflammatory effects of HDL (Besler et al. 2011).
4.2 Impaired HDL Capacity to Stimulate NO Production in
Patients with Cardiovascular Disease
We and others have recently shown that HDL isolated from patients with stable
CAD, diabetes, chronic kidney diseases (CKD), or acute coronary artery syndrome
(ACS) displays altered endothelial effects when compared to HDL from healthy
subjects. Of note, HDL from patients with diabetes in contrast to HDL from healthy
subjects failed to stimulate endothelial cell NO production and to promote endo-
thelial repair in a carotid artery injury model in mice (Sorrentino et al. 2010).
Moreover, HDL from patients with either stable CAD or an ACS, in contrast to
HDL from age- and gender-matched healthy subjects, inhibited endothelial cell NO
production and lost the capacity to limit endothelial inflammatory activation as well
as to promote endothelial repair in vivo (Besler et al. 2011). Interestingly, the
capacity to stimulate endothelial NO production could be improved upon exercise
training (Adams et al. 2013).
HDL from patients with CAD and chronic heart failure (CHF) showed an
elevated malondialdehyde (MDA) content as compared to HDL from healthy
subjects, which may contribute to the impaired endothelial NO production (Besler
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et al. 2011). The MDA-lysine adducts in HDL was determined to act via lectin-type
oxidized LDL receptor 1 (LOX-1) activation of protein kinase C-βII, which blocks
Akt-activating phosphorylation at Ser473 and eNOS-activating phosphorylation at
Ser1177. Furthermore, inactivation of PON1 in HDL from healthy subjects resulted
in attenuated NO production, in greater protein kinase C-βII activation, decreased
activating eNOS-Ser1177 phosphorylation, and increased inactivating eNOS-
Thr495 phosphorylation. Furthermore, HDL isolated from PON1-deficient mice
failed to stimulate endothelial cell NO production (Besler et al. 2011). These
observations likely suggest that alterations of HDL-associated PON1 may severely
affect endothelial effects of HDL.
Very recently, we have also shown that MPO and PON1 reciprocally modulate
each other’s function in vivo (Huang et al. 2013). MPO may promote site-specific
oxidative modification of PON1, therefore limiting its activity. In addition, HDL
isolated from patients with an ACS carries enhanced chlorotyrosine content, site-
specific PON1 methionine oxidation, and reduced PON1 activity (Huang
et al. 2013).
Several groups have reported an inverse relationship between PON1 serum
activity and cardiovascular events (Bhattacharyya et al. 2008; Regieli
et al. 2009). Interestingly, analysis of SNPs for PON1 identified in genome wide
association studies did not reveal a significant association between SNPs,
associated with mildly reduced PON1 activity, and the risk of cardiovascular events
(Tang et al. 2012). The interpretation of PON1 activity is difficult because it is not
known to which extent the paraoxonase and arylesterase activities represent bio-
logically relevant functions. Furthermore, we and others observed important post-
translational modifications of the proteins, which could explain alterations of
biological properties of the enzymes (Aviram et al. 1999; Besler et al. 2011;
Huang et al. 2013).
5 Endothelial Anti-Inflammatory Effects of HDL
5.1 Mechanisms Under Physiological Conditions
Atherosclerosis is a chronic inflammatory disorder. The cellular inflammatory
response is triggered by modified LDL accumulated in the subendothelium and
the induction of proinflammatory cytokines and adhesion protein expression. As a
consequence monocytes/macrophages infiltrate and accumulate in the arterial wall
and express scavenger receptors and toll-like receptors to sequester cholesterol. The
cholesterol-loaded macrophages together with T lymphocytes produce a wide array
of proinflammatory cytokines and accelerate plague progression (Hansson 2005).
In vitro, HDL has been shown to inhibit the expression of monocyte
chemoattractant protein (MCP)-1, an important proinflammatory chemokine in
endothelial cells (Mackness et al. 2004; Navab et al. 1991). Furthermore, the
potential anti-inflammatory effects of HDL have been demonstrated by several
in vivo studies. Infusion of native HDL as well as reconstituted HDL containing
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apoA-I or apoA-I Milano suppressed cytokine and chemokine expression in animal
models of inflammation (Calabresi et al. 1997; Cockerill et al. 1995). Reduced
VCAM-1 expression and decreased monocyte/macrophage infiltration were
reported after carotid artery cuff injury in apoE-deficient mice (Dimayuga
et al. 1999). In the streptozotocin-induced diabetic cardiomyopathy rat model,
human apoA-I gene transfer increased HDL-C plasma levels and blocked the
diabetes-induced myocardial mRNA expression of VCAM-1 and ICAM-1 (Van
Linthout et al. 2008). In contrast, overexpression of human apoA-I in apoE-
deficient mice did not result in any change of endothelial VCAM-1 expression
and monocyte adherence in early atherosclerotic lesions at the aortic branch sites,
despite overall reduction in aortic atherosclerotic lesion formation (Dansky
et al. 1999). These studies support the concept that the anti-inflammatory capacity
of HDL is heterogeneous, and is dependent on the pathophysiological conditions. In
vitro studies showed variations in the capacity of HDL isolated from different
human subjects to reduce TNF-α stimulated endothelial VCAM-1 expression
(Ashby et al. 1998; Van Lenten et al. 1995). In human studies, the administration
of reconstituted HDL increased the anti-inflammatory capacity of HDL from
patients with type-2 diabetes (Patel et al. 2009).
One of the proposed mechanisms for the anti-inflammatory effect of HDL is the
removal of cholesterol from cell membranes of macrophages and also endothelial
cells. The cholesterol depletion and consequently the lipid rafts disruption may
downregulate signaling pathways and interfere with the antigen presentation or the
expression of toll-like receptor (Anderson et al. 2000; Norata and Catapano 2012;
Wang et al. 2012). Additional studies suggest that HDL and apoA-I are able to
inhibit the capacity of antigen-presenting cells to stimulate T-cell activation. This
inhibition was attributed to cholesterol efflux through ABCA1, an ATP-binding
transporter (Tang et al. 2009; Zhu et al. 2010).
The anti-inflammatory capacity of HDL has been mainly attributed to apoA-I,
the major protein constituent of HDL. In an in vivo study, apoA-I infusion in rabbits
in acute vascular inflammation model reduced neutrophil infiltration and endothe-
lial cell inflammatory activation (Puranik et al. 2008). In addition, apoA-1 mimetic
peptides have been shown to reduce vascular inflammation in type I diabetic rats
and improve insulin sensitivity in obese mice (Peterson et al. 2007, 2008). It has
also been demonstrated that treatment with lipid-free apoA-I and rHDL treatment
reduced the expression of chemokines and chemokine receptors in vitro and in vivo
by modulating NF-κB and peroxisome proliferator-activated receptor γ (Bursill
et al. 2010). Interestingly, apoA-I has also been shown to inhibit palmitate-induced
NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts
(Cheng et al. 2012). More recently, De Nardo et al. using a systems biology
approach identified the transcription factor ATF3 as an HDL-inducible gene to
suppress Toll-like receptor-induced proinflammatory cytokines. Mice deficient in
ATF3 and apoE revealed enhanced atherosclerotic lesions, and administration of
rHDL into apoE-deficient mice resulted in ATF3 upregulation. The authors used
rHDL in their study, suggesting that apoA-I is a key mechanistic player, and of
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note, the effects seem to be unrelated to cholesterol transport (De Nardo
et al. 2014).
The lipid moiety of HDL has also been proposed to be important for the anti-
inflammatory effects of HDL. In vitro studies using reconstituted HDL containing
only apoA-I with a few phospholipid molecules suggested that inhibitory effects of
HDL on endothelial cell adhesion molecule expression are also, at least in part,
dependent on HDL-associated phospholipid species (Baker et al. 2000). The inhi-
bition of cytokine-induced expression of VCAM-1 by reconstituted HDL varied
when different phosphatidylcholine species were used. This suggests that the lipid
composition of HDL influences its anti-inflammatory capacity and is likely an
important determinant of HDL functionality (Baker et al. 2000; Barter
et al. 2004). In addition there are multiple reports suggesting the involvement of
sphingosine-1-phosphate (S1P), a biologically active sphingolipid that plays key
functions in the immune, inflammatory, and cardiovascular systems. S1P carried by
HDL is believed to regulate arterial tone, vascular permeability, and tissue perfu-
sion. During inflammation it induces endothelial adhesion molecules and recruits
inflammatory cells, and furthermore it activates a negative feedback loop that
consecutively decreases vascular leakage by improving the endothelial barrier
function and preventing cytokine-induced leukocyte adhesion (Garcia et al. 2001;
Lucke and Levkau 2010; Takeya et al. 2003).
5.2 Impaired Endothelial Anti-Inflammatory Effects of HDL in
Patients with CAD, Diabetes, or Chronic Kidney Dysfunction
HDL isolated from patients with inflammatory disease such as CAD, diabetes, or
chronic kidney disease display reduced eNOS activation and impaired endothelial
repair capacity in a carotid artery injury mouse model. There have been various
mechanisms proposed to account for the impaired endothelial anti-inflammatory
effects of HDL. Reduced HDL apoA-I levels in inflammatory states has been
related to accelerated HDL catabolism and apoA-I substitution in HDL particles
by serum amyloid A (SAA) (Esteve et al. 2005; Khovidhunkit et al. 2004). In acute
phase, SAA is able to replace apoA-I in HDL, resulting in reduced plasma levels of
apoA-I (Parks and Rudel 1985). ApoA-I can be completely replaced by SAA in
rabbits and mice, in a subset of small, dense HDL particles and therefore function-
ing as a structural apolipoprotein (Cabana et al. 1999). HDL isolated from patients
with chronic kidney disease is enriched in SAA, which correlated with its reduced
anti-inflammatory capacity to inhibit monocyte chemoattractant protein-1 forma-
tion in vascular smooth muscle cells (Tolle et al. 2012).
Moreover, HDL carries potential cardioprotective molecules that are signifi-
cantly altered in compositions in patients with CAD or ACS (Riwanto et al. 2013;
Vaisar et al. 2007). Oxidative modifications of HDL, in particular the amino acid
residues in apoA-I, have been shown to contribute to the generation of dysfunc-
tional HDL (Bergt et al. 2004; Shao et al. 2006, 2012; Zheng et al. 2004). In vitro
study has demonstrated that MPO-catalyzed oxidative modification of HDL or
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apoA-I converts HDL into a proinflammatory particle which promotes NF-κB
activation and endothelial VCAM-1 expression (Undurti et al. 2009). Furthermore,
glycation of HDL and apoA-I, a process that is known to occur in diabetes in vivo
(Curtiss and Witztum 1985), has been shown to impair the anti-inflammatory
capacity of HDL (Nobecourt et al. 2010). Infusion of glycated lipid-free apoA-I
failed to decrease adhesion molecule expression following vascular injury
(Nobecourt et al. 2010). Moreover, glycation of HDL has also been shown to
inhibit the HDL capacity to inhibit oxLDL-induced monocyte adhesion to human
aortic endothelial cells in vitro (Hedrick et al. 2000).
6 Effects of HDL on Endothelial Cell Apoptotic Pathways
6.1 Mechanisms Under Physiological Conditions
Endothelial cell dysfunction and injury has been associated with the pathogenesis
of atherosclerosis (Landmesser et al. 2004; Nabel and Braunwald 2012; Ross 1999).
Studies in pigs have shown that atherosclerotic lesion-prone regions are
characterized by a high endothelial cell turnover (Caplan and Schwartz 1973),
which has been suggested to be due to increased endothelial cell apoptosis (Caplan
and Schwartz 1973). Several studies have indicated an important contribution of
endothelial cell apoptosis to the pathophysiology of CAD (Burke et al. 1997; Rossig
et al. 2001). Furthermore, it is evident that apoptosis of endothelial cells and smooth
muscle cells is detrimental to plaque stability (Bombeli et al. 1997; Kockx and
Herman 2000). In the normal arterial wall, endothelial cells may protect themselves
against apoptosis using NO-dependent mechanisms. The situation is completely
different in atherosclerotic plaques, in a high oxidative stress environment where
macrophages produce high amounts of nitric oxide or peroxynitrite that could
induce apoptotic cell death (Kockx and Herman 2000). In the aorta the capacity
of HDL to quench endothelial cell apoptosis may therefore represent an
antiatherogenic property of HDL (de Souza et al. 2010; Nofer et al. 2001; Suc
et al. 1997; Sugano et al. 2000).
HDL has been shown to attenuate endothelial cell apoptosis induced by different
stimuli such as TNF-α, oxLDL, and growth factor deprivation (de Souza et al. 2010;
Nofer et al. 2001; Suc et al. 1997; Sugano et al. 2000). It has been suggested that
HDL may inhibit both death-receptor and mitochondrial-mediated apoptotic
pathways. Importantly, both the protein and lipid moieties have been reported to
contribute to the antiapoptotic capacity of HDL. ApoA-I has been shown to inhibit
endothelial cell apoptosis induced by oxLDL, VLDL, and TNF-α (Speidel
et al. 1990; Suc et al. 1997; Sugano et al. 2000). In a more detailed study, HDL
subpopulations enriched with apoA-I account for approximately 70 % of the
antiapoptotic activity of HDL in a cell culture model with human microvascular
endothelial cells that were treated with mildly oxidized LDL. Using rHDL
consisting of apoA-I, cholesterol and phospholipids potently inhibited oxLDL-
induced apoptosis in these cells (de Souza et al. 2010). This suggests that apoA-I
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plays an important role for the antiapoptotic capacity of HDL in oxLDL-stimulated
endothelial cells.
HDL-associated lysosphingolipids have been identified to inhibit endothelial
cell apoptosis induced by growth factor deprivation (Kimura et al. 2001, 2003;
Nofer et al. 2001). The antiapoptotic capacity of the lipid moiety of HDL was
further supported by the findings that the ratio of sphingosine-1-phosphate and
sphingomyelin in small dense HDL3 particles was increased and correlated posi-
tively with the characteristics of these HDL subpopulations to inhibit endothelial
cell apoptosis (Kontush et al. 2007).
Several mechanisms have been suggested for the endothelial antiapoptotic
effects of HDL, depending on the stimulus of apoptosis. Endothelial cell death
triggered by oxLDL causes a delayed but sustained increase in intracellular calcium
which is shown to be prevented by HDL (Suc et al. 1997). HDL inhibits tumor
necrosis factor-α-induced endothelial cell death by association as well as suppres-
sion of caspase-3, which is a key factor of all primary apoptotic pathways (Sugano
et al. 2000). Nofer et al. suggested that sphingosine-1-phosphate (S1P) carried by
HDL prevents the growth factor deprived activation of the intrinsic pathway to cell
death (Nofer et al. 2001). Of note, lysophospholipids have been shown to enhance
endothelial cell survival, but the effects were inhibited by S1P receptor knockdown,
as well as by the presence of phosphoinositide 3 (PI3) kinase and Erk pathway
antagonists (Kimura et al. 2003).
In addition, HDL activates Akt and causes phosphorylation of the Akt target
Bcl-2-associated death promoter (BAD), preventing it from binding to the
antiapoptotic protein Bcl-xL (Nofer et al. 2001). HDL also causes phosphoinositide
3 (PI3) kinase-mediated upregulation of the antiapoptotic Bcl-2 family protein
Bcl-xL expression (Riwanto et al. 2013). Interestingly, HDL retained its
antiapoptotic activity after knockdown of eNOS using specific RNA interference
or pharmacological inhibition using L-NAME (Riwanto et al. 2013), indicating that
HDL may exert its antiapoptotic activity independently of eNOS activation.
6.2 Impairment of the Endothelial Anti-Apoptotic Effects of HDL
in Patients with Cardiovascular Disease
Recently, we reported that HDL isolated from patients with stable CAD or ACS, in
contrast to HDL from healthy subjects, failed to inhibit endothelial cell apoptosis
in vitro and in apoE-deficient-mice in vivo. Using proteomic analysis of HDL, we
observed reduced clusterin and increased apo C-III content in HDL isolated from
patients with CAD. Both, supplementing HDL from healthy subjects with apoC-III
or pretreatment of healthy HDL with an antibody against clusterin, lead to the
activation of proapoptotic signaling pathways in endothelial cells (Riwanto
et al. 2013). HDL isolated from these patients stimulated endothelial proapoptotic
pathways, in particular p38-MAPK-mediated activation of the proapoptotic Bcl-2-
protein tBid. Our study further suggests that differences in the proteome of HDL
from patients with CAD, in particular reduced HDL-associated clusterin and
increased HDL-associated apoC-III, play an important role for altered activation
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of endothelial anti- and proapoptotic signaling pathways (Riwanto et al. 2013). In
line with this, a nested case-control study found that cholesterol levels in apoC-III-
containing HDL particles show a positive association with cardiovascular risk,
whereas both total HDL-C and cholesterol in apoC-III-free HDL particles show
the expected inverse associations (Jensen et al. 2012). In addition, Undurti
et al. demonstrated that MPO-catalyzed oxidation of HDL impaired its capacity
to inhibit endothelial apoptosis in vitro (Undurti et al. 2009).
7 HDL Protein Cargo and Prognostic Biomarkers
As highlighted above, alterations in HDL functions are likely, at least in part,
attributed to changes in the composition of HDL particles. HDL particles are highly
heterogenous in their structure and compositions. They undergo continuous
remodeling through apolipoprotein exchanges with other circulating lipoproteins
and tissues (Lund-Katz et al. 2003; Saito et al. 2004).
An early study has shown that acute phase response causes significant changes in
the HDL-associated proteins and apolipoprotein composition, i.e., enrichment in
C-reactive protein (CRP), secretory phospholipase A2-IIa (sPLA2-IIa), serum amy-
loid A (SAA), and cholesterol ester transfer protein (CETP) (Coetzee et al. 1986). It
has been suggested that such remodeling may compromise the antiatherogenic
functions of HDL (Jahangiri et al. 2009). These observations have prompted
explorative studies into HDL composition. Evaluations of the HDL proteome
have been reported with one- or two-dimensional electrophoresis combined with
high performance liquid chromatography (HPLC) and tandem mass spectrometry
(MS/MS) or matrix-assisted laser desorption/ionization-time flight mass spectrom-
etry (MALDI-TOF-MS) (Heller et al. 2007; Karlsson et al. 2005). More recent
studies have used shotgun proteomics, through label-free MS techniques, such as
spectral counting and XIC inspection, to analyze HDL protein compositions
(Riwanto et al. 2013; Vaisar et al. 2007). Overall, the identification techniques
currently available for the analysis of the HDL proteome are semi-quantitative.
Given the complexity of HDL and its multitude of biological functions, it is
conceivable to expect that sets of functionally associated proteins can provide
information about their participation in the spectrum of atheroprotective actions
attributed to HDL. This has further led to studies comparing the HDL proteome of
healthy subjects with that of particles from patients with dyslipidemias or CAD
(Green et al. 2008; Heller et al. 2007; Riwanto et al. 2013; Vaisar et al. 2007). In the
study by Vaisar et al., HDL was shown to carry apolipoproteins and proteins with
functions in lipid metabolism, the acute phase response, complement regulation,
and blood coagulation (Vaisar et al. 2007). The same group further compared the
proteome of HDL3 from 6 CAD patients before and after 1-year treatment with
combined statin/niacin therapy (Green et al. 2008). In this study, HDL3 of CAD
patients is significantly enriched in apoE and apoCII and carry less apoJ and
phospholipid transport protein (PLTP) as compared to HDL from control subjects.
Treatment with niacin/statin decreases HDL3 apoE and raises apoJ and PLTP levels
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(Green et al. 2008). In our recent study, we have observed that reduced clusterin and
increased apoC-III content in HDL isolated from patients with CAD lead to
activation of proapoptotic signaling pathways in endothelial cells (Riwanto
et al. 2013).
Of note, oxidative modifications of HDL-associated proteins have also been
demonstrated to contribute to the functional impairment of HDL. In particular,
MPO-mediated oxidation of apoA-I has been linked to the generation of dysfunc-
tional forms of HDL (Huang et al. 2014; Shao et al. 2010; Undurti et al. 2009; Wang
et al. 2007b; Zheng et al. 2004). Recently, we have shown that MPO and PON1
interact and reciprocally modulate each other’s function in vivo, i.e., PON1 par-
tially inhibits MPO activity, while MPO oxidizes and inactivates PON1 (Huang
et al. 2013). Furthermore, HDL isolated from patients with an ACS carries
enhanced chlorotyrosine content, site-specific PON1 methionine oxidation, and
reduced PON1 activity (Huang et al. 2013).
Taken together, these observations indicate that the HDL proteomic composition
may be altered in different disease states which likely have an impact on HDL
function. Unraveling the complexities of the HDL through proteomics studies may
therefore allow for better understanding of the HDL composition and function.
However, proteomics studies of HDL have been limited in size and number due to
the labor-intensive nature of the approach. Furthermore, given the diverse concen-
tration range of the proteins in the HDL particles, some proteomics approaches may
fail to reflect the actual amount or alteration of low abundant proteins due to signal
suppression in the presence of highly abundant proteins. Targeted proteomics using
selected reaction monitoring is a powerful tandem mass spectrometry method that
can be used to monitor target peptides within a complex protein digest (Picotti and
Aebersold 2012; Picotti et al. 2010). The approach will enable absolute quantifica-
tion of the individual protein contained within HDL particles.
Conclusion and Perspectives
Over the past two decades, many studies have emerged showing various
antiatherogenic effects of HDL, including the capacity of HDL to mediate
reverse cholesterol transport, and antioxidative, anti-inflammatory, and
antiapoptotic effects (Riwanto and Landmesser 2013). Growing evidence has
shown that HDL particles are highly heterogeneous and the vasoprotective
effects of HDL are altered in patients with CAD, diabetes, and chronic kidney
dysfunction, i.e., patients with a high cardiovascular risk profile. Of note, these
findings have more recently been supported by observations in cohort studies,
suggesting that in patients with advanced CAD, higher plasma levels of HDL-C
are no longer associated with reduced risk of cardiovascular events (Angeloni
et al. 2013; Schwartz et al. 2012). Importantly, the increase in HDL-C observed
with some lipid-modifying drugs has not been uniformly associated with clinical
benefit (Barter et al. 2007; Schwartz et al. 2012). These findings have clearly
indicated that the association between HDL and cardiovascular disease is far
more complex than previously thought and is likely mediated by different HDL
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functional properties, independent of the cholesterol component of the HDL
particle (Heinecke 2011).
It is increasingly evident that the functional heterogeneity of HDL may be
attributed to the complexity of the HDL particles, containing proteins and lipids
that can be modified or altered in their composition. Of note, rapid advances in
the MS proteome technology have allowed tremendous leaps in characterizing
the HDL proteome. Studies investigating the lipidome of HDL are still some-
what limited by the available technologies. Importantly, several studies have
associated changes in specific HDL protein either due to altered composition or
modification to the loss of function of HDL (Besler et al. 2011; Huang
et al. 2013; Riwanto et al. 2013; Shao et al. 2006, 2012; Zheng et al. 2004).
Nevertheless, it remains to be determined if the alterations are secondary to
changes that occur during the disease progression or if the alteration has indeed a
causal effect on disease etiology. In this context it is also important to emphasize
the problem of confounding between different diseases: for example, many
diabetic patients have (sub)clinical chronic kidney disease and/or CAD. As a
consequence one must also expect considerable overlap of HDL modifications
which were initially identified in patients with either diabetes, CAD, or CKD. It
is hence rather unlikely that each disease has its specific footprint of HDL
dysfunction and alterations in proteome and lipidome.
Taken together, it is becoming clear that plasma HDL-C levels are not an
appropriate marker of vascular effects of high-density lipoproteins and therefore
do not represent a reliable therapeutic target. Importantly, HDL-targeted treat-
ment approaches need to take into account the altered vascular effects of HDL in
cardiovascular disease. Therefore, targeting HDL-mediated antiatherogenic
mechanisms, rather than plasma HDL-C levels, may represent a more promising
and interesting therapeutic target. Studies looking into the specific mechanisms
leading to a loss of antiatherogenic effects of HDL are of particular importance,
in order to develop therapeutic approaches that aim to restore the vasoprotective
properties of HDL.
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Abstract
High-density lipoproteins (HDLs) exert many beneficial effects which may help
to protect against the development or progression of atherosclerosis or even
facilitate lesion regression. These activities include promoting cellular choles-
terol efflux, protecting low-density lipoproteins (LDLs) from modification,
preserving endothelial function, as well as anti-inflammatory and antithrombotic
effects. However, questions remain about the relative importance of these
activities for atheroprotection. Furthermore, the many molecules (both lipids
and proteins) associated with HDLs exert both distinct and overlapping
activities, which may be compromised by inflammatory conditions, resulting
in either loss of function or even gain of dysfunction. This complexity of HDL
functionality has so far precluded elucidation of distinct structure–function
relationships for HDL or its components. A better understanding of HDL
metabolism and structure–function relationships is therefore crucial to exploit
HDLs and its associated components and cellular pathways as potential targets
for anti-atherosclerotic therapies and diagnostic markers.
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ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
ATF3 Activating transcription factor 3
β-ATPase β-Chain of F0F1 ATPase
BSEP Bile salt export pump
CETP Cholesteryl ester transfer protein
CYP7A1 Cholesterol 7α-hydroxylase
eNOS Endothelial nitric oxide synthase
EPC Endothelial progenitor cell
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HO-1 Heme oxygenase-1
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MAP Mitogen-activated protein





PAF-AH Platelet-activating factor acetylhydrolase
PDZK1 PDZ domain-containing protein 1
PI3K Phosphatidylinositol 3-kinase
PON1 Paraoxonase 1
rHDL Reconstituted high-density lipoprotein
ROS Reactive oxygen species
S1P Sphingosine-1-phosphate
SMC Smooth muscle cell
SR-BI Scavenger receptor BI
STAT3 Signal transducer and activator of transcription 3
TCFA Thin-cap fibroatheroma
TLR Toll-like receptor
TNFα Tumor necrosis factor α
VCAM-1 Vascular cell adhesion molecule 1
VSMC Vascular smooth muscle cell
1 Introduction
Atherothrombotic diseases, such as coronary heart disease, stroke, and peripheral
arterial disease, are the world’s leading cause of death. The first-line therapy for
prevention and treatment of coronary heart disease is low-density lipoprotein
(LDL) lowering by statin therapy. Although statin drugs are very effective in
reducing plasma LDL cholesterol concentrations, the risk of major cardiovascular
events is only decreased by 15–40 % (Baigent et al. 2005; Ridker et al. 2010).
Additional therapeutic approaches are needed to minimize this considerable
remaining cardiovascular risk in statin-treated patients. It has been postulated that
part of this residual risk may be explained by low circulating levels of high-density
lipoproteins (HDLs). Clinical and large population-based epidemiological studies
have consistently shown that low HDL cholesterol is independently associated with
an increased risk of atherothrombotic diseases (Di Angelantonio et al. 2009; Barter
et al. 2007a). However, this long-standing inverse relationship between HDL and
atherosclerotic cardiovascular disease has been challenged by recent findings.
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Indeed, high plasma concentrations of HDL cholesterol might not be beneficial for
certain subgroups of patients. Thus, in high-risk postinfarction patients
characterized by high total cholesterol and C-reactive protein, elevated levels of
HDL cholesterol were paradoxically found to be related to poor clinical outcome
(Corsetti et al. 2006). Similarly, the inverse relationship between HDL cholesterol
levels and major cardiovascular events was found lost in patients with established
coronary artery disease undergoing diagnostic angiography or coronary artery
bypass grafting (Angeloni et al. 2013; Silbernagel et al. 2013). Moreover, several
large randomized clinical trials assessing the effects of new therapies targeting
HDL metabolism, such as cholesteryl ester transfer protein (CETP) inhibitors and
niacin, reported disappointing results. The Investigation of Lipid Level Manage-
ment to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
revealed that the combination of atorvastatin with the CETP inhibitor torcetrapib
increased HDL cholesterol levels by 72.1 % relative to atorvastatin alone (Barter
et al. 2007b). This raise in HDL cholesterol upon torcetrapib administration did,
however, not lower the risk of the major cardiovascular outcome (Barter
et al. 2007b). On the contrary, patients in the atorvastatin/torcetrapib group unex-
pectedly experienced significantly more adverse events (Barter et al. 2007b). More
recently, another phase 3 clinical trial involving patients with a recent acute
coronary syndrome, named dal-OUTCOMES, was designed to evaluate the effects
of the CETP inhibitor dalcetrapib (Schwartz et al. 2012). Addition of dalcetrapib to
statin therapy raised HDL cholesterol levels by 31–40 % but failed to reduce the
risk of recurrent cardiovascular events (Schwartz et al. 2012). Niacin is another
effective agent for raising HDL cholesterol and also lowering LDL cholesterol,
triglycerides, and lipoprotein(a). Data from the Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health
Outcomes (AIM-HIGH) trial, which included patients with established cardiovas-
cular disease, showed that adding extended-release niacin to statin therapy was not
effective in reducing the risk of cardiovascular events during a follow-up of
36 months despite a 25 % increase in HDL cholesterol (Boden et al. 2011).
Genetic studies also questioned a role for HDLs in atherothrombotic diseases.
Lifelong reductions of plasma HDL cholesterol levels due to heterozygosity for a
loss-of-function mutation in ABCA1 did not affect the risk for ischemic heart
disease (Frikke-Schmidt et al. 2008). Likewise, genetic variation in the apolipopro-
tein A-I (apoA-I) gene, APOA1, affecting apoA-I and HDL cholesterol levels did
not predict ischemic heart disease or myocardial infarction in the general popula-
tion (Haase et al. 2010). A more recent Mendelian randomization analysis
demonstrated that there is no significant association between risk of myocardial
infarction and a loss-of-function SNP in the gene coding for endothelial lipase
(LIPG Asn396Ser), which results in elevated levels of HDL cholesterol (Voight
et al. 2012). Hence, there is ongoing discussion whether HDLs are causally
involved in the development of atherothrombotic diseases or are merely an innocent
bystander. On the other hand, there is considerable evidence from in vitro and
in vivo studies that HDL particles isolated from human plasma as well as artificially
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reconstituted HDLs (rHDLs) exert multiple atheroprotective effects (Annema and
von Eckardstein 2013).
The above-outlined controversies have shifted the interest of the cardiovascular
research field to HDL functionality, meaning that the functional quality of the
particles might be more important than the absolute amount of HDL cholesterol.
Currently, the available HDL-targeted therapies for atherothrombotic diseases raise
plasma HDL cholesterol levels per se. Nonetheless, plasma concentrations of HDL
cholesterol do not necessarily reflect the functional capacity of HDL particles. In
addition, there is evidence that the anti-atherogenic functions of HDLs are impaired
in patients with cardiovascular disease (Annema and von Eckardstein 2013), and
these dysfunctional HDLs might even promote atherothrombotic diseases. There-
fore, a better understanding of the molecular mechanisms behind the protective
functions of HDLs in the context of atherothrombotic diseases is fundamental for
successful exploitation of HDLs for the treatment of coronary heart disease.
2 Interactions of HDLs with the Endothelium
2.1 Preservation of Endothelial Integrity
Perturbations in the function of endothelial cells lining the lumen of blood vessels are
an important hallmark of the earliest stages of the atherosclerotic process. HDLs may
improve or help reverse endothelial dysfunction by several endothelial-vasoprotective
means. Several in vitro studies indicate that HDLs are able to counteract endothelial
cell death. Treatment of endothelial cells with HDLs caused a marked attenuation of
apoptosis in response to pro-atherogenic signals such as oxidized LDL (Suc et al. 1997;
de Souza et al. 2010; Kimura et al. 2001), tumor necrosis factor α (TNFα) (Sugano
et al. 2000; Riwanto et al. 2013), and growth factor deprivation (Kimura et al. 2001;
Nofer et al. 2001b; Riwanto et al. 2013). Although the underlying mechanism has not
been fully elucidated, it has been suggested that HDLs regulate endothelial cell survival
by interfering with critical steps in apoptotic pathways. Several studies reported that
HDLs block the activation of the mitochondrial pathway of apoptosis by preventing
depolarization of the mitochondrial transmembrane and subsequent mitochondrial
release of cytochrome c and apoptosis-inducing factor into the cytoplasm (Nofer
et al. 2001b; de Souza et al. 2010). As a consequence, HDLs inhibit the cytochrome
c-initiated caspase activation cascade (Sugano et al. 2000; Nofer et al. 2001b; de Souza
et al. 2010). Moreover, levels of the apoptosis-inducing protein truncated Bid are
reduced in endothelial cells cultured in the presence of HDLs, whereas endothelial
expression of the antiapoptotic protein Bcl-xL is enhanced (Riwanto et al. 2013). The
capacity of HDLs to attenuate apoptosis in endothelial cells requires induction of
phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric oxide synthase (eNOS)
signaling (Nofer et al. 2001b; Riwanto et al. 2013) and was attributed to apoA-I
(Radojkovic et al. 2009) as well as HDL-associated lysophospholipids (Kimura
et al. 2001; Nofer et al. 2001b). More recently, a lower clusterin (or apoJ) and increased
apoC-III content in the HDLs of patients with stable coronary artery disease or acute
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coronary syndrome was found to be associated with reduced antiapoptotic activities in
human endothelial cells (Riwanto et al. 2013).
Disruption of vascular endothelium integrity is another central event promoting
atherosclerotic plaque formation. Sphingosine-1-phosphate (S1P), a bioactive
sphingolipid metabolite, has been identified as an important endothelial barrier
function-enhancing agonist (Garcia et al. 2001). In plasma S1P preferentially
associates with HDL particles via binding to apoM (Christoffersen et al. 2011). In
vitro studies provided evidence that delivery of S1P carried by apoM-containing
HDLs to S1P1 receptors on endothelial cells leads to activation of Akt and eNOS,
which in turn promotes endothelial barrier integrity (Argraves et al. 2008;
Wilkerson et al. 2012). Interestingly, the lung vascular barrier function, as deter-
mined by Evan’s blue extravasation, is decreased in mice that lack S1P in their
HDL fraction due to deficiency of apoM (Christoffersen et al. 2011). These data
underline a significant role of HDL-associated S1P in endothelial barrier protection
in vivo. In this context it is important to highlight the submicromolar concentration
of S1P in HDLs which amounts to only 5–10 % of HDL particle concentration but is
in the range of the affinity constants of the G-protein-coupled S1P receptors
(Annema and von Eckardstein 2013; Karuna et al. 2011). Moreover, erythrocytes
release S1P in response to HDLs (Lucke and Levkau 2010) so that in vivo the local
concentration of S1P may be considerably higher than in isolated HDLs.
Acceleration of reendothelialization after vascular injury is another mechanism
proposed to contribute to the positive influence of HDLs on endothelial function. In
this respect, HDLs might be specifically important in driving endothelial cell
migration during repair. Incubation of cultured endothelial cells with HDLs
stimulated cell migration in response to wounding (Seetharam et al. 2006). More-
over, hepatic expression of human apoA-I rescued the impaired carotid artery
reendothelialization following perivascular electric injury in apoA-I knockout
mice (Seetharam et al. 2006). The promotion of endothelial cell migration by
HDLs has been demonstrated to involve scavenger receptor BI (SR-BI)-mediated
activation of Rac-directed formation of actin-based lamellipodia (Seetharam
et al. 2006). An SR-BI-dependent mechanism for the promigratory actions of
HDL was confirmed by experiments showing that the capacity of HDLs to stimulate
endothelial cell migration was reduced by transfection of endothelial cells with
siRNA specific to PDZ domain-containing protein 1 (PDZK1), an SR-BI adaptor
protein that controls steady-state SR-BI levels, and that the reendothelialization
capacity of injured vessels is lost in mice in which the pdzk1 gene has been
disrupted (Zhu et al. 2008). Other studies suggested that HDL-induced endothelial
cell migration is mediated by stimulation of Akt/eNOS phosphorylation through
HDL-bound S1P in an S1P1-dependent manner and that this process is facilitated
by endothelial lipase (Tatematsu et al. 2013).
Besides endothelial cell migration, also recruitment and incorporation of bone
marrow-derived endothelial progenitor cells (EPCs) to sites of vessel injury
contributes to the repair of the damaged vessel wall. HDLs activate the PI3K/Akt
pathway in EPCs resulting in enhanced EPC proliferation, migration, and survival
(Sumi et al. 2007; Petoumenos et al. 2009; Zhang et al. 2010). Moreover,
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preincubation of EPCs with HDL augmented their adhesive capacity to endothelial
cells and potentiated their transendothelial migration (Petoumenos et al. 2009).
Mice that were injected with rHDLs had an increased number of circulating EPCs
and showed improved reendothelialization after carotid artery injury (Petoumenos
et al. 2009). Additional mouse studies indicated that infusion of rHDLs enhanced
bone marrow progenitor cell mobilization, neovascularization, and functional
recovery after hind limb ischemia in wild-type mice (Sumi et al. 2007). In contrast,
no beneficial effects of rHDL treatment on ischemia-induced angiogenesis were
observed in eNOS knockout mice (Sumi et al. 2007), suggesting an essential role
for eNOS in mediating HDL-stimulated EPC recruitment and the subsequent
functional effects on the ischemic limb. There is some evidence that HDLs also
affect circulating EPCs in humans. In patients with coronary artery disease, higher
HDL cholesterol levels were significantly correlated with higher circulating EPC
numbers (Petoumenos et al. 2009). These findings are corroborated by data from a
study in patients with type 2 diabetes mellitus which found that rHDL infusion at a
dose of 80 mg/kg body weight markedly increased circulating EPC levels compared
to baseline (van Oostrom et al. 2007).
2.2 Preservation of Endothelial Function
Other reports on HDL functionality in endothelial cells established that HDLs have
direct effects on vascular endothelium-relaxing properties. HDLs induce
endothelium-derived vasorelaxation in aortic segments ex vivo in a dose-dependent
manner (Nofer et al. 2004). Mechanistically, binding of HDL to SR-BI and the
lysophospholipid receptor S1P3 on endothelial cells leads to PI3K-stimulated
activation of Akt and mitogen-activated protein (MAP) kinase pathways, and Akt
in turn phosphorylates eNOS at Ser-1177 to increase endothelial nitric oxide
(NO) production and ultimately endothelium-dependent vasorelaxation (Nofer
et al. 2004; Mineo et al. 2003; Yuhanna et al. 2001). The stimulatory effect of
HDLs on NO-dependent vasorelaxation could be mimicked by three
HDL-associated lysophospholipids, i.e., sphingosylphosphorylcholine, S1P, and
lysosulfatide (Nofer et al. 2004). In addition to eNOS activation, modulation of Akt
and MAP signaling by HDLs has been reported to delay the degradation of eNOS
mRNA in endothelial cells, thereby upregulating eNOS protein levels (Ramet
et al. 2003). Dietary oxysterols, in particular 7-oxysterols, impair endothelial
vasorelaxant function by disrupting the active dimeric form of eNOS and by inducing
production of reactive oxygen species (ROS) (Terasaka et al. 2010). HDLs can
counteract the negative effects of 7-oxysterols on endothelial eNOS function by
promoting efflux of 7-oxysterols from endothelial cells via ATP-binding cassette
transporter G1 (ABCG1) (Terasaka et al. 2010). The same researchers revealed that
HDL-mediated removal of cholesterol and oxysterols from endothelial cells through
ABCG1 could reverse the cholesterol loading-induced inactivation of eNOS resulting
from its increased interaction with caveolin (Terasaka et al. 2010). Similar to NO,
there is evidence to suggest that the release of the endothelium-derived vasodilator
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prostacyclin can be influenced by HDLs. In human umbilical vein endothelial cells,
HDLs elevated cyclooxygenase-2 protein expression and thereby induced prostacy-
clin synthesis via a pathway that involved PKC, ERK1/2, and sphingosine kinase
SphK-2 (Xiong et al. 2014). The human relevance of these findings is underscored by
studies demonstrating that infusion of rHDLs in hypercholesterolemic patients led to
normalization of endothelium-dependent vasodilation in response to acetylcholine
(Spieker et al. 2002). Moreover, heterozygosity for a loss-of-function mutation in
ABCA1 has been reported to be associated with low levels of HDL cholesterol as well
as an impaired endothelium-dependent forearm vasodilatory response, a phenotype
which could be restored by intravenous administration of apoA-I/
phosphatidylcholine discs (Bisoendial et al. 2003).
3 Anti-inflammatory Effects
3.1 Suppression of Myelopoiesis
Vascular inflammation, one of the main forces driving the formation of atheroscle-
rotic plaques, is accompanied by the rolling, firm adhesion, and subsequent migra-
tion of monocytes across the vascular endothelium. A first critical determinant for
monocyte transmigration is the number of monocytes present in the circulation.
HDL-mediated cholesterol efflux pathways appear to play a prime role in the
proliferation of myeloid cells in the bone marrow, cell mobilization from the
bone marrow, and subsequent myeloid differentiation, at least in mice. Mice that
lack both ABCA1 and ABCG1 have increased numbers of myeloid progenitor
cells in bone marrow, blood, spleen, and liver, suggestive of aberrant myeloproli-
feration, myeloid progenitor cell mobilization, and extramedullary hematopoiesis
(Yvan-Charvet et al. 2010; Westerterp et al. 2012). As a consequence monocyte
counts in blood are elevated in ABCA1 x ABCG1 double knockout mice (Yvan-
Charvet et al. 2010). In addition, the myeloproliferative phenotype and the
enhanced mobilization of hematopoietic progenitor cells associated with bone
marrow deficiency of ABCA1 and ABCG1 were reversed in mice carrying a
human apoA-I transgene, and in high cholesterol diet-fed LDL receptor knockout
mice, this was associated with less severe atherosclerosis (Yvan-Charvet
et al. 2010; Westerterp et al. 2012). Correspondingly, raising HDL cholesterol
levels in other murine models of myeloproliferative disorders also efficiently
reduced the appearance of hematopoietic progenitor cells in the circulation
(Westerterp et al. 2012). Direct proof for a link between HDL and myeloproli-
feration was provided by experiments showing that incubation of myeloid progeni-
tor cells with HDLs ex vivo suppressed cell expansion (Yvan-Charvet et al. 2010).
Taken together, these findings indicate that HDLs may beneficially impact the
number of circulating monocytes. In humans there is some evidence for a correla-
tion between HDL cholesterol levels and monocyte numbers in patients with
familial hypercholesterolemia (Tolani et al. 2013). However, only few and incon-
sistent data on the association between monocyte counts and risk of atherosclerotic
376 W. Annema et al.
vascular disease in humans has been reported. In addition, it will be important to
consider the heterogeneity of monocytes for any association with coronary heart
disease (Zawada et al. 2012).
3.2 Suppression of Monocyte Extravasation
The arrest of circulating monocytes on inflamed endothelial monolayers is triggered
by chemokines and their corresponding receptors, which both have been
demonstrated to be subject to regulation by HDLs. Infusions of lipid-free apoA-I
in apoE-deficient mice that were fed a high-fat diet reduced the relative abundance
of cells stained positive for the chemokine receptors CCR2 and CX3CR1 in
atherosclerotic plaques in the aortic sinus and decreased the circulating levels of
the chemokines CCL2 and CCL5 (Bursill et al. 2010). Moreover, in vitro rHDLs
were found to downregulate cell surface expression of chemokine receptors on
monocytes and to render human monocytes and endothelial cells partly resistant to
phytohemagglutinin- or cytokine-induced expression of chemokines (Bursill
et al. 2010; Spirig et al. 2013). Although it was shown that HDLs counterbalance
the upregulation of chemokines in response to pro-inflammatory cytokines by
reducing nuclear factor-κβ (NF-κβ) pathway activation, how HDLs modulate
monocyte expression of chemokine receptors on the molecular level remains to
be established (Bursill et al. 2010). In addition to these effects on monocytes and
endothelial cells, HDLs were also able to limit the production of CCL2 in vascular
smooth muscle cells (VSMCs) exposed to thrombin (Tolle et al. 2008). The study
identified HDL as a negative regulator of thrombin-induced activation of Rac1-
dependent NADPH oxidases and subsequent ROS generation. This process is
mediated by binding of HDL to SR-BI on VSMCs, and moreover lysosphingolipids
present in HDL particles can act on local S1P3 receptor to inhibit CCL2 expression
(Tolle et al. 2008).
Once monocytes are attracted by chemokines to inflamed endothelium,
monocyte–endothelial cell interactions are mediated by several cell adhesion
molecules. Experiments in vitro provided compelling evidence that cytokine-
induced adhesion molecule expression on the endothelial cell surface is diminished
in the presence of either native HDLs (Cockerill et al. 1995; Ashby et al. 1998) or
rHDLs (Baker et al. 1999; Clay et al. 2001). Notably, the effects of HDLs on
endothelial expression of adhesion molecules not only occurred in cultured cells but
also in the in vivo setting under inflammatory conditions. For example, a single
injection of discoidal rHDL particles in pigs prevented upregulation of E-selectin
expression in response to intradermal interleukin-1α (Cockerill et al. 2001). More-
over, daily treatment of normocholesterolemic rabbits with rHDLs or lipid-free
apoA-I markedly attenuated periarterial collar-induced endothelial expression of
vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule
1 as well as concomitant neutrophil infiltration into the vessel wall and generation
of ROS (Nicholls et al. 2005). The positive effects of lipid-free apoA-I on
pro-inflammatory vascular changes were still observed when administered as a
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single low dose 3 h after insertion of the non-occlusive periarterial collar (Puranik
et al. 2008), indicating that infusion of apoA-I may also be able to rescue
preestablished vascular inflammation. In patients suffering from claudication, treat-
ment with rHDLs led to a significant reduction in the percentage of VCAM-1
positive cells in femoral artery lesions (Shaw et al. 2008). Diminution of adhesion
molecule expression on endothelial cells by HDLs may involve the activation of
multiple receptors and signaling cascades. There are data supporting that HDLs
alter adhesion molecule expression as a consequence of perturbation of cellular
sphingolipid metabolism and the NF-κβ signaling pathway. HDL3 was found to
impede TNFα-induced upregulation of VCAM-1 and E-selectin expression in
human umbilical vein endothelial cells by antagonizing activation of sphingosine
kinase and subsequent intracellular formation of S1P (Xia et al. 1999). Further-
more, it has been documented that in cultured endothelial cells, incubation with
HDLs prevented NF-κβ activation, movement of p65 to the nucleus, and expression
of NF-κβ target genes in response to TNFα (Xia et al. 1999; Park et al. 2003;
Kimura et al. 2006; McGrath et al. 2009). The basal molecular mechanisms of
the beneficial effects of HDL on endothelial inflammation are dependent on an
increase in the expression of 3β-hydroxysteroid-Δ24 reductase that results in
activation of PI3K and downstream activation of eNOS and heme oxygenase-1
(HO-1) (McGrath et al. 2009; Wu et al. 2013). Specific knockdown of SR-BI or
S1P1 receptor by treatment of human endothelial cells with small interfering RNAs
against SR-BI and PDZK1 or S1P1, respectively, markedly reduced the ability of
HDLs to inhibit VCAM-1 expression and NF-κβ activation (Kimura et al. 2006; Wu
et al. 2013), suggesting that both receptors may be critical for the anti-inflammatory
endothelial actions of HDLs. Corresponding with the possible involvement of the
S1P1 receptor, the inhibitory activity of HDLs on the expression of endothelial cell
adhesion molecules has been proposed to be a function of biologically active
lysosphingolipids carried by HDL particles (Nofer et al. 2003; Kimura
et al. 2006). Besides the lipid component, the anti-inflammatory properties of
HDLs could also be related to the microRNA content of HDL particles. Recently,
it has been reported that transfer of microRNA-223 by HDLs to human aortic
endothelial cells significantly repressed expression of intracellular adhesion mole-
cule 1 (Tabet et al. 2014).
Monocytes bind to adhesion molecules on activated endothelial cells through
monocytic cell surface receptors, such as CD11b. Ex vivo incubation of stimulated
human peripheral blood monocytes with apoA-I in the lipid-free or HDL-associated
state caused a reduction in cell surface expression of CD11b (Murphy et al. 2008).
These results might be directly translatable to the human in vivo situation, as
evidenced by the observation that infusion of rHDLs in patients with atherosclerosis
disease in the femoral artery led to a significantly lower expression of CD11b on
circulating monocytes (Shaw et al. 2008). The fact that cellular depletion of
cholesterol by cyclodextrin mimicked the protective effects of apoA-I on the
expression of monocyte CD11b and that inhibition of CD11b expression is lost in
the presence of an antibody against ABCA1 or in monocytes derived from Tangier
disease patients is indicative of a role for ABCA1-mediated cholesterol efflux in the
mechanism of monocyte deactivation by apoA-I (Murphy et al. 2008).
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3.3 Interference with Macrophage Differentiation and Activation
Monocytes that have entered the arterial intima subsequently differentiate into
resident macrophages of at least two major subtypes that differentially produce a
variety of pro- and anti-inflammatory mediators. In the subendothelial space, the
macrophages become activated and comprise key targets for the anti-inflammatory
action of HDLs. Incubation with HDLs primed isolated murine bone marrow
macrophages into alternative M2 macrophages with anti-inflammatory features
(Sanson et al. 2013). Moreover, HDLs were potent inhibitors of interferon-
gamma-mediated expression of pro-inflammatory M1 markers in isolated mouse
macrophages, and, interestingly, experiments performed with macrophages from
STAT6-deficient mice demonstrated that STAT6 plays an essential role in the
HDL-mediated shift of the macrophage phenotype to M2 (Sanson et al. 2013).
However, other investigators could not replicate these observations, when using
primary human monocyte-derived macrophages (Colin et al. 2014). A recent study
provided novel mechanistic insights into the anti-inflammatory effects of HDLs in
macrophages. Thus, administration of native HDL, rHDL, or apoA-I to mice
challenged with a toll-like receptor (TLR) agonist protected from liver damage
and reduced serum levels of pro-inflammatory cytokines, which was supposed to be
due the ability of HDLs to reduce cytokine production in activated macrophages
(De Nardo et al. 2014). The anti-inflammatory action of HDL particles on
macrophages was explained by their ability to induce the expression of activating
transcription factor 3 (ATF3), which functions as a repressor of pro-inflammatory
target genes (De Nardo et al. 2014).
During the past decades, a considerable amount of data has been published
revealing that natural regulatory T cells, which dampen inflammatory responses,
may help decrease the atherosclerotic disease burden. The findings of a recent
murine study imply that apoA-I could promote the expansion of regulatory T cells.
Subcutaneous injection of human lipid-free apoA-I in LDL receptor/apoA-I double
knockout mice fed an atherogenic diet restored the regulatory T-cell population in
the lymph nodes (Wilhelm et al. 2010). In these animals the raise in the number of
regulatory T cells in the lymph nodes was accompanied by a reversal of the
inflammatory and autoimmune phenotype.
4 Effects of HDLs on Vascular Lipid and Lipoprotein
Homeostasis
4.1 From LDL Retention to Atheroma Formation
4.1.1 Initial Lipid Accumulation in Atherosclerosis-Prone Arterial
Intima: A Sign of LDL Retention
The intima is disproportionally thick at the outer curvatures of the proximal
branches of coronary and carotid arteries, where turbulent flow conditions prevail
and the pulse wave amplitude is relatively high (Wentzel et al. 2012). The
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thickening is a physiological response to these conditions and ensues when the
vascular smooth muscle cells (VSMCs) divide and secrete various components of
the extracellular matrix at the stressed sites. One major factor explaining the
relationship between the thickness of the intima and its susceptibility to atheroscle-
rotic lesion development is the lack of a capillary delivery system and lack of a
lymphatic drainage system in this tissue (Hulten and Levin 2009; Eliska
et al. 2006). As a consequence, the inflowing apoB100-containing lipoprotein
particles (notably LDL and also VLDL remnants) are only slowly conveyed by
the intimal fluid from the subendothelial superficial layer into the deeper intimal
layers and ultimately to the medial layer of the arterial wall where lymphatic
capillaries are present. Indeed, in cholesterol-fed rabbits, intimal LDL concentra-
tion initially increases in atherosclerosis-susceptible sites, where their intimal
residence time of the LDL particles is long, the transit time being calculated to be
hours (Schwenke and Carew 1989a, b).
Since progressive accumulation of LDL cholesterol is a key feature of athero-
genesis, we can deduce that some intimal LDL particles never leave the site. The
constant inflow without compensatory outflow of LDL particles results in a dra-
matic increase in their concentration in the intimal fluid to reach values equaling or
even exceeding (by twofold) those in the corresponding human blood plasma
(Smith 1990). Thus, the concentration of LDL in the arterial intimal fluid is
10–20 times higher than in the extracellular fluids of other extrahepatic tissues, in
which its concentration is about 1/10th of that in the corresponding plasma, so
rendering the intima a truly “hypercholesterolemic” site.
During their lengthy passage across the thick avascular tissue, the LDL particles
tend to bind to the subendothelial extracellular proteoglycan matrix, a phenomenon
known as retention of LDL (Williams and Tabas 1995). The proteoglycans form a
tight network that is negatively charged. To this network the LDL particles bind via
ionic interactions, when positively charged lysine and arginine residues located in
the proteoglycan binding site of apoB100 interact with the negatively charged
sulfate groups of the glycosaminoglycan components of the proteoglycans (Camejo
et al. 1998). The prolonged residence time of LDL particles in the intima, whether
the particles are in solution or trapped in the matrix, enhances their exposure to a
variety of local LDL-modifying factors. Thus, during their long extracellular
residence time, the LDL particles are modified, for example, by oxygen radicals
secreted by the resident cells of the intima, notably by endothelial cells, and also by
SMCs. It is of particular relevance that the endothelial cells become activated to
secrete pro-oxidative compounds at sites with turbulent flow, i.e., at the
atherogenesis-prone sites of the arterial tree (Nigro et al. 2011). Moreover, the
subendothelially located LDL particles are not protected by the powerful antioxi-
dant systems present in the circulating blood plasma, and they also gradually
become depleted of their own antioxidant molecules capable of protecting them
from free radical attack and oxidation (Esterbauer et al. 1991). In addition to the
oxidative processes, various hydrolytic (both proteolytic and lipolytic) enzymes
may also modify the LDL particles in the intima (Tabas 1999). Importantly, the
oxidative and hydrolytic changes of LDL particles render them unstable, trigger
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their aggregation and fusion into lipid droplets, and markedly strengthen their
binding to arterial proteoglycans (Oorni et al. 2000). These in vitro observations
have their close counterparts in various animal models, and also in the human
carotid arteries, in which tiny proteoglycan-, collagen-, and elastin-associated lipid
deposits, detectable only by aid of special electron microscopic techniques, are
located in the subendothelial extracellular space even before any microscopic signs
of atherosclerosis are visible (Nievelstein-Post et al. 1994; Tamminen et al. 1999;
Pasquinelli et al. 1989).
4.1.2 Formation of a Fatty Streak
As stated above, atherosclerosis typically develops at certain predilection sites as a
response to the hemodynamic stress and other types of injury affecting the endo-
thelial cells. Importantly, in such stressed areas with disturbed flow conditions,
endothelial inflammatory signaling pathways become activated and a local
pro-inflammatory environment is created (Nigro et al. 2011). We can consider
this local scenario as a singular starting condition to the development of atheroscle-
rosis. Thus, the flow-mediated preconditioning of the intima renders it a suitable
soil for the retention, modification, and accumulation of LDL particles. Because the
subendothelially located modified LDL particles and the products released from
them are pro-inflammatory, they are likely to have profound local cell-activating
effects and to worsen the inflammation by inducing local generation of various
LDL-modifying enzymes and agents and so creating a positive feedback loop
(Pentikainen et al. 2000; Tabas et al. 2007). Moreover, synthesis and secretion of
pro-inflammatory cytokines and chemokines, such as the monocyte chemotactic
protein-1 (MCP-1; CCL2), are induced (Libby 2002; Zernecke and Weber 2010).
Indeed, monocytes preferentially adhere to the endothelium covering inflamed
tissue sites, i.e., regarding atherogenesis, they tend to enter the intimal areas
containing oxidized or otherwise modified LDL particles (Schmitt et al. 2014a, b).
The extracellularly located modified LDL particles, whether free floating in the
intimal fluid or whether matrix bound, are ingested by intimal macrophages and, to
some extent, also by intimal SMCs (Witztum 2005; Wang et al. 1996). On their
surfaces, the macrophages express scavenger receptors, which recognize oxidized
and otherwise modified LDL particles (Krieger and Herz 1994). The macrophages
may also phagocytose modified LDL particles, provided the particles are in aggre-
gate form or have been converted into droplets via fusion. Since uptake of LDL
cholesterol by macrophages is not negatively feedback regulated by the inflowing
cholesterol, uptake of LDL cholesterol, be it scavenger receptor dependent or
mediated by other mechanisms, may continue until the cells are filled with choles-
terol (Brown and Goldstein 1983). Of great interest, also unmodified native LDLs
can be ingested by macrophages at a rate which is linear to their concentration in the
extracellular fluid (Kruth 2011). Since the concentration of LDL in the intimal fluid
is exceptionally high (see above), such micropinocytotic uptake of LDLs by
macrophages may actually be of great significance in the atherosclerosis-prone
arterial intima.
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In the macrophages, the excess of intracellular cholesterol is esterified with fatty
acids and stored in their cytoplasm as cholesteryl ester droplets (Brown and
Goldstein 1983). Macrophages full of such droplets look foamy under the micro-
scope and are called foam cells. When numerous foam cells form clusters, they
have yellow appearance visible to the naked eye and the site appears as a fatty
streak (Stary et al. 1994). Importantly, when fatty streaks develop in human carotid
arteries, the subendothelial perifibrous lipid droplets disappear (Pasquinelli
et al. 1989). This switch conceivably reflects uptake of the perifibrous droplets by
the subendothelial macrophages. Thus, in a fatty streak the LDL-derived choles-
terol is located mostly intracellularly. Taken together, an important role of
subendothelial macrophages in the arterial intima is to clear unmodified or modified
LDL particles from their surrounding and to store their cholesterol as cholesteryl
esters. Indeed, foam cells in the arterial intima are the most defining feature of
atherosclerosis.
HDLs directly bind unesterified cholesterol. As the consequence, HDL can
mobilize unesterified cholesterol both from cells and extracellular locations (Free-
man et al. 2014). Regarding cholesteryl esters, the extracellularly stored esters,
present either in the core of the matrix-bound LDL particles or in the core of the
perifibrous lipid droplets derived from modified LDL particles, are likely to fully
resist transfer to HDLs. In sharp contrast, intracellular cholesterol stored as
cholesteryl esters in the cytoplasmic lipid droplets of macrophage foam cells is
sensitive to transfer to HDLs (Rosenson et al. 2012). Thus, regarding the return of
LDL cholesterol from the arterial intima back to the circulating blood, it appears to
be of fundamental importance that the LDL particles are first taken up and
metabolized by intimal macrophages. Accordingly, this macrophage-dependent
preparative step appears to be mandatory for the initiation of reverse cholesterol
transport in the arterial intima. However, since the macrophages accumulate
LDL-derived cholesterol, an imbalance between cholesterol influx and cholesterol
efflux exists in the atherosclerosis-prone arterial intima. One reason for the relative
inability of HDLs to effectively remove cholesterol from the intimal macrophages
is their functional modification including proteolysis, oxidation, and lipolysis to
various extents (Lee-Rueckert and Kovanen 2011; DiDonato et al. 2013).
4.1.3 Development of an Atheroma
Conversion of a fatty streak into an atheroma is the next phase in atherogenesis
(Stary et al. 1995). It is characterized by extracellular accumulation of cholesterol
in the deep layers of the intima, i.e., below the superficial foam cell layers.
However, in sharp contrast to the superficial layers of the intima, where atherogen-
esis initiates and where macrophages swiftly arrive and efficiently remove the lipids
so preventing their extracellular accumulation, in the deep layers, the macrophages
arrive late (Nakashima et al. 2008). Accordingly, once formed, the deep extracellu-
lar lipids are not rapidly scavenged by macrophages. Rather, the continuous
formation of lipid droplets without their concomitant removal leads to their pro-
gressive deposition, which ultimately leads to the appearance of “lipid lakes”. The
lakes consist of huge numbers of such droplets, and together the lakes form a lipid
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core (Guyton and Klemp 1996). The presence of a lipid core is the hallmark of an
atheroma.
During the process of lipid core formation, macrophages start to migrate from
the superficial layer into the deep intimal area where they ingest the extracellular
lipid droplets in the periphery of the lipid core and themselves become converted
into foam cells. Since the deep intimal region is distant from the circulating blood, it
easily becomes hypoxic (Hulten and Levin 2009). Although survival mechanisms
are activated in macrophages trapped in such hypoxic areas (Ramkhelawon
et al. 2013), promotion of lipid accumulation, ATP depletion, and immobilization
of the macrophage foam cells is likely to ultimately lead to their death. Of note,
death of a foam cell is bound to liberation of its cytoplasmic cholesteryl ester
droplets into the extracellular space, where the droplets mix with the preexisting
extracellular lipid droplets. Moreover, the nonviable macrophages (foam cells) fail
to effectively remove the cellular debris derived from the dying or dead foam cells
(Thorp et al. 2011), so leaving the formed debris deposited among the lipids of the
growing core. A lipid core also containing remnants derived from dead cells is
called a “necrotic lipid core”.
In summary, regarding cholesterol metabolism in the arterial intima, the super-
ficial and the deep layers appear to be fundamentally different. Mechanistically, in
the superficial compartment of the arterial intima, viable macrophages ingest and
store LDL cholesterol as cholesteryl esters, and transfer it to HDLs for ultimate
return to the circulation, continual hydrolysis of the cytoplasmic cholesteryl esters
being the critical factor for the transfer of cholesterol from LDL to HDL. In
contrast, in the deep intimal compartment, macrophages only inefficiently remove
LDL cholesterol, and, provided a macrophage is converted into a foam cell, it may
die and release its cholesteryl ester cargo into the extracellular space, where the
cholesteryl esters are not available for removal by HDLs. Thus, in the absence of an
efficient transfer of cholesterol from LDL to HDL, the necrotic lipid core grows
progressively and may convert an atheroma into a clinically significant atheroscle-
rotic lesion.
4.2 Inhibition of LDL Modification by HDLs
Resident macrophages in the subendothelial space take up oxidized LDLs via
scavenger receptors and become macrophage foam cells, the hallmark cell type of
atherosclerotic lesions. HDLs have been proven to help to reduce the formation of
lipid-laden macrophage foam cells by rendering LDL particles resistant to oxida-
tion. Preexposure of LDL particles to apoA-I or mature HDL particles completely
prevented the oxidative modification of LDLs by cultured human aortic endothelial
cells and SMCs (Navab et al. 2000). Moreover, the human artery wall cells were no
longer able to oxidize LDLs isolated from mice and humans that received a single
treatment with human apoA-I. Likewise, HDLs have been shown to possess potent
antioxidative activity in chemical in vitro models for oxidative modifications of
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LDLs, using, for example, copper ions (Parthasarathy et al. 1990) or the more mild
oxidizing agent 2,20-azobis(2-amidinopropane) dihydrochloride (AAPH) (Kontush
et al. 2003). At least part of the ability of HDLs to inhibit LDL oxidation was
attributed to the capacity of apoA-I to remove seeding molecules present in freshly
isolated LDLs (Navab et al. 2000). Notably, the reduction of lipid hydroperoxides
to their corresponding hydroxides by HDLs was associated with the selective
oxidation of Met residues in apoA-I to their Met sulfoxide form (Garner
et al. 1998), suggesting that Met residues in apoA-I may act as endogenous
antioxidants within the HDL particle.
In addition to apoA-I, antioxidant properties of HDLs are conferred by
paraoxonase 1 (PON1), an antioxidant enzyme transported in the circulation by
HDL particles. The inhibitory effect of HDLs on LDL oxidation by human artery
wall cells or copper could be mimicked by incubation of LDLs with purified PON1
(Navab et al. 2000; Liu et al. 2008). After treatment of oxidized phospholipids with
PON1, oxygenated polyunsaturated fatty acids were no longer detectable (Watson
et al. 1995a), indicating that PON1 was able to destroy these multi-oxygenated
biologically active molecules which are abundantly formed during the atherogenic
oxidation of LDL particles. Studies in transgenic and knockout mice on the role of
PON1 in the pathogenesis of atherosclerosis have supported the protective effects
of PON1 on LDL oxidation. The lack of PON1 in the HDL fraction of PON1
knockout mice resulted in an inability of these HDL particles to prevent the
formation of oxidized LDLs, and accordingly pon1-null mice were more suscepti-
ble to atherosclerosis than their wild-type littermates (Shih et al. 1998). Expression
of human PON1 in transgenic mice led to the opposite phenotype. On the
atherosclerosis-prone apoE/ background, mice transgenic for human PON1
developed significantly less atherosclerotic plaques in the aorta than the control
mice. Moreover, in vitro PON1-enriched HDLs from PON1 transgenic/apoE
knockout were more potent inhibitors of copper-catalyzed oxidation of LDL
particles (Tward et al. 2002).
Another antioxidant enzyme that has been related to the cardioprotective
antioxidative function of HDL particles is lipoprotein-associated phospholipase
A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase
(PAF-AH). In human plasma a small proportion of the circulating Lp-PLA2 enzyme
activity is found in HDL particles (Tellis and Tselepis 2009). Inhibition of the
enzymatic activity of Lp-PLA2 rendered HDLs unable to prevent monocyte binding
induced by oxidized LDLs in endothelial cells, and supplementation of the dys-
functional HDL particles with purified Lp-PLA2 restored the normal protective
function (Watson et al. 1995b). In mice, adenovirus-mediated expression of human
Lp-PLA2 leads to a reduction in the autoantibody titers against oxidized LDLs
and malondialdehyde (MDA)-modified LDLs (Quarck et al. 2001; Noto
et al. 2003). Despite the fact that the antioxidative potential of HDL-bound
Lp-PLA2 has been well documented, several lines of evidence suggest that the
presence of Lp-PLA2 in LDL particles may actually stimulate atherogenesis. The
pro-atherogenic actions of Lp-PLA2 in LDLs are thought to arise from oxidized free
fatty acids and lysophospholipids, two inflammatory mediators which are released
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after the hydrolysis of oxidized phospholipids by Lp-PLA2 (Tellis and Tselepis
2009). LDLs are the preferred lipoprotein carriers for Lp-PLA2 in the circulation,
which would explain why previous prospective cohort studies paradoxically linked
high plasma Lp-PLA2 levels with adverse cardiovascular outcomes (Brilakis
et al. 2005; Koenig et al. 2004; Sabatine et al. 2007). In support of the hypothesis
that Lp-PLA2 is atheroprotective only when incorporated in HDL particles, Rallidis
et al. found that elevated total plasma Lp-PLA2 mass and activity increased the risk
for future cardiac death in patients with stable coronary artery disease, while
Lp-PLA2 mass and activity in apoB-depleted plasma showed a significant associa-
tion with future cardiac death in the opposite direction (Rallidis et al. 2012).
The protective effect of HDLs on LDL oxidation has been tentatively ascribed to
the antioxidant activities of lecithin-cholesterol acyltransferase (LCAT). Similar to
HDLs, purified LCAT has been shown to diminish the formation of both lipid
hydroperoxides and conjugated dienes in copper-oxidized LDLs (Vohl et al. 1999).
Moreover, adenovirus-mediated transfer of the human LCAT gene into mice with
combined leptin and LDL receptor deficiency decreased circulating levels of
autoantibodies binding to MDA-LDL by 40 % and accordingly limited the accu-
mulation of oxidized LDLs in the arterial wall (Mertens et al. 2003).
4.3 Macrophage Cholesterol Efflux and Reverse Cholesterol
Transport
The uptake of modified LDLs in arterial macrophages leads to the cellular accumu-
lation of cholesterol and oxidized lipids. This process causes the macrophages to
transform into lipid-laden macrophage foam cells which can no longer escape the
arterial wall (Potteaux et al. 2011). The excessive cellular cholesterol in macro-
phage foam cells can be efficiently removed by the potent cholesterol acceptors
lipid-free apoA-I and HDLs to be transported back to the liver by a process termed
reverse cholesterol transport.
4.3.1 Transendothelial HDL Transport
In order to reach these resident macrophage foam cells in the innermost layer of the
arterial wall, apoA-I and HDLs first need to passage across the endothelial cell
layer. There is cell culture evidence that lipid-free apoA-I binds to specific saturable
high-affinity binding sites on aortic endothelial cells, which is followed by inter-
nalization, transcytosis, and delivery of lipidated apoA-I to the basolateral side
(Rohrer et al. 2006). A similar phenomenon was observed when cultivated aortic
endothelial cells were treated with mature HDLs (Rohrer et al. 2009). However, the
mechanisms involved in regulating this endothelial transport of apoA-I and HDLs
are not fully understood. The ABCA1 transporter is thought to play major role in
the apical-to-basolateral transport of apoA-I in aortic endothelial cells (Cavelier
et al. 2006). Induction of ABCA1 expression by a combination of oxysterol and
9-cis-retinoic acid increased the binding and internalization of apoA-I in endothe-
lial cells, whereas knockdown of endothelial ABCA1 by RNA interference reduced
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the cellular uptake and transcytosis of apoA-I (Cavelier et al. 2006). Conversely,
siRNA-mediated gene silencing experiments revealed that the cell surface binding
and transport of HDLs through aortic endothelial cells are highly dependent on
SR-BI and ABCG1, but not on ABCA1 (Rohrer et al. 2009). Subsequent research
has demonstrated expression of the ectopic β-chain of F0F1 ATPase (β-ATPase) on
the endothelial cell surface (Cavelier et al. 2012). The results of this study further
suggest that the binding of lipid-free apoA-I to endothelial cell surface β-ATPase
facilitates the uptake and transport of lipidated apoA-I and mature HDLs by
enhancing β-ATPase-mediated hydrolysis of extracellular ATP into ADP and
inducing consecutive activation of the purinergic P2Y12 receptor (Cavelier
et al. 2012). More recently, transendothelial transport of HDL particles was found
to be modulated by endothelial lipase both through its enzymatic lipolytic activity
and its ability to bridge the binding of lipoproteins to the endothelial surface
(Robert et al. 2013). Initiation of an atherosclerosis-related inflammatory pheno-
type after stimulation of vascular endothelial cells with interleukin-6 significantly
increased the binding, cell association, and transport of HDLs, which was linked
mechanistically to the increase in endothelial lipase expression in response to
interleukin-6 (Robert et al. 2013).
4.3.2 Cholesterol Efflux from Macrophages
Once apoA-I and HDLs have reached macrophage foam cells in the atheromatous
vessel wall, macrophage cholesterol efflux can be elicited via several different
pathways. It is well documented that lipid-free apoA-I and pre-beta HDL particles
are able to remove cholesterol and phospholipids from macrophage foam cells via
the ABCA1 transporter (Wang et al. 2000; Wang and Tall 2003). It has been
postulated that apoA-I-dependent cholesterol efflux from cells is mediated either
by a direct protein–protein interaction between apoA-I and ABCA1 or indirectly by
ABCA1-induced changes in the membrane cholesterol distribution (Wang and Tall
2003). The ability of ABCA1 to mobilize cellular lipids to apoA-I is essential for
the initial lipidation of apoA-I. The ABCG1 transporter is responsible for a major
part of the macrophage cholesterol efflux towards mature HDL particles (Wang
et al. 2004). Since cellular removal of cholesterol via ABCG1 was not accompanied
by specific binding of HDLs to the plasma membrane (Wang et al. 2004), the
molecular basis of efflux of cholesterol mediated by ABCG1, like ABCA1, is not
fully understood and warrants further investigation. Another cell surface receptor
involved in macrophage cholesterol efflux elicited by mature HDLs is SR-BI.
Binding of HDL to macrophage SR-BI facilitates a bidirectional exchange of
unesterified cholesterol and other lipids between the cell membrane and HDL
acceptor particles according to the cholesterol concentration gradient (de La
Llera-Moya et al. 2001). This cholesterol concentration gradient between cells
and HDL not only allows cholesterol transfer via SR-BI but also passive diffusion
of cholesterol molecules to nearby HDL particles by receptor-independent pro-
cesses (von Eckardstein et al. 2001; Yancey et al. 2003). The HDL-associated
enzyme LCAT catalyzes the esterification of cholesterol in HDL particles
(Calabresi and Franceschini 2010). The generated cholesteryl esters leave the
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particle surface and form the core of the maturing HDL particle; hence, a local
gradient of unesterified cholesterol is created that maintains a continuous flow of
unesterified cholesterol from macrophages towards HDLs (Calabresi and
Franceschini 2010).
4.3.3 Exit from the Arterial Wall
There is little reported data on the route used by HDLs to leave the arterial intima.
Recent lines of evidence support a role for the lymphatic vasculature in the
transport of HDLs from the interstitial space back to the bloodstream. Following
injection of fluorescently labeled HDLs in the mouse footpad, HDLs were subse-
quently found in the draining lymph node and its afferent and efferent lymphatic
vessels (Lim et al. 2013). Moreover, the movement of cholesterol from
macrophages in the footpad to the lymph and plasma was substantially reduced in
mice with surgical interruption of the afferent lymphatic vessels or in Chy mutant
mice that lack dermal lymphatic capillaries (Lim et al. 2013; Martel et al. 2013).
The importance of the lymphatic system in the reentry of cholesterol originating
from macrophages via HDLs in the circulation was further confirmed by additional
experiments showing that the appearance of macrophage-derived cholesterol in the
plasma was impaired after implantation of [3H]-cholesterol-labeled macrophages in
the tail skin of apoA-I transgenic mice with microsurgical ablation of the major
lymphatic conduits in the tail (Martel et al. 2013). To provide more direct proof for
the involvement of the lymphatic vasculature in the transport of cholesterol from
the atherosclerotic plaque, aortic segments with advanced atherosclerotic lesions
were loaded with D6-cholesterol and transplanted in apoE knockout mice (Martel
et al. 2013). Inhibition of regrowth of a functional lymphatic vasculature in the
aortic donor wall by an antibody blocking the function of vascular endothelial
growth factor receptor 3 markedly suppressed the apoE-induced removal of
D6-cholesterol from the transplanted aorta (Martel et al. 2013), hence emphasizing
the pivotal role of the lymphatic system for the egress of cholesterol from the aortic
wall. The entry of HDL particles into lymphatic vessels appears to be primarily
dependent on SR-BI. Experiments in cultured cells demonstrate that the internali-
zation and transcytosis of HDL particles by lymphatic endothelial cells are dimin-
ished by an SR-BI blocking antibody or a selective SR-BI inhibitor (Lim
et al. 2013). In agreement, lymphatic transport of HDLs is compromised in SR-
BI-null mice and in mice treated with an antibody against SR-BI (Lim et al. 2013).
Although not formally tested, it is also possible that, in order to reach the circulation
again, HDL particles undergo transcytosis through the luminal endothelial cell
barrier or transfer cholesterol to endothelial cells for delivery to circulating
HDLs. The importance of a well-regulated homeostasis between entry and exit of
HDL particles into and from the arterial wall, respectively, is indicated by the
enrichment of modified and dysfunctional HDLs and apoA-I in atherosclerotic
lesions (DiDonato et al. 2013, 2014; Huang et al. 2014).
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4.3.4 Delivery of Cholesterol to the Liver and Intestine
After having left the arterial wall and entered the circulation, the HDL particles
transport the cholesterol either directly or indirectly via apoB-containing
lipoproteins to the liver for either secretion into bile or for de novo assembly of
lipoproteins. The first direct way by which HDL can deliver cholesterol to the liver
is via SR-BI, a cell surface receptor that binds HDLs and mediates the selective
uptake of HDL-associated cholesteryl esters and the subsequent resecretion of
cholesteryl ester-poor HDLs (Acton et al. 1996). Secondly, HDL particles can be
taken up from the circulation by the liver via HDL holoparticle endocytosis (i.e.,
uptake of the whole HDL particle). The binding of apoA-I to the ectopic β-chain of
F0F1 ATPase on hepatocytes triggers extracellular production of ADP, which in
turn acts on the P2Y13 receptor to stimulate HDL holoparticle endocytosis
(Martinez et al. 2003; Jacquet et al. 2005). In humans, the major fraction of the
cholesteryl esters in HDL particles are shuttled via the action of CETP to apoB-
containing lipoproteins (Charles and Kane 2012). These cholesteryl esters
originating from HDLs are internalized as part of apoB-containing lipoproteins
by hepatic LDL receptors. Following hepatic uptake, HDL-derived cholesterol is, at
least in part, targeted for fecal excretion via the biliary route (Lewis and Rader
2005; Nijstad et al. 2011). Hepatic cholesterol can either be secreted directly in the
free form into the bile by the ABCG5/G8 heterodimer or alternatively be converted
by cholesterol 7α-hydroxylase (CYP7A1) and other enzymes into bile acids for
hepatic excretion via the bile salt export pump (BSEP) (Dikkers and Tietge 2010).
Secretion into bile enables cholesterol to move from the hepatocyte to the intestinal
lumen for final excretion via the stool. This major HDL-driven pathway to elimi-
nate atherogenic cholesterol from the body is also known as reverse cholesterol
transport (Annema and Tietge 2012). Although reverse cholesterol transport from
plaque macrophages to feces only represents a very small proportion of the total
reverse cholesterol transport flux from peripheral tissues, it is key component of the
reverse transport potentially capable of initiating and maintaining the regression of
atherosclerosis (Lee-Rueckert et al. 2013).
5 Atherothrombosis
The most important mechanism of acute coronary syndromes, i.e., unstable angina,
acute myocardial infarction, and sudden cardiac death, is rupture or erosion of a
coronary atheroma (Libby 2013b). The risk of atheromatous rupture or erosion
appears to critically depend on both the cellular and extracellular compositions of
the atheroma. The superficial layer of an atheroma separating a necrotic lipid core
from the circulating blood is called the “fibrous cap”. Although a cap usually contains
foam cells, its critical components are VSMCs, which synthesize and secrete collagen
and other components of the extracellular matrix. It is current understanding that the
cap is thinning as the necrotic lipid core is growing. Whether the thinning is a
response to the enlargement of the necrotic core, or whether thinning is an indepen-
dent process and just allows the core to expand, has not been established.
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As expected, a lesion with a thick fibrous cap and a small lipid core is stable,
whereas a lesion with a thin fibrous cap and a large lipid core is unstable and prone
to rupture. Indeed, it is now well recognized that acute coronary syndromes most
commonly result from rupture of a thin-cap fibroatheroma (TCFA), which is
characterized by a large necrotic core with an overlying thin fibrous cap measuring
less than 65 μm (Sakakura et al. 2013; Fujii et al. 2013).
Provided a stable lesion with a thick fibrous cap causes significant stenosis of the
arterial lumen, and turbulent flow conditions are created, some endothelial cells
may detach, that is, the plaque surface becomes eroded (Libby 1995; Farb
et al. 1996). Apoptosis of endothelial cells also leads to endothelial denudation,
i.e., to plaque erosion when, for example, subendothelial mast cells degrade the
basement membrane of endothelial cells (Durand et al. 2004; Mayranpaa
et al. 2006). The exposed subendothelial structures are prothrombotic and a
platelet-rich thrombus is formed locally. Since the activated platelets secrete
platelet-derived growth factor which stimulates SMCs to divide and generate
extracellular matrix, a neointima is formed at the site of erosion. This is one
mechanism by which the fibrotic cap of a stenosing plaque becomes thicker and
the plaque grows into the lumen and so aggravates the local stenosis.
When an unstable TCFA ruptures, the flowing blood becomes exposed to the
necrotic lipid core. The various components of the core, notably tissue factor
released by macrophages, apoptotic bodies, remnants of dead cells, and extracellu-
larly located lipids, all are contributing to the strong thrombogenic response usually
associated with a plaque rupture (Fuster et al. 2005; Corti et al. 2003). Thus, the
platelet-rich arterial thrombus growing at the site of plaque rupture easily becomes
occlusive, even if the plaque only had caused a mild stenosis which was hemody-
namically nonsignificant.
In view of the importance of the thickness of collagen-rich matrix of the fibrous
cap in determining plaque stability and instability, it is essential to understand the
factors that may regulate its thickness. Regarding such regulation, two related
observations made in advanced human atherosclerotic plaques are of prime impor-
tance. First, irrespective of the structure of an atherosclerotic plaque, the actual site
of atheromatous ulceration with ensuing local formation of a platelet-rich thrombus
is characterized by an inflammatory process (van der Wal et al. 1994). Thus,
atheromatous coronary and carotid ulcerations have invariably shown the presence
of inflammatory cell infiltrates, composed of macrophages, T cells, and mast cells
(Kovanen et al. 1995; Bui et al. 2009). When compared with the evolving athero-
sclerotic plaques, which contain inflammatory cell infiltrates, composed of various
subsets of macrophages and T cells and also of mast cells and neutrophils
(Woollard 2013), the vulnerable plaques appear to be equally, if not even more
immunologically, active. The second critical aspect of a vulnerable atherosclerotic
plaque is the fact that SMCs are dying in their fibrous caps (Bennett 1999).
Fundamentally, the various activities of SMCs tend to thicken the cap, while
those of the inflammatory cells tend to oppose them. The net production of matrix
components depends on the number of the matrix-producing SMCs and the ability
of the individual cells to produce such components. The number of SMCs depends
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on the balance of cell replication and cell death. In human atherosclerotic plaques,
the infiltrating lymphocytes are of the Th1 subpopulation of CD4+ cells and the
pro-inflammatory Th1-derived cytokines, notably interferon-gamma, dominate
(Hansson 2005). This cytokine is able to inhibit the capacity of SMCs to produce
collagen (Libby 1995) and together with TNFα and interleukin-1β (IL-1β) contrib-
ute to their apoptotic death. Thus, activation of Th1 cells, together with IL-1-
β-producing macrophages and TNFα-producing mast cells within the cap of an
atheroma, could lower the local rate of collagen production by lowering the number
of SMCs and by inhibiting the rate of synthesis in those SMCs that survive
(Kaartinen et al. 1996). Importantly, the fibrous caps often contain cholesterol
crystals, which have the potential to activate the NLRP3 inflammasome in
macrophages and so trigger release of IL-1β from the macrophages (Rajamaki
et al. 2010; Duewell et al. 2010). Since it is unlikely that HDLs are capable of
removing crystalline cholesterol from the intima, the crystals, once formed, may
permanently stimulate cap macrophages to secrete IL-1β and so contribute to the
ongoing cap thinning.
The various components of the extracellular matrix are degraded by members of
the superfamily of matrix metalloproteinases (MMPs) primarily produced by the
macrophages of the caps (Newby 2005). For the MMPs to become active, they need
to be proteolytically activated. Among the proteolytic enzymes capable of
activating plaque MMPs are plasmin, chymase, and tryptase, the two latter ones
being neutral proteases secreted by activated mast cells in atherosclerotic lesions
(Johnson et al. 1998). Once activated, interstitial collagenase, MMP-1, can degrade
the otherwise protease-resistant fibrillar collagen fibers into fragments, and another
member of the family, MMP-9, can break collagen fragments further. Importantly,
stromelysin, MMP-3, has a broad spectrum and can degrade other components of
the extracellular matrix as well, including proteoglycans and elastin (Libby 2013a).
Cathepsins are another group of enzymes capable of effectively degrading the
various components of the fibrous cap (Fonovic and Turk 2014). Thus, the presence
of inflammatory cells in the caps of advanced plaques tends to render the plaque
unstable and prone to rupture by both decreasing the production and increasing the
degradation of the extracellular matrix of the fibrous cap.
5.1 Effects of HDLs on Smooth Muscle Cells
VSCMs can indirectly influence the development of atherosclerosis by the secretion
of growth factors and vasoactive agents, and the protective effects of HDLs on
atherosclerotic lesion formation might, at least partly, be related to their impact on
the secretory function of VSMCs. Exposure of aortic SMCs to mildly oxidized LDLs
enhanced the production and release of platelet-derived growth factor and basic
fibroblast growth factor, while addition of HDLs abolished the stimulatory effect of
oxidized LDLs on growth factor secretion by these VSMCs (Cucina et al. 1998,
2006). Conversely, treatment of rabbit SMCs in culture with HDLs potentiated the
synthesis of the vasodilator prostacyclin via a mechanism involving MAP kinase
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kinase signaling and increased cyclooxygenase-2 expression (Vinals et al. 1997,
1999). VSMCs are also considered to protect the atherosclerotic plaque against
destabilization and rupture. In this respect, HDLs regulate both the proliferation and
migration of VSMCs. Nofer and colleagues showed that HDLs accelerate prolifer-
ation of VSMCs by driving the cell cycle forward in the G1 phase via cyclin
D1-induced phosphorylation of pRb (Nofer et al. 2001a). Elevated cyclin D1
expression in VSMCs in response to treatment with HDLs in turn relies on activa-
tion of the Raf/MEK/ERK signal transduction pathway (Nofer et al. 2001a). On the
other hand, the platelet-derived growth factor-mediated migration of VCMCs is
limited by HDLs through the interaction of HDL-bound S1P with the S1P2 receptor
(Tamama et al. 2005). Finally, HDLs were found to suppress inflammatory
responses in VSMCs. Oxidized LDLs, via formation of ROS, induced NF-κβ
activation in cultured VSMCs, while their pretreatment with HDLs inhibited the
intracellular rise in ROS and the subsequent upregulation of NF-κβ elicited by the
oxidized LDLs (Robbesyn et al. 2003).
5.2 Antithrombotic Effects of HDLs
5.2.1 HDLs and Platelets
The majority of acute coronary syndromes are caused by the rupture of an athero-
sclerotic plaque in a coronary artery and subsequent formation of an occlusive
coronary thrombus. There appears to be a relationship between plasma HDLs and
the thrombogenic potential of blood, as evidenced by the fact that the total throm-
bus area in an ex vivo flow chamber model for coronary thrombosis was lower in
human subjects with higher HDL cholesterol levels (Naqvi et al. 1999). HDLs have
several favorable effects on platelets that might explain its interference with
thrombus formation in the coronary vasculature. First, it has been reported that
HDLs can block the activation and aggregation of platelets. In a small clinical trail,
13 patients with type 2 diabetes mellitus were randomized to a single infusion of
rHDLs (CSL-111) or placebo (Calkin et al. 2009). Study results established that a
40 % increase in HDL cholesterol levels in patients with type 2 diabetes mellitus
was associated with a 50–75 % reduction in platelet aggregation (Calkin
et al. 2009). A similar decrease in the aggregation of platelets was observed when
isolated human platelets were incubated with rHDLs or native HDLs in vitro
(Calkin et al. 2009; Nofer et al. 1998; Badrnya et al. 2013). Native HDLs and
rHDLs not only modulate platelet aggregation but also prevent platelet degranula-
tion and spreading as well as adhesion of platelets to fibrinogen (Calkin et al. 2009;
Nofer et al. 1998; Badrnya et al. 2013). In addition, rHDLs limited the
incorporation of platelets in growing thrombi under flow conditions in vitro (Calkin
et al. 2009). The ability of HDLs to block platelet aggregation was proposed to be
due to a reduction in the availability of the second messengers 1,2-diacylglycerol
and inositol 1,4,5-trisphosphate, a decreased mobilization of intracellular calcium,
activation of protein kinase C, and elevated Na+/H+ exchange (Nofer et al. 1996;
1998). The role of SR-BI for the anti-aggregatory effect of HDLs is controversial.
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One study reported that inhibition of platelet reactivity by HDLs results from
cholesterol depletion in lipid rafts but that this is independent of ABCG1 and
SR-BI (Calkin et al. 2009). In contrast, Brodde et al. found that SR-BI is the
receptor responsible for binding of HDL to platelets and that HDLs are no longer
able to attenuate thrombin-induced adhesion of platelets to fibrinogen when using
platelets isolated from SR-BI knockout mice (Brodde et al. 2011). The inhibitory
activity of HDLs on platelets is mimicked by soybean phosphocholine (Calkin
et al. 2009) and phosphatidylserine-containing liposomes (Brodde et al. 2011),
underlining the importance of the phospholipid component in this antithrombotic
function of HDLs. As a final point, HDLs may regulate the platelet coagulant
activity by reducing the synthesis of platelet-activating factor in endothelial cells
(Sugatani et al. 1996).
Another step of the arterial atherothrombotic process in which HDLs may
interfere is the production of platelets from bone marrow megakaryocyte progenitor
cells. In vitro experiments have revealed that rHDLs promote the removal of
cholesterol from megakaryocyte progenitor cells in an ABCG4-dependent fashion,
thereby decreasing cellular proliferation (Murphy et al. 2013). Consistent with
these observations, intravenous administration of rHDLs resulted in a decrease in
the amount of bone marrow megakaryocyte progenitor cells and concomitantly
reduced circulating platelets in Ldlr/ mice transplanted with wild-type bone
marrow, while rHDLs lost their effects on bone marrow megakaryocyte progenitor
cells and platelet numbers when injected into Ldlr/ mice that were transplanted
with ABCG4-deficient bone marrow (Murphy et al. 2013). A small placebo-
controlled clinical study demonstrated that a single injection of rHDLs significantly
reduced platelet counts in patients with peripheral vascular disease (Murphy
et al. 2013). The importance of deregulation of cholesterol homeostasis in mega-
karyocyte progenitor cells for atherothrombosis was supported by evidence that
selective disruption of ABCG4 in bone marrow cells of LDL receptor knockout
mice accelerated the progression of atherosclerotic lesion formation and was
associated with marked thrombocytosis and an increased tendency to develop
arterial thrombosis (Murphy et al. 2013).
5.2.2 HDLs and Coagulation
Various publications have described an impact of HDLs on the extrinsic coagula-
tion pathway that might result in a decreased tendency for thrombosis. Inhibition of
the catalytic activity of the tissue factor–factor VIIA complex by HDLs has been
shown to impede the activation of the procoagulant factor X (Carson 1981). Besides
direct inactivation of tissue factor and factor Va, HDLs are able to modulate the
tissue factor-activated coagulation cascade by downregulating tissue factor expres-
sion in thrombin-stimulated endothelial cells through suppression of RhoA and
induction of PI3K (Viswambharan et al. 2004). In addition, incorporation of anionic
phospholipids into apoA-I-containing rHDL particles resulted in the loss of their
procoagulant properties, revealing that, by scavenging anionic phospholipids,
apoA-I may control blood coagulation (Oslakovic et al. 2009). HDLs have also
been shown to promote the ability of the anticoagulant activated protein C and its
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cofactor protein S to cause inactivation of factor Va through Arg306 cleavage, and in
normal healthy subjects, plasma levels of apoA-I were positively correlated with
the anticoagulant potency of activated protein C and protein S in a prothrombin-
time clotting assay (Griffin et al. 1999). Of note, these findings were later
questioned by another study revealing that the previously observed capacity of
the HDL fraction to boost the activated protein C system was not an actual property
of HDLs, but instead was due to co-isolation of anionic phospholipid membranes
with the HDL fraction during ultracentrifugation (Oslakovic et al. 2010).
6 Myocardial Injury
The main pathophysiological manifestation of coronary heart disease is myocardial
damage due to ischemia–reperfusion. It has been postulated that HDLs can provide
protection against myocardial injury following ischemia–reperfusion. In an in vivo
murine ischemia–reperfusion model, it was found that the infarcted area was
decreased when mice were treated 30 min before ischemia–reperfusion with either
human HDLs or S1P (Theilmeier et al. 2006). In this regard, HDL or S1P injection
mitigated the inflammatory response to ischemia–reperfusion as manifested by a
lower accumulation of leukocytes in the infarcted area (Theilmeier et al. 2006).
Furthermore, cardiomyocytes were better able to resist ischemia–reperfusion-
induced apoptosis in the presence of HDLs or S1P (Theilmeier et al. 2006), poten-
tially due to a higher tolerance of HDL-treated cardiomyocytes to hypoxia-induced
opening of the mitochondrial permeability transition pore (Frias et al. 2013). S1P3
was identified as the receptor responsible for the beneficial effect of HDLs and S1P
on reperfusion injury (Theilmeier et al. 2006). The finding that HDLs ameliorate
myocardial ischemia–reperfusion damage has subsequently been confirmed and
extended by others. Ex vivo exposure of isolated hearts from wild-type mice to
HDLs provided dose-dependent cardioprotection from reperfusion injury (Frias
et al. 2013). On the other hand, HDL-mediated protection of isolated hearts or
cardiomyocytes against hypoxia was lost in mice deficient in tumor necrosis factor
and in mice with cardiomyocyte-restricted knockout of signal transducer and
activator of transcription 3 (STAT3) (Frias et al. 2013), suggesting a role for the
survivor activating factor enhancement pathway which is initiated by tumor necro-
sis factor and involves activation of STAT3. In another study, HDL cholesterol
levels were raised in LDL receptor-deficient mice using adenovirus-mediated gene
transfer of human apoA-I (Gordts et al. 2013). After induction of myocardial
infarction by permanent ligation of the left anterior descending coronary artery,
mice that were injected with an adenovirus expressing human apoA-I exhibited a
higher survival rate, reduced infarct expansion, attenuated dilatation of the left
ventricle, as well as improved systolic and diastolic cardiac function when com-
pared with controls (Gordts et al. 2013).
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Conclusions
HDL particles exert many effects which may help either to protect arteries from
the development, progression, and complication of atherosclerosis or even
facilitate repair and regression of lesions. Nevertheless, HDL has not yet been
successfully exploited for preventive or curative therapy of cardiovascular
diseases. One potential reason for this shortfall is the structural and functional
complexity of HDL particles which is further increased in several inflammatory
conditions including CAD itself and which is not discerned by the biomarker
HDL cholesterol. Moreover, the relative importance of the many physiological
and pathological activities of normal and dysfunctional HDL, respectively, for
the pathogenesis of atherosclerosis is unknown. The elucidation of structure–
function relationships of HDL-associated molecules is essential to exploit HDL
for the development of anti-atherogenic drugs as well as of diagnostic
biomarkers for the identification, personalized treatment stratification, and mon-
itoring of patients at increased cardiovascular risk. In addition to the metabolism
of HDL or its anti-atherogenic molecules, also the cellular pathways positively
regulated by HDL are interesting targets for anti-atherosclerotic therapies.
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Abstract
The prevalence of type 2 diabetes mellitus and of the metabolic syndrome is
rising worldwide and reaching epidemic proportions. These pathologies are
associated with significant morbidity and mortality, in particular with an excess
of cardiovascular deaths. Type 2 diabetes mellitus and the cluster of pathologies
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including insulin resistance, central obesity, high blood pressure, and hypertri-
glyceridemia that constitute the metabolic syndrome are associated with low
levels of HDL cholesterol and the presence of dysfunctional HDLs. We here
review the epidemiological evidence and the potential underlying mechanisms
of this association. We first discuss the well-established association of type
2 diabetes mellitus and insulin resistance with alterations of lipid metabolism
and how these alterations may lead to low levels of HDL cholesterol and the
occurrence of dysfunctional HDLs. We then present and discuss the evidence
showing that HDL modulates insulin sensitivity, insulin-independent glucose
uptake, insulin secretion, and beta cell survival. A dysfunction in these actions
could play a direct role in the pathogenesis of type 2 diabetes mellitus.
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1 Type 2 Diabetes Mellitus and the Metabolic Syndrome
Diabetes mellitus (DM) is characterized by increased fasting and/or postprandial
glucose levels. The disease had been known for many centuries (Laios et al. 2012).
Its etiology1 however started to be unraveled in the late nineteenth century/early
twentieth century. During this period, it was eventually discovered that a compound
in pancreatic extracts (later identified to be insulin) could cure young diabetic
patients (Banting et al. 1922). From the early work of H. P. Himsworth in 1936, a
concept emerged that diabetes could be divided into what he termed “insulin
sensitive” and “insulin insensitive” [the pioneering work of Himsworth is nicely
portrayed in a historical perspective written by Gerald Reaven (Reaven 2005)]. But
it is only once a reliable radioimmunoassay became available to measure
circulating insulin levels (Bray 1996) that it was realized that some patients
suffered from a disease associated with low to undetectable insulin levels and
prone to ketoacidosis (type 1 DM [T1DM]), while others, the vast majority, had
high circulating insulin levels despite increased glucose levels (type 2 DM
[T2DM]) (Inzucchi 2012). Patients with T2DM are often overweight and obese,
and their diabetes develops later in life. These patients are characterized as having
insulin resistance (IR), i.e., a decreased response of insulin-sensitive tissues to the
effects of the hormone, in particular its ability to induce glucose uptake. Insulin
resistance is usually associated with compensatory hyperinsulinemia in an attempt
to maintain normoglycemia. Insulin resistance is a hallmark of T2DM as well as of
overweight and obesity. Insulin resistance precedes the development of T2DM, and
it is once that the beta cell can no longer compensate to the insulin resistance that
the full-blown disease with hyperglycemia develops (Tabak et al. 2009). Gerald
1 The study of causes or origins (of a disease).
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Reaven, in his seminal Banting Lecture in 1988 (Reaven 1988), summarized his
work that put insulin resistance not only at the center of diabetes research but
proposed that insulin resistance may directly contribute to the increased risk of
coronary artery disease associated with T2DM or obesity. In this chapter, he
suggested that IR and hyperinsulinemia were, together with increased VLDL/
triglyceride levels, low HDL cholesterol levels, and hypertension, directly
associated with and responsible for the development of diabetes. He termed “syn-
drome2 X” the clustering of these features. Syndrome X was also named “insulin
resistance syndrome” but is now generally called “metabolic syndrome.” This
syndrome corresponds to a cluster of increased abdominal obesity (a good proxy
of insulin resistance), increased blood glucose levels, high blood pressure and
elevated triglycerides, and low HDL cholesterol levels. Several definitions of the
Table 1 Definitions of the metabolic syndrome
NCEP ATP III WHO (1998) IDF (2005)
Criteria Three of the
following
Presence of DM, IGF, IGT,
or insulin resistance and
two of the following
Central obesity
(ethnicity specificity)






















TG 1.7 mmol/l and/or
HDL-C< 0.9 mmol/l








or treatment for these
specific lipid
abnormalities
Blood pressure 130/85 mmHg
or treatment
140/90 mmHg 130/85 mmHg
r treatment
Blood glucose FPG 5.6 mmol/l
or treatment
FPG 5.6 mmol/l or
treatment
Others Urinary albumin
excretion 20 μg/min or
albumin/creatinine
ratio 30 mg/g
BMI body mass index, DM diabetes mellitus, FPG fasting plasma glucose, HDL-C high-density
lipoprotein cholesterol, IDF International Diabetes Federation, IFG impaired fasting glucose, IGT
impaired glucose tolerance, NCEP National Cholesterol Education Program, TG triglycerides,
WHO World Health Organization, WHR waist-hip ratio
2 A group of symptoms that collectively indicate or characterize a disease.
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metabolic syndrome have been proposed with the National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III) definition being the one most
widely used. TheWorld Health Organization (WHO) and the International Diabetes
Federation (IDF) have suggested other definitions. Table 1 summarizes these
various definitions. These current definitions, albeit arbitrary in the cutoffs that
were chosen for the different variables included, are intended to provide a useful
tool for clinicians to identify individuals at increased risk for the development of
T2DM, atherosclerotic cardiovascular disease, and cardiovascular death. T2DM
and the metabolic syndrome are characterized not only by insulin resistance but
also by a dyslipidemia that includes high triglyceride and low HDL cholesterol
levels. With the presence of small dense LDLs in T2DM, these lipid abnormalities
substantially contribute to the increased cardiovascular morbidity and mortality
associated with these conditions (Grundy 2012). Several epidemiological studies
have clearly shown that these lipid abnormalities are present before the develop-
ment of T2DM. Furthermore, longitudinal studies have provided evidence that
these abnormalities represent an independent risk factor for T2DM (von
Eckardstein et al. 2000). Hence, the concept has emerged that lipid abnormalities
associated with IR and the metabolic syndrome are not only bystanders of the
metabolic dysfunctions but contribute directly to the progression to type DM.
2 Low HDL Cholesterol Levels in Diabetes and Metabolic
Syndrome
T2DM and the metabolic syndrome are characterized by the presence of an
atherogenic dyslipidemia typically including low HDL cholesterol, hypertrigly-
ceridemia, and increased small dense LDL blood concentrations. Individuals with
low HDL cholesterol are often insulin resistant and at increased risk of developing
T2DM (Li et al. 2014; von Eckardstein and Sibler 2011). T2DM, the metabolic
syndrome, and IR are characterized by hyperinsulinemia and increased free fatty
acids (FFA). Both insulin resistance and FFAs appear to contribute to the patho-
genesis associated with decreased HDL levels (Rohrer et al. 2004).
2.1 Insulin Resistance, Hypertriglyceridemia, and Decreased
HDL Cholesterol Levels
Insulin has pleiotropic effects on lipid metabolism, in particular on the metabolism
of HDLs and the TG-rich VLDLs. In rats, insulin can acutely decrease the hepatic
production of ApoB100 (Chirieac et al. 2000), the apolipoprotein required for
VLDL assembly, by favoring ApoB100 degradation. In the Hep2G liver cell line,
insulin also decreases the levels of microsomal TG transfer protein that is essential
for VLDL synthesis and secretion (Lin et al. 1995). Insulin could therefore nega-
tively affect the hepatic production of VLDL. However, the situation is more
complex than this because there are two VLDL subtypes that are differentially
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regulated by insulin, the larger and more buoyant VLDL1 particles and the smaller
and denser VLDL2 particles. VLDL2 particles are intermediates in the synthesis of
VLDL1 in the liver, but they can also be secreted directly by this organ. Addition-
ally, VLDL2 can be generated in the circulation from VLDL1 through lipoprotein
lipase activity (Taskinen 2003). Insulin does not appear to affect the hepatic
production of VLDL2 (at least not in humans, see below) but seems to only inhibit
hepatic VLDL1 production by inhibiting the conversion of VLDL2 into VLDL1
(Taskinen 2003). VLDL1 particles are seen by some authors as “liver-derived”
chylomicron-like particles (Taskinen 2003). It makes sense therefore that insulin
inhibits their production following meals in a situation where chylomicrons are
produced by the intestine. In contrast, VLDL1 particle production could be favored
in the fasting state. While insulin inhibits VLDL1 production, it favors the hepatic
production of VLDL2 particles because insulin can increase the activity of the
sterol regulatory element-binding protein (SREBP) 1c transcription factor that
induces the expression of enzymes required for fatty acid and TG synthesis, such
as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) (Horton
et al. 2002). However, insulin was not found to modulate VLDL2 blood levels in
humans (Malmstrom et al. 1997a, b). The physiological importance of the regula-
tion of fatty acid and TG synthesis by insulin on VLDL production is therefore
unclear. In type 2 diabetic individuals (i.e., in the presence of an insulin-resistant
state), insulin is no longer able to inhibit VLDL1 production (Malmstrom
et al. 1997a), and this can thus favor overall VLDL hepatic secretion. This presum-
ably contributes to the hypertriglyceridemia seen in type 2 diabetic and metabolic
syndrome patients (Brown and Goldstein 2008). In addition, hyperinsulinemia
resulting from insulin resistance can enhance SREBP1c transcription and thereby
microRNA33b (miR33b) that is encoded by an intron of the SREBP1c gene. Both
SREBP1c and miR33b can drive VLDL production and favor hypertriglyceridemia
by stimulating fatty acid and triglyceride synthesis (Rayner et al. 2011).
A high production of VLDLs can decrease the stability of HDL particles by
increasing the transfer of TG from TG-rich particles to HDLs via the activity of the
cholesteryl ester transfer protein (CETP) enzyme (Rashid et al. 2003). This is one
possible mechanism linking high TG blood levels with decreased HDL cholesterol
levels. Insulin participates in the clearance of TG from TG-rich lipoproteins by
stimulating the secretion of lipoprotein lipase (LPL) in certain adipose tissues (e.g.,
subcutaneous depot) (Fried et al. 1993). Consequently, insulin resistance would
lead to increased circulating TG-rich particles and augmented TG loading of HDLs.
Additionally, reduced TG hydrolysis in VLDLs and chylomicrons will decrease the
release of surface remnants which contribute to the maturation of HDL (Eisenberg
1984; Rashid et al. 2003). These two effects combined—decreased surface remnant
production and enhanced CETP activity—favor the reduction in HDL cholesterol
levels via the mechanism mentioned above (i.e., decreased HDL stability due TG
enrichment of the particle).
Insulin has the potential to directly affect HDL production by the liver, either in
a positive or in a negative manner. In the Hep2G liver cell line, insulin can stimulate
the expression of apolipoprotein A-I (ApoA-I) (Murao et al. 1998), the most
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abundant apolipoprotein in HDLs (Eisenberg 1984; Rye and Barter 2012), raising the
possibility that hepatic insulin resistance contributes to decreased production of
HDLs. The relevance of this effect has however not been validated in vivo. In
contrast, insulin may also negatively impact on hepatic HDL production by enhanc-
ing miR33 transcription. Indeed, miR33 suppresses the production of the adenosine
triphosphate-binding cassette transporter A1 (ABCA1) at the posttranscriptional level
and thereby compromises phospholipid and cholesterol efflux needed for HDL
formation (Besler et al. 2012; Rader 2006; Rayner et al. 2011; Tang and Oram 2009).
2.2 FFAs and Decreased HDL Levels
In vitro, FFAs decrease the expression of SREBP1c by inhibiting the transcriptional
activity of liver X receptor (LXR) (Ou et al. 2001; Yoshikawa et al. 2002). This
represents a negative feedback loop ensuring that the production of VLDLs occurs
when there is a need to deliver TGs to peripheral tissues (muscles, adipose tissue,
etc.). Reduction in LXR activity, and consequently VLDL production, would be
expected to lead to increased HDL cholesterol blood levels as a result of increased
HDL stability. However, in the liver, unsaturated FFAs inhibit the expression of
ABCA1 (Uehara et al. 2002). Moreover, free fatty acids stimulate the proteasomal
degradation of ABCA1 (Wang and Oram 2005, 2007). So even though FFAs can
lower the production of hepatic triglycerides, which will favor HDL stability, FFAs,
at the same time, directly inhibit the generation of HDL particles.
2.3 HDL Metabolism, Subclasses, and Catabolism
Nascent HDLs are the precursors of the mature HDL3 and HDL2 particles. They are
generated from lipid-free ApoA-I that acquires phospholipids and cholesterol
extracellularly. ABCA1-mediated lipid efflux from cells is important for this initial
lipidation. Further acquisition of lipids and subsequent LCAT-driven cholesterol
esterification leads to the formation of mature HDL3 particles. These particles can
absorb more phospholipids and free cholesterol by a mechanism involving ABCG1.
Altogether, this transforms the HDL3 particles into larger and less dense HDL2
particles. Like ABCA1, this transporter is regulated by LXR and hence suppressed
by unsaturated fatty acids at the transcriptional level (Uehara et al. 2007) so that the
production of larger HDL2 is compromised. In addition, the conversion of HDL2
into HDL3 is enhanced in diabetic dyslipidemia by increased activities of CETP and
hepatic lipase: First, the transfer rate of cholesteryl esters from HDL to VLDL in
normal individuals depends on the concentration of CE acceptors, that is, VLDL
particles, but not on CETP activity (Mann et al. 1991). However, in individuals with
hypertriglyceridemia, cholesteryl ester transfer from HDL to VLDL can be aug-
mented by increasing CETP plasma activity (Mann et al. 1991). Second, HL and
endothelial lipase can convert HDL2 particles back to HDL3 particles that begin a
new cycle of maturation or are further degraded by the liver or cleared through the
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kidneys (Borggreve et al. 2003; Ginsberg 1998; Rader 2006). HL activity is increased
in T2DM (Tan et al. 1999) and contributes to the production of smaller and denser
HDL particles (i.e., HDL2 to HDL3) that are then catabolized as indicated above.
3 Does HDL Play a Causal Role in the Pathogenesis
of Diabetes?
Several epidemiological studies have shown the association between low plasma
concentrations of HDL-C and increased risks not only of CHD but also T2DM
(Di et al. 2009; von Eckardstein et al. 2000).
We have seen that some of the metabolic perturbations (hyperglycemia,
hypertriglyceridemia, etc.) associated with diabetes (and the metabolic syndrome)
are mechanistically linked to decreased HDL cholesterol levels in blood. Tradition-
ally, a reduced plasmatic level of HDL cholesterol has been interpreted to be the
result of such metabolic perturbations, which are already present in the prediabetic
state, and hence an innocent bystander of T2DM. However, several more recent
studies suggest that HDLs help to maintain euglycemia via both insulin-dependent
and insulin-independent pathways (Drew et al. 2012; von Eckardstein and Sibler
2011). The infusion of artificially reconstituted HDL (rHDL) was found to improve
glycemia in patients with T2DM (Drew et al. 2009). In a post hoc analysis of data
from diabetic participants in the ILLUMINATE trial, the addition of the CETP
inhibitor torcetrapib to atorvastatin was found to increase HDL-C and to improve
glycemic control (Barter et al. 2011). Several in vitro and animal experiments
provided evidence that HDL improves the function and survival of beta cells as
well as glucose-lowering metabolism in the muscle, liver, and adipose tissue (Drew
et al. 2012; von Eckardstein and Sibler 2011; von Eckardstein and Widmann 2014).
In mice, the absence of ApoA-I leads to hyperinsulinemia and hyperglycemia as
well as altered responses to insulin tolerance tests. Vice versa, ApoA-I transgenic
mice exhibit lower fasting glucose levels and improved glucose tolerance test
compared with wild-type mice (Han et al. 2007; Lehti et al. 2013). These data
point to a modulating role of HDLs in maintaining normal glucose homeostasis.
Moreover, genetically increased HDL cholesterol and ApoA-I levels in mice
prevented high-fat diet-induced glucose homeostasis impairment (Lehti et al. 2013).
Although it remains to be determined whether this is related to differences in
skeletal muscle insulin resistance, adipose tissue mass, or differences in beta cell
function, these data obtained in mice indicate that ApoA-I plays a modulatory role
in the regulation of glucose homeostasis. This notion is also supported by studies in
humans displaying altered HDL metabolism due to polymorphisms in the ApoA-I
and ABCA1 genes that have been associated with increased risk of diabetes and
impaired glucose uptake (Morcillo et al. 2005; Villarreal-Molina et al. 2008).
Heterozygotes for rare mutations in the ABCA1 gene that profoundly decrease
HDL-C levels were found to be less glucose tolerant than their unaffected relatives
(Vergeer et al. 2010). However, it should also be noted that larger population
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studies did not find any association between heterozygosity for ABCA1 mutations
and risk of diabetes (Schou et al. 2012).
3.1 Effects of HDL on Obesity
Augmented adipose tissue content is the hallmark of obesity. There is increasing
evidence that HDL or ApoA-I regulate adipose tissue content. In humans,
polymorphisms within the ApoA-I gene have been associated with increased risk
of developing obesity and hypertension in a Brazilian cohort (Chen et al. 2009).
More evidence for a potential role of HDL cholesterol on adipose tissue content
regulation and obesity stems from genetic mouse models either lacking or
overexpressing ApoA-I or treated with ApoA-I mimetic peptides. For example,
ApoA-I-deficient mice have an increased fat content (Han et al. 2007). On the other
hand, mice overexpressing ApoA-I or treated with the D-4F ApoA-I mimetic
peptide3 (Navab et al. 2005; Van Lenten et al. 2009) showed decreased white
adipose tissue mass gain when fed a high-fat diet for 3 months (Ruan et al. 2011).
ApoA-I transgenic and D-4F-treated mice had slightly improved insulin sensitivity
when fed a high-fat diet compared to wild-type mice. This was associated with
increased energy expenditure as measured in metabolic cages and related to
increased expression of uncoupling protein 1 (UCP-1) in brown adipose tissue
and AMPK phosphorylation (Ruan et al. 2011). Consistent with these results is
the observation that administration of D-4F and L-4F in high-fat diet-fed mice
reduced weight gain and improved insulin sensitivity when compared with
age-matched vehicle-treated mice (Peterson et al. 2009). Taken together, these
observations implicate a potential antiobesity effect of ApoA-I. In another study,
ApoA-I gene transfer in the liver of mice increased adiponectin plasma levels and
potently attenuated the rise of triglycerides and free fatty acids induced by lipopoly-
saccharide administration (Van Linthout et al. 2010). In vitro, incubation of 3 T3-
L1 adipocytes with HDLs induced adiponectin expression in a phosphatidy-
linositol-3-kinase-dependent manner (Van Linthout et al. 2010). This set of
experiments showed that ApoA-I and HDLs affect adipose tissue metabolism and
adiponectin expression. ApoA-I and HDL have been shown to have anti-
inflammatory properties in adipocytes similarly to what has been observed in
macrophages and endothelial cells. It was found that both HDL and ApoA-I inhibit
palmitate-mediated gene induction of pro-inflammatory chemotactic factor (e.g.,
monocyte chemotactic protein-1, serum amyloid A3) in cultured adipocytes
(Umemoto et al. 2013). Furthermore, there was a reduction in chemotactic factor
3 This peptide, albeit lacking any sequence homology to ApoA-I, forms a class A amphipatic helix
similar to those found in ApoA-I. D-4F favors HDL formation and has anti-inflammatory and anti-
atherogenic properties. The “D” in D-4F indicates that the peptide was synthesized with nonnatural
D-amino acids (if synthesized with the natural L-amino acids, the peptide is called L-4F). D-amino
peptides are very stable in biological fluids as they are not efficiently recognized by proteases
(Chorev and Goodman 1995; Fischer 2003; Michod et al. 2009).
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expression and macrophage accumulation in ApoA-I transgenic mice fed a high-fat
diet compared to similarly treated control mice (Umemoto et al. 2013). Because
macrophage accumulation and adipose tissue inflammation are strongly correlated
with insulin resistance, these observations provide potential implications for the
prevention and management of insulin resistance.
The molecular mechanisms involved in the antiobesity effects of ApoA-I are
poorly understood. A recent suggestion is that ApoA-I and HDL might regulate
autophagy in adipocytes. Decreased autophagy in pre-adipocytes has been
associated with a preferential differentiation into “brown-like” adipocytes and
improved energy expenditure, with reduced generation of white adipose tissue
that serves mostly as an energy storage tissue (Wang and Peng 2012). Another
potential mechanism is the direct capture of cholesterol from adipocytes by HDLs
or ApoA-I (von Eckardstein and Sibler 2011; Zhang et al. 2010).
3.2 Effects of HDL on Insulin Sensitivity and Glucose Utilization
by Skeletal Muscle
There is increasing evidence that HDLs regulate glucose uptake in insulin-sensitive
tissues. In a set of elegant experiments in patients with T2 DM, Drew et al. showed
that reconstituted HDL (rHDL) infusion over 4 h induced larger decreases of
plasma glucose levels than placebo. This effect was associated with increased
insulin secretion (Drew et al. 2009). In the C2C12 myocyte cell line, ApoA-I
increased glucose uptake in an insulin-independent manner and also potentiated
insulin- and adiponectin-induced glucose uptake (Han et al. 2007). ApoA-I effects
on glucose uptake were dependent on the endocytosis of the protein and subsequent
phosphorylation of AMPK and acetyl-coenzyme A carboxylase (ACC). In agree-
ment with these observations, ApoA-I also increased glucose uptake in isolated
mouse soleus muscle. Furthermore, in ApoA-I-deficient mice, AMPK phosphory-
lation status was decreased in skeletal muscle as well as in liver (Han et al. 2007).
These data suggest that in vivo, ApoA-I levels are able to regulate AMPK phos-
phorylation. In ApoA-I-/- mice, expression of liver enzymes regulating gluconeo-
genesis (e.g., phosphoenolpyruvate carboxykinase, glucose-6-phosphatase) was
also increased (Han et al. 2007), suggesting that hepatic glucose output is increased
in animals lacking the main HDL apolipoprotein.
HDLs were also found to directly enhance glucose oxidation by increasing
glycolysis and mitochondrial respiration rate in C2C12 muscle cells (Lehti
et al. 2013). ATP synthesis was blunted in mitochondria isolated from the gastroc-
nemius muscle of ApoA-I knockout mice. Endurance capacity of ApoA-I knockout
mice was reduced upon exercise exhaustion testing. Conversely, mice
transgenically overexpressing human ApoA-I exhibited increased lactate levels,
reduced fat mass, and protection against age-induced decline of endurance capacity.
Circulating levels of fibroblast growth factor 21, a factor potentially involved in
mitochondrial respiratory chain activity and inhibition of white adipose lipolysis,
were significantly reduced in ApoA-I transgenic mice (Lehti et al. 2013).
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3.3 The Beneficial Effects of HDL in Pancreatic Beta Cells
HDLs also exert potentially antidiabetogenic functions on pancreatic beta cells by
potently inhibiting stress-induced cell death and possibly enhancing glucose-
stimulated insulin secretion.
3.3.1 Beneficial Effects of HDL on Insulin Secretion
In vivo and in vitro evidence suggests that HDLs support the insulin secretory
capacity of beta cells (Drew et al. 2012). Infusion of reconstituted HDLs in type
2 diabetes patients increased their HOMA-B index, an indirect measurement of
pancreatic beta cell function (Drew et al. 2009). Also, the increase of HDL
cholesterol levels in healthy volunteers treated for 2 weeks with a CETP inhibitor
was found to increase postprandial insulin and C-peptide plasma levels (Siebel
et al. 2013). The plasma of the CETP inhibited volunteers but not the CETP
inhibitor itself also showed an increased capacity to enhance glucose-stimulated
insulin secretion from MIN6 cells.
In vitro data on the effects of HDL or ApoA-I on insulin secretion are however
controversial. Fryirs and collaborators showed that stimulation of the Min6
insulinoma cell line for 1 h with lipid-free recombinant ApoA-I, ApoA-II, or
discoidal reconstituted HDLs dose-dependently increased both basal and glucose-
stimulated insulin secretion (Fryirs et al. 2010). By RNA interference, the authors
showed that the stimulatory effect of lipid-free ApoA-I and reconstituted HDLs on
insulin secretion depended on ABCA1 and ABCG1, respectively (Fryirs
et al. 2010). By contrast, other experiments in Min6 cells as well as islets of mice
and humans did not find conclusive evidence that HDL enhances insulin production
or basal and glucose-stimulated insulin secretion (Abderrahmani et al. 2007;
Roehrich et al. 2003; Rutti et al. 2009). Therefore and considering the supra-
physiological concentrations of lipid-free ApoA-I used by Fryirs et al., it appears
uncertain of whether HDLs have a direct effect on the insulin secretory capacity of
beta cells.
However, there is good evidence that ABCA1 and ABCG1 modulate insulin
secretion from pancreatic beta cells. Mice with a targeted knockout of ABCA1 in
pancreatic beta cells and crossbred with hypercholesterolemic LDL-receptor
knockout mice were found to be less glucose tolerant than LDL-receptor knockout
only mice (Brunham et al. 2007). The beta cell-specific ABCA1 knockout mice also
showed reduced insulin secretion in response to glucose administration. Islets
isolated from these mice showed altered cholesterol homeostasis and impaired
insulin secretion in vitro (Brunham et al. 2007). In vitro, beta cells lacking
ABCA1 showed impaired depolarization-induced insulin granule release,
disturbances in membrane micro-domain organization, and alteration in Golgi
and insulin granule morphology. Acute cholesterol depletion rescued the exocytotic
defect in beta cells lacking ABCA1, suggesting that elevated islet cholesterol
accumulation directly impairs granule fusion and insulin secretion (Kruit
et al. 2011). Posttranscriptional suppression of ABCA1 in beta cells by adenoviral
overexpression of miR33a and miR145 also led to increased cholesterol levels and
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to decreased glucose-stimulated insulin secretion (Kang et al. 2013; Wijesekara
et al. 2012). This compromised insulin secretion was again rescued by cholesterol
depletion. Inhibition of miR33a expression in apolipoprotein E knockout islets and
ABCA1 overexpression in beta cell-specific ABCA1 knockout islets rescued nor-
mal insulin secretion and reduced islet cholesterol (Wijesekara et al. 2012). ABCG1
knockout mice also show glucose intolerance due to reduced insulin secretion
(Sturek et al. 2010). In contrast to ABCA1 knockout, this defect was rescued by
the addition of cholesterol rather than by depletion of cholesterol (Sturek
et al. 2010). These studies show that a delicate balance of cholesterol
concentrations between different subcellular compartments must be achieved to
allow optimal beta cell functionality. As the consequence of the nonredundant roles
of ABCA1 and ABCG1 in beta cell activity, the combined inactivation of ABCA1
and ABCG1 increased intracellular cholesterol accumulation and induced inflam-
mation in beta cells and aggravated the diabetic phenotype found in the single
knockout animals (Kruit et al. 2012).
Taken together, these findings indicate that cholesterol homeostasis and its
regulation by ABCA1 and ABCG1 are critical for the secretory function of beta
cells. However, the human genetic data mentioned before do not unequivocally
support the findings made in the genetic mouse models. On the one hand, decreased
glucose-induced insulin secretion has been reported in ABCA1-deficient patients
with Tangier disease or heterozygous carriers of ABCA1 mutations (Koseki
et al. 2009; Vergeer et al. 2010). On the other hand, mutations in ABCA1 have
not been associated with increased risk of diabetes (Schou et al. 2012).
3.3.2 Effects of HDL on Pancreatic Beta Cell Survival and ER Stress
Several studies have shown that HDLs are very efficient in inhibiting apoptosis of
beta cells induced by a variety of stimuli including inflammatory cytokines, free
fatty acids (e.g., palmitate), thapsigargin, tunicamycin, or protein overexpression
(Abderrahmani et al. 2007; Petremand et al. 2012; Roehrich et al. 2003; Rutti
et al. 2009). Many of these stimuli induce endoplasmic reticulum (ER) stress. As
ER stress has been proposed to be a driving parameter in beta cell dysfunction and
death in the course of diabetes development (Eizirik et al. 2008; Oyadomari
et al. 2002; Volchuk and Ron 2010), the capacity of HDLs to protect beta cells
from ER stressors could be one mechanism underlying their potential ability to
prevent T2DM.
Pancreatic beta cells are professional secretory cells. Half of the proteins pro-
duced by these cells are insulin. These cells have therefore developed an extensive
ER network to fulfill their physiological function (Like and Chick 1970; Marsh
et al. 2001). In response to the development of insulin resistance, triggered by
obesity, for example, more insulin needs to be secreted by beta cells to compensate
for insulin resistance and to achieve proper glycemic control. Such a sustained
demand in insulin production can eventually cause ER dysfunction leading to
chronic ER stress. This may promote beta cell dysfunction and ultimately beta
cell death (Eizirik et al. 2008; Eizirik and Cnop 2010; Volchuk and Ron 2010).
There is a wealth of evidence demonstrating that HDLs activate antiapoptotic
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responses in beta cells (Abderrahmani et al. 2007; Cnop et al. 2002; Petremand
et al. 2009; Rutti et al. 2009). HDLs are particularly potent in inhibiting beta cell
death induced by ER stressors (Petremand et al. 2009; Rutti et al. 2009). Recently, it
was shown that HDLs maintain, despite the presence of ER stressors, a proper ER
morphology and functionality in terms of the capacity of the ER to fold proteins and
to allow protein trafficking out of the ER. Maintenance of the functionality of the
ER was shown to be required for the beta cell protective activity of HDLs
(Petremand et al. 2012). The ER stressors used included palmitate that is thought
to mimic pro-diabetogenic conditions found in individuals with impaired glucose
tolerance that are at risk of developing diabetes (Biden et al. 2004; Maedler
et al. 2001; Shimabukuro et al. 1998). While this work identified a cellular mecha-
nism mediating the beneficial effect of HDLs on beta cells against pro-diabetogenic
factors, the underlying molecular mechanisms remain largely unresolved.
The agonist for the potentially antidiabetic activity of HDL on beta cell apopto-
sis has not yet been identified. The available information is mostly of negative
nature. In beta cells, in contrast to endothelial cells, the SR-BI receptor is not
required for HDL-mediated antiapoptotic responses (Petremand et al. 2012; Rutti
et al. 2009). There is also no evidence that Akt, which plays a pivotal role in
mediating the antiapoptotic activity of HDL in endothelial cells, participates in the
protective function of HDLs in beta cells (Puyal et al. 2013). It appears therefore
that the molecular mechanisms underlying the antiapoptotic property of HDLs in
beta cells differ from those employed in endothelial cells. These mechanisms
remain unknown (von Eckardstein and Widmann 2014).
Conceivably, individual components of HDLs may mediate their protective
functions in beta cells. Actually, there is evidence that this could be the case. In
primary islets, IL1β-induced beta cell apoptosis can be inhibited by either the
delipidated HDL protein or the deproteinated lipid moieties of HDL as well as by
ApoA-I and by S1P (Rutti et al. 2009). This is a good indication that proteins and
lipids found in HDL particles carry pro-survival activities. However, pancreatic
islets do not only contain beta cells (70–80 %) but also alpha cells (15–20 %), delta
cells, PP cells, and immigrating blood-borne cells such as macrophages. Therefore,
it is not clear whether ApoA-I and S1P exert their antiapoptotic effects on beta cells
directly or indirectly, for example, by interfering with the release of proapoptotic
signals from non-beta cells. To distinguish direct from indirect effects and to
unravel the molecular basis for the antiapoptotic effects, it will be essential to
substitute the complex model of pancreatic islets with purified beta cells or surro-
gate beta cell lines.
Conclusion
HDL possibly enhances glucose-stimulated insulin secretion (Drew et al. 2012;
Fryirs et al. 2010; von Eckardstein and Sibler 2011) and reverses the
proapoptotic effects of native and oxidized LDLs, IL1β, or thapsigargin
(Abderrahmani et al. 2007; Petremand et al. 2012; Roehrich et al. 2003; Rutti
et al. 2009). In addition, HDL and ApoA-I promote glucose uptake and activate
AMP-kinase in primary human skeletal muscle cells and differentiated
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adipocytes by an insulin-independent way (Drew et al. 2009; Han et al. 2007;
Zhang et al. 2011) and enhance oxidative metabolism in skeletal muscle through
phosphorylation of acetyl-CoA carboxylase (Drew et al. 2009). Unfortunately,
the identity of the agonists and their cognate receptors as well as the elicited
signaling pathways and downstream targets of the antidiabetogenic HDL
activities are yet poorly resolved. Understanding these pathways is a prerequisite
for the development of drugs that stimulate or mimic the antidiabetic effects of
HDLs and thereby help to lower the risk, for example, in overweight patients, to
manifest T2DM.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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Consequences
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Abstract
High-density lipoprotein (HDL) has attracted interest as a therapeutic target in
cardiovascular diseases in recent years. Although many functional mechanisms
of the vascular protective effects of HDL have been identified, increasing the
HDL plasma level has not been successful in all patient cohorts with increased
cardiovascular risk. The composition of the HDL particle is very complex and
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includes diverse lipids and proteins that can be modified in disease conditions. In
patients with chronic kidney disease (CKD), the accumulation of uremic toxins,
high oxidative stress, and chronic micro-inflammatory conditions contribute to
changes in the HDL composition and may also account for protein/lipid
modifications. These conditions are associated with a decreased protective
function of HDL. Therefore, the HDL quantity and the functional quality of
the particle must be considered.
This review summarizes the current knowledge of dyslipidemia in CKD
patients, the effects of lipid-modulating therapy, and the structural modifications
of HDL that are associated with dysfunction.
Keywords
Chronic kidney disease • Dyslipidemia • High-density lipoprotein • Uremia •
Uremic toxin
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SDMA Symmetric dimethylarginine
SHARP Study of Heart and Renal Protection
S1P Sphingosine-1-phosphate
sPLA2 Secretory phospholipase type 2
SR-BI Scavenger receptor BI
VA-HIT Veterans’ Affairs High-Density Lipoprotein Intervention Trial
VLDL Very low-density lipoprotein
1 Introduction
Plasma lipoproteins are composed of non-covalent aggregates of different lipids
and proteins. They transport water-insoluble substances in the blood by building
micelle-like structures. These structures are classified by their density into the
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following groups: very low-density lipoprotein (VLDL), intermediate-density lipo-
protein (IDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL).
In previous years, several clinical studies have found that HDL cholesterol
(HDL-C) plasma levels were inversely correlated with cardiovascular risk, whereas
high LDL-C levels were related to increased cardiovascular mortality
(Di Angelantonio et al. 2009; Gordon et al. 1977; Mori et al. 1999). Initially, due
to the crucial role of HDL in reverse cholesterol transport (RCT), HDL was
associated with a decreased cardiovascular risk. Therefore, the theory of the
“good HDL” and “bad LDL” emerged. Further studies, primarily in vitro or animal
studies, identified the pleiotropic cardiovascular protective effects of HDL in
addition to its RCT function: HDL has anti-atherosclerotic, anti-inflammatory,
antioxidative, antithrombotic, and endothelial-protective properties (Navab
et al. 2011). Accordingly, there is growing interest in the study of HDL metabolism
and the cellular and the molecular signaling pathways involved in its vascular
protective effects.
Therefore, enhancing HDL plasma levels has been a principal approach for the
reduction of cardiovascular risks in different patient cohorts. Pharmacologically
active substances, such as cholesterol ester transfer protein (CETP) inhibitors,
fibrates, and niacin, have been tested in large clinical trials to evaluate the occur-
rence of cardiovascular endpoints (Longenecker et al. 2005; van Capelleveen
et al. 2014). However, raising HDL-C plasma levels did not protect against cardio-
vascular events in all patient cohorts tested. In addition, despite a significant
HDL-C increase in patients, large clinical trials were terminated because of a
lack of positive effects or, in some cases, an increase in the rate of cardiovascular
events.
These findings indicate that a better understanding of lipoprotein modifications
in disease conditions is necessary to establish possible indications and target
mechanisms in the therapy of cardiovascular diseases. Patients with chronic kidney
disease (CKD) suffer from a dramatic increase in cardiovascular morbidity and
mortality. The disease condition is associated with dyslipidemia and/or
modifications in lipoprotein composition and function (Keane et al. 2013; Vaziri
2006).
This review summarizes current knowledge regarding the structural and func-
tional changes of HDL in the context of renal dysfunction. A brief overview of
CKD epidemiology and pathophysiology is presented, followed by aspects of
dyslipidemia and its therapy in CKD patients. Subsequently, CKD-dependent
structural and functional changes of HDL are summarized.
2 Chronic Kidney Disease: Epidemiology
and Pathophysiology
Kidney disease is defined as an abnormality of kidney structure or function. The
criteria for abnormalities include: albuminuria, urine sediment abnormalities, elec-
trolyte and other abnormalities due to tubular disorders, abnormalities detected by
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histology or imaging, and history of kidney transplantation (Levey et al. 2005).
Kidney disease can occur abruptly, and it can either resolve or become chronic.
CKD is defined as kidney damage that persists for more than 3 months (Levey
et al. 2005). CKD is one of the major medical concerns associated with premature
morbidity and mortality, especially due to cardiovascular complications. The epi-
demic of CKD is globally driven by demographic aging, as well as an increase in
other risk factors leading to CKD (e.g., diabetes mellitus, hypertension, and
obesity).
CKD is divided into different stages, which are summarized in Fig. 1, based on
the glomerular filtration rate (GFR) (Levey et al. 2005). CKD patients have a high
occurrence of cardiovascular disease. In recent years, several studies have
implicated an inverse correlation of kidney function and cardiovascular mortality
(Tonelli et al. 2006). Thereby, the cardiovascular phenotype of the CKD population
is heterogeneous, and the cardiovascular risk depends on the CKD stage. In addition
to traditional risk factors, such as hypertension, diabetes mellitus, and smoking,
nontraditional risk factors also contribute to cardiovascular diseases. In CKD
patients, the nontraditional risk factors of anemia and enhanced oxidative stress
or uremic toxins play a major role in cardiovascular disease progression
(Mizobuchi et al. 2009). Under normal conditions, uremic toxins are cleared by
the kidneys, and many of these toxins have been recently identified (Duranton
et al. 2012). Uremic toxins are classified as water-soluble molecules with low
molecular weight (e.g., uric acid), middle molecules (e.g., parathyroid hormone),
and protein-bound toxins (e.g., hippuric acid) (Duranton et al. 2012). A number of
different uremic toxins are elusive, and biological functions have not been
identified for all toxins. Clinical studies have shown that cardiovascular morbidity
and mortality in CKD patients are associated with uremic toxin accumulation,
which leads to a progression of vascular alterations. Recently, Moradi
et al. summarized the influence of uremic toxins on vascular cells and pathological
pathways in the vascular wall (Moradi et al. 2013). The activation of leukocytes;
Fig. 1 Categories of chronic renal failure. CKD categories were divided into subgroups according
to KDIGO 2013
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endothelial damage, for example, by the disruption of glycocalyx and production of
reactive oxygen species (ROS); the proliferating effects on smooth muscle cells;
and platelet activation are only some of the described effects (Moradi et al. 2013).
In addition, uremic toxins influence lipoprotein modifications. Urea induces the
formation of carbamylated LDL (cLDL) (Apostolov et al. 2010). Some uremic
toxins are lipid-bound and may occur in a different subfraction of lipoproteins.
Additionally, HDL function may be affected by the accumulation of uremic toxins.
Nonetheless, further studies are necessary to characterize the impact of different
compounds on cardiovascular outcome and the precise signaling pathways
involved. The therapeutic goal should be to remove the solutes associated with
the highest cardiovascular risk to minimize fatal cardiovascular outcomes in
patients with CKD. To date, cardiovascular morbidity in patients with CKD
remains high despite the utility of dialysis and renal transplantation (Foley
et al. 1998).
3 Dyslipidemia, Lipid-Modulating Therapy,
and Cardiovascular Risk in CKD Patients
In the general population, plasma lipid levels correlate with the level of cardiovas-
cular risk (Di Angelantonio et al. 2009). Increased LDL-C levels have been
associated with cardiovascular mortality. LDL-C is a primary risk biomarker for
cardiovascular disease in the general population; however, it loses its prognostic
association in CKD patients (Kilpatrick et al. 2007), especially for patients with
end-stage renal disease (ESRD) (Baigent et al. 2011; Kovesdy et al. 2007). In
addition, traditional risk factors, such as hypercholesterolemia, hypertension, and
obesity, no longer appear to be related to the level of cardiovascular risk in ESRD
patients. One explanation might be the accumulation of nontraditional risk factors
in CKD patients (Appel 2004; Coresh et al. 1998; Muntner et al. 2004). Presumably,
the complexity of traditional and nontraditional risk factors determines patient
outcome. An alternative explanation may be that patient outcome is determined
by the numerous quantitative and qualitative lipid abnormalities in triglycerides,
phospholipids, and lipoproteins that are observed in CKD patient cohorts (Keane
et al. 2013; Vaziri 2006).
3.1 Dyslipidemia in CKD Patients
Several studies have demonstrated a characteristic switch in the lipid phenotype at
different stages of CKD. Data from the “Multi-Ethnic Study of Atherosclerosis”
(MESA) have indicated an elevation of triglyceride-rich lipoproteins (Lamprea-
Montealegre et al. 2013). Triglyceride-rich VLDL or other apoB-rich lipoproteins
accumulate in patients with ESRD as a consequence of increased triglyceride levels
(Vaziri and Norris 2011). The VLDL particle increase depends on the CKD stage
and is aggravated by a decline in kidney function (Lamprea-Montealegre
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et al. 2013). Hypertriglyceridemia is caused by reduced lipoprotein lipase (LPL)
levels (Vaziri 2006; Vaziri et al. 2012) and results in the limited delivery of
triglyceride-rich fuel lipoproteins to adipocytes and myocytes (Vaziri et al. 2012).
The enrichment of triglyceride-containing lipoprotein particles results in a higher
susceptibility to oxidative modifications. These particles are highly
pro-inflammatory (Vaziri 2013). In addition, other apoB-rich lipoproteins, such as
small dense LDL or IDL-C, are commonly increased in patients with CKD (Saland
and Ginsberg 2007; Vaziri 2006). The reduced clearance rate of LDL particles
contributes to the increase in LDL levels (Ikewaki 2013).
Lipoprotein a (Lp(a)), which consists of apoA and apoB and is similar to LDL-C,
is increased in CKD patients (Longenecker et al. 2005; Muntner et al. 2004). Lp
(a) serves as an independent biomarker that predicts cardiovascular complications
(Jacobson 2013; Thompson and Seed 2013).
Dyslipidemia is further enhanced by hyperparathyroidism, which frequently
occurs in CKD patients (Moe and Sprague 2012). Normal lipid metabolism depends
on proper parathyroid function, and hyperparathyroidism tends to result in hypertri-
glyceridemia (Liang et al. 1998) as well as in a deficiency in lipid metabolism
enzymes, such as hepatic lipase and LPL (Klin et al. 1996). The enrichment of
apoB-containing lipoproteins is correlated with decreased HDL-C levels (Saland
and Ginsberg 2007; Vaziri 2006).
The lipid profile is altered in CKD patients compared with healthy subjects and
differs depending on the stage of CKD progression (e.g., stage I to V, pre/post-
dialysis, and time on dialysis) and the dialysis procedure (e.g., hemodialysis
(HD) or peritoneal dialysis (PD)). As a consequence, the lipid profiles of the
CKD population are heterogeneous. Extrinsic factors, including drug administra-
tion for kidney disease and associated disorders (hypertension, diabetes mellitus,
and malnutrition), contribute to dyslipidemia in this patient cohort.
To overcome the complex dyslipidemia in CKD patients, diverse clinical trials
have addressed the influence of lipid-modulating therapies on cardiovascular
outcomes. The results of these therapies in the general population suggest that the
incidence of cardiovascular events in CKD patients is expected to decrease (van
Capelleveen et al. 2014).
3.2 Lipid-Modulating Therapy in CKD Patients
Currently, drugs that treat dyslipidemia are in use or under investigation. Statins,
which primarily lower the LDL-C level; peroxisome proliferator-activated receptor
(PPAR) agonists; inhibitors of lipid metabolism (CETP, niacin); and apoAI
mimetics have been evaluated in preclinical and/or clinical studies. The currently
established lipidemic drugs have been reviewed elsewhere; therefore, this article
summarizes aspects of therapy related to CKD. Although lipid-modulating
therapies have had a positive impact on the cardiovascular outcome in patients
with normal kidney function, the effect in CKD patients has been disappointing.
These observations have originated predominantly from statin trials.
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Statin treatment leads to a reduction in LDL-C through the inhibition of
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the initial
enzyme in endogenous cholesterol biosynthesis. In several clinical trials, it has
been clearly demonstrated that for patients without renal disease, a reduction of
LDL-C upon statin therapy is associated with a decreased cardiovascular mortality
rate (The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group 1998; Scandinavian Simvastatin Survival Study Group 1994; Baigent
et al. 2005; Collins et al. 2003; LaRosa et al. 2005; Sever et al. 2003). Due to the
substantially high cardiovascular risk in CKD patients, the effect of statin therapy
was also evaluated in three large clinical trials (>1,000 patients included): the
“Deutsche Diabetes Dialyse Studie” (4D) (Wanner et al. 2005), “A Study to
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assess-
ment of Survival and Cardiovascular Events” (AURORA) (Fellstrom et al. 2009a),
and “Study of Heart and Renal Protection” (SHARP) (Baigent et al. 2011). The
“Prevention of Renal and Vascular End-Stage Disease Intervention Trial”
(PREVEND-IT) (Asselbergs et al. 2004; Brouwers et al. 2011) has also addressed
the effect of statin therapy in a smaller cohort (<1,000 patients) but included a
longer follow-up period. The “Assessment of LEscol in Renal Transplantation”
(ALERT) (Holdaas et al. 2003) trial investigated cardiovascular outcomes in renal
transplant recipients. The 4D study consisted of a randomized control trial that
examined Western HD patients with diabetes (Wanner et al. 2005). No benefits in
the primary endpoints were observed in a follow-up period of approximately
4 years (Wanner et al. 2005) (Table 1). A subsequent subgroup analysis of the 4D
study cohort showed a reduction in cardiovascular disease after statin treatment in
patients with LDL-C >145 mg/dL (Marz et al. 2011). The 4D trial with 1,225
patients was followed by the larger AURORA trial, which enrolled 2,776 HD
patients with and without diabetes mellitus. Nonetheless, the reduction in LDL-C
that was observed did not have an effect on cardiovascular outcomes (Fellstrom
et al. 2009a). Another large randomized trial, the SHARP trial, enrolled HD patients
and CKD patients in stages III to V: (Baigent et al. 2011). The combination therapy
of simvastatin and ezetimibe lowered the LDL-C level but did not reduce the
overall vascular mortality (Baigent et al. 2011). However, the risk for atheroscle-
rotic events was reduced in a wide range of CKD patients (Baigent et al. 2011). The
longest follow-up period, up to 9.5 years, was in the PREVEND-IT trial
(Asselbergs et al. 2004; Brouwers et al. 2011). Here, patients with
microalbuminuria were enrolled and treated with pravastatin and fosinopril. In
the follow-up period of 46 months, pravastatin treatment had no effect on cardio-
vascular endpoints (Asselbergs et al. 2004). The extended follow-up period of
9.5 years showed that elevated urinary albumin excretion was associated with
increased cardiovascular morbidity and mortality (Brouwers et al. 2011).
Thus, the large clinical trials examining statin therapy in CKD patients failed to
show a significant reduction in overall cardiovascular mortality for patients
undergoing dialysis treatment (Table 1). Based on the data from the US Renal
Data System, the majority of cardiovascular deaths in CKD patients are due to
chronic heart failure and are not influenced by statin treatment (Collins et al. 2013).
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Therefore, other uremia-related pathways and/or the previously existing vascular
damage may contribute to the increase in cardiovascular risk. A trial that
investigated the effect of statin therapy in renal transplant recipients observed
similar effects. In the ALERT trial (Holdaas et al. 2003), statin therapy reduced
the LDL-C plasma concentration in treated patients (Holdaas et al. 2003). Although
fewer cardiac deaths and nonfatal MIs were observed, no significant reduction in
the primary endpoint was achieved (Holdaas et al. 2003).
Based on the findings of the current clinical trials with CKD patients, the
therapies tested had either no real impact on cardiovascular outcome or resulted
in fatal effects (Kilpatrick et al. 2007). Interestingly, despite a robust reduction in
the LDL-C level, only negative or neutral effects on acute cardiovascular events
were measured (Baigent et al. 2011; Fellstrom et al. 2009b; Wanner et al. 2005).
Effective prevention of cardiovascular events was only documented in patients with
mild to moderate CKD (Baigent et al. 2011).
In addition to statins, which primarily lower LDL-C plasma levels, other lipid-
modulating drugs are currently used in non-renal-insufficient patients. Here, differ-
ent targets in HDL metabolism have been identified to overcome dyslipidemia.
Initial studies addressed the effect of enzyme inhibition on lipid metabolism, such
as CETP inhibition. PPAR agonists, niacin, and apoAI mimetics are other thera-
peutic options that have been tested in clinical and/or preclinical studies. However,
these studies often excluded patients with CKD from recruitment. Therefore,
further studies are necessary to determine the effects of these therapies on patients
with renal insufficiency.
CETP is responsible for the shuttling of cholesteryl esters between HDL and
apoB-containing lipoprotein particles. Inhibition of this enzyme results in a dra-
matic increase in HDL levels. Torcetrapib was the first CETP inhibitor examined in
a large clinical trial, “Investigation of Lipid Level Management to Understand Its
Impact in Atherosclerotic Events” (ILLUMINATE) which included approximately
15,000 patients (Barter et al. 2007). The treatment increased the HDL concentration
by more than 50 % (Barter et al. 2007). However, the study was prematurely
terminated because an increased risk of cardiovascular events was observed (e.g.,
increase in arterial blood pressure) (Barter et al. 2007). In the ILLUMINATE trial,
patients with severe CKDwere not enrolled. The mean eGFR in patients included in
the study was 79.5 ml/min/1.73 m2 with creatinine concentration of 1 mg/dL
(Barter et al. 2007). In subsequent trials with other CETP inhibitors, which
attempted to overcome the off-target effects of torcetrapib, CKD patients were
excluded. The “Determining the Efficacy and Tolerability of CETP Inhibition with
Anacetrapib” (DEFINE) study (Cannon et al. 2010) investigated anacetrapib, and a
key exclusion criteria in this study was an eGFR <30 ml/min/1.73 m2 or severe
renal impairment (Cannon et al. 2010). In the dal-OUTCOMES trial with
dalcetrapib (Schwartz et al. 2009, 2012), the exclusion criteria was a creatinine
level of>2.2 mg/dL (Schwartz et al. 2009). For the “Randomized Evaluation of the
Effects of Anacetrapib Through Lipid-Modification” (REVEAL) study, patient
recruitment is ongoing, and the study is expected to be completed in 2017 (Gutstein
et al. 2012). On the basis of the current CETP inhibitor studies, the effects of CETP
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inhibition on cardiovascular mortality cannot be determined, and patients with
severe CKD were excluded from all studies.
Niacin treatment most effectively raises HDL-C levels and decreases triglycer-
ide, LDL-C, and Lp(a) levels. The mechanism underlying the influence of niacin on
HDL metabolism is unknown (Linsel-Nitschke and Tall 2005). The beneficial
effects on lipoprotein levels and the corresponding cardiovascular outcome have
been described in several small-scale clinical trials. Unfortunately, the large-scale
trials AIM-HIGH (AIM-HIGH Investigators 2011; Boden et al. 2011) and HPS2-
THRIVE (2013), in which patients were treated with niacin in combination with a
statin, were prematurely terminated because of a high prevalence of side effects. In
both studies, no patients with severe CKD were included. In AIM-HIGH, the mean
eGFR was 82.8 ml/min/1.72 m2 (2011), and in HPS2-THRIVE, severe renal
insufficiency was an exclusion criteria for patient recruitment (2013).
The family of PPAR transcription factors is involved in the regulation of fatty
acid metabolism and influences lipid levels. The family consists of three members:
PPAR-α, PPAR-γ, and PPAR-δ. PPAR-γ agonists, such as rosiglitazone and
pioglitazone, are high-affinity agonists at the receptor site (Linsel-Nitschke and
Tall 2005), and their effects on cardiovascular outcome have been tested. However,
only a minimal benefit or an increase in heart failure rates was observed in a study
population with diabetes in the “Rosiglitazone Evaluated for Cardiovascular
Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes” (RECORD)
trial (Home et al. 2009). The mean serum creatinine level in the study cohort was
approximately 62 μmol/L (Home et al. 2009). The activation of PPAR-α via
fibrates, which are weak agonists of this receptor (Linsel-Nitschke and Tall
2005), results in reductions in LDL-C and triglycerides, whereas HDL-C plasma
levels are moderately increased (Linsel-Nitschke and Tall 2005; Sahebkar
et al. 2014). The “Veterans’ Affairs High-Density Lipoprotein Intervention Trial”
(VA-HIT) (Tonelli et al. 2004) investigated the effects of the fibrate gemfibrozil in a
cohort of individuals with CKD. Gemfibrozil treatment did not reduce overall
mortality, but the rate of major cardiovascular events and nonfatal myocardial
infarctions (MIs) was significantly reduced in patients with mild to moderate
CKD (Tonelli et al. 2004). Currently, there are no synthetic ligands for PPAR-δ
in clinical use (Sahebkar et al. 2014).
In the secondary prevention of cardiovascular disease, there is evidence that
n3-polyunsaturated fatty acids (n3-PUFAs) are effective (Studer et al. 2005). A
study with HD patients failed to show a reduction in cardiovascular events or death
after treatment with an n3-PUFA (Svensson et al. 2006). However, a significant
reduction of MIs was observed in this patient cohort (Svensson et al. 2006).
Additional pharmacotherapeutic strategies are currently under development.
apoAI-based drugs and reconstituted/engineered HDL particles have been tested
in animal and human studies. Recently, van Capelleveen et al. summarized current
knowledge of these novel therapeutics (van Capelleveen et al. 2014). The human
trials were completed with a limited patient number (<200 patients) and a short
follow-up period (several weeks). However, the clinical impact of these novel drugs
is highly interesting and must be evaluated in larger clinical trials. Several trials are
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currently under way (van Capelleveen et al. 2014); however, the high treatment
costs may limit their use in routine clinical practice. After the promising results in
animal studies, treatment with apoAI mimetics did not improve biomarkers that
were selected to describe HDL function (Watson et al. 2011).
To date, the benefit of apoAI-based therapy for CKD patients remains elusive.
The studies described indicate that with a decline in renal function, lipid-
modulating therapies lose their capacity to prevent the occurrence of cardiovascular
nonfatal and fatal events. Consequently, the lipid compositional and corresponding
functional changes that occur with declining renal function are not fully understood.
In Table 1, the different therapeutic approaches in patients with variable renal
function and the effects on cardiovascular outcome are summarized.
Recent guidelines for the management of lipid disorders in patients with chronic
renal failure recommend lipid-lowering therapy only in patients with CKD who are
not undergoing renal replacement therapy (National Kidney Foundation 2003;
Tonelli and Wanner 2013). The guidelines clearly indicate our inadequate under-
standing of how to address the complex lipid changes in CKD patients.
3.3 Protective Effects of HDL on the Kidney
Based on the current evidence, the causal association between the HDL level, HDL
function, and cardiovascular outcome in CKD patients is not fully understood.
Dysregulated HDL metabolism might be caused by reduced kidney function.
Abnormalities in lipid metabolism enzymes and transport processes have been
described (Hirano 2013; Pahl et al. 2009; Vaziri and Norris 2011). The changes
involve enrichment of free cholesterol, triglycerides, and fatty acids as well as the
depletion of cholesterol esters within HDL. However, there is evidence that HDL
might be an independent protective factor for kidney function. Epidemiologic data
from a multi-study cohort demonstrated an association between a low HDL-C level
and reduced kidney function (Odden et al. 2013). Additional trials addressed the
question of whether HDL-C is associated with the progression of CKD. A recent
study, which included 3,303 patients with CKD stages III to V and a median follow-
up period of 2.8 years, supports the hypothesis that dyslipidemia is independently
associated with rapid renal progression (Chen et al. 2013). Two meta-analyses
suggest that statin therapy has a benefit on GFR and inhibits GFR decline (Fried
et al. 2001; Sandhu et al. 2006). However, other studies found no impact on renal
outcome with statin treatment (Atthobari et al. 2006; Rahman et al. 2008). Focusing
on HDL-C, Baragetti and coworkers observed an association between low HDL-C
and earlier entry in dialysis or doubling of the plasma creatinine in a patient cohort
of 176 subjects with mild to moderate kidney dysfunction (Baragetti et al. 2013).
Moreover, a cross-sectional analysis of 4,925 patients with normal kidney function
strengthened the association between HDL-C and eGFR (Wang et al. 2013).
Confounders (e.g., age, blood pressure, and lipid parameters) influenced the rela-
tionship (Wang et al. 2013). Furthermore, malnutrition and hypoalbuminemia,
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which are frequently present in patients with CKD (Kaysen 2009; Peev et al. 2014),
affected the HDL level and functionality (Khovidhunkit et al. 2004).
Further studies are necessary to determine whether HDL-targeted therapies are
beneficial for renal outcome. The difference in the HDL quantity and functional
quality in CKD patients must be considered. The results of clinical trials, such as
ILLUMINATE (Barter et al. 2007) and HPS2-THRIVE (2013), suggest that
increasing HDL-C plasma levels is not an optimal therapeutic target. Furthermore,
as shown in the “European Prospective Investigation into Cancer and Nutrition”
(EPIC) study and the MESA study, intima/media thickness and cardiovascular
events had a stronger association with HDL particle number compared with HDL
cholesterol levels (Arsenault et al. 2009; El Harchaoui et al. 2009; Mackey
et al. 2012). Figure 2 summarizes the potential protective effects of HDL on kidney
function.
Additional studies that address the structure-dependent functions of the hetero-
geneous HDL particles are necessary to assess the benefit of HDL-increasing
therapy for different disease conditions.
Fig. 2 Interaction of HDL level/function with the kidney. HDL has a pleiotropic protective
function. A decrease in HDL level/function has an impact on the vascular alterations associated
with kidney damage. The decline in kidney function induces/strengthens the decrease in HDL
level/function. For further information and references, refer to the text
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4 Structural and Functional Modifications of HDL in CKD
Patients
In the last several years, HDL and its structural composition in disease conditions,
especially cardiovascular, metabolic, and renal diseases, have been a focus of
experimental research. Compositional changes of the proteome, alterations of the
lipid moiety, and posttranslational modifications of HDL isolated from these patient
cohorts contribute to a lower protective function of the lipoprotein particle
(Annema and von Eckardstein 2013). The following section summarizes the current
knowledge of the HDL changes identified in patients with reduced renal function. It
is important to keep in mind that the investigations were performed in a heteroge-
neous group of patients with different stages of renal failure. Therefore, it is often
difficult to define the role of uremia on the functionality of HDL.
The HDL particle contains hundreds of different lipids and a multitude of
proteins that form a lipoprotein with different shapes, sizes, and densities through-
out its metabolism (Camont et al. 2011; Shah et al. 2013). Because of its amphi-
philic character and the presence of specific binding proteins, HDL serves as cargo
for vitamins, hormones, toxins, and microRNA (Vickers and Remaley 2014). There
is evidence of biological activity for many of the lipid and protein components.
These components can bind to specific receptors and activate signaling pathways in
vascular cells, thereby influencing atherogenesis, thrombosis, apoptosis, oxidative
reactions, endothelial properties, and inflammatory reactions (Calabresi et al. 2003;
Navab et al. 1991; Nofer et al. 2004; Watson et al. 1995). The functions of the
associated proteins and lipids in the vascular wall have been characterized in vitro
and in animal studies, as well as in clinical trials. It has been shown that composi-
tional changes are related to functionality and are influenced by uremic toxins. For
example, (1) the dysregulation of proteins in the HDL metabolism affects HDL
plasma level and cholesterol clearance. Furthermore, (2) changes in HDL apolipo-
protein composition occur, and finally (3) the loss of proteins with a protective
function or (4) the accumulation of substances with a fatal function within HDL
influences its vascular protective properties. The compositional changes may not
only result in a decrease in function but may also lead to increased dysfunction
(Fig. 3), and both are associated with an increased cardiovascular risk profile.
4.1 Dysregulation of Proteins in HDL Metabolism
As discussed in the preceding paragraph, CKD is associated with a decreased
HDL-C plasma concentration and dyslipidemia. The uremic condition is responsi-
ble for the disrupted protein metabolism (Vaziri 2006) due to uremic-induced liver
damage (Yeung et al. 2013). Many proteins important in HDL metabolism are
predominantly produced within the liver, and their production is dysregulated in
uremia. For proper HDL maturation and metabolism, enzymes such as LCAT and
CETP are responsible. Furthermore, diverse receptors on intestinal and peripheral
cells, as well as hepatic cells, are necessary for cholesterol transport via HDL to the
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liver for biliary excretion (Fig. 4). There is evidence that the expression of enzymes
and receptors in HDL metabolism is altered in patients who suffer from kidney
disease. To date, most studies have been completed with CKD stage V patients
dependent on dialysis (ESRD), and less information on enzyme expression has been
obtained from patients prior to dialysis. LCAT is important for HDL maturation. In
ESRD patients, the LCAT enzyme concentration and activity were reduced (Miida
et al. 2003; Moradi et al. 2009; Pahl et al. 2009; Shoji et al. 1992; Tolle et al. 2012).
Fig. 3 Functional vs. dysfunctional HDL particles. Depending on the substances that accumulate
within the HDL, the particle may exert functional or dysfunctional properties
Fig. 4 Dysregulation in HDL metabolism under uremic conditions. # decrease, " increase, $ no
effect. For references, refer to the text
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The association between the plasma levels of cholesterol transport proteins, such as
CETP and CKD, remains unclear. Some studies have failed to show any significant
changes in the CETP protein level or activity (Pahl et al. 2009), whereas other
studies have identified an increased (Dullaart et al. 1993) or decreased (Miida
et al. 2003) CETP level. These controversial data may result from the heterogeneity
of CKD patients and the analysis of different patient subgroups: increased levels
were identified in proteinuric patients (Dullaart et al. 1993), and unchanged or
decreased levels were identified in HD patients with different lengths of minimum
dialysis treatment (minimum of 3 months vs. 1 year) (Miida et al. 2003; Pahl
et al. 2009). The expression of receptors important for RCT appears to be affected
by kidney dysfunction. In nephrectomy animal models, SR-BI (Liang and Vaziri
1999) and ABCA1 (Zuo et al. 2009) receptor expression is decreased. A reduction
of these receptors in humans would subsequently be associated with altered HDL
metabolism in CKD patients.
4.2 Changes of HDL Apolipoproteins (Modifications and Levels)
HDL contains different apolipoproteins. Under uremic conditions, the composition
of the proteins within HDL changes: some protein levels decrease, whereas other
protein levels increase. The main apolipoprotein of HDL under normal physiologi-
cal conditions is apoAI. The presence of altered apoAI levels in CKD patients
remains controversial. Some studies have identified decreased apoAI levels in
dialysis patients (Holzer et al. 2011a; Moradi et al. 2009; Vaziri et al. 1999,
2009), whereas other studies did not identify a significant change in apoAI concen-
tration (Shoji et al. 1992; Tolle et al. 2012). While apoAII and apoCI levels
decreased in CKD patients (Holzer et al. 2011a), apoCII (Holzer et al. 2011a;
Weichhart et al. 2012) and apoCIII (Holzer et al. 2011a) increased. ApoAIV was
not identified in the HDL obtained from healthy subjects, but was detected in
dialysis patients via mass spectrometry analysis (Holzer et al. 2011a). No signifi-
cant difference was found in apoD and apoE levels, whereas apoM levels decreased
(Holzer et al. 2011a). Table 2 summarizes the main apolipoprotein changes in CKD
patients. Currently, most identified changes are based on studies with HD patients.
The discrepancy in apolipoprotein levels may be a result of the heterogeneous
patient population (e.g., CKD stage, time on dialysis, medication, or secondary
disease), different HDL isolation protocols (e.g., one-step vs. multistep ultracentri-
fugation, chromatography, or differentiation between HDL2/3), and different apo-
lipoprotein detection methods (e.g., enzyme-linked immunosorbent assay vs. mass
spectrometry).
In addition to changes in the apolipoprotein levels, modifications of the proteins
within HDL occurred, which were closely connected to altered functionality. To
date, oxidative modifications, carbamylation, and glycosylation have been detected.
These effects may be a consequence of the high level of ROS in patients with renal
failure.
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Patients with CKD suffer from increased reactive oxygen stress (Sung
et al. 2013; Tucker et al. 2013). The pro-oxidant state is multifactorial but is related
to high amounts of uremic toxins. Uremic toxins are directly involved in the
oxidative response, e.g., phenyl acetic acid is a strong inducer of ROS (Schmidt
et al. 2008), and indoxyl sulfate has a dual role that consists of pro-oxidant
properties in the uremic condition and antioxidative properties under normal
physiological conditions (Miyamoto et al. 2011). The increase in highly reactive
radicals contributes to the oxidation of proteins and lipids. For example, the
oxidation of LDL is known to occur in CKD patients (Ribeiro et al. 2012;
Samouilidou et al. 2012). Furthermore, oxidative modifications of apoAI have
been identified (Nicholls et al. 2005; Undurti et al. 2009; Zheng et al. 2004).
ApoAI oxidation is dependent on the binding activity between apoAI and its
receptors ABCA1 (Zheng et al. 2004) and SR-BI (Undurti et al. 2009). Therefore,
ox-apoAI impairs HDL metabolism. In addition, an association between oxidative
modifications of HDL and a higher risk for cardiovascular events in dialysis
patients has been identified (Honda et al. 2012).
Another reactive compound that leads to protein modification is reactive cya-
nate, which induces the carbamylation of proteins. Cyanates emerge from the
degradation of urea or via myeloperoxidase (MPO) at the sites of inflammation
(Holzer et al. 2012; Sirpal 2009). CKD patients are prone to carbamylated proteins
because urea levels are increased in the uremic condition, and these patients
experience increased inflammation. MPO associates with HDL (Nicholls
et al. 2005); thus, HDL proteins in addition to LDL proteins (Apostolov
et al. 2005) become targets for carbamylation. Carbamylation impairs HDL func-
tion by decreasing the cholesterol efflux capacity of HDL from macrophages
(Hadfield et al. 2013; Holzer et al. 2011b).
CKD patients are also prone to glycated protein modifications caused by insulin
resistance, which is a condition that is frequently observed with reduced renal
function (DeFronzo et al. 1981; Kobayashi et al. 2005). Insulin resistance appears
Table 2 Differences in apolipoprotein composition within the HDL in CKD patients compared
with healthy control subjects (" increase, #decrease, $ no change vs. healthy control)
Apolipoprotein
Change in the HDL
in CKD patients References
apoAI #$ Holzer et al. (2011a), Moradi et al. (2009), Shoji
et al. (1992), Tolle et al. (2012), Vaziri et al. (1999),
Vaziri et al. (2009)
apoAII # Holzer et al. (2011a)
apoAIV " Holzer et al. (2011a)
apoCI # Holzer et al. (2011a)
apoCII " Holzer et al. (2011a), Weichhart et al. (2012)
apoCIII " Holzer et al. (2011a)
apoD $ Holzer et al. (2011a)
apoE $ Holzer et al. (2011a)
apoM # Holzer et al. (2011a)
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to be associated with a high burden of oxidative stress. The reduction of oxidative
stress by treatment with a superoxide dismutase/catalase mimetic reduces not only
ROS production but also insulin resistance in a CKD mouse model (D’Apolito
et al. 2010). The modified proteins are advanced glycated end products (AGEs),
which are usually found at high levels in CKD patients. Glycated apoAI is likely an
AGE (Lapolla et al. 2008). It has been speculated that these modified apoAIs have
reduced RCT activity.
Additional proteins are also associated with HDL under physiological and
pathophysiological conditions. Many proteins within HDL have been identified
using a proteomic approach. Some proteins are increased, whereby other proteins
are decreased in HD patients (Holzer et al. 2011a; Weichhart et al. 2012). However,
an association between all of the proteins identified by proteome analysis and HDL
functionality/dysfunctionality in the vessel wall could not be identified. Retinol-
binding protein 4 (RBP4) was detected in the HDL from CKD patients, whereas it
was not found within the HDL of healthy controls (Holzer et al. 2011a). Plasma
levels of RBP4 were increased in dialysis patients (Frey et al. 2008), and the
increase was dependent upon the CKD stage (Henze et al. 2010). Furthermore,
surfactant protein B and α-1-microglobulin/bikunin precursor proteins were signif-
icantly increased in ESRD patients (Weichhart et al. 2012). Transthyretin was not
identified within the HDL from healthy controls, but was detectable in the HDL
from dialysis patients (Holzer et al. 2011a). An overview of the identified proteins
was recently presented (Holzer et al. 2011a; Weichhart et al. 2012).
4.3 Loss of Protective Proteins or Lipids
Oxidative stress participates in the pathogenesis and progression of CKD and was
increased in CKD patients (Mimic-Oka et al. 1999; Puchades et al. 2013). This
results from an imbalance of pro-oxidative and antioxidative signals that is favored
by uremic toxins (Mimic-Oka et al. 1999). Navab et al. postulated that HDL itself
can become pro-inflammatory (Navab et al. 2006). In this condition, serum
lipoproteins are prone to oxidative modification. The enzymes linked to HDL that
have an antioxidative capacity are thought to facilitate oxidative protection. A
higher pro-inflammatory index of HDL in CKD patients resulted in a higher
adjusted death hazard ratio (Kalantar-Zadeh et al. 2007). Furthermore, it was
shown that the in vitro antioxidative function of HDL was impaired in CKD
patients (Moradi et al. 2009). The primary antioxidative HDL-linked enzymes are
PON and glutathione peroxidase, and of these two enzymes, PON is the most
studied one. The PON family consists of three members: PON1, PON2, and
PON3. In contrast to PON2, PON1 and PON3 are secreted in the blood and are
associated within HDL (Macharia et al. 2012). PON1 remains the best-studied
enzyme of this family in cardiovascular disease and kidney dysfunction. In CKD
patients, proteomic analysis did not indicate a significant difference in PON1
compared with healthy individuals (Holzer et al. 2011a), whereas its enzyme
activity was reduced in CKD patients (Dantoine et al. 1998; Kennedy et al. 2013;
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Moradi et al. 2009). The reduction negatively correlated with the CKD stage
(Dantoine et al. 1998). For glutathione peroxidase, decreased concentration and
activity were identified in dialysis patients (Moradi et al. 2009).
The loss of this antioxidative capacity combined with an increased level of
pro-oxidative molecules (see below) may, at least in part, account for the increased
oxidative stress in CKD patients.
A component that contributes to several of the protective functions of HDL is
sphingosine-1-phosphate (S1P) (Nofer et al. 2004, 2007; Schuchardt et al. 2011;
Theilmeier et al. 2006). HDL-associated apoM binds S1P (Christoffersen
et al. 2011). In CKD patients, apoM levels are decreased (Holzer et al. 2011a),
which may lead to higher levels of S1P free from HDL. There are several
indications that non-HDL-bound S1P signaling differs compared with
HDL-bound S1P (Schuchardt et al. 2011).
4.4 Increase of Molecules within HDL with a Fatal Function
in the Vascular Wall
In vitro and in vivo studies and/or clinical trials have identified proteins that
accumulate within HDL. Interestingly, the albumin content in HDL from uremic
patients was elevated, and apolipoprotein displacement may occur (Holzer
et al. 2011a).
The acute phase protein serum amyloid A (SAA), which is secreted by the liver
during inflammation, is primarily transported by HDL within the blood (Uhlar and
Whitehead 1999). In uremic patients, elevated SAA (Holzer et al. 2011a; Tolle
et al. 2012; Weichhart et al. 2012; Zimmermann et al. 1999) is a sign of a chronic
inflammatory status. This is closely related to an increased cardiovascular risk in
humans (Zimmermann et al. 1999). In vitro studies support these findings, as the
accumulation of SAA in HDL was correlated with a reduced anti-inflammatory
capacity of HDL and a pro-inflammatory potential (Tolle et al. 2012; Weichhart
et al. 2012). Furthermore, the cholesterol efflux capacity was decreased when the
SAA level dramatically increased during acute sepsis (Annema et al. 2010). In
addition, SAA accumulation results in the replacement of apoAI and influences
HDL remodeling and metabolism. Nonetheless, the replacement was not identified
in all patient cohorts (Tolle et al. 2012), which may be because of the different
experimental settings. A displacement of other protective proteins during the acute
phase response by SAA was also observed for PON1 and PAF-AH (Van Lenten
et al. 1995). Thus, SAA enrichment within HDL affects the anti-inflammatory
response. Recently, a pro-inflammatory response of SAA-rich HDL in CKD
patients was observed (Tolle et al. 2012; Weichhart et al. 2012). The effects of
SAA accumulation on the cholesterol efflux function of HDL remain controversial.
In some experiments, a reduction of the cholesterol efflux capacity of HDL was
observed if it was enriched with SAA (Artl et al. 2000; Marsche et al. 2007),
whereas other studies found normal efflux capacity even with SAA-rich HDL
(Banka et al. 1995; van der Westhuyzen et al. 2005).
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Furthermore, phospholipases (PLA) associated with cardiovascular mortality are
elevated in uremic patients. For example, lipoprotein-associated PLA (Lp-PLA)
2 was increased in uremic patients (Holzer et al. 2011a). The secreted PLA
2 (sPLA2) concentration and activity were also higher in ESRD patients. This
elevation contributes to excessive oxidative stress in these patients (van der Giet
et al. 2010a).
Dimethylarginines (DMAs), such as asymmetric dimethylarginine (ADMA) and
its structural isomer symmetric DMA (SDMA), have been correlated with cardio-
vascular risk factors. As uremic toxins, they have been associated with cardiovas-
cular outcomes and renal dysfunction (Duranton et al. 2012; Kielstein et al. 2006).
DMAs originate from protein proteolysis and are mainly excreted in the urine.
DMAs influence nitric oxide (NO) synthesis and negatively influence its vascular
protective effects (Bode-Boger et al. 2006). The accumulation of SDMA in HDL
from CKD patients and its association with decreased NO have recently been
demonstrated (Speer et al. 2013).
MPO is another protein associated with the pathogenesis of cardiovascular
disease because of its pro-oxidative and carbamylating potential (Nicholls
et al. 2005; Undurti et al. 2009; Zheng et al. 2004). As discussed earlier, MPO
associates with HDL (Nicholls et al. 2005) and contributes to reduced RCT in
inflammatory diseases (Annema et al. 2010; Zheng et al. 2004). Furthermore,
MPO-derived oxidative products modify apoAI (Hadfield et al. 2013). The
modifications induced by MPO result in a pro-inflammatory HDL particle (Undurti
et al. 2009). In patients with diabetes mellitus type 2, MPO activity was increased in
HDL (Sorrentino et al. 2010). Interestingly, in a CKD cohort, the MPO plasma level
decreased with advancing renal failure (Madhusudhana Rao et al. 2011). Further
studies are necessary to determine the role of MPO in HDL dysfunction in a CKD
cohort.
The HDL from ESRD patients on HD was less effective at accepting cholesterol
from macrophages compared with the HDL from healthy subjects (Holzer
et al. 2011a; Yamamoto et al. 2012). The reverse cholesterol transport may be
affected in uremic patients.
5 Possibility of Functional Restoration of HDL
HDL function has been a recent focus of experimental research. With respect to
weak effects on cardiovascular outcome after an increase of HDL quantity in CKD
patients, HDL function capacity appears important for the design of new therapeu-
tic approaches. Therefore, the question arose whether structural modifications and
associated dysfunctions under uremic conditions are reversible. The best approach
to test this hypothesis in the case of renal function is to study patients after
successful renal transplantation. A limitation of this model is that these patients
often require immunosuppressive drugs, which may affect lipid metabolism and
function (Badiou et al. 2009). Some investigations have attempted to observe
changes in HDL function after renal transplantation. Dantoine and coworkers
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reported that the PON enzyme activity in patients after kidney transplantation was
comparable to that in control subjects, whereas in dialysis patients, it was decreased
(Dantoine et al. 1998). Furthermore, the anti-inflammatory capacity of HDL from
ESRD patients compared with healthy controls increased after successful renal
transplantation (van der Giet et al. 2010b). The observed effect appears to be related
to a decreased SAA level in transplant recipients. Other indicators of the reversibil-
ity of HDL dysfunction are based on studies with chronic heart failure patients. In
this cohort, exercise training, which is an accepted intervention strategy to decrease
cardiovascular risk in heart failure patients, resulted in increased HDL. The authors
demonstrated that changes in HDL function induced by exercise training correlated
with improved endothelial function (Adams et al. 2013).
According to these data it has been suggested that a restoration of HDL is
possible. The lipid metabolism and the composition of different lipoprotein
particles are primarily influenced by the metabolic condition. To date, little infor-
mation is available regarding whether the CKD stage before transplantation is
dependent on the HDL functionality after kidney transplantation or whether a
point-of-no-return exists for functional restoration, vessel damage, and
cardiovascular risk.
6 Laboratory Tests to Measure HDL Function
According to previous clinical and experimental trials, it has become clear that
HDL particle modifications in disease conditions are associated with reduced HDL
function; specific factors that determine HDL functionality remain unclear. It is
known that various structural features are associated with HDL function, which can
be measured by in vitro studies. A limitation arises in the difficulty of comparing
experimental results. The standardization of the experimental design for HDL
isolation, separation of proteins/lipids, sample preparation for proteomic
approaches, and detection methods for components within HDL would help to
overcome certain limitations that may result in discrepancies between findings. In
addition, in vitro functionality assays are very complex and further hamper compa-
rability. The complexity and cost preclude these tests from routine clinical labora-
tory analyses, thus limiting the validation of experimental findings of functionality
in large clinical trials. Standardization, validation, and optimization for high
throughput must first be established.
Recently, an overview of the laboratory tests that measure HDL subclasses
(shape, density) and several HDL functions was described (Eren et al. 2012).
There is a growing need to identify an optimal biomarker that describes HDL
functionality. The development of reproducible, standardized, and validated
methods to assess HDL function for routine use is of substantial interest. The
knowledge regarding individual HDL function can help identify patients who
may benefit from HDL-C increasing therapy or patients with a normal HDL-C
level but at particularly high risk for cardiovascular events.
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Conclusion and Perspective
HDL is a plasma lipoprotein with many pleiotropic protective functions in the
vascular wall, including anti-atherosclerotic properties. Emerging evidence from
clinical and laboratory studies indicates that HDL-C plasma levels in humans do
not adequately represent HDL function. The pleiotropic protective effects of
HDL depend on its composition, which is influenced by pathophysiological
conditions. With the decline of renal function, HDL modifications occur. Evi-
dence suggests that HDL composition, rather than plasma level, may be an
important determinant for its pleiotropic protective function in the vascular
wall. The goal is to identify robust biomarkers that describe HDL functionality
and are measurable in validated, standardized assays that can be used routinely.
Improvement of HDL functionality may serve as an interesting therapeutic
target in the future for populations beyond CKD patients.
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di Milano, Milan, Italy
Center for the Study of Atherosclerosis, Società Italiana Studio Aterosclerosi,
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Abstract
The cholesterol of high-density lipoproteins (HDLs) and its major proteic
component, apoA-I, have been widely investigated as potential predictors of
acute cardiovascular (CV) events. In particular, HDL cholesterol levels were
shown to be inversely and independently associated with the risk of acute CV
diseases in different patient populations, including autoimmune and chronic
inflammatory disorders. Some relevant and direct anti-inflammatory activities
of HDL have been also recently identified targeting both immune and vascular
cell subsets. These studies recently highlighted the improvement of HDL func-
tion (instead of circulating levels) as a promising treatment strategy to reduce
inflammation and associated CV risk in several diseases, such as systemic lupus
erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory
treatments targeting HDL function might improve both disease activity and
CV risk. In this narrative review, we will focus on the pathophysiological
relevance of HDL and apoA-I levels/functions in different acute and chronic
inflammatory pathophysiological conditions.
Keywords
Systemic inflammation • Autoimmune disease • apoA-I • HDL • Innate
immunity
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LPL Lipoprotein lipase







SAA Serum amyloid A
SLE Systemic lupus erythematosus
SMAD Small mothers against decapentaplegic
SR-BI Scavenger receptor BI
Th1 T helper type 1
TGF-β Transforming growth factor beta
UC Ulcerative colitis
1 Introduction
Since the seminal publication by Miller and coworkers in 1975, HDL-C has
consistently been shown to be inversely and independently associated with the
risk of acute CVD (such as myocardial infarction) (Miller and Miller 1975; Castelli
et al. 1986; Di Angelantonio et al. 2009) and became one of the most commonly
measured biomarkers (Expert Panel 2001). Nevertheless, the recent failures of
HDL-C-raising therapies to reduce CV complications and atherosclerosis
(Davidson 2012) as well as Mendelian randomization studies to demonstrate
associations of genetically determined HDL-C levels with altered CV risk (Voight
et al. 2012; Shah et al. 2013; Haase et al. 2012) raised the question whether HDL is
an innocent bystander or a mediator of atherogenesis and CVD.
Among the important progresses in our understanding about HDL physiopathol-
ogy, many studies stress the importance of HDL functions rather than HDL-C blood
levels. This in turn could be of key importance to understand the negative outcome
of both interventional trials and Mendelian randomization studies which did not
take HDL functionality into account. Indeed, there is a growing body of evidence
indicating that both acute and chronic inflammatory conditions induce posttransla-
tional modifications of HDL, impairing both its lipid homoeostasis-regulating and
anti-inflammatory properties, and even turn HDL into a proinflammatory molecule
(Navab et al. 2011).
Those observations are shifting the attention from HDL-C levels to HDL
function, emphasizing the importance of taking into account the clinical situations
in which HDL-C levels are measured. Therefore, the precise knowledge of the
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different chronic or acute conditions susceptible to affect both the quantity and
quality of HDL is likely to be paramount in order to understand the actual contro-
versy about the causal role of HDL in CVD. Furthermore, because many of the
functional properties of HDL can be recapitulated by apolipoprotein A-1 (apoA-I)
(Phillips 2013), we will review the different acute and chronic inflammatory
pathophysiological conditions reported to affect both HDL and apoA-I levels and
functions, as potential modulators of the innate immune system.
2 HDL/apoA-I Structure and Function
Since HDL structure is predominantly affected by the presence of apoA-I (Phillips
2013), both molecules will be presented in a joint manner. Depending on the lipid
state of apolipoproteins, HDL molecules are heterogeneous in shape, size, and
density. The predominant HDL species are spherical HDL, consisting of a core of
cholesteryl ester (CE) and triacylglycerol, encapsulated by a monolayer of
phospholipids, unesterified cholesterol, and different lipoproteins. The latter is
mostly represented by apoA-I which constitutes the major protein fraction of
HDL and represents up to 80 % of HDL mass (Heinecke 2009). The second more
abundant lipoprotein of HDL is apoA-II, followed by less abundant proteins
including apoCs, D, E, J, and M; several enzymes such as lecithin-cholesterol
acyltransferase (LCAT), serum paraoxonase 1 (PON1), and platelet-activating
factor acetylhydrolase (PAF-AH); and sphingosine-1-phosphate (S1P) (see chapter
“Structure of HDL: Particle Subclasses and Molecular Components” for more
details).
The atheroprotective role of HDL on the cardiovascular system has been
attributed to the pleiotropic effects of HDL, including reverse cholesterol transport,
vasodilatation, antithrombotic, anticoagulant, and anti-inflammatory effects
(Gordon and Davidson 2012). Reflecting those versatile properties, mass spectrom-
etry analyses revealed that HDL encompasses up to 80 different proteins.
Two-thirds of them are either acute-phase proteins, proteases, antioxidants,
antithrombotic enzymes, or proteins involved in complement regulation, and only
one-third are dedicated to lipid transport (Heinecke 2009).
On top of being the major protein fraction of HDL and a limiting factor for HDL
formation, apoA-I per se executes many of the HDL-related properties, ranging
from reverse cholesterol efflux and LPS and LTA scavenging to the inhibition of
different proinflammatory, pro-oxidant, and prothrombotic pathways
(Gu et al. 2000; Thuahnai et al. 2003; Yuhanna et al. 2001; Vuilleumier
et al. 2013). Thus, HDL and apoA-I appear to contribute to host defense against
many biological and chemical hazards. Nevertheless, chronic or acute inflammation
induces major changes in HDL-C levels and functions, compromising and
perverting the protective activities of HDL to harm.
Infection and inflammation generate an acute-phase response (APR), leading to
important changes affecting the metabolism of different lipids and lipoproteins and
thereby resulting in increased plasma levels of triglycerides and very-low-density
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lipoprotein (VLDL) cholesterol (reviewed in Khovidhunkit et al. 2004). Concomi-
tantly, the APR also induces major changes in HDL functions since in this context
apoA-I is replaced by other acute-phase proteins, such as SAA protein, ceruloplas-
min, and haptoglobin (Navab et al. 2011), with SAA representing up to 87 % of
HDL proteins and transforming HDL into a proinflammatory molecule (Van Lenten
et al. 1995). Furthermore, recent evidence suggests that APR can also induce
specific posttranslational modifications, such as chlorination, nitration, and
carbamylation of amino acids by myeloperoxidase (MPO), oxidation by reactive
carbonyls, as well as glycation, which compromise HDL and apoA-I functions,
perverting them to harm (Vuilleumier et al. 2013).
3 HDL and apoA-I as Members of the Innate Immune System
The innate immune system represents the first line of defense against infectious
agents and modified self-antigens (modified/oxidized lipids and apoptotic cells)
consisting of a cellular and a humoral part. Cellular components are represented
mostly by antigen-presenting cells (APCs), such as macrophages and dendritic
cells, whereas the humoral counterpart is mostly represented by the pentraxin
family and the complement system. Being extensively conserved throughout the
evolution, and existing in early evolutionary species not affected by CVD (Babin
et al. 1997), HDLs are believed to be part of the humoral innate immune system,
helping mammals to fight against invading pathogens. Indeed, thanks to the pres-
ence of different proteins on HDL molecules, such as apoA-I, apoL-1, and
haptoglobin-related proteins, HDLs are known to behave as antimicrobial agents
protecting mammals against different parasites and bacteria, such as Trypanosoma
brucei, Escherichia coli, and Klebsiella pneumoniae (Shiflett et al. 2005; Beck
et al. 2013) (see chapter “HDL in Infectious Diseases and Sepsis”).
Furthermore, on top of interfering directly with invading pathogens, HDL and
apoA-I also modulate the APR-induced activation of the innate immune system by
both neutralizing major bacterial membrane components, such as LPS of Gram-
negative bacteria and LTA of Gram-positive bacteria, and modulating the
proinflammatory signaling at the level of innate receptors, such as Toll-like
receptors (TLRs), scavenger receptors (SRs), and Nod-like receptors (NLRs).
Mathison and colleagues demonstrated for the first time in 1979 that HDL could
reduce LPS toxicity in vivo (Mathison and Ulevitch 1979). This observation was
subsequently inferred to the ability of HDL to sequester LPS, preventing the latter
to elicit a proinflammatory response through TLR4/CD14 complex interaction
(Levine et al. 1993). Later on, this scavenging effect of HDL was attributed to a
specific apoA-I region on the N-terminal segment of apoA-I (aa: 52–74) (Wang
et al. 2008). More recently, apoA-I was shown to have a similar ability to bind to
LTA and to neutralize its proinflammatory effect (Jiao and Wu 2008). Interestingly,
this effect was much weaker with HDL, suggesting that apoA-I is the key effector of
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LTA scavenging (Grunfeld et al. 1999). The integrity of innate immune receptor
signaling is largely dependent on their localization into lipid rafts, as well as on the
integrity of the latter (Triantafilou et al. 2002). In this respect, apoA-I has been
shown to deplete cholesterol from lipid rafts, leading to a decrease in TLR4
functionality, followed by an inhibition of LPS-induced inflammatory responses
(Triantafilou et al. 2002). In the same line of thought, on top of altering the lipid raft
composition, apoA-I has also been shown to impede TLR4 transport into lipid rafts,
thereby preventing its ability to promote an efficient proinflammatory response
(Smythies et al. 2010; Cheng et al. 2012). These findings indicate that apoA-I and
HDL, albeit to a lesser extent, can effectively modulate TLR activity at the
preceptor, receptor, and post-receptor levels (De Nardo et al. 2014).
4 Relationship Between Lipid Raft Modulation
and Lymphocyte Function
Adaptive immune response relies on the activation of lymphocytes and the expan-
sion of specific subsets in response to antigens. B lymphocytes represent an
essential component of the humoral adaptive response through the synthesis of
immunoglobulins, while T lymphocytes play a central role in cell-mediated immu-
nity, and indeed the different T phenotypes orchestrate the immune response
through different mechanisms. Two main aspects suggest a link between
lipoproteins and adaptive immunity: first, the key receptors of B and T cells
(BCR and TCR, respectively) are located in the lipid rafts, and their activity is
modulated upon changes in the lipid raft composition and structure (Gupta and
DeFranco 2007; Kabouridis and Jury 2008; Norata et al. 2012); second, B- and
T-cell trafficking and T-cell subset differentiation are controlled also by lysosphin-
golipids, mainly S1P (Mandala et al. 2002; Liu et al. 2010). Lipid rafts, which
concentrate specific proteins, thus limiting their ability to freely diffuse over the
plasma membrane, act as platforms, bringing together molecules essential for the
activation of immune cells (immunological synapse), but also separating such
molecules when the conditions for activation are not appropriate (Ehrenstein
et al. 2005). Lipid rafts compartmentalize key signaling molecules during the
different stages of B-cell activation including BCR-initiated signal transduction,
endocytosis of BCR-antigen complexes, loading of antigenic peptides onto MHC
class II molecules, MHC-II-associated antigen presentation to T cells, and receipt
of helper signals via the CD40 receptor (Gupta and DeFranco 2007). Critical
regulators of BCR signaling lose their association with membrane rafts in disease
conditions; for instance, the LMP2A gene product of the EBV constitutively resides
in membrane raft of EBV-transformed human B cells and blocks the entry of
ligand-clustered BCRs and BCR translocation (Longnecker and Miller 1996).
Furthermore, an alteration of Lyn, an accessory protein of BCR signaling, has
been reported in patients with systemic lupus erythematosus (SLE) (Flores-Borja
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et al. 2005). It is therefore reasonable to speculate that HDL, by removing choles-
terol from lipid rafts, could affect B-cell function. While a direct evidence for HDL
effects on B-cell function is still lacking, several reports indicate that HDL and
apoA-I stimulate cholesterol efflux from cells, leading to cholesterol depletion and
disruption of lipid rafts, which induces profound functional changes (Smythies
et al. 2010) in macrophages and also affects antigen presentation and TCR signaling
(Gruaz et al. 2010; Norata and Catapano 2012).
The response of T lymphocytes to antigen is orchestrated by a number of
molecules that cluster in lipid rafts. TCR complex integrity is vital for the induction
of optimal and efficient immune responses (Baniyash 2004). In immune-mediated
disorders, such as rheumatoid arthritis (RA) and SLE, and in chronic infectious
diseases, T cells are dysfunctional with a characteristic loss of expression of the
TCRζ chain (also called CD249), a key component of the TCR complex that
couples surface antigen recognition with intracellular signal transduction (Baniyash
2004). Also other molecules associated with the TCR signaling are reduced or
altered in autoimmune disorders, such as lymphocyte-specific protein tyrosine
kinase (Lck) (Jury et al. 2006). T-cell immunological synapses are altered in
circulating T cells from patients with coronary artery disease (CAD), and increased
memory T-cell subsets were observed in particular in CAD patients with increased
inflammatory markers (Ammirati et al. 2012a, b). Molecular mechanisms of how
reduced levels of blood lipids can affect lipid rafts in immune-mediated disorders
still remain to be addressed. However, atorvastatin reversed many of the signaling
defects characteristic of T cells from patients with SLE (Jury et al. 2006). The
possibility that atorvastatin targets lipid raft-associated signaling abnormalities in
autoreactive T cells has been proposed as the rationale for its use in the therapy of
autoimmune disease (Jury et al. 2006). This is further supported by a large obser-
vational study that demonstrated an association between persistence with statin
therapy and reduced risk of developing RA (Chodick et al. 2010). More recently,
Yvan-Charvet et al. reported that two key proteins involved in HDL cholesterol
efflux such as ATP-binding cassette transporters ABCA1 and ABCG1 play a key
role in hematopoietic stem and multipotential progenitor cell proliferation, thus
further linking cholesterol efflux and lipid raft modulation to immune cell function
(Yvan-Charvet et al. 2010a, b). Finally, a key role for apoA-I in controlling
cholesterol-associated lymphocyte activation and proliferation in peripheral
lymph nodes was observed in animal models (Wilhelm et al. 2009). The prevalence
of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in
hypoalphalipoproteinemia should also be taken into account as could impact on the
different polarization on APC cells (Sala et al. 2013). More recently, Wang
et al. (2012) demonstrated that HDL and apoA-I-induced cholesterol depletion
and consequent disruption of plasma membrane lipid rafts in APCs inhibit their
capacity to stimulate T-cell activation. This mechanism is highly dependent on the
reduction of MHC class II molecules present on the cell surface following ABCA1
activation and on cholesterol efflux supporting a role for HDL in controlling also
lymphocyte-mediated responses.
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5 Modulation of Spinghosine-1-Phosphate (S1P)/
S1P-Receptor Axis and Lymphocyte Function
Among the lipids that concentrate in lipid rafts, sphingolipids represent a major
class that is metabolized to generate ceramide and subsequently sphingosine that in
turn could be phosphorylated by sphingosine kinase (SPHK) (expressed mainly in
platelets and in other peripheral blood cells) to generate S1P (Scanu and Edelstein
2008). Free or albumin-bound S1P is more susceptible to degradation than S1P
bound to HDL (Yatomi 2008), which suggests that the latter might have a role in
determining the uptake, cellular degradation, and systemic function. S1P carried by
HDL positively correlates with HDL cholesterol, apoA-I, and apoA-II levels;
furthermore, S1P is enriched in small dense HDL3 (Scanu and Edelstein 2008).
S1P signals through five known G protein-coupled receptors (S1P1–S1P5). Over
the last few years, it become apparent that S1P and the key enzymes SPHKs play a
central role in the pathogenesis of several inflammatory disorders, including rheu-
matoid arthritis, asthma, and atherosclerosis by modulating macrophage function
through the control of apoptosis as well as cell trafficking (Weigert et al. 2009).
Many of these effects might depend on the activation of different S1P receptors.
The activation of the lysosphingolipid receptor-PI3K/Akt axis by sphingosine-1-
phosphate or other S1P mimetics is responsible for the induction by HDL of several
genes involved in the immune response including the long pentraxin PTX3 or the
transforming growth factor beta 2 (Norata et al. 2005, 2008). The S1P/S1P-receptor
axis also plays a key role in lymphocyte function. The activation of S1P receptors
and the consequent downstream signaling facilitate the egress of T cells from
lymphoid organs (Mandala et al. 2002; Matloubian et al. 2004) and play a role in
the lineage determination of peripheral T cells (Liu et al. 2010). S1P inhibits the
differentiation of forkhead box P3 (FoxP3)+ regulatory T cells (Tregs) while pro-
moting the development of T helper type 1 (Th1) in a reciprocal manner (Liu
et al. 2010). S1P receptor antagonizes TGF-β receptor function through an inhibi-
tory effect on SMAD-3 activities to control the dichotomy between these two T-cell
lineages (Liu et al. 2010). In animal models, apoA-I reduces inflammation in LDL
receptor (/), apoA-I(/) mice by augmenting the effectiveness of the lymph
nodes’ Treg response, with an increase in Treg and a decrease in the percentage of
effector/effector memory T cells (Wilhelm et al. 2010). While marked changes of
Treg number/function (two- to threefold difference) have been associated with
atheroprotective functions in animal models (Ait-Oufella et al. 2006; Mor
et al. 2007), in humans the correlation between Treg, immune, and cardiometabolic
disorders is less clear. We found no association between circulating CD3 +CD4
+CD25highCD127low Treg levels and the extent or progression of human athero-
sclerotic disease at carotid and coronary sites (Ammirati et al. 2010). In a series of
immune-mediated diseases such as rheumatoid arthritis, increased Treg levels in
synovial fluid of inflamed joints were observed (Mottonen et al. 2005; Bacchetta
et al. 2007). Furthermore, Liu et al. observed relatively high Treg-cell levels in
patients with type 1 diabetes mellitus (Liu et al. 2006), and pathogenic T cells have
been shown to have a paradoxical protective effect in murine autoimmune diabetes
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by boosting Tregs (Grinberg-Bleyer et al. 2010). Of note, excessive IL-6 or
TNF-alpha production was associated with increased Treg levels (Fujimoto
et al. 2011; Bilate and Lafaille 2010). This evidence suggests the possibility that
Treg numbers could increase during some stages of disease as an attempt to regulate
effector-cell activity. Unexpectedly, in the general population, we observed an
inverse relation between HDL-C and Treg count (Ammirati et al. 2010); whether
this finding suggests that HDL could influence the polarization of lymphocyte
subsets or could be a bystander of the T-cell status remains to be addressed. Recent
evidence on the role of S1P in immune surveillance and the discovery of regulatory
mechanisms in S1P-mediated immune trafficking has prompted extensive investi-
gation in the field of S1P-receptor pharmacology. Fingolimod (FTY720), an
S1P-receptor modulator, prevents lymphocyte egress from lymph nodes and
modulates lymphocyte differentiation (Chi 2011). Initially, fingolimod was used
as immunosuppressant in solid organ transplantation (Tedesco-Silva et al. 2006),
while MS has been the first disease in which fingolimod was tested. In MS the
myelin sheaths around the axons of the brain and spinal cord are damaged by
inflammatory processes, leading to demyelination. Current therapeutic approaches
are focused on the suppression of the immune system and on the blockage of T-cell
blood–brain barrier transmigration into the brain parenchyma. Treatment with
fingolimod was effective in reducing the disability progression on a large cohort
of patients with relapsing MS (Cohen et al. 2010; Kappos et al. 2010). Of note, MS
patients during the phase of clinical remission showed increased levels of HDL and
total cholesterol levels (Salemi et al. 2010), whereas in immune-mediated disorders
with increased markers of systemic inflammation, HDL levels are often decreased.
Fingolimod was assessed also in diseases with an immunological component, such
as atherosclerosis (Nofer et al. 2007; Keul et al. 2007). In LDL receptor-deficient
mice, fingolimod inhibits atherosclerosis by modulating lymphocyte and macro-
phage function. In this study plasma lipids remained unchanged during the course
of fingolimod treatment, whereas fingolimod lowered blood lymphocyte count
(Nofer et al. 2007). As S1P levels are increased in many inflammatory conditions,
such as in asthma and autoimmunity, the exact mechanism by which S1PR agonists
could modulate its function is debated (Rivera et al. 2008). Interestingly,
fingolimod is highly active in inducing the internalization, ubiquitination, and
subsequent degradation of S1PR1 (Graler and Goetzl 2004) which suggests that
its inhibitory action on immune cell trafficking might be through receptor
downregulation. It is therefore crucial to understand the effect of HDL contained
S1P on receptor expression and activity in immune disorders.
In spite of the presence of a number of experimental and clinical observations
suggesting a relation between HDL and innate immunity, several questions remain
to be addressed. Are the altered HDL-C levels a consequence of the atherogenic
process, a cause of increased atherosclerosis observed in immune disorders, or
independently related to the latter? How is HDL function altered in these diseases?
Does raising HDL-C improve the outcome of immune disorders? As HDLs are a
reservoir for several biologically active substances that may impact the immune
system (Norata et al. 2012), how does the fine-tuning of lipid and protein exchange
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among lipoproteins affect HDL-related immune functions? Is there a specific HDL
subfraction that is relevant? Addressing these aspects will be critical to understand
the connection between HDL and the immune response.
6 Inflammatory Diseases
6.1 Inflammatory Bowel Diseases
The inflammatory bowel diseases (IBD) Crohn’s disease (CD) and ulcerative colitis
(UC) are chronic inflammatory diseases whose pathogenesis is not completely
understood (Williams et al. 2012) but seems to be linked to autoimmune phenomena
in a genetically prone background, following an abnormal immune response to
colonic bacteria, and facilitated by a Western-type diet. IBD are associated with
marked atherosclerosis and increased cardiovascular risk. Infection and chronic
inflammation impair and alter lipoprotein metabolism and cause a variety of changes
in plasma concentrations of lipids and lipoproteins (Borba et al. 2006; de Carvalho
et al. 2008). An increase in inflammatory cytokines may result in a decrease in LPL
enzyme activity, leading to a characteristic lipoprotein profile with decreased HDL-C
levels as seen in patients with IBD that have high circulatory levels of inflammatory
cytokines (Williams et al. 2012; Sappati Biyyani et al. 2010).
CD is a chronic inflammatory bowel disease that can affect any region of the
gastrointestinal tract (Grand et al. 1995) with increased chronic inflammatory cell
infiltrates in the mucosal lesions. The excessive local production of soluble
mediators from activated monocytes and polymorphonuclear leukocytes has been
implicated in mediating the tissue injury (Weiss 1989). Important among these
mediators are oxygen free radicals. The chronic gut inflammation promotes an
imbalance between oxidant and antioxidant mechanisms at the tissue level
(Buffinton and Doe 1995) and may even compromise circulating antioxidant
concentrations. A chronic inflammatory state is a risk factor for accelerated athero-
genesis (van Leuven et al. 2007). A recent exploratory analysis demonstrated that
CD is associated with an acceleration of the atherosclerotic process, as illustrated
by an increased carotid intima-media thickness (IMT) in CD patients compared to
healthy controls. In addition, CD patients were characterized during an inflamma-
tory exacerbation by profoundly decreased levels of HDL combined with biochem-
ical changes of the HDL particles, such as association with serum amyloid A,
suggesting that early detection of atherosclerosis and subsequent cardiovascular
prevention in patients with CD might be warranted (Romanato et al. 2009).
6.2 Vasculitis
Behçet’s disease (BD) is a systemic vasculitis, most common in the Mediterranean
area and in Asia, which can involve nearly every organ system and results from the
interplay between infectious agent exposure and genetic factors. High production of
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cytokines, T and B lymphocyte activation, autoantibody production, and hyperco-
agulable/prothrombotic state are all characteristics of BD. Evidence for accelerated
atherosclerosis in BD has been observed, but the relationship between cardiovas-
cular risk factors and accelerated atherosclerosis in patients with BD is still
controversial (Messedi et al. 2011). A study published by Messedi and colleagues
demonstrated that in BD patients, HDL concentration and their subfraction levels
are decreased. The same study reported that the percentage of HDL2 subpopulation
was also decreased and HDL3 subfraction was significantly higher. The LDL-C/
HDL-C ratio and CRP level were increased, and HDL and its subfractions were
correlated with CRP and TG levels, suggesting that all these parameters may be
considered as important predictors of cardiovascular events in BD patients
(Messedi et al. 2011). This study confirms what seen in some previous studies in
which, compared to control subjects, BD patients were characterized by reduced
levels of HDL (Cimen et al. 2012; Musabak et al. 2005; Orem et al. 2002).
Kawasaki disease (KD) is an acute vasculitis that predominantly occurs in
infancy and early childhood. It is commonly thought that KD results from the
exposure of a genetically predisposed individual to an as-yet unidentified, possibly
infectious environmental trigger. Coronary artery aneurysms or ectasia develops in
approximately 15–25 % of affected children (Dhillon et al. 1996; Newburger
et al. 1991; Cheung et al. 2004). There is increasing evidence to suggest that
children with a history of KD might be predisposed to premature atherosclerosis
and a significant association between carotid IMT and systemic arterial stiffness in
children after KD has been demonstrated (Cheung et al. 2007). This syndrome is
associated with significant abnormalities in lipid profile. In one of the first studies
on this subject, it was shown that in the earliest days of illness, mean plasma
concentrations of total cholesterol and HDL cholesterol are profoundly depressed,
whereas mean triglyceride concentration is very high. Total cholesterol values
rapidly return to normal and remain stable for more than 3 months after the onset
of illness. HDL concentration recovered more slowly after illness onset, and mean
HDL was significantly lower than expected more than 3 years after illness onset
(Newburger et al. 1991). The persistence of low HDL for many years suggests a
more lasting effect of KD on endothelial function, perhaps attributable to dimin-
ished activity of lipoprotein lipase. This enzyme resides on the capillary walls of
most tissues and functions at the luminal surface of the vascular endothelium (Eckel
1989). This observation is confirmed, at least in part, in later studies on the lipid
derangement in KD (Cheung et al. 2004; Chiang et al. 1997; Cabana et al. 1997).
The results showed that during the acute phase, the concentrations of plasma
HDL-C, apoA-I, and apoA-II were significantly reduced and the reduction of
HDL was mainly related to the lowering of esterified and unesterified cholesterol
in HDL2 (Chiang et al. 1997). In parallel, another study demonstrated that the lipid
changes involved not only HDL-C concentration but also HDL composition. The
authors showed that children with KD have extremely low serum HDL-C and
apoA-I levels at the time of the acute illness and that serum amyloid A (SAA) is
present in the acute stage and is associated mainly with HDL particles of HDL3
density (Cabana et al. 1997). Moreover, a more recent study demonstrated a
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significant induction of MCP-1, CCR2, and iNOS expression in THP-1
macrophages in vitro by the serum of children with a history of KD, showing that
this induction correlated positively with serum high-sensitivity C-reactive protein
(hs-CRP) and LDL and negatively with HDL-C levels (Cheung et al. 2005).
6.3 Psoriasis
Psoriasis is a chronic inflammatory skin disease associated with arthritis in up to
40 % of cases. Genetic and environmental factors contribute to the activation of
lymphocytes, particularly Th1 and Th17, monocytes/macrophages, and dendritic
cells and to the high cytokine content typical of psoriatic lesions. Psoriasis is
associated with increased incidence of stroke and CVD (Yu et al. 2012) and with
increased mean carotid IMT (Troitzsch et al. 2012). The mechanism behind such
associations is still unknown. It is possible that the chronic inflammatory environ-
ment and high cytokine production typical of psoriasis induce abnormal HDL
particle composition (El Harchaoui et al. 2009; McGillicuddy et al. 2009). A similar
chronic inflammatory environment is observed in psoriasis (Davidovici et al. 2010)
and contributes to the increased incidence of aortic inflammation, stroke, and
myocardial infarction seen in this patient population (Mehta et al. 2011; Gelfand
et al. 2006).
Lipoprotein profiling by NMR spectroscopy showed a reduction of HDL in
psoriatic patients compared to controls, with an atherogenic profile with respect
to HDL particles. In particular, high HDL-C concentration and large HDL size were
associated with less aortic inflammation, while small HDL particles were more
prevalent in cases with strong inflammation. Such association persisted following
adjustment for CV risk factors, suggesting that HDL particle characteristics may
play an important role in psoriatic vascular inflammation and CVD (Yu et al. 2012).
HDL reduction in psoriatic patients has also been described to be associated to a
reduction of serum cholesterol efflux capacity compared to control subjects (Mehta
et al. 2012). In this study, psoriasis activity was inversely associated with HDL
efflux capacity in a way depending on HDL particle size. Holzer and colleagues
demonstrated that the protein composition of HDL is markedly altered in patients
with psoriasis. ApoA-I and apoM levels are decreased, whereas the levels of several
acute-phase proteins such as SAA, prothrombin, α-2-HS-glycoprotein, and α-1-acid
glycoprotein 1 are increased (Holzer et al. 2012). Additionally, also the lipid
composition of HDL from patients with psoriasis was altered, with a decrease in
total cholesterol, cholesterol ester, free cholesterol, phosphatidylcholine, and
sphingomyelin. These investigators confirmed that HDL from patients with psoria-
sis was less efficient in promoting cholesterol efflux from macrophages and that this
defect in HDL function correlated with the severity of psoriasis. Surprisingly, the
antioxidant properties of HDL were similar in control and psoriatic HDL and PON
activity was not altered. However, Lp-PLA2 activity was increased and correlated
with disease activity (Holzer et al. 2012). This observation does not completely
agree with a report showing that the PON1 55 M allele is a risk factor for psoriasis.
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Carriers of this allele have high levels of apoB and Lp(a) and a high apoB/apoA-I
ratio, indicating that oxidative stress, impairment of the antioxidant system, and
abnormal lipid metabolism may play a role in the pathogenesis and progression of
psoriasis and its related complications (Asefi et al. 2012). Moreover, the paper by
Holzer and coworkers demonstrates that a relatively mild chronic inflammatory
state can similarly result in dysfunctional HDL, leading to decreased cholesterol
efflux from macrophages (Holzer et al. 2012).
7 Autoimmune Diseases: The Role of Autoantibodies
7.1 Systemic Lupus Erythematosus (SLE)
SLE is a systemic autoimmune disease of multifactorial origin, in which genetic
and environmental factors induce innate and acquired immunity derangement, with
type I interferon (INF) production, T- and B-cell dysregulation, autoantibody
production, and finally multiple organ damage. SLE is associated with accelerated
atherosclerosis and markedly increased cardiovascular risk (CVR) (Shoenfeld
et al. 2005). As in other autoimmune disorders, CVR cannot be fully explained
by traditional risk factors, and various specific immune and inflammatory
mechanisms have been demonstrated or proposed. The modifications of HDL
level and function occurring in SLE have been indicated as possible factors
contributing to cardiovascular damage.
Decreased circulating HDL-C levels have been often reported, although not
unanimously, in SLE patients with active disease (de Carvalho et al. 2008; Hahn
et al. 2008; Kiss et al. 2007), but the actual relevance of this finding with respect to
CVR has not been clarified so far. The most important pro-atherogenic
modifications seem to be those relative to composition and function of HDL.
HDLs in SLE have impaired anti-inflammatory and antioxidant properties. In
SLE, the so-called proinflammatory HDL (piHDL) can be detected in as many as
45 % of patients, correlating with increased oxidized LDL formation, carotid plaque,
and carotid intima-media thickness (cIMT) (McMahon et al. 2011). piHDL are
characterized by decreased content in the protective proteins paraoxonase (PON1)
and apoA-I and by markedly increased levels of the pro-oxidant SAA (Hahn
et al. 2008). These HDLs can be defined as proinflammatory because they actually
enhance the oxidation of LDL and therefore monocyte attraction/activation, anti-
oxLDL antibody production, and immune complex formation (Hahn et al. 2008;
Teixeira et al. 2012; Carbone et al. 2013; Vuilleumier et al. 2014). It has been shown
that the reduced activity of PON1 in some cases may be due also to the action of anti-
apoA-I and anti-HDL antibodies (O’Neill et al. 2010; Batuca et al. 2007). Anti-apoA-
I antibodies, first described in SLE patients but detected also in patients with acute
coronary syndrome, have shown independent association and predictive value with
respect to cardiovascular events in various patient populations (Carbone et al. 2013).
Proposed mechanisms for such association include the ability of anti-apoA-I
antibodies to induce HDL dysfunction, scavenger receptor B1 (SR-BI) function
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impairment in endothelial cells, neutrophil infiltration and matrix-metalloproteinase
9 production in plaques, activation of NFkB via TLR2/CD14 complex interaction,
and cytokine release (Carbone et al. 2013). Interestingly, anti-apoA-I and anti-HDL
antibodies have been shown to correlate also with disease activity in SLE patients
(O’Neill et al. 2010).
In addition, HDL dysfunction in SLE involves their capacity to promote cell
cholesterol efflux (Ronda et al. 2014). In particular, in SLE patients HDL choles-
terol efflux capacity (CEC) is reduced with respect to the ABCG1 and ABCA1
transporter pathways, while the SR-BI-mediated CEC is unchanged. In addition the
correlation between SR-BI-mediated CEC and HDL-C levels was stronger in SLE
plasmas as compared to control plasma. This pattern is consistent with a possible
reduction/dysfunction of the small HDL populations (Favari et al. 2009) and a shift
to larger HDL, typical acceptors of cholesterol effluxed by SR-BI. Indeed, HDLs of
SLE patients were found increased in size (Hua et al. 2009; Juárez-Rojas
et al. 2008). The impaired ABCA1- and ABCG1-mediated CEC in SLE patients
may have a great impact because cholesterol efflux not only opposes lipid deposi-
tion in vessels but is also crucial for the modulation of macrophage, endothelial, and
T-cell inflammatory functions (Prosser et al. 2012; Yvan-Charvet et al. 2010a, b).
7.2 Rheumatoid Arthritis (RA)
RA is a systemic autoimmune disease characterized by lymphocyte activation,
autoantibody production, high serum and tissue cytokine levels, and strong inflam-
mation of synovia and vessels; similarly to SLE, it is associated with high CV risk
(Shoenfeld et al. 2005). Circulating levels of HDL-C are often reduced, especially
in active disease, and generally return to normal values during drug-induced
remission; however, as such modifications are mirrored by those relative to LDL
cholesterol and total cholesterol, the actual clinical significance of HDL-C variation
is not clear. Complex and specific mechanisms underlie lipid metabolism derange-
ment in RA, in which cardiovascular risk inversely correlates with circulating
LDL-C levels (the so-called RA lipid paradox) (Myasoedova et al. 2011). As in
SLE, the clinical relevance of HDL-C lowering (when present) in RA patients has
yet to be clarified.
Composition and functional characteristics of HDL are altered in RA. piHDL
levels are increased in RA patients as compared to healthy controls (Hahn
et al. 2008) and correlate positively with disease activity (Charles-Schoeman
et al. 2009). Profound modifications of HDL composition in patients with active
RA have been described, particularly with respect to protein content. These changes
include increased amount of serum amyloid A (SAA), apoJ, fibrinogen, and hapto-
globin and reduced PON1 (Charles-Schoeman et al. 2009; Watanabe et al. 2012).
As in SLE, anti-apoA-I autoantibodies are detectable in the serum of RA patients.
In particular, in this population anti-apoA-I IgG levels have been shown to predict
acute cardiovascular events and improve the prognostic power of the Framingham
Risk Score (Carbone et al. 2013).
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Finally, functional impairment of HDL as cholesterol acceptors for cell choles-
terol efflux has been reported in RA (Ronda et al. 2014; Charles-Schoeman
et al. 2012), independent of serum HDL-C levels and with a pattern of
modifications differing from that found in SLE patients with respect to single
cholesterol transporters (Ronda et al. 2014). In particular, ABCG1-mediated CEC
is impaired in RA patients independently of HDL-C levels but inversely correlating
with disease activity (Ronda et al. 2014). On the one hand, such correlation may
reflect the impact of inflammation and autoimmunity on HDL function, but on the
other hand, it may indicate the adverse effect of reduced ABCG1-mediated CEC on
vessel inflammation and immune reaction promotion. In fact, by promoting choles-
terol and 7-ketocholesterol release, ABCG1 promotes anti-inflammatory
phenotypes of macrophages and endothelial cells (Terasaka et al. 2007; Hassan
et al. 2006; O’Connell et al. 2004).
Modifications of HDL occurring in SLE and RA compromise cholesterol efflux-
promoting, anti-inflammatory, and antioxidant properties of HDL and thereby may
have an important role in the progression of both atherosclerosis and autoimmune
as well as inflammatory phenomena typical for these diseases.
8 Impact of Anti-inflammatory Treatments
HDL exerts potent and multifactorial anti-inflammatory effects, which makes it an
attractive target for pharmacological intervention. As extensively discussed in this
chapter, several molecular principles exploited by HDL particles to interfere with
innate or acquired immunity might be well utilized for designing new drugs
effectively combating atherosclerosis and/or autoimmune diseases. By contrast,
little efforts have been devoted to assess the influence of medication traditionally
used in acute or chronic inflammatory diseases on HDL-C levels and HDL function.
Most information regarding the interrelationship between HDL and anti-
inflammatory therapy stems from interventional studies designed to examine the
impact of drugs on the primary disease rather than on lipid metabolism. Despite this
limited approach, currently available data strongly suggest that anti-inflammatory
medication may exert positive adjuvant effects both on HDL quantity and its
functionality.
It is well known that HDL is a negative acute-phase reactant and that HDL-C
levels decline—sometimes dramatically—at the onset of acute inflammation and
infection. For instance, sepsis, extensive surgery, or viral infections are commonly
associated with low HDL-C levels that are significantly and rapidly increased
following spontaneous or treatment-related reductions in disease activity (Marik
2006; Akgun et al. 1998; Marchesi et al. 2005). In addition, several chronic
autoimmune disorders including SLE, RA, Kawasaki disease, and Behçet’s disease
as well as periodontal disease are accompanied by decreased HDL levels in plasma
(Haas and Mooradian 2011). Hence, the administration of nonsteroidal anti-
inflammatory drugs (NSAIDs), which represent the most often prescribed class of
anti-inflammatory drugs, might be expected to produce HDL-C elevations by the
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simple reversal of the acute-phase reaction. However, the effect of NSAIDs on the
quantity and quality of HDL remains controversial. In animal studies rising effects
of aspirin on ABCA1 expression and cholesterol efflux as well as on lecithin-
cholesterol acyltransferase (LCAT) activity and plasma HDL-C levels were occa-
sionally observed (Sethi et al. 2011; Jafarnejad et al. 2008; Viñals et al. 2005).
However, these effects apparently did not translate into increased HDL generation,
as similar plasma HDL-C levels were noted in a small prospective study in aspirin-
and placebo-treated groups (Eritsland et al. 1989). In one study, the administration
of ibuprofen was found to slightly elevate HDL-C levels both in smokers and
nonsmokers, whereas in another study treatment with naproxen failed to show
any effect (Zapolska-Downar et al. 2000; Young et al. 1995). The influence of
selective cyclooxygenase-2 inhibitors such as celecoxib or rofecoxib on HDL-C
plasma levels has not been reported to date. In a more recent investigation,
atreleuton (VIA-2291)—the first clinically tested 5-lipooxygenase inhibitor—was
found to decrease leukotriene B4 production and CRP levels in blood and to
concomitantly reduce coronary plaque burden, but these favorable effects were
observed in the absence of any changes in plasma lipid profile including HDL-C
(Tardif et al. 2010).
In a major contrast to nonsteroidal antiphlogistics, corticosteroids were repeat-
edly reported to increase plasma HDL-C levels in patients with chronic autoim-
mune diseases including RA, psoriatic arthritis, and SLE as well as in a
non-autoimmune chronic inflammation (sarcoidosis) (Ettinger et al. 1987; Salazar
et al. 2002; Boers et al. 2003; Sarkissian et al. 2007; Peters et al. 2007; Georgiadis
et al. 2008; Garcı́a-Gómez et al. 2008). Furthermore, the addition of corticosteroids
to disease-modifying antirheumatic drugs (DMARDs, such as methotrexate or
sulfasalazine), which on their own increase HDL-C in plasma, significantly
potentiated their effects on HDL-C levels (Boers et al. 2003). In one study,
corticosteroids were also found to favorably affect HDL subfractions by preferen-
tially increasing the amount of HDL2-C over HDL3-C (Garcı́a-Gómez et al. 2008).
The beneficial effects exerted by corticosteroids on HDL quantity may appear at the
first glimpse counterintuitive, since protracted therapy with these compounds is
known to enhance insulin resistance and to produce a prediabetic state, which is
almost obligatorily accompanied by low HDL-C. Actually, endogenous hypercor-
tisolism (Cushing disease) has been related both to decreased HDL-C levels and to
increased cardiovascular risk in several studies (Faggiano et al. 2003). However,
the relationship between steroid use and cardiovascular risk is complicated by the
fact that these drugs tend to be used more often in patients with severe or intractable
chronic disease; in such patients, the anti-inflammatory HDL-C elevating effect of
corticosteroids may outweigh the HDL-C decreasing effect related to aggravation
of insulin resistance. The mechanisms underlying modulatory effects of
corticosteroids on HDL metabolism remain obscure. These compounds were
found to increase the activity of lipoprotein lipase (LPL) and to decrease the activity
of hepatic triglyceride lipase, which are both critically involved in the generation of
HDL precursors and in HDL particle remodeling (Ewart et al. 1997; Dolinsky
et al. 2004). In addition, corticosteroids may stimulate the production of nascent
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HDL as they enhance apoA-I gene expression in hepatocytes (Hargrove
et al. 1999). Finally, corticosteroids were found to inhibit the activity of cholesteryl
ester transfer protein (CETP), which may well explain their modulatory effect on
the HDL subfraction composition (Georgiadis et al. 2006).
Studies involving biological pharmaceuticals, which selectively interfere with
proinflammatory signaling pathways, add further evidence underscoring the bene-
ficial effects of anti-inflammatory therapies on HDL quantity in plasma. The
greatest amount of research into the effects of biologicals on lipids has been
performed with TNF-alpha antagonists, in particular, with infliximab. In general,
these studies demonstrated a consistent action of this drug in patients with RA,
ankylosing spondylitis, and inflammatory bowel disease characterized by increases
in total cholesterol mostly due to the elevation of HDL-C (Choy and Sattar 2009;
Pollono et al. 2010; Mathieu et al. 2010; Koutroubakis et al. 2009; Parmentier-
Decrucq et al. 2009). Similar effects on HDL-C were observed in studies utilizing
two other TNF-alpha antagonists, adalimumab and, most recently, golimumab,
whereas the application of etanercept—a TNF-alpha receptor antagonist—pro-
duced less consistent results (Pollono et al. 2010; Stagakis et al. 2012; Navarro-
Millán et al. 2013; Lestre et al. 2011; Kirkham et al. 2014). Positive effects on
plasma lipid profile encompassing the elevation of HDL-C levels were also
observed in patients with RA undergoing IL-6 receptor blockade with tocilizumab
or CD20 signaling blockade with rituximab (Pollono et al. 2010; Kawashiri
et al. 2011; Kerekes et al. 2009). In a major contrast, canakinumab—a compound
neutralizing IL-1beta—failed to change plasma lipid profile in a large randomized
study involving 556 men and women at high cardiovascular risk, albeit the treat-
ment led to significant reductions in acute-phase proteins such as CRP and fibrino-
gen (Ridker et al. 2012). The molecular mechanisms underlying the beneficial
effects of biological therapies on HDL-C levels are poorly understood. While it
cannot be entirely excluded that HDL-C increases are at least partly related to the
retardation of acute-phase reaction brought about by the inhibition of selected
proinflammatory signaling pathways, it seems more likely that treatment with
TNF-alpha or IL-6 antagonists leads to derepression of the APOA1 gene, the
activity of which is known to be downregulated in hepatocytes exposed to
proinflammatory cytokines (Haas and Mooradian 2011).
In addition to the reduction of HDL quantity, acute-phase reaction was
demonstrated to profoundly affect HDL composition. HDL particles isolated
from subjects suffering from acute or chronic inflammatory diseases were found
to lose proteins and enzymes with established or presumed antiatherogenic function
such as apoA-I, LCAT, or PON1 and to concomitantly acquire proinflammatory or
pro-oxidative factors such as SAA, ceruloplasmin, Lp-PLA2, or MPO. Such
inflammatory HDL particles are severely impeded in their ability to exert several
antiatherogenic functions including initiation of reversed cholesterol transport,
inhibition of pro-oxidative processes, inhibition of leukocyte migration and recruit-
ment into arterial wall, or inhibition of thrombocyte activation. The picture
emerging from few recent studies suggests that anti-inflammatory medications
may not only elevate HDL quantity in plasma but also help to restore its proper
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composition and thereby the antiatherogenic functionality. For instance, treatment
of RA patients with adalimumab, etanercept, tocilizumab, or rituximab decreased
and increased the content of SAA and apoA-I in HDL particles, respectively
(Raterman et al. 2013; McInnes et al. 2014; Jamnitski et al. 2013). In addition,
prolonged therapy with methotrexate was found to improve the capacity of HDL to
inhibit both LDL oxidation and leukocyte migration in patients with RA (Charles-
Schoeman et al. 2009). Increased levels of HDL-associated PON1 and improved
anti-oxidative capacity were seen in patients with psoriasis treated with etanercept
(Bacchetti et al. 2013).
Conclusions
HDL particles have been shown to play a protective and an anti-inflammatory
role in autoimmune and inflammatory disorders. Their pathophysiological rele-
vance directly implies the regulation of both immune and vascular cell functions
that influence the common inflammatory processes underlying disease progres-
sion and the associated CV risk. Numerous studies have demonstrated that
inflammatory disorders increase the risk of CVD and that this increase cannot
be totally accounted for by traditional risk factors. Alterations in the quantity,
composition, and function of HDL may contribute to the promotion of athero-
sclerosis process. In this prospective the assessment of HDL function, evaluated
as the capacity to promote cell cholesterol efflux, may offer a better prediction of
CVD than classical HDL-C levels. In addition, HDL function impairment, which
involves their anti-inflammatory and antioxidant properties as well as their
ability to interact with cellular cholesterol transporters, may have an important
role in accelerating atherosclerosis but also autoimmune and inflammatory
mechanisms typical for these diseases. Therefore, the improvement of HDL
function (instead of HDL-C levels) represents an interesting therapeutic strategy
to reduce inflammation and associated CV risk in several immune diseases, such
as systemic lupus erythematosus and rheumatoid arthritis. We believe that
selective treatments improving HDL function or reducing the adverse
modifications of HDL structure might be of pathophysiological relevance.
Both basic and clinical studies are needed to validate this promising therapeutic
issue in a near future.
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Abstract
During infection significant alterations in lipid metabolism and lipoprotein
composition occur. Triglyceride and VLDL cholesterol levels increase, while
reduced HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels are
observed. More importantly, endotoxemia modulates HDL composition and
size: phospholipids are reduced as well as apolipoprotein (apo) A-I, while
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Department of Pharmacological and Biomolecular Sciences, University of Milan,
Via Balzaretti 9, 20133 Milan, Italy
e-mail: Danilo.Norata@unimi.it
# The Author(s) 2015
A. von Eckardstein, D. Kardassis (eds.), High Density Lipoproteins, Handbook of
Experimental Pharmacology 224, DOI 10.1007/978-3-319-09665-0_15
483
serum amyloid A (SAA) and secretory phospholipase A2 (sPLA2) dramatically
increase, and, although the total HDL particle number does not change, a
significant decrease in the number of small- and medium-size particles is
observed. Low HDL-C levels inversely correlate with the severity of septic
disease and associate with an exaggerated systemic inflammatory response.
HDL, as well as other plasma lipoproteins, can bind and neutralize Gram-
negative bacterial lipopolysaccharide (LPS) and Gram-positive bacterial
lipoteichoic acid (LTA), thus favoring the clearance of these products. HDLs
are emerging also as a relevant player during parasitic infections, and a specific
component of HDL, namely, apoL-1, confers innate immunity against trypano-
some by favoring lysosomal swelling which kills the parasite. During virus
infections, proteins associated with the modulation of cholesterol bioavailability
in the lipid rafts such as ABCA1 and SR-BI have been shown to favor virus entry
into the cells. Pharmacological studies support the benefit of recombinant HDL
or apoA-I mimetics during bacterial infection, while apoL-1–nanobody
complexes were tested for trypanosome infection. Finally, SR-BI antagonism
represents a novel and forefront approach interfering with hepatitis C virus entry
which is currently tested in clinical studies. From the coming years, we have to
expect new and compelling observations further linking HDL to innate immu-
nity and infections.
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LPS Gram-negative bacterial lipopolysaccharide
LTA Gram-positive bacterial lipoteichoic acid
PAF-AH Platelet-activating factor acetylhydrolase




SAA Serum amyloid A
S1P Sphingosine-1-phosphate
sPLA2 Secretory phospholipase A2
SR-BI Scavenger receptor class B member 1
TG Triglycerides
TLF-1 Trypanosome lytic factor-1
TLRs Toll-like receptors
TNF-α Tumor necrosis factor-α
1 Introduction
HDLs are heterogeneous particles generated by the continuous remodeling by
lipolytic enzymes and lipid transporters and by lipid and apolipoprotein exchange
with other circulating lipoproteins and tissues (Kontush and Chapman 2006).
Mature HDL particles have a hydrophobic core containing cholesteryl esters and
triglycerides, while proteins are embedded in a lipid monolayer composed mainly
of phospholipids and free cholesterol. HDLs contain two main proteins, apolipo-
protein A-I (apoA-I) and apoA-II, but several other minor apoproteins as well as
enzymes such as lecithin-cholesterol acyltransferase (LCAT), serum paraoxonase
(PON1), and platelet-activating factor acetylhydrolase (PAF-AH) are associated
with HDL particles (Navab et al. 2004). HDLs possess several biological functions
(Pirillo et al. 2013), but the role of HDL in innate immunity has emerged in the
1970s with the first observation associating HDL cholesterol (HDL-C) plasma
levels to protection against sepsis. In the coming years, it has emerged that the
ability of HDL to modulate cholesterol bioavailability in the lipid rafts, membrane
microdomains enriched in glycosphingolipids and cholesterol, is evolutionary
conserved and affects the properties of cells involved in the innate and adaptive
immune response, tuning inflammatory response and antigen presentation functions
in macrophages as well as activation of B and T cells. In the context of infections,
HDL and their components have been linked with protection toward Gram-negative
and Gram-positive bacteria and parasites, while the role during virus infection is
debated (Fig. 1). Furthermore, HDLs influence humoral innate immunity by tuning
the activation of the complement system and the expression of pentraxin 3 (PTX3).
HDLs are critical not only during sepsis but also in other bacterial, parasitic, and
viral infection. The aim of this chapter is to discuss the relevant findings on the link
between HDL and immune response, shedding a new light on the role of these
lipoproteins during sepsis and infectious disease.
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2 HDL and Bacterial Infections
Increasing observations suggest that persistent low-grade inflammation is
associated with the pathogenesis of severe chronic diseases such as atherosclerosis,
diabetes, and other aging-related neurological diseases. Low levels of circulating
Gram-negative bacterial endotoxin lipopolysaccharide (LPS) appear to sustain a
non-resolving low-grade inflammation. As a consequence, low-grade
endotoxinemia may skew host immune environment into a mild non-resolving
pro-inflammatory state, which eventually leads to the pathogenesis and progression
of inflammatory diseases.
During infection, significant changes in the lipid metabolism are observed. At
first, plasma levels of lipid and lipoproteins may change: triglyceride (TG) and
VLDL cholesterol levels increase due to several mechanisms, including reduction
of TG hydrolysis, LPS- and pro-inflammatory cytokines-induced de novo free fatty
acid production, and TG synthesis in the liver and reduction of lipoprotein lipase
activity thus resulting in reduced VLDL clearance and increased TG levels (Wendel
et al. 2007). In addition, the increase in free fatty acids induces insulin resistance,
thus contributing to increased glucose levels during systemic inflammation. On the





TYPE OF INFECTION HDL-MEDIATED EFFECT
•Favor LPS/LTA binding and neutralizaon.
•Favor LPS/LTA clearance
• Inhibit LPS (LTA)-induced cytokine release
• Inhibit of LPS (LTA)-induced cell acvaon
• Induce an early inflammatory response
•Support ApoL1, Apo-AI and HRP interacon 
to form the trypanosoma lyc factor-1  (TLF-
1). complex. ApoL1  then traffics to the 
trypanosomal lysosome, where causes 
swelling which kills the trypanosome.
•Dampen (ApoA-1 mimec pepdes) the 
ABCA-1 impairment induced by the HIV-1 
Nef protein.
• Inhibit cell fusion, both in HIV-1-infected T 
cells and in recombinant vaccinia-virus-
infected CD4+ HeLa cells.
•Compete with Hepas C virus on SRBI 
interacon to dampen virus entry?
Fig. 1 HDL and infections
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HDL-C level (associated with a low plasma apoA-I level) is a poor prognostic
factor for severe sepsis, as it is associated with increased mortality and adverse
clinical outcomes (Chien et al. 2005); more importantly, significant alterations in
lipoprotein composition are observed, and increased levels of acute-phase proteins,
including serum amyloid A (SAA) and secretory phospholipase A2 (sPLA2), may
contribute to decreased HDL-C levels, by replacing some structural and functional
HDL components (Fig. 2).
Endotoxinemia also modulates HDL composition and size: phospholipids are
reduced while SAA dramatically increases and apoA-I decreases, and, although the
total HDL particle number does not change, a significant decrease in the numbers of
small- and medium-size particles is observed (de la Llera et al. 2012). The apoA-I
content is reduced due to the rapid association of SAA, which displaces apoA-I and
becomes the main protein of acute-phase HDL (Coetzee et al. 1986; Khovidhunkit
et al. 2004); the content of other proteins associated with HDL (PON1, PAF-AH) is
altered, resulting in reduced antioxidant properties of HDL (Feingold et al. 1998)
and increased content of pro-atherogenic lipids (Cao et al. 1998; Memon
et al. 1999). Also the lipid composition of HDL is altered during the acute-phase
response (Khovidhunkit et al. 2004). Endotoxemia induces the increase of some
enzymes involved in HDL remodeling, including endothelial lipase (Badellino
et al. 2008) and secretory phospholipase A2 (de la Llera et al. 2012), and the
decrease of other, such as CETP and LCAT (de la Llera et al. 2012; Wendel
et al. 2007). Altogether these changes result in the loss of functional properties of







Fig. 2 Acute-phase HDL
HDL in Infectious Diseases and Sepsis 487
2.1 Interaction of HDL with LPS and Gram-Negative Bacteria
Sepsis is a major cause of death in hospitalized patients. Mortality is mainly due to
the cytotoxic actions of lipid components of the bacterial outer membrane
Lipopolysaccharide (LPS) is the toxic component of endotoxin in the outer mem-
brane of Gram-negative bacteria. Lipoteichoic acid (LTA) is a heat-stable compo-
nent of the cell membrane and wall of most Gram-positive bacteria that shares
structural similarities with LPS and induces cytokine cascades alike LPS
(Grunfeld et al. 1999).
LPS, the major pathogenic factor in Gram-negative sepsis, is an essential
component of the bacterial cell wall, and it is not toxic when incorporated into
the membrane; after release in the blood following bacterial cell reproduction, lysis,
or death, lipid A, the most essential part of LPS, induces an inflammatory response
(Van Amersfoort et al. 2003). This is mediated by pro-inflammatory cytokines
released primarily from monocytes/macrophages and neutrophils, such as tumor
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) (Levine
et al. 1993). LPS is recognized mainly by toll-like receptor 4 (TLR4) in cooperation
with other proteins including MD-2, CD14, and LPS-binding protein (LBP) (Jerala
2007). LBP catalyzes the transfer of LPS to CD14, thus enhancing LPS-induced
cell activation (Van Amersfoort et al. 2003). To prevent exaggerated responses to
LPS, the host has developed several control mechanisms that include inhibitory
LPS-binding proteins and plasma lipoproteins (Van Amersfoort et al. 2003).
In patients with severe sepsis, HDL-C decreases rapidly, and SAA is the major
protein present in HDL (45 %) at the start of sepsis and is slowly replaced by apoA-I
during recovery (van Leeuwen et al. 2003). Low HDL-C levels inversely correlate
with the severity of septic disease and associate with an exaggerated systemic
inflammatory response (Wendel et al. 2007), although it is difficult to establish
whether changes in plasma lipoproteins simply reflect the severity of disease or they
can directly modify the host response to inflammation. Also in healthy subjects low
HDL levels are associated with increased inflammatory response on endotoxin
challenge compared to subjects with normal or high HDL levels (Birjmohun
et al. 2007), without differences in the HDL proteome (Levels et al. 2011). These
observations indicate a positive role of HDL in the protection against sepsis.
Several mechanisms are involved in HDL-mediated protection. HDL, as well as
other plasma lipoproteins (LDL, TG-rich lipoproteins), can bind and neutralize
Gram-negative bacterial LPS as well as Gram-positive bacterial lipoteichoic acid
(LTA) (Grunfeld et al. 1999; Murch et al. 2007). ApoA-I knockout mice, which
lack HDL, exhibit decreased LPS neutralization in the serum compared with serum
from control mice (Guo et al. 2013); overexpression of apoA-I moderately
improves survival compared to controls, suggesting that HDL elevation may
protect against septic death. In endotoxemic rats, in which LPS has been infused
after HDL administration, HDLs attenuate LPS-induced organ damage
accompanied by lower TNF-α and nitric oxide production (Lee et al. 2007). In
addition to its role in LPS neutralization, HDLs exert its protection against
sepsis also by promoting LPS clearance; in fact, almost all LPS exists in the
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complex LPS–HDL in the blood (Ulevitch et al. 1979, 1981), the HDL receptor
SR-BI binds and mediates LPS uptake, and HDLs promote SR-BI-mediated LPS
uptake (Vishnyakova et al. 2003).
Administration of reconstituted HDL (rHDL) efficiently inhibits the
LPS-induced cytokine release from the whole-blood system in vitro (Parker
et al. 1995); however, the first study that demonstrated the LPS-neutralizing ability
of rHDL in humans was performed by intravenous infusion of rHDL before
induction of endotoxemia in healthy volunteers (Pajkrt et al. 1996). rHDL signifi-
cantly reduced endotoxemia-induced inflammatory response, as it reduced clinical
symptoms, reduced inflammatory cytokine (TNF-α, IL-6, IL-8) production, and
attenuated LPS-induced leukocyte activation, in part due to the downregulation of
the main LPS receptor monocyte-bound CD14 (Pajkrt et al. 1996). In
LPS-challenged macrophages, HDLs selectively inhibit the activation of type I
IFN response genes (Suzuki et al. 2010), which play a critical role in the antiviral
response of cells, although emerging evidence also implicates this response in host
defense during bacterial infection. This inhibitory effect of HDL does not require
LPS binding to lipoproteins (Suzuki et al. 2010). HDLs (and apoA-I) attenuate also
LPS-induced neutrophil activation (Murphy et al. 2011). More recently Di Nardo
et al. (2014) have shown that HDLs promote the expression of ATF3 in
macrophages, a transcriptional regulator which inhibits TLR2 expression. Of note
the protective effects of HDL against TLR-induced inflammation were shown to be
fully dependent on ATF3 in vitro and in vivo.
Another mechanism by which HDLs exert a protection against sepsis is by
inducing an early inflammatory response to Gram-negative bacteria, thus helping
to maintain a sensitive host response to LPS; HDLs exert this effect by suppressing
the inhibitory activity of LBP (Thompson and Kitchens 2006). In contrast to native
HDL, recombinant HDL did not increase cell response at early time points and are
strongly inhibitory of cell response; this different effect is due to the composition of
rHDL, which contain only apoA-I and PC and are optimized for LPS binding and
neutralization (Thompson and Kitchens 2006).
Indeed apoA-I is a major HDL component that plays a central role in the anti-
inflammatory functions of this lipoprotein class and exhibits protective effects
against sepsis. ApoA-I in fact can directly inactivate bacterial endotoxin by
protein–protein interaction (Emancipator et al. 1992), being the C-terminal half
of apoA-I the main domain responsible for LPS neutralization (Henning
et al. 2011), but also inhibits LPS-induced cytokine release from human monocytes
(Flegel et al. 1993); in addition, apoA-I reduces TNF-α levels during LPS challenge
in rats and increases the survival rates (Humphries et al. 2006), suggesting that
apoA-I might inhibit LPS binding to macrophages thus inhibiting the production of
inflammatory cytokines that are related to sepsis. In mice, the overexpression of
apoA-I (that results in an increased serum level of both apoA-I and HDL) attenuates
LPS-induced acute injury in lung and kidney (Li et al. 2008); LPS-induced pro-
inflammatory cytokines decrease, as well as CD14 expression in liver and lung,
resulting in a protective effect against systemic inflammation and multiple organ
damage (Li et al. 2008). Similar to what reported in mice, subjects with low plasma
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HDL levels (hypoalphalipoproteinemia) present an increased prevalence of classi-
cal CD14++/CD16 but not of intermediate CD14++/CD16+ monocytes, further
linking HDL- to LPS-mediated responses (Sala et al. 2013). Septic HDLs are
almost depleted of apoC-I (Barlage et al. 2001). ApoC-I contains a consensus
LPS-binding motif and is able to enhance the biological response to LPS thus
reducing mortality in mice with Gram-negative-induced sepsis (Berbee
et al. 2006). In fact, apoC-I binds to LPS and prevents its clearance by the liver
and spleen, resulting in the stimulation of the LPS-induced pro-inflammatory
response and protection against septic death (Berbee et al. 2006). These findings
suggest that when LPS is released into the plasma following bacteria proliferation
in the blood, apoC-I binds to LPS and presents it to responsive cells such as
macrophages, leading to a rapid and enhanced production of pro-inflammatory
cytokines, which are essential for effective eradication of the bacterial infection.
2.2 Interaction of HDL with LTA and Gram-Positive Bacteria
The effects of HDL on components of the bacterial outer membrane are not
restricted to Gram-negative bacteria but also involve cell wall components of
Gram-positive bacteria such as LTA which is able to induce an inflammatory
response similar to that induced by LPS. Indeed it induces a massive production
of mediators of inflammation that may result in systemic inflammatory response
syndrome, septic shock, and multiorgan damage (Bhakdi et al. 1991; De Kimpe
et al. 1995). LTA may also trigger disturbances of lipid metabolism, interfering
with both lipoprotein production and lipoprotein clearance (Grunfeld et al. 1999).
All lipoproteins can bind LTA, but the majority of LTA is found in the HDL
fraction (Levels et al. 2003), suggesting that HDLs have the highest affinity. In
contrast to LPS, HDLs (as well as other lipoproteins) alone do not inhibit the
cytokine production induced by LTA, but require the presence of lipoprotein-
depleted plasma (Grunfeld et al. 1999), suggesting that lipoproteins contain
cofactors in sufficient amounts to facilitate LPS binding to lipoproteins but not
LTA binding. LBP is a plasma component (normally bound to HDL, but it can be
found in lipoprotein-depleted plasma following ultracentrifugation) which
enhances the activation of macrophages by LPS in the absence of lipoproteins
and facilitates LPS binding to lipoproteins; LBP can also bind LTA (Tobias
et al. 1989) and allows HDL to efficiently inactivate LTA (Grunfeld et al. 1999).
The inhibition of LBP with neutralizing antibodies significantly decreases (53 %)
the ability of lipoprotein-depleted plasma to facilitate LTA inactivation, but also
suggests the presence of other plasma factors playing a role in HDL inactivation of
LTA (Grunfeld et al. 1999).
ApoA-I has been shown to bind directly LTA in vitro and to attenuate
LTA-induced NF-kB activation (Jiao and Wu 2008); apoA-I dose-dependently
inhibits L-929 cell death induced by LTA-activated macrophages, and
lipoprotein-depleted plasma strengthened this effect of apoA-I (Jiao and Wu
2008). In mice, apoA-I attenuates LTA-induced acute lung injury and significantly
inhibits LTA-induced pro-inflammatory cytokine production (Jiao and Wu 2008).
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These findings suggest that apoA-I can inhibit LTA activation by multiple
mechanisms, by direct binding to LTA, and by interfering with LTA-mediated
inflammatory response.
2.3 HDL and Mycobacteria
HDLs were reported to be protective also toward intracellular bacteria such as
mycobacteria (Cruz et al. 2008). Intracellular pathogens survive by evading the host
immune system and accessing host metabolic pathways to obtain nutrients for their
growth. Mycobacterium leprae, the causative agent of leprosy, is thought to be the
mycobacterium most dependent on host metabolic pathways, including host-
derived lipids. Although fatty acids and phospholipids accumulate in the lesions
of individuals with the lepromatous (also known as disseminated) form of human
leprosy (L-lep), the origin and significance of these lipids remains unclear. Host-
derived oxidized phospholipids were detected in macrophages within L-lep lesions,
and one specific oxidized phospholipid, 1-palmitoyl-2-(5,6-epoxyisoprostane E2)-
sn-glycero-3phosphorylcholine (PEIPC), accumulates in macrophages infected
with live mycobacteria (Cruz et al. 2008). Mycobacterial infection and host-derived
oxidized phospholipids both inhibited innate immune responses, and this inhibition
was reversed by the addition of normal HDL, a scavenger of oxidized
phospholipids, but not by HDL from patients with L-lep (Cruz et al. 2008). The
accumulation of host-derived oxidized phospholipids in L-lep lesions is strikingly
similar to observations in atherosclerosis, which suggests that the link between host
lipid metabolism and innate immunity could contribute to the pathogenesis of both
microbial infection and metabolic disease.
2.4 General Innate Host Defense Mechanisms Exerted by HDL
After Bacterial Infection
In addition to limiting LPS or LTA responses during infection, HDLs exert addi-
tional functions during the innate immune response. In normal plasma, about 5 % of
HDL particles contain apolipoprotein M (apoM) which binds sphingosine-1-phos-
phate (S1P), an important bioactive lipid mediator known to be associated with
HDL (Christoffersen et al. 2011). The inhibition of apoM production results in the
decrease of HDL-C levels and changes in HDL size, subclass profile, and functions
(Wolfrum et al. 2005); apoM is a negative acute-phase protein that decreases during
infection and inflammation (Feingold et al. 2008); in patients with severe sepsis and
systemic inflammatory response syndrome (SIRS), a leading cause of mortality in
non-coronary intensive care units, apoM plasma levels decrease dramatically
suggesting a reduction of the vasculoprotective effects of apoM and its ligand
S1P, with a strong correlation between apoM decrease and the severity of disease
(Kumaraswamy et al. 2012). It is still unclear whether apoM and S1P levels may
have prognostic value and whether changes in apoM levels contribute to the
pathogenesis of SIRS and septic shock.
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Another key player during the immune response regulated by HDL is the long
pentraxin 3 (PTX3). This protein belongs, together with the C-reactive protein
(CRP) and other acute-phase proteins, to the pentraxin superfamily: soluble, multi-
functional, pattern recognition proteins. Pentraxins share a common C-terminal
pentraxin domain, which in the case of PTX3 is coupled to an unrelated long
N-terminal domain (Bonacina et al. 2013). PTX3, which is the prototypic long
pentraxin, was identified in the early 1990s, as a molecule rapidly induced by IL-1
in endothelial cells (ECs) or by TNF-α in both ECs and fibroblasts (Breviario
et al. 1992; Lee et al. 1993). The protein presents a high degree of conservation
from mouse to human (82 % identical and 92 % conserved amino acids) and is
induced in a variety of somatic and innate immunity cells by primary inflammatory
stimuli (Garlanda et al. 2005). PTX3 is a key player of the humoral arm of the
innate immunity, and its physiological functions are associated with the recognition
and binding to different ligands, including microbial moieties, complement
components, and P-selectin. This protein plays also a key role in cardiovascular
diseases including atherosclerosis (Norata et al. 2009, 2010). Similarly to short
pentraxins, PTX3 recognizes the highly conserved pathogen-associated molecular
patterns (PAMPs) expressed by microorganisms (Iwasaki and Medzhitov 2010) and
binds a number of bacteria, fungi, and viruses. A specific binding has been observed
to conidia of Aspergillus fumigatus (Garlanda et al. 2002), Paracoccidioides
brasiliensis, and zymosan (Diniz et al. 2004), to selected Gram-positive and
Gram-negative bacteria (Bozza et al. 2006; Garlanda et al. 2002; Jeannin
et al. 2005), and finally to some viral strains, including human and murine cyto-
megalovirus and influenza virus type A (IVA) (Bozza et al. 2006; Reading
et al. 2008). Both short pentraxin and PTX3 bind apoptotic cells and facilitate
their clearance (Doni et al. 2012; Jaillon et al. 2009). Surface bound CRP activates
the classical pathway of complement through interaction with C1q, thus leading to
cell elimination (Nauta et al. 2003). Cell-bound PTX3 might favor the clearance of
apoptotic cells (Jaillon et al. 2009; Poon et al. 2010) by enhancing the deposition of
both C1q and C3 on cell surfaces (Nauta et al. 2003). On the contrary, when in the
fluid phase, PTX3 interacts with C1q and dampens the deposition on apoptotic cells
and the resulting phagocytosis by dendritic cells and phagocytes (Baruah
et al. 2006; Gershov et al. 2000; Rovere et al. 2000; van Rossum et al. 2004). In
addition to PTX3, C1q recognizes and binds to ficolin-2 and mannose-binding
lectin (MBL), thus modulating the classical and the lectin pathways of complement
activation (Bottazzi et al. 1997). The best described and characterized ligand of
PTX3 is the first component of the classical complement system C1q (Bottazzi
et al. 1997; Nauta et al. 2003); PTX3 interacts with the globular head of the protein
(Roumenina et al. 2006) thus resulting in the activation of the classical complement
cascade only when C1q is plastic immobilized, a situation that mimics C1q bound
to a microbial surface. Anti-inflammatory molecules were shown to modulate
PTX3 expression. Under inflammatory conditions, glucocorticoid hormones
(GCs) induce and enhance the protein expression in fibroblasts but not in myeloid
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cells (Doni et al. 2008). Also HDLs, which possess a series of vascular protective
activities, induce PTX3 expression in endothelial cells (Norata et al. 2008). The
latter mechanism requires the activation of the PI3K/Akt pathway through
G-coupled lysosphingolipid receptors and is mimicked by sphingosine-1-phosphate
and others S1P mimetics (Norata et al. 2008), physiologically present in HDL and
responsible for some of the activities linking HDL to the immunoinflammatory
response (Norata et al. 2005, 2012). In vivo, an increased expression of PTX3
mRNA was detected in the aorta of transgenic mice overexpressing human apoA-I,
compared to apoA-I knockout mice, and plasma levels of PTX3 are significantly
increased in C57BL/6 mice injected with HDL (Norata et al. 2008). These data
suggest that some of the beneficial effects in immunity of HDLmay result also from
the modulation of molecules that act as sensors of the immunoinflammatory
balance.
In summary, all the observations showing that the increase of HDL is associated
with an attenuation of LPS-induced inflammatory response (Levine et al. 1993; van
Leeuwen et al. 2003) strongly favor the hypothesis that raising plasma HDL may
represent a therapeutic approach in the treatment of sepsis and its complications.
The picture however is more complicated, and not only HDL quantity but also HDL
quality/composition is critical. For instance, the increase in sepsis-related mortality
of the ILLUMINATE trial observed in the torcetrapib (a cholesteryl ester transfer
protein inhibitor, increasing HDL-C levels) arm (Barter et al. 2007) was unlikely
due to a direct effect of torcetrapib on LBP or bactericidal/permeability increasing
protein function nor to inhibition of an interaction of CETP with LPS (Clark
et al. 2010). It is rather possible that changes in plasma lipoprotein composition
despite increased HDL levels, or the known off-target effects of torcetrapib, such as
aldosterone elevation, could have aggravated the effects of sepsis (Clark
et al. 2010). Apolipoprotein mimetic peptides represent an emerging area of HDL
therapy; the most effective apoA-I mimetic peptide is 4F, which has been shown to
improve HDL quality/function (Sherman et al. 2010; White et al. 2009). 4F mimics
also anti-inflammatory properties of HDL: in vitro, 4F inhibits the expression of
pro-inflammatory mediators in LPS-treated cells by directly binding to LPS, thus
resulting in the inhibition of LPS binding to LBP (Gupta et al. 2005). In
endotoxemic rats, the administration of 4F after LPS injection results in the
attenuation of acute lung injury and increased survival, probably due to the preser-
vation of circulating HDL-C and the downregulation of inflammatory pathways
(Kwon et al. 2012); 4F also prevents defects in vascular functions and is associated
with a decrease in plasma endotoxin activity in rats (Dai et al. 2010) and improved
cardiac performance in LPS-treated rats (Datta et al. 2011). These observations
indicate that, by scavenging LPS, 4F may prevent LPS-induced release of
pro-inflammatory cytokines and changes in HDL composition resulting in an
effective reduction of clinical complications associated with sepsis. Although
promising, future studies are warranted to translate these findings into the clinical
setting.
HDL in Infectious Diseases and Sepsis 493
3 HDL and Parasitic Infections
The connection between HDL and parasitic infections mainly relates on the ability
of specific apolipoproteins, which circulate as part of the HDL3 complex, to limit
Trypanosoma brucei or Leishmania infection. The most relevant apolipoprotein in
this context is apoL-1 which was discovered in 1997 (Duchateau et al. 1997) and
was shown to be a part of a primate-specific complex named trypanosome lytic
factor-1 (TLF-1) that also contains apoA-I and haptoglobin-related protein as the
main protein components. TLF-1 has lytic activity toward African Trypanosoma
brucei brucei and renders humans and most other primates resistant to infection
with this parasite causing endemic infections of African cattle. The Trypanosoma
species brucei rhodesiense and brucei gambiense, however, are resistant to TLF-1
and cause sleeping sickness in humans. Sleeping sickness is fatal when untreated
and thus is an important health problem in many African countries. The trypano-
some lytic activity has been associated with apoL-1 (Vanhamme et al. 2003); the
apoL-1-containing complex is taken up by T. b. brucei via a receptor that binds
hemoglobin and haptoglobin-related protein (Hb-Hpr). ApoL-1 traffics to the
trypanosomal lysosome, where the acidic pH causes a conformational change,
leading to activation of anion channel function in the apoL-1 N terminus. Lyso-
somal swelling kills the trypanosome (Perez-Morga et al. 2005). Thus, apoL-1
confers innate immunity against this parasite (Wheeler 2010). Over time, T. b.
brucei developed a virulence factor called SRA that can inactivate apoL-1 protein,
although the cellular location of this interaction is unknown. These SRA-expressing
trypanosomes evolved into T. b. rhodesiense, the etiologic agent that causes acute
African sleeping sickness (Wheeler 2010). This discovery has now been used to
engineer a potential fusion protein drug for treating sleeping sickness caused by
brucei rhodesiense in human (Baral et al. 2006). The active component in the novel
protein drug candidate is a recombinant apoL-1 where the C-terminal SRA-binding
region of wild-type apoL-1 has been deleted. This truncated apoL-1 alone probably
has low biological activity when injected into plasma due to competition with
endogenous apoL-1 (~6 mg/l) for uptake by trypanosomes. To circumvent this
problem and effectively target recombinant apoL-1 to trypanosomes, the
SRA-resistant apoL-1 without the C-terminal sequences was fused with a fragment
of a high-affinity camel antibody (designated nanobody) specifically recognizing
conserved epitopes of variant surface glycoprotein on trypanosomes (Baral
et al. 2006). In vitro, the recombinant apoL-1–nanobody specifically bound to
trypanosomes and was capable of lysing them in vivo. When mice infected with
Trypanosoma brucei brucei were treated with the apoL-1–nanobody fusion protein,
the parasites were promptly cleared from the circulation.
Another trypanosomatida, Leishmania, is also targeted by apoL-1 (Samanovic
et al. 2009). It is certainly possible that apoL-1 has broad innate immunity
properties, shaping the relative frequencies of the APOL1 alleles. Of note the
chronic kidney disease (CKD)-associated G1 and G2 variants (Parsa et al. 2013)
encode forms of apoL-1 that evade SRA and remain active against T. b.
rhodesiense. This, and/or other biological effects, may have conferred a selective
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advantage to G1 and G2 heterozygotes, causing a selective sweep. The contribution
of apoL-1 to CKD could also be related to the HDL functionality (Baragetti
et al. 2013) under specific immunopathological conditions such as those observed
during CKD. Hence, HDL could represent the bridge between apoL-1 and CKD and
should be taken into consideration when exploring the contribution of apoL-1 to the
disease. The delineation of how primates in late evolution have exploited HDL to
fight parasite infections highlights the need of investigations on other potential roles
of plasma HDL beyond those in lipid metabolism and reverse cholesterol transport.
4 HDL and Viral Infections
Changes in plasma HDL-C levels have been reported to occur also during infection
with viruses including human immunodeficiency virus (HIV) and hepatitis C virus
(HCV). Furthermore, proteins related to HDL life cycle, such as SR-BI, were shown
to play a key role in HCV infection. So far HDLs were proposed to increase virus
infection and inhibit virus neutralizing antibodies; however, recent findings are
challenging previous data and proposing a more complicated picture based on the
ability of virus to take advantage of HDL–lipid transfer activity in host cells. Most
of the available evidences linking HDL to viral infection are available for HIV
and HCV.
4.1 HIV Infection
HIV infects and depletes CD4 lymphocytes, resulting in immunodeficiency and a
slowly progressive disease. HIV is associated with dyslipidemia, namely,
hypocholesterolemia, low levels of LDL, and hypertriglyceridemia (Riddler
et al. 2003; Shor-Posner et al. 1993). HIV infection is commonly associated also
with hypoalphalipoproteinemia; however, it is unclear whether virion replication
plays a causative role in these changes. Some data suggest that hypoalphalipopro-
teinemia in patients with HIV is likely to be secondary to HIV infection itself (Rose
et al. 2006). Systemic inflammation has been shown to lower the antioxidant and
anti-inflammatory activity by transforming HDL to a pro-oxidant,
pro-inflammatory acute-phase HDL (Kelesidis et al. 2013; Norata et al. 2006). A
small pilot study of HIV-1-infected individuals with suppressed viremia on combi-
nation antiretroviral therapy showed that oxidative stress and inflammation in
HIV-1 are associated with a marked reduction of HDL antioxidant–anti-inflamma-
tory activities. In vitro, these abnormalities were significantly improved by treat-
ment with the apoA-1 mimetic peptide 4F (Kelesidis et al. 2011). HIV infection is
associated with modified HDL metabolism redirecting cholesterol to the apoB-
containing lipoproteins and likely reducing the functionality of reverse cholesterol
transport (Rose et al. 2008). Of note, the HIV-1 Nef protein can impair ABCA1
cholesterol efflux from macrophages, thus supporting atherosclerosis. This viral
inhibition of efflux was correlated with a direct interaction between ABCA1 and
Nef (Fitzgerald et al. 2010; Mujawar et al. 2006). More recently it was shown that
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Nef downregulates ABCA1 function by a posttranslational mechanism that
stimulates ABCA1 degradation but does not require the ability of Nef to bind
ABCA1 (Mujawar et al. 2010).
Not all data are however concordant on this, and although HDL cholesterol and
preβ1-HDL were significantly lower in all HIV-infected groups ( p< 0.05), mean
levels of apoA-I and the ability of plasma to promote cholesterol efflux were similar
in treatment-naı̈ve HIV-infected patients or in HIV-infected patients on long
therapy break. Of note a positive correlation between apoA-I and levels of CD4+
cells was also observed (r2¼ 0.3, p< 0.001) (Rose et al. 2008). Furthermore apoA-
I, the major protein component of high-density lipoprotein, and its amphipathic
peptide analogue were found to inhibit cell fusion, both in HIV-1-infected T cells
and in recombinant vaccinia-virus-infected CD4+ HeLa cells expressing HIV
envelope protein on their surfaces (Srinivas et al. 1990). The amphipathic peptides
inhibited the infectivity of HIV-1. The inhibitory effects were manifest when the
virus, but not cells, was pretreated with the peptides. Also, a reduction in
HIV-induced cell killing was observed when virus-infected cell cultures were
maintained in the presence of amphipathic peptides. These results have potential
implications for HIV biology and therapy (Srinivas et al. 1990).
An aspect debated is how much the HIV infection and/or treatment contribute to
the changes in HDL-C levels. With highly active antiretroviral therapy (HAART)
intervention, mortality due to HIV was greatly reduced (Madamanchi et al. 2002).
However, there have been several reports of increases in cardiovascular
complications in patients with HIV. It is now established that some HAART
regimens cause severe dyslipidemia, characterized by high levels of TC and
LDL-C, hypertriglyceridemia, and hypoalphalipoproteinemia (Riddler
et al. 2003). This clearly pro-atherogenic lipoprotein profile is associated with a
rise in the incidence of CAD (Depairon et al. 2001). The rate of inflammation
predicts changes in HDL-C and apoA-I following the initiation of antiretroviral
therapy and indeed in a subgroup of participants not taking ART at study entry who
were randomized in the Strategies for Management of Antiretroviral Therapy
(SMART) to immediately initiate ART (“VS group”) or to defer it (“DC group”);
HDL-C and ApoA-I levels increased among VS participants (n¼ 128) after starting
ART compared to DC. The effect of starting ART on changes in HDL-C and apoA-I
was greater for those with higher versus lower baseline levels of IL-6 or hsCRP
indicating that the activation of inflammatory pathways could contribute to
HIV-associated changes in HDL (Baker et al. 2011). Also non-nucleoside reverse
transcriptase inhibitors (NNRTI), such as nevirapine (NVP), were shown to
increase apoA-I production, which contributes to the HDL-C increase after intro-
duction of NVP-containing regimens. In view of the potent anti-atherogenic effects
of apoA-I, the observed increase was suggested to contribute to the favorable
cardiovascular profile of NVP (Franssen et al. 2009). Also efavirenz, another
NNRTI antiretroviral treatment, was associated with HDL particles with a better
antioxidant function, i.e., with a higher PON-1 activity. The PON-1 activity of
black patients is higher than that found in whites regardless of treatment suggesting
that ethnicity should be taken into consideration when studying drug effects on
PON-1 activity (Pereira et al. 2009).
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Overall the available evidences suggest that HIV infection could be associated
with modified HDL metabolism redirecting cholesterol to the apoB-containing
lipoproteins and likely reducing the functionality of reverse cholesterol transport
and promote atherosclerosis. Additional pro-atherogenic mechanisms could be
associated with a decrease in the anti-inflammatory properties of HDL.
4.2 HCV Infection
HCV is a major cause of liver cirrhosis and hepatocellular carcinoma. Viral entry is
required for initiation, spread, and maintenance of infection and thus is a promising
target for antiviral therapy. HCV exists in heterogenous forms in human serum and
may be associated with VLDL, LDL, and HDL which can shield the virus from
neutralizing antibodies targeting the HCV envelope glycoproteins (Agnello
et al. 1999; Hijikata et al. 1993; Nielsen et al. 2006; Thomssen et al. 1992). HCV
binding and entry into hepatocytes is a complex process involving the viral enve-
lope glycoproteins E1 and E2, as well as several host factors, including highly
sulfated heparan sulfate, CD81, the low-density lipoprotein receptor, claudin-1,
occludin, and receptor tyrosine kinases (Lupberger et al. 2011; Zeisel et al. 2011).
Also SR-BI which binds a variety of lipoproteins and mediates the selective
uptake of HDL cholesterol ester (CE) as well as bidirectional free cholesterol
transport at the cell membrane emerged as a critical receptor affecting HCV
entry. SR-BI directly binds HCV E2 (Bartosch et al. 2003; Evans et al. 2007;
Scarselli et al. 2002), but virus-associated lipoproteins, including apoB containing,
also contribute to host cell binding and uptake (Dao Thi et al. 2012; Maillard
et al. 2006). Moreover, physiological SR-BI ligands modulate HCV infection
(Bartosch et al. 2005; Voisset et al. 2005; von Hahn et al. 2006), suggesting the
existence of a complex interplay between lipoproteins (not only HDL), SR-BI and
HCV envelope glycoproteins for HCV entry. Earlier studies using small molecule
inhibitors indicated a role for SR-BI lipid transfer function in HCV infection and
HDL-mediated entry enhancement (Bartosch et al. 2003; Dreux et al. 2009; Syder
et al. 2011; Voisset et al. 2005). A human anti-SR-BI mAb has been reported to
inhibit HDL binding, to interfere with cholesterol efflux, and to decrease cell
culture-derived HCV (HCVcc) entry during attachment steps without having a
relevant impact on SR-BI-mediated post-binding steps (Catanese et al. 2007,
2010). However, SR-BI mediates the uptake of HDL-C in a two-step process
including HDL binding and subsequent transfer of CE into the cell without inter-
nalization of HDL; a novel emerging hypothesis suggests that the interference with
SR-BI lipid transfer function may be relevant for both initiation of HCV infection
and viral dissemination independently of HDL function (Zahid et al. 2013).
Indeed SR-BI has also been demonstrated to mediate post-binding events during
HCV entry (Haberstroh et al. 2008; Syder et al. 2011; Zeisel et al. 2007). HCV–SR-
BI interaction during post-binding steps occurs at similar time points as the HCV
utilization of CD81 and claudin-1 suggesting that HCV entry may be mediated
through the formation of co-receptor complexes (Harris et al. 2008; Krieger
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et al. 2010; Zeisel et al. 2007). Also the SR-BI partner PDZK1 was shown to
facilitate hepatitis C virus entry (Eyre et al. 2010).
These data suggest that SR-BI plays a multifunctional role during HCV entry at
both binding and post-binding steps (Catanese et al. 2010). Furthermore the HCV
post-binding function of human SR-BI can be dissociated from its E2-binding
function. Murine SR-BI does not bind E2 although it is capable of promoting
HCV entry (Catanese et al. 2010; Ploss et al. 2009), and SR-BI, although able to
directly bind E2 and virus-associated lipoproteins, could play additional functions
during HCV infection (Bartosch et al. 2003; Dreux et al. 2009; Zeisel et al. 2007).
Although the addition of HDL enhances the efficiency of HCVcc infection, anti-
SR-BI antibodies and SR-BI-specific siRNA efficiently inhibited HCV infection
independently of lipoproteins (Zeisel et al. 2007). In this context, the post-binding
activity of SR-BI is of key relevance for cell-free HCV infection as well as cell-to-
cell transmission and by using antibodies which do not inhibit HDL binding to
SR-BI; it was observed that post-binding function of SR-BI appears to be unrelated
to HDL interaction but to be directly linked to its lipid transfer function (Zahid
et al. 2013). So far small molecules and mAbs targeting SR-BI and interfering with
HCV infection have been described (Bartosch et al. 2003; Catanese et al. 2007;
Syder et al. 2011). A codon-optimized version of this mAb has been demonstrated
to prevent HCV spread in vivo (Meuleman et al. 2012), and ITX5061, a SR-BI
inhibitor, is in clinical development as HCV entry inhibitor (phase I, http://
clinicaltrials.gov/ct2/show/NCT01560468?term¼ITX+5061&rank¼3).
Despite this promising approach, some open questions remain. First, it has been
shown in vitro that apoA-I is required for HCV production (Mancone et al. 2011)
and that serum amyloid A has antiviral activities against HCV which are reduced
when HDL are co-incubated with SAA (Lavie et al. 2006). Given the changes
between apoA-I and SAA occurring in HDL during the acute phase (Norata
et al. 2012), it is still unknown whether this mechanism could be the consequence
of viral infection or may represent part of the immune response which HCV learned
to escape. Second, as the inhibition of SR-BI represents one of the most promising
targets for HCV infection, the potential side effects on the impairment of HDL
function should be carefully evaluated. The new data showing that HCV infection
does not require receptor-E2–HDL interactions, coupled with the observation that
HCV entry and dissemination can be inhibited without blocking HDL–SR-BI
binding (Zahid et al. 2013), open a novel perspective for the design of entry
inhibitors interfering specifically with the proviral function of SR-BI.
Conclusion
HDLs are emerging as a relevant player in both innate and adaptive immunity
(Norata et al. 2011, 2012; Sala et al. 2012). HDL activities rely not only on the
ability to modulate cholesterol availability in immune cells but also on the role
of specific molecules shuttled by HDL. During infections and acute conditions,
HDL-C levels decrease very rapidly, and HDL particles undergo changes that
dramatically alter their composition and function. Whether this is the conse-
quence of a humoral innate response aimed at scavenging lipid bacterial
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products such as LPS from the circulation and driving them into the liver for
catabolism and elimination is still debated. Experimental evidence in genetically
manipulated animal models suggests, however, that alterations in HDL struc-
ture/composition are associated with poor prognosis following endotoxemia or
sepsis, further supporting a protective role for HDL. The same is true for some
parasitic infections, where the key player appears to be a specific and minor
apolipoprotein of HDL–apoL-1. For viral infections, the landscape is more
complicated; SR-BI was clearly indicated as a player favoring virus entry;
however, it is not clear whether viruses, such as HCV, evolved to take advantage
of the HDL–SR-BI interaction to entry liver cells as in vitro studies suggest or
whether in vivo HDL can compete for the interaction between HCV and SR-BI.
Further studies are warranted in this context. Despite this, proteins related to
HDL physiology represent already a target in clinical development for
infections, and SR-BI antagonism represents a novel and forefront approach to
interfere with hepatitis C virus entry.
All the observations showing that the increase of HDL-C is associated with an
attenuation of LPS-induced inflammatory responses strongly favor the hypothe-
sis that raising plasma HDL may represent a therapeutic approach in the treat-
ment of sepsis and its complications (Table 1). HDL-related therapies are of
great interest also in the context of parasites and virus infections (Table 1). As of
beginning of 2014, the research in the field of HDL and immunity is in its
infancy compared to the body of data available for HDL and atherosclerosis.
From the coming years, we have to expect new and compelling observations
further linking HDL to innate immunity.
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Abstract
Besides their well-documented function of reverse transport of cholesterol, high-
density lipoproteins (HDLs) display pleiotropic effects due to their antioxidant,
antithrombotic, anti-inflammatory and antiapoptotic properties that may play a
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major protective role in acute stroke, in particular by limiting the deleterious
effects of ischaemia on the blood–brain barrier (BBB) and on the parenchymal
cerebral compartment. HDLs may also modulate leukocyte and platelet activa-
tion, which may also represent an important target that would justify the use of
HDL-based therapy in acute stroke. In this review, we will present an update of
all the recent findings in HDL biology that could support a potential clinical use
of HDL therapy in ischaemic stroke.
Keywords
HDL • Ischaemic stroke • Endothelium • Animal models
1 Introduction
Stroke is usually divided according to the type of cerebrovascular lesion into
ischaemic and haemorrhagic stroke. Ischaemia is the leading cause of stroke, due
to obstruction within a blood vessel supplying blood to the brain. It accounts for
about 80–90 % of all stroke cases. Haemorrhagic stroke occurs when a weakened
vessel ruptures due to an aneurysm or arteriovenous malformations. Uncontrolled
hypertension is often associated with haemorrhagic stroke.
Numerous epidemiological studies demonstrate that HDLs are a strong indepen-
dent negative predictor of vascular events (Miller and Miller 1975; Nofer
et al. 2002), supporting HDL-raising therapies. The SPARCL study (Stroke Pre-
vention by Aggressive Reduction in Cholesterol Levels) was designed to assess the
effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or
transient ischaemic attack, but without known coronary heart disease (Amarenco
et al. 2003). In this study, a negative correlation between HDL-C levels and stroke
recurrence was found among these 4,731 patients, but only when ischaemic stroke
was considered. Only baseline HDL-C and LDL/HDL ratio were associated with a
good outcome in the ischaemic stroke subgroup (Amarenco et al. 2009). Each
13.7 mg/dL (0.35 mmol/L) increment in HDL-C was associated with a 13 %
reduction in the risk of ischaemic stroke (Amarenco et al. 2008). Interestingly,
decreased LDL levels and high HDL levels did not have any effect on haemorrhagic
stroke. In a different study, low HDL-C levels have been also associated with a
worse outcome after ischaemic stroke. Of 489 patients treated with rtPA for IS, the
low concentration of HDL-C was also associated with a poor prognosis at 3 months
(Makihara et al. 2012). More recently, another study in patients with atherosclerotic
ischaemic stroke reported that low levels of HDL-C (35 mg/dL) at admission
were associated with higher stroke severity and poor clinical outcome during
follow-up (Yeh et al. 2013).
Data from studies investigating the effect of HDL subfractions on vascular
prognosis are conflicting, mainly due to the variety of techniques used to assess
HDL particle size (Camont et al. 2011; Krauss 2010). Only the inverse relationship
between large HDLs (alpha1) and vascular risk was found in several studies
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(Asztalos et al. 2004; Schaefer and Asztalos 2007; Asztalos and Schaefer 2003).
Two large cohorts comprising a total of more than 160,000 people used the
Mendelian randomisation single nucleotide polymorphism associated with
HDL-C to assess a causative role of HDLs in preventing myocardial infarction
(Voight et al. 2012). The authors found no significant relationship and therefore
concluded that HDL-C was not causal in vascular disease but merely a risk marker.
Another interpretation could be that HDL-C, i.e. cholesterol associated with HDL,
is not an appropriate prognostic marker or therapeutic target. Given the pleiotropic
functions of HDLs (see below), in particular their protective action on the endothe-
lium (Tran-Dinh et al. 2013), their functionality should be evaluated in addition to
the concentration of HDL cholesterol.
The long-term beneficial effect of HDLs has been largely attributed to their role
in reverse cholesterol transport and atherosclerotic burden regression. However,
short-term HDL elevation has also been shown to be beneficial: in patients with
acute coronary syndromes, each 1 mg/dL increment of HDL-C during the course of
a 16-week treatment with atorvastatin resulted in a 1.4 % risk reduction for
recurrent adverse events (Olsson et al. 2005).
2 Pleiotropic Effects of HDLs
HDLs represent a heterogeneous class of lipoproteins as far as size, shape and
composition are concerned. Whereas their principal function is to transport choles-
terol from peripheral tissues to the liver, additional functions have been attributed to
HDLs, which may depend on their composition in lipids, proteins, vitamins or
antioxidant molecules. In this review, we will focus on pleiotropic effects of HDLs
other than reverse transport of cholesterol that can impact on stroke at different
levels and particularly on ischaemic stroke.
3 HDL Potential Effects on the Blood–Brain Barrier
The blood–brain barrier (BBB) is composed of endothelial cells interconnected by
means of tight junctions lining the microvasculature of the central nervous system
(CNS), pericytes, astrocytes, end feet and neuron processes. The first barrier
separating the blood and cerebral compartments is represented by endothelial
cells, which play a pivotal role in regulating the traffic of molecules and blood
cells. Many protective properties of HDLs have been documented in endothelial
cells (Tran-Dinh et al. 2013) and are developed below, including vasodilatation,
antioxidant, anti-inflammatory and antiapoptotic effects. However, most of the
in vitro results have been obtained using HUVECs (human umbilical vein endothe-
lial cells) or BAEC (bovine aortic endothelial cells), which do not present the same
characteristics as endothelial cells composing the BBB, in terms of permeability
and establishment of tight junctions. In this review, we will summarise the different
effects attributed to HDLs that could support their use as therapeutic tools in acute
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stroke or in secondary prevention. Effects of reconstituted HDLs, HDL mimetics
and HDLs isolated from plasma will be presented.
3.1 Reconstituted HDLs and HDL Mimetics
Apo A-1 is the major protein of HDLs, able to recruit lipids and organise HDL
particles. Reconstituted HDLs consist of an in vitro combination of apo A-I and
phospholipids, producing disc-shaped particles resembling nascent HDL. Apo A-I
may be either purified from human plasma or produced by recombinant technology.
Carriers of the apo A-I Milano mutation, characterised by the replacement of an
arginine by a cysteine at position 173, have reduced plasma levels of apo A-I and
HDL-C without increased cardiovascular disease (Sirtori et al. 2001). This obser-
vation has led to a strong interest in using apo A-I Milano peptides or proteins as
potential therapeutic agent to treat cardiovascular disease (Nissen et al. 2003).
Intravenous injection of apo A-I Milano in humans was shown to reduce the
atheromatous plaque volume in both murine models and in humans.
However, controversial data have been published as to whether apo A-I Milano
is more effective than apo A-I in reverse transporting cholesterol. In mice, gene
transfer of wild-type human apo A-I and human apo A-I Milano inhibited the
progression of native atherosclerosis and allograft vasculopathy to a similar extent.
An equivalent increase in endothelial progenitor cell (EPC) number/function and
endothelial regeneration in allografts was also observed (Feng et al. 2009). The use
of either native or mutated apo A-I may however be beneficial for endothelial
protection and repair in pathological situations such as ischaemic stroke.
The lipid-binding activity of apo A-1 was attempted to be mimicked by synthetic
peptides containing the class A amphipathic helix modified by phenylalanine
residues on the hydrophobic face. Improvement of the apo A-1 mimetic peptide
stability was reached by using D-amino acids instead of L-amino acids which are
more readily degraded in plasma. For example, D4F was shown to reduce athero-
sclerotic lesions in apo E-null mice (Navab et al. 2005) and to improve the anti-
inflammatory properties of HDL in humans (Bloedon et al. 2008). Very few data are
currently available on the potential beneficial effects, in stroke, of reconstituted
HDLs containing wild-type or mutated apo A-I.
4 Part 1: Pleiotropic Effects of HDLs—In Vitro
and In Vivo Data
4.1 HDLs and Nitric Oxide (NO)
Hypertension represents a major risk factor for stroke, and polymorphisms
governing endothelial NO synthase (NOS3) gene expression/function have been
reported to increase the risk of stroke (Berger et al. 2007; Howard et al. 2005). A
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recent meta-analysis indicates that NOS3 gene 4b/a, T-786C and G894T polymor-
phism could be associated with IS (Wang et al. 2013). NO may participate in
neuroprotection in cerebral ischaemia by its vasodilatory effects but also by
increasing erythrocyte membrane fluidity which could limit the microviscosity
(Tsuda et al. 2000). In experimental stroke, administration of NO appears to reduce
the infarct volume in both permanent and transient models (Willmot et al. 2005).
The results of ongoing clinical studies using NO donors are needed to validate
experimental data (Sare et al. 2009). Several lines of evidence suggest that HDLs
increase NO bioavailability, in particular via the induction of NOS3 [increased
expression and activity (Mineo et al. 2006)]. NO exerts many beneficial effects on
the microvasculature during reperfusion including vasodilatation, reflow and
decreased permeability (Schulz et al. 2004). The results of the trial “Efficacy of
Nitric Oxide in Stroke” are still not available. This study should give more insight
into the effects of the glyceryl trinitrate patch (transdermal diffusion of NO) on the
outcome post-stroke (ENOS Trial Investigators, 2006).
4.2 HDLs and Sphingosine 1-Phosphate
Sphingosine 1-Phosphate (S1P) is an important lipid component identified in HDLs
(Kimura et al. 2001) that may account for NO-mediated vasodilatory effects of
HDLs (Nofer et al. 2004). S1P is secreted by activated platelets (Yatomi et al. 1995)
but mainly transported in plasma by HDL particles (54 %) (Argraves et al. 2008).
HDLs, and in particular S1P, were demonstrated to directly protect the heart
against ischaemia/reperfusion in a mouse model (Theilmeier et al. 2006). The
authors report that this protection could be attributed to inhibition of neutrophil
recruitment and cardiomyocyte apoptosis in the infarcted area by a mechanism
involving NO and S1P signalling.
S1P has been shown to promote endothelial barrier function in cultured pulmo-
nary endothelial cells (Garcia et al. 2001) by enhancing tight junction formation
[in HUVECs (Lee et al. 2006)] and cortical actin assembly (Garcia et al. 2001),
resulting in a decreased permeability. HDL-associated S1P was also reported to
promote endothelial motility, a process of potential importance in case of vascular
injury, via Gi-coupled S1P receptors and the Akt signalling pathway (in HUVECs
(Argraves et al. 2008)).
In a model of transient middle cerebral artery occlusion in rats, an agonist or the
S1P receptor 1 was shown to be neuroprotective, after intraperitoneal injection at
the time of reperfusion (Hasegawa et al. 2010). Most studies using this agonist
(fingolimod or FTY720) report reduced infarct volumes and improved functional
outcomes, as summarised in a recent meta-analysis (Liu et al. 2013). This protective
effect could be due to a reduced cerebral lymphocyte infiltration (Rolland
et al. 2013). In a thromboembolic model, FTY720 was reported to reduce rtPA-
associated haemorrhagic transformations (Campos et al. 2013). Since HDL
particles are the major transporter of S1P, it could be expected that at least part of
their beneficial effect on the BBB could be attributed to this sphingolipid.
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4.3 Antioxidative Stress
In stroke, a plethora of studies have shown that oxidative stress is associated with
ischaemia and reperfusion and still more so after rtPA treatment. Many experimen-
tal studies report that antioxidant treatment displays neuroprotective effects
(Margaill et al. 2005). However, hitherto, no concluding clinical study could
provide evidence of a potential benefit of antioxidant therapy in stroke (Amaro
and Chamorro 2011).
Antiatherogenic functions of HDLs have been related, at least in part, to their
antioxidant properties. HDLs contain lipid-soluble vitamins, antioxidants and
enzymes such as paraoxonase 1 (PON1), platelet-activating factor acetylhydrolase
(PAF-AH) and glutathione phospholipid peroxidase (Florentin et al. 2008). Apo A-I
and apo A-II also display antioxidant properties. This antioxidant arsenal confers to
HDLs the capacity to limit LDL oxidation and to scavenge lipid hydroperoxides
(Navab et al. 2000; Negre-Salvayre et al. 2006). In a rat model of renal ischaemia/
reperfusion, rHDLs were shown to reduce the severity of acute ischaemic renal
failure associated with decreased malondialdehyde, suggesting attenuation of lipid
peroxidation subsequent to oxidative stress (Thiemermann et al. 2003).
4.4 Anti-inflammatory and Antiprotease Properties
Acute stroke is characterised by an activated endothelium favouring the recruitment
of leukocytes. In particular, neutrophil proteases such as elastase and matrix
metalloprotease-9 may induce BBB breakdown and produce deleterious effects
on the parenchymal compartment (Stowe et al. 2009). Proinflammatory cytokines
such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1) and IL-6 are
increased in plasma of patients with acute stroke (Tuttolomondo et al. 2008).
HDLs may exert anti-inflammatory effects on the endothelium but also on
leukocytes. In endothelial cells, HDLs (both native and rHDLs) inhibited TNFα
and IL-1 induction of leukocyte adhesion molecules VCAM-1, ICAM-1 and
E-selectin but had no effect on the expression of platelet endothelial cell adhesion
molecule (PECAM) (Cockerill et al. 1995). More recently, McGrath and colleagues
reported that the modulatory effects of rHDL on endothelial cells stimulated
TNF-alpha and were mediated by DHCR24, an antioxidant enzyme involved in
cholesterol biosynthesis (McGrath et al. 2009). Reconstituted HDLs were also
reported to limit PMN adhesion to endothelial cells stimulated by TNFα and LPS
(Moudry et al. 1997). These effects were later confirmed in vitro using both native
and rHDL on HUVECs but also in vivo, in a rat model of haemorrhagic shock
(Cockerill et al. 2001). In monocytes, HDL reduced activation of CD11b induced
by PMA leading to decreased adhesion to an endothelial cell monolayer, monocytic
spreading under shear flow, and transmigration. This process was mimicked by apo
A-1 and reported to be ABCA1-dependent (Murphy et al. 2008). More recently, the
same group reported that plasma HDLs were potent inhibitors of neutrophil activa-
tion both in vitro and in vivo, using mice models of inflammation (Murphy
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et al. 2011). In patients with peripheral vascular disease treated by rHDL, they
showed a decreased expression of CD11b by neutrophils 5–7 days post-injection
versus saline-injected patients. HDLs can also neutralise circulating inflammatory
molecules such as C-reactive protein (Wadham et al. 2004) and LPS (Wurfel
et al. 1994).
In addition, proteomic studies have shown that HDLs may transport different
antiproteases (Karlsson et al. 2005; Vaisar et al. 2007) and in particular alpha-1
antitrypsin (AAT), the natural inhibitor of elastase (Ortiz-Munoz et al. 2009). HDLs
displayed antielastase activity and protected vascular cells against elastase-induced
apoptosis. Using an in vitro model of BBB (Weksler et al. 2005), we have recently
reported that HDLs could limit the deleterious, elastase-mediated role of activated
neutrophils under oxygen-glucose deprivation conditions leading to BBB disrup-
tion (Bao Dang et al. 2013). In stroke, inhibition of neutrophil elastase may be a
therapeutic target, as shown by using specific inhibitors (Ikegame et al. 2010).
4.5 Endothelial Cell Integrity, EPCs and Antiapoptotic Action
Apoptosis is an important mechanism involved in BBB breakdown and associated
cerebral damage. In vivo imaging of apoptotic cells using annexin V was reported
to be correlated with BBB permeability in patients with acute stroke (Lorberboym
et al. 2006). Prevention of apoptosis of all cells composing the neurovascular unit is
therefore of major importance to reduce deleterious effects of ischaemia. Plasma
HDL-C and apo A-I were reported to prevent apoptosis of endothelial cells induced
by mildly oxidised LDL independently of paraoxonase activity (Suc et al. 1997). In
this in vitro model (bovine and human endothelial cell lines), HDL binding was
specific (receptor-mediated) and HDLs blocked the intracellular calcium increase
preceding apoptosis (Escargueil-Blanc et al. 1997). It was suggested that the Apo A-I
moiety mediates this cytoprotective effect rather than SP1 (de Souza et al. 2010).
Hypoxia has been reported to induce an autophagic process in endothelial cells
(Zhang et al. 2011). Autophagy can be regarded as an adaptive response of the cell
to deleterious environmental conditions that could delay apoptosis but could also
represent an early step of the apoptotic process. HDLs were shown to inhibit
endoplasmic reticulum stress and autophagic response induced by oxidised LDLs
in endothelial cells (Muller et al. 2011), suggesting that they impact on very early
events of the apoptotic cascade. In the brain, autophagy was significantly increased
in the cortex immediately following experimental subarachnoid haemorrhage
(SAH) (Lee et al. 2009). During SAH, the BBB is disrupted subsequent to endothe-
lial cell death by apoptosis. In this model, inhibition of apoptosis was shown to
significantly reduce the formation of cerebral oedema and associated mortality
(Yan et al. 2011). HDLs could thus modulate apoptosis of BBB endothelial cells
by preventing autophagy.
Endothelial cell progenitor (EPC) therapy has been envisaged as a potential
therapy in stroke [for review, see (Rouhl et al. 2008)]. EPCs can repair damaged
vessels and form new ones that could promote recovery after ischaemic injury. In a
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mouse model of transient middle cerebral artery occlusion (tMCAO), systemic
delivery of EPCs limited brain damage associated with ischaemic injury
(i.e. improved neurovascular repair and long-term neurobehavioral outcomes)
(Fan et al. 2010). In rats, EPCs injected 24 h after tMCAO were shown to reach
the injured area and improved functional recovery, potentially attributable to
antiapoptotic factors secreted by EPCs (Moubarik et al. 2011). In humans, erythro-
poietin therapy significantly increased the number of circulating EPCs and
improved a 90-day major adverse neurological effect (Yip et al. 2011). Different
studies report that reconstituted HDLs may increase circulating EPC number (Tso
et al. 2006) and their differentiation from mononuclear cells as well as their
angiogenic capacity (Sumi et al. 2007). This was shown in mouse models of
endothelial injury in response to LPS and hind limb ischaemia but also in humans
after injection of rHDLs in type 2 diabetic patients (van Oostrom et al. 2007). This
increase in circulating EPCs was significant at day 7 post-injection. In hypercho-
lesterolemic subjects, HDL concentration was linked to EPC number and function
(Rossi et al. 2010). Low EPC number was also reported to be an independent risk
factor for endothelial dysfunction in these patients. Petoumenos et al. reported a
correlation between circulating EPCs and HDL concentrations in patients with
coronary artery disease (Petoumenos et al. 2009). In addition, they have shown
that recombinant HDLs improved the function of circulating EPCs in a model of
endothelial denudation, which could be one explanation for the vasculoprotective
actions of HDLs.
4.6 Antithrombotic Actions
In stroke, haemostasis disorders are associated with dysfunction of vascular endo-
thelium, or with abnormalities of or interference with anticoagulant proteins
(i.e. protein C, protein S and antithrombin III) (Coull and Clark 1993). However,
all factors favouring clot formation may increase the risk of ischaemic stroke,
involving all cellular components (endothelium, erythrocytes, platelets and
leukocytes).
HDLs may modulate haemostasis by impacting on platelet, red blood cell (RBC)
and endothelial functions (Mineo et al. 2006). For example, thrombin-induced
endothelial tissue factor expression in vitro was shown to be downregulated by
rHDLs (Viswambharan et al. 2004). Since tissue factor induction on endothelial
cells is regulated by NO production, HDLs may inhibit its production in response to
endotoxins or cytokines, by increasing the synthesis of NO (Yang and Loscalzo
2000).
Apo A-I, its amphipathic peptide analogues and HDLs were also shown to
protect erythrocytes against the generation of procoagulant activity (Epand
et al. 1994). HDL2 subfraction was reported to be inversely correlated with eryth-
rocyte aggregation in hypercholesterolemic patients (Razavian et al. 1994). A
multiple regression analysis demonstrated that this association was independent
of fibrinogen, the major determinant of erythrocyte aggregation. The mechanisms
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by which HDL2 may prevent RBC aggregability have not been elucidated, but this
effect is relevant in small-sized arteries where increased blood viscosity may trigger
clot formation. Apo A-I, its amphipathic peptide analogues and HDLs were also
shown to protect erythrocytes against the generation of procoagulant activity
(Epand et al. 1994). HDLs may inhibit phospholipid flip-flop and the associated
procoagulant activity. In healthy volunteers receiving low doses of LPS, injection
of rHDLs reduced collagen-induced platelet aggregation and modified the
procoagulant state associated with endotoxemia (Pajkrt et al. 1997). More recently,
reconstituted HDL infusion in patients with type 2 diabetes induced a 50–75 %
attenuation of platelet aggregation in response to ADP and collagen (Calkin
et al. 2009). In vitro, this effect was shown to be dose-dependent and remained
after removal of rHDLs. Ex vivo, under blood flow conditions, rHDL limited
thrombus formation on a matrix of collagen. This effect was attributed to the
phospholipid moiety of rHDLs, since it was not reproduced by apo A-I, whereas
phosphatidylcholine reached the same level of reduction of aggregation as intact
rHDLs. However, in this study, plasma HDLs did not display similar in vitro effects
on platelet aggregation. The authors suggest that this may be due to limited efflux of
cholesterol from platelet membranes induced by native HDLs.
5 HDLs in the Cerebral Compartment
5.1 Lipoproteins in the Brain
Various studies have described the capacity of the brain to synthesise lipoproteins
that are different from plasma lipoproteins (for review, see Wang and Eckel 2014).
Lipoproteins found in the cerebrospinal fluid (CSF) mainly originate from
astrocytes and are characterised by a small size (resembling the size and density
of HDLs) and contain mainly apo E (Ladu et al. 2000; Koch et al. 2001). Apo E, J,
D and A-I are the main apolipoproteins synthesised in the brain, in an age-dependent
manner for apo J and E (Elliott et al. 2010). Apo E and more particularly apo J are
thought to be involved in the clearance of amyloid β-peptide by astrocytes and
microglial cells (Mulder et al. 2014; Calero et al. 2000). Most of lipoproteins
isolated from the CSF are associated with amyloid β-peptide and may participate
in its polymerisation, transport and clearance (Ladu et al. 2000). The BBB requires
a local homeostasis of cholesterol. Whereas astrocytes are thought to be the major
lipoprotein factory, neurons may also participate in the regulation of their synthesis
and redistribution in the brain (Pfrieger and Ungerer 2011). After cortical spreading
depression (a stimulus that provides long-lasting ischaemic tolerance), apo J
expression is increased, suggesting that this apolipoprotein may participate in
neuroprotection subsequently to an ischaemic episode (Wiggins et al. 2003). In a
model of middle cerebral artery occlusion, apo J-deficient mice displayed a worse
structural restoration in the vicinity of the infarct scar as compared to WT mice
(Imhof et al. 2006).
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5.2 Plasma HDLs in the Brain
Under physiological conditions, it is not clear whether HDLs reach the cerebral
parenchymal compartment. Based on in vitro results using bovine cerebral endo-
thelial cells, HDLs have been suggested to cross the BBB via paracellular transport
(de Vries et al. 1995). More recent data describe an active process of transcytosis
involving receptors for HDLs at the surface of endothelial cells. In particular,
SRB1seems to be involved in HDL uptake whereas ABCA1 (ATP-binding cassette
transporter A1) is responsible for internalisation of apo A-1 alone (for review, see
von Eckardstein and Rohrer 2009). However, most studies on transendothelial
transport of HDLs were performed on aortic endothelial cells that may differ
from endothelial cells of the BBB. Few studies are available on HDL actions on
neurons and astrocytes. Ferretti et al. reported that HDLs reduced oxidative stress
and cell death induced by copper ions in rat astrocytes (Ferretti et al. 2003). In rat
type I astrocytes and glioma cells, HDLs stimulated DNA synthesis and expression
of fibroblast growth factor-2, a potent neurotrophic factor, which was associated
with the activation of proliferative intracellular signalling (Malchinkhuu
et al. 2003). It is likely that in pathological conditions (haemorrhage or transient
increase of BBB permeability), HDLs have an improved access to the cerebral
parenchymal compartment and then act on both neurons and astrocytes (Lapergue
et al. 2010, 2013).
6 Part 2: HDLs and Acute Stroke (In Vivo Data)
Under acute stroke conditions, the lipid profile has been reported to be modified
(Santos-Silva et al. 2002). These authors have shown that patients with diagnosed
ischaemic stroke (CT imaging, n¼ 21) had lower plasma concentrations of both
HDL and apo A-I than healthy subjects with no history of cardiovascular events and
normal haematologic values (n¼ 29). Blood was sampled after a 12-h fasting
period. In these patients, leukocyte count was increased relative to controls, but
the concentration of granulocytes accounted for most of this increase (monocytes
were moderately augmented whereas lymphocyte count was decreased in stroke
patients). More importantly, markers of neutrophil activation, including lactoferrin
and elastase, were strongly increased in plasma of stroke patients when compared
to controls.
6.1 HDLs and Acute Stroke: Experimental Models
Few studies have attempted to use HDL therapy in acute stroke. Based on the
observation that low HDL cholesterol levels were associated with cerebrovascular
events (Sacco et al. 2001; Wannamethee et al. 2000), Paterno et al. showed that
pretreatment with reconstituted HDL reduced neuronal damage in two experimen-
tal models of stroke in rats (Paterno et al. 2004). They showed that high doses of
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rHDLs (120 mg/kg) infused 2 h before the onset of stroke reduced the brain necrotic
area by 61 and 76 %, respectively, in an excitotoxic (NMDA) and a transient
MCAO model of stroke in rats. More recently, we have shown that plasma HDLs
(10 mg/kg), injected immediately or at 3 or 5 h after stroke, also reduced cerebral
infarct volume by 74, 68 and 70 %, respectively, in a rat model of thromboembolic
stroke (Lapergue et al. 2010). This was associated with a reduced BBB breakdown
and decreased neutrophil recruitment in the infarct area. In this model, injection of
fluorescent-labelled HDLs showed a staining of endothelial cells (but also glial
cells), suggesting that their primary protective effect was on the BBB. Thus, HDLs
may be a powerful neuroprotective tool for the treatment of cerebrovascular
diseases by preventing BBB breakdown. We have confirmed these in vivo results
by a study using a model of BBB in vitro (Bao Dang et al. 2013).
In humans, recombinant tissue plasminogen activator (rtPA) is the only effective
fibrinolytic treatment in ischaemic stroke. The disruption of the BBB is involved in
oedema and haemorrhagic transformation following tPA treatment. We assessed
whether HDL-rtPA combined treatment could improve the safety and efficacy of
tPA in experimental stroke. We showed that HDL injection decreased tPA-induced
haemorrhagic transformation in two models of focal middle cerebral artery occlu-
sion (MCAO) (embolic and 4-h monofilament MCAO). Both the blood–brain
barrier in vitro model and in vivo results support the vasculoprotective action of
HDLs on BBB under ischaemic conditions. Finally, HDLs do not interfere with the
fibrinolytic activity of rtPA (Lapergue et al. 2013).
Conclusion
In addition to reverse transport of cholesterol, HDL particles display different
protective effects that could support their use in the acute phase of stroke.
Different neuroprotective drugs proven to be effective in animal models have
failed to translate into clinical settings (Xu and Pan 2013). Early treatments that
could be used without interfering with fibrinolytic treatments should be consid-
ered as a good option to limit the deleterious effects of ischaemic stroke. HDLs
may represent a good candidate, particularly with respect to their protective
effects on the endothelium in ischaemia/reperfusion conditions. As discussed by
Navab et al., HDL mimetic peptides should be more appropriate for use in
chronic settings since they can be administrated orally or by subcutaneous
route, whereas reconstituted HDLs may be more suitable for acute treatment
by intravenous injection (Navab et al. 2010). Whether apo A-I combined with
phospholipids are sufficient to prevent the effects of ischaemia is questionable. It
is likely that enrichment of reconstituted HDLs with protective molecules such
as antioxidants or antiproteases should provide an optimal beneficial effect as
observed when using plasma HDLs isolated from healthy subjects in different
animal models of stroke.
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Abstract
Epidemiological studies support a strong association between high-density lipo-
protein (HDL) cholesterol levels and heart failure incidence. Experimental evi-
dence from different angles supports the view that low HDL is unlikely an
innocent bystander in the development of heart failure. HDL exerts direct
cardioprotective effects, which are mediated via its interactions with the myocar-
dium and more specifically with cardiomyocytes. HDL may improve cardiac
function in several ways. Firstly, HDL may protect the heart against ischaemia/
reperfusion injury resulting in a reduction of infarct size and thus in myocardial
salvage. Secondly, HDL can improve cardiac function in the absence of
ischaemic heart disease as illustrated by beneficial effects conferred by these
lipoproteins in diabetic cardiomyopathy. Thirdly, HDL may improve cardiac
function by reducing infarct expansion and by attenuating ventricular
remodelling post-myocardial infarction. These different mechanisms are
substantiated by in vitro, ex vivo, and in vivo intervention studies that applied
treatment with native HDL, treatment with reconstituted HDL, or human apo A-I
gene transfer. The effect of human apo A-I gene transfer on infarct expansion and
ventricular remodelling post-myocardial infarction illustrates the beneficial
effects of HDL on tissue repair. The role of HDL in tissue repair is further
underpinned by the potent effects of these lipoproteins on endothelial progenitor
cell number, function, and incorporation, which may in particular be relevant
under conditions of high endothelial cell turnover. Furthermore, topical HDL
therapy enhances cutaneous wound healing in different models. In conclusion,
the development of HDL-targeted interventions in these strategically chosen
therapeutic areas is supported by a strong clinical rationale and significant
preclinical data.
Keywords
High-density lipoproteins • Apolipoprotein A-I • Heart failure • Ventricular
remodelling • Drug development • Ischaemia/reperfusion injury • Tissue repair •
Wound healing • Diabetic ulcer
Abbreviations
Apo Apolipoprotein
AT1R Angiotensin II receptor, type 1
BOEC Blood outgrowth endothelial cells
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CAV Cardiac allograft vasculopathy
ECFCs Endothelial colony-forming cells
eNOS Endothelial nitric oxide synthase
EPC Endothelial progenitor cell
ERK Extracellular signal-regulated kinase
HDL High-density lipoprotein
ICAM Intercellular adhesion molecule
IDL Intermediate-density lipoprotein
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
IL Interleukin
IRI Ischaemia/reperfusion injury
JNK c-Jun N-terminal kinase
LDL Low-density lipoprotein
L-NAME L-NG-nitroarginine methyl ester
NADPH Nicotinamide adenine dinucleotide phosphate
NO Nitric oxide
p38 MAPK p38 mitogen-activated protein kinase
PI3K Phosphoinositide 3-kinase
S1P Sphingosine-1-phosphate
STAT3 Signal transducer and activator of transcription 3
SR-BI Scavenger receptor class B, type I
TBARS Thiobarbituric acid reactive substances
TLR4 Toll-like receptor 4
TNF-α Tumour necrosis factor-α
VCAM Vascular cell adhesion molecule
VEGF Vascular endothelial growth factor
VLDL Very-low-density lipoprotein
1 Introduction
Heart failure is the pathophysiological state in which cardiac dysfunction is respon-
sible for failure of the heart to pump blood at a rate commensurate with the
requirements of metabolising tissues. This clinical syndrome is characterised by
symptoms and signs of increased tissue and organ water and of decreased tissue and
organ perfusion. Heart failure is a growing public health problem, the leading cause
of hospitalisation and a major cause of mortality (Rathi and Deedwania 2012). The
prevalence of heart failure can be estimated at 2 % in the Western world, and the
incidence approaches 5–10 per 1,000 persons per year (Mosterd and Hoes 2007).
However, the prevalence and incidence progressively increase with age. The
prevalence of heart failure is 7 % in the age group 75–84 years and over 10 % in
those older than 85 years (Mosterd et al. 1999). Projections show that by 2030, the
Therapeutic Potential of HDL in Cardioprotection and Tissue Repair 529
prevalence of heart failure will increase 25 % from 2013 estimates (Go et al. 2013).
The 5-year age-adjusted mortality rates after onset of heart failure are 50 % in men
and 46 % in women (Roger et al. 2004).
Epidemiological studies support a strong association between high-density lipo-
protein (HDL) cholesterol levels and heart failure incidence. In Framingham Heart
Study participants free of coronary heart disease at baseline, low HDL cholesterol
levels were independently associated with heart failure incidence after adjustment
for interim myocardial infarction and clinical covariates (Velagaleti et al. 2009).
These seminal prospective data are in agreement with earlier cross-sectional studies
showing that post-infarct ejection fraction is lower in patients with low HDL
cholesterol levels (Kempen et al. 1987; Wang et al. 1998). Low HDL cholesterol
levels and low levels of apolipoprotein (apo) A-I, the main apo of HDL, indicate an
unfavourable prognosis in patients with heart failure independent of the aetiology
(Iwaoka et al. 2007; Mehra et al. 2009). An intriguing observation is that apo A-I is
expressed in the human heart and in the heart of human apo A-I transgenic mice
(Baroukh et al. 2004; Lowes et al. 2006).
The observed relationship between HDL and heart failure in epidemiological
studies might be due to residual confounding. Low HDL may be an integrated
biomarker of adverse metabolic processes including abnormal metabolism of
triglyceride-rich lipoproteins, insulin resistance, and ongoing tissue inflammation.
Crosstalk between inflammatory processes and metabolic dysregulation may be a
critical player in the pathogenesis of heart failure (Palomer et al. 2013). Here, we
will present experimental evidence from different angles, which support the view
that low HDL is unlikely an innocent bystander in the development of heart failure.
As will be discussed in the next sections, HDL exerts direct cardioprotective
effects, which are mediated via their interactions with the myocardium and more
specifically with cardiomyocytes (Sect. 2). HDL may improve cardiac function in
several ways. Firstly, HDL may protect the heart against ischaemia/reperfusion
injury resulting in a reduction of infarct size and thus in myocardial salvage
(Sect. 3). Secondly, HDL can improve cardiac function in the absence of ischaemic
heart disease as illustrated by its beneficial effects in diabetic cardiomyopathy
(Sect. 4). Thirdly, HDL may improve cardiac function by reducing infarct expan-
sion and by attenuating ventricular remodelling (Sect. 7). Since this latter effect is
an example of the role of HDL in tissue repair, the reparative functions of HDL will
be further dealt with in Sect. 5 on HDL and endothelial progenitor cells (EPCs) and
in Sect. 6 on topical HDL therapy for cutaneous wound healing.
2 In Vitro Effects of HDL on Cardiomyocytes
HDL may exert an indirect protective influence on the heart derived from their
ability to limit atherosclerotic plaque formation, thus preventing myocardial ischae-
mia and loss of myocardial tissue in acute coronary syndromes. Data are now
accumulating to indicate that HDL have a more immediate and direct effect on
cardiomyocytes. Discussion of these direct effects in this section will provide a
530 S. Van Linthout et al.
more complete picture of the cardioprotective role of these lipoproteins and will
also raise questions about the use of the HDL complex itself as a therapeutic agent.
Although HDL is found in plasma, they are also present in the interstitial space
in amounts that correspond to approximately 25 % of their plasma concentration
(Parini et al. 2006). It is therefore physiologically relevant to evaluate their direct
impact on cells. The direct impact of HDL on cardiomyocytes has mainly been
studied in two in vitro models: (1) rat neonatal cardiomyocytes and (2) adult mouse
cardiomyocytes. These models allow the investigation of the specific actions of
HDL on cardiomyocytes independent of the systemic parameters and of endothelial
cells whose activity is regulated by HDL. Although studies investigating the direct
role of HDL on cardiomyocytes are relatively limited, they all show a beneficial
impact of HDL. These protective effects have been attributed to the activation of
intracellular signalling cascades involved in pro-survival cell fate.
2.1 Effects of HDL in Rat Neonatal Cardiomyocytes
In cultured rat neonatal cardiomyocytes, HDL treatment inhibits the cytotoxic
effects induced by oxidative stress from glucose and growth factor depletion or
doxorubicin incubation. This protective effect has mainly been evaluated by its
capacity to counteract the proapoptotic signals such as caspase 3 activation and
DNA fragmentation (Frias et al. 2010; Theilmeier et al. 2006). HDL incubation
induces the phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt, extracellular
signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (p38
MAPK), and the transcription factor signal transducer and activator of transcription
3 (STAT3) (Frias et al. 2009). Although the precise mechanism of action has not
been completely elucidated, experiments using specific inhibitors have defined their
role in counteracting apoptotic signals induced by doxorubicin. These studies
suggest that the cardioprotective effect involves the activation of the pro-survival
proteins ERK1/2 and STAT3, but not p38 MAPK. HDL also induces the phosphor-
ylation of connexin 43 (Morel et al. 2012). This phosphorylation leads to a
reduction in gap junction permeability, which may limit the spread of mediators
implicated in death pathways. Connexin 43 phosphorylation requires the activation
of protein kinase C (Morel et al. 2012). Although there is not yet direct proof of the
implication of connexin 43 in the protective effects of HDL, connexin 43 has been
shown to be implicated in ischaemic conditioning (Schulz et al. 2007; Schulz and
Heusch 2004).
2.2 Adult Mouse Cardiomyocytes
In mouse adult cardiomyocytes, the protective actions of HDL have been
demonstrated using a model of hypoxia and reperfusion. Incubation of
cardiomyocytes with HDL before the hypoxia period (preconditioning) improved
cell survival (Frias et al. 2013). This protection involves the preservation of
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mitochondrial integrity, as HDL treatment inhibits mitochondrial permeability
transition pore opening. Similarly to the results obtained in neonatal
cardiomyocytes, HDL induces that activation of intracellular signalling pathways
such as PI3K/Akt, ERK1/2, and STAT3, which play a role in this protection. This
protective action of HDL is significantly inhibited in cardiomyocytes from
cardiomyocyte-restricted STAT3 knockout mice (Frias et al. 2013). Similarly,
cardiomyocytes treated with HDL after hypoxia (at reperfusion) show improved
cell survival compared to non-treated cells. In this context, the effects of HDL were
attributed to PI3K/Akt and ERK1/2 (Tao et al. 2010). The possible role of STAT3
has not been investigated in this reperfusion protocol.
Taken together, HDL-induced activation of several target proteins in
cardiomyocytes appears to be cardioprotective. These beneficial effects cannot be
attributed to its role in cholesterol transport.
2.3 Apo A-I and Sphingosine-1-Phosphate Mediate
the Cytoprotective Effects of HDL
As mentioned above, HDL can modulate the activation of signalling pathways
in cardiac cells. HDL is a complex particle, which is composed of numerous
proteins and bioactive lipids. Among these constituents, apo A-I and sphingosine-
1-phosphate (S1P) are the two major effectors that have been involved in the
activation of signalling pathways. Activation occurs via the binding of the HDL
particle to scavenger receptor class B, type I (SR-BI), and of S1P to S1P receptors.
S1P binds to five (S1P1–S1P5) high-affinity G protein-coupled receptors generating
multiple downstream signals. Of the different S1P receptor subtypes, only S1P1,
S1P2, and S1P3 receptors are expressed in the heart (Means and Brown 2009). S1P
has been shown to be cytoprotective and to confer cardioprotection. For a more
detailed discussion of the cardioprotective role of S1P, the interested reader is
referred to recent reviews (Karliner 2013; Sattler and Levkau 2009).
In vitro, most of the beneficial effects of HDL mentioned above have been
attributed to S1P. Data from experiments using pharmacological antagonists spe-
cific for S1P1, S1P2, and S1P3 receptors demonstrate an inhibition of the HDL
actions. For example, several experiments suggest that S1P3 is involved in PI3K/
Akt signalling and that S1P2 and/or S1P1 might be involved in ERK1/2 and STAT3
signalling (Frias et al. 2009; Tao et al. 2010). S1P2 was shown to play a key role in
the HDL-induced protection against the apoptotic effects of doxorubicin (Frias
et al. 2010). In the protection against hypoxia reperfusion injury, a predominant,
mediatory role was indicated for the S1P1 and S1P3 receptors, via ERK1/2 and
PI3K/Akt activation. No role was attributed to S1P2, but neither was it investigated
(Tao et al. 2010). The evidence that reinforces the cytoprotective role of S1P comes
from experiments, where addition of S1P to reconstituted HDL (rHDL) containing
apo A-I improved the protection against the apoptotic action of doxorubicin (Frias
et al. 2010).
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It should be acknowledged that S1P cannot freely circulate in plasma and that
the major plasma lipoprotein source of this lipid is HDL. Therefore, it is not
surprising that the effects of HDL can be mediated by S1P. However, conflicting
data suggest S1P-independent effects of apo A-I. One explanation proposed
initially by Nofer and colleagues (2004) is that SR-BI can anchor the HDL particle
at the cell membrane and allow S1P to interact with its specific receptors. In this
context, Means and colleagues (Means et al. 2008) have shown that S1P1 is present
in lipid raft structures from adult mouse cardiomyocytes. Lipid rafts are known to
harbour SR-BI (Babitt et al. 1997). Although increasing evidence suggests a major
role of S1P, the mechanism of signal transduction from HDL particle to cell is still
under intensive investigation, and a possible role of SR-BI cannot be eliminated.
Crosstalk between intracellular signalling pathways increases the complexity of
the regulation of HDL-induced cascades and impedes identification of the specific
role of HDL constituents. Nevertheless, it is important to keep in mind that such
complexity can result in differing and conflicting data. Further investigations will
be necessary to elucidate the precise mechanism of action of HDL in
cardiomyocytes in vitro.
3 HDL Confer Protection Against Ischaemia Reperfusion
Injury
Whereas the previous section was dedicated to HDL-induced signalling in
cardiomyocytes and to cytoprotective effects of HDL in vitro, the role of HDL in
this section is extended to cardiac ischaemia/reperfusion injury (IRI).
Ischaemic heart disease is the leading cause of death in the world. After
myocardial infarction, early reperfusion is the most effective strategy to limit cell
death and subsequent complications that can lead to heart failure. However,
re-establishing perfusion is paradoxically detrimental to the heart, giving rise to
IRI. This phenomenon is termed lethal reperfusion injury and is defined as a
myocardial injury caused by the restoration of coronary flow after an ischaemic
episode. This injury culminates in the death of cardiomyocytes that were viable
immediately before the myocardial reperfusion. Combating IRI is a notable focus of
attempts to improve treatment strategies.
Experimental animal models of IRI are adequate to investigate the precise
mechanisms of action and the potential targets of therapeutic drugs. Most
investigations used the isolated rodent heart (ex vivo model) or transient ligature
of the left anterior descending coronary artery (in vivo model). All studies that
evaluated the effects of HDL on the heart submitted to the IRI protocol are
unanimous and demonstrate a beneficial effect on cardiac function. Among these
studies, a few demonstrated similar effects using rHDL, composed of apo A-I and
phospholipids (palmitoyl-oleoyl-phosphatidylcholine). Some studies used rHDL
containing the apo A-I Milano mutant.
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3.1 IRI in the Isolated Heart Model
An early study using HDL perfusion in isolated hearts suggested that HDL signifi-
cantly reduced post-ischaemic arrhythmias (Mochizuki et al. 1991). In contrast,
perfusion with low-density lipoproteins (LDL) had no effects indicating HDL
specificity. The mechanism was not defined, but it was hypothesised that the
lipoprotein stabilised bioactive arachidonic acid metabolites (Mochizuki
et al. 1991). These antiarrhythmogenic effects were later confirmed in vivo when
treatment with rHDL decreased the incidence of post-ischaemic arrhythmias
(Imaizumi et al. 2008). Surprisingly, treatment with apo A-I or phospholipids did
not significantly reduce these arrhythmogenic responses. The effect of rHDL was
mediated via the production of nitric oxide (NO), through an Akt/ERK/NO pathway
in endothelial cells (Imaizumi et al. 2008). Unfortunately, the direct impact on
cardiomyocytes was not investigated.
The direct cardioprotective impact of HDL on IRI has been studied by Calabresi
and colleagues (Calabresi et al. 2003). They reported that treatment with rHDL
improved post-ischaemic functional recovery and decreased creatine kinase release
in the coronary effluent. Lipid-free apo A-I or phosphatidylcholine liposomes were
not effective in protecting the heart from IRI. rHDL caused a dose-dependent
reduction of ischaemia-induced cardiac tumour necrosis factor-α (TNF-α) expres-
sion and content, which correlated with the improved functional recovery
(Calabresi et al. 2003). In agreement with this prior study, rHDL improved cardiac
function (Rossoni et al. 2004) and reduced infarct size compared to non-treated
animals (Gu et al. 2007). Recent studies showed that treatment with HDL signifi-
cantly reduced the infarct size in rodents submitted to IRI compared to non-treated
IRI animals (Frias et al. 2013; Morel et al. 2012). The protective impact of HDL or
rHDL did not depend on the timing of injection. Indeed, the treatment at the
moment of reperfusion was also effective, but to a lesser extent than the treatment
before the ischaemic period.
The precise mechanism of HDL-induced cardioprotection is under intensive
investigation, and the activation of intracellular signalling pathways plays an
important role in such cardioprotection. In this context, the protective role of
STAT3, previously shown in cardiomyocytes, has been confirmed in the isolated
heart model. The reduction of the infarct size induced by HDL was significantly
inhibited in STAT3 knockout mice (Frias et al. 2013). Mitochondria play an
important role in cell survival and may be the key player in cardioprotection.
Interestingly, HDL and rHDL containing apo A-I Milano have been shown to
preserve mitochondrial integrity (Frias et al. 2013; Marchesi et al. 2008), consistent
with a direct impact of HDL and rHDL on cardiac cells.
3.2 IRI in In Vivo Models
The data obtained ex vivo were extended to in vivo models. The first in vivo data on
cardiac function after HDL injection demonstrated that HDL injection stimulates
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myocardial perfusion. This effect was mediated via the activation of endothelial
nitric oxide synthase (eNOS) (Nofer et al. 2004). Although this study did not
investigate IRI, it underlines the potential response of the heart to HDL in vivo.
The effect of HDL was extended to an in vivo transient ligature of the left anterior
descending coronary artery model (Theilmeier et al. 2006). One single injection of
native HDL before ischaemia reduced infarct size, apoptotic cell death, and neutro-
phil infiltration. These protective effects were also significantly inhibited in the
presence of the eNOS inhibitor L-NG-nitroarginine methyl ester (L-NAME) and
were partially inhibited in S1P receptor subtype 3 KOmice (Theilmeier et al. 2006).
Taken together, these results suggest that the HDL action is mediated via NO
production and is dependent on the S1P content of HDL.
Similarly to the results obtained in the isolated heart, the protective role of rHDL
containing apo A-I Milano during ischaemia or at reperfusion significantly reduced
the infarct size induced by IRI in rabbits (Marchesi et al. 2004). Protective effects of
apo A-I were also demonstrated (Gu et al. 2007). Injection of apo A-I 10 min before
reperfusion significantly improved cardiac function, which was associated with a
reduction of myocardial TNF-α and interleukin (IL)-6 levels. Histological analysis
of cardiac tissue from rats treated with apo A-I showed a decrease in intercellular
adhesion molecule (ICAM) expression and neutrophil infiltration compared to
non-treated animals (Gu et al. 2007). It should be acknowledged that apo A-I and
rHDL can absorb phospholipids, including S1P, in plasma. This could modulate
their impact on IRI.
3.3 Apo A-I and S1P Confer Cardioprotective Effects on HDL
Based on all published reports, it is not easy to delineate the precise role of S1P or
apo A-I in the cardioprotective effects of HDL. Both constituents have been
investigated individually, and both have been shown to protect against IRI individ-
ually. However, their precise impact on the actions of HDL has not always been
investigated in the same study or in the same model. Interestingly, levels of
HDL-associated S1P were diminished in patients with coronary artery disease
(Sattler et al. 2010). Very recent data demonstrate a key role of apolipoprotein M
(apoM) in S1P binding to HDL particles (Christoffersen et al. 2011). Indeed, the
amount of S1P contained in HDL was very low in apoM KO and higher in apoM
overexpressing mice. Unfortunately, IRI in these mice has not yet been investigated.
With respect to S1P, given that its plasma concentration is many times higher
than its affinity for S1P receptors, it has been suggested that HDL might play the
role of neutralising and limiting the actions of circulating S1P (Murata et al. 2000).
The impact of S1P association with HDL on the function of HDL still remains to be
elucidated. It is probable that in the HDL particle, both are necessary to obtain the
maximal positive response.
The mechanisms of HDL-induced cardioprotection against IRI are complex and
cannot be attributed to the role of HDL in reverse cholesterol transport. More
precise knowledge on the role of different HDL constituents in intracellular
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signalling and cardioprotection would help to design a therapeutic compound,
which replicates all the beneficial aspects of HDL in the heart. Figure 1 illustrates
conceptually the direct actions of HDL on cardiomyocytes.
4 Human Apo A-I Gene Transfer Attenuates Diabetic
Cardiomyopathy
Diabetic cardiomyopathy is a cardiac disorder, which takes place in the absence of
coronary artery disease and hypertension, and is characterised by impaired left
ventricular function due to cardiac inflammation, oxidative stress, cardiomyocyte
apoptosis, cardiac perivascular and interstitial fibrosis, intramyocardial
microangiopathy, endothelial dysfunction, disturbed cardiac substrate metabolism,
cardiomyocyte hypertrophy, abnormal intracellular Ca2+ handling, and impaired
functionality of cardiac stem cells. This cardiac entity has first been recognised by
Rubler et al. (1972), and its existence has been confirmed during the last three
decades via epidemiological, clinical, and experimental studies. Hyperglycaemia,
hyperinsulinaemia, and dyslipidaemia each contribute to the pathogenesis of dia-
betic cardiomyopathy via triggering cellular signalling and subsequent specific
alterations in cardiac structure. However, hyperglycaemia-induced oxidative stress
has been proposed to be the key determinant in the development of diabetic
cardiomyopathy. Left ventricular diastolic dysfunction represents the earliest pre-
clinical manifestation of diabetic cardiomyopathy, preceding systolic dysfunction,
which can progress to symptomatic heart failure (Cosson and Kevorkian 2003;
Freire et al. 2007; Raev 1994).
Fig. 1 Proposed protective intracellular signalling pathways induced by HDL in cardiomyocytes.
HDL induces the activation of intracellular signalling pathways in cardiomyocytes. This activation
leads to cardioprotection. Most of the activated signalling pathways induced by HDL involve its
S1P constituent (HDL-S1P) and the participation of S1P receptor subtypes. Further investigations
are necessary to elucidate the precise role of SR-BI in cardioprotection induced by HDL. The
arrows indicate intracellular signalling as described in cardiomyocytes. Cx 43; connexin 43; PKC
protein kinase C; MEK1/2: ERK (MAPK) kinase 1/2
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HDLs have antidiabetic properties. They reduce hyperglycaemia via their capac-
ity to decrease pancreatic β-cell apoptosis (Abderrahmani et al. 2007; Fryirs
et al. 2010; Rutti et al. 2009) and to stimulate glucose disposal in skeletal muscle
(Han et al. 2007). They decrease dyslipidaemia via lowering adipocyte lipolysis
(Van Linthout et al. 2010a) and induce insulin sensitivity (Berg et al. 2001) via
upregulating the expression of adiponectin (Van Linthout et al. 2010a), which
abrogates the development of hyperinsulinaemia. Consequently, increased HDL
may, from a theoretical point of view, antagonise the main triggers of diabetic
cardiomyopathy.
The main hallmarks of diabetic cardiomyopathy, including cardiac oxidative
stress, interstitial inflammation, apoptosis, fibrosis, and endothelial dysfunction, on
the one hand and the pleiotropic effects of HDL on the other hand further support
the hypothesis that an increase in HDL may reduce the development of diabetic
cardiomyopathy (Fig. 2). Via a human apo A-I gene transfer strategy, this
Fig. 2 HDL reduces the development of diabetic cardiomyopathy. Type 2 diabetes mellitus is
associated with hyperglycaemia, dyslipidaemia, and hyperinsulinaemia. Hyperglycaemia is the
main trigger that contributes to the development of diabetic cardiomyopathy via the induction of
oxidative stress. Hallmarks of diabetic cardiomyopathy are, besides cardiac oxidative stress,
cardiac fibrosis, inflammation, apoptosis, and endothelial dysfunction, which reciprocally affect
one another (interconnected grey lines). HDLs have antidiabetic features (dotted lines): they
reduce hyperglycaemia and dyslipidaemia via—among other mechanisms—their capacity to
decrease pancreatic β-cell apoptosis and adipocyte lipolysis, respectively, and they increase
insulin sensitivity via the induction of adiponectin, abrogating the development of hyperinsu-
linaemia. Besides interference with the triggers that lead to diabetic cardiomyopathy, HDLs reduce
the features of diabetic cardiomyopathy via their pleiotropic effects, including their anti-oxidative,
antifibrotic, anti-inflammatory, antiapoptotic, and endothelial-protective effects ( full lines)
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hypothesis has been evaluated in an experimental rat model of streptozotocin-
induced diabetes mellitus associated with severe hyperglycaemia and an LDL to
HDL ratio of 1:1 (Van Linthout et al. 2007; Young et al. 1988).
4.1 Human Apo A-I Gene Transfer Influences Metabolic
Parameters in Streptozotocin-Induced Diabetes Mellitus
Apo A-I transfer resulted in a 60 % increase in HDL cholesterol, which was
paralleled with a significant decline in very-low-density lipoprotein (VLDL) cho-
lesterol, intermediate-density lipoprotein (IDL) cholesterol, and triglycerides,
whereas LDL cholesterol was unaffected (Van Linthout et al. 2008). Despite the
well-described antidiabetic effects of HDL involving their ability to reduce pancre-
atic β-cell apoptosis (Abderrahmani et al. 2007; Fryirs et al. 2010; Rutti et al. 2009),
apo A-I transfer did not reduce blood glucose levels (Van Linthout et al. 2008),
potentially due to the severity of the streptozotocin model, which is associated with
a remaining insulin production below 1 % (Hughes et al. 2001). The decline in
triglycerides and in the triglyceride-rich lipoproteins VLDL and IDL (Sztalryd and
Kraemer 1995) after apo A-I transfer suggests an HDL-mediated decrease in
lipolysis in adipose tissue, leading to less free fatty acids in the circulation, less
triglyceride synthesis in the liver, and subsequent less VLDL and IDL synthesis
(Tunaru et al. 2003). This hypothesis is corroborated by the ability of HDL to
reduce the expression of hormone-sensitive lipase (Van Linthout et al. 2010a), the
rate-limiting enzyme of adipocyte lipolysis in abdominal fat (Sztalryd and Kraemer
1995), and to increase the phosphorylation of the PI3K downstream target Akt in
abdominal fat (Van Linthout et al. 2010a). Akt is involved in the anti-lipolytic and
lipogenic effects of insulin in adipose tissue (Whiteman et al. 2002) and in the
regulation of the expression of the adipokine adiponectin (Cong et al. 2007; Pereira
and Draznin 2005), which is known to improve insulin sensitivity under diabetes
(Peterson et al. 2008). However, an involvement of HDL in the hepatic expression
of genes involved in triglyceride metabolism may not be excluded. The decrease in
cardiac glycogen content (Van Linthout et al. 2008) suggests that apo A-I transfer in
streptozotocin rats partly restored glucose metabolism as an energy source in the
heart instead of nearly exclusive reliance on fatty acid metabolism for production of
ATP (Kota et al. 2011).
4.2 Human Apo A-I Gene Transfer Attenuates Diabetes-
Associated Oxidative Stress, Cardiac Fibrosis,
and Endothelial Dysfunction
Hyperglycaemia induces oxidative stress via creating a disbalance between the
generation of reactive oxygen species and their resolution by antioxidant enzymes,
like superoxide dismutases, which convert O2
 anions into molecular oxygen and
hydrogen peroxide (Nishikawa et al. 2000). Reactive oxygen species initiate diverse
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stress-signalling pathways including ERK, c-Jun N-terminal kinase (JNK),
and p38 MAPK, alter cellular proteins, and induce lipid peroxidation. In
diabetic cardiomyocytes, reactive oxygen species are predominantly generated
by mitochondria, due to mitochondrial oxidation of fatty acids (Kota et al. 2011),
and by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(Li et al. 2010b). The pathological importance of p38 MAPK in the diabetic heart
follows from the observation that p38 MAPK inhibition reduces cardiac inflamma-
tion and improves left ventricular dysfunction in streptozotocin-induced diabetic
mice (Westermann et al. 2006). Besides decreasing the activity of p38 MAPK, apo
A-I transfer reduced cardiac oxidative stress via upregulating the expression of the
diabetes-downregulated mitochondrial superoxide dismutase-2 and extracellular-
superoxide dismutase (Van Linthout et al. 2008). Both forms of superoxide
dismutase are important for the heart as outlined in studies whereby cardiac
overexpression of superoxide dismutase-2 protected the mitochondrial respiratory
function and blocked apoptosis induction (Shen et al. 2006; Suzuki et al. 2002) and
overexpression of extracellular-superoxide dismutase decreased macrophage infil-
tration and fibrosis and improved left ventricular dysfunction (Dewald et al. 2003).
These studies postulate that the decrease in cardiac fibrosis after apo A-I transfer in
streptozotocin-diabetic rats can be partly explained by the reduction in oxidative
stress and inflammation, including downregulated expression of pro-fibrotic
cytokines (inflammatory fibrosis) (Tschope et al. 2005), as well as by the decrease
in cardiac apoptosis (cfr. supra) and subsequent replacement fibrosis, resulting in
improved left ventricular function. The anti-inflammatory and antifibrotic effects of
HDL are supported by findings in apo A-I knockout mice, which are associated with
increased inflammatory cells and collagen deposition in the lung (Wang et al. 2010),
and from observations with the mimetic apo A-I peptide 4F demonstrating an
L-4F-mediated decreased endothelial cell matrix production (Ou et al. 2005).
Since cardiac NADPH oxidases play a predominant role in the development of
diabetic cardiomyopathy (Guo et al. 2007; Wold et al. 2006) and in diabetic cardiac
remodelling (Li et al. 2010b), decreased cardiac NADPH oxidase activity following
apo A-I transfer (Van Linthout et al. 2009) may be a critical mediator of reduced
cardiac oxidative stress and subsequent fibrosis in the myocardium.
Systemically, apo A-I transfer decreased the oxidative stress in rats with
streptozotocin-induced diabetes as indicated by the decline in serum levels of
thiobarbituric acid reactive substances (TBARS) (Van Linthout et al. 2008), a
marker of lipid peroxidation (Tschope et al. 2005). This finding is corroborated
by Mackness et al. (1991), who reported that HDLs decrease the formation of
TBARS on oxidised LDL. This is likely mediated by an increase in the activity of
paraoxonase or platelet-activating factor-acetyl hydrolase, 2 enzymes with anti-
oxidative features, which are associated with HDL and which are known to be
induced after apo A-I gene transfer (De Geest et al. 2000).
In the vasculature of diabetic rats, apo A-I transfer decreased oxidative stress as
indicated by the reduction in diabetes-enhanced NADPH oxidase activity and
eNOS uncoupling (Van Linthout et al. 2009), a phenomenon occurring when
eNOS produces O2
 rather than NO. Uncoupling of eNOS is, besides NADPH
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oxidases (Cai 2005), an important source of reactive oxygen species in diseased,
including diabetic, blood vessels (Hink et al. 2001). Consistent with the
demonstrated role of the angiotensin II receptor, type 1 (AT1R) in mediating
increased NADPD oxidase activity, and eNOS uncoupling in diabetes (Oak and
Cai 2007), the downregulation in diabetes-induced AT1R (Hodroj et al. 2007; Nyby
et al. 2007) after apo A-I transfer (Van Linthout et al. 2009) was postulated to be the
predominant mediator of reduced NADPH oxidase activity and eNOS uncoupling.
This hypothesis is further supported by in vitro findings showing that the
HDL-mediated reduction in AT1R expression in human aortic endothelial cells
was associated with a decline in hyperglycaemia-induced oxidative stress and a
reduced responsiveness to angiotensin II (Van Linthout et al. 2009). These
observations underline the finding of Tolle et al. (2008), who showed that HDL
reduce NADPH oxidase-dependent reactive oxygen species generation via inhibi-
tion of the activation of Rac1, which is a downstream AT1R-dependent mediator of
angiotensin II (Ohtsu et al. 2006). The exact mechanism by which HDL affect
AT1R regulation under diabetes mellitus requires further fundamental studies.
However, since oxidised LDL (Li et al. 2000) and reactive oxygen species
(Gragasin et al. 2003) play a role in the induction of the AT1R in human aortic
endothelial cells, one may speculate that HDL via intrinsic anti-oxidative features
(cfr. supra, via paraoxonase and platelet-activating factor-acetyl hydrolase) may
contribute to the downregulation of the AT1R under diabetes mellitus, which
results in less NADPH oxidase activity and reactive oxygen formation and in turn
may decrease AT1R expression. Concomitant with the reduced vascular oxidative
stress, including decreased eNOS uncoupling, apo A-I transfer in streptozotocin rats
resulted in an enhanced NO bioavailability (Chalupsky and Cai 2005) and conse-
quently in a decrease in endothelial dysfunction (Van Linthout et al. 2009), which is
another hallmark of diabetic cardiomyopathy.
4.3 Human Apo A-I Gene Transfer Reduces Diabetes-Induced
Cardiac Inflammation
In agreement with the direct anti-inflammatory properties of HDL (Cockerill
et al. 2001; Hyka et al. 2001), apo A-I transfer decreased the diabetes-induced
intramyocardial inflammation (Westermann et al. 2007b, c) as indicated by the
reduction in ICAM-1, vascular cell adhesion molecule (VCAM)-1, and TNF-α
mRNA expression (Van Linthout et al. 2008) and VCAM-1 protein expression
(Van Linthout et al. 2010b). Downregulation of VCAM-1/ICAM-1 expression
suppresses monocyte-endothelial cell adhesion and subsequent transendothelial
migration of inflammatory cells. This in turn reduced local expression of cytokines
like TNF-α and consequently may attenuate the potentiation of the intramyocardial
inflammatory reaction. Hyperglycaemia (Li et al. 2010a; Piga et al. 2007), oxidised
LDL (Lee et al. 2010) (Hodgkinson et al. 2008; Peterson et al. 2007), and increased
angiotensin II (Alvarez et al. 2004; Rius et al. 2010) under diabetes mellitus
upregulate the expression of VCAM-1/ICAM-1. Since HDL did not affect blood
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glucose levels, the reduction in adhesion molecule expression was not an indirect
consequence of an HDL-mediated antidiabetic effect. However, the reduced levels
of TBARS, which are also retrieved on oxidised LDL, in diabetic rats treated with
apo A-I transfer compared to diabetic rats treated with control vector suggest that
apo A-I transfer decreases oxidised LDL and subsequent cardiac inflammation.
Oxidised LDLs are agonists of Toll-like receptor 4 (TLR4), which is expressed on
the cell surface of cardiac cells, including cardiomyocytes, smooth muscle cells,
and endothelial cells. A role for TLR4 in the development of diabetic cardiomyop-
athy has recently been suggested (Zhang et al. 2010). The documented
HDL-mediated reduction in endothelial TLR4 expression and subsequent decrease
in NF-κB activity (Van Linthout et al. 2011) suggest that the reduction in cardiac
inflammation after apo A-I transfer is further partly mediated via a decrease in
endothelial TLR4 expression, limiting oxidised LDL-endothelial TLR4 interactions
and subsequent activation of NF-κB. Furthermore, the activation of the AT1R,
whose expression is upregulated under diabetes mellitus (Cohen 1993; Nyby
et al. 2007), contributes to the development of diabetic cardiomyopathy. After all,
AT1R antagonism under diabetes mellitus improves endothelial function
(Cheetham et al. 2000) and reduces cardiac inflammation and fibrosis, resulting in
an improvement in cardiac function (Westermann et al. 2007a). The observations
that apo A-I transfer reduces aortic AT1R expression in streptozotocin-induced
diabetic rats and that HDLs decrease the hyperglycaemia-induced AT1R expression
in endothelial cells (Van Linthout et al. 2009) suggest that apo A-I transfer reduces
cardiac endothelial AT1R and subsequent angiotensin II responsiveness including
the induction of VCAM-1/ICAM-1 expression and subsequent monocyte-
endothelial cell adhesion (Alvarez et al. 2004; Rius et al. 2010). Downregulation
of the expression of the anti-inflammatory adipokine adiponectin (Ouchi
et al. 2000, 2001; Ouedraogo et al. 2007) as observed in diabetic patients and in
streptozotocin rats (Thule et al. 2006) has been implicated in chronic inflammatory
phenotype in these subjects/rats. The positive correlation between apo A-I/HDL
plasma levels and adiponectin concentrations (Verges et al. 2006) and the finding
that apo A-I transfer increases the expression of adiponectin in an experimental
model of extreme inflammation (Van Linthout et al. 2010a) further suggest that the
effects of HDL on adiponectin expression may contribute to its anti-inflammatory
effects and to the attenuation of cardiac inflammation in rats with streptozotocin-
induced diabetes. Finally, since apo A-I induces regulatory T cells (Wilhelm
et al. 2010), which protect against the pro-inflammatory status of endothelial cells
(He et al. 2010), an induction in regulatory T cells following apo A-I transfer may
also partly account for the reduced cardiac inflammation in diabetic rats.
Since inflammation triggers fibrosis (Ismahil et al. 2013; Savvatis et al. 2012;
Westermann et al. 2011), the less pronounced diabetes-induced cardiac fibrosis (cfr.
infra) following apo A-I transfer might partly be explained by the decrease in
cardiac inflammation. In this context, the influence of a systemic HDL-mediated
immunomodulation on cardiac inflammation and fibrosis needs further
investigation.
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4.4 Human Apo A-I Gene Transfer Reduces Diabetes-Associated
Cardiac Apoptosis and Improves the Cardiac Endothelial
Integrity
Cardiac apoptosis is another hallmark of diabetic cardiomyopathy. The incidence of
cardiac apoptosis is higher in diabetic patients (Frustaci et al. 2000) and in diabetic
animals (Cai et al. 2002) compared to non-diabetic controls and is directly linked to
hyperglycaemia-induced oxidative stress (Cai et al. 2002). Mitochondria play an
important role in oxidative stress-induced apoptosis. Caspase 3 and caspase 7 are
essential mediators in the mitochondrial processes of apoptosis (Lakhani
et al. 2006). In accordance with the reduction in oxidative stress, including the
upregulation of cardiac mitochondrial superoxide dismutase-2 expression, apo A-I
transfer decreased the induced caspase 3/7 activity in streptozotocin rats (Van
Linthout et al. 2008). Concomitantly, apo A-I transfer raised the ratio of the
antiapoptotic Bcl-2, a ‘guardian’ against mitochondrial initiation of caspase activa-
tion (Susin et al. 1996), towards the proapoptotic Bax. This ratio is a marker of
increased cardiomyocyte survival probability (Condorelli et al. 1999). Furthermore,
apo A-I transfer normalised the diabetes-reduced phosphorylation of the
pro-survival protein kinase B Akt (Montanari et al. 2005; Uchiyama et al. 2004)
and of its effector eNOS to levels found in non-diabetic hearts (Van Linthout
et al. 2008). This finding was further corroborated by experiments in
cardiomyocytes. HDL supplementation on cardiomyocytes in the presence of
in vitro hyperglycaemia reduced apoptosis in a PI3K- and NO-dependent manner
(Van Linthout et al. 2008). The antiapoptotic effects of apo A-I transfer were
reflected at ultrastructural level by a reduced number of cardiomyocytes with
swollen mitochondria and apoptotic bodies and a more intact endothelium and
basement membrane (Van Linthout et al. 2008). These findings and the presence of
activated Akt in cardiomyocytes, as well as in cardiac endothelial cells documented
via immunofluorescence staining, underscore the importance of Akt activation after
apo A-I transfer in the reduction of cardiomyocyte apoptosis as well as in the
improvement in endothelial integrity. The ameliorated integrity of the endothelium
suggests a potential restoration of the microvascular homeostasis, which has been
demonstrated to reduce cardiomyocyte apoptosis and to result in the recovery of
cardiac function in diabetic cardiomyopathy (Yoon et al. 2005). The significance of
the cardiac endothelium on the contractile state and Ca2+ handling of subjacent
cardiomyocytes (Brutsaert 2003; Nishida et al. 1993; Ramaciotti et al. 1992)
suggests that part of the HDL-mediated improvement in left ventricular function
in rats with streptozotocin-induced diabetes was indirectly due to their protective
effect on the cardiac endothelium. This hypothesis is supported by the improvement
in endothelial function found after apo A-I transfer in streptozotocin-induced
diabetic rats (Van Linthout et al. 2009). In addition, HDL supplementation on
isolated cardiomyocytes directly improved their contractility under
hyperglycaemia-induced stress in a PI3K- and NO-dependent manner (Van
Linthout et al. 2008).
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Besides the direct HDL-mediated cardiomyocyte-protective effects and the
endothelial-protective features, the decrease in cardiac apoptosis after apo A-I
transfer in diabetic rats might be attributed to several other in parallel
HDL-mediated triggered processes: (1) HDL may act as biological buffers capable
of rapidly removing active proapoptotic TNF-α from the heart; (2) they have the
potential to increase (Rossoni et al. 2004), stabilise, and activate prostaglandins
(Aoyama et al. 1990). This enhanced prostanoid availability/activity may contrib-
ute to the HDL-mediated cardioprotection, by acting directly on cardiomyocytes
(Zacharowski et al. 1999) and/or by inhibiting cardiac TNF-α production
(Shinomiya et al. 2001); (3) HDL may reduce the expression of TLR 4 (Van
Linthout et al. 2011), which has recently been shown to play an important role in
cardiac apoptosis in diabetic cardiomyopathy.
In conclusion, apo A-I transfer attenuates the development of experimental
diabetic cardiomyopathy via its anti-oxidative, anti-inflammatory, antifibrotic,
and antiapoptotic actions (Fig. 2). Beyond beneficial vascular/cardioprotective
long-term effects, direct myocardial effects of HDL may contribute to the improve-
ment of cardiac function under severe streptozotocin-induced stress. Further studies
are required to investigate the potential of apo A-I transfer to ameliorate established
diabetic cardiomyopathy, especially in the context of type 2 diabetes mellitus, and
to improve the function of HDL, which is impaired under diabetic conditions
(Hedrick et al. 2000; Persegol et al. 2006; Sorrentino et al. 2009; Zheng
et al. 2004). Finally, also the impact of the apo A-I/HDL-induced immunomodula-
tory effects on diabetes-associated endothelial dysfunction and cardiac fibrosis
needs further clarification.
5 HDL and Tissue Repair: Modulation of EPC Biology via
SR-BI
The term EPC is most often used in a very broad sense. There is no consensus
definition of EPCs, which is a major source of confusion in the literature. EPCs
encompass different categories of cells with different phenotypic and functional
properties that affect neovascularisation and reendothelialisation. In a narrow,
literally correct, and unambiguous sense, EPCs are immature precursor cells capa-
ble of differentiating into mature endothelial cells in vivo (Hagensen et al. 2010).
Thus, an EPC sensu stricto corresponds to an in vivo category and is defined from a
functional point of view. However, there are very significant methodological
challenges to detect incorporation of circulating progenitor cells in the endothelium
(Hagensen et al. 2010). Incorporation of EPCs is in general a relatively rare event
(Feng et al. 2008, 2009a, b; Hagensen et al. 2010). High-resolution multichannel
sequential confocal scanning microscopy provides a platform for colocalisation
analysis with high specificity, which is required in lege artis cell tracking studies
(De Geest 2009). Alternatively, EPCs may act in a paracrine way by releasing
angiogenic factors and proteases to stimulate sprouting of local vessels or promote
reendothelialisation indirectly (Rehman et al. 2003; Takakura et al. 2000; Urbich
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et al. 2005). To make a distinction with EPCs sensu stricto, these cells may be
designated as proangiogenic haematopoietic progenitor cells (Fig. 3).
Different protocols for short-term culture of blood mononuclear cells on fibro-
nectin (with or without gelatin)-coated plates have been established by Vasa
et al. (2001) and Hill et al. (2003). These cells are stimulated by in vitro culture
conditions to mimic many features of endothelial cells (Hirschi et al. 2008). How-
ever, the putative EPCs identified by these assays do not give rise to a lineage of
endothelial progeny, but cultured cells in these assays consist of monocytes or a
population of haematopoietic cells with monocyte-macrophage or T-cell lineage
commitment. Nevertheless, these so-called early EPCs or early outgrowth EPCs
may regulate the angiogenic response in a paracrine way (Hirschi et al. 2008). In
Fig. 3 Role of bone marrow-derived proangiogenic haematopoietic progenitor cells and EPCs
sensu stricto in endothelial repair and neovascularisation. Proangiogenic haematopoietic progeni-
tor cells, the in vivo equivalent of ‘early EPCs’, contribute to vascularisation and endothelial repair
indirectly by secreting paracrine factors such as VEGF, hepatocyte growth factor (HGF), granulo-
cyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor
(GM-CSF), placental growth factor (PLGF), and IL-8. These factors stimulate local endothelial
cell proliferation. On the other hand, EPCs sensu stricto enhance neovascularisation and endothe-
lial repair directly by incorporation into the endothelium. EPCs sensu stricto can be considered to
constitute the in vivo equivalent of ECFCs or BOECs (‘late outgrowth EPCs’). ECs endothelial
cells; SMCs smooth muscle cells
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contrast, endothelial colony-forming cells (ECFCs) (also called ‘late outgrowth
EPCs’ or ‘blood outgrowth endothelial cells’ (BOECs)) are immature precursor
cells capable of differentiating into mature endothelial cells in vivo. They are
derived from long-term culture of adherent peripheral blood mononuclear cells in
endothelial conditions (‘late outgrowth EPCs’) and consist of colonies that display
a cobblestone morphology (Ingram et al. 2004). ECFCs express cell surface
antigens like primary endothelium, clonally propagate, can be replated into second-
ary and tertiary ECFCs, form capillary-like structures in vitro, and become endo-
thelial cells in vivo (Ingram et al. 2004). ECFCs display postnatal vasculogenic
activity upon transplantation in a matrix scaffold (Richardson and Yoder 2011).
ECFCs could be considered to be similar to EPCs sensu stricto: they have a
potential for postnatal vasculogenesis and endothelial repair at sites of endothelial
damage. However, one should always consider that cell categories that are defined
based on in vitro cell culture conditions have always a rather artificial character.
HDLs enhance EPC-mediated repair (Feng et al. 2008, 2009a, b; Tso
et al. 2006). The effect of HDL on EPC number, function, and incorporation occurs
via SR-BI (Feng et al. 2009b). Since HDLs have been demonstrated to increase
vascular endothelial growth factor (VEGF) production by early EPCs in vitro,
HDLs may improve reendothelialisation by its effects on these circulating
proangiogenic cells (Feng et al. 2011). On the other hand, HDLs also improve
ECFC function in vitro, and these effects are dependent on signalling via SR-BI,
ERKs, and NO and on increased β1 integrin expression (Feng et al. 2011). Taken
together, HDL exerts potent effects on different functional categories of EPCs via
SR-BI.
The endothelial-protective and endothelial-reparative properties of HDL may be
pathophysiologically and clinically relevant under conditions of high endothelial
turnover. In healthy individuals, the endothelial layer is renewed at a low replica-
tion rate of 0–1 % per day (Erdbruegger et al. 2006). In pathological conditions of
arteriosclerosis, endothelial turnover may be higher. Arteriosclerosis is a broad
term that encompasses all diseases that lead to arterial hardening, including native
atherosclerosis, post-injury neointima formation, cardiac allograft vasculopathy
(CAV), and vein graft atherosclerosis. Areas of low shear stress in human arteries
have an increased rate of endothelial turnover (Tricot et al. 2000). Augmented
endothelial turnover is also observed in atherosclerosis-prone areas in apo E/
mice (Foteinos et al. 2008). However, the highest degree of endothelial turnover is
likely observed after arterial injury, in allografts (Rahmani et al. 2006), and in vein
grafts. Although there is significant evidence that HDLs exert beneficial effects in
models of angioplasty- or injury-induced arteriosclerosis (Ameli et al. 1994; De
Geest et al. 1997; Shah and Amin 1992), we will focus here on allograft
vasculopathy and vein graft atherosclerosis.
Orthotopic heart transplantation is a well-established therapy for selected
patients with end-stage congestive heart failure. The long-term success of heart
transplantation is limited by CAV. EPC-mediated repair may inhibit the progres-
sion of CAV. Although CAV is primarily the result of chronic rejection,
non-immunological factors are modifiers of CAV progression. In the ‘response to
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injury’ concept of CAV, vascular lesions are considered to be the result of cumula-
tive endothelial injury both by alloimmune responses and by non-alloimmune
insults (Vassalli et al. 2003). T-cell alloimmunity, antibody-mediated immune
attack, and non-immune factors induce endothelial cell death or endothelial dys-
function. Since the endothelium regulates vascular tone, inflammation, smooth
muscle cell proliferation, and thrombosis (Behrendt and Ganz 2002), restoration
of endothelial integrity and function is pivotal to attenuate the development of CAV
(Pinney and Mancini 2004). Markers of endothelial injury have been shown to
discriminate between CAV-positive and CAV-negative heart transplant recipients
(Singh et al. 2012), which is consistent with a postulated pivotal role of endothelial
injury in the pathogenesis of CAV.
Current strategies to prevent or treat CAV are clearly insufficient. Disruption of
the endothelial lining due to endothelial cell apoptosis can be restored by prolifera-
tion of adjacent endothelial cells but also by incorporation of circulating bone
marrow-derived EPCs (Friedrich et al. 2006; Walter et al. 2002; Werner
et al. 2002, 2003). Hu et al. (2003) have demonstrated that EPCs contribute to
endothelial regeneration in murine allografts. Moreover, increased HDL induced by
hepatocyte-directed human apo A-I gene transfer in C57BL/6 apo E/ mice
enhanced the incorporation of bone marrow-derived EPCs into the injured endo-
thelium of allografts from donor BALB/c mice and reduced neointima formation in
these allografts (Feng et al. 2008). In subsequent experiments using BALB/c
allografts in wild-type C57BL/6 mice, it was demonstrated that increased EPC
incorporation and attenuation of allograft vasculopathy induced by hepatocyte-
directed human apo A-I gene transfer are strictly dependent on SR-BI expression
in bone marrow and bone marrow-derived cells. This conclusion was reached based
on experiments in mice transplanted with wild-type bone marrow or alternatively
with SR-BI/ bone marrow. These data suggest that the effect of HDL on EPC
incorporation and/or paracrine effects of EPCs are critical for the attenuation of
allograft vasculopathy in this model. Nevertheless, the implications of these data
for clinical CAV are unknown since murine experiments are performed in the
absence of immunosuppressive therapies.
Surgical revascularisation using autologous vein grafts is limited by vein graft
failure, which is frequently due to an aggressive form of atherosclerosis (Campeau
et al. 1984). Vein graft failure is observed in 30–50 % of coronary bypass grafts
within 10 years (Fitzgibbon et al. 1996). Hypercholesterolaemia is a risk factor for
vein graft failure (Goldman et al. 2004), which may be related to adverse effects on
endothelial integrity and function (Raja et al. 2004). Previously, it has been
demonstrated that endothelial regeneration is retarded, and neointima formation is
accelerated in vein grafts in hypercholesterolaemic apo E/ mice compared to
normocholesterolaemic controls (Dietrich et al. 2000; Xu et al. 2003). Topical HDL
therapy reduced vein graft atherosclerosis in apo E/ mice (Feng et al. 2011).
Topical HDL application involves formulation of HDL in 20 % pluronic F-127 gel
(pH 7.2) (Feng et al. 2011). Pluronic F-127 is a biocompatible and non-toxic
substance and is characterised by thermoreversible gel formation at temperatures
above 21 C (Hu et al. 1999). One of the main advantages of topical HDL therapy is
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that the ‘distribution volume’ of the therapeutic agent is small compared to sys-
temic administration. In addition, the extracellular protein concentration of HDL is
300–400 μg/ml (Parini et al. 2006; Sloop et al. 1987). This is approximately 20 % of
the plasma protein concentration. Therefore, therapeutic effects of topical HDL can
be expected at HDL concentrations that are substantially lower than the plasma
concentration. Topical HDL administration on the adventitial side of vein grafts
improved vein graft patency and function (Feng et al. 2011). Caval veins of C57BL/
6 apo E/ mice were grafted to the right carotid arteries of recipient C57BL/6
TIE2-LacZ/apo E/ mice. HDL in 20 % pluronic F-127 gel was applied on the
adventitial side of vein grafts. Topical HDL application reduced intimal area by
55 % ( p< 0.001) at day 28 compared to control mice. Blood flow quantified by
micro-magnetic resonance imaging at day 28 was 2.8-fold ( p< 0.0001) higher in
grafts of topical HDL-treated mice than in control mice. Topical HDL potently
reduced intimal inflammation and resulted in enhanced endothelial regeneration as
evidenced by an increase in the number of CD31-positive endothelial cells. As
stated supra, HDL potently enhanced migration and adhesion of ECFCs in vitro,
and these effects were dependent on signalling via SR-BI, ERK, and NO and on
increased β1-integrin expression. Correspondingly, the number of CD31
β-galactosidase double-positive cells, reflecting incorporated circulating progenitor
cells, was 3.9-fold ( p< 0.01) higher in grafts of HDL-treated mice than in control
grafts. Importantly, the effects of topical HDL therapy on vein graft atherosclerosis
were similar compared to the effects of systemically increased HDL cholesterol
after human apo A-I gene transfer. Taken together, topical HDL application is a
new paradigm of HDL therapy.
Whereas this section was focused on HDL- and EPC-mediated endothelial
repair, the next two sections will deal with HDL and tissue repair. In these
therapeutic areas, the effect of HDL on EPCs may be an important mediator of
the beneficial effects of HDL-targeted therapies.
6 Development of Topical HDL Therapy for Cutaneous
Wound Healing
Wound healing results from complex interactions between extracellular matrix
molecules, soluble mediators, resident skin cells, and infiltrating leukocytes as
well as infiltrating EPCs. Rather artificially, wound healing can be divided in an
inflammation phase, a phase of tissue formation with accumulation of granulation
tissue and reepithelialisation, and finally a phase of tissue remodelling (Diegelmann
and Evans 2004).
Granulation tissue contains tissue macrophages, fibroblasts, numerous new
vessels, and extracellular matrix molecules. Macrophages stimulate fibroplasia
and angiogenesis by secretion of various growth factors. Fibroblasts deposit and
remodel the extracellular matrix of wounds. Blood vessels are needed to provide
oxygen and nutrients, whereas extracellular matrix provides a conduit for cell
migration and cell ingrowth. Formation of granulation tissue starts a few days
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after injury and is mainly triggered by growth factors such as platelet-derived
growth factor and transforming growth factor-β, which stimulate fibroblast prolif-
eration and migration (Singer and Clark 1999). Fibroblasts start to deposit and
remodel extracellular matrix, which initially consists of fibronectin and hyaluronan
but is later on replaced by proteoglycans and type I and III collagens (Toriseva and
Kahari 2009). The formation of new blood vessels is a critical component of to
granulation tissue formation. Angiogenesis is initially induced by tissue destruction
and hypoxia and is subsequently stimulated by various molecules such as basic
fibroblast growth factor, VEGF, and transforming growth factor-β, secreted by
macrophages, keratinocytes, and endothelial cells. A role of EPCs in granulation
tissue formation is directly suggested by experiments demonstrating that cell
therapy with EPCs enhances wound healing in mice (Suh et al. 2005). The release
of various growth factors such as VEGF and platelet-derived growth factor by EPCs
appears to enhance wound healing (Suh et al. 2005). Reepithelialisation is the term
used to describe the appearance of a new epithelial layer on top of a healing skin
wound. It is dependent on the formation of a provisional wound bed matrix and
involves the migration and proliferation of keratinocytes, the differentiation and
stratification of new epithelium, and finally the reformation of the basement
membrane.
Typical chronic cutaneous wounds are diabetic ulcers, ischaemic ulcers, and
pressure ulcers. Diabetic ulcers occur in patients with type 1 and type 2 diabetes,
whereas ischaemic ulcers are observed in patients with peripheral arterial diseases.
Pressure ulcers occur in patients with paralysis or in other conditions that inhibit
movement of body parts. Pressure ulcers or decubitus wounds typically occur on
sacrum, shoulder blades, and heels. Several factors contribute to deficient wound
healing in patients with diabetes: deficient growth factor production (Galkowska
et al. 2006), impaired neovascularisation (Galiano et al. 2004b), attenuated
keratinocyte and fibroblast proliferation and migration (Gibran et al. 2002), and
altered balance between extracellular matrix accumulation and remodelling of the
extracellular matrix by matrix metalloproteinases (Lobmann et al. 2002). Foot
ulcers occur in a diabetic population with a prevalence of 5 % and lifetime
incidence of 15 % (Abbott et al. 2002; Muller et al. 2002). Even with lege artis
treatment, amputation is required in 14–24 % of cases. Every 30 s, a lower limb is
lost due to diabetes. Approximately 85 % of these amputations are preceded by an
ulcer. Mortality is up to 50 % in the first 3 years after amputation. Various studies
show that costs to treat diabetic foot ulcers are extremely high, especially if
hospitalisation is required (Matricali et al. 2007).
HDL may beneficially affect wound healing by accelerating resolution of
inflammation, by enhancing granulation tissue formation involving increased
EPC incorporation and increased paracrine effects of EPCs, and by accelerating
reepithelialisation. Keratinocytes express SR-BI, and SR-BI expression is
upregulated in dividing keratinocytes (Tsuruoka et al. 2002). Whereas in humans
healing is primarily the result of reepithelialisation and granulation tissue forma-
tion, wound healing in mice occurs predominantly by wound contraction
(Greenhalgh 2003). In the excisional wound healing model (Galiano
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et al. 2004a), a circular full-thickness wound is applied on the back of each mouse.
Subsequently, a silicone splint is fixed around the wound with nylon sutures to
counteract wound contraction. Consequently, wound healing in this model occurs
by granulation tissue formation and reepithelialisation from the border. Granulation
tissue formation and reepithelialisation were significantly delayed in C57BL/6 apo
E/ mice compared to C57BL/6 mice (Gordts et al. 2014). Topical administration
of HDL (protein concentration 800 μg/ml; volume 80 μl) formulated in 20 %
pluronic F-127 gel (pH 7.2) every 2 days on wounds in C57BL/6 apo E/ mice
significantly improved granulation tissue formation and reepithelialisation. Wound
healing in mice treated with topical HDL therapy was very similar compared to
C57BL/6 mice. Topical gel without HDL did not enhance wound healing.
Improved wound healing induced by topical HDL therapy was also observed in
C57BL/6 mice with streptozotocin-induced diabetes mellitus and in male type
2 diabetic leptin receptor-deficient mice (unpublished data).
Further preclinical studies are required to evaluate the robustness of this strategy
in other models of delayed wound healing. However, murine models of diabetic
wound healing differ in many respects to clinical diabetic wound healing. They do
not take into account that there is a significant degree of heterogeneity of ulcers in
patients with diabetes. Three categories can be discerned: ‘purely neurotrophic’
diabetic ulcers, ‘purely ischaemic’ ulcers in patients with diabetes, and poorly
healing ulcers in diabetic patients with microangiopathy. The ‘purely neurotrophic’
diabetic ulcers heal well after off-loading. The ‘purely ischaemic’ ulcers should be
treated with revascularisation strategies. Typically, diabetic ulcers in patients with
more pronounced microangiopathy and macroangiopathy are characterised by
defects in granulation tissue formation and constitute a potential therapeutic area
for HDL-targeted therapies. However, no murine model can adequately mimic
these chronic diabetic ulcers. Decubitus wounds constitute another target for topical
HDL therapy but lack of adequate animal models hinders preclinical development.
7 Beneficial Effects of Selective HDL-Raising Gene Transfer
on Cardiac Remodelling and Cardiac Function After
Myocardial Infarction in Mice
Loss of myocardial tissue following acute myocardial infarction results in a
decreased systolic ejection and increased left ventricular end-diastolic volume
and pressure. The Frank-Starling mechanism, implying that an increased
end-diastolic volume results in an increased pressure developed during systole,
may help to restore cardiac output. However, the concomitant increased wall stress
may induce regional hypertrophy in the non-infarcted segment, whereas in the
infarcted area expansion and thinning may occur. Experimental animal studies
show that the infarcted ventricle hypertrophies and that the degree of hypertrophy
is dependent on the infarct size (Anversa and Sonnenblick 1990). Taken together,
architectural remodelling is characterised by the formation of a discrete collagen
scar, ventricular dilatation, and ventricular hypertrophy. This process may continue
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for weeks or months until the distending forces are counterbalanced by the tensile
strength of the collagen scar. Remodelling post-myocardial infarction is complex
since it involves the infarct area, the infarct border zone, and the non-infarcted
myocardium (Sutton and Sharpe 2000). Following myocardial infarction, dyski-
netic bulging may occur in infarct area. The myocardial fibres contiguous to this
segment in the infarct border zone become exposed to a more pronounced increase
in wall stress because of the more prominent change in the radius of curvature
induced by the regional dilatation. Cardiomyocytes in the border zone of the infarct
become larger than cardiomyocytes in the remote area of the ventricle. This is
consistent with the view that the infarct-induced stress on the chamber walls is an
important determinant of cardiomyocyte hypertrophy (Cohn 1993).
Post-infarct remodelling occurs in the setting of volume overload, since the
stretched and dilated infarcted tissue increases the left ventricular volume. An
increased ventricular volume not only implies increased preload (passive ventricu-
lar wall stress at the end of diastole) but also increased afterload (total myocardial
wall stress during systolic ejection). Afterload is increased since the systolic radius
is increased. Since both systolic and diastolic wall stress are increased, remodelling
and hypertrophy post-myocardial infarction are characterised by mixed features of
pressure overload and volume overload.
The myocardium consists of 3 integrated components: cardiomyocytes, extra-
cellular matrix, and capillary microcirculation. All 3 components are involved in
the remodelling process. The role of the extracellular matrix is distinct in the early
phase of remodelling (within 72 h) and the late phase (beyond 72 h). Neutrophil
infiltration of matrix metalloproteinases induces degradation of intermyocyte col-
lagen struts and cardiomyocyte slippage. This leads to infarct expansion
characterised by the disproportionate thinning and dilatation of the infarct segment
(Erlebacher et al. 1984). Infarct expansion predisposes to myocardial rupture and
congestive heart failure (Eaton et al. 1979; Erlebacher et al. 1982; Jugdutt and
Michorowski 1987; Schuster and Bulkley 1979). Increased wall stress as a result of
infarct expansion leads to mechanical stretch-elicited local angiotensin II release
and activation of a fetal gene programme (Sutton and Sharpe 2000). Local angio-
tensin II release promotes cardiomyocyte hypertrophy. In later stages of
remodelling, interstitial fibrosis is induced. Transforming growth factor-β1
transforms fibroblasts into myofibroblasts and induces activation of tissue inhibitors
of metalloproteinases and production of type I and type III collagen. The resultant
interstitial fibrosis negatively affects the diastolic properties of the heart.
Post-infarct ejection fraction is lower in patients with low HDL cholesterol
levels (Kempen et al. 1987; Wang et al. 1998). Although this could be due to
differences in atherosclerosis or in the microvasculature or could be related to a
decrease in infarct size due to beneficial effects of HDL in IRI, the possibility that
HDL beneficially affects infarct expansion and ventricular remodelling should be
considered. This can be investigated in models of permanent ligation of, e.g. the left
anterior descending coronary artery. An attenuation of post-infarct left ventricular
remodelling and improved infract healing was induced by infusion of rHDL once a
week for 4 weeks in rats following ligation of the proximal left coronary artery
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(Kiya et al. 2009). Interestingly, rHDL-treated rats also showed an increase of
phosphorylation of ERK1/2 in the left ventricular tissue, but not of p38 MAPK or
JNK (Kiya et al. 2009). Gordts et al. (2013) have recently shown that human apo
A-I gene transfer in C57BL/6 LDL receptor-deficient mice increases survival,
decreases infarct expansion, attenuates left ventricular dilatation, and improves
cardiac function following permanent ligation of the left anterior descending
coronary artery. Gene transfer in C57BL/6 LDL receptor-deficient mice was
performed with the E1E3E4-deleted adenoviral vector AdA-I, inducing
hepatocyte-specific expression of human apo A-I, or with the control vector Adnull.
A ligation of the left anterior descending coronary artery was performed 2 weeks
after transfer or saline injection. Permanent ligation of the left anterior descending
coronary artery excludes salutary coronary effects of HDL on myocardial salvage
as observed in models of IRI (Theilmeier et al. 2006). Consequently, the infarct area
and the area at risk were nearly identical at 24 h after ligation implying that the
initial increase in loading conditions was not different between human apo A-I gene
transfer myocardial infarction mice and control myocardial infarction mice. HDL
cholesterol levels were persistently 1.5 times ( p< 0.0001) higher in AdA-I mice
compared to controls. Survival was increased ( p< 0.01) in AdA-I myocardial
infarction mice compared to control myocardial infarction mice during the
28-day follow-up period (hazard ratio for mortality 0.42; 95 % CI 0.24–0.76).
Longitudinal morphometric analysis demonstrated attenuated infarct expansion
(reduced infract length and increased infarct thickness of the infarct in AdA-I
myocardial infarction mice) and inhibition of left ventricular dilatation in AdA-I
myocardial infarction mice compared to controls. AdA-I transfer exerted immuno-
modulatory effects and increased neovascularisation in the infarct zone. Increased
HDL after AdA-I transfer significantly improved systolic and diastolic cardiac
function post-MI and led to a preservation of peripheral blood pressure.
The effects of AdA-I transfer on remodelling have significant consequences for
the progressive development of heart failure. Ventricular dilatation increases the
loading conditions of the heart. After all, ‘preload’ at the organ level corresponds to
passive ventricular wall stress at the end of diastole (preloadLV¼ (EDPLV)
(EDRLV)/2WTLV where EDP is end-diastolic pressure, EDR is end-diastolic radius,
and WT is wall thickness). ‘Afterload’ at the organ level reflects myocardial wall
stress during systolic ejection (afterloadLV¼ (SPLV) (SRLV)/2WTLV where SP is
systolic pressure, SR is systolic radius, and WT is wall thickness). Thus, the
attenuation of infarct expansion and ventricular dilatation induced by increased
HDL is critical for long-term preservation of left ventricular function. Although an
increase of end-diastolic volume may be physiologically beneficial in terms of the
Frank–Starling mechanism, the increase in afterload in a larger ventricle is clearly
not beneficial. The increase in afterload corresponds at the cellular level to an
increase in tension that each muscle fibre must develop, and correspondingly,
oxygen consumption increases. In addition, ventricular hypertrophy may be
associated with an imbalance between the vascular and cardiomyocyte compart-
ment in the myocardium (Shimizu et al. 2010; Tirziu et al. 2007). Increased oxygen
consumption together with a decrease in relative vascularity may lead to tissue
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hypoxia, cardiomyocyte dysfunction, and late cardiomyocyte death. There was a
trend for a higher capillary density and a higher relative vascularity at day 28 in
AdA-I myocardial infarction mice compared to control myocardial infarction mice.
Taken together, ventricular dilatation initially produced by an external stimulus
(ligation of the left anterior descending coronary artery) induces a vicious cycle
where an increase of loading conditions leads to an intrinsic pathological heart
muscle (cardiomyopathy) characterised by cardiomyocyte death and dysfunction
(reduced intrinsic myocardial contractility and relaxation), collagen deposition, and
progressive dilatation of the heart. Although no follow-up was performed in the
current study after 28 days, we speculate that differences in ventricular function
between control MI mice and human apo A-I gene transfer MI mice will be more
marked after longer follow-up.
Neovascularisation may play a role in scar formation and scar tissue remodelling
(Wang et al. 2005). Increased neovascularisation was observed in the infarcts of
AdA-I myocardial infarction mice at day 28 after gene transfer. HDL exerts potent
effects on the endothelium. These effects occur via enhanced endothelial survival
(Nofer et al. 2001), endothelial cell migration (Seetharam et al. 2006), and
EPC-mediated repair (Feng et al. 2009a, b; Tso et al. 2006). Beneficial effects on
EPCs may have contributed to improved infarct healing.
Taken together, attenuation of remodelling following human apo A-I gene
transfer may be considered to constitute the cardiac equivalent of enhanced
wound healing and tissue repair induced by HDL.
Conclusions
One of the pitfalls in the field of HDL-targeted interventions is the lack of
selective HDL-raising drugs. The development of gene transfer technologies
with a sufficiently high therapeutic index may pave the road for a selective and
effective HDL-targeted therapeutic intervention (Jacobs et al. 2012; Van
Craeyveld et al. 2010). Nathwani et al. (2011) performed a landmark study
that demonstrated for the first time long-term expression of a transgene product
at therapeutic levels following systemic hepatocyte-directed gene transfer in
humans. In this study (Nathwani et al. 2011), haemophilia B was successfully
treated with an adeno-associated viral serotype 8 human FIX expressing vector.
These seminal data highlight that hepatocyte-directed adeno-associated viral
serotype 8 gene transfer may become a clinical reality in the next decades.
The recent positive assessment by the European Medicines Agency’s Committee
for Medicinal Products for Human Use of the marketing authorisation for the
first gene transfer product in Europe (alipogene tiparvovec (Glybera®))
highlights an important paradigm shift by regulatory agencies, as well as the
biotechnological entrepreneurs and investors. Nevertheless, there is no short-
term perspective for widespread clinical use of gene transfer technologies.
Three modalities discussed in this review are selective HDL-targeted
therapies: infusion of rHDL, human apo A-I gene transfer, and topical HDL
therapy. The main strategic questions with regard to HDL-targeted therapies are
related to the choice of therapeutic areas in which a real clinical difference could
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be made. These questions are inextricably linked to the current state of the art of
evidence-based medicine. Since a significant part of this review is focused on
heart failure, we will illustrate this point on the basis of a very significant
dichotomous classification of these patients.
Among patients with hospitalised heart failure, approximately 50 % have
heart failure with reduced ejection fraction (HFrEF), and 50 % have heart failure
with preserved ejection fraction (HFpEF) with the proportion of patients with
HFpEF increasing with time (Liu et al. 2013; Vaduganathan and Fonarow 2013).
The cutoff value for preserved ejection fraction is 0.5. Most clinical heart failure
trials have been focused on patients with HFrEF. Inhibition of the renin-
angiotensin-aldosterone and sympathetic nervous systems improves survival
and decreases hospitalisations in patients with HFrEF (Reed et al. 2014). In
contrast to these significant advances in treatment and reduction in mortality
in patients with HFrEF, drug strategies with strong evidence in HFrEF have
proved unsuccessful in HFpEF, and the mortality in patients with HFpEF has
remained unchanged (Liu et al. 2013). HFpEF is a complex clinical syndrome
that is characterised by classical heart failure symptoms with increased left
ventricular filling pressures and preserved left ventricular ejection fraction.
Increased end-diastolic ventricular stiffness is observed in HFpEF, but the
exact mechanisms that induce HFpEF are unknown. This heart failure subtype
disproportionately affects women and the elderly and is commonly associated
with other cardiovascular comorbidities, such as hypertension and diabetes.
Most therapeutic gains can likely be made in the field HFpEF. Interestingly,
human apo A-I gene transfer has been shown to improve diastolic function in
C57BL/6 LDL receptor-deficient mice (Gordts et al. 2012). The same strategic
questions should also be raised in relation to the role of HDL in prevention and
treatment of coronary artery disease. One might speculate that perspectives for
an HDL-targeted therapy in patients with stable coronary artery disease are
limited, whereas beneficial coronary and myocardial effects in the setting of
acute coronary syndromes may still constitute a window of opportunity.
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Abstract
The main lifestyle interventions to modify serum HDL cholesterol include
physical exercise, weight loss with either caloric restriction or specific dietary
approaches, and smoking cessation. Moderate alcohol consumption can be
permitted in some cases. However, as these interventions exert multiple effects,
it is often difficult to discern which is responsible for improvement in HDL
outcomes. It is particularly noteworthy that recent data questions the use of HDL
cholesterol as a risk factor and therapeutic target since randomised interventions
and Mendelian randomisation studies failed to provide evidence for such an
approach. Therefore, these current data should be considered when reading and
interpreting this review. Further studies are needed to document the effect of
lifestyle changes on HDL structure–function and health.
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Abbreviations
ABC Adenosine triphosphate-binding cassette transporter
Apo Apolipoprotein
CVD Cardiovascular disease
CETP Cholesteryl ester transfer protein
HL Hepatic lipase
HDL-C High-density lipoprotein cholesterol
LCAT Lecithin–cholesterol acyltransferase
LDL-C Low-density lipoprotein cholesterol
LPL Lipoprotein lipase
Lp-PLA2 Lipoprotein-associated phospholipase A2
MUFA Monounsaturated fatty acids
PLTP Phospholipid transfer protein
PON1 Paraoxonase 1
PUFA Polyunsaturated fatty acids
RCT Reverse cholesterol transport
SFA Saturated fatty acids
SR-BI Scavenger receptor class-BI
TAG Triacylglycerol
570 J.C. Escolà-Gil et al.
1 HDL and Diet
The landmark cross-cultural and migration studies of Ancel Keys in the 1950s were
the first to identify associations between serum HDL cholesterol (HDL-C) and diet
and lifestyle factors in free-living populations (Keys 1980a). These early studies
laid the foundation for the development of the diet–heart hypothesis, by revealing
links between the incidence of coronary heart disease, raised serum cholesterol and
energy derived from saturated fat. They also helped to establish diet as a determi-
nant of low HDL in obesity (Keys 1980b). It has been established that certain
dietary saturated fatty acids (SFA), with a chain length of between 12 and
16 carbons, and dietary cholesterol can increase both serum low-density lipoprotein
cholesterol (LDL-C) and, somewhat paradoxically with respect to cardiovascular
disease (CVD) risk, HDL-C (Grundy and Denke 1990). Conversely, the replace-
ment of SFA with either polyunsaturated (PUFA) or monounsaturated fatty acids
(MUFA) has been shown to reduce serum HDL-C. Moreover, the replacement of
dietary fat with carbohydrate has also been shown to produce significant reductions
in serum HDL-C (Katan et al. 1997; Stanhope et al. 2013). Heightened awareness of
the risk associated with dietary sugars in the early 1970s (Yudkin 1972) has
resurfaced recently, in part, through escalation of obesity-related cardiometabolic
risk and increased understanding of how extrinsic sugars influence HDL by
adversely affecting the metabolism of triacylglycerol (TAG) (Lustig 2010). The
history of diet and HDL has evolved in the era of the LDL-lowering statins, which
are relatively ineffective in raising HDL-C, and leave behind what is often
described as untreated ‘residual risk’ (Belsey et al. 2008). This situation has created
a need for alternative HDL-targeted drugs and also increased awareness of the
importance of diet as a modifier of HDL structure and function.
1.1 Effects of Substituting Dietary Saturated Fatty Acids
Serum HDL-C has been shown to be influenced by both the amount and quality of
dietary fatty acids and carbohydrate. In the past, the relative effects of dietary fatty
acids on HDL-C have been described in absolute terms, that is, SFA tends to raise
HDL-C, whilst PUFA, trans fatty acids and carbohydrate, all tend to reduce
HDL-C, with MUFA being relatively neutral (Grundy and Denke 1990). However,
in reality the absolute effect of fatty acids, or any macronutrient, on HDL-C cannot
be measured, as its addition or replacement may be counter-affected by whatever
fatty acid or carbohydrate takes its place to maintain a feasible diet. This phenome-
non of substitution limits the ability to interpret the impact of dietary
macronutrients on HDL and CVD risk to ‘relative’, rather than ‘absolute’ effects.
Meta-analyses of intervention studies have provided strong evidence to show that
the iso-energetic replacement of SFA with PUFA, MUFA and carbohydrate
decreases HDL-C, with carbohydrate exerting the greatest impact in lowering
both HDL-C and the total cholesterol–HDL-C ratio (Mensink et al. 2003). In
contrast, the iso-energetic replacement of carbohydrate with all dietary fatty
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acids, other than trans fatty acids, tends to raise HDL-C (Micha and Mozaffarian
2010). Estimates for the relative magnitude of change in the concentration of serum
HDL-C in response to these dietary substitutions are directly proportional to the
amount of energy being exchanged. An iso-energetic exchange of 5 % energy from
carbohydrate to SFA, MUFA and PUFA is associated with increases in HDL-C of
0.05, 0.04 and 0.03 mmol/L, respectively, with trans fatty acids reducing HDL by
0.02 mmol/L. In addition, individual SFA is known to exert differential effects on
serum HDL-C, so that replacing 5 % energy as carbohydrate with lauric, myristic,
palmitic and stearic, increases HDL-C by 0.13, 0.09, 0.05 and <0.01 mmol/L,
respectively. These associations between dietary fatty acids and serum HDL-C are
statistically robust and have been used to formulate dietary guidelines. However,
because they rely heavily upon data from measures of dietary intake, as estimated
from dietary recall, food frequency questionnaires or diet diaries, this can limit their
value in predicting the biological effects of complex foods on HDL (Astrup
et al. 2011). In other words, foods are not single nutrients, but complex mixtures
of nutrients within a food matrix, all of which interact together to produce a
biological effect. Because a food is rich in one particular fatty acid, it does not
mean that consumption of this food will result in an effect on HDL that is typical of
that fatty acid.
1.2 Dietary MUFA
Interest in the potential health benefits of dietary MUFA originated from the use of
olive oil in the Mediterranean diet. Whilst substitution of SFA with MUFA is less
effective in lowering LDL cholesterol than n-6 PUFA, there is evidence to suggest
that this substitution may be more effective in preventing the decrease in HDL-C
that accompanies the removal of SFA (Schwingshackl and Hoffmann 2012). This
finding is supported by data to show that MUFA is relatively less effective in
stimulating cholesteryl ester transfer protein (CETP), and thus the remodelling and
increased clearance of HDL from serum, than either SFA or n-6 PUFA (Groener
et al. 1991; Lagrost et al. 1999). This finding is in accord with data from a recent
study which concluded that dietary MUFA reduced the catabolic rate of the
principal apolipoprotein (apo) in HDL, apo A-I (Labonte et al. 2013).
1.3 n-3 Polyunsaturated Fatty Acids
The principal essential fatty acid of the n-3 series, α-linolenic acid (18:2) is the most
abundant fatty acid on earth, but is consumed in significantly less quantity by
humans than linoleic acid (18:2 n-6) (National Diet and Nutrition Survey. Depart-
ment of Health 2011). When fed in physiologically relevant amounts, α-linolenic
acid has been shown to be equivalent to linoleic acid as a substitute for SFA in
lowering LDL cholesterol (Harris 1997). However, even though a recent meta-
analysis indicated a benefit of α-linolenic acid intake on CVD risk (Pan et al. 2012),
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human interventions with α-linolenic acid-enriched diets have shown variable
effects on serum HDL-C (Harper et al. 2006; Goyens and Mensink 2006; Kaul
et al. 2008; Griffin et al. 2006). The longer-chain derivatives of α-linolenic acid,
chiefly eicosapentaenoic and docosahexaenoic acids (EPA, DHA), which in
humans are mainly obtained directly from oily fish, exert only a moderate elevating
effect on HDL-C (Harris 1989). This is perhaps surprising given the potent
TAG-lowering effect of these long-chain fatty acids.
1.4 Carbohydrate and Extrinsic Sugars
The replacement of dietary fat with carbohydrate in low-fat, high-carbohydrate
diets has long been associated with a reduction in serum HDL-C that may be linked
to the carbohydrate-induced increase in TAG (Katan et al. 1997). The latter is
known to promote lipid exchanges between HDL- and TAG-rich lipoproteins that
remodel HDL into smaller and denser particles with an increased catabolic rate and
thus reduced residence time in serum. Adverse effects of carbohydrate on HDL-C in
the longer term may also be mediated through increased body weight and the
accumulation of body fat (Stanhope et al. 2013). Whilst the reduction in HDL-C
has been attributed to diets with a high glycaemic index (Frost et al. 1999), there is
now little doubt that the extrinsic sugars, sucrose and fructose make a major
contribution to this effect (Lustig 2010). The findings of a recent meta-analysis
which concluded that a very high intake of fructose (>100 g/d) increases serum
LDL cholesterol, but has no significant effects on HDL-C, are somewhat surprising
in both respects (Zhang et al. 2013) and in contrast to the outcome of dietary
interventions with beverages sweetened with fructose. One example of the latter
showed marked increases in cardiometabolic risk factors, including significant
reductions in serum HDL-C, relative to glucose-sweetened beverages (Stanhope
et al. 2009). A vital question to be answered is whether populations are consuming
amounts of extrinsic sugars which are sufficient to elicit these adverse changes in
HDL in the long term. Dietary intakes in the United Kingdom (National Diet and
Nutrition Survey. Department of Health 2011) indicate that the upper 2.5th percen-
tile of the population may be approaching intakes of extrinsic sugars which have the
potential to induce adverse effects on metabolism and increase body weight. The
overconsumption of sweetened beverages in adolescents is of particular concern in
promoting premature obesity and lowering of HDL-C, as shown in a recent
Australian study (Ambrosini et al. 2013).
1.5 Effects of Dietary Fatty Acids and Cholesterol on HDL
Function
HDL-C is a surrogate marker of HDL particle size and number and may convey
little or no information about the anti-atherosclerotic properties of HDL in the
process of reverse cholesterol. There is evidence to suggest that paradoxical
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increase in HDL-C induced by dietary SFA and cholesterol in mice (Escola-Gil
et al. 2011) and in egg-fed humans (Andersen et al. 2013) results in a beneficial
increase in cholesterol efflux capacity. Beneficial effects of dietary fatty acids on
cholesterol efflux capacity have also been described for EPA and DHA supplemen-
tation in hamsters (Kasbi Chadli et al. 2013) and MUFA-rich extra-virgin olive oil
consumption in humans (Helal et al. 2013). Conversely, several intervention studies
in humans showed no effect on cholesterol efflux capacity of replacing of SFA with
either PUFA (Kralova Lesna et al. 2008) or carbohydrate (De Vries et al. 2005), or
differences between diets enriched with trans fatty acids (8.3 % energy), SFA
(13.2 % energy) and PUFA (14.6 %) elicited by either total plasma HDL or HDL
subfractions (Buonacorso et al. 2007).
In conclusion, evidence from meta-analyses to support the relative effects of
dietary fatty acids on HDL-C may be statistically incontrovertible, but they do not
necessarily translate directly to the effects of complex foods and diets on HDL-C
and CVD risk. Reduction in HDL-C induced by the overconsumption of dietary
extrinsic sugars in sugar-sweetened beverages may have major implications for
cardiometabolic health, especially in adolescents. Finally, evidence for the effects
of dietary components on the anti-atherogenic, functional properties of HDL is
inconclusive and warrants further study.
2 Weight Loss
Obesity, defined as an excess of body fat, is a major health problem in Western
societies (Tchernof and Despres 2013; Bays et al. 2013). Excess body fat is also an
independent risk factor for CVD (Tchernof and Despres 2013). Excessive adipose
tissue accumulation, but more importantly its distribution in the body, particularly
visceral obesity, has been identified as a main correlate of cardiometabolic
disorders including not only alterations in glucose tolerance and insulin sensitivity
but also in blood lipids, including HDL-C.
2.1 Impact of Adiposity on HDL Concentration and Function
Abnormally low plasma HDL-C concentrations accompany hypertriacylgly-
cerolaemia and are a common trait in many obese subjects that contributes to the
development of atherosclerosis (Bays et al. 2013; Tchernof and Despres 2013). In
obesity, the low plasma HDL-C concentration has been mainly attributed to
increased HDL clearance, in part, due to enhanced uptake of HDL by adipocytes
(Wang and Peng 2011; Rashid and Genest 2007). Plasma concentrations of larger
HDL particles are decreased in patients with high cardiovascular risk (Pirillo
et al. 2013) and, similarly, appear to be low in overweight and obese subjects
(Tian et al. 2006, 2011). Moreover, a switch towards a higher proportion of smaller
HDL particles in relation to larger HDL has been reported in the plasma of obese
subjects with ectopic fat and dysfunctional adipose tissue (Tchernof and Despres
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2013). Obesity is commonly associated with increased oxidative stress (Wang and
Peng 2011), and, in this context, there may be impairment of HDL functions,
including reverse cholesterol transport and protection against lipoprotein oxidation.
In this regard, the ability of HDL to mediate cholesterol efflux from cells, which is
considered the first step of reverse cholesterol transport (RCT) (Escola-Gil
et al. 2009), is reduced in the obese (Sasahara et al. 1998; Vazquez et al. 2012).
In addition, although the protection against LDL oxidation conferred by HDL has
not been assessed to date, the antioxidant action of apoA-I has been reported to be
attenuated in scenarios of increased oxidative stress (Kontush and Chapman 2010),
such as that present in obesity (Wang and Peng 2011). Other HDL-associated
proteins such as paraoxonase 1 (PON1) and lipoprotein-associated phospholipase
A2 (Lp-PLA2), which are also main contributors to the antioxidant properties of
HDL (Kontush and Chapman 2010), have been found to be altered in obesity (Seres
et al. 2010; da Silva et al. 2013).
2.2 Effect of Weight-Loss Therapies on HDL Concentration
and Function
Weight loss has been widely thought to be an effective means of achieving a
substantial reduction in cardiometabolic risk (Vest et al. 2012). Obesity-associated
metabolic disorders can, in theory, be treated by lifestyle modifications including
reduced energy intake and/or increased regular, moderate physical activity (Sacks
et al. 2009; Bays et al. 2013). A further strategy to achieve excess weight loss in
severely obese patients is bariatric surgery (Bays et al. 2013). In particular, the
Roux-en-Y gastric bypass (RYGBP) has been reported to induce a sustained weight
reduction without relapse in morbidly obese patients. In contrast, the metabolic
results of lifestyle interventions are variable and insufficient to achieve sustained
weight loss (Vest et al. 2012; Bays et al. 2013), whilst surgery has been shown to
stably improve the lipid profile in most randomised, prospective trials (Bays
et al. 2013; Vest et al. 2012). However, in both approaches, only modest effects
on plasma HDL-C concentrations were reported in most recent systematic reviews
and meta-analyses of stabilised weight-loss clinical trials which examined the
effects of different dietary (Bays et al. 2013; Chapman et al. 2011; Dattilo and
Kris-Etherton 1992; Hu et al. 2012; Sacks et al. 2009; Schwingshackl and
Hoffmann 2013; Singh et al. 2007; Poobalan et al. 2004) or bariatric surgery
programmes (Bays et al. 2013; Vest et al. 2012; Poobalan et al. 2004). There are
few reports directly assessing the effect of weight reduction on HDL remodelling
and its relationship, if any, with its anti-atherogenic properties. In this regard, recent
studies showed that weight loss exerts beneficial changes in HDL subpopulations in
the obese (Aron-Wisnewsky et al. 2011; Asztalos et al. 2010), leading to a switch
towards predominantly larger HDL particles and increased circulating plasma HDL
mass despite no significant impact on plasma HDL-C concentrations. Interestingly,
in one of these studies, an elevation in HDL mass was strongly associated with an
increased capacity of sera from postoperative patients to mediate cholesterol efflux
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via adenosine triphosphate-binding cassette transporter (ABC) G1 and scavenger
receptor class-BI (SR-BI) pathways, relative to baseline values (Aron-Wisnewsky
et al. 2011), thus suggesting that the removal of excess cholesterol from cells by
HDL particles might be enhanced after surgery. Excess weight loss also improves
oxidative stress (Uzun et al. 2004; Gletsu-Miller et al. 2009; Rector et al. 2007).
However, whilst the impact of weight loss on HDL’s antioxidant properties in
severely obese patients undergoing bariatric surgery has been reported in observa-
tional studies, it has not yet been examined in detail (Gletsu-Miller et al. 2009). For
instance, increased PON1 activity levels have been found in serum of patients
undergoing gastric surgery (Uzun et al. 2004), whereas the Lp-PLA2 mass concen-
tration did not change in another study (Hanusch-Enserer et al. 2009). Given that
the distribution of Lp-PLA2 activity between serum lipoproteins is still uncertain,
and evidence to suggest that Lp-PLA2 may be anti-atherogenic when associated
with HDL (Kontush and Chapman 2010), it is reasonable to speculate that the
increase in plasma concentration of larger HDL particles following weight loss
might lead to a proportional increase in anti-atherogenic HDL-associated Lp-PLA2.
Taken together, HDL changes may, in part, account for the significant improve-
ment in the cardiovascular risk observed in obese patients after weight reduction.
Thus, in summary, weight loss has long-term beneficial effects on plasma lipids in
the obese. Regarding the plasma concentration of HDL-C, the impact of lifestyle
interventions appears to be variable and modest in response to different weight-loss
treatments. However, data on the effect of weight-reducing lifestyle interventions
on the functional properties of HDL are scant. Bariatric surgery is becoming a
frequent approach for reducing adiposity and improving the lipid profile in the
severely obese. The excess weight loss following intervention may provide an
interesting scenario for assessing the potential favourable changes in HDL
remodelling and functionality.
3 Effects of Regular Aerobic Exercise
Sedentary behaviour is a major health problem that is associated with increased
cardiometabolic risk. Regular aerobic physical activity results in improved exercise
performance which depends on an increased ability to utilise oxygen to derive
energy for work. These effects usually require exercise intensities ranging from
40 to 85 % of maximal oxygen consumption (VO2 max) or heart rate reserve, with
higher exercise intensities being necessary for higher levels of initial fitness, and
vice versa (Chapman et al. 2011).
3.1 Effects of Exercise on HDL
Regular aerobic physical activity has a positive effect on many of the established
risk factors for CVD by causing a long-lasting reduction in TAGs by up to 20 % and
increasing HDL-C by up to 10 %. It also increases the size of LDL and HDL
particles. All these changes are considered potentially protective against
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atherosclerosis (Kraus et al. 2002; Tall 2002). Given the close interrelation between
plasma TAG-rich particles and HDL, changes in HDL-C after regular aerobic
exercise are probably dependent on an increased HDL synthesis induced by raised
TAG lipolysis (Tall 2002; Olchawa et al. 2004) and, perhaps, also on a reduced
HDL catabolism secondary to decreased hepatic lipase (HL) activity (Bergeron
et al. 2001).
The effect of physical activity on TAG levels varies depending on baseline
TAGs and exercise characteristics such as intensity, caloric expenditure and dura-
tion (Chapman et al. 2011; Miller et al. 2011; Kraus et al. 2002; Kodama
et al. 2007). The reduction in plasma TAGs of 20 % induced by daily exercise
was similar to that obtained by caloric restriction in nonobese subjects (Fontana
et al. 2007). Daily exercise blocked, at least in the short term, the increase in TAGs
induced by a high-carbohydrate diet in healthy postmenopausal women (Koutsari
et al. 2001). Even with a variable adherence to diet, exercise did have a significant
effect on plasma TAG and HDL-C levels (Huffman et al. 2012). In healthy,
non-smoking men, the increase in HDL-C was dependent on exercise intensity
(for instance, miles run per week) (Kokkinos et al. 1995; Tambalis et al. 2009;
Duncan et al. 2005), thus suggesting a dose–response relationship. Between 1,200
and 2,200 Kcal of energy expenditure per week (15–20 miles/week of brisk walking
or jogging) has been estimated to be the threshold for obtaining a significant change
in plasma TAGs and HDL-C (Durstine et al. 2002). The TAG decrease was greater
in individuals with fasting TAGs >1.69 mmol/L than in those with TAGs
<1.69 mmol/L (Couillard et al. 2001). HDL-C increased, particularly in men
with TAGs >1.69 mmol/L and low HDL-C, compared with those with low
HDL-C and TAGs <1.69 mmol/L, and was associated with a reduction in abdomi-
nal adipose tissue (Couillard et al. 2001). This improvement may have been
associated with decreased insulin resistance, adiposity and TAG levels, at least in
part, through increased fatty acid oxidation by the muscle under the control of Rev-
erb-alpha (Tall 2002; Woldt et al. 2013). Whilst data regarding the changes in HDL
functionality induced by regular aerobic training are to date scant and inconsistent,
there is evidence to implicate beneficial changes in some functions of HDL (Iborra
et al. 2008; Kazeminasab et al. 2013; Meissner et al. 2010, 2011).
3.2 Effects of Exercise on Prevention and Treatment
of Cardiometabolic Risk
Obviously, exercise exerts many different effects at a molecular level, rendering it
very difficult to attribute the final effects on disease prevention or treatment to one
effect, including HDL-C.
Several prospective cohort trials have shown a reduction in the risk of type
2 diabetes in individuals participating in physical activity of moderate intensity
compared with being sedentary (Wing 2010; Uusitupa et al. 2009). This difference
was also found in people who walked regularly (typically >2.5 h of brisk walking)
(reviewed by Jeon et al. 2007).
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Regular aerobic exercise is widely considered an important tool for primary and
secondary cardiovascular prevention since it is thought to reduce the risk of fatal
and nonfatal events in the general population (Chapman et al. 2011; Heran
et al. 2011). Although the volume of moderate-intensity physical activity able to
provide a reduction in cardiovascular mortality was initially considered to range
from 2.5 to 5 h/week, similar results appear to be obtainable with 1–1.5 h/week of
vigorous-intensity or a combination of vigorous- and moderate-intensity exercises
(Wen et al. 2011; Sattelmair et al. 2011). However, a systematic review of exercise-
based rehabilitation found a decrease in total and cardiovascular mortality but no
difference in the number of new myocardial infarctions (Heran et al. 2011). Further,
the Look AHEAD Trial which had, as a goal, to achieve and maintain a weight loss
of at least 7 % by both reducing caloric intake and increasing physical activity in
type 2 diabetic patients found no reduction in cardiovascular events in a 10-year
follow-up (Wing et al. 2013). Similar negative results were obtained by the Finnish
Diabetes Prevention Study after a 10-year lifestyle intervention (diet + exercise) in
middle-aged, overweight people with impaired glucose tolerance (Uusitupa
et al. 2009). To interpret these discrepant results, one has to consider differences
in patient disease (type 2 diabetes versus established coronary artery disease) versus
the general population, follow-up time and patient intervention type(s) (Sattelmair
et al. 2011; Wen et al. 2011; Heran et al. 2011; Uusitupa et al. 2009).
Exercise improved the components of the metabolic syndrome in affected
patients (Pattyn et al. 2013). In patients with established type 2 diabetes mellitus
included in the Look AHEAD Trial, increased physical activity had beneficial
effects on glycaemic control and cardiovascular risk factors, including HDL-C
and TAGs (Wing 2010). However, in other studies, aerobic and/or resistance
training was shown to improve glycaemic control, but did not change HDL-C or
TAGs in adults with type 2 diabetes (Sigal et al. 2007). There were major
differences in the number of patients and follow-up time between studies that
should be considered when interpreting these different results (Wing 2010; Sigal
et al. 2007). Furthermore, one study included a hypo-caloric diet together with
exercise (Wing 2010), whereas the other only included exercise (Sigal et al. 2007).
In summary, there appears to be a consensus that regular aerobic exercise raises
HDL-C in a way closely related to plasma TAG reduction. Regular aerobic exercise
may prevent type 2 diabetes and CVD, probably with more intensity in primary than
in secondary prevention. In particular, aerobic exercise does not seem to prevent
CVD in patients with established type 2 diabetes. The role of exercise-induced
changes in HDL in these outcomes is largely unknown.
4 Smoking Cessation
Smoking is a well-documented risk factor for CVD that is amenable to intervention.
A potential mechanism for the atherogenic effect of cigarette smoke is via plasma
HDL. Most research to date has looked at smoking effects on HDL-C concentration
rather than HDL structure or function. One issue that is particularly difficult to
address in observational smoking research is the presence of confounding lifestyle
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behaviours that may cluster with smoking behaviour (such as low physical activity,
poor diet and increased alcohol consumption). Thus, comparison of the properties
of HDL isolated from smokers and non-smokers does not allow direct causal
relationships to be determined, and there is a need for more direct experimental
approaches to dissect the biological effects of smoking and to identify specific
mediating factors (i.e. the combustible products of tobacco such as nicotine, carbon
monoxide and other gaseous products and free radicals). To further complicate the
issue, smoking has effects on TAG metabolism, via increased sympathetic drive,
insulin resistance or both, leading to increased plasma TAG concentrations and
consequent remodelling effects of plasma HDL resulting in higher plasma turnover
[reviewed in Freeman and Packard (1995)].
4.1 Smoking and HDL-C Concentration
Ameta-analysis carried out almost 25 years ago indicated that smoking has a strong
independent effect on plasma HDL-C levels with smokers having on average 6 %
lower HDL-C concentrations compared to non-smokers (Craig et al. 1989). A more
recent meta-analysis, which compared within individual differences before and
after stopping smoking, indicated that the absolute HDL-C concentration difference
was between 0.06 and 0.11 mmol/L (Forey et al. 2013). There also appears to be a
larger smoking effect in women than men (Freeman and Packard 1995). HDL-C
concentrations rise after stopping smoking and fall on restarting, and the magnitude
of the effect on HDL-C is related to the number of cigarettes smoked (Fortmann
et al. 1986; Moffatt et al. 1995; Stubbe et al. 1982; Tuomilehto et al. 1986). There
are no long-lasting effects of smoking on HDL-C concentration after cessation
(Forey et al. 2013), and there is no association between number of years stopped
and plasma HDL-C (Wilson et al. 1983). Passive smoking is also associated with
lower plasma HDL (Moffatt et al. 1995; Neufeld et al. 1997), and a reduction in
HDL-C has been observed acutely only 6 h after exposure to environmental tobacco
smoke (Moffatt et al. 2004). The reduction in plasma HDL-C levels appears to be
limited to a 0.15 mmol/L reduction in the larger HDL2 particles, independent of
confounders, as determined by analytical ultracentrifugation (Freeman et al. 1993).
This has been confirmed by others (Moriguchi et al. 1991; Shennan et al. 1985;
Moffatt et al. 2004), although one study attributed the acute effects of smoking to
the smaller HDL3 fraction (Gnasso et al. 1984). Plasma apoA-I levels are also 6 %
lower in smokers (Craig et al. 1989), and in some studies apoA-II has also been
shown to be reduced in smokers (Berg et al. 1979; Haffner et al. 1985) and
ex-smokers (Richard et al. 1997).
4.2 Potential Mechanisms for the Smoking-Related
Reduction in HDL-C
Because of the intrinsic link between plasma TAG and HDL metabolism,
demonstrated by their negative association in populations, and the biological effects
of smoking on plasma TAG metabolism (Freeman and Packard 1995), it is likely
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that changes in plasma HDL-C concentration could be an indirect effect of
smoking-related increases in plasma TAG concentration. Indeed, much of the effect
of smoking on plasma HDL is lost after statistical correction for changes in plasma
TAGs (Freeman et al. 1993; Phillips et al. 1981). Cigarette smoking affects the
activities of plasma enzymes involved in regulating HDL size and turnover:
lecithin–cholesterol acyltransferase (LCAT) (Freeman et al. 1998; Haffner
et al. 1985) and lipoprotein lipase (LPL) (Freeman et al. 1998; Elkeles
et al. 1983) activities are reduced, whilst HL (Moriguchi et al. 1991) and CETP
(Dullaart et al. 1994) activities are increased. These changes result in a shift in the
size distribution of HDL into smaller particles which have increased clearance from
the plasma compartment (Brinton et al. 1994). However, there is a residual effect of
smoking after correction for changes in plasma TAG, suggesting TAG-independent
effects of smoking on plasma HDL concentration also exist. These
TAG-independent effects appear to be more important in men than women (Free-
man et al. 1993).
There is evidence for structural/compositional changes in HDL brought about by
smoking. Ex vivo experiments, in which human plasma was acutely exposed to
cigarette smoke, resulted in cross-linking of apoA-I and apoA-II (McCall
et al. 1994) that may impair activation of LCAT. Similarly, chemically cross-
linked HDL has an increased clearance in rodents (Senault et al. 1990). Smoking
is associated with a reduction in the HDL content of Lp-PLA2, an enzyme thought
to play an anti-atherogenic role in HDL (Tselepis et al. 2009). Early studies showed
that chronic inhalation of cigarette smoke in pigeons inhibits liver HDL uptake
(Mulligan et al. 1983). Recent data have shown that a by-product of cigarette
smoking, benzo(a)pyrene, inhibited apoA-I synthesis in HepG2 cells, via activation
of the aryl hydrocarbon nuclear steroid receptor, whilst nicotine had no effect
(Naem et al. 2012). Modelling of the monocyte transcriptome in smokers compared
to non-smokers identified SLC39A8 to be on a causal pathway between smoking
and plaque formation (Verdugo et al. 2013). This gene is known to be associated
with the cellular uptake of cadmium from tobacco and was negatively associated
with HDL cholesterol levels in this study.
There are very few studies on the effects of smoking on HDL function. HDL
isolated from smokers showed reduced ability to induce cholesterol efflux from
macrophages, possibly via apoA-I-mediated effects (Kralova Lesna et al. 2012). Ex
vivo cigarette smoke treated HDL, which resulted in an increased conjugated diene
and denatured apoA-I content, reduced the efflux capacity of HDL to a level similar
to that of copper-oxidised HDL (Ueyama et al. 1998). Co-incubation with superox-
ide dismutase prevented approximately half of the impairment and reduced the
level of conjugated dienes, but not the apoA-I denaturation. There is also some
evidence that plasma thiocyanates found in high levels in smokers could cause HDL
oxidation and reduced apoA-I cholesterol efflux ability (Hadfield et al. 2013).
Smoking is associated with reduced activity and concentration of PON1, an
HDL-associated antioxidant enzyme, effects which are reversed after smoking
cessation (James et al. 2000). The mechanistic data for the effects of smoking on
HDL function are far from comprehensive and merit further investigation.
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4.3 Smoking Cessation Intervention to Increase Plasma HDL
Concentration
The majority of smoking cessation studies are small, and most, but not all, have
been shown to result in a rise in HDL concentration. A meta-analysis of 27 studies
incorporating over 6,000 subjects indicated that HDL-C increased by 0.10 mmol/L
after smoking cessation, whilst plasma total cholesterol, LDL-C and TAG did not
change (Maeda et al. 2003).
A number of lifestyle changes may also occur when smokers cease smoking, and
at least one study has shown that the rise in HDL after smoking cessation is not
independent of the change in diet (Quensel et al. 1989b). However, refuting this, a
recent large randomised, double-blind controlled trial was carried out in over 1,500
smokers smoking an average of 21 cigarettes per day (Gepner et al. 2011). Patients
were randomised to one of six treatments: nicotine lozenge, nicotine patch,
sustained-release bupropion, nicotine patch plus nicotine lozenge, sustained-release
bupropion plus nicotine lozenge, or placebo. Of the 923 participants who returned
after 1 year intervention, 36 % who had stopped smoking showed a significantly
greater rise in HDL-C than those who did not, despite gaining an average of 4 kg
more weight than those who continued to smoke. The effects of smoking cessation
in this study were particularly evident in women.
Transdermal nicotine replacement therapy is a commonly used approach to
support smoking cessation. A small study was carried out to compare the effects
of transdermal nicotine patches, used as part of a smoking cessation intervention, on
plasma HDL-C levels (Moffatt et al. 2000). Subjects who used transdermal nicotine
patches over 35 days showed no improvement in HDL-C concentration. However,
if the use of patches was then stopped, HDL-C concentrations rose to normal,
non-smoking levels over the next 42 days. Others have observed contrasting effects
in a larger study where smoking cessation, accompanied by the use of higher-dose
nicotine transdermal patches, resulted in an immediate increase in HDL, whereas in
contrast, low-dose nicotine did not (Allen et al. 1994). These latter findings are
somewhat contradictory to data indicating that nicotine administration to
non-smokers, via chewing gum, does not affect HDL-C levels (Quensel
et al. 1989a). The potential effects of nicotine patches during smoking cessation
on plasma HDL have yet to be clarified.
In summary, smoking leads to a reduction in plasma HDL-C, HDL2-C, apo A-I
and probably apoA-II concentrations. The effects of smoking on HDL are dose
dependent and reversed upon smoking cessation. Much of the effect of smoking
may be TAG dependent where increased plasma TAG concentration leads to
remodelling of HDL to a smaller particle size which is more rapidly cleared from
the circulation. TAG-independent effects have not yet been thoroughly investigated
but include modification of apoA-I, reductions in HDL antioxidant enzyme activity
and reduced ability of HDL to promote cholesterol efflux. The effect of nicotine
aids, used to support smoking cessation interventions, on HDL-C concentration and
function is unclear.
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5 Effects of Alcohol on HDL and Cardiovascular Risk
Multiple studies have established a known J-shaped relationship between alcohol
intake and cardiovascular risk including coronary heart disease and ischaemic
stroke (Krenz and Korthuis 2012). The term ‘drink’ is imprecise; however, the
amount of alcohol in one drink is similar for wine, spirits or beer. Thus, a 100 ml
glass of table wine at 13 % alcohol, 35 ml of distilled spirits at 40 % alcohol and
300 ml of beer at 5 % alcohol all contain around 10–12 g of pure ethyl alcohol. The
general consensus is that men consuming two standard alcoholic drinks per day and
women consuming half that intake appear to have a lower cardiovascular event rate
than persons abstaining from alcohol (Krenz and Korthuis 2012). Estimates of the
risk reduction associated with moderate alcohol intake drinkers compared with
those abstaining from alcohol range from 25 to 30 % (Krenz and Korthuis 2012).
5.1 Alcohol Intake and HDL-C
Several plausible mechanisms have been proposed to explain the positive moderate
alcohol intake-mediated effects on CVDs: reduced thrombogenic and coagulation
factors (platelet aggregation and fibrinogen levels), low plasma concentrations of
inflammation markers (C-reactive protein, interleukin-6 and adiponectin), lowered
blood pressure, increased insulin sensitivity and lipoprotein profile via a lowering
of LDL-C and increase in HDL-C (Klatsky 2010). However, this alcohol–CVD
relationship is nonlinear, and excessive alcohol consumption has adverse effects on
hypertension and other pro-inflammatory factors, despite increasing HDL-C
(Foerster et al. 2009).
Some reports have suggested that wine carries a lower risk of mortality than beer
or spirits and that this may be related to the ability of nonalcoholic phenolic
compounds to inhibit LDL oxidation and its pro-inflammatory effects (Frankel
et al. 1993; Gronbaek et al. 2000; Klatsky et al. 2003). However, other studies
have failed to identify an additional advantage associated with red wine
(Di Castelnuovo et al. 2002; Mukamal et al. 2003), thereby suggesting that ethyl
alcohol is the main factor for the cardioprotective effect.
A recent meta-analysis demonstrated that alcohol exerts favourable effects on
several cardiovascular biomarkers (higher HDL-C, apoA-I and adiponectin levels
and lower fibrinogen levels) which seems to be independent of the alcoholic
beverage type (Brien et al. 2011). This systematic review found that 1–2 drinks
per day increased HDL-C by 0.10 mmol/L (Brien et al. 2011). However, the
contribution of alcohol-induced HDL-C-raising effects to cardiovascular risk
remains largely unknown. Early studies indicated that the atheroprotective effects
were mediated, largely, by the increase in HDL-C, since the addition of HDL-C to
the multivariate model attenuated the inverse association between alcohol intake
and myocardial infarction (Gaziano et al. 1993). Nevertheless, one recent report
describing a large Norwegian cohort with extensive control for confounding factors
showed that HDL-C levels were not on the causal pathway connecting alcohol to
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the lower risk of death from coronary heart disease (Magnus et al. 2011). These
findings raise the question of which specific HDL subpopulation particles are
affected by alcohol intake and their significance for coronary heart disease
protection.
5.2 Effects of Alcohol on HDL Atheroprotective Functions
Studies on the effect of alcohol consumption on HDL particle size are inconsistent.
In some studies, moderate alcohol consumption increased small HDL subfractions,
mainly HDL3 (Haskell et al. 1984; Gardner et al. 2000; Nishiwaki et al. 1994), and
lipid-poor preβ-HDL particles (Beulens et al. 2004). These effects on HDL size
could be related to the ability of alcohol to stimulate LPL activity (Nishiwaki
et al. 1994). However, other studies on moderate drinkers found increased
concentrations of both HDL2 and HDL3 (Gaziano et al. 1993; Clevidence
et al. 1995; De Oliveira et al. 2000), and human kinetic studies demonstrated that
moderate alcohol consumption resulted in dose-dependent increases in HDL-C,
apoA-I and apoA-II through an increase in the HDL apolipoprotein transport rate,
but without altering their catabolic rate and LPL activity (De Oliveira et al. 2000).
These changes might explain the ability of HDL from moderate alcohol drinkers to
enhance macrophage cholesterol efflux (Beulens et al. 2004). However, cholesterol
efflux was also enhanced in heavy drinkers who usually show larger HDL (Makela
et al. 2008); these changes were associated with decreased CETP activity and
increased phospholipid transfer protein (PLTP) activity (Makela et al. 2008). It
should be noted that these macrophage cholesterol efflux assays only quantified the
first-step RCT pathway without addressing the efficiency of the rest of the RCT
steps or the other HDL cardioprotective functions. Nevertheless, moderate alcohol
intake was not associated with changes in the activities of other HDL remodelling
factors, such as LCAT or CETP (Nishiwaki et al. 1994; Riemens et al. 1997;
Sierksma et al. 2004), and, furthermore, the ability of HDL to deliver cholesterol
into the liver cells seemed to be decreased in both moderate and heavy drinkers
(Rao et al. 2000; Marmillot et al. 2007).
Beyond the RCT pathway, moderate alcohol consumption increased serum
PON1 (van der Gaag et al. 1999; Sierksma et al. 2002; Rao et al. 2003), along
with liver PON1 mRNA levels (Rao et al. 2003), although this effect was not found
in one study with moderate red wine drinkers (Sarandol et al. 2003). In contrast,
heavy alcohol drinking produced the opposite effects (Rao et al. 2003). Further-
more, alcohol promotes the conversion of phosphatidylcholine into phosphatidy-
lethanol, and it was reported that HDL-associated phosphatidylethanol increased
endothelial secretion of the vascular endothelial growth factor (Liisanantti and
Savolainen 2009), which could partly explain the positive effect of alcohol on
angiogenesis induction.
In summary, the inverse relationship between moderate and regular alcohol
intake and cardiovascular risk as well as the ability of alcohol to increase HDL-C
is well documented in the literature. Although some studies reported favourable
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effects of alcohol on HDL cardioprotective functions, it is unclear how many of the
alcohol-mediated cardioprotective effects were mediated by the HDL increase.
Finally, the American Heart Association recommendation that alcoholic beverage
consumption should be limited to no more than 2 drinks per day for men and 1 drink
per day for women and should be consumed with meals should be taken into
account. Alcohol should not be considered a therapeutic option for cardiovascular
risk reduction (Lichtenstein et al. 2006).
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Abstract
The knowledge of an inverse relationship between plasma high-density lipopro-
tein cholesterol (HDL-C) concentrations and rates of cardiovascular disease has
led to the concept that increasing plasma HDL-C levels would be protective
against cardiovascular events. Therapeutic interventions presently available to
correct the plasma lipid profile have not been designed to specifically act on
HDL, but have modest to moderate effects on plasma HDL-C concentrations.
Statins, the first-line lipid-lowering drug therapy in primary and secondary
cardiovascular prevention, have quite modest effects on plasma HDL-C
concentrations (2–10 %). Fibrates, primarily used to reduce plasma triglyceride
levels, also moderately increase HDL-C levels (5–15 %). Niacin is the most
potent available drug in increasing HDL-C levels (up to 30 %), but its use is
limited by side effects, especially flushing.
The present chapter reviews the effects of established hypolipidemic drugs
(statins, fibrates, and niacin) on plasma HDL-C levels and HDL subclass distri-
bution, and on HDL functions, including cholesterol efflux capacity, endothelial
protection, and antioxidant properties.
Keywords
HDL • HDL subclasses • Cell cholesterol efflux • Endothelial cells • Statins •
Fibrates • Niacin
Abbreviations
ABCA1 ATP-binding cassette A1
CETP Cholesteryl ester transfer protein
CEC Cholesterol efflux capacity
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ROS Reactive oxygen species
SR-BI Scavenger receptor class B type I
S1P Sphingolipid sphingosine-1-phosphate
T2DM Type 2 diabetes
TNFα Tumor necrosis factor alpha
1 Effects on Plasma HDL-C Concentration
1.1 Statins
Statins are inhibitors of the hydroxymethylglutaryl coenzyme A (HMG-CoA)
reductase enzyme, a key enzyme in cholesterol synthesis. In addition to effectively
reducing low-density lipoprotein cholesterol (LDL-C), all statins modestly increase
HDL-C levels across the range of doses used, with important differences between
different statins (Jones et al. 2003). The increase in HDL-C is dose dependent with
some statins, e.g., simvastatin and rosuvastatin, but not with others. In the case of
atorvastatin, the highest increase in HDL-C levels is observed at the lowest dose
used. Statin-induced changes in HDL-C are normally paralleled by an increase in
apoA-I levels (Barter et al. 2010). Interestingly, variations in LDL-C and in HDL-C
levels are independent from each other (Barter et al. 2010). The mechanism by
which statins increase plasma HDL-C and apoA-I levels remains unknown, and it is
apparently unrelated to the inhibition of the HMG-CoA reductase enzyme. The
ability of statins to upregulate hepatic ABCA1 gene expression (Tamehiro
et al. 2007), as well as the described statin-induced inhibition of cholesteryl ester
transfer protein (CETP) (Guerin et al. 2000; Kassai et al. 2007) can contribute to
explain the effect of statin on HDL-C levels.
1.2 Fibrates
Fibrates (fibric acid derivates), synthetic ligands for PPAR-α, significantly reduce
plasma triglyceride levels (30–50 %) and moderately increase HDL-C
concentrations (5–15 %), with no major differences among available molecules
(Khoury and Goldberg 2011). Activation of PPAR-α leads to β-oxidation of free
fatty acids in the liver reducing VLDL synthesis and secretion. Furthermore, the
expression of the gene coding for lipoprotein lipase is increased and apolipoprotein
C-III expression in the liver is decreased, resulting in increased hydrolysis of
triglyceride-rich lipoproteins. HDL-C raises results from the increased expression
of apoA-II and, at a much lesser extent, apoA-I (Yetukuri et al. 2011), as well as to
the enhanced cholesterol efflux via the induction of ABCA1 in the liver (Berger
et al. 2005). In addition, animal studies have shown that fenofibrate reduces CETP
hepatic expression (van der Hoogt et al. 2007).
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1.3 Niacin
Niacin (nicotinic acid), a GPR109a agonist used clinically for more than 50 years to
lower cholesterol and triglycerides, increases HDL-C levels up to 30 % (Vega and
Grundy 1994). All the different niacin formulations (regular and extended release,
ER) are equally effective in increasing HDL-C levels, whereas acipimox
(a nicotinic acid analog) only induces a 7 % increase (Birjmohun et al. 2005).
Niacin side-effect profile, including flushing, gastrointestinal upset, and liver func-
tion testing abnormalities, has, however, limited its use, especially in warmer
Mediterranean countries (Birjmohun et al. 2005). Coadministration of the prosta-
glandin receptor antagonist laropiprant significantly reduces but does not eliminate
niacin-induced skin symptoms (Yadav et al. 2012). It is not quite clear how niacin
leads to an increase in HDL-C levels, and various theories have been proposed
(Soudijn et al. 2007). These include the ability of niacin to inhibit CETP
(Hernandez et al. 2007), to induce ABCA1 expression (Rubic et al. 2004), and to
reduce HDL catabolism (Bodor and Offermanns 2008).
2 Effects on HDL Subclass Distribution
Plasma HDL is highly heterogeneous and can be separated in several subclasses
according to density, size, shape, and lipid and protein composition (Calabresi
et al. 2010). According to density, two HDL subclasses can be identified, the less
dense HDL2 and the more dense HDL3 (De Lalla and Gofman 1954). HDL2 and
HDL3 could be further fractionated in five distinct subclasses on the basis of
particle size (from large to small: HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c)
(Nichols et al. 1986). According to surface charge, HDL could be separated into
α-HDL and preβ-HDL. The separation by charge and size, using a two-dimensional
(2-D) gel electrophoresis, allow the identification of up to 12 distinct apoA-I-
containing HDL subclasses (Asztalos and Schaefer 2003). Finally, according to
the protein component, HDL can be separated into particles containing only apoA-I
(LpA-I) or containing also apoA-II (LpA-I:A-II).
2.1 Statins
The reported effects of statins on HDL subclass distribution are not consistent,
likely depending on the technique used for the analysis. Some studies showed no
effect of statins on HDL subclasses (Alaupovic et al. 1994; Bard et al. 1989;
Franceschini et al. 2007; Tomas et al. 2000), and on HDL particle size distribution
(Franceschini et al. 1989; Homma et al. 1995). On the contrary, studies evaluating
HDL subclasses by 2-D gel electrophoresis showed that all statins, although with
different potency, increase the levels of the large HDL particles and decrease the
levels of small particles (Asztalos et al. 2002a, b, 2007).
596 M. Gomaraschi et al.
2.2 Fibrates
A number of studies have shown that treatment with fibrates causes a shift of HDL
from large to small particles in low HDL (Franceschini et al. 2007; Otvos
et al. 2006), hypertriglyceridemic (Miida et al. 2000; Sasaki et al. 2002), and
hypercholesterolemic (Franceschini et al. 1989) patients. These effects could be
explained by the fibrate-induced increase in hepatic lipase activity (Miida
et al. 2000; Patsch et al. 1984). In addition, bezafibrate has been shown to increase
small discoidal preβ1-HDL particles in hypertriglyceridemic patients (Miida
et al. 2000). The analysis of HDL subclasses by 2-D electrophoresis in the large
cohort of the VA-HIT trial confirmed that gemfibrozil treatment is associated with a
decrease in large (α-1 and α-2) HDL and with an increase in the small, lipid-poor
HDL particles (Asztalos et al. 2008).
2.3 Niacin
Sheperd et al. were the first to demonstrate in the late 1970s that niacin (3 g/day) in
healthy volunteers significantly increases the large HDL2 particles, associated with
a parallel reduction of the small HDL3 (Shepherd et al. 1979). Several studies have
confirmed this observation in patients with different types of dyslipidemia treated
with 2, 3, or 4 g/day of regular or ER niacin (Johansson and Carlson 1990; Knopp
et al. 1998; Morgan et al. 2003; Wahlberg et al. 1990) and in patients with coronary
artery disease (Kuvin et al. 2006). A very recent study showed that also 1 g/day of
ER niacin increases large HDL particles in dyslipidemic patients, with a concomi-
tant significant increase in mean HDL size (Franceschini et al. 2013). The analysis
of HDL subclasses by 2-D gel electrophoresis recently confirmed the observation
that niacin promotes the maturation of HDL into large particles (Lamon-Fava
et al. 2008), likely explained by a reduction in CETP activity. In addition, Sakai
et al. reported that niacin selectively increases LpA-I particles in patients with low
HDL-C, due to a prolongation of apoA-I residence time (Sakai et al. 2001).
3 Effects on Cholesterol Efflux Capacity
The most relevant antiatherogenic function of HDL is the ability to promote reverse
cholesterol transport, the physiological process by which excess cholesterol is
removed from peripheral tissues and transported to the liver for excretion (Cuchel
and Rader 2006). The first and limiting step of this process is the efflux of cellular
cholesterol from lipid-laden macrophages of the arterial wall (Lewis and Rader
2005). Multiple mechanisms for efflux of cholesterol exist in macrophages (Adorni
et al. 2007). The release of free cholesterol via passive diffusion occurs in all cell
types and is accelerated when the scavenger receptor class B type I (SR-BI) is
present on the cell plasma membrane. Both passive diffusion and SR-BI-mediated
efflux occur to phospholipid-containing acceptors (i.e., HDL and lipidated
Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass. . . 597
apolipoproteins). ATP-binding cassette A1 (ABCA1) belongs to the ATP-binding
cassette transporter family and promotes unidirectional efflux of membrane choles-
terol and phospholipids to lipid-poor apolipoproteins. Macrophages may also
release cholesterol via the ABCG1 pathway, another ABC transporter that mediates
net mass efflux of cellular cholesterol to mature HDL (Favari et al. 2009). HDL
cholesterol efflux capacity (CEC) from macrophages can be measured in vitro and
provides a reliable measure of HDL functionality (Khera et al. 2011).
3.1 Statins
The impact of statin therapy on HDL ability to promote cholesterol efflux has been
investigated in a number of studies. Khera et al. measured HDL CEC in patients
treated with 10 and 80 mg atorvastatin or 40 mg pravastatin for 16 weeks and
reported no effects of statin therapy on HDL CEC from macrophages expressing all
the known cholesterol efflux pathways (ABCA1, ABCG1, SR-BI, and passive
diffusion) (Khera et al. 2011). As opposed to these results, Guerin et al. have
shown that atorvastatin therapy for 12 weeks (10 and 40 mg daily) could increase
SR-BI-dependent CEC of plasma from patients with type IIB hyperlipidemia, in a
dose-dependent manner (Guerin et al. 2002). The effect of simvastatin on HDL’s
ability to promote cholesterol efflux was assessed in a randomized, double-blind,
parallel group trial carried out in dyslipidemic patients with low HDL-C levels
receiving either fenofibrate (160 mg/day) or simvastatin (40 mg/day) for 8 weeks
(Franceschini et al. 2007). Simvastatin led to a small, significant increase in the
capacity of plasma to promote SR-BI-mediated cholesterol efflux, likely related to
the slight increase in HDL-C plasma levels that occurred after simvastatin treat-
ment. The latter results are in contrast with data obtained by de Vries et al. who
demonstrated that HDL from moderately hypercholesterolemic type 1 diabetic
patients after 10, 20, and 40 mg simvastatin treatment does not increase their ability
to promote cellular cholesterol efflux via SR-BI (De Vries et al. 2005). The effect of
simvastatin on HDL functionality was further investigated recently in a small
number of diabetic patients treated with simvastatin 40 mg/day or bezafibrate
400 mg/day, alone or in combination. CEC of apoB-depleted plasma samples
from cholesterol-loaded macrophages, a cellular model which expresses simulta-
neously all the pathways of known relevance in cholesterol efflux, was increased by
14 % in response to simvastatin compared to placebo (Triolo et al. 2013a). Sviridov
et al. showed that treatment with 40 mg/day rosuvastatin in overweight subjects
with defined metabolic syndrome did not significantly modify HDL capacity to
promote cholesterol efflux from LXR-activated human macrophages (Sviridov
et al. 2008). Finally, a recent study showed a moderate ability of pitavastatin to
enhance HDL CEC from macrophage foam cells in dyslipidemic subjects
(Miyamoto-Sasaki et al. 2013). Overall, the impact of statin therapy on HDL
CEC does not appear to be substantial, in agreement with the modest effect of
statins on HDL-C concentration and on HDL subclass distribution.
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3.2 Fibrates
The effect of fibrates on HDL cholesterol efflux capacity was assessed by Guerin
et al. showing a significant ciprofibrate-mediated 13 % elevation in the capacity of
plasma from type IIB hyperlipidemic subjects to mediate cholesterol efflux from
SR-BI-expressing Fu5AH hepatoma cells (Guerin et al. 2003). The study by
Franceschini et al., comparing fenofibrate and simvastatin in dyslipidemic patients
(Franceschini et al. 2007), provided evidence that fenofibrate increases the plasma
capacity to promote ABCA1-mediated efflux with no changes in SR-BI efflux.
These observed results might be explained by a shift of HDL from large to small
particles, the preferential cholesterol acceptors for ABCA1 (Adorni et al. 2007).
This result was not confirmed in a more recent paper by the same group
(Franceschini et al. 2013), likely because of the different HDL particle profile in
the two investigated populations of patients. In the first study (Guerin et al. 2002),
patients displayed a greater content of large HDL particles, whereas in patients with
dyslipidemia of the last study (Franceschini et al. 2013), the small, ABCA1-
interacting HDL was the predominant fraction, and no further increase in this
HDL population was observed after fenofibrate therapy, consistent with the lack
of changes in ABCA1-mediated CEC. Whether fenofibrate therapy modulate the
ability of plasma or HDL to facilitate cholesterol efflux from macrophages has been
investigated also in a subset of the FIELD study showing that cholesterol efflux
values from macrophage foam cells to HDL and plasma in the fenofibrate group
(200 mg/day for 5 years) were comparable to those of the placebo group (Maranghi
et al. 2011). Finally, in a small study carried out in diabetic patients, it was shown
that bezafibrate increases CEC of apoB-depleted plasma samples from cholesterol-
loaded THP-1 macrophages (Triolo et al. 2013a). Overall, studies on the ability of
fibrates to modulate HDL cholesterol efflux capacity seem not consistent, likely due
to the different cell models used in the different studies and also to the different
types of patients.
3.3 Niacin
The impact of niacin on HDL cholesterol efflux capacity was investigated in a
placebo-controlled study carried out by Khera et al. who measured HDL CEC
before and after ER niacin therapy in a small number of patients with carotid
atherosclerosis (Khera et al. 2013). The study showed that niacin treatment led to
favorable changes in patients’ lipid profiles without significantly improving CEC of
HDL from macrophages. In the study by Franceschini et al., the effect of ER niacin
therapy on plasma CEC was evaluated in a population of dyslipidemic subjects
(Franceschini et al. 2013). The tendency of ER niacin in enhancing passive diffu-
sion, SR-BI-, and ABCG1-mediated CEC observed in this study is in line with the
results of a previous investigation, which demonstrated that niacin increased both
HDL-C levels and CEC from human macrophages (Yvan-Charvet et al. 2010). In
this study the increase in CEC achieved statistical significance, possibly because of
a greater increase in plasma HDL-C levels compared with that observed in study by
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Franceschini et al., because passive diffusion, SR-BI-, and partially ABCG1-
mediated CECs are known to be dependent on HDL-C concentrations. Consis-
tently, a previous investigation by Morgan et al. reported that ER niacin therapy in
patients with a history of primary dyslipoproteinemia had a beneficial effect on SR-
BI-mediated efflux and that it was related to the change in level of HDL-C (Morgan
et al. 2007). Another study evaluated specific cholesterol efflux pathway-mediated
CECs (ABCA1, SR-BI, and ABCG1) of serum from men with HDL deficiency
before and after treatment with niacin, but no changes were reported in all the
considered efflux pathways (Alrasadi et al. 2008). Taken together, available data on
the effect of niacin on the HDL-mediated ability to promote cell cholesterol efflux
show modest effects on the pathways involving large HDL, in agreement with the
changes observed on HDL particles.
4 Effect on HDL Ability to Preserve Endothelial Cell
Homeostasis
Several in vitro and in vivo evidences indicate that the anti-atherosclerotic activity
of HDL is also due to their ability to preserve endothelial cell homeostasis
(Calabresi et al. 2003). HDL is able to promote vasorelaxation, to inhibit the
production of cell adhesion and proinflammatory molecules, and to favor the
integrity and repair of the endothelial layer, thus preventing and correcting the
main features of endothelial dysfunction typical of the atherosclerotic process.
HDL can modulate vascular tone by promoting the release of vasoactive molecules
like nitric oxide (NO) and prostacyclin (PGI2) which also exert powerful
antithrombotic effects. HDL is able to increase the protein abundance and to induce
the activation of endothelial nitric oxide synthase (eNOS) (Kuvin et al. 2002;
Yuhanna et al. 2001). This latter effect is driven by the interaction of HDL with
the scavenger receptor SR-BI and by the subsequent activation of the PI3K/Akt
signaling pathway leading to eNOS phosphorylation; in addition, the sphingolipid
sphingosine-1-phosphate (S1P) carried by HDL can also mediate eNOS activation
by binding with its receptor S1P3 (Nofer et al. 2004). PGI2 is a metabolite of
arachidonate and HDL was shown to increase its production by different
mechanisms. HDL can provide endothelial cells with the substrate arachidonate
or promote its release from cellular phospholipids by activating calcium-sensitive
membrane-bound phospholipases (Calabresi et al. 2003). Another feature of endo-
thelial dysfunction is the increased production of molecules favoring blood cell
adhesion to the endothelial layer and their consequent extravasation and activation.
Studies on endothelial cells have shown that HDL are able to inhibit the cytokine-
induced expression of cell adhesion molecules (Calabresi et al. 1997; Cockerill
et al. 1995), but the precise mechanism responsible for this effect has not been fully
elucidated to date (Barter et al. 2002). Different studies have shown an
HDL-mediated inhibition of sphingosine kinase activity and NF-kB nuclear trans-
location and an increased expression of heme-oxygenase 1 mediated by SR-BI
(McGrath et al. 2009; Xia et al. 1999). HDL was also shown to inhibit the
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production of proinflammatory cytokines, as interleukin-6 and chemokines
(Gomaraschi et al. 2005). Finally, HDL was shown to promote endothelial cell
migration and proliferation, to inhibit cell apoptosis through different mechanisms
(Mineo and Shaul 2012), and to promote endothelial progenitor cells (EPC) differ-
entiation and survival (Mineo and Shaul 2012; Petoumenos et al. 2009).
In certain pathological conditions HDL may lose their ability to protect the
endothelium and even become dysfunctional. In particular, conditions associated
with both acute and chronic inflammatory processes, such as ischemic vascular
events, infections, type 2 diabetes (T2DM), obesity, metabolic syndrome, autoim-
mune disorders, and chronic kidney disease, have been associated with HDL
displaying impaired endothelial protective activities (Riwanto and Landmesser
2013). Indeed, HDL isolated from these patients failed to promote NO production,
to exert antioxidant and anti-inflammatory effects, and to favor endothelial integrity
in vitro (Riwanto and Landmesser 2013).
The measurement of vasodilation in response to changes in forearm blood flow
(flow-mediated vasodilation, FMD) is currently considered the best method to
evaluate endothelial function in vivo (Deanfield et al. 2007) and is commonly
used to assess in vivo vascular condition and to evaluate the effects of pharmaco-
logical treatments. In addition, plasma levels of the soluble forms of adhesion
molecules and of proinflammatory cytokines can be used as in vivo markers of
endothelial inflammatory activation. Recently, circulating EPC number and migra-
tory capacity emerged as novel biomarkers of endothelial repair (Petoumenos
et al. 2009).
4.1 Statins
Several studies have shown that statins are able to improve FMD, to reduce the
plasma levels of inflammatory markers, and to increase EPC number in
dyslipidemic subjects (Antonopoulos et al. 2012; Liu et al. 2012; Reriani
et al. 2011). These effects are likely not related to statin-induced changes in
HDL. In vitro experiments have indeed shown that statin-mediated improvement
of endothelial function is due to a direct effect of the drug on endothelial cells.
Incubation of endothelial cells with different statins promotes a significant increase
expression of SR-BI and S1P receptors and of eNOS, with a consequent increased
production of NO after incubation with HDL (Igarashi et al. 2007; Kimura
et al. 2008). A recent study performed on subjects with isolated low HDL-C showed
that FMD was significantly improved after 4 weeks treatment with pravastatin, and
multiple regression analysis revealed that changes in HDL-C and EPC number were
independent predictors of FMD increase (Higashi et al. 2010). Despite the
limitations due to the small number of analyzed subjects, this latter study suggests
a potential role of statins on HDL capacity to maintain endothelial homeostasis.
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4.2 Fibrates
Different fibrates have been tested for their ability to modulate endothelial function
in dyslipidemic patients. Fenofibrate was shown to improve FMD and to decrease
inflammatory biomarkers, as C-reactive protein (CRP), tumor necrosis factor alpha
(TNFα), interleukin-1, and soluble CD40 ligand, in patients with combined hyper-
lipidemia (Malik et al. 2001; Wang et al. 2003). FMD improvement was inversely
related to baseline HDL-C levels and indeed fenofibrate significantly increased
FMD only in the subgroup with low HDL-C and not in subjects with normal
HDL-C, in which a statin was instead effective (Wang et al. 2003). Fenofibrate,
alone or in combination with a statin, was also effective in modulating FMD and
decreasing plasma levels of CRP and TNFα in hypertriglyceridemic subjects (Koh
et al. 2004, 2005), and a significant decrease of plasma levels of sCAMs was
observed in subjects with low HDL-C levels (Calabresi et al. 2002); in this latter
study, the decrease of plasma sCAMs was inversely related to the fenofibrate-
induced increase of HDL-C, while no correlation was found with triglyceride
reduction (Calabresi et al. 2002).
Recently, particular attention has been devoted to the effects of fibrates in
subjects with T2DM. Four studies consistently demonstrated that different fibrates,
i.e., ciprofibrate, gemfibrozil, fenofibrate, and bezafibrate, were all able to signifi-
cantly improve FMD in T2DM, in a way that was not dependent on changes in lipid
parameters, including HDL-C (Avogaro et al. 2001; Evans et al. 2000; Ghani
et al. 2013; Triolo et al. 2013b). Interestingly, after 12 weeks of treatment with
ciprofibrate, T2DM subjects displayed improved FMD measured in fasting
conditions and in the postprandial phase (Evans et al. 2000). Ciprofibrate treatment
also markedly modified lipid metabolism: the fasting triglyceride content of all
lipoproteins was reduced and the increase during the postprandial phase blunted;
the improvement of fasting FMD was correlated with the decreased triglyceride
content in VLDL and HDL (but not with changes of HDL-C), while in the
postprandial phase changes of FMD were correlated with the reduced lipoprotein
TG content (Evans et al. 2000).
4.3 Niacin
The effect of niacin treatment on endothelial function has been assessed in a variety
of clinical conditions, including established coronary artery disease, T2DM, meta-
bolic syndrome, and low HDL-C. Overall, when niacin was used as monotherapy,
the studies showed an increase in FMD and a reduction in inflammatory biomarkers
but failed in demonstrating a correlation with the niacin-mediated increase of
HDL-C levels. In 2002, Kuvin et al. demonstrated that a 3-month treatment with
niacin improved FMD in patients with CAD and low HDL-C and that this improve-
ment could be related to the HDL ability to increase eNOS protein abundance
in vitro (Kuvin et al. 2002). Some years later, the same authors also showed that in
statin treated patients with established CAD, the addition of niacin caused a
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reduction of the plasma levels of inflammatory biomarkers as CRP and lipoprotein-
associated phospholipase A2 (Kuvin et al. 2006); unfortunately, likely due to the
small number of participants, correlation analyses between changes of endothelial
function parameters and the increase of HDL-C or other lipid variables were not
performed (Kuvin et al. 2006). Later on, the ability of niacin to improve FMD and
reduce inflammatory biomarkers as CRP was confirmed in subjects with isolated
low HDL-C (Benjo et al. 2006), with the metabolic syndrome (Thoenes et al. 2007),
and in patients after myocardial infarction (Bregar et al. 2013); the relationship
between increase of HDL-C and changes of FMD was analyzed only in the latter
case, and no correlation was found with any lipid parameter. The absence of
correlation between niacin-mediated changes of HDL-C and endothelial function
could be explained by the direct antioxidant, anti-inflammatory, and anti-adhesive
activities of niacin which are independent from its role on lipid metabolism (Yadav
et al. 2012). However, a recent study clearly showed that HDL isolated from
subjects with T2DM after 3 months of treatment with niacin displayed an improved
ability to stimulate NO production, to reduce reactive oxygen species, and to
promote EPC-mediated endothelial repair in vitro when compared to HDL isolated
at baseline (Sorrentino et al. 2010), further strengthening the concept that plasma
HDL-C and its change may not be a reliable indicator of HDL function. Recent
studies analyzed the effect of niacin treatment in patients with established CAD on
top of the existing statin therapy; two of them failed to detect any significant
improvement of FMD, while in one case FMD was significantly increased only in
the subgroup of patients with a low baseline HDL-C level (Lee et al. 2009; Philpott
et al. 2013; Warnholtz et al. 2009).
5 Effect on HDL Antioxidant Properties
ApoA-I plays a major role in HDL-mediated protection from oxidative damage
(Rosenson et al. 2013). Many studies have indicated that the antioxidant function of
HDL also depends upon such enzymes as lipoprotein-associated phospholipase A2
(Lp-PLA2), paraoxonase 1 (PON1), lecithin-cholesterol acyltransferase (LCAT),
and glutathione selenoperoxidase (GSPx) (Florentin et al. 2008; Otocka-Kmiecik
et al. 2012; Podrez 2010). GSPx can reduce lipoprotein lipid hydroperoxides
(LOOHs) to the corresponding hydroxides and thereby detoxify them (Rosenson
et al. 2013). Besides apoA-I, other apolipoproteins such as apoE, apoJ, apoA-II, and
apoA-IV also display antioxidant properties but to a less degree than apoA-I
(Otocka-Kmiecik et al. 2012). An antioxidant mechanism of HDL may also result
from their ability to accept phospholipid-containing hydroperoxides (PLOOHs) and
other lipid peroxidation products from oxidized LDL (Stremler et al. 1991) and
their subsequent reduction by redox-active methionine residues of apoA-I, with the
formation of redox-inactive phospholipid hydroxides (Kontush and Chapman
2010). In addition, HDL functions as an antioxidant enzyme by hydrolyzing
oxidized phospholipids, such as F2-isoprostanes, formed during the oxidative
modification of LDL. Antioxidant properties differ for the different HDL subclasses
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(Kontush and Chapman 2010). Activities of HDL-associated enzymes—LCAT,
PON1, and platelet-activating factor acetyl hydrolase (PAF-AH)—are elevated in
small, dense HDL3c (Davidson et al. 2009), which thus seem to have a potent role
in protecting LDL from oxidation (Podrez 2010). It is worth emphasizing that
small, dense HDL3 particles are also more resistant to oxidative modification
compared with large, light HDL2 (Shuhei et al. 2010).
5.1 Statins
The role of statins in improving plasma oxidative status has been reported in a
number of studies, although this effect was not always related to drug-induced
changes in HDL. Different statins have been shown to significantly enhance the
antioxidant activity of PON1. Atorvastatin has a positive impact on plasma total
antioxidant status and PON1 activity by reducing plasma susceptibility to lipid
peroxidation induced by free radicals (Fuhrman et al. 2002; Harangi et al. 2004,
2009; Nagila et al. 2009). Pitavastatin was also shown to increase the promoter
activity and protein expression of PON1 in vitro via p44/42 mitogen-activated
protein kinase-mediated phosphorylation of sterol-regulatory-element-binding
protein-2 and binding of Sp1 to PON1 DNA (Arii et al. 2009; Yamashita
et al. 2010). The improvement of antioxidant properties of HDL, via increased
PON1 activity, was also observed after simvastatin and fluvastatin therapy
(Bergheanu et al. 2007; Mirdamadi et al. 2008; Muacevic-Katanec et al. 2007).
Atorvastatin also suppresses the enhanced cellular uptake of oxidized LDL by
macrophages and reduces expression of cellular scavenger receptors (Fuhrman
et al. 2002; Otocka-Kmiecik et al. 2012). Similar results were observed in the
study by Kassai et al. which showed a significant increase in serum PON1 specific
activity, PON/HDL ratio, and LCAT activity, as well as significant reduction of
oxidized LDL and CETP activities after atorvastatin therapy (Kassai et al. 2007).
Finally, statin treatment enhances the defective antioxidative activity of HDL3 in
patients with acute coronary syndrome by increasing the activity of
HDL-associated enzymes (Otocka-Kmiecik et al. 2012).
5.2 Fibrates
Tsimihodimos et al. reported that fenofibrate induces redistribution of Lp-PLA2
from apoB-containing lipoproteins to HDL in dyslipidemic patients (Tsimihodimos
et al. 2003). This effect enhanced the anti-inflammatory and antioxidant potential of
the enzyme. In a recent study, Vazanna et al. examined whether HDL levels are
related to in vivo oxidative stress and platelet activation in patients with coronary
heart disease treated with fenofibrate (Vazzana et al. 2013). The authors measured
urinary 8-iso-prostaglandin (PG) F2α and 11-dehydrothromboxane (TX) B2—
in vivo markers of oxidative stress and platelet activation, respectively. They
observed significantly higher urinary 8-iso-PGF2α and 11-dehydro-TXB2 in
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patients with low HDL than in individuals with higher HDL levels, as well as an
inverse relation between the markers of oxidation and HDL concentrations.
Fenofibrate treatment significantly reduced the 2 eicosanoids in healthy subjects,
in parallel with an HDL increase (Vazzana et al. 2013). Tkac et al. showed a
significant reduction of circulating conjugated dienes, a nonsignificant decrease in
the production of malondialdehyde, and an increase in the GPx activity in patients
with combined hyperlipidemia treated with fenofibrate (Tkac et al. 2006). Similar
results were obtained in patients with visceral obesity and dyslipidemia treated with
micronized fenofibrate (Broncel et al. 2006). Few studies have evaluated the effect
of fibrates on PON1 activity. Paragh et al. evaluated this effect in a group of
coronary patients with type IIb hyperlipidemia; after 3 months of treatment,
HDL-C and apoA-I levels increased significantly, and PON1 specific activity also
increased significantly (Paragh et al. 2003). Very similar results were obtained by
Phuntuwate et al., who evaluated the effect of fenofibrate on PON1 levels, as well
as the effects of the PON1 polymorphisms on lipid and PON1 responses to the drug,
in dyslipidemic patients with low HDL (Phuntuwate et al. 2008). A significant
increases in PON1 concentration and activity was observed after treatment, and a
significant positive correlation between changes in HDL-C and changes in PON1
concentration/activity was detected (Phuntuwate et al. 2008). The response of lipid
parameters to fenofibrate was independent of PON1 polymorphisms; however,
PON1 Q192R and T-108C polymorphisms significantly affected the increase in
PON1 activity and concentration (Phuntuwate et al. 2008). An increase of PON1
activity, which was significantly correlated with the changes in HDL-C, was also
observed in patients with combined hyperlipidemia (Yesilbursa et al. 2005). On the
contrary, Dullart et al. did not observe such increase after short-term (8 weeks)
administration of simvastatin and bezafibrate, even when combined in diabetic
patients (Dullaart et al. 2009). It needs to be also emphasized that besides the
above mentioned positive HDL associated antioxidant properties of fibrates, they
also elevate plasma total homocysteine, which is known to induce oxidative stress
and endothelial dysfunction. Among others, a subgroup analysis of the FIELD
study showed that fenofibrate treatment was associated with an increase of homo-
cysteine levels, with no changes of serum PON-1 mass (Maranghi et al. 2011).
5.3 Niacin
There is still very limited data on the potential role of niacin therapy on
HDL-related antioxidant properties. Recent studies indicate that niacin increases
vascular endothelial cell redox state, resulting in the inhibition of oxidative stress
(Kamanna and Kashyap 2008). These effects were investigated by Ganji
et al. in vitro, who showed that in cultured endothelial cells niacin increases
NADPH levels and reduces GSH (Ganji et al. 2009). In the same study, niacin
also inhibited angiotensin II-induced reactive oxygen species (ROS) production
(Ganji et al. 2009). These findings indicate for the first time that niacin inhibits
vascular inflammation by decreasing endothelial ROS production and subsequent
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LDL oxidation (Ganji et al. 2009). Kaplon et al. have recently tested the hypothesis
that vascular endothelial function and oxidative stress are related to dietary niacin
intake among healthy middle-aged and older adults (Kaplon et al. 2014). They
observed that plasma ox-LDL was inversely related to niacin intake. Moreover, in
endothelial cells sampled from the brachial artery of a subgroup patients, dietary
niacin intake was inversely related to nitrotyrosine, a marker of oxidative damage,
leading to the hypothesis that higher dietary niacin intake is associated with greater
vascular endothelial function related to lower systemic and vascular oxidative stress
(Kaplon et al. 2014). The antioxidant properties of niacin were also observed
patients with hypercholesterolemia and low HDL-C treated with niacin for
12 weeks (Hamoud et al. 2013). Subjects with low HDL-C levels exhibited higher
oxidative stress compared with subjects with normal HDL-C levels. Niacin treat-
ment in hypercholesterolemic patients caused a significant increase in HDL-C and
apoA-I levels and a decrease in TG levels. Niacin also significantly reduced
oxidative stress, as measured by a significant decrease in the serum content of
thiobarbituric acid reactive substances and lipid peroxides and increase of PON
activity, compared with the levels before treatment (Hamoud et al. 2013).
Conclusions and Perspectives
Currently, optimal statin treatment manages to achieve a risk reduction for
cardiovascular mortality of approximately 25–35 %, mainly due to a reduction
of LDL-C. This leaves an important residual risk that needs to be considered for
the optimal management of patients at risk of cardiovascular disease. Raising
HDL-C was seen as a viable and promising way to further reduce the risk of
cardiovascular mortality. However, things look to be difficult with HDL (Table 1).
Although all fibrates have been shown to increase HDL-C significantly, their
beneficial effect on cardiovascular and all-cause mortality remains controversial
(Saha et al. 2007). The early VA-HIT and BIP secondary prevention trials have
shown that treating CHD patients with low plasma HDL-C levels and especially
Table 1 Effects of established hypolipidemic drugs on HDL concentration and function
Statins Fibrates Niacin
HDL-C " 2–10 % " 5–15 % " 15–30 %
HDL subclasses " large HDL particles " small HDL particles " large HDL particles
Cell cholesterol
efflux
" up to 14 % (mainly
SR-BI mediated)
" up to 21 % (mainly
ABCA1 mediated)

















" PON1 activity " PON1 activity
" HDL-bound LpPLA2
" PON1 activity
aNot necessarily related to HDL changes
bIn vitro data
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those with moderate triglyceride elevations and some degree of insulin resis-
tance (Rubins et al. 2002; The Bezafibrate Infarction Prevention (BIP) Study
Group 2000) with a fibrate leads to significant reductions in the risk of a
recurrent cardiovascular event, part of the effect being mediated by the fibrate-
induced increase in HDL-C (Robins et al. 2001). In the FIELD study in people
with type 2 diabetes mellitus, fenofibrate induced a highly significant reduction
of cardiovascular events in patients with low HDL-C levels, versus a minimal
effectiveness of the drug in patients with higher HDL-C (The FIELD study
investigators 2005). The more recent ACCORD trial shows no benefits of adding
fibrate therapy to statin on cardiovascular events except possibly in patients with
residual atherogenic dyslipidemia (Ginsberg et al. 2010).
Earlier studies with niacin suggested a favorable effect of the drug on
cardiovascular mortality (Canner et al. 1986), but the AIM-HIGH trial, which
compared the combination niacin/simvastatin with simvastatin alone, was
stopped for lack of efficacy, as niacin on the top of statin, despite increasing
HDL-C levels, failed to determine an incremental clinical benefit in patients with
LDL-C values at target (Boden et al. 2011). The more recent and much larger
HPS2-THRIVE trial, also designed to assess the effect of adding niacin to a
statin therapy in patients with established cardiovascular disease, also gave
disappointing results (HPS2-THRIVE Collaborative Group 2013).
Novel HDL-raising drugs targeting new players in the HDL system, and more
potent than the available drugs, are urgently needed. The promising CETP
inhibitors, despite substantially increasing HDL-C levels, did not give so far
positive results on cardiovascular risk (Barter et al. 2007; Schwartz et al. 2013).
Different is the case of the HDL mimetics, which appears to be more promising,
at least from results on surrogate end points (Nissen et al. 2003; Tardif
et al. 2007), awaiting morbidity and mortality studies.
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Université Lille 2, F-59000 Lille, France
Inserm, U1011, F-59000 Lille, France
Institut Pasteur de Lille, F-59019 Lille, France
European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
e-mail: bart.staels@pasteur-lille.fr
J.A. Kuivenhoven
Section Molecular Genetics, Department of Pediatrics, University Medical Center
Groningen, University of Groningen, 9713 AV Groningen, The Netherlands
# The Author(s) 2015
A. von Eckardstein, D. Kardassis (eds.), High Density Lipoproteins, Handbook of
Experimental Pharmacology 224, DOI 10.1007/978-3-319-09665-0_20
617
Abstract
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacologi-
cal lowering of LDL-C levels using statins reduces cardiovascular risk. How-
ever, a substantial residual risk persists especially in patients with type 2 diabetes
mellitus. Because of the inverse association observed in epidemiological studies
of HDL-C with the risk for cardiovascular diseases, novel therapeutic strategies
to raise HDL-C levels or improve HDL functionality are developed as comple-
mentary therapy for cardiovascular diseases. However, until now most therapies
targeting HDL-C levels failed in clinical trials because of side effects or absence
of clinical benefits. This chapter will highlight the emerging small molecules
currently developed and tested in clinical trials to pharmacologically modulate
HDL-C and functionality including new CETP inhibitors (anacetrapib,
evacetrapib), novel PPAR agonists (K-877, CER-002, DSP-8658, INT131 and
GFT505), LXR agonists (ATI-111, LXR-623, XL-652) and RVX-208.
Keywords
HDL therapy • CETP inhibitors • PPAR • LXR • RVX-208
Abbreviations
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
ACC Acetyl-CoA carboxylase
Apo apolipoprotein
CETP Cholesteryl ester transfer protein
CVD Cardiovascular disease
FAS Fatty acid synthase
HDL High-density lipoprotein
LDL Low-density lipoprotein
LXR Liver X receptor
MTTP Microsomal triglyceride transfer protein
PPAR Peroxisome proliferator-activated receptor
PCSK9 Proprotein convertase subtilisin/kexin type 9
SCD-1 Stearoyl-CoA desaturase-1
SREBP-1 Sterol regulatory element-binding protein
1 Introduction
Dyslipidaemia is a major risk factor for cardiovascular diseases, a main cause of
morbidity and mortality worldwide, with 17.3 million deaths per year (Laslett
et al. 2012). LDL-C-lowering therapy, especially with statins, has shown to be an
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efficient approach to reduce cardiovascular risk on average by 25–35 %. Although
lowering LDL-C with statins has beneficial effects and reduces cardiovascular
events, significant numbers of residual cardiovascular events remain in high-risk
patients, prompting the search for alternative complementary approaches. Among
these strategies, new agents combined with statins, such as proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, microsomal triglyceride transfer protein
(MTTP) inhibitors or ezetimibe can provide additional lowering LDL-C effects.
Because HDL-C levels are inversely correlated with cardiovascular risk (Gordon
et al. 1977), raising HDL-C levels has spawned high hopes as additional therapy for
cardiovascular diseases. However, so far none of the pharmacological interventions
aimed at raising HDL-C levels has yielded convincing results with respect to
reduction of cardiovascular risk.
In this chapter we will focus on these emerging small molecule drugs in
development, including cholesteryl ester transfer protein (CETP) inhibitors, novel
peroxisome proliferator-activated receptor (PPAR) agonists, liver X receptor
(LXR) agonists and RVX-208. For each drug, the biological mechanisms of these
molecules, an overview of the current state of the clinical trials and the future
perspectives will be provided.
2 Cholesteryl Ester Transfer Protein Inhibitors
2.1 Biological Mechanisms
The cholesteryl ester transfer protein (CETP) promotes the transfer of triglycerides
from apoB-containing lipoproteins (LDL, IDL and VLDL) to HDL-C in exchange
for cholesteryl esters. Interest in CETP inhibitor development came from studies in
families with CETP deficiency with hyperalphalipoproteinaemia CETP deficiency
(Inazu 1990) and epidemiological studies showing that CETP gene variants are
associated with increased HDL-C levels and a lower risk of coronary heart disease
events (Curb et al. 2004).
2.2 Current State
Four CETP inhibitors have been developed in humans: torcetrapib, anacetrapib,
dalcetrapib and evacetrapib. The first CETP inhibitor designed by Pfizer and tested
in phase III clinical trials was torcetrapib. The initial results of the ILLUMINATE
(Investigation of Lipid Level Management to Understand its Impact in Atheroscle-
rotic Events) trial were encouraging, with a 72 % increase in HDL-C and a 25 %
decrease in LDL-C in patients with high CVD risk treated with torcetrapib on top of
atorvastatin (Kastelein et al. 2007). However, all studies were interrupted because
of an increased risk of cardiovascular events and an excess of mortality upon
torcetrapib usage, possibly due to an increase in aldosterone level and blood
pressure (Barter et al. 2007). Further analyses have demonstrated that the effect
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on blood pressure was independent of CETP inhibition. Indeed, torcetrapib
increases blood pressure in mice that do not express CETP (Forrest et al. 2008).
Furthermore, genetic association studies in 58,948 subjects with polymorphism in
CETP gene report that CETP genotype was not associated with systolic nor
diastolic blood pressure (Sofat et al. 2010). These results suggest that toxicity
upon torcetrapib treatment could be CETP independent.
Even though the dal-OUTCOMES trial with dalcetrapib (Roche) showed an
increase of HDL-C by 30 %, the results showed futility and trials were halted due to
the absence of obvious benefit (Schwartz et al. 2012). Furthermore, the effect of
dalcetrapib on vessel wall structure and vascular inflammation was investigated
after a 2-year treatment in the dal-PLAQUE trial (Fayad et al. 2011). No significant
benefit was reported in dalcetrapib-treated patients, but in patients with low HDL-C
at baseline, beneficial effects on endothelial function were observed. However, in
the dal-VESSEL study, designed to validate these results, the beneficial effects
were not confirmed (Lüscher et al. 2012). Nevertheless, despite these failures, no
vascular toxicity and blood pressure increase were observed on top of dalcetrapib
treatment (Lüscher et al. 2012). Based on these results, two other more potent CETP
inhibitors, anacetrapib and evacetrapib, have been developed and are still in phase
III clinical trials.
2.3 Future Perspectives
Anacetrapib is a potent CETP inhibitor developed by Merck. In a first clinical trial,
anacetrapib increased HDL-C by 138 % and reduced LDL-C by 40 % in patients
with coronary artery disease or at high risk for coronary heart disease on statin
therapy. This clinical trial with the acronym DEFINE (Determining the EFficacy
and Tolerability of CETP Inhibition with Anacetrapib), demonstrated the safety of
anacetrapib and absence of significant changes in blood pressure, aldosterone and
electrolyte levels (Cannon et al. 2010). Currently, a phase III clinical trial is
ongoing, acronym REVEAL (Randomized EValuation of the Effects of
Anacetrapib Through Lipid-modification), which will determine whether lipid
modification on anacetrapib therapy reduces the risk of coronary death, myocardial
infarction (MI) or coronary revascularisation in patients with circulatory problems
and low LDL-C on statin therapy (ClinicalTrials.gov identifier: NCT01252953).
The results of this trial are expected at the beginning of 2017.
Evacetrapib, designed by Eli Lilly & Company, is the fourth member of the
CETP inhibitor class that is tested in clinical trials. A phase II clinical trial
evaluated the efficacy of evacetrapib as monotherapy or in combination with the
most prescribed statins in patients with either hypercholesterolaemia or low HDL-C
levels. As monotherapy, evacetrapib (30 mg, 100 mg or 500 mg/day) dose-
dependently reduced LDL-C from 14 to 36 % and increased HDL-C from 54 to
129 %. Although the decrease of LDL-C was higher in combination with statins
(49 % vs. 24 %), the increase of HDL-C was not stronger when compared to
evacetrapib monotherapy (Nicholls et al. 2011). No adverse effects were observed
in this trial, with no changes in blood pressure or aldosterone levels. Thus
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evacetrapib appears to be well-tolerated (Nicholls et al. 2011). The benefits of
evacetrapib in combination with statins will be determined in a phase III
randomised outcome trial, acronym ACCELERATE (Assessment of Clinical
Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients
at a High-Risk for Vascular Outcomes) (Estimated end date: January 2016;
ClinicalTrials.gov identifier: NCT01687998).
3 Novel PPAR Agonists
3.1 Biological Mechanisms
Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor sub-
family with three members, PPARα, PPARγ and PPARβ/δ, encoded by distinct
genes. The three isoforms display distinct patterns of expression with PPARα being
highly expressed in liver, kidney, heart, muscle and brown adipose tissue, PPARγ is
most abundant in adipose tissue, whereas PPARβ/δ is ubiquitously expressed
(Lefebvre et al. 2006). Upon heterodimerisation with the retinoic X receptor,
PPARs bind to PPAR response elements (PPRE) located in the promoters of their
target genes and thus exert negative or positive control on their transcription.
The role of PPARα was initially studied in the liver where it enhances fatty acid
oxidation, regulates gluconeogenesis through an increase of pyruvate dehydroge-
nase kinase 4 expression and ketone body production in response to the fasting
state. Through its natural ligands, such as long-chain unsaturated fatty acids,
arachidonic acid derivatives and oxidised phospholipids, PPARα regulates also
some genes involved in lipid and lipoprotein metabolism. The increase of apoAV
and lipoprotein lipase expression by PPARα activation associated with the reduc-
tion of apoCIII expression contributes to reduced plasma triglyceride levels in
humans. Moreover, plasma HDL cholesterol levels increase as a result of the
stimulation of two major HDL-associated apolipoproteins, apoAI and apoAII, by
PPARα (Staels et al. 1998). In addition to these hepatic effects, PPARα activation
enhances reverse cholesterol transport related to the increase of ATP-binding
cassette transporter A1 (ABCA1) in macrophages (Chinetti et al. 2001) and exerts
many pleiotropic effects on vascular remodelling and inflammatory responses.
PPARγ is activated by natural ligands such as polyunsaturated fatty acids,
15-deoxy-Δ12,14-prostaglandin J2 and oxidised fatty acids. In addition, pharmaco-
logical PPARγ agonists, the thiazolidinediones, are used as insulin sensitisers.
Furthermore, PPARγ is the major regulator of adipogenesis (Tontonoz and
Spiegelman 2008). PPARγ regulates the expression of adipokines such as
adiponectin (Yu et al. 2002). In addition to this adipogenic effect, PPARγ displays
anti-inflammatory actions and promotes the polarisation of monocytes towards
alternative M2 macrophages (Bouhlel et al. 2007).
PPARβ/δ is activated by long-chain unsaturated fatty acids, and several syn-
thetic ligands have been designed including L-165041, GW501516 and GW0742.
However, no PPARβ/δ agonists are in clinical use yet. PPARβ/δ is highly expressed
in skeletal muscle where it increases the expression of fatty acid oxidation-related
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genes. This nuclear receptor also improves lipid metabolism by reducing
triglycerides and LDL-C levels and by increasing HDL-C levels. Moreover,
PPARβ/δ activation increases insulin sensitivity (Oliver et al. 2001).
Overall, PPARs are involved in the control of lipid lipoprotein and glucose
metabolism as well as in the inflammatory response (Lefebvre et al. 2006).
3.2 Current State
Among the pharmacologically used PPARα ligands are the fibrates, which are
currently clinically used as hypolipidaemic drugs. Clinical benefits of fibrates
were reported in primary and secondary intervention trials and reviewed in a
meta-analysis (Jun et al. 2010). In line with their capacity to increase HDL-C and
reduce triglycerides and LDL-C (Jun et al. 2010), their effects on the incidence of
coronary heart disease appear most pronounced in patients with high triglycerides
(>200 mg/dL) and/or low HDL-C (<40 mg/dL), although this has not yet been
formally proven in a dedicated trial in type 2 diabetes patients (Suh et al. 2012;
Keech et al. 2005).
Each PPAR isoform displays specific roles, with PPARα controlling lipid
metabolism, whereas PPARδ improves also glucose metabolism. An interesting
strategy consisted in the development of dual agonists with synergistic effects on
different PPAR isoforms and minimal side effects (Rosenson et al. 2012). In this
context, Roche developed a dual PPAR α/γ agonist, aleglitazar. Despite promising
results in the synchrony study, with an improvement of lipid and glucose
parameters in type 2 diabetes patients (Henry et al. 2009), the AleCardio phase
III trial failed due to adverse effects on heart failure. Subsequently, all trials with
aleglitazar were stopped (press report: http://www.roche.com/media/media_
releases/med-cor-2013-07-10.htm).
3.3 Future Perspectives
Some limitations of fibrate therapy are their relatively weak activity on PPARα and
their efficacy that depends on the targeted population (Staels 2010). To address
these issues, several highly selective and potent PPAR agonists were developed
(Fruchart 2013). The KOWA Company is developing K-877, a potent PPARα
agonist. In a comparative clinical trial (International Clinical Trials identifier:
JPRN-JapicCTI-121764), patients with hypertriglyceridaemia and low HDL-C
were treated with K-877 or fenofibrate for 12 weeks. The first results showed that
the increase of HDL-C is stronger by K-877 than by fenofibrate. In addition, none of
the adverse effects induced by fenofibrate, such as increased levels of serum
homocysteine and creatinine, were observed in K-877-treated patients (http://
www.kenes.com/eas2012/abstracts/pdf/525.pdf). This molecule is currently in
phase II in the USA and EU (International Clinical Trials identifier:
EUCTR2013-001517-32-SE) and in phase III clinical trials for atherosclerotic
dyslipidaemia in Japan (International Clinical Trials identifier: JPRN-JapicCTI-
132067).
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A HDL-inducer developed by Cerenis Therapeutics is a specific PPARδ agonist,
CER-002. The phase I clinical trial demonstrated that CER-002 is well-tolerated
without major adverse effects (press report: http://www.drugs.com/clinical_trials/
cerenis-therapeutics-announces-successful-completion-phase-clinical-trial-cer-
002-cardiovascular-4272.html). Another selective PPARδ agonist, HPP593, is cur-
rently tested in healthy subjects, and its effect on LDL and HDL cholesterol as well as
triglycerides will be determined (press report: http://www.ttpharma.com/
TherapeuticAreas/MetabolicDisorders/Dyslipidemia/HPP593/tabid/118/Default.aspx).
The synthetic, non-thiazolidinedione PPARγ compound, INT131, improves
glucose tolerance in rodent models of diabetes to a similar extent as rosiglitazone.
However, no major adverse events, such as weight gain, haemodilution or plasma
volume increase, were observed in INT131-treated rats compared to rosiglitazone-
treated rats (Motani et al. 2009). In a randomised, double-blind study, type 2 diabe-
tes patients were treated 4 weeks with 1 or 10 mg of INT131. Consistent with the
in vitro data, INT131 displayed a glucose-lowering activity and increased HDL-C
levels without changing other lipid parameters (Dunn et al. 2011). This molecule is
currently tested in a comparative clinical study in type 2 diabetes patients treated
for 24 weeks with INT131 or pioglitazone (ClinicalTrials.gov Identifier:
NCT00631007).
In addition, a phase I clinical trial is ongoing to evaluate safety, tolerability and
pharmacokinetic behaviour of a new PPAR α/γ modulator, DSP-8658, in type
2 diabetes mellitus and healthy subjects (ClinicalTrials.gov Identifier:
NCT01042106). DSP-8658 is a non-thiazolidinedione compound which exhibits
potent anti-hyperglycaemic effects, reduces plasma triglycerides and increases
HDL-C levels with less side effects on, e.g., body weight gain (press report:
www.ds-pharma.com/ir/library/presentation/pdf).
Finally, the new dual PPAR α/δ agonist GFT505, developed by Genfit, reduced
plasma triglycerides and increased HDL-C levels in abdominally obese patients
with either dyslipidaemia or prediabetes (Cariou et al. 2011). A phase IIb clinical
trial is ongoing to evaluate the efficacy of GFT505 in patients with non-alcoholic
steatohepatitis (ClinicalTrials.gov identifier: NCT01694849), an unmet clinical
need because of the continuous increasing incidence of fatty liver disease due to
abdominal obesity (Tailleux et al. 2012).
These novel selective PPAR agonists, K-877, CER-002, DSP-8658, INT131 and
GFT505 appear promising drugs to treat the cardiovascular risk associated with
metabolic syndrome and type 2 diabetes.
4 Novel LXR Agonists
4.1 Biological Mechanisms
Liver X receptors (LXRs) are nuclear receptors. There are two isoforms, LXRα and
LXRβ, with LXRα mainly expressed in the liver, intestine, kidney and spleen,
whereas LXRβ is ubiquitously expressed (Repa and Mangelsdorf 2000). Oxysterols
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and other cholesterol metabolites are natural ligands for LXRs, and several syn-
thetic ligands were also developed (T0901317, GW3965). After their binding,
LXRs modulate the expression of genes involved in cholesterol metabolism and
transport and glucose metabolism (Schultz et al. 2000; Laffitte et al. 2003). Activa-
tion of LXR in macrophages induces ABCA1, ABCG1 and apoE expression which
promotes cholesterol efflux and reverses cholesterol transport (Sabol et al. 2005;
Venkateswaran et al. 2000; Laffitte et al. 2001). Besides their effects on lipid
metabolism, LXRs display anti-inflammatory properties (Joseph et al. 2003) and
improve glucose tolerance. In contrast to their beneficial effects, LXR activation
induces fatty acid synthesis (de novo lipogenesis) related to a modulation of the
hepatic expression of sterol regulatory element-binding protein (SREBP-1),
stearoyl-CoA desaturase-1 (SCD-1), fatty acid synthase (FAS) and acetyl-CoA
carboxylase (ACC) (Schultz et al. 2000). This upregulation of hepatic SREBP-1c
expression may contribute to the elevation of plasma triglycerides.
4.2 Current State
T0901317 and GW3965, the most studied agonists, have been extensively
described to exert beneficial effects in preclinical animal models of cardiovascular
diseases, neurodegenerative diseases and inflammation (Terasaka et al. 2003;
Joseph et al. 2002, 2003; Zelcer et al. 2007). However, LXR ligands have not yet
been tested in clinical trials because of their adverse effects such as an increase of
hepatic lipogenesis, hypertriglyceridaemia and hepatosteatosis (Calkin and
Tontonoz 2012). These lipogenic effects have been assigned to LXRα which is
highly expressed in the liver (Lehrke et al. 2005; Bradley et al. 2007). Therapeutic
strategies are now focusing on the development of selective LXR modulators,
LXRβ-specific agonists and/or ligands which act selectively in specific tissues in
order to maintain positive effects on cholesterol metabolism and minimise the lipid
side effects.
LXR-623 (WAY-252623) is a novel synthetic ligand with higher potency for
LXRβ, which induces plaque regression in combination with statins in a rabbit
model of atherosclerosis (Giannarelli et al. 2012). LXR-623 entered in a phase I
trial (NCT00366522) to test tolerance and safety in humans (Katz et al. 2009).
However, its development was interrupted because of adverse effects in the central
nervous system with potential induction of psychiatric disorders.
4.3 Future Perspectives
A novel synthetic, steroidal LXR ligand, ATI-111, has been developed. This mole-
cule is most potent on LXRα with modest effects on LXRβ. The higher efficiency on
LXRα allows its utilisation at lower concentrations than T0901317, which probably
reduces cytotoxicity and also adverse effects such as hypertriglyceridaemia. To
determine whether ATI-111 does not provoke hypertriglyceridaemia, mice were
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treated with 5 mg.kg-1.day-1 of ATI-111 for 8 weeks. Interestingly, a decrease of
plasma triglyceride levels and VLDL cholesterol was observed in ATI-111-treated
mice (Peng et al. 2011). In addition, ATI-111 exhibits anti-inflammatory properties
with a decrease of LPS-induced inflammatory gene expression. Furthermore,
ATI-111 reduced atherosclerotic lesions in LDL-receptor-deficient mice (Peng
et al. 2011). Altogether, accumulating proofs from in vitro and in vivo animal studies
show beneficial effects of ATI-111 on atherosclerosis with anti-inflammatory effects,
a reduction of hypertriglyceridaemia and a consequential decrease of atherosclerotic
lesions. Further molecular investigations are necessary to assess the full potential of
ATI-111 in clinical trials.
A phase I clinical trial with XL-652 (XL-014), a novel LXR ligand, is currently
ongoing to evaluate its safety (www.exelixis.com/pipeline/xl652).
5 RVX-208
5.1 Biological Mechanisms
An alternative strategy to raise the serum level of HDL-C is to increase one of the
major HDL proteins, apolipoprotein AI (apoAI). In this context, after a screening
assay in HepG2 cells to identify molecules inducing apoAI, Resverlogix Corpora-
tion has selected and developed an oral quinazoline molecule, RVX-208
(RVX-000222). This molecule, a derivative of resveratrol, increases hepatic
apoAI production (Bailey et al. 2010). Thus RVX-208 is a small molecule for
potential treatment of cardiovascular diseases.
5.2 Current State
First in vitro experiments have shown that RVX-208 increases apoAI mRNA,
protein and the release of apoAI in the medium of HepG2 cells (Bailey
et al. 2010). To test its efficiency in vivo, male monkeys were orally treated with
RVX-208 for 63 days. This in vivo study in nonhuman primates demonstrated that
RVX-208 increases in a dose-dependent manner serum levels of apoAI and pre-
β-HDL-C (Bailey et al. 2010). No adverse effects were observed in monkeys. In
humans, 7 days of treatment increased preβ-HDL, apoAI and cholesterol efflux
(Bailey et al. 2010). The efficacy and safety of RVX-208 was furthermore
investigated in a phase II randomised trial including 299 statin-treated patients
with coronary artery diseases (ASSERT study: NTC01058018). Twice daily admin-
istration of RVX-208 (50, 100 and 150 mg) was well tolerated; however, a transient
elevation in transaminase levels was found in some RVX-208-treated patients.
Furthermore, only a modest increase of HDL-C level (3.2–8.3 %) was observed
(Nicholls et al. 2011). In a next phase IIb clinical study, the ASSURE (ApoAI
Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma
Regression Evaluation) trial, the effect of 26 weeks treatment with RVX-208
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(100 mg) was determined on the progression of coronary atherosclerosis in
323 patients with symptomatic coronary artery disease and low HDL-C levels.
The primary end point, change in atheroma volume determined by intravascular
ultrasound (IVUS), was not met. No significant change in plaque regression was
observed between placebo and RVX-208 group. The question is whether this lack
of beneficial effect on plaque regression is due to the weak efficacy of RVX-208 or
the impossibility to confer beneficial effects on top of statins, since 84 % of patients
were on statin therapy. Furthermore, the increases of apoAI and HDL-C levels did
not differ from placebo, whereas transaminases were again found to be elevated.
Thus, so far, no clinical benefit has been demonstrated with RVX-208 (press report:
communication Nicholls SJ www.clinicaltrialresults.org/Nicholls_ASSURE).
Conclusion
To reduce residual cardiovascular risk persisting after statin therapy, novel
therapeutic strategies based on raising HDL-C are currently under investigation.
However, the utility of increasing HDL-C is not yet established, and pharma-
ceutical manipulation of HDL-C appears to be less efficient than lowering
LDL-C to reduce cardiovascular risk. Moreover, the failure of several clinical
trials with the first members of the CETP inhibitor class, torcetrapib and
dalcetrapib, and the lack of beneficial effects of an increase of HDL-C and the
reduction of cardiovascular events raises doubts about the relevance of the
“HDL-C hypothesis”. These disappointing results highlight the complexity of
HDL metabolism in contrast to that of LDL.
Many biological activities of HDL, such as antioxidant, anti-inflammatory
and antiapoptotic properties, are mediated by different HDL subclasses, and
solely increasing HDL-C may not enhance these functions. Moreover, plasma
HDL contains heterogeneous particle subpopulations whose composition,
metabolism and functionality differ depending on the metabolic status (Besler
et al. 2011). Thus far, the larger randomised placebo controlled phase III clinical
trials have shown that an increase in HDL-C does not benefit the patient, and
thus, future strategies should aim at improving HDL function.
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Abstract
A wealth of evidence indicates that plasma levels of high-density lipoprotein
cholesterol (HDL-C) are inversely related to the risk of cardiovascular disease
(CVD). Consequently, HDL-C has been considered a target for therapy in order
to reduce the residual CVD burden that remains significant, even after applica-
tion of current state-of-the-art medical interventions. In recent years, however, a
number of clinical trials of therapeutic strategies that increase HDL-C levels
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failed to show the anticipated beneficial effect on CVD outcomes. As a result,
attention has begun to shift toward strategies to improve HDL functionality,
rather than levels of HDL-C per se. ApoA-I, the major protein component of
HDL, is considered to play an important role in many of the antiatherogenic
functions of HDL, most notably reverse cholesterol transport (RCT), and several
therapies have been developed to mimic apoA-I function, including administra-
tion of apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides. Based
on the potential anti-inflammatory effects, apoA-I mimetics hold promise not
only as anti-atherosclerotic therapy but also in other therapeutic areas.
Keywords
ApoA-I mimetics • ApoA-I analogues • ApoA-I infusion
Abbreviations
ACS Acute coronary syndrome
ABCA1 ATP-binding cassette transporter A1






FPHA Familial primary hypoalphalipoproteinemia
HCAEC Human coronary artery endothelial cells
HDL-C High-density lipoprotein cholesterol
HDL-sdl HDL selectively delipidated
HDL-VHDL High-density lipoprotein-very high-density lipoprotein
IVUS Intravascular ultrasound
LDL-C Low-density lipoprotein cholesterol
LDL-R Low-density lipoprotein receptor
LPA Lysophosphatidic acid
RCT Reverse cholesterol transport
rHDL Reconstituted HDL
ROS Radical oxygen species
sdLDL Small dense LDL
WD Western diet
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1 Introduction
The beneficial consequences of lowering low-density lipoprotein cholesterol
(LDL-C) on cardiovascular (CVD) events have been unequivocally shown in
numerous intervention studies. A plasma LDL-C reduction of 1.0 mmol/L has
been shown to reduce the risk of major cardiovascular events by approximately
20 %, irrespective of baseline cholesterol or risk. Intensive LDL-C lowering is
therefore advocated in most guidelines (Baigent et al. 2010). However, despite the
efficiency of established therapies, the residual burden of disease remains substan-
tial (Roger et al. 2012). Novel targets for therapy are therefore eagerly awaited in
order to decrease the residual CVD risk.
A large number of epidemiological studies have shown that levels of high-
density lipoprotein cholesterol (HDL-C) are inversely associated with CVD risk.
In fact, it has been calculated from these studies that a 1 mg/dL (0.03 mmol/L)
increase in HDL-C would translate into a 2–3 % reduction of risk for subsequent
coronary events (Gordon et al. 1989). Moreover, levels of HDL-C have been
considered a stronger predictive factor of incident coronary heart disease than
levels of LDL-C (Gordon et al. 1977). Even among patients who attain low levels
of LDL-C while receiving LDL-C lowering therapy, levels of HDL-C remain
predictive for subsequent CVD events (Barter et al. 2007; Jafri et al. 2010).
These epidemiological data do not infer a causal relation between levels of
HDL-C and CVD risk. However, a number of antiatherogenic mechanisms have
been ascribed to HDL. HDL has been shown to play a pivotal role in reverse
cholesterol transport (RCT), a pathway by which cholesterol is transported from
peripheral cells (e.g., macrophages within the vessel wall) to the liver for biliary
excretion (Fielding and Fielding 1995). In addition, HDL has been shown to possess
antioxidant, anti-inflammatory (Barter et al. 2004), antithrombotic (Mineo
et al. 2006), and antiapoptotic properties (Suc et al. 1997).
HDL has been considered a target for therapy to lower CVD risk, based on both
these epidemiological and biological arguments of atheroprotection. In recent
years, a number of large clinical trial programs investigating the efficacy of drugs
with an established effect on HDL-C levels have been terminated because of the
inability to induce improvement in clinical outcomes. In addition, treatment-
induced changes in HDL-C were not associated with CVD risk after adjusting for
LDL-C (Briel et al. 2009). Moreover, a number of common genetic variants in
genes coding for proteins involved in HDL metabolism have been shown to alter
levels of HDL-C without showing the anticipated effect on CVD risk (Haase
et al. 2011; Voight et al. 2012). These findings challenge the concept that levels
of circulating HDL-C are causally related to atherosclerosis, and assessment of
HDL functionality has therefore been proposed to better reflect the therapeutic
potential of therapies targeting HDL (deGoma et al. 2008).
Although levels of HDL-C alone may thus be a poor target for therapies,
apolipoprotein A-1 (apoA-I) itself could in fact represent a promising target.
ApoA-I is the major protein component of the HDL particle and considered to
play a pivotal role in many of the antiatherogenic properties attributed to HDL. The
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role of apoA-I in the protection against atherosclerosis has been shown in a number
of rodent studies. In low-density lipoprotein receptor (LDL-R) null mice, apoA-I
deficiency was shown to result in increased atherosclerosis (Moore et al. 2003).
Increased atherosclerotic lesion development was also seen in apoA-I knockout
mice expressing human apolipoprotein B (apoB) when fed a Western diet
(WD) (Voyiaziakis et al. 1998). Additional proof of the antiatherogenic role of
apoA-I was derived from animal models of human apoA-I overexpression and in
mice treated with apoA-I infusions, in which it was consistently shown that apoA-I
provides protection against atherosclerotic lesion formation in proatherogenic
animal models (Duverger et al. 1996; Miyazaki et al. 1995; Rubin et al. 1991).
Moreover, mutations in the gene coding for apoA-I have been shown to alter CVD
risk in humans. Most of the carriers of mutations in the apoA-I gene are
characterized by low levels of HDL-C and an increased risk of CVD (Hovingh
et al. 2004). ApoA-I is widely accepted as an attractive target for therapy based on
the consistent data derived in animal and human studies. Several therapies have
been developed that mimic apoA-I function, including administration of full length
apoA-I, mutated variants of apoA-I, and apoA-I mimetic peptides.
2 ApoA-I Mimetic Peptides
ApoA-I comprises a total of 243 amino acids and its secondary structure resembles
10 amphipathic α-helices that are crucial for its efficient interaction with lipids.
Recently, there has been increasing interest in the application of peptides that
resemble the amphipathic helices in apoA-I as therapeutic agents.
Anantharamaiah et al. synthesized the first apoA-I mimetic peptide, 18A, com-
prising 18 amino acids. Subsequently, several modifications to 18A have been made
to create peptides that more closely mimic apoA-I in its antiatherogenic functions.
For example, blocking the ends of 18A with an amide group and an acetyl group,
thereby creating a peptide called 2 F, increased its helicity and efficiency in
inducing cholesterol efflux (Venkatachalapathi et al. 1993; Yancey et al. 1995).
In addition, tandem peptides composed of more than one amphipathic helix were
shown to have a superior lipid affinity and ability to induce cholesterol efflux from
macrophages compared to peptides that contain only one helix (Anantharamaiah
et al. 1985; Garber et al. 1992; Wool et al. 2008). D’Souza et al. investigated the
effect on cholesterol efflux and anti-inflammatory and antioxidant properties of
22 different bihelical apoA-I mimetic peptides. None of the compounds was
superior in all antiatherogenic functions, and each of the examined antiatherogenic
functions was shown to be primarily affected by specific structural features
(D’Souza et al. 2010). These results indicate that apoA-I mimetic peptides more
closely resembling apoA-I do not necessarily improve all various anti-
atherosclerotic functions. Moreover, combining several apoA-I mimetic peptides,
each mimicking different structural aspects of apoA-I, may prove to be a valuable
strategy to mimic the various anti-atherosclerotic properties of apoA-I.
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2.1 4F
Despite potent anti-inflammatory and antioxidant effects in vitro and in experimen-
tal models, the promise of 4 F in humans has not been a success to date (Navab
et al. 2002, 2004). Two trials of 4 F in patients with CHD or at high risk of CVD
assessed the effect of orally and parenterally administered 4 F on the HDL inflam-
matory index, a measure of HDL-mediated protection against LDL-induced mono-
cyte chemotaxis, providing conflicting results (Bloedon et al. 2008; Watson
et al. 2011). The development of 4 F by Novartis has subsequently been
discontinued. Although a number of differences between the studies may partially
account for the observed discrepancy, the primary outcome measure “HDL inflam-
matory index” has been proven to be largely irreproducible in the majority of
laboratories. In fact, it has been difficult to identify an efficacy parameter for
apoA-I mimetic peptides in human trials altogether, and in lack of standardization,
all trials using HDL quality as readout have been disappointing.
2.2 6F
A disadvantage of many apoA-I mimetic peptides is that they require end blocking
to be effective, which precludes its synthesis by living organisms. Large-scale
production of the peptides for therapeutic use would therefore be too expensive.
In a search for apoA-I mimetic peptides that do not require end blocking, 6 F
yielded promising results.
L-6 F has been shown to possess antioxidant and anti-inflammatory properties in
several mice models (Chattopadhyay et al. 2013; Navab et al. 2013). Given that the
small intestine may be an important site of action for apoA-I mimetic peptides, the
observed reduction in plasma levels of the proinflammatory and proatherogenic
lipid lysophosphatidic acid (LPA) following administration of L-6 F is of particular
interest. Feeding LDL-R knockout mice a Western diet does result in changes in
intestinal gene expression and proinflammatory and hypercholesterolemic changes
in serum. Similar changes were observed when mice were fed unsaturated LPA.
Administration of L-6 F reduced intestinal LPA levels and prevented the Western
diet-mediated proatherogenic changes in intestinal gene expression. In addition,
when L-6 F was administered to mice on chow supplemented with LPA, intestinal
levels of unsaturated LPA were significantly reduced, and this decrease correlated
with reduced systemic inflammation and hypercholesterolemia (Chattopadhyay
et al. 2013; Navab et al. 2013). Thus, reducing levels of intestinal LPA may be an
important mechanism of action for L-6 F.
To enable the large-scale production of the peptide, transgenic, 6 F expressing
tomatoes have been developed. Feeding LDL-R knockout mice a Western diet with
and without transgenic tomatoes expressing 6 F improved an array of biomarkers of
inflammation and antioxidant status and significantly reduced aortic lesion area
compared to controls following 13 weeks of treatment (Chattopadhyay et al. 2013).
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2.3 FX-5A
The peptide 5A is synthesized by replacing 5 amino acids of the apoA-I mimetic
peptide 37pA with alanine residues, thereby decreasing its lipid affinity. Although
37pA effectively induces cholesterol efflux, its high lipid affinity is associated with
cytotoxicity because of adverse effects on the integrity of the plasma membrane
(Remaley et al. 2003). As a result of the amino acid substitutions, 5A is less
cytotoxic and induces cholesterol efflux more specifically through ATP-binding
cassette transporter A1 (ABCA1) (Sethi et al. 2008).
The 5A-phospholipid complex has been shown to induce cholesterol efflux both
through ABCA1 and ATP-binding cassette transporter G1 (ABCG1). Administra-
tion of a single intravenous dose of a 5A-phospholipid complex was shown to
enhance reverse cholesterol transport, as evidenced by a flux of cholesterol from
peripheral cells to plasma, an increased amount of cholesterol and phospholipids in
the HDL fraction, and an enhanced fecal sterol and bile acid secretion (Amar
et al. 2010). In addition, 5A has been shown to possess anti-inflammatory and
antioxidant properties (Tabet et al. 2010). To mimic acute inflammation, a
nonocclusive collar was placed around the carotid artery in rabbits following
infusion with 5A-phospholipid. Treatment with 5A-phospholipid significantly
reduced the expression of proinflammatory endothelial adhesion molecules and
neutrophil infiltration compared to placebo, and this effect of 5A infusion was
similar to the effect observed after infusing lipid-free apoA-I or recombinant HDL.
In the same rabbit model, it was shown that 5A-phospholipid reduced the produc-
tion of radical oxygen species (ROS), such as O2
 (Tabet et al. 2010).
The ability of 5A-phospholipid to inhibit the formation of atherosclerosis in vivo
has been demonstrated in apolipoprotein E (apoE) knockout mice. Treatment with
30 mg/kg of intravenous 5A-phospholipid three times per week for 13 weeks
resulted in 30 % reduction in aortic plaque area in both young apoE knockout
mice and older apoE knockout mice with established lesions. The efficiency of the
complex to inhibit plaque formation was shown to be dependent on the constitution
of the phospholipid component. Reconstituting 5A with a sphingomyelin-
containing combination of phospholipids enhanced its anti-atherosclerotic
properties. When apoE knockout mice were treated with this complex using the
same dosing regimen as used in the previously described experiments, there was a
superior 54 % reduction in aortic lesions compared to controls.
In addition to its potent anti-atherosclerotic effects, 5A has been shown to reduce
airway inflammation in murine models of asthma (Yao et al. 2011). Thus, the
therapeutic potential of 5A extends beyond atherosclerotic cardiovascular disease.
As of yet, 5A has not been tested in humans. However, the first clinical trial is
planned in the near future.
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2.4 ATI-5261
Bielicki et al. developed ATI-5261, a peptide consisting of 36 amino acids forming
a single amphipathic helix with high aqueous solubility that induced ABCA1-
mediated cholesterol efflux with similar efficiency as apoA-I (Bielicki
et al. 2010). LDL-R knockout mice received a high-fat Western diet for 13 weeks
while concomitantly receiving daily intraperitoneal injections of ATI-5261 during
the last 6 weeks. In another model, ApoE knockout mice received aWestern diet for
18 weeks, followed by a chow diet with concomitant intraperitoneal injections of
ATI-5261 every other day for another 6 weeks. The aortic lesion area and plaque
lipid content were significantly reduced in mice treated ATI-5261 compared to
mice receiving placebo. The decrease in atherosclerosis was accompanied by
increased fecal sterol excretion, which is indicative of increased RCT upon
ATI-5261 treatment.
2.5 ETC-642
ETC-642 is a complex of a 22-amino acid peptide that forms an amphipathic helix
and phospholipids. The complex has been shown to exert multiple favorable effects
on LDL and HDL particles (Di Bartolo et al. 2011b). Following 12 weeks of
treatment in rabbits, a shift in LDL subfractions toward less negatively charged
particles was observed, indicating a reduction in proinflammatory oxidized LDL.
Moreover, a reduction in the particularly atherogenic small dense LDL (sdLDL)
subfraction was noticed. Shortly after infusion of ETC-642, there was also a shift in
HDL subfractions toward the antiatherogenic pre-β fraction. Moreover, ETC-642
was shown to be a potent inducer of cholesterol efflux from human macrophages in
in vitro assays. It has also been shown in vivo to increase the cholesterol content in
the HDL fraction, which may indicate increased reverse cholesterol transport
(Di Bartolo et al. 2011a; Iwata et al. 2011). The anti-inflammatory effects of
ETC-642 have been demonstrated in rabbit models of acute and chronic inflamma-
tion (Di Bartolo et al. 2011a, b). ETC-642 reduced endothelial adhesion molecule
expression both in collared carotid arteries and in the aorta of cholesterol-fed
rabbits, and this reduction was similar to effect observed in animals treated with
reconstituted HDL. ETC-642 has been shown to induce an anti-inflammatory
effect, as HDL isolated from ETC-642-treated rabbits decreased TNF-α-induced
expression of NF-kB and endothelial adhesion molecules in human coronary artery
endothelial cells (HCAECs) (Di Bartolo et al. 2011b). In addition, ETC-642
inhibited TNF-α-induced monocyte adhesion in HCAECs (Di Bartolo et al. 2011a).
The efficiency of ETC-642 as an anti-atherosclerotic agent has been
demonstrated using intravascular ultrasound (IVUS) in hyperlipidemic rabbits
that were treated with either low or high dose (15 or 50 mg/kg, respectively) or
placebo two times per week for 12 weeks. Treatment with high-dose ETC-642
significantly inhibited plaque formation compared to controls (Iwata et al. 2011).
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3 ApoA-I-Based Infusion Therapy
Lipid-poor pre-β HDL is the main acceptor of cholesterol from peripheral cells,
including macrophages in the subendothelial vessel wall, by means of the interac-
tion between apoA-I and the ABCA1 (Kontush and Chapman 2006). Largely based
on the findings that apoA-I overexpression and apoA-I infusion in animal models
do inhibit plaque formation, it is anticipated that infusion of apoA-I-containing
particles, such as lipid-poor pre-β HDL, has direct beneficial effects on
atherosclerosis.
3.1 HDL-VHDL Infusions
The atheroprotective effect of infusions of apoA-I-containing particles was first
shown in the 1980s by Badimon et al. Cholesterol-fed rabbits were treated with
8 weekly infusions of homologous high-density lipoprotein-very high-density lipo-
protein (HDL-VHDL) obtained by ultracentrifugation. Following the 8-week treat-
ment period, a significant reduction in the aortic surface area covered by
atherosclerotic-like lipid-rich lesions was found in HDL-VHDL-treated animals,
compared to controls (37.9 % vs. 14.9 %). The reduced formation of aortic lesions
was accompanied by a reduced total lipid deposition in the vascular wall and liver,
whereas no significant differences in plasma lipid profiles were noted between both
groups (Badimon et al. 1989).
It was subsequently shown that HDL-VHDL infusions did not only inhibit
plaque formation, but also reduced the extent of preexisting lesions in a model
where rabbits were fed an atherogenic diet for 60 days to induce atherosclerotic
lesions (group 1). Two groups were treated with an additional 30 days of
cholesterol-rich diet, with or without weekly HDL-VHDL infusions during the
last 30 days (groups 2 and 3). Treatment with HDL-VHDL significantly reduced
the aortic surface area covered by fatty streaks (17.8 % in treated rabbits vs. 34 and
38.8 % in control groups) as well as aortic lipid accumulation (Badimon
et al. 1990).
3.2 Purified ApoA-I Infusions
The initial studies performed by Badimon et al. showed that infusions of
HDL-VHDL did result in protection against atherosclerosis. Miyazaki
et al. subsequently tested the hypothesis that infusions of purified apoA-I would
have similar effects. In their first experiment, rabbits were fed an atherogenic diet
for 90 days. During the last 30 days, half of the rabbits received weekly injections of
purified apoA-I. Treatment with purified apoA-I resulted in a significant reduction
in the proportion of the aortic surface area covered by fatty streaks, to a similar
extent to treatment with HDL-VHDL (46.0 % vs. 23.9 %). In a second experiment,
Miyazaki et al. studied whether purified apoA-I infusions induced regression of
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established plaques. Rabbits were fed an atherogenic diet for 105 days. Group 1 was
sacrificed on day 105. Groups 2, 3, and 4 were fed a chow diet for an additional
60 days. Group 3 received infusions of purified apoA-I every other day, and group
4 received weekly infusions of a higher dose, while rabbits in group 2 served as
untreated controls. The aortic surface area covered by atherosclerotic lesions
progressed from day 105 to day 165 despite chow diet (50.0 % vs. 86.2 % for
groups 1 and 2, respectively). Compared to the controls in group 2, both groups
3 and 4 showed less aortic surface area covered by atherosclerosis (86.2 %
vs. 70.2 % and 65.7 %, respectively). However, apoA-I infusions did not induce
plaque regression (Miyazaki et al. 1995).
3.3 ApoA-IMilano Infusions
Carriers of the apoA-IMilano mutation are characterized by reduced levels of HDL-C
without the anticipated increased risk of CVD (Franceschini et al. 1980). Compared
to native apoA-I, apoA-IMilano has been shown to induce more ABCA1-mediated
cholesterol efflux, and, in addition, apoA-IMilano has been shown to exert superior
anti-inflammatory and plaque stabilizing properties (Ibanez et al. 2012). Ameli
et al. showed that infusion of recombinant apoA-IMilano effectively reduced the
formation of intimal lesions in cholesterol-fed rabbits following balloon-induced
vascular injury. Twenty rabbits on an atherogenic diet underwent balloon injury of
the femoral and iliac arteries. Eight animals received injections with a complex of
apoA-IMilano and phospholipids on alternating days during a 10-day period, starting
5 days prior to the balloon injury. Eight other animals received only the phospho-
lipid carrier, and 4 animals served as controls; they did not receive any treatment.
Infusions of apoA-IMilano were found to significantly inhibit intimal thickening
following balloon injury (0.49 mm2 vs. 1.14 mm2 and 1.69 mm2) and to reduce
intimal macrophage content. This effect was present while plasma cholesterol
levels remained similar among the groups (Ameli et al. 1994). Subsequent animal
studies have confirmed the ability of infusion of recombinant apoA-IMilano to inhibit
plaque progression and reduce plaque area of established lesions in models of
arterial injury and in apoE-deficient mice (Chiesa et al. 2002; Shah et al. 1998,
2001; Soma et al. 1995). A reduction in plaque lipid and macrophage content has
been demonstrated after only 48 h of a single infusion (Shah et al. 2001).
In the “ApoA-I Milano Trial,” 57 patients with an acute coronary syndrome
(ACS) were randomized to 5 weekly infusions of either a high (45 mg/kg) or a low
dose (15 mg/kg) of a complex of recombinant apoA-IMilano with phospholipid
carriers (ETC-216) or placebo, and the treatment began within 2 weeks after
ACS. Percentage and total atheroma volume and plaque thickness were signifi-
cantly reduced in patients treated with apoA-IMilano compared to baseline as
assessed by IVUS. The infusions with ETC-216 were generally well tolerated.
The small pilot study lacked power to detect dose effects and differences between
the treatment and placebo groups (Nissen et al. 2003). Additional analysis revealed
that treatment with apoA-IMilano had a beneficial effect on arterial wall remodeling
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(Nicholls et al. 2006). In conclusion, regression of atherosclerosis was
demonstrated following short-term infusions, and the results of larger studies with
longer follow-up and clinically relevant end points are eagerly awaited.
3.4 CSL-111 and CSL-112 Infusions
Two subsequent studies investigated the safety and efficacy of infusion of
reconstituted HDL (rHDL), consisting of native apoA-I and phospholipids, on
coronary atherosclerosis. CSL-111 is composed of human apoA-I and soybean
phosphatidylcholine and thereby resembles native HDL. In the “Effect of rHDL
on Atherosclerosis-Safety and Efficacy” (ERASE) trial, a total of 183 patients was
randomized to 4 weekly infusions of either 40 or 80 mg/kg of CSL-111 or placebo,
and this treatment was started within 2 weeks after an ACS. An IVUS and a
quantitative coronary angiography were obtained prior to randomization and
2 weeks after the last infusion. Administration of high-dose CSL-111 was
associated with a high incidence of transaminase elevations, which led to early
discontinuation of the 80 mg/kg study arm. Treatment with 4 weekly infusions of
40 mg/kg of CSL-111 significantly reduced atheroma volume compared to baseline,
to a similar extent as seen in the ApoA-I Milano Trial. However, the differences in
atheroma volume between the study groups did not reach statistical significance.
Nonetheless, the authors conclude that CSL-111 may exert a favorable treatment
effect, as treatment improved plaque characterization index on IVUS and coronary
score on quantitative angiography (Tardif et al. 2007).
Further development of CSL-111 was discontinued after the observation that the
therapy induced a high incidence of liver function abnormalities, possibly related to
the high cholate content of the CSL-111 particle.
CSL-112, a second-generation compound with no liver toxicity (Krause and
Remaley 2013), has been tested in two phase 1 studies comprising a total of
93 healthy individuals. In the single-dose study, subjects received doses of up to
135 mg/kg, and in the multiple-dose study, 36 subjects were divided into four
groups. Groups 1 and 2 received 4 weekly infusions of either low- or high-dose
CSL-112, group 3 received a low dose of CSL-112 twice weekly for 4 weeks, and
group 4 received placebo. Infusion of CSL-112 resulted in a dose-dependent
increase in apoA-I, which remained above baseline levels for 3 days. A rapid
36-fold increase in pre-β HDL levels was noted, which was accompanied by
increased ABCA1-mediated cholesterol efflux (maximum increase 270 % com-
pared to baseline). Importantly, CSL-112 did not cause clinically relevant
elevations of liver function parameters (Easton et al. 2013). A phase 2a study of
CSL-112 in patients with stable CVD was recently completed, and the results are
eagerly awaited.
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3.5 CER-001 Infusions
CER-001, an engineered rHDL particle comprising recombinant human wild-type
apoA-I and diphosphatidylglycerol and sphingomyelin, was designed to mimic
nascent pre-β HDL. CER-001 infusions were shown to reduce atherosclerotic
plaque size and aortic macrophage and lipid content in atherosclerosis-prone
mice (Goffinet et al. 2012). A phase 1 randomized crossover study evaluated dose
ranges from 0.25 to 45 mg/kg in 32 dyslipidemic volunteers. CER-001 infusions
were well tolerated and did not show any safety issue at any dose; in particular there
were no liver enzyme elevations. Following administration of a single infusion of
low doses of CER-001, plasma total cholesterol and cholesterol in the HDL fraction
were significantly elevated (almost 700 % increase in the HDL fraction at the
45 mg/kg dose), which may indicate mobilization of cholesterol from peripheral
tissues (Keyserling et al. 2011). Cholesterol esterification was also observed,
consistent with LCAT activation. Three phase 2 trials are currently investigating
the effects of CER-001 on atherosclerotic plaques. The “Can HDL Infusions
Significantly Quicken Atherosclerosis Regression” (CHI-SQUARE) trial is
designed to investigate whether CER-001 infusions induce plaque regression in
patients with ACS. In total, 507 patients have been randomized to 6 weekly
infusions of three ascending doses of CER-001, or placebo. The primary outcome
measure is the absolute change in plaque volume, as determined by IVUS, from
baseline to 3 weeks after the last infusion (NCT01201837). In parallel, two open-
label trials are currently evaluating the effects of CER-001 on plaque volume. In the
Modifying Orphan Disease Evaluation (MODE) trial (NCT01412034), a total of
23 patients with homozygous familial hypercholesterolemia (FH) is treated for
6 months with biweekly infusions with CER-001. The primary outcome measure
in this trial is the percent change in carotid mean vessel wall area as assessed by
3Tesla MRI. A similar regimen is followed in the investigator-driven SAMBA trial,
conducted in patients with very low or absent HDL due to genetic defects—familial
primary hypoalphalipoproteinemia (FPHA) (EudraCT number 2011-006188-23).
Preliminary results presented at the 2013 PACE Snapshot session (ESC,
Amsterdam) indicate that CER-001 increases RCT and may effectively reduce
aortic atheroma volume.
These studies will provide valuable information about the clinical utility of
CER-001 infusions in patients at increased CVD risk.
3.6 Modified ApoA-I
The rapid renal clearance of lipid-poor apoA-I may limit the therapeutic potential of
apoA-I-based therapies. TripA-I represents a trimeric apoA-I analogue that func-
tionally resembles wild-type apoA-I, with a prolonged half-life in plasma due to its
increased size (Graversen et al. 2008; Ohnsorg et al. 2011). Intravenous treatment
with tripA-I decreased the progression of atherosclerotic lesion size in LDL-R
knockout mice on an atherogenic diet, although tripA-I did not affect aortic
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atherosclerotic lesion size in uremic apoE knockout mice (Graversen et al. 2008;
Pedersen et al. 2009).
4 Selective Delipidation
Given that cholesterol-poor HDL particles are particularly effective in inducing
reverse cholesterol transport, a procedure has been developed that selectively
delipidates large, cholesterol-rich HDL particles, thereby creating small, lipid-
poor HDL particles similar to small α- and pre-β-like HDL (HDL selectively
delipidated or HDL-sdl). The technique involves mixing plasma with two
delipidation reagents, followed by bulk separation by gravity and subsequent
passage through a charcoal column to remove residual reagents (Sacks
et al. 2009). Potential benefits of this technique are the fact that autologous particles
are reinfused, which is anticipated to limit potential toxicity, and that the reinfused
pre-β HDL particles are deemed particularly effective in promoting cholesterol
efflux. Sacks et al. showed that 12 weekly infusions of selectively delipidated HDL
reduced diet-induced atherosclerosis in monkeys, as assessed using IVUS.
Delipidated small HDL particles were entirely converted into large α-HDL particles
after infusion. Combined with the finding that selectively delipidated plasma
induced a seven-fold increase in ABCA1-mediated cholesterol efflux, this may
indicate enhanced reverse cholesterol transport (Sacks et al. 2009). Waksman
et al. subsequently randomized 28 patients undergoing cardiac catheterization for
ACS to 7 weekly infusions with either selectively delipidated HDL or control
plasma to evaluate the safety of the Lipid Sciences Plasma Delipidation System-
2 (LS PDS-2) and to explore the potential effects on atheroma volume. The
treatment was well tolerated by all patients. On average, there was a 28-fold
increase in pre-β-like HDL following delipidation compared to baseline. IVUS
was obtained during cardiac catheterization for the ACS and after 2 weeks of the
last treatment. A trend toward regression of total atheroma volume was found in
patients treated with selective delipidation, while a small increase in atheroma
volume was observed in the control group. Although the sample size was too
small to detect significant effects on atheroma volume, the trend toward plaque
regression can be considered as a beneficial effect. Additional studies in larger
cohorts of patients will provide a more definite answer to the question whether
delipidation is a potential benefit for patients suffering from an ACS (Waksman
et al. 2010).
Conclusion
The development of apoA-I analogues has been driven by the observation that
apoA-I plays a pivotal role in the antiatherogenic capacity of HDL particles.
A large number of apoA-I analogue proteins have been studied in vitro and
some did show beneficial effects. However, “the proof of the pudding will be in
the eating:” well-designed clinical trials in patients are indispensable to address
the role of apoA-I mimetics and alike in atherosclerosis regression.
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The clinical potential of rHDL particles reaches beyond the treatment of
atherosclerosis. For example, rHDL particles labeled with contrast-generating
agents, such as gadolinium or 125I, can be used as natural nanoparticles in
medical imaging to visualize natural targets such as macrophages in atheroscle-
rotic plaques or other targets by attaching targeting molecules (Ryan 2010;
Stanley 2014). In addition, rHDL can be used as a vector for drug transport by
incorporating lipophilic drugs into rHDL particles, which may decrease drug
toxicity and increase bioavailability (Stanley 2014).
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Abstract
The specificity of Watson–Crick base pairing and the development of several
chemical modifications to oligonucleotides have enabled the development of
novel drug classes for the treatment of different human diseases. This review
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focuses on promising results of recent preclinical or clinical studies on targeting
HDL metabolism and function by antisense oligonucleotides and miRNA-based
therapies. Although many hurdles regarding basic mechanism of action, deliv-
ery, specificity, and toxicity need to be overcome, promising results from recent
clinical trials and recent approval of these types of therapy to treat dyslipidemia
suggest that the treatment of HDL dysfunction will benefit from these unique
clinical opportunities. Moreover, an overview of monoclonal antibodies (mAbs)
developed for the treatment of dyslipidemia and cardiovascular disease and
currently being tested in clinical studies is provided. Initial studies have shown
that these compounds are generally safe and well tolerated, but ongoing large
clinical studies will assess their long-term safety and efficacy.
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1 Antisense Oligonucleotides
Milestone discoveries of the specificity of Watson–Crick base pairing and of RNA
interference and the importance of different RNAs in the genomic regulation of
living organisms have led to the emergence of different RNA-based therapeutics
that hold the promise for the silencing of “drug-able” targets. Although several
classes of RNA-derived therapeutics have reached clinical trials, many hurdles and
challenges have reduced the number of RNA drugs that reach the market. The
recent approvals of an antisense oligonucleotide (mipomersen) by FDA and a gene
therapy (Glybera) by EMA, as well as several ongoing clinical trials, envision to
this type of therapeutics with real future successes. Antisense oligonucleotides
(ASOs), ribozymes, aptamers, miRNAs, and siRNAs are only some examples of
the wide range of RNA-based therapeutics.
1.1 Making Sense of Antisense
The concept underlying antisense technology is simple and straightforward.
Making it simple, during the first step of protein synthesis, DNA is transcribed
into the complementary sequence of a messenger RNA (mRNA) molecule. The
sequences of these “sense” molecules are translated into amino acids to form
proteins. The use of an oligonucleotide sequence tailored complementary, by
virtue of Watson–Crick base pair formation—an “antisense” strand—recognizes
the specific sequence on the mRNA strand, thus preventing it from being translated
into a protein and blocking the function of a gene, as it was first shown by Paul
C. Zamecnik (Zamecnik and Stephenson 1978). This conceptually simple approach
has given rise to a wide variety of oligonucleotide chemistries, and a new class of
therapeutic compounds called antisense drugs continues to expand.
A milestone in this therapeutic arena was the FDA approval of fomivirsen
(marked as Vitravene) as the first antisense oligonucleotide-based therapeutic for
the treatment of a human disease in 1998, namely, for the treatment for cytomega-
lovirus retinitis. After numerous clinical trials of therapeutic oligonucleotides
against several types of diseases (Sehgal et al. 2013), it was not until 2013
(15 years later) that the FDA approved the second antisense oligonucleotide-
based therapeutic, mipomersen (marked as Kynamro), for the treatment of homo-
zygous familial hypercholesterolemia by the inhibition of apolipoprotein B.
ASOs, both RNA and DNA molecules, are unstable in vivo due to the large
amount of nucleases in plasma or cells. Moreover, problems of immune activation
delivery, specificity, and other hurdles have delayed the jump from clinical trials to
the market. For this, significant effort has been expanded to develop nuclease-
resistant oligonucleotides with reduced immunogenicity as well as improved phar-
macokinetic and pharmacodynamic properties. Many chemical modifications
(Fig. 1) have been successfully developed to overcome all these hurdles.
One of the earliest chemical modification for therapeutic oligonucleotides was
the phosphorothioate backbone modification (Marcus-Sekura et al. 1987; Campbell
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et al. 1990). The replacement of the nonbridging oxygens by sulfur dramatically
changed the biological properties of the oligonucleotide, making them excellent
candidates for antisense application: The modified oligonucleotides display
increased resistance to nucleolytic degradation, increased affinity for plasma
proteins, and thus reduced clearance. They are also highly soluble and elicit
RNase H activity which mediate the cleavage of the target mRNA (Bennett and
Swayze 2010).
Sugar modification—mostly chemical substitution at the 20hydroxyl group—has
conferred better drug-like properties to these molecules and have differentiated the
various therapeutic strategies followed by pharmaceutical companies. 20–O-meth-
ylation (20-OMe) enhances both binding affinity and nuclease resistance, but
reduces off-target effects (Yoo et al. 2004; Prakash et al. 2005). 20-fluoro (20-F)
modification also increases the binding affinity for the target driven by the electro-
negative substituent at this position (Monia et al. 1993; Bennett and Swayze 2010).
The 20O-methoxyethyl (20-MOE) modification increases binding affinity and resis-
tance to nucleases as well (Geary et al. 2001; Yu et al. 2004). These kinds of
modifications allow the oligonucleotides to adopt the most energy-favorable con-
formation, thus improving their pharmacological properties, and have enabled
Fig. 1 Examples of chemical modifications used in antisense oligonucleotides and miRNA
therapy
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several MOE-modified drugs to enter clinical trials (Bennett and Swayze 2010).
Another revolutionary sugar modification is the locked nucleic acids (LNA). In the
LNA, the ribose moiety is modified with an extra bridge connecting the 20 oxygen
and 40 carbon (Fig. 1) (Kumar et al. 1998). The bridge “locks” the ribose in the
30-endo (Northern) conformation of sugar, which is often found in the A-form
duplexes. This chemical characteristic increases hybridization, potency, and nucle-
ase resistance but also toxicity in some cases (Swayze et al. 2007). Several
LNA-modified drugs have also entered clinical trials (Sehgal et al. 2013). Several
other chemical modifications to the sugar moiety have been reported in the litera-
ture; however not much of them are on clinical trials yet.
An alternative interesting strategy that improves the cellular uptake, in vivo
stability, and pharmacokinetic properties is the conjugation of the oligonucleotides
to different ligands, for example, to certain types of cell-permeable/penetrating
peptides (Oehlke et al. 2002) or carbohydrates (Zatsepin and Oretskaya 2004).
Moreover several other conjugation methods have been experimentally developed
including nanostructures, liposomes, bile acid, flavin, poly(ethylene glycol), and
others (Karinaga et al. 2006; Singh et al. 2010; Gonzalez-Carmona et al. 2013).
However, for most of them, several challenges remain to be addressed before their
preclinical and clinical development (Lee et al. 2013a, b). Cholesterol conjugation
of oligonucleotides has been reported to work for multiple antisense mechanisms.
Cholesterol conjugation enhances the cellular uptake, particularly hepatic, and
increases in vivo stability (Holasova et al. 2005; Krutzfeldt et al. 2005, 2007).
Even when it is not free of unwanted side effects, as many other antisense
chemistries, cholesterol conjugation is a promising strategy to develop drug
therapies.
1.2 Therapeutic Antisense Oligonucleotides to Treat
Dyslipidemia
After less than 7 years of clinical trials (Kastelein et al. 2006; Raal et al. 2010), the
first antisense oligonucleotide to treat dyslipidemia reached the market in 2013.
Mipomersen sodium (marketed as Kynamro™; ISIS Pharmaceutical) is an ASO
inhibitor of apolipoprotein B-100 synthesis. It is indicated as an adjunct to lipid-
lowering medications to reduce LDL cholesterol, apolipoprotein B (apoB), total
cholesterol, and non-HDL cholesterol in patients with homozygous familial hyper-
cholesterolemia. Other antisense therapies for the treatment of dyslipidemia are
in clinical or preclinical studies, namely, the antisense drug to reduce apoli-
poprotein C-III (ISIS-APOCIIIRx) (Graham et al. 2013), intended to lower tri-
glyceride production in patients with familial chylomicronemia or severe high
hypertriglyceridemia, the antisense drug to reduce apolipoprotein(a) LP(a) in
the liver (ISIS-APO(a)Rx) or the antisense drug to reduce angiopoietin-like 3 pro-
tein (ISIS-ANGPTL3Rx). An ASO against the hepatic microsomal triglyceride
transfer protein (MTP) has also been evaluated, but even when it consistently
reduced the hepatic VLDL/triglyceride secretion, it led to hepatic triglyceride
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accumulation and biomarkers of hepatotoxicity relative to apoB ASO, due in part to
enhanced expression of peroxisome proliferator activated receptor γ target genes
and the inability to reduce hepatic fatty acid synthesis (Lee et al. 2013a).
Thanks to genetic studies, mutations in the proprotein convertase subtilisin/
kexin type 9 (PCSK9) were originally found to cause autosomal dominant hyper-
cholesterolemia (Abifadel et al. 2003), which was further validated by loss-of-
function mutations (Cohen et al. 2005) that lead to reduced cholesterol levels and
reduced coronary heart disease (Cohen et al. 2006). PCSK9 encodes NARC-1
(neural apoptosis-regulated convertase), a human subtilase that is highly expressed
in the liver and the intestine and circulates in plasma. PCSK9 binds to the LDL
receptor and promotes its degradation in the endosomal/lysosomal pathway,
thereby reducing LDL uptake from the circulation and increasing plasma choles-
terol levels. After the premature Phase I trial termination of the PCSK9 phosphor-
othioate LNA RNase H antisense inhibitor SPC5001 (Santaris Pharma) and the
phosphorothioate 20 MOE RNase H PCSK9 antisense inhibitor (BMS-844421;
BMS/ISIS), probably due to side effects (van Poelgeest et al. 2013), only
ALN-PCS siRNA (Alnylam Pharmaceutical) entered Phase II clinical studies to
target PCSK9 for the treatment of hypercholesterolemia. However, this strategy
competes with monoclonal antibodies against PCSK9 that have already entered
Phase III clinical trials (see below).
1.3 Therapeutic Antisense Oligonucleotides for the Increase
of HDL-Cholesterol Levels and Improvement of HDL Function
HDL-cholesterol levels and function can be modified directly or indirectly by
several pathways, some of which have been targeted by ASOs.
1.3.1 Cholesteryl Ester Transfer Protein
One of the first ASO experimentally approached to target HDL levels was directed
against CETP. Sugano’s lab first demonstrated that a single injection of the ASO,
coupled with the complex asialoglycoprotein-poly-L-lysine, into cholesterol-fed
rabbits, reduced CETP activity and increased plasma HDL-cholesterol levels
(Sugano and Makino 1996). This effect was due to reduced liver CETP mRNA
levels, which was accompanied by a reduction in LDL- and/or VLDL-cholesterol
levels. In a longer study, 8-week treatment with the same molecule (30 μg/kg twice
a week) reduced both CETP mass and atherosclerosis in cholesterol-fed rabbits
(Sugano et al. 1998). While triglyceride levels did not change, LDL- and VLDL-
cholesterol levels were significantly decreased by the ASO treatment (Sugano
et al. 1998). Despite these promising preclinical antiatherogenic findings, the
controversial clinical development of CETP inhibitors (Barter et al. 2007; Schaefer
2013) increased the caution for the future development of this type of therapy. In
this context, recent preliminary finding suggests that inhibition of CETP by ASOs
may differ from CETP inhibition by small-molecule inhibitors (Bell et al. 2013).
Indeed, the 20-mer phosphorothioate ASO containing 20-O-methoxyethyl (20MOE)
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targeted to human CETP (ISIS Pharmaceutical) did not only reduce CETP activity
and increase HDL-C levels but also enhance macrophage reverse cholesterol
transport and reduce the accumulation of aortic cholesterol in a CETP transgenic
LDLR/ mice (Bell et al. 2013). This finding together with a previous study
regarding the lack of association of genetic inhibition of CETP (Johannsen
et al. 2012) and possible side effects previously reported for torcetrapib suggests
that not all inhibitors of CETP are equal. Thus inhibition of CETP still holds
promise as a beneficial therapeutic target, but as for other drugs, this needs to be
experimentally and clinically validated.
1.3.2 Endothelial Lipase
Endothelial lipase plays an important role in HDL metabolism (Kuusi et al. 1980;
Voight et al. 2012), and it has been suggested that its inhibition may improve
cardioprotection (Singaraja et al. 2013). In a preliminary study, a 20-mer ASO
containing 20-O-(methoxy)-ethyl (20MOE) modifications on the first five and last
five bases (ISIS Pharmaceutical) to target the rabbit endothelial lipase was tested
in rabbits for 6 weeks (Zhang et al. 2012b). Even though the experimental protocol
did not show a clear increase in HDL-cholesterol levels, the cholesterol content of
large HDL (>12.1 nm) was increased (Zhang et al. 2012b). Whether other ASO
chemistries may increase the impact on HDL-C levels and function is not known,
but this deserves further investigation.
1.3.3 ACAT2
The sterol O-acyltransferase 2, encoded by the SOAT2 gene and originally named
ACAT2 (referred here as ACAT2), is a membrane-bound enzyme, with an acyl-
CoA cholesterol acyltransferase activity, localized in the endoplasmic reticulum.
SOAT2/ACAT2 catalyzes the synthesis of cholesteryl esters from long-chain fatty
acyl-CoA and cholesterol and is involved in cholesterol absorption and the secre-
tion of cholesteryl esters into apoB-containing lipoproteins. ACAT2 is expressed
exclusively in lipoprotein-producing cells, the enterocytes and hepatocytes
(Anderson et al. 1998). While both hepatic and intestinal deletion of ACAT2
improves atherogenic hyperlipidemia and limits hepatic cholesteryl ester accumu-
lation (Zhang et al. 2012a), it has been proposed that specific tissue ACAT inhibi-
tion would be beneficial for atheroprotection (Nissen et al. 2006; Brown
et al. 2008). However, ACAT inhibition is not free of controversies in clinical
development (Nissen et al. 2006). A 20-mer antisense phosphorothioate oligonu-
cleotide containing 2-0-methoxyethyl groups at positions 1–5 and 15–20 was
originally found to reduce hepatic ACAT2 levels and mediate protection against
diet-induced hypercholesterolemia and aortic cholesteryl ester deposition (Bell
et al. 2006). Interestingly, in mice this antisense oligonucleotide (ISIS Pharmaceu-
tical) therapy (25 mg/kg biweekly for 8 weeks) promoted fecal neutral sterol
excretion without altering biliary sterol secretion (Brown et al. 2008). This poten-
tially important finding indicates that the antisense oligonucleotide promotes
non-biliary fecal sterol loss and thus reverses cholesterol transport enhancement.
Pharmacological inhibition of liver ACAT2 by using ASOs has also been shown to
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reduce cholesterol-associated hepatic steatosis (Alger et al. 2010) which may
explain the hypertriglyceridemia observed in mice lacking ACAT2, probably by
enhancing hepatic TG mobilization. In overall, ASO treatment against hepatic
ACAT2 has uncovered other novel benefits distinct from that of HDL function
and increased its therapeutic potential.
Although we are expecting the results of several ongoing clinical trials with
ASOs for different pathologies (Sehgal et al. 2013), the recent approval for com-
mercialization of Kynamro will really increase our interest to follow this therapeu-
tic arena. Even when the long-term toxicity effects and other forms of delivery need
to be evaluated, the promising preclinical results on ASOs to treat HDL levels and
function make them an interesting alternative to small-molecule inhibitors. After
all, opening new possible avenues to treat HDL dysfunction using ASOs makes
more sense than simply awaiting for the discovery of potential small-molecule
inhibitors.
2 miRNAs
Mature microRNAs (miRNAs) are single-stranded, ~21–23 nucleotide (nt) long,
and noncoding RNAs that directly bind, via Watson–Crick base pairing, to
sequences commonly located within the 30untranslated region (30-UTR) of target
mRNAs. This interaction inhibits the translation and/or degradation of mRNAs
(Guo et al. 2010; Krol et al. 2010). However, certain miRNAs can interact with
other target mRNA regions including the 50UTR, coding region, or intron–exon
junction and even increase rather than decrease target mRNA expression
(Vasudevan et al. 2007; Orom et al. 2008; Tay et al. 2008; Schnall-Levin
et al. 2010). RNA sequencing studies have identified ~2,000 miRNAs in our
human genome which are predicted to regulate ~ a third of our genes. The binding
of the “seed” sequence (nucleotides 2–8 at the 50 end of the mature miRNA) is
critical for target selection (Bartel 2009). However, other regions of the miRNA can
bind to the target mRNA and, therefore, almost 60 % of seed interactions are
noncanonical (Helwak et al. 2013). Many miRNAs are evolutionary conserved
among different species. While some of them are ubiquitously expressed, certain
miRNAs are highly expressed or even restricted (Lagos-Quintana et al. 2002; Small
and Olson 2011) to certain cell types and can only target their mRNA target if they
are co-expressed in the same tissue at the same time.
Based on short sequences (“seed”), computational methods and previous valida-
tion studies have revealed that a single miRNA can target hundreds of genes with
either multiple related or different functions in different physiological/pathological
processes or tissues. Likewise, a single mRNA may have different miRNA binding
sites, allowing a coordinated regulation by different miRNAs. While the primary
role of miRNAs seems to be the “fine-tuning” of gene expression (Flynt and Lai
2008), the appearance of this complex RNA-based regulatory network suggests that
miRNAs have probably evolved as buffers against deleterious variation in gene-
expression programs. Even when a single miRNA exerts modest effects on many
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target mRNAs, the additive effect of coordinated regulation of a large suite of
transcripts that govern the same biological process is believed to result in strong
phenotypic outputs (Mendell and Olson 2012). These basic principles of miRNA
mode of function are the basis for a novel and revolutionary type of therapeutics,
called the miRNA-based therapy. However, as the devil is in the details, the high
redundancy among related and non-related miRNAs in the regulation of gene
expression described above reduces the importance of a particular miRNA under
conditions of normal cellular homeostasis. Nevertheless, since under conditions of
stress, the function of miRNAs becomes especially pronounced (Mendell and Olson
2012), the modulation of miRNA function may represent a real alternative to the
conventional one-target drug therapy. However, many hurdles need to be overcome
as other novel players have entered the equation, including pseudo genes (Poliseno
et al. 2010), long noncoding RNAs (lncRNAs) (Cesana et al. 2011), and circular
RNAs (circRNAs) that contain miRNA binding sites. As competing endogenous
RNAs (ceRNAs), they may sequester miRNAs and prevent them from binding to
their mRNA targets (Salmena et al. 2011).
2.1 miRNA-Based Therapy
miRNAs as potential therapeutics have received special attention from the scientific
and clinical audience primarily because of their “promiscuous” mode of action and
the multifactorial nature of most modern metabolic diseases. Moreover, previous
antisense technology and gene therapy approaches, some of them already in market,
have catalyzed the efforts to develop therapies to modulate miRNA levels in vivo.
Although certain questions regarding their biological function, regulation, and
delivery still remain to be answered, the simultaneous modulation of different
components of a complex disease pathway by an miRNA offers a unique and
alternative opportunity to treat disease in a manner that is completely different
from our conventional classical one-target-directed drugs. Eventually this feature
may also enable to bypass tissue insensitivity or drug resistance, characterizing
classical one-target-directed drugs.
Different pharmacological tools have been developed to target miRNA
pathways (van Rooij et al. 2008, 2012; van Rooij and Olson 2012) (Fig. 2). As
miRNAs are generally inhibitors of gene expression, the use of therapies to increase
or block gene expression will result in a decreased or derepression of their mRNA
targets, respectively. Based on these opposite approaches we can classify the
therapeutic application of miRNAs into two strategies. The first strategy involves
an miRNA “gain of function” phenotype, also called “inhibitors,” and aims to
inhibit the function of miRNAs. Several approaches can be utilized for this purpose,
including (1) small-molecule inhibitors directed to regulate miRNA expression,
(2) miRNA masking due to molecules complementary to the 30-UTR of the target
miRNA, resulting in competitive inhibition of the downstream target effects,
(3) miRNA sponges that utilize oligonucleotide constructs with multiple comple-
mentary miRNA binding sites to the target miRNA, and (4) antisense
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oligonucleotides, also known as miRNA antagonists or inhibitors, such as anti-
miRs, locked nucleic acids (LNA), or antagomiRs that by complementarity bind to
miRNAs inducing either duplex formation or miRNA degradation (Davalos and
Suarez 2013). The second strategy involves an miRNA “loss-of-function”
Fig. 2 miRNA-based therapy. Endogenous miRNAs bind to a complementary sequence generally
localized within the 30UTR of target genes and repress the synthesis of the corresponding protein
or degrade the mRNA target. For miRNA replacement therapy, an exogenous miRNA mimic is
delivered systemically to exert a repression of their target genes. Small-molecule activators of
miRNA expression can also be used for this purpose. For endogenous miRNA inhibition, and thus
derepression of their target genes, several approaches can be used. Small-molecule inhibitors can
be directed to repress an miRNA expression. miRNA masking employs molecules complementary
to the 30-UTR of the target miRNA, resulting in competitive inhibition of the downstream target
effects. miRNA sponges use oligonucleotide constructs with multiple complementary miRNA
binding sites to the target miRNA, thereby preventing them from binding to their target mRNAs.
Antisense oligonucleotides, also known as miRNA antagonists, inhibitors, or anti-miRs, comple-
mentary bind to a target miRNA inducing either duplex formation or miRNA degradation. Novel
approaches can arise from recent discovery of other noncoding RNAs that regulate miRNA
activity. That is, circular RNAs can sequester a large amount of miRNAs acting as competitive
inhibitors for miRNA binding, thereby preventing the mRNA repression of the target miRNA. PA
protocatechuic acid, DHA docosahexaenoic acid
658 A. Dávalos and A. Chroni
phenotype, also called “mimic,” and aims to enhance the function of miRNAs. The
approaches that can be utilized for this strategy include (1) small-molecule
activators or inductors of miRNA expression and (2) miRNA mimics, which as
exogenous miRNAs aim to repress the function of their mRNA targets. They are
also called “miRNA replacement therapy.”
2.1.1 Therapeutic miRNA Mimics or miRNA Replacement Therapy
In principle, delivery of miRNA mimics as pharmacological therapy could be used
in situations in which a reduction in miRNA levels is responsible for the develop-
ment of a pathological state, such as those produced in the human rare Mendelian
disorders or certain types of cancer, where regions containing miRNAs are deleted
(Calin et al. 2002). Genetic mutation in either miRNA seed region or other miRNA
regions that results in a reduced functional miRNA with a significant reduction of
mRNA targeting required for normal function (Mencia et al. 2009; Ryan
et al. 2010) could also benefit from these therapies. The use of miRNA mimics
for therapy has been really challenging and their development has been catalyzed
by gene therapy. Gene therapy was first conceptualized in 1972 (Friedmann and
Roblin 1972) as an approach to deliver a gene or alter the expression of a gene in
order to replace a mutated gene or deliver a therapeutic functional gene using a
vector to treat a disease. Since then, the FDA has approved hundreds of clinical
trials during the last 20 years using different approaches, for different diseases, with
some promising results. However, it was not until 2012 that the European
Medicines Agency (EMA) has approved the first gene therapy drug, alipogene
tiparvovec (marked as Glybera)—for the treatment for lipoprotein lipase defi-
ciency—and the first of its kind in the western society. It uses a viral vector, the
adeno-associated virus serotype 1 (AAV1), to deliver a copy of the human lipopro-
tein lipase gene. As proof of concept, many preclinical data generated in animal
models suggest that pharmacological delivery of miRNA mimics is feasible and
current strategies to deliver miRNA mimics are promising. Indeed, a synthetic
version of miR-34a (MRX34, Mirna Therapeutics), delivered using a liposomal
delivery formulation, was the first miRNA to advance into a human Phase 1 clinical
trial for cancer (clinicaltrials.gov number NCT01829971).
Different experimental strategies to deliver miRNA mimics have been tested.
Synthetic miRNA or pre-miRNA duplexes, normally modified for better stability
and cellular uptake, have been incorporated into different delivery systems, includ-
ing lipid nanoparticles with surface receptor ligands or other components to
increase tissue/cell specificity (Wiggins et al. 2010; Trang et al. 2011; Piao
et al. 2012). Adeno-associated viruses (AAV) (Miyazaki et al. 2012) are another
interesting alternative. Certain tissue specificity due to the natural tropism of
different AAV serotypes (Zincarelli et al. 2008) could be achieved. Viral-based
vectors, including adenoviruses and lentiviruses (Chistiakov et al. 2012; Langlois
et al. 2012), consist another well-studied delivery method.
There are still questions regarding the biological function of miRNAs, particu-
larly those related to extracellular miRNAs, intercellular communication by
miRNAs, and their presence in numerous biological fluids that need to be
addressed. As miRNAs can circulate in the blood or different biological fluids in
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microvesicles, exosomes, Ago2-containing complexes, or HDL (Arroyo et al. 2011;
Vickers et al. 2011; Chen et al. 2012), opportunities will probably arise for
therapeutically exploiting the physiologic forms of miRNA delivery (Davalos and
Fernandez-Hernando 2013). The basic function of miRNAs, which is to target
different mRNAs of different biological pathways, raises the possibility of unin-
tended off-target effects (van Rooij et al. 2008). Several hurdles need to be solved
including the delivery issues, as uptake of a miRNA by tissues that normally do not
express them will result in the repression of their targets that could ultimately cause
side effects. Moreover, the overexpression of a particular miRNA, even in its
specific target cell, could modify either its own secretion or the secretion of other
miRNAs that could target a different cell/tissue type causing unwanted side effects.
2.1.2 Therapeutic miRNA Inhibition or Anti-miR Therapy
In contrast to miRNA replacement therapy, miRNA inhibitors as therapy have
benefits compared to existing antisense technology in the market. Over the last
decade, several miRNAs have been characterized, and it was found that their
induction or overexpression plays a causal role in a disease or directly contributes
to it. Thus, pharmacological inhibition of miRNA activity in vivo has been
achieved through the use of different chemically modified single-stranded reverse
complement oligonucleotides known as antisense oligonucleotide (Fig. 1). Anti-
sense oligonucleotides (ASOs) complementary to the mature miRNA sequence,
“antagomiRs,” were the first miRNA inhibitors in mammals (Krutzfeldt
et al. 2005). Since then different chemical modifications were performed to ASOs
in order to modify their pharmacological, pharmacokinetic, and pharmacodynamic
properties: cholesterol, conjugated via a 20-O-methyl (20-O-Me) linkage in the
30end, to increase cellular uptake and stability; phosphorothioate linkage to increase
stability and reduce clearance by promoting plasma protein binding; 20-O-methyl
(20-O-methyl)-modified ribose sugar to protect from endonuclease activity
(Krutzfeldt et al. 2005, 2007); 20,40-constrained 20-O-ethyl(cET)-modified
nucleotides to improve potency and stability (Seth et al. 2010; Pallan et al. 2012);
20-O-methoxyethyl (20-MOE) and 20-fluoro (20-F) modifications to improve in vivo
efficacy (Davis et al. 2009); and the 20-fluoro/methoxyethyl (20-F/MOE) modified
with phosphorothioate backbone-modified anti-miR technology which has been
shown to be efficacious in nonhuman primates (Rayner et al. 2011a). Lastly, locked
nucleic acid (LNA) gives promising properties in order to be used as miRNA
therapy. As LNA anti-miR has high-binding affinity and increased selectivity to
complementary RNA, the sequence length can be reduced. LNA also increases the
duplex’s melting temperature and stability in biological systems (Vester and
Wengel 2004; Elmen et al. 2005; Veedu and Wengel 2010). In preclinical studies
LNA-modified anti-miR technology has been widely shown to be efficacious in
nonhuman primates (Elmen et al. 2008; Lanford et al. 2010). Moreover, it was the
first anti-miR therapy to show efficacy in human trials (clinicaltrials.gov number
NCT01200420) (Janssen et al. 2013). A phosphorothioate backbone tiny 8-mer
LNA-modified anti-miRs for in vivo use (Obad et al. 2011) has also been developed
particularly for reducing the activity of entire miRNA families that share a common
seed region.
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For now, anti-miR therapy is administered parenterally. Although miRNA
inhibitors are generally water soluble, their size and charge prevent them to be
absorbed by the intestine, thus becoming bad candidates for oral therapy. Their
long-lasting effects shown in different studies (Krutzfeldt et al. 2005; Elmen
et al. 2008; Lanford et al. 2010; Obad et al. 2011; Rayner et al. 2011a, b; van
Rooij and Olson 2012) suggest their potential use for chronic rather than acute
disease. Whereas under normal unstressed conditions miRNAs only slightly change
protein expression (Selbach et al. 2008), pharmacological inhibition under patho-
logical stress conditions may become relevant (Mendell and Olson 2012). Even
when specific toxicity associated with the inhibition of a particular miRNA has not
been clearly reported, as for other LNA-containing ASO therapies, they might not
be free of potential off-target effects (Swayze et al. 2007). Thus, their evaluation
might be challenging and should be done in long-lasting studies. Moreover, other
miRNAs and mRNAs (independent of miRNA mediated) modified by the stress
conditions and other regulatory mechanism exerted by ceRNA, lncRNAs, and
circRNAs will greatly influence the pharmacodynamics of every particular anti-
miR chemistry.
Although there are many aspects of anti-miR biology that need to be addressed,
this therapeutic approach successfully led up to the first miRNA-based clinical
trials for the treatment of hepatitis C virus infection by targeting miR-122 with an
LNA-anti-miR (miravirsen or SPC3649; Santaris Pharma, Denmark) with very
promising results (Janssen et al. 2013). Thus, the biological interest in controlling
miRNAs level therapeutically anticipates the further development of this new class
of drugs.
2.2 Micromanaging Cholesterol Efflux, RCT, HDL Levels, and HDL
Function
Several miRNAs have been investigated for their potential use as therapeutics for
different aspects of HDL function. Although still in preclinical studies, the phar-
macological inhibition of the miRNA-33a/b is leading this aspect of research. These
and other miRNAs directly or indirectly related to cellular cholesterol efflux, RCT,
and HDL function that could potentially be used as pharmacological therapy will be
discussed below.
2.2.1 miR-33a/b
The genomic localization of this family of miRNAs within the introns of the master
regulators of lipid and cholesterol metabolism, the SREBPs-, has catalyzed the
discovery of this miRNA as major player in HDL function and cholesterol efflux
(Horton et al. 2002; Horie et al. 2010; Marquart et al. 2010; Najafi-Shoushtari
et al. 2010; Rayner et al. 2010). Modulation of miR-33a/b levels in preclinical
studies resulted in changes in cellular cholesterol efflux (Najafi-Shoushtari
et al. 2010; Rayner et al. 2010; Davalos et al. 2011). In vivo modulation of
miR-33a/b either by target disruption of the gene, LNA anti-miR, or viral delivery
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of sense and antisense oligonucleotides significantly alters circulating HDL-C and
reverse cholesterol transport (Horie et al. 2010; Marquart et al. 2010; Najafi-
Shoushtari et al. 2010; Rayner et al. 2010), which is consistent with the regulation
of its targets ABCA1, ABCG1, and NPC1. miR-33 deficiency reduces the progres-
sion of atherosclerotic plaque (Horie et al. 2012). Likewise the antisense inhibition
of this miRNA for 4 weeks in LDLR/ mice led to the regression of atherosclero-
sis by enhancing Abca1 expression and cholesterol removal in plaque macrophages,
reducing the size and inflammatory gene expression of plaques, and increasing
markers of plaque stability (Rayner et al. 2011b). Even when there is conflicting
results in this aspect (Marquart et al. 2013), there is still therapeutic potential in
inhibiting this miRNA family for atherosclerotic cardiovascular disease. The dra-
matic increase of SREBP1c (host of miR-33b)—in insulin resistance states—which
contributes to both increased levels of plasma triglycerides and low HDL levels
(Brown et al. 2010) also suggests the therapeutic use of anti-miR-33 for metabolic
syndrome. Indeed, as proof of concept, in African green monkeys fed with a high
carbohydrate diet, the inhibition of miR-33b for 12 weeks reduced hepatic expres-
sion of Abca1, increased the function of HDL evaluated as macrophage cholesterol
efflux, raised plasma HDL levels, and reduced VLDL triglyceride levels (Rayner
et al. 2011a).
Thus, the therapeutic potential of anti-miR-33 is not only based on Abca1,
cholesterol efflux, and RCT, but miR-33a/b also controls the expression of impor-
tant genes involved in fatty acid β-oxidation, insulin signaling, lipid metabolism,
and biliary transporters (Allen et al. 2012; Horie et al. 2013) (Gerin et al. 2010;
Davalos et al. 2011; Rayner et al. 2011a, b), including carnitine palmitoyl-
transferase 1A (Cpt1a), the carnitine O-octanoyltransferase (Crot), the mitochon-
drial beta hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA
hydratase (Hadhb), sirtuin 6 (Sirt6), 50-AMP-activated protein kinase catalytic
subunit alpha-1 (PRKAA1 gene, Ampkα), insulin receptor substrate 2 (Irs2),
SREBP-1, and the biliary transporters ABCB11 and ATP8B1. Although specific
toxicity associated to miR-33 inhibition has not been reported, its safety should be
carefully evaluated as other targets related to cell proliferation, cell cycle, and
inflammation, including cyclin-dependent kinase 6 (Cdk6), cyclin D1 (Ccnd1), the
tumor suppressor p53, and the nuclear receptor coregulator receptor interacting
protein 140 (Rip140) have also been described (Herrera-Merchan et al. 2010; Ho
et al. 2011; Cirera-Salinas et al. 2012).
Different anti-miR chemistries were tested for inhibiting miR-33 family
members including LNA-antisense oligonucleotide (Najafi-Shoushtari et al. 2010)
and 20F/MOE-modified phosphorothioate backbone-modified ASO (Rayner
et al. 2011a, b) (Regulus Therapeutics). Interestingly, the miR-33 family has special
structural characteristics, not common in most mammalian miRNAs. They have a
repetitive sequence similar to that of seed (UGCAUUG) between nucleotides
13 and 19 apart from their native seed sequence between nucleotides 2 and 8 at
the 50 end of the mature miRNA. This could be benefited by the use of phosphor-
othioate backbone tiny 8-mer LNA-modified anti-miRs chemistry. Indeed recent
promising results suggest the efficacy and safety of an 8-mer LNA anti-miR against
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miR-33 family during a 108-day treatment in a nonhuman primate metabolic
disease model (Rottiers et al. 2013) (Santaris Pharma). Which anti-miR chemistry
will have the best pharmacologic and safety profile for human use is not known, but
pharmaceutical industries (Santaris Pharma and Regulus Therapeutics) are inten-
sively researching on this topic and anti-miRs will probably soon enter clinical
trials.
2.2.2 miR-758 and miR-106b
Like miR-33a/b, miR-758 and miR-106b target ABCA1. The expression of
miR-758 is somehow mediated by high cholesterol levels and regulates cellular
cholesterol efflux by directly targeting the 30UTR of Abca1. As the relative expres-
sion of miR-758 is particularly elevated in the brain (Ramirez et al. 2011), it seems
that it regulates other important proteins involved in several neurological functions
including SLC38A1, IGF1, NTM, XTXBP1, and EPHA1. Although our under-
standing of the role of miR-758 under physiological and pathological conditions
needs to be enhanced first, the development of appropriate anti-miR chemistries for
targeting the brain miR-758 still remains to be dealt with, including bypassing the
blood–brain barrier and delivery to specific cell types. Also in neuronal cells,
miR-106b was found to directly target the 30UTR of Abca1 as having a perfect
8-mer and several supplementary pairing sites in mammals (Bartel 2009; Kim
et al. 2012). The miR-106b not only reduces cholesterol efflux to apoA-I but also
increases amyloid β (Aβ) peptide secretion and clearance (Kim et al. 2012). The
production and/or aggregation of Aβ peptide is believed to play a central role in the
pathogenesis of Alzheimer disease (AD). While the final effect might be directly
linked to miR-106b effects on Abca1 rather than other target genes in neuronal cells
(Kim et al. 2012), we should not discard other indirect effects as this miRNA also
targets various other proteins related to cell proliferation and differentiation (Brett
et al. 2011). Moreover, the amyloid precursor protein (APP) is also a target of
miR-106b (Hebert et al. 2009). The final phenotype of the inhibition of the neuronal
miR-106b is not known, but in the context of cholesterol efflux in the CNS,
miR-106b could be an interesting target for the regulation of neuronal cholesterol
excess.
2.2.3 miR-26 and miR-144
The nuclear liver X receptors (LXRs) control distinct aspects of cholesterol homeo-
stasis at the transcriptional level including uptake (IDOL) or efflux (ABCA1,
ABCG5, ABCG8). Induction of LXR by using agonists revealed the repression of
the miR-26 and the induction of the miR-144 family. LXR activation increased the
expression of Abca1 and ADP-ribosylation factor-like7 (Arl7), both of which
participate in apoA-I-dependent cholesterol efflux (Engel et al. 2004). The
miR-26-a-1 expression is also regulated by LXR (Sun et al. 2012) and directly
targets the 30UTR of Abca1 and Arl7. Thus the inhibition of this miRNA, in
principle, should enhance cholesterol efflux and RCT as LXR activation does. By
contrast, LXR activation induces the expression of miR-144 (Ramirez et al. 2013).
Interestingly, miR-144 is not only activated by LXR but also by the nuclear receptor
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farnesoid X receptor (FXR) (Vickers and Rader 2013). FXR is highly expressed in
the liver and the intestine. It controls the hepatic sterol and bile acid levels through
transcriptional regulation of lipid-associated and bile acid genes. The miR-144
directly targets the 30UTR of ABCA1, thus reducing ABCA1 protein levels and
cholesterol efflux, but not ABCA1 mRNA in all models tested (de Aguiar Vallim
et al. 2013; Ramirez et al. 2013; Vickers and Rader 2013). In vivo therapeutic
inhibition of miR-144 by using either 20-fluoro/20-methoxyethyl, phosphorothioate
backbone-modified anti-miRs (Regulus Therapeutics) 5 mg/kg biweekly treatments
(intraperitoneal injections) for 4 weeks (de Aguiar Vallim et al. 2013) or mirVana
inhibitors (7 mg/kg) coupled with In vivo fectamine (Invitrogen) for intravenous
injections twice every 3 days (Ramirez et al. 2013) increased both hepatic ABCA1
protein expression and HDL-C levels in mice. It is important to note that the hepatic
effect of miR-144 might differ from that of miR-33a/b (Vickers and Rader 2013).
Activation of FXR will induce both the scavenger receptor B1 (SCARB1) and
miR-144, thereby increasing the uptake of plasma HDL cholesterol and reducing
both ABCA1 protein levels and cholesterol efflux to lipid-poor apoA-I. This would
lead to increased biliary excretion of cholesterol via ABCG5/ABCG8 rather than
resecretion of cholesterol via ABCA1 to preβ-HDL and the formation of HDL
(de Aguiar Vallim et al. 2013). The final therapeutic outcome by modulating
miR-144 levels in vivo and other questions regarding safety issues still need to be
experimentally tested, as other miR-144 targets are directly related to cancer
proliferation (Guo et al. 2013; Zhang et al. 2013).
2.2.4 miR-10b, miR-128-2, miR-145
Several other miRNAs have been described to regulate ABCA1, ABCG1, and other
genes related to cholesterol efflux. In the context of small-molecule activators to
either induce or repress miRNAs expression, polyphenols and fatty acids are
emerging as possible candidates to exert part of their biological effects by this
mechanism (Visioli et al. 2012; Tome-Carneiro et al. 2013). Anthocyanidins are
pigmented polyphenols found in different vegetables, fruits, as well as common
beverages including grape and berry juice and red wine. Protocatechuic acid (PCA)
was found to be an intestinal microbiota metabolite of Cyanidin-3-O-glucoside
(Cy-3-G), a major anthocyanidin. Interestingly the antiatherogenic effect of PCA
was recently found to be mediated through miR-10b (Wang et al. 2012). Indeed,
PCA increases macrophage cholesterol efflux through the repression of miR-10b.
The miR-10b directly represses Abca1 and Abcg1 and negatively regulates choles-
terol efflux from lipid-loaded macrophages (Wang et al. 2012). Although several
genes involved in cancer progression are targets of the oncogenic miR-10b
(Gabriely et al. 2011; Tsukerman et al. 2012), its inhibition by either anti-miR
chemistries or dietary intervention with anthocyanidins may be an interesting
pharmacological approach to increase cholesterol efflux and RCT. The use of
other pharmacological approaches, including small natural dietary compounds, is
still under intense investigation (Visioli and Davalos 2011) and provides an attrac-
tive alternative to the use of ASOs or miRNA mimic technology.
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miR-145 was described as a major regulator of smooth muscle fate by targeting a
network of transcription factors, including Klf4, myocardin, and Elk-1 which
regulate the quiescent versus proliferative phenotype of smooth muscle cells
(Cordes et al. 2009). miR-145 also regulate ABCA1 expression and function. In
pancreatic beta cells, its inhibition improves glucose-stimulated insulin secretion.
Inhibition of miR-145b has been shown to increase ABCA1 expression, promoting
HDL biogenesis in the liver and improving glucose-stimulated insulin secretion in
islets (Kang et al. 2013). The miR-128-2 was described to be frequently
downregulated in breast cancer, and its overexpression impeded several oncogenic
traits of mammary carcinoma cells (Qian et al. 2012). ABCA1, ABCG1, and RXRα
are direct targets of miR-128-2, and its inhibition induces cholesterol efflux
(Adlakha et al. 2013). Although we lack in vivo evidence of their pharmacological
modulation and HDL function, recent evidence of association of cholesterol levels
and cancer (Nelson et al. 2013) warrants further investigation of these miRNAs.
2.2.5 Other miRNA Related to Cholesterol Efflux and Cholesterol
Homeostasis
Several other miRNAs have been described to indirectly regulate different aspects
of cholesterol efflux, RCT, and cholesterol metabolism, but their real physiological
contribution to HDL function is not well understood. Several miRNAs have been
described that regulate different targets in autophagy (Xu et al. 2012), the cell
catabolism process by which unnecessary or dysfunctional cellular components are
degraded through the lysosomal machinery. Lipid droplet cholesteryl ester hydro-
lysis is being recognized as an important step in cholesterol efflux (Ouimet
et al. 2011); thus miRNAs that target key pathways in lipid-loaded macrophage
autophagy and/or cholesterol ester hydrolases might be interesting targets to pro-
mote cholesterol efflux (Davalos and Fernandez-Hernando 2013). Caveolin, the
major protein coat of caveolae, has also been proposed to contribute to cellular
cholesterol efflux (Truong et al. 2010; Kuo et al. 2011). Even when there is
increasing evidence of several miRNAs including miR-103, miR-107, miR-133a,
miR-192, miR-802, and others that target caveolin (Nohata et al. 2011; Trajkovski
et al. 2011), their contribution to cholesterol efflux and RCT remains unknown.
miR-125a and miR-455 were found to repress the lipoprotein-supported steroido-
genesis by targeting SR-BI (Hu et al. 2012). miR-185, miR-96, and miR-223 were
also found to target SR-BI and repress HDL-cholesterol uptake (Wang et al. 2013).
Even though there is lack of evidence for any effect on HDL metabolism and
in vivo pharmacological modulation for any of those miRNAs, the major role of
SR-BI in HDL metabolism warrants further research on this topic.
Although the potential of LNA anti-miR-122-based therapy (Miravirsen,
Santaris Pharma) is fascinating, much more needs to be elucidated about miRNA
biology and miRNA regulatory networks in human diseases before we can intro-
duce such research into clinical care. Moreover, new opportunities for therapeutic
interventions by exploiting the different physiologic forms of miRNA delivery in
biological fluids (associated with microvesicles, exosomes, Ago2-containing
complexes, or HDL particles) will arise. In addition, in the postgenomic and
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“RNA world” era, new types and new roles of noncoding RNAs continue to
emerge, suggesting that there is much yet to be discovered in this therapy arena.
3 Antibodies
The use of monoclonal antibodies (mAbs) for the treatment of various diseases,
including cancers and autoimmune diseases, has been established for at least
15 years. The specificity of mAbs to the target antigen offers clear benefit for
their use over conventional pharmacotherapy. Today mAbs are being developed for
the treatment of dyslipidemia and cardiovascular disease. An overview of
approaches to antibody therapy for the decrease of LDL cholesterol, increase of
HDL cholesterol, treatment of HDL dysfunction, and reduction of cardiovascular
events is provided below. In addition, approaches of active immunization to
modulate atherosclerosis with promising results in preclinical studies are discussed.
3.1 LDL-Cholesterol Lowering Approaches: Proprotein
Convertase Subtilisin/Kexin Type 9 Blocking Antibodies
Statins reduce LDL-cholesterol (LDL-C) levels by increasing the hepatic uptake of
LDL through inhibiting HMG CoA reductase and subsequently cholesterol biosyn-
thesis. A meta-analysis of data from 90,056 participants in 14 randomized trials
showed that statin therapy can safely reduce the 5-year incidence of major coronary
events, coronary revascularization, and stroke by about one fifth per mmol/L
reduction in LDL-C (Baigent et al. 2005). In addition a newer meta-analysis of
data from 170,000 participants in 26 randomized trials of statins showed that each
1 mmol/L LDL-cholesterol reduction reduces the risk of occlusive vascular events
by about a fifth, irrespective of baseline cholesterol concentration, which implies
that a 2–3 mmol/L reduction would reduce risk by about 40–50 % (Baigent
et al. 2010). However, a significant proportion of patients treated with statins fail
to achieve the recommended levels of LDL-C (Catapano 2009). Furthermore, even
when LDL-C is reduced at the recommended levels by statins, there is a residual
50–60 % risk, and therefore, new targets for therapeutic intervention need to be
developed.
Loss-of-function mutations in proprotein convertase subtilisin/kexin type
9 (PCSK9) gene result in low levels of LDL-C and protect against coronary heart
disease. These observations have made PCSK9 one of the most intensively
investigated novel targets to treat hypercholesterolemia (Cohen et al. 2005,
2006). PCSK9, a protein mainly expressed in the liver and intestine, is present in
human plasma (Lambert et al. 2012). PCSK9 binds to LDL receptors (LDLRs) and
thereby targets the internalized receptor to lysosomal degradation and thus limits
recycling of receptor to the plasma membrane for LDL uptake (Zhang et al. 2007).
Statins have been shown to increase PCSK9 expression, an effect that blunts the
LDL-C lowering effectiveness of statins (Mayne et al. 2008). Therefore, the
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inhibition of interaction between PCSK9 and LDLR is expected to increase the
LDLRs that are available in the plasma membrane of hepatocytes and as a conse-
quence reduce plasma LDL-C. In addition, blocking the interactions between
PCSK9 and LDLR may increase the lipid-lowering efficacy of statins.
Various approaches for decreasing PCSK9 levels or blocking PCSK9/LDLR
interactions are being explored. By far the most advanced approach aims to inhibit
PCSK9/LDLR interactions by the use of monoclonal antibodies targeting PCSK9
(Catapano and Papadopoulos 2013; Kramer 2013). Currently, clinical or preclinical
trials for at least 13 different anti-PCSK9 antibodies are being conducted, with two
compounds having entered Phase 3 of clinical development (Catapano and
Papadopoulos 2013; Kramer 2013) (Table 1).
Preclinical studies in rodents and nonhuman primates showed that several anti-
PCSK9 antibodies increased hepatic LDLR protein levels and reduced plasma
LDL-C levels up to 80 % (Chan et al. 2009; Gusarova et al. 2012; Liang
et al. 2012; Chaparro-Riggers et al. 2012; Zhang et al. 2012c; Ni et al. 2011).
Reported results from Phase 1 studies in humans using REGN727/SAR236553
(alirocumab), AMG 145 (evolocumab), and PF-04950615 (RN316, bococizumab)
anti-PCSK9 antibodies showed that the treatments are generally well tolerated and
significantly reduce plasma LDL-C levels in healthy subjects or hypercholes-
terolemic patients, both as monotherapy and when added to statin treatment
(Stein et al. 2012b; Dias et al. 2012; Gumbiner et al. 2012a, b). Phase 2 trial results
have also been reported for alirocumab and evolocumab anti-PCSK9 antibodies.
When alirocumab was administered subcutaneously at doses ranging from 50 to
150 mg every 2 weeks or 200–400 mg every 4 weeks to patients with primary
hypercholesterolemia on top of ongoing stable atorvastatin therapy (10, 20,
40, 80 mg/day), additional reductions in LDL-C, than that accomplished with
atorvastatin alone, were observed (McKenney et al. 2012; Roth et al. 2012). The
reduction of LDL-C levels was found to be similar irrespective of statin dose,
indicating that the coadministration of alirocumab with atorvastatin may provide
benefit to patients that fail to achieve their LDL-C target using high-dose statins or
are intolerant to high-dose statins (McKenney et al. 2012; Roth et al. 2012). Great
reductions in LDL-C levels were also obtained when evolocumab was administered
at doses ranging from 70 to 140 mg every 2 weeks or 280–420 mg every 4 weeks to
patients with hypercholesterolemia, either as a monotherapy or in combination with
a stable dose of statin with or without ezetimibe therapy, or to statin-intolerant
patients due to muscle-related side effects on ezetimibe therapy (Giugliano
et al. 2012; Koren et al. 2012; Sullivan et al. 2012). In other studies of patients
with heterozygous familial hypercholesterolemia and elevated LDL-C on intensive
statin use, with or without ezetimibe therapy, the administration of alirocumab or
evolocumab resulted in substantial further LDL-C reduction (Stein et al. 2012a;
Raal et al. 2012). In addition to their capacity to reduce LDL-C levels, alirocumab
and evolocumab were shown to reduce lipoprotein(α) levels in patients with
hypercholesterolemia receiving statin therapy (McKenney et al. 2012; Desai
et al. 2013) or patients with heterozygous familial hypercholesterolemia on statins,
with or without ezetimibe therapy (Stein et al. 2012a; Raal et al. 2012).
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Alirocumab and evolocumab are currently further tested in 13 and 10 Phase
3 clinical trials, respectively (Table 1), for long-term efficacy and safety, either as
monotherapy or on top of other lipid-modifying therapies and in various patient
populations (e.g., subjects with primary hypercholesterolemia or mixed
dyslipidemia, with high cardiovascular risk and with hyperlipidemia or mixed
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dyslipidemia, with heterozygous familial hypercholesterolemia, with clinically
evident cardiovascular disease, with a 10-year Framingham risk score of 10 % or
less, undergoing coronary catheterization, who recently experienced an acute
coronary syndrome, with statin intolerance). Among these Phase 3 clinical studies,
two studies, which are conducted in numerous study centers across the United
States, Canada, Western and Eastern Europe, South America, Australia, Africa, and
Asia, will assess the effect of candidate drugs on the occurrence of cardiovascular
events for up to 64 months in large-sized patient groups. Specifically, the effect of
alirocumab (ODYSSEY Outcomes, NCT01663402) on the occurrence of cardio-
vascular events (composite endpoint of coronary heart disease (CHD) death, non-
fatal myocardial infarction (MI), fatal and nonfatal ischemic stroke, unstable angina
requiring hospitalization) is evaluated in 18,000 patients who have experienced an
acute coronary syndrome event 4–16 weeks prior to randomization and are treated
with evidence-based medical and dietary management of dyslipidemia (time frame:
up to month 64). Another objective of the study is the evaluation of the effect of
alirocumab on secondary endpoints (any CHD event, major CHD event, any
cardiovascular event, composite of all-cause mortality/nonfatal MI/nonfatal ische-
mic stroke, all-cause mortality), as well as on blood lipids and lipoprotein levels
(time frame: up to month 64). In addition, the long-term safety and tolerability of
alirocumab will be evaluated. In another large clinical trial (FOURIER,
NCT01764633), the effect of evolocumab used in combination with statin therapy
on additional LDL-C reduction and risk of cardiovascular death, MI, hospitalization
for unstable angina, stroke, or coronary revascularization is evaluated in 22,500
patients with clinically evident cardiovascular disease. The primary endpoint is the
time to cardiovascular death, MI, hospitalization for unstable angina, stroke, or
coronary revascularization, whichever occurs first (time frame: 5 years). Another
objective of the study is the evaluation of the effect of evolocumab on secondary
endpoints, such as time to death by any cause, cardiovascular death, hospitalization
for worsening heart failure, ischemic fatal or nonfatal stroke, and transient ischemic
attack, whichever occurs first (time frame: 5 years).
3.2 Approaches to Antibody Therapy for the Increase of HDL-
Cholesterol Levels
Numerous clinical and epidemiological studies have demonstrated an inverse
association between HDL-cholesterol (HDL-C) levels and the risk of cardiovascu-
lar disease (Gordon et al. 1977; Assmann et al. 1996). Furthermore, HDL exerts a
series of antiatherogenic properties (Navab et al. 2011). Thus, raising of HDL-C
levels is expected to translate into a reduction of cardiovascular events and has led
to serious efforts to develop new therapies that can increase the concentration of
HDL-C. Therapeutic strategies using antibody-based blocking of proteins of the
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HDL metabolism pathway that result in increase of HDL-C levels are discussed
below.
3.2.1 Cholesteryl Ester Transfer Protein
Cholesteryl ester transfer protein (CETP) promotes net mass transfer of cholesteryl
esters from HDL to other plasma lipoprotein fractions (Barter and Rye 2012).
Therefore, inhibition of CETP can increase the concentration of HDL-C and
CETP inhibitors have been capable to increase HDL-C levels in preliminary
clinical trials, while clinical outcome trials are ongoing (Barter and Rye 2012;
Landmesser et al. 2012). The properties and effects of different CETP small-
molecule inhibitors that were observed in clinical trials are being described by
Staels et al. in chapter “Emerging Small-Molecule Drugs.”
An alternative approach involves the blocking of CETP action with an antibody,
named CETi-1 (developed by AVANT Immunotherapeutics), raised against a
dimerized synthetic peptide, including residues 461–476 of human CETP and T
cell epitope of tetanus toxoid (residues 830–843), and formulated with aluminum-
containing adjuvants (Davidson et al. 2003). In a Phase II study, CETi-1 was shown
to be safe, and >90 % of treated patients with the highest dose of vaccine showed
1 year after vaccination with CETi-1 an immune response with an increase of
HDL-C by 8 % (Komori 2004). However, this trial failed to meet the primary
endpoint of increasing plasma HDL-C concentrations in the vaccine-treated groups
as compared to the placebo group, due to the low titers of antihuman CETP
antibody achieved in a number of the vaccinated subjects, and CETi-1 is no longer
in development (Komori 2004).
A few years ago, in order to improve the efficacy of the CETi-1 vaccine,
AVANT Immunotherapeutics researchers examined in mice and rabbits the immu-
nogenicity of CETi-1 with the coadministration of the investigational TLR9 agonist
VaxImmuneTM (CPG 7909) as an adjuvant (Thomas et al. 2009). In parallel, they
studied the immunogenicity of another anti-CETP antibody, the PADRE-CETP,
raised against a monomeric peptide, in which a PADRE T cell epitope
(aK-Cha-VAAWTLKAa) replaces the TT(830–843) T cell epitope of CETi-1,
with or without the coadministration of VaxImmuneΤM. The studies showed that
PADRE T cell epitope is more potent than the TT(830–843) epitope in providing
help for the anti-CETP antibody response and that the coadministration of
VaxImmuneΤM with either vaccine increased immunogenicity as measured by
antibody response (Thomas et al. 2009). However, there is no information for the
initiation of clinical trials using these new vaccination approaches up to date.
Another recent CETP vaccination approach involves the ATH-03 anti-CETP anti-
body (developed by Affiris AG), using a small peptide fragment of the CETP
protein acting as a B cell epitope (Kramer 2013), which has entered Phase 1 trials
to assess its safety and immunogenicity (ClinicalTrials.gov Identifier:
NCT01284582).
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3.2.2 Endothelial Lipase
Endothelial lipase (EL) is a phospholipase that participates in HDL metabolism and
regulates HDL-C levels in humans and mice (Yasuda et al. 2010; Annema and
Tietge 2011). Early studies in which EL was inhibited in wild-type, hepatic lipase-
deficient, and human apolipoprotein (apo) A-I transgenic mice by intravenous
infusion of a polyclonal inhibitory anti-mouse-EL antibody resulted in a 25–60 %
increase in HDL-C levels in three mouse models, while triglyceride and non-HDL-
cholesterol levels were not changed (Jin et al. 2003). In human apoA-I transgenic
mice, apoA-I levels were also increased and the HDL phospholipid turnover was
retarded (Jin et al. 2003). Based on this and other studies in mice lacking EL
activity, as well as on studies in humans expressing loss-of-function EL variants,
the inhibition of EL in humans would be expected to raise plasma HDL-C levels
(Brown et al. 2009; Ishida et al. 2003; Ma et al. 2003; Edmondson et al. 2009).
Although the effect of EL inhibition in the reduction of atherosclerotic cardiovas-
cular disease risk has not been proven (Yasuda et al. 2010; Annema and Tietge
2011), EL remains a potential target for pharmacological inhibition, possibly by
antibodies against EL, as a novel strategy to raise HDL-C and reduce the risk of
cardiovascular disease.
3.3 Effect of Antibodies Used for the Treatment of Chronic
Inflammatory Diseases on HDL Antiatherogenic Functions
Patients with chronic inflammatory rheumatic diseases, such as rheumatoid arthritis
and systemic lupus erythematosus, have increased risk for cardiovascular disease
morbidity and mortality (Onat and Direskeneli 2012; Farragher and Bruce 2006;
Popa et al. 2012). Various studies have shown that during the course of these
chronic inflammatory conditions, the levels as well as the antiatherogenic
properties of HDL are affected (Onat and Direskeneli 2012; Popa et al. 2012).
Specifically, patients with rheumatoid arthritis and systemic lupus erythematosus
were found to have proinflammatory HDL (McMahon et al. 2006; Charles-
Schoeman et al. 2009). In addition, cholesterol efflux capacity of HDL was
impaired in rheumatoid arthritis patients with high disease activity and was
correlated with systemic inflammation and HDL’s antioxidant capacity (Charles-
Schoeman et al. 2012). Recommendations for the treatment of rheumatic diseases
propose a tight control of the inflammatory process which probably will favorably
impact the risk of cardiovascular disease. New therapeutics include antibodies
designed to block inflammatory proteins or cells that are produced in abundance
during the disease, such as TNF-α, IL-6, or B cells (Onat and Direskeneli 2012;
Popa et al. 2012). Anti-TNF therapy of rheumatoid arthritis patients with monoclo-
nal antibody infliximab was shown to increase plasma paraoxonase-1 activity and
to improve HDL antioxidative capacity, an effect that was sustained 6 months after
anti-TNF therapy has been initiated (Popa et al. 2009). In addition, another recent
study in rheumatoid arthritis patients treated with rituximab, a B cell depleting
monoclonal antibody against the protein CD20, which is primarily found on the
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surface of B lymphocytes, showed beneficial changes in HDL composition
(Raterman et al. 2013). Specifically, during 6 months of treatment with rituximab,
HDL-associated serum amyloid A decreased in patients with good response to the
therapy, rendering HDL from proatherogenic to less proatherogenic (Raterman
et al. 2013). Future large-scale studies are needed to establish the value of monitor-
ing HDL function during antibody therapy, as well as the impact of this therapy on
cardiovascular disease risk of rheumatic disease patients and possibly other patients
with coronary artery disease who remain at high vascular risk despite contemporary
prevention strategies.
3.4 Vaccines Against Atherosclerosis
A large body of evidence has shown that atherosclerosis is a multifactorial, multi-
phase disease characterized by chronic inflammation and altered immune response.
Therefore, approaches of active immunization have been developed to modulate
atherosclerosis with promising results in preclinical studies. Many studies have
reported reduced atherosclerosis in animal models after immunization using as
antigens LDL (native or modified), apoB100 peptides, heat shock proteins, and
other proteins or phospholipids associated with the initiation and progression of the
atherosclerotic plaque.
Immunization with homologous LDL, oxLDL (copper-oxidized LDL), or
MDA-LDL (LDL modified by malondialdehyde (MDA), an epitope of oxLDL)
generated high titers of antibodies and reduced atherogenesis development in
hypercholesterolemic rabbits, LDLR-deficient rabbits, or apoE-deficient mice
(Palinski et al. 1995; Ameli et al. 1996; George et al. 1998; Zhou et al. 2001).
Similar results were achieved using homologous plaque homogenates (containing
immunogen(s) sharing epitopes on MDA-LDL, MDA-VLDL, and oxidized
cardiolipin) as the antigen (Zhou et al. 2001). The generation of antibodies against
oxidation epitopes in LDL has been proposed to inhibit the binding and uptake of
oxLDL by macrophage scavenger receptors CD36 and SR-BI and therefore to
reduce the formation of foam cells (Steinberg and Witztum 2010). In addition,
induction of oral tolerance to oxLDL can induce a significant increase in CD4
+CD25+Foxp3+ Tregs in spleen and mesenteric lymph nodes, and these cells
specifically respond to oxLDL with increased TGF-β production and significant
attenuation of the initiation and progression of atherogenesis in LDLR-deficient
mice (van Puijvelde et al. 2006). However, since atherosclerosis immune responses
can been triggered against autoantigens, such as anti-oxLDL, all the efforts toward
the development of a successful vaccine against oxLDL should result in the
restoration of tolerance against autoantibodies and balance of pro- and
antiatherogenic immune responses (Samson et al. 2012).
Screening of a library of 302 polypeptides covering the complete sequence of
apoB-100, the major protein component in LDL, in their native state and after MDA
modification, using pooled plasma derived from healthy control subjects, resulted
in the identification of more than 100 different human antibodies reacting against
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MDA-modified apoB100 sequences (Fredrikson et al. 2003a). Immunization with
apoB100 peptide sequences, against which high levels of IgG and IgM antibodies
are present in healthy human controls, was found to reduce atherosclerosis in apoE-
deficient mice by about 60 % (Fredrikson et al. 2003b). Studies on the mechanisms
underlying active immunization using a specific apoB100-related peptide, namely,
the p210, indicated that the atheroprotective effect of immunization with this
peptide is mediated via the activation of CD8+T cells (Chyu et al. 2012) and
CD4+ CD25+Foxp3+ Tregs (Wigren et al. 2011).
Other approaches to reduce atherosclerosis involve the immunization with
antigens other than LDL or apoB100-related peptides. Immunization of hypercho-
lesterolemic rabbits with protein-free liposomes containing dimyristoyl phosphati-
dylcholine, dimyristoyl phosphatidylglycerol, cholesterol (71 %), and lipid A from
Salmonella Minnesota R595 as adjuvant induced the generation of anticholesterol
antibodies and reduced the diet-induced hypercholesterolemia and plaque forma-
tion (Alving et al. 1996). In another study, pneumococcal vaccination was also
found to decrease the atherosclerotic lesion formation (Binder et al. 2003). The use
of Streptococcus pneumoniae as an antigen was based on the finding that during the
progression of atherosclerosis in apoE-deficient mice, autoantibodies against
epitopes of oxLDL, and more specifically against the oxidized phospholipids,
share complete genetic and structural identity with antibodies from the classic
anti-phosphorylcholine B cell clone, T15, which protect against common infectious
pathogens, including pneumococci (Shaw et al. 2000). The reduction of atheroscle-
rosis in LDLR-deficient mice after immunization with S. pneumoniae suggested
molecular mimicry between epitopes of oxLDL and S. pneumonia (Binder
et al. 2003). In another recent study, it was found that T cell hybridomas from
oxLDL-immunized human apoB100 transgenic mice responded against native LDL
and purified apoB100, but not against oxLDL and expressed a single T cell receptor
variable beta chain, TRBV31. Immunization of double human apoB100 transgenic
and LDLR-deficient mice with a TRBV31-derived peptide generated anti-TRBV31
antibodies that blocked T cell recognition of apoB100 and reduced atherosclerosis
(Hermansson et al. 2010).
In the last decade, various therapeutic approaches for reducing atherosclerosis
by immunization were based on heat shock proteins (HSPs). HSPs, which are
named according to their molecular weight, are a highly conserved group of
proteins that have been implicated in atherogenesis (Kilic and Mandal 2012;
Grundtman et al. 2011). Intracellularly, HSPs act as molecular chaperones and
assist in the folding of misfolded proteins, but extracellularly, HSPs can promote
immune responses. Immunization of rabbit or mouse atherosclerotic models with
HSP65 resulted in conflicting results, with some studies showing induction of
atherosclerotic lesions (Xu et al. 1992; George et al. 1999; Zhang et al. 2012d)
and others reduction of atherosclerosis (Maron et al. 2002; Harats et al. 2002; Long
et al. 2012; Klingenberg et al. 2012). Vaccination of high-cholesterol-fed athero-
sclerotic rabbits with a recombinant HSP65-CETP fusion protein resulted in pro-
duction of more protective IL-10 and less adverse IFN-γ, reduction of total
cholesterol and LDL-C levels, as well as decrease of the area of aortic lesions
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(Jun et al. 2012). In addition, the immunization of apoE-deficient or double
apoB48- and LDLR-deficient mice with chimeric proteins containing apoB-100
and/or hHSP60 peptides resulted in the reduction of atherosclerotic lesions
(Li et al. 2011; Lu et al. 2010).
Another target for the treatment of atherosclerosis by immunization involves a
specific cell population, the vascular endothelial growth factor receptor 2
(VEGFR2)-overexpressing cells. Highly VEGFR2 expressing cells include
proliferating endothelial cells that are involved in angiogenesis, a process that
may be associated with the initiation and progression of atherosclerosis (Shi
et al. 1998; Li et al. 2002; Moulton et al. 2003). Vaccination of apoE- or LDLR-
deficient mice against VEGFR2 by an orally administered DNA vaccine, compris-
ing a plasmid encoding murine VEGFR2 carried by live attenuated Salmonella
typhimurium, resulted in a marked induction of CD8+ cytotoxic T cells specific for
VEGFR2 and attenuated the initiation and progression of atherosclerosis (Hauer
et al. 2007). Oral administration of another DNA vaccine, one against CD99, a
membrane protein expressed on vascular endothelium overlying atherosclerotic
plaques, also generated antigen-specific cytotoxic CD8+ T cells and reduced
atherosclerosis in LDLR-deficient mice (van Wanrooij et al. 2008).
In a recent study of a potential treatment option for atherosclerosis, immuniza-
tion of apoE-deficient mice with a virus-like particle-based vaccine against IL-1α,
a cytokine exerting proinflammatory functions and implicated in the development
of atherosclerosis (Kamari et al. 2007), reduced both the inflammatory reaction in
the plaque and plaque progression (Tissot et al. 2013). A current Phase 3 clinical
study that aims to test the inflammatory hypothesis of atherothrombosis has been
designed to evaluate whether Canakinumab can reduce rates of recurrent MI,
stroke, and cardiovascular death among stable patients with coronary artery disease
who remain at high vascular risk due to persistent elevations of high-sensitivity
C-reactive protein (CRP) (>2 mg/L) despite contemporary secondary prevention
strategies (Ridker et al. 2011). Canakinumab is a human monoclonal antibody that
selectively neutralizes IL-1β, a cytokine that exerts proinflammatory effects and has
been implicated in the pathogenesis of atherothrombosis (Fearon and Fearon 2008).
The study which is named Canakinumab Anti-inflammatory Thrombosis Outcomes
Study (CANTOS, ClinicalTrials.gov Identifier: NCT01327846) will randomly
allocate 17,200 patients to either placebo or to Canakinumab at doses of 50, 150,
or 300 mg every 3 months, administered subcutaneously, and all participants will be
followed up over an estimated period of up to 4 years (Ridker et al. 2011). As part of
the CANTOS study, a multinational Phase IIb randomized, placebo-controlled trial
was conducted to evaluate the effects of Canakinumab agent on hemoglobin A1c,
glucose, lipids, CRP, IL-6, and fibrinogen among 556 men and women with
diabetes mellitus and high cardiovascular risk (Ridker et al. 2012). The patients
were randomly allocated to subcutaneous placebo or to subcutaneous Canakinumab
at doses of 5, 15, 50, or 150 mg monthly and followed over 4 months. No effects
were seen for hemoglobin A1c, glucose, insulin, LDL-C, HDL-C, or non-HDL-
cholesterol levels. By contrast, there were significant reductions in CRP, IL-6, and
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fibrinogen levels in both women and men. The CANTOS Investigative Group
members support that these data provide a strong basis for the use of Canakinumab
in humans as an approach to test whether therapeutic targeting of inflammation can
reduce the risk of recurrent events in patients on current standard of care treatment
after MI (Ridker et al. 2012).
Conclusions
Antisense oligonucleotide or gene therapy has been discussed for more than
30 years. The approval for commercial use of the first antisense oligonucleotide
in 1998 by the FDA has catalyzed the development of these types of therapy for
several diseases. Moreover, recent approvals of mipomersen or the gene therapy
drug Glyvera have opened avenues for the use of these novel therapeutic
approaches to treat lipid metabolism disorders. While miRNA and mAbs therapy
to treat dyslipidemia have benefitted from previous existing technology, the
recent clinical trials to target miR-122 through anti-miR technology and to target
PCSK9 through mAbs technology will probably encourage the development of
novel therapies to modulate HDL metabolism and function. mAbs are currently
being investigated for their capacity to decrease LDL-C levels, increase HDL-C
levels, and reduce the risk of cardiovascular events in clinical studies. Initial
studies showed that these compounds are generally safe and well tolerated.
Ongoing, large clinical studies will assess the long-term safety as well as the
efficacy of these new antibody-based drugs in a wide range of dyslipidemic and
cardiovascular disease patients. Even though the complex biological structure
and functions of HDL are probably delaying the benefits of having a drug using
any of these technologies in clinical care, ongoing preclinical or clinical studies
using antisense oligonucleotides, miRNAs, or mAbs envision a bright future for
the HDL field.
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